Tag | Content |
---|---|
Uniprot ID | P04637; Q15086; Q15087; Q15088; Q16535; Q16807; Q16808; Q16809; Q16810; Q16811; Q16848; Q2XN98; Q3LRW1; Q3LRW2; Q3LRW3; Q3LRW4; Q3LRW5; Q86UG1; Q8J016; Q99659; Q9BTM4; Q9HAQ8; Q9NP68; Q9NPJ2; Q9NZD0; Q9UBI2; Q9UQ61; |
Entrez ID | 7157 |
Genbank protein ID | AAF36356.1; CAA42630.1; ABA29757.1; AAF63442.1; AAA61212.1; CAA42627.1; AAF36358.1; AAF36379.1; CAA42635.1; AAF36359.1; AAK76359.1; CAA26306.1; AAA59987.1; AAA59989.1; AAF36362.1; CAA42626.1; ABA29756.1; ABB80266.1; AAR10356.1; AAF36377.1; AAK76358.1; CAA42632.1; CAA42634.1; AAF36355.1; BAG35463.1; ABA29754.1; CAA42631.1; AAC12971.1; AAF36376.1; AAF36360.1; EAW90144.1; CAA42633.1; CAA42629.1; AAF36378.1; AAQ90158.1; AAA59988.1; AAF36357.1; AAD28628.1; AAF36381.1; AAP30003.1; CAA38095.1; AAF36375.1; BAC16799.1; AAF63443.1; AAF36374.1; AAF36354.1; ABA29755.1; AAG28785.1; CAA25652.1; AAR13239.1; AAB39322.1; AAH03596.1; AAF36361.1; EAW90143.1; AAF36382.1; CAA42628.1; AAD28535.1; AAA61211.1; ABB80262.1; AAF36380.1; AAV80424.1; ABA29753.1; |
Genbank nucleotide ID | NM_001126116.1; NM_001276697.1; NM_001276761.1; NM_001126112.2; NM_001276699.1; NM_001126118.1; NM_001276695.1; NM_001276698.1; NM_001276760.1; NM_001126114.2; NM_001126113.2; NM_000546.5; NM_001126117.1; NM_001126115.1; NM_001276696.1; |
Ensembl protein ID | ENSP00000481638; ENSP00000480868; ENSP00000482222; ENSP00000478219; ENSP00000482258; ENSP00000484409; ENSP00000391478; ENSP00000391127; ENSP00000481179; ENSP00000482537; ENSP00000398846; ENSP00000269305; ENSP00000478499; |
Ensembl nucleotide ID | ENSG00000141510 |
Gene name | Cellular tumor antigen p53 |
Gene symbol | TP53 |
Organism | Homo sapiens |
NCBI taxa ID | 9606 |
Cleft type | |
Developmental stage | |
Data sources | Homology search |
Reference | |
Functional description | Acts as a tumor suppressor in many tumor types; induces growth arrest or apoptosis depending on the physiological circumstances and cell type. Involved in cell cycle regulation as a trans-activator that acts to negatively regulate cell division by controlling a set of genes required for this process. One of the activated genes is an inhibitor of cyclin-dependent kinases. Apoptosis induction seems to be mediated either by stimulation of BAX and FAS antigen expression, or by repression of Bcl-2 expression. Its pro-apoptotic activity is activated via its interaction with PPP1R13B/ASPP1 or TP53BP2/ASPP2 (PubMed:12524540). However, this activity is inhibited when the interaction with PPP1R13B/ASPP1 or TP53BP2/ASPP2 is displaced by PPP1R13L/iASPP (PubMed:12524540). In cooperation with mitochondrial PPIF is involved in activating oxidative stress-induced necrosis; the function is largely independent of transcription. Induces the transcription of long intergenic non-coding RNA p21 (lincRNA-p21) and lincRNA-Mkln1. LincRNA-p21 participates in TP53-dependent transcriptional repression leading to apoptosis and seems to have an effect on cell-cycle regulation. Implicated in Notch signaling cross-over. Prevents CDK7 kinase activity when associated to CAK complex in response to DNA damage, thus stopping cell cycle progression. Isoform 2 enhances the transactivation activity of isoform 1 from some but not all TP53-inducible promoters. Isoform 4 suppresses transactivation activity and impairs growth suppression mediated by isoform 1. Isoform 7 inhibits isoform 1-mediated apoptosis. Regulates the circadian clock by repressing CLOCK-ARNTL/BMAL1-mediated transcriptional activation of PER2 (PubMed:24051492). |
Sequence | MEEPQSDPSV EPPLSQETFS DLWKLLPENN VLSPLPSQAM DDLMLSPDDI EQWFTEDPGP 60 DEAPRMPEAA PPVAPAPAAP TPAAPAPAPS WPLSSSVPSQ KTYQGSYGFR LGFLHSGTAK 120 SVTCTYSPAL NKMFCQLAKT CPVQLWVDST PPPGTRVRAM AIYKQSQHMT EVVRRCPHHE 180 RCSDSDGLAP PQHLIRVEGN LRVEYLDDRN TFRHSVVVPY EPPEVGSDCT TIHYNYMCNS 240 SCMGGMNRRP ILTIITLEDS SGNLLGRNSF EVRVCACPGR DRRTEEENLR KKGEPHHELP 300 PGSTKRALPN NTSSSPQPKK KPLDGEYFTL QIRGRERFEM FRELNEALEL KDAQAGKEPG 360 GSRAHSSHLK SKKGQSTSRH KKLMFKTEGP DSD 393 |
Abbreviation :
CLO : cleft lip only. CPO : cleft palate only.
CLP : cleft lip and palate. CL/P : cleft lip with/without cleft palate.
For humans: CL/P, CLO, CPO, and CLP. For mice: CLO, CLP, and CPO.
Relation | Gene symbol | Entrez ID | UniProt ID | Cleft type | Developmental stage | Species | Evidence | Details |
---|---|---|---|---|---|---|---|---|
1:1 ortholog | TP53 | 281542 | P67939 | Bos taurus | Prediction | More>> | ||
1:1 ortholog | TP53 | A0A452G0L9 | Capra hircus | Prediction | More>> | |||
1:1 ortholog | TP53 | 7157 | P04637 | Homo sapiens | Prediction | More>> | ||
1:1 ortholog | Tp53 | 22059 | P02340 | CPO,CLP | Mus musculus | Publication | More>> | |
1:1 ortholog | TP53 | 455214 | H2QC53 | Pan troglodytes | Prediction | More>> | ||
1:1 ortholog | TP53 | G1SEU0 | Oryctolagus cuniculus | Prediction | More>> | |||
1:1 ortholog | Tp53 | M0R497 | Rattus norvegicus | Prediction | More>> | |||
1:1 ortholog | tp53 | 30590 | G1K2L5 | Danio rerio | Prediction | More>> |
ID | Variant | Type | Disease | Chromosome\Coordinate | Evidence |
---|---|---|---|---|---|
RCV000695387 | p.Glu2Lys | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676591C>T | ClinVar |
rs769884991 | p.Glu2Lys | missense variant | - | NC_000017.11:g.7676591C>T | ExAC,TOPMed,gnomAD |
RCV000579480 | p.Glu2Lys | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676591C>T | ClinVar |
rs786203938 | p.Glu3Gly | missense variant | - | NC_000017.11:g.7676587T>C | - |
RCV000167456 | p.Glu3Gly | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676587T>C | ClinVar |
RCV000534086 | p.Glu3Gly | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676587T>C | ClinVar |
rs878854064 | p.Pro4Arg | missense variant | - | NC_000017.11:g.7676584G>C | - |
RCV000780782 | p.Pro4Leu | missense variant | - | NC_000017.11:g.7676584G>A | ClinVar |
RCV000662489 | p.Pro4Leu | missense variant | Li-Fraumeni syndrome 1 (LFS) | NC_000017.11:g.7676584G>A | ClinVar |
RCV000571530 | p.Pro4Leu | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676584G>A | ClinVar |
RCV000229754 | p.Pro4Leu | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676584G>A | ClinVar |
RCV000475451 | p.Pro4Arg | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676584G>C | ClinVar |
RCV000759369 | p.Pro4Leu | missense variant | - | NC_000017.11:g.7676584G>A | ClinVar |
rs1356004172 | p.Pro4Thr | missense variant | - | NC_000017.11:g.7676585G>T | TOPMed |
rs878854064 | p.Pro4Leu | missense variant | - | NC_000017.11:g.7676584G>A | - |
rs781595324 | p.Gln5Arg | missense variant | - | NC_000017.11:g.7676581T>C | ExAC,TOPMed,gnomAD |
RCV000220312 | p.Gln5Arg | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676581T>C | ClinVar |
RCV000550564 | p.Gln5Arg | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676581T>C | ClinVar |
VAR_044543 | p.Gln5His | Missense | - | - | UniProt |
rs1357147493 | p.Ser6Pro | missense variant | - | NC_000017.11:g.7676579A>G | gnomAD |
VAR_044544 | p.Ser6Leu | Missense | - | - | UniProt |
rs587781277 | p.Asp7Glu | missense variant | - | NC_000017.11:g.7676574A>T | - |
RCV000132048 | p.Asp7His | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676576C>G | ClinVar |
RCV000574520 | p.Asp7Glu | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676574A>C | ClinVar |
NCI-TCGA novel | p.Asp7HisPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7676543_7676576TTTCCTGACTCAGAGGGGGCTCGACGCTAGGATC>- | NCI-TCGA |
rs587782646 | p.Asp7His | missense variant | - | NC_000017.11:g.7676576C>G | TOPMed,gnomAD |
rs587782646 | p.Asp7His | missense variant | - | NC_000017.11:g.7676576C>G | UniProt,dbSNP |
VAR_005851 | p.Asp7His | missense variant | - | NC_000017.11:g.7676576C>G | UniProt |
rs587781277 | p.Asp7Glu | missense variant | - | NC_000017.11:g.7676574A>C | - |
RCV000802467 | p.Asp7Glu | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676574A>T | ClinVar |
rs876659415 | p.Pro8Leu | missense variant | - | NC_000017.11:g.7676572G>A | TOPMed |
RCV000221732 | p.Pro8Leu | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676572G>A | ClinVar |
VAR_044545 | p.Pro8Ser | Missense | - | - | UniProt |
rs1555527015 | p.Ser9Asn | missense variant | - | NC_000017.11:g.7676569C>T | - |
rs757282628 | p.Ser9Arg | missense variant | - | NC_000017.11:g.7676568G>C | ExAC,TOPMed,gnomAD |
RCV000587100 | p.Ser9Arg | missense variant | - | NC_000017.11:g.7676568G>C | ClinVar |
RCV000534258 | p.Ser9Asn | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676569C>T | ClinVar |
rs1555527017 | p.Ser9Arg | missense variant | - | NC_000017.11:g.7676570T>G | - |
RCV000633332 | p.Ser9Arg | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676570T>G | ClinVar |
rs535274413 | p.Val10Leu | missense variant | - | NC_000017.11:g.7676567C>G | 1000Genomes,ExAC,TOPMed,gnomAD |
RCV000115717 | p.Val10Ile | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676567C>T | ClinVar |
RCV000220427 | p.Val10Leu | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676567C>G | ClinVar |
rs535274413 | p.Val10Ile | missense variant | - | NC_000017.11:g.7676567C>T | UniProt,dbSNP |
VAR_044546 | p.Val10Ile | missense variant | - | NC_000017.11:g.7676567C>T | UniProt |
rs1418778734 | p.Val10Gly | missense variant | - | NC_000017.11:g.7676566A>C | gnomAD |
rs535274413 | p.Val10Ile | missense variant | - | NC_000017.11:g.7676567C>T | 1000Genomes,ExAC,TOPMed,gnomAD |
RCV000791760 | p.Val10Leu | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676567C>G | ClinVar |
RCV000663228 | p.Glu11Lys | missense variant | Li-Fraumeni syndrome 1 (LFS) | NC_000017.11:g.7676564C>T | ClinVar |
RCV000485338 | p.Glu11Lys | missense variant | - | NC_000017.11:g.7676564C>T | ClinVar |
RCV000548671 | p.Glu11Lys | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676564C>T | ClinVar |
RCV000161016 | p.Glu11Gln | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676564C>G | ClinVar |
rs201382018 | p.Glu11Lys | missense variant | - | NC_000017.11:g.7676564C>T | 1000Genomes,ExAC,TOPMed,gnomAD |
rs201382018 | p.Glu11Gln | missense variant | - | NC_000017.11:g.7676564C>G | 1000Genomes,ExAC,TOPMed,gnomAD |
rs1482497533 | p.Pro12Arg | missense variant | - | NC_000017.11:g.7676560G>C | gnomAD |
RCV000633363 | p.Pro12Leu | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676560G>A | ClinVar |
RCV000701186 | p.Pro12His | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676560G>T | ClinVar |
RCV000772527 | p.Pro12Leu | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676560G>A | ClinVar |
rs1482497533 | p.Pro12Leu | missense variant | - | NC_000017.11:g.7676560G>A | gnomAD |
rs1060501208 | p.Pro13Ser | missense variant | - | NC_000017.11:g.7676558G>A | gnomAD |
RCV000468196 | p.Pro13Ser | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676558G>A | ClinVar |
RCV000478642 | p.Pro13Ser | missense variant | - | NC_000017.11:g.7676558G>A | ClinVar |
RCV000574176 | p.Pro13Ser | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676558G>A | ClinVar |
RCV000571735 | p.Pro13Arg | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676557G>C | ClinVar |
RCV000226793 | p.Pro13Leu | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676557G>A | ClinVar |
rs878854070 | p.Pro13Arg | missense variant | - | NC_000017.11:g.7676557G>C | TOPMed |
rs878854070 | p.Pro13Leu | missense variant | - | NC_000017.11:g.7676557G>A | TOPMed |
RCV000576812 | p.Leu14Ter | frameshift | Li-Fraumeni syndrome 1 (LFS) | NC_000017.11:g.7676561dup | ClinVar |
RCV000699996 | p.Leu14Val | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676555G>C | ClinVar |
NCI-TCGA novel | p.Ser15LysPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7676545_7676551TCCTGAC>- | NCI-TCGA |
VAR_044549 | p.Ser15Arg | Missense | - | - | UniProt |
RCV000633337 | p.Gln16Ter | frameshift | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676550del | ClinVar |
VAR_044550 | p.Gln16Leu | Missense | - | - | UniProt |
VAR_044551 | p.Glu17Asp | Missense | - | - | UniProt |
RCV000213243 | p.Thr18Ter | frameshift | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676545del | ClinVar |
RCV000492768 | p.Ser20Ter | frameshift | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676540del | ClinVar |
NCI-TCGA novel | p.Ser20GlnPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7676537A>- | NCI-TCGA |
NCI-TCGA novel | p.Ser20Ter | stop gained | - | NC_000017.11:g.7676536G>C | NCI-TCGA |
rs876659913 | p.Ser20Pro | missense variant | - | NC_000017.11:g.7676537A>G | - |
RCV000219749 | p.Ser20Pro | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676537A>G | ClinVar |
rs1800369 | p.Asp21Glu | missense variant | - | NC_000017.11:g.7676532G>C | 1000Genomes,ExAC,TOPMed,gnomAD |
COSM4436144 | p.Leu22TyrPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7676531G>- | NCI-TCGA Cosmic |
COSM4556687 | p.Trp23Ter | stop gained | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7676526C>T | NCI-TCGA Cosmic |
VAR_044552 | p.Lys24Asn | Missense | - | - | UniProt |
RCV000569180 | p.Leu26Ter | frameshift | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676398_7676401delinsACGTTCTT | ClinVar |
RCV000036535 | p.Leu26Ter | frameshift | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676398_7676401delinsACGTTCTT | ClinVar |
RCV000468603 | p.Pro27Thr | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676399G>T | ClinVar |
RCV000771430 | p.Pro27Ser | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676399G>A | ClinVar |
COSM296199 | p.Pro27LeuPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7676398G>- | NCI-TCGA Cosmic |
COSM5614514 | p.Pro27LeuPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7676400A>- | NCI-TCGA Cosmic |
rs1555526933 | p.Pro27Leu | missense variant | - | NC_000017.11:g.7676398G>A | - |
rs922736614 | p.Pro27Thr | missense variant | - | NC_000017.11:g.7676399G>T | gnomAD |
rs922736614 | p.Pro27Ser | missense variant | - | NC_000017.11:g.7676399G>A | gnomAD |
RCV000572822 | p.Pro27Leu | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676398G>A | ClinVar |
RCV000633393 | p.Pro27Ser | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676399G>A | ClinVar |
rs786202289 | p.Glu28Val | missense variant | - | NC_000017.11:g.7676395T>A | - |
RCV000165025 | p.Glu28Val | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676395T>A | ClinVar |
VAR_044553 | p.Glu28Ala | Missense | - | - | UniProt |
rs1011445550 | p.Asn29Lys | missense variant | - | NC_000017.11:g.7676391G>C | TOPMed |
RCV000633338 | p.Asn29Ter | frameshift | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676395del | ClinVar |
VAR_047158 | p.Asn29_Asn30delinsLysAsp | deletion_insertion | - | - | UniProt |
RCV000122173 | p.Val31Ile | missense variant | - | NC_000017.11:g.7676387C>T | ClinVar |
RCV000493979 | p.Val31Ter | frameshift | - | NC_000017.11:g.7676387_7676388insT | ClinVar |
RCV000222526 | p.Val31Phe | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676387C>A | ClinVar |
rs201753350 | p.Val31Ile | missense variant | - | NC_000017.11:g.7676387C>T | 1000Genomes,ExAC,TOPMed,gnomAD |
rs201753350 | p.Val31Phe | missense variant | - | NC_000017.11:g.7676387C>A | 1000Genomes,ExAC,TOPMed,gnomAD |
rs201753350 | p.Val31Ile | missense variant | - | NC_000017.11:g.7676387C>T | UniProt,dbSNP |
VAR_044554 | p.Val31Ile | missense variant | - | NC_000017.11:g.7676387C>T | UniProt |
COSM5048959 | p.Leu32CysPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7676385A>- | NCI-TCGA Cosmic |
NCI-TCGA novel | p.Ser33PhePheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7676271_7676272insA | NCI-TCGA |
rs1555526832 | p.Ser33Tyr | missense variant | - | NC_000017.11:g.7676271G>T | - |
RCV000561224 | p.Ser33Tyr | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676271G>T | ClinVar |
RCV000492612 | p.Ser33Ter | frameshift | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676272dup | ClinVar |
RCV000819381 | p.Ser33Tyr | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676271G>T | ClinVar |
VAR_044555 | p.Ser33Thr | Missense | - | - | UniProt |
RCV000772948 | p.Pro34Arg | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676268G>C | ClinVar |
RCV000165887 | p.Pro34Ala | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676269G>C | ClinVar |
RCV000164526 | p.Pro34Thr | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676269G>T | ClinVar |
rs786201968 | p.Pro34Thr | missense variant | - | NC_000017.11:g.7676269G>T | - |
rs786201968 | p.Pro34Ala | missense variant | - | NC_000017.11:g.7676269G>C | - |
rs1322947350 | p.Pro34Arg | missense variant | - | NC_000017.11:g.7676268G>C | gnomAD |
RCV000483753 | p.Pro34Ala | missense variant | - | NC_000017.11:g.7676269G>C | ClinVar |
RCV000205889 | p.Pro34Ala | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676269G>C | ClinVar |
VAR_044556 | p.Pro34Leu | Missense | - | - | UniProt |
rs121912661 | p.Leu35Phe | missense variant | - | NC_000017.11:g.7676264C>G | TOPMed,gnomAD |
RCV000470404 | p.Leu35Met | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676266A>T | ClinVar |
RCV000572574 | p.Leu35Met | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676266A>T | ClinVar |
RCV000633325 | p.Leu35Phe | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676264C>G | ClinVar |
RCV000481187 | p.Leu35Phe | missense variant | - | NC_000017.11:g.7676264C>G | ClinVar |
RCV000013170 | p.Leu35Phe | missense variant | Carcinoma of pancreas | NC_000017.11:g.7676264C>A | ClinVar |
RCV000131759 | p.Leu35Phe | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676264C>G | ClinVar |
COSM27164 | p.Leu35PhePheSerTerUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7676264_7676265insA | NCI-TCGA Cosmic |
COSM4612592 | p.Leu35CysPheSerTerUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7676265A>- | NCI-TCGA Cosmic |
COSM290545 | p.Leu35ProPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7676272_7676273insCT | NCI-TCGA Cosmic |
COSM128679 | p.Leu35CysPheSerTerUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7676267G>- | NCI-TCGA Cosmic |
NCI-TCGA novel | p.Leu35PhePheSerTerUnk | frameshift | - | NC_000017.11:g.7676263_7676264GC>- | NCI-TCGA |
rs121912661 | p.Leu35Phe | missense variant | - | NC_000017.11:g.7676264C>A | TOPMed,gnomAD |
rs121912661 | p.Leu35Phe | missense variant | - | NC_000017.11:g.7676264C>A | UniProt,dbSNP |
VAR_005852 | p.Leu35Phe | missense variant | - | NC_000017.11:g.7676264C>A | UniProt |
rs1060501211 | p.Leu35Met | missense variant | - | NC_000017.11:g.7676266A>T | - |
rs587781866 | p.Pro36Leu | missense variant | - | NC_000017.11:g.7676262G>A | UniProt,dbSNP |
VAR_044557 | p.Pro36Leu | missense variant | - | NC_000017.11:g.7676262G>A | UniProt |
rs587781866 | p.Pro36Leu | missense variant | - | NC_000017.11:g.7676262G>A | ExAC,TOPMed,gnomAD |
RCV000469733 | p.Pro36Gln | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676262G>T | ClinVar |
RCV000161017 | p.Pro36Ser | missense variant | - | NC_000017.11:g.7676263G>A | ClinVar |
COSM111569 | p.Pro36TrpPheSerTerUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7676251_7676263TTGCTTGGGACGG>- | NCI-TCGA Cosmic |
RCV000662689 | p.Pro36Gln | missense variant | Li-Fraumeni syndrome 1 (LFS) | NC_000017.11:g.7676262G>T | ClinVar |
rs730881993 | p.Pro36Ser | missense variant | - | NC_000017.11:g.7676263G>A | - |
rs587781866 | p.Pro36Gln | missense variant | - | NC_000017.11:g.7676262G>T | ExAC,TOPMed,gnomAD |
RCV000213046 | p.Pro36Gln | missense variant | - | NC_000017.11:g.7676262G>T | ClinVar |
RCV000130183 | p.Pro36Gln | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676262G>T | ClinVar |
RCV000688189 | p.Ser37Phe | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676259G>A | ClinVar |
NCI-TCGA novel | p.Ser37ValPheSerTerUnk | frameshift | - | NC_000017.11:g.7676236_7676261GCATCAAATCATCCATTGCTTGGGAC>- | NCI-TCGA |
NCI-TCGA novel | p.Ser37ProPheSerTerUnk | frameshift | - | NC_000017.11:g.7676261C>- | NCI-TCGA |
VAR_044559 | p.Ser37Thr | Missense | - | - | UniProt |
VAR_044558 | p.Ser37Pro | Missense | - | - | UniProt |
COSM5047932 | p.Gln38LysPheSerTerUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7676257G>- | NCI-TCGA Cosmic |
COSM236889 | p.Gln38Ter | stop gained | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7676257G>A | NCI-TCGA Cosmic |
RCV000544374 | p.Gln38Ter | frameshift | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676259del | ClinVar |
RCV000690309 | p.Ala39Val | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676253G>A | ClinVar |
rs1353016807 | p.Ala39Val | missense variant | - | NC_000017.11:g.7676253G>A | TOPMed |
rs1353016807 | p.Ala39Val | missense variant | - | NC_000017.11:g.7676253G>A | UniProt,dbSNP |
VAR_044561 | p.Ala39Val | missense variant | - | NC_000017.11:g.7676253G>A | UniProt |
RCV000582613 | p.Ala39Ter | frameshift | - | NC_000017.11:g.7676252_7676253del | ClinVar |
VAR_044560 | p.Ala39Pro | Missense | - | - | UniProt |
rs587782877 | p.Met40Thr | missense variant | - | NC_000017.11:g.7676250A>G | - |
COSM1318427 | p.Met40LeuPheSerTerUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7676251_7676252insCCATCCAG | NCI-TCGA Cosmic |
RCV000132511 | p.Met40Thr | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676250A>G | ClinVar |
COSM46244 | p.Asp41MetPheSerTerUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7676248C>- | NCI-TCGA Cosmic |
rs1555526789 | p.Asp41Asn | missense variant | - | NC_000017.11:g.7676248C>T | - |
RCV000822098 | p.Asp41Asn | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676248C>T | ClinVar |
RCV000562780 | p.Asp41Asn | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676248C>T | ClinVar |
rs587781767 | p.Asp42Gly | missense variant | - | NC_000017.11:g.7676244T>C | - |
NCI-TCGA novel | p.Asp42IlePheSerTerUnk | frameshift | - | NC_000017.11:g.7676245C>- | NCI-TCGA |
RCV000566048 | p.Asp42GlyTer | nonsense | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676248_7676251dup | ClinVar |
rs756847009 | p.Asp42Asn | missense variant | - | NC_000017.11:g.7676245C>T | ExAC,gnomAD |
RCV000129995 | p.Asp42Gly | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676244T>C | ClinVar |
VAR_044562 | p.Asp42Tyr | Missense | - | - | UniProt |
rs1555526777 | p.Leu43Ter | stop gained | - | NC_000017.11:g.7676241A>T | - |
COSM984983 | p.Leu43Ter | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7676241A>- | NCI-TCGA Cosmic |
COSM69023 | p.Leu43AlaPheSerTerUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7676238_7676242ATCAA>- | NCI-TCGA Cosmic |
RCV000521967 | p.Leu43Ter | nonsense | - | NC_000017.11:g.7676241A>T | ClinVar |
rs754332870 | p.Leu43Phe | missense variant | - | NC_000017.11:g.7676240C>G | ExAC,gnomAD |
VAR_005853 | p.Leu43Ser | Missense | - | - | UniProt |
NCI-TCGA novel | p.Met44IlePheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7676237C>- | NCI-TCGA |
NCI-TCGA novel | p.Met44ThrPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7676226_7676238TCCGGGGACAGCA>- | NCI-TCGA |
rs1060501190 | p.Met44Ile | missense variant | - | NC_000017.11:g.7676237C>T | - |
RCV000459820 | p.Met44Ile | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676237C>T | ClinVar |
VAR_044565 | p.Met44Val | Missense | - | - | UniProt |
VAR_044564 | p.Met44Thr | Missense | - | - | UniProt |
rs879254066 | p.Leu45Pro | missense variant | - | NC_000017.11:g.7676235A>G | - |
RCV000235508 | p.Leu45Pro | missense variant | - | NC_000017.11:g.7676235A>G | ClinVar |
VAR_044566 | p.Leu45Met | Missense | - | - | UniProt |
RCV000132061 | p.Ser46Ter | frameshift | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676232delinsAC | ClinVar |
RCV000218555 | p.Ser46Pro | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676233A>G | ClinVar |
NCI-TCGA novel | p.Ser46Ter | frameshift | - | NC_000017.11:g.7676204_7676232AGTGAACCATTGTTCAATATCGTCCGGGG>- | NCI-TCGA |
NCI-TCGA novel | p.Ser46ThrPheSerTerUnk | frameshift | - | NC_000017.11:g.7676217_7676233TCAATATCGTCCGGGGA>- | NCI-TCGA |
rs876659630 | p.Ser46Pro | missense variant | - | NC_000017.11:g.7676233A>G | - |
rs876659630 | p.Ser46Pro | missense variant | - | NC_000017.11:g.7676233A>G | UniProt,dbSNP |
VAR_044568 | p.Ser46Pro | missense variant | - | NC_000017.11:g.7676233A>G | UniProt |
VAR_044567 | p.Ser46Phe | Missense | - | - | UniProt |
rs1800371 | p.Pro47Ser | missense variant | - | NC_000017.11:g.7676230G>A | 1000Genomes,ESP,ExAC,TOPMed,gnomAD |
COSM13161 | p.Pro47ArgPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7676229G>- | NCI-TCGA Cosmic |
rs1800371 | p.Pro47Thr | missense variant | - | NC_000017.11:g.7676230G>T | 1000Genomes,ESP,ExAC,TOPMed,gnomAD |
RCV000036530 | p.Pro47Ser | missense variant | - | NC_000017.11:g.7676230G>A | ClinVar |
RCV000774798 | p.Pro47Thr | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676230G>T | ClinVar |
RCV000696659 | p.Pro47Ter | frameshift | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676232del | ClinVar |
RCV000463583 | p.Pro47Thr | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676230G>T | ClinVar |
VAR_044569 | p.Pro47Leu | Missense | - | - | UniProt |
RCV000129395 | p.Asp48Glu | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676225G>T | ClinVar |
COSM5688468 | p.Asp48ThrPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7676227C>- | NCI-TCGA Cosmic |
COSM2745131 | p.Asp48Asn | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7676227C>T | NCI-TCGA Cosmic |
RCV000813083 | p.Asp48Glu | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676225G>T | ClinVar |
NCI-TCGA novel | p.Asp48GlyPheSerTerUnk | frameshift | - | NC_000017.11:g.7676228_7676229insG | NCI-TCGA |
NCI-TCGA novel | p.Asp48AsnPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7676218_7676227CAATATCGTC>- | NCI-TCGA |
rs587781460 | p.Asp48Glu | missense variant | - | NC_000017.11:g.7676225G>T | TOPMed |
VAR_044570 | p.Asp48Gly | Missense | - | - | UniProt |
rs587780728 | p.Asp49His | missense variant | - | NC_000017.11:g.7676224C>G | UniProt,dbSNP |
VAR_044571 | p.Asp49His | missense variant | - | NC_000017.11:g.7676224C>G | UniProt |
RCV000410497 | p.Asp49His | missense variant | Li-Fraumeni syndrome 1 (LFS) | NC_000017.11:g.7676224C>G | ClinVar |
RCV000129275 | p.Asp49His | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676224C>G | ClinVar |
RCV000165946 | p.Asp49Asn | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676224C>T | ClinVar |
rs587780728 | p.Asp49Asn | missense variant | - | NC_000017.11:g.7676224C>T | ExAC,gnomAD |
NCI-TCGA novel | p.Asp49SerPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7676209_7676224ACCATTGTTCAATATC>- | NCI-TCGA |
rs587780728 | p.Asp49His | missense variant | - | NC_000017.11:g.7676224C>G | ExAC,gnomAD |
rs587780728 | p.Asp49Asn | missense variant | - | NC_000017.11:g.7676224C>T | UniProt,dbSNP |
VAR_044572 | p.Asp49Asn | missense variant | - | NC_000017.11:g.7676224C>T | UniProt |
rs759728549 | p.Asp49Gly | missense variant | - | NC_000017.11:g.7676223T>C | ExAC,gnomAD |
RCV000219898 | p.Asp49Gly | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676223T>C | ClinVar |
RCV000702036 | p.Asp49Gly | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676223T>C | ClinVar |
RCV000123095 | p.Asp49His | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676224C>G | ClinVar |
VAR_044573 | p.Asp49Tyr | Missense | - | - | UniProt |
RCV000662678 | p.Ile50Thr | missense variant | Li-Fraumeni syndrome 1 (LFS) | NC_000017.11:g.7676220A>G | ClinVar |
RCV000220760 | p.Ile50Thr | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676220A>G | ClinVar |
rs370502517 | p.Ile50Thr | missense variant | - | NC_000017.11:g.7676220A>G | ESP,TOPMed |
rs370502517 | p.Ile50Asn | missense variant | - | NC_000017.11:g.7676220A>T | ESP,TOPMed |
RCV000633380 | p.Ile50Asn | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676220A>T | ClinVar |
RCV000197538 | p.Ile50Thr | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676220A>G | ClinVar |
RCV000167020 | p.Ile50Asn | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676220A>T | ClinVar |
COSM112062 | p.Glu51GlyPheSerTerUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7676217_7676218insC | NCI-TCGA Cosmic |
NCI-TCGA novel | p.Glu51HisPheSerTerUnk | frameshift | - | NC_000017.11:g.7676208_7676218AACCATTGTTC>- | NCI-TCGA |
RCV000689241 | p.Glu51Ter | nonsense | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676218C>A | ClinVar |
RCV000700746 | p.Glu51Gly | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676217T>C | ClinVar |
COSM1750375 | p.Gln52Ter | stop gained | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7676215G>A | NCI-TCGA Cosmic |
RCV000562350 | p.Gln52Arg | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676214T>C | ClinVar |
rs1195793509 | p.GlnTrp52GlnTerMetUnk | stop gained | - | NC_000017.11:g.7676211_7676214dup | gnomAD |
rs587782609 | p.GlnTrp52GlnTerTrp | stop gained | - | NC_000017.11:g.7676212_7676214dup | - |
rs774656101 | p.Gln52Arg | missense variant | - | NC_000017.11:g.7676214T>C | ExAC,gnomAD |
RCV000633379 | p.Gln52Ter | frameshift | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676213_7676214del | ClinVar |
RCV000785248 | p.Gln52Ter | frameshift | Ovarian Neoplasms | NC_000017.11:g.7676217dup | ClinVar |
RCV000227571 | p.Gln52Arg | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676214T>C | ClinVar |
VAR_044574 | p.Gln52His | Missense | - | - | UniProt |
RCV000785268 | p.Trp53Ter | nonsense | Ovarian Neoplasms | NC_000017.11:g.7676211_7676214dup | ClinVar |
RCV000480240 | p.Trp53Ter | nonsense | - | NC_000017.11:g.7676210C>T | ClinVar |
RCV000222677 | p.Trp53Ter | nonsense | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676211C>T | ClinVar |
COSM1162685 | p.Trp53Ter | stop gained | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7676210_7676211insCATT | NCI-TCGA Cosmic |
COSM5079662 | p.Trp53MetPheSerTerUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7676212_7676213insT | NCI-TCGA Cosmic |
RCV000131982 | p.Trp53Ter | nonsense | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676212_7676214dup | ClinVar |
NCI-TCGA novel | p.Trp53CysPheSerTerUnk | frameshift | - | NC_000017.11:g.7676210_7676211insA | NCI-TCGA |
RCV000785314 | p.Trp53Ter | nonsense | Ovarian Neoplasms | NC_000017.11:g.7676211C>T | ClinVar |
rs1064794618 | p.Trp53Ter | stop gained | - | NC_000017.11:g.7676210C>T | - |
rs876658483 | p.Trp53Ter | stop gained | - | NC_000017.11:g.7676211C>T | - |
RCV000528831 | p.Trp53Ter | frameshift | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676214dup | ClinVar |
RCV000693351 | p.Trp53Ter | nonsense | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676211C>T | ClinVar |
VAR_005854 | p.Trp53Cys | Missense | - | - | UniProt |
VAR_044575 | p.Trp53Gly | Missense | - | - | UniProt |
rs1555526742 | p.Phe54Leu | missense variant | - | NC_000017.11:g.7676209A>G | UniProt,dbSNP |
VAR_044576 | p.Phe54Leu | missense variant | - | NC_000017.11:g.7676209A>G | UniProt |
rs1555526742 | p.Phe54Leu | missense variant | - | NC_000017.11:g.7676209A>G | - |
COSM5271791 | p.Phe54SerPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7676208A>- | NCI-TCGA Cosmic |
RCV000571144 | p.Phe54Leu | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676209A>G | ClinVar |
VAR_044577 | p.Phe54Tyr | Missense | - | - | UniProt |
COSM5024964 | p.Glu56LysPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7676203C>- | NCI-TCGA Cosmic |
COSM12168 | p.Glu56Ter | stop gained | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7676203C>A | NCI-TCGA Cosmic |
NCI-TCGA novel | p.Glu56LysPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7676204A>- | NCI-TCGA |
VAR_044579 | p.Glu56Val | Missense | - | - | UniProt |
VAR_044578 | p.Glu56Lys | Missense | - | - | UniProt |
RCV000411346 | p.Asp57Glu | missense variant | Li-Fraumeni syndrome 1 (LFS) | NC_000017.11:g.7676198G>T | ClinVar |
COSM5990594 | p.Asp57Asn | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7676200C>T | NCI-TCGA Cosmic |
RCV000132310 | p.Asp57Glu | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676198G>T | ClinVar |
NCI-TCGA novel | p.Asp57LysPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7676200_7676201insTT | NCI-TCGA |
rs1442824382 | p.Asp57Gly | missense variant | - | NC_000017.11:g.7676199T>C | gnomAD |
rs587782776 | p.Asp57Glu | missense variant | - | NC_000017.11:g.7676198G>T | TOPMed |
rs144386518 | p.Pro58Arg | missense variant | - | NC_000017.11:g.7676196G>C | ESP,ExAC,TOPMed,gnomAD |
RCV000662515 | p.Pro58Arg | missense variant | Li-Fraumeni syndrome 1 (LFS) | NC_000017.11:g.7676196G>C | ClinVar |
COSM2745096 | p.Pro58GlnPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7676196G>- | NCI-TCGA Cosmic |
VAR_044580 | p.Pro58Gln | Missense | - | - | UniProt |
VAR_044581 | p.Pro58Thr | Missense | - | - | UniProt |
RCV000785292 | p.Gly59Ter | frameshift | Ovarian Neoplasms | NC_000017.11:g.7676194del | ClinVar |
rs1237722021 | p.Gly59Cys | missense variant | - | NC_000017.11:g.7676194C>A | gnomAD |
VAR_045783 | p.Gly59Asn | Missense | - | - | UniProt |
VAR_044583 | p.Gly59Asp | Missense | - | - | UniProt |
COSM295960 | p.Pro60GlnPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7676190G>- | NCI-TCGA Cosmic |
VAR_044584 | p.Pro60Leu | Missense | - | - | UniProt |
VAR_005855 | p.Pro60Ser | Missense | - | - | UniProt |
VAR_044585 | p.Pro60Gln | Missense | - | - | UniProt |
rs1460793472 | p.Asp61Gly | missense variant | - | NC_000017.11:g.7676187T>C | TOPMed,gnomAD |
rs1460793472 | p.Asp61Gly | missense variant | - | NC_000017.11:g.7676187T>C | UniProt,dbSNP |
VAR_044586 | p.Asp61Gly | missense variant | - | NC_000017.11:g.7676187T>C | UniProt |
COSM984979 | p.Asp61Ter | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7676187_7676188TC>- | NCI-TCGA Cosmic |
VAR_044587 | p.Asp61Asn | Missense | - | - | UniProt |
COSM116688 | p.Glu62Lys | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7676185C>T | NCI-TCGA Cosmic |
NCI-TCGA novel | p.Glu62LysPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7676185C>- | NCI-TCGA |
RCV000754578 | p.Glu62Ter | nonsense | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676185C>A | ClinVar |
VAR_044588 | p.Glu62Asp | Missense | - | - | UniProt |
rs372201428 | p.Ala63Gly | missense variant | - | NC_000017.11:g.7676181G>C | ExAC,gnomAD |
RCV000614877 | p.Ala63Gly | missense variant | - | NC_000017.11:g.7676181G>C | ClinVar |
RCV000663264 | p.Ala63Val | missense variant | Li-Fraumeni syndrome 1 (LFS) | NC_000017.11:g.7676181G>A | ClinVar |
RCV000216082 | p.Ala63Gly | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676181G>C | ClinVar |
RCV000467874 | p.Ala63Val | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676181G>A | ClinVar |
rs876658902 | p.Ala63Thr | missense variant | - | NC_000017.11:g.7676182C>T | - |
rs876658902 | p.Ala63Thr | missense variant | - | NC_000017.11:g.7676182C>T | UniProt,dbSNP |
VAR_044589 | p.Ala63Thr | missense variant | - | NC_000017.11:g.7676182C>T | UniProt |
rs372201428 | p.Ala63Val | missense variant | - | NC_000017.11:g.7676181G>A | ExAC,gnomAD |
rs372201428 | p.Ala63Val | missense variant | - | NC_000017.11:g.7676181G>A | UniProt,dbSNP |
VAR_044590 | p.Ala63Val | missense variant | - | NC_000017.11:g.7676181G>A | UniProt |
RCV000161018 | p.Ala63Val | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676181G>A | ClinVar |
RCV000587780 | p.Ala63Gly | missense variant | - | NC_000017.11:g.7676181G>C | ClinVar |
RCV000213047 | p.Ala63Val | missense variant | - | NC_000017.11:g.7676181G>A | ClinVar |
RCV000465288 | p.Ala63Gly | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676181G>C | ClinVar |
RCV000213479 | p.Ala63Thr | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676182C>T | ClinVar |
COSM4866240 | p.Pro64Thr | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7676179G>T | NCI-TCGA Cosmic |
NCI-TCGA novel | p.Pro64Ser | missense variant | - | NC_000017.11:g.7676179G>A | NCI-TCGA |
NCI-TCGA novel | p.Pro64GlnPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7676179_7676180GA>- | NCI-TCGA |
RCV000471826 | p.Arg65Thr | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676175C>G | ClinVar |
COSM5752247 | p.Arg65GluPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7676177G>- | NCI-TCGA Cosmic |
COSM1159553 | p.Arg65GlnPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7676176_7676177insG | NCI-TCGA Cosmic |
rs1060501210 | p.Arg65Thr | missense variant | - | NC_000017.11:g.7676175C>G | - |
RCV000785253 | p.Arg65Ter | nonsense | Ovarian Neoplasms | NC_000017.11:g.7676176T>A | ClinVar |
rs1555526711 | p.Met66Ile | missense variant | - | NC_000017.11:g.7676171C>T | UniProt,dbSNP |
VAR_044592 | p.Met66Ile | missense variant | - | NC_000017.11:g.7676171C>T | UniProt |
rs1555526711 | p.Met66Ile | missense variant | - | NC_000017.11:g.7676171C>T | - |
NCI-TCGA novel | p.Met66IlePheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7676171_7676172insATTCTGGG | NCI-TCGA |
RCV000565744 | p.Met66Ile | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676171C>T | ClinVar |
VAR_044593 | p.Met66Arg | Missense | - | - | UniProt |
COSM44199 | p.Pro67Ser | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7676170G>A | NCI-TCGA Cosmic |
NCI-TCGA novel | p.Pro67ArgPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7676153_7676169GGGGGGAGCAGCCTCTG>- | NCI-TCGA |
rs1555526709 | p.Pro67Gln | missense variant | - | NC_000017.11:g.7676169G>T | - |
RCV000633377 | p.Pro67Gln | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676169G>T | ClinVar |
VAR_044594 | p.Pro67Leu | Missense | - | - | UniProt |
VAR_044595 | p.Pro67Arg | Missense | - | - | UniProt |
VAR_044596 | p.Pro67Ser | Missense | - | - | UniProt |
RCV000580822 | p.Glu68Gln | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676167C>G | ClinVar |
RCV000210192 | p.Glu68Ter | nonsense | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676167C>A | ClinVar |
VAR_044598 | p.Glu68Gln | Missense | - | - | UniProt |
VAR_044597 | p.Glu68Gly | Missense | - | - | UniProt |
rs756233241 | p.Ala69Gly | missense variant | - | NC_000017.11:g.7676163G>C | UniProt,dbSNP |
VAR_044600 | p.Ala69Gly | missense variant | - | NC_000017.11:g.7676163G>C | UniProt |
RCV000222309 | p.Ala69Gly | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676163G>C | ClinVar |
RCV000698086 | p.Ala69Thr | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676164C>T | ClinVar |
NCI-TCGA novel | p.Ala69GlyPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7676163_7676164insC | NCI-TCGA |
rs756233241 | p.Ala69Val | missense variant | - | NC_000017.11:g.7676163G>A | UniProt,dbSNP |
VAR_044602 | p.Ala69Val | missense variant | - | NC_000017.11:g.7676163G>A | UniProt |
RCV000633366 | p.Ala69Val | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676163G>A | ClinVar |
VAR_044601 | p.Ala69Thr | Missense | - | - | UniProt |
VAR_044599 | p.Ala69Asp | Missense | - | - | UniProt |
COSM44736 | p.Ala70Thr | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7676161C>T | NCI-TCGA Cosmic |
RCV000774900 | p.Ala70Val | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676160G>A | ClinVar |
VAR_044603 | p.Ala70Thr | Missense | - | - | UniProt |
RCV000230713 | p.Pro71Arg | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676157G>C | ClinVar |
COSM5926982 | p.Pro71Leu | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7676157G>A | NCI-TCGA Cosmic |
RCV000700185 | p.Pro71Ala | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676158G>C | ClinVar |
rs878854065 | p.Pro71Arg | missense variant | - | NC_000017.11:g.7676157G>C | - |
RCV000693744 | p.Pro71Ser | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676158G>A | ClinVar |
RCV000771703 | p.Pro71Ser | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676158G>A | ClinVar |
VAR_044604 | p.Pro71Thr | Missense | - | - | UniProt |
rs1042522 | p.Pro72His | missense variant | - | NC_000017.11:g.7676154G>T | 1000Genomes,ESP,ExAC,TOPMed,gnomAD |
rs1042522 | p.Pro72Arg | missense variant | - | NC_000017.11:g.7676154G>C | 1000Genomes,ESP,ExAC,TOPMed,gnomAD |
RCV000132165 | p.Pro72Arg | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676154G>C | ClinVar |
RCV000492601 | p.Pro72Ter | frameshift | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676154_7676155insC | ClinVar |
RCV000144668 | p.Pro72Arg | missense variant | Li-Fraumeni syndrome 1 (LFS) | NC_000017.11:g.7676154G>C | ClinVar |
RCV000079202 | p.Pro72Arg | missense variant | - | NC_000017.11:g.7676154G>C | ClinVar |
RCV000034639 | p.Pro72Arg | missense variant | - | NC_000017.11:g.7676154G>C | ClinVar |
RCV000164487 | p.Pro72His | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676154G>T | ClinVar |
RCV000300782 | p.Pro72Arg | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676154G>C | ClinVar |
RCV000223537 | p.Pro72Thr | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676155G>T | ClinVar |
RCV000409340 | p.Pro72Ala | missense variant | Li-Fraumeni syndrome 1 (LFS) | NC_000017.11:g.7676155G>C | ClinVar |
RCV000554325 | p.Pro72Cys | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676154_7676155delinsCA | ClinVar |
RCV000161055 | p.Pro72Cys | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676154_7676155delinsCA | ClinVar |
RCV000473980 | p.Pro72Ala | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676155G>C | ClinVar |
RCV000132297 | p.Pro72Ala | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676155G>C | ClinVar |
RCV000573116 | p.Pro72Ser | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676155G>A | ClinVar |
rs587782769 | p.Pro72Ser | missense variant | - | NC_000017.11:g.7676155G>A | ExAC,TOPMed,gnomAD |
rs1042522 | p.Pro72Arg | missense variant | - | NC_000017.11:g.7676154G>C | UniProt,dbSNP |
VAR_005856 | p.Pro72Arg | missense variant | - | NC_000017.11:g.7676154G>C | UniProt |
RCV000587915 | p.Pro72Cys | missense variant | - | NC_000017.11:g.7676154_7676155delinsCA | ClinVar |
RCV000233585 | p.Pro72Arg | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676153_7676154delinsAC | ClinVar |
rs878854066 | p.Pro72Arg | missense variant | - | NC_000017.11:g.7676153_7676154delinsAC | - |
rs1042522 | p.Pro72His | missense variant | - | NC_000017.11:g.7676154G>T | UniProt,dbSNP |
VAR_045786 | p.Pro72His | missense variant | - | NC_000017.11:g.7676154G>T | UniProt |
rs587782769 | p.Pro72Thr | missense variant | - | NC_000017.11:g.7676155G>T | ExAC,TOPMed,gnomAD |
rs587782769 | p.Pro72Ala | missense variant | - | NC_000017.11:g.7676155G>C | ExAC,TOPMed,gnomAD |
RCV000410841 | p.Pro72Cys | missense variant | Li-Fraumeni syndrome 1 (LFS) | NC_000017.11:g.7676154_7676155delinsCA | ClinVar |
RCV000478624 | p.Pro72Ala | missense variant | - | NC_000017.11:g.7676155G>C | ClinVar |
RCV000013144 | p.Pro72Arg | missense variant | CODON 72 POLYMORPHISM | NC_000017.11:g.7676154G>C | ClinVar |
RCV000227427 | p.Pro72His | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676154G>T | ClinVar |
rs730882014 | p.Pro72Cys | missense variant | - | NC_000017.11:g.7676154_7676155delinsCA | - |
RCV000780780 | p.Pro72Arg | missense variant | - | NC_000017.11:g.7676153_7676154delinsAC | ClinVar |
VAR_045787 | p.Pro72Leu | Missense | - | - | UniProt |
VAR_045785 | p.Pro72Gly | Missense | - | - | UniProt |
RCV000553568 | p.Val73Met | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676152C>T | ClinVar |
RCV000785475 | p.Val73Ter | frameshift | Ovarian Neoplasms | NC_000017.11:g.7676158del | ClinVar |
COSM1268331 | p.Val73TrpPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7676153G>- | NCI-TCGA Cosmic |
RCV000161059 | p.Val73Ter | frameshift | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676158dup | ClinVar |
RCV000538223 | p.Val73Ter | frameshift | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676158dup | ClinVar |
RCV000492385 | p.Val73Ter | frameshift | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676158del | ClinVar |
RCV000013157 | p.Val73Ter | frameshift | Li-Fraumeni-like syndrome (LFL) | NC_000017.11:g.7676158dup | ClinVar |
rs587782423 | p.Val73Met | missense variant | - | NC_000017.11:g.7676152C>T | ExAC,TOPMed,gnomAD |
rs587782423 | p.Val73Met | missense variant | - | NC_000017.11:g.7676152C>T | UniProt,dbSNP |
VAR_044607 | p.Val73Met | missense variant | - | NC_000017.11:g.7676152C>T | UniProt |
rs730882018 | p.Val73ArgPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7676152_7676153insG | NCI-TCGA,NCI-TCGA Cosmic |
VAR_044606 | p.Val73Leu | Missense | - | - | UniProt |
VAR_044605 | p.Val73Glu | Missense | - | - | UniProt |
RCV000130119 | p.Ala74Val | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676148G>A | ClinVar |
rs587781832 | p.Ala74Val | missense variant | - | NC_000017.11:g.7676148G>A | ExAC,gnomAD |
RCV000487230 | p.Ala74Val | missense variant | - | NC_000017.11:g.7676148G>A | ClinVar |
RCV000816275 | p.Ala74Val | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676148G>A | ClinVar |
VAR_044608 | p.Ala74Thr | Missense | - | - | UniProt |
COSM166227 | p.Pro75LeuPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7676145G>- | NCI-TCGA Cosmic |
VAR_044610 | p.Pro75Arg | Missense | - | - | UniProt |
VAR_044609 | p.Pro75Leu | Missense | - | - | UniProt |
VAR_044611 | p.Pro75Ser | Missense | - | - | UniProt |
COSM69022 | p.Ala76HisPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7676144A>- | NCI-TCGA Cosmic |
rs1235781676 | p.Ala76Glu | missense variant | - | NC_000017.11:g.7676142G>T | gnomAD |
NCI-TCGA novel | p.Ala76HisPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7676143C>- | NCI-TCGA |
RCV000785450 | p.Ala76Ter | frameshift | Ovarian Neoplasms | NC_000017.11:g.7676148dup | ClinVar |
RCV000492268 | p.Ala76Ter | frameshift | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676099_7676151del | ClinVar |
VAR_044613 | p.Ala76Thr | Missense | - | - | UniProt |
VAR_044612 | p.Ala76Gly | Missense | - | - | UniProt |
rs753085009 | p.Pro77Ser | missense variant | - | NC_000017.11:g.7676140G>A | ExAC,gnomAD |
COSM6082218 | p.Pro77Leu | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7676139G>A | NCI-TCGA Cosmic |
COSM5833437 | p.Pro77CysPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7676140_7676141insTGCA | NCI-TCGA Cosmic |
RCV000633383 | p.Pro77Ser | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676140G>A | ClinVar |
NCI-TCGA novel | p.Pro77GlyPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7676122_7676141CCGGTGTAGGAGCTGCTGGT>- | NCI-TCGA |
rs753085009 | p.Pro77Thr | missense variant | - | NC_000017.11:g.7676140G>T | ExAC,gnomAD |
RCV000546598 | p.Pro77Thr | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676140G>T | ClinVar |
RCV000563835 | p.Pro77Thr | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676140G>T | ClinVar |
VAR_044614 | p.Pro77Ala | Missense | - | - | UniProt |
NCI-TCGA novel | p.Ala78Pro | insertion | - | NC_000017.11:g.7676135_7676136insGGG | NCI-TCGA |
RCV000573984 | p.Ala78Thr | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676137C>T | ClinVar |
rs876658527 | p.Ala78Gly | missense variant | - | NC_000017.11:g.7676136G>C | TOPMed,gnomAD |
rs1555526673 | p.Ala78Thr | missense variant | - | NC_000017.11:g.7676137C>T | - |
RCV000552207 | p.Ala78Gly | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676136G>C | ClinVar |
RCV000219512 | p.Ala78Gly | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676136G>C | ClinVar |
VAR_044615 | p.Ala78Val | Missense | - | - | UniProt |
COSM1386920 | p.Ala79Val | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7676133G>A | NCI-TCGA Cosmic |
NCI-TCGA novel | p.Ala79SerPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7676134_7676135CT>- | NCI-TCGA |
NCI-TCGA novel | p.Ala79ArgPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7676123_7676135CGGTGTAGGAGCT>- | NCI-TCGA |
NCI-TCGA novel | p.Ala79Pro | missense variant | - | NC_000017.11:g.7676134C>G | NCI-TCGA |
VAR_044616 | p.Ala79Gly | Missense | - | - | UniProt |
VAR_044617 | p.Ala79Val | Missense | - | - | UniProt |
VAR_005857 | p.Ala79Thr | Missense | - | - | UniProt |
RCV000566683 | p.Pro80Ser | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676131G>A | ClinVar |
RCV000477161 | p.Pro80Ser | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676131G>A | ClinVar |
NCI-TCGA novel | p.Pro80SerPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7676132_7676133insG | NCI-TCGA |
rs1060501204 | p.Pro80Ser | missense variant | - | NC_000017.11:g.7676131G>A | - |
VAR_044618 | p.Pro80Leu | Missense | - | - | UniProt |
RCV000707346 | p.Thr81Ile | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676127G>A | ClinVar |
VAR_044620 | p.Thr81Ile | Missense | - | - | UniProt |
RCV000545821 | p.Pro82Arg | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676124G>C | ClinVar |
COSM4603762 | p.Pro82ArgPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7676124G>- | NCI-TCGA Cosmic |
RCV000213048 | p.Pro82Leu | missense variant | - | NC_000017.11:g.7676124G>A | ClinVar |
RCV000205955 | p.Pro82Leu | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676124G>A | ClinVar |
rs534447939 | p.Pro82Arg | missense variant | - | NC_000017.11:g.7676124G>C | ExAC,TOPMed,gnomAD |
rs1555526664 | p.Pro82Ala | missense variant | - | NC_000017.11:g.7676125G>C | - |
rs534447939 | p.Pro82Leu | missense variant | - | NC_000017.11:g.7676124G>A | ExAC,TOPMed,gnomAD |
rs534447939 | p.Pro82Leu | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676124G>A | UniProt,dbSNP |
VAR_044621 | p.Pro82Leu | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676124G>A | UniProt |
RCV000573848 | p.Pro82Ala | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676125G>C | ClinVar |
VAR_044622 | p.Pro82Ser | Missense | - | - | UniProt |
rs201717599 | p.Ala83Val | missense variant | - | NC_000017.11:g.7676121G>A | UniProt,dbSNP |
VAR_044624 | p.Ala83Val | missense variant | - | NC_000017.11:g.7676121G>A | UniProt |
RCV000492289 | p.Ala83Ter | frameshift | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676121_7676122del | ClinVar |
RCV000130694 | p.Ala83Glu | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676121G>T | ClinVar |
RCV000409540 | p.Ala83Val | missense variant | Li-Fraumeni syndrome 1 (LFS) | NC_000017.11:g.7676121G>A | ClinVar |
RCV000785483 | p.Ala83Ter | frameshift | Ovarian Neoplasms | NC_000017.11:g.7676118_7676125del | ClinVar |
RCV000657303 | p.Ala83Ter | frameshift | - | NC_000017.11:g.7676114_7676123del | ClinVar |
NCI-TCGA novel | p.Ala83GlyPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7676121_7676122insC | NCI-TCGA |
rs201717599 | p.Ala83Glu | missense variant | - | NC_000017.11:g.7676121G>T | 1000Genomes,ExAC,TOPMed,gnomAD |
rs201717599 | p.Ala83Glu | missense variant | - | NC_000017.11:g.7676121G>T | UniProt,dbSNP |
VAR_044623 | p.Ala83Glu | missense variant | - | NC_000017.11:g.7676121G>T | UniProt |
rs201717599 | p.Ala83Val | missense variant | - | NC_000017.11:g.7676121G>A | 1000Genomes,ExAC,TOPMed,gnomAD |
RCV000679367 | p.Ala83Val | missense variant | - | NC_000017.11:g.7676121G>A | ClinVar |
RCV000785281 | p.Ala83Ter | frameshift | Ovarian Neoplasms | NC_000017.11:g.7676123del | ClinVar |
RCV000759372 | p.Ala84Thr | missense variant | - | NC_000017.11:g.7676119C>T | ClinVar |
COSM5639468 | p.Ala84ProPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7676119C>- | NCI-TCGA Cosmic |
RCV000462026 | p.Ala84Thr | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676119C>T | ClinVar |
RCV000129026 | p.Ala84Thr | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676119C>T | ClinVar |
rs587781307 | p.Ala84Thr | missense variant | - | NC_000017.11:g.7676119C>T | ExAC,TOPMed,gnomAD |
RCV000409852 | p.Ala84Thr | missense variant | Li-Fraumeni syndrome 1 (LFS) | NC_000017.11:g.7676119C>T | ClinVar |
VAR_044625 | p.Ala84Gly | Missense | - | - | UniProt |
VAR_044626 | p.Ala84Val | Missense | - | - | UniProt |
NCI-TCGA novel | p.Pro85LeuPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7676115G>- | NCI-TCGA |
RCV000486807 | p.Pro85Ter | frameshift | - | NC_000017.11:g.7676118del | ClinVar |
VAR_044627 | p.Pro85Leu | Missense | - | - | UniProt |
VAR_044628 | p.Pro85Ser | Missense | - | - | UniProt |
COSM69021 | p.Ala86ProPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7676105_7676114GGCTGGTGCA>- | NCI-TCGA Cosmic |
COSM1480096 | p.Ala86CysPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7676114_7676115insG | NCI-TCGA Cosmic |
COSM5546781 | p.Ala86ValPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7676090_7676112CAGGGGCCAGGAGGGGGCTGGTG>- | NCI-TCGA Cosmic |
RCV000478688 | p.Ala86Thr | missense variant | - | NC_000017.11:g.7676113C>T | ClinVar |
RCV000365382 | p.Ala86Ter | frameshift | - | NC_000017.11:g.7676098_7676120del | ClinVar |
rs587782148 | p.Ala86Thr | missense variant | - | NC_000017.11:g.7676113C>T | - |
RCV000633343 | p.Ala86Thr | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676113C>T | ClinVar |
RCV000709410 | p.Ala86Ter | frameshift | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676098_7676120del | ClinVar |
VAR_044629 | p.Ala86Val | Missense | - | - | UniProt |
RCV000785459 | p.Pro87Ter | frameshift | Ovarian Neoplasms | NC_000017.11:g.7676100_7676110del | ClinVar |
VAR_005858 | p.Pro87Gln | Missense | - | - | UniProt |
RCV000565147 | p.Ala88Val | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676106G>A | ClinVar |
rs1555526631 | p.Ala88Val | missense variant | - | NC_000017.11:g.7676106G>A | - |
rs1555526631 | p.Ala88Val | missense variant | - | NC_000017.11:g.7676106G>A | UniProt,dbSNP |
VAR_044631 | p.Ala88Val | missense variant | - | NC_000017.11:g.7676106G>A | UniProt |
RCV000773977 | p.Ala88Pro | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676107C>G | ClinVar |
VAR_044630 | p.Ala88Thr | Missense | - | - | UniProt |
RCV000560488 | p.Pro89Leu | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676103G>A | ClinVar |
RCV000161019 | p.Pro89Leu | missense variant | - | NC_000017.11:g.7676103G>A | ClinVar |
rs730881994 | p.Pro89Leu | missense variant | - | NC_000017.11:g.7676103G>A | - |
VAR_044633 | p.Pro89Ser | Missense | - | - | UniProt |
RCV000144663 | p.Ser90Ter | frameshift | Li-Fraumeni syndrome 1 (LFS) | NC_000017.11:g.7676106del | ClinVar |
COSM5211825 | p.Ser90ProPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7676101A>- | NCI-TCGA Cosmic |
NCI-TCGA novel | p.Ser90ProPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7676101_7676102insGG | NCI-TCGA |
NCI-TCGA novel | p.Ser90ValPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7676092_7676102GGGGCCAGGAG>- | NCI-TCGA |
NCI-TCGA novel | p.Ser90PhePheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7676084_7676100AGATGACAGGGGCCAGG>- | NCI-TCGA |
rs1555526625 | p.Ser90Phe | missense variant | - | NC_000017.11:g.7676100G>A | - |
rs1555526625 | p.Ser90Phe | missense variant | - | NC_000017.11:g.7676100G>A | UniProt,dbSNP |
VAR_044634 | p.Ser90Phe | missense variant | - | NC_000017.11:g.7676100G>A | UniProt |
rs587783062 | p.Ser90ProPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7676102G>- | NCI-TCGA,NCI-TCGA Cosmic |
RCV000633387 | p.Ser90Phe | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676100G>A | ClinVar |
RCV000785494 | p.Ser90Ter | frameshift | Ovarian Neoplasms | NC_000017.11:g.7676106dup | ClinVar |
VAR_044635 | p.Ser90Tyr | Missense | - | - | UniProt |
RCV000479803 | p.Trp91Ter | frameshift | - | NC_000017.11:g.7676094_7676100del | ClinVar |
COSM323933 | p.Trp91Ter | stop gained | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7676097C>T | NCI-TCGA Cosmic |
rs876660548 | p.Trp91Ter | stop gained | - | NC_000017.11:g.7676096C>T | - |
RCV000785284 | p.Trp91Ter | nonsense | Ovarian Neoplasms | NC_000017.11:g.7676096C>T | ClinVar |
RCV000220815 | p.Trp91Ter | nonsense | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676096C>T | ClinVar |
RCV000657656 | p.Trp91Ter | nonsense | - | NC_000017.11:g.7676096C>T | ClinVar |
RCV000233967 | p.Trp91Ter | nonsense | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676096C>T | ClinVar |
VAR_044636 | p.Trp91Cys | Missense | - | - | UniProt |
RCV000566433 | p.Pro92Leu | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676094G>A | ClinVar |
RCV000811514 | p.Pro92Leu | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676094G>A | ClinVar |
NCI-TCGA novel | p.Pro92AlaPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7676095_7676096insC | NCI-TCGA |
rs1210700121 | p.Pro92Leu | missense variant | - | NC_000017.11:g.7676094G>A | gnomAD |
rs1210700121 | p.Pro92Leu | missense variant | - | NC_000017.11:g.7676094G>A | UniProt,dbSNP |
VAR_044638 | p.Pro92Leu | missense variant | - | NC_000017.11:g.7676094G>A | UniProt |
VAR_044639 | p.Pro92Ser | Missense | - | - | UniProt |
VAR_044637 | p.Pro92Ala | Missense | - | - | UniProt |
COSM5833432 | p.Leu93ValPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7676091_7676092AG>- | NCI-TCGA Cosmic |
RCV000785287 | p.Leu93Ter | frameshift | Ovarian Neoplasms | NC_000017.11:g.7676091del | ClinVar |
RCV000785294 | p.Leu93Ter | frameshift | Ovarian Neoplasms | NC_000017.11:g.7676095del | ClinVar |
VAR_044640 | p.Leu93Met | Missense | - | - | UniProt |
VAR_044641 | p.Leu93Pro | Missense | - | - | UniProt |
COSM1564166 | p.Ser94CysPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7676088_7676089insAC | NCI-TCGA Cosmic |
COSM2745056 | p.Ser94Ter | stop gained | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7676088G>C | NCI-TCGA Cosmic |
COSM1386891 | p.Ser94Ter | stop gained | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7676088G>T | NCI-TCGA Cosmic |
VAR_044642 | p.Ser94Leu | Missense | - | - | UniProt |
VAR_005859 | p.Ser94Thr | Missense | - | - | UniProt |
RCV000785322 | p.Ser95Ter | frameshift | Ovarian Neoplasms | NC_000017.11:g.7676082_7676086del | ClinVar |
VAR_044643 | p.Ser95Phe | Missense | - | - | UniProt |
VAR_044644 | p.Ser95Thr | Missense | - | - | UniProt |
NCI-TCGA novel | p.Ser96PhePheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7676076_7676082GGGACAG>- | NCI-TCGA |
VAR_044647 | p.Ser96Pro | Missense | - | - | UniProt |
VAR_044645 | p.Ser96Cys | Missense | - | - | UniProt |
VAR_044646 | p.Ser96Phe | Missense | - | - | UniProt |
rs730882023 | p.Val97Ile | missense variant | - | NC_000017.11:g.7676080C>T | gnomAD |
RCV000161064 | p.Val97Leu | missense variant | - | NC_000017.11:g.7676080C>G | ClinVar |
NCI-TCGA novel | p.Val97SerPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7676081A>- | NCI-TCGA |
NCI-TCGA novel | p.Val97GluPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7676071_7676081GGGAAGGGACA>- | NCI-TCGA |
NCI-TCGA novel | p.Val97SerPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7676080C>- | NCI-TCGA |
RCV000545045 | p.Val97Phe | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676080C>A | ClinVar |
rs730882023 | p.Val97Phe | missense variant | - | NC_000017.11:g.7676080C>A | gnomAD |
rs730882023 | p.Val97Leu | missense variant | - | NC_000017.11:g.7676080C>G | gnomAD |
rs730881995 | p.Val97Asp | missense variant | - | NC_000017.11:g.7676079A>T | - |
RCV000161020 | p.Val97Asp | missense variant | - | NC_000017.11:g.7676079A>T | ClinVar |
VAR_044649 | p.Val97Phe | Missense | - | - | UniProt |
VAR_044648 | p.Val97Ala | Missense | - | - | UniProt |
RCV000633328 | p.Pro98Leu | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676076G>A | ClinVar |
NCI-TCGA novel | p.Pro98LeuPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7676076G>- | NCI-TCGA |
NCI-TCGA novel | p.Pro98AlaPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7676077_7676078insC | NCI-TCGA |
rs1245723119 | p.Pro98Leu | missense variant | - | NC_000017.11:g.7676076G>A | gnomAD |
rs1245723119 | p.Pro98Leu | missense variant | - | NC_000017.11:g.7676076G>A | UniProt,dbSNP |
VAR_044651 | p.Pro98Leu | missense variant | - | NC_000017.11:g.7676076G>A | UniProt |
VAR_044652 | p.Pro98Ser | Missense | - | - | UniProt |
RCV000161056 | p.Ser99Ter | frameshift | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676074_7676077del | ClinVar |
RCV000702643 | p.Ser99Phe | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676073G>A | ClinVar |
RCV000686905 | p.Ser99Cys | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676073G>C | ClinVar |
RCV000633340 | p.Ser99Ter | frameshift | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676075del | ClinVar |
rs730882015 | p.Ser99ArgPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7676072_7676075GGAA>- | NCI-TCGA,NCI-TCGA Cosmic |
VAR_044653 | p.Ser99Phe | Missense | - | - | UniProt |
VAR_044654 | p.Ser99Pro | Missense | - | - | UniProt |
RCV000785260 | p.Gln100Ter | frameshift | Ovarian Neoplasms | NC_000017.11:g.7676073del | ClinVar |
RCV000785339 | p.Gln100Ter | nonsense | Ovarian Neoplasms | NC_000017.11:g.7676071G>A | ClinVar |
VAR_044655 | p.Gln100Arg | Missense | - | - | UniProt |
rs878854069 | p.Lys101Asn | missense variant | - | NC_000017.11:g.7676066T>A | UniProt,dbSNP |
VAR_044656 | p.Lys101Asn | missense variant | - | NC_000017.11:g.7676066T>A | UniProt |
rs878854069 | p.Lys101Asn | missense variant | - | NC_000017.11:g.7676066T>A | - |
rs1373046761 | p.Lys101Glu | missense variant | - | NC_000017.11:g.7676068T>C | TOPMed |
RCV000234638 | p.Lys101Asn | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676066T>A | ClinVar |
COSM2745038 | p.Lys101Ter | stop gained | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7676068T>A | NCI-TCGA Cosmic |
RCV000776369 | p.Lys101Asn | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676066T>A | ClinVar |
VAR_044657 | p.Lys101Arg | Missense | - | - | UniProt |
RCV000819967 | p.Thr102Ile | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676064G>A | ClinVar |
COSM45766 | p.Thr102ProPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7676065T>- | NCI-TCGA Cosmic |
RCV000771730 | p.Thr102Ser | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676065T>A | ClinVar |
rs786202717 | p.Thr102Ile | missense variant | - | NC_000017.11:g.7676064G>A | - |
rs786202717 | p.Thr102Ile | missense variant | - | NC_000017.11:g.7676064G>A | UniProt,dbSNP |
VAR_044658 | p.Thr102Ile | missense variant | - | NC_000017.11:g.7676064G>A | UniProt |
RCV000706015 | p.Thr102Ser | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676065T>A | ClinVar |
RCV000165667 | p.Thr102Ile | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676064G>A | ClinVar |
rs1555526589 | p.Tyr103His | missense variant | - | NC_000017.11:g.7676062A>G | - |
COSM1716938 | p.Tyr103ThrPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7676063G>- | NCI-TCGA Cosmic |
COSM1645399 | p.Tyr103Ter | stop gained | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7676060G>C | NCI-TCGA Cosmic |
COSM1646882 | p.Tyr103Ter | stop gained | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7676060G>T | NCI-TCGA Cosmic |
NCI-TCGA novel | p.Tyr103LeuPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7676061_7676062insA | NCI-TCGA |
NCI-TCGA novel | p.Tyr103ThrPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7676062A>- | NCI-TCGA |
RCV000559575 | p.Tyr103His | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676062A>G | ClinVar |
RCV000785246 | p.Gln104Ter | frameshift | Ovarian Neoplasms | NC_000017.11:g.7676060del | ClinVar |
RCV000570916 | p.Gln104Ter | frameshift | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676040_7676059del | ClinVar |
NCI-TCGA novel | p.Gln104ThrPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7676059_7676060insGT | NCI-TCGA |
RCV000785541 | p.Gln104Ter | nonsense | Ovarian Neoplasms | NC_000017.11:g.7676059G>A | ClinVar |
RCV000686865 | p.Gln104Ter | nonsense | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676059G>A | ClinVar |
VAR_044659 | p.Gln104His | Missense | - | - | UniProt |
VAR_044660 | p.Gln104Leu | Missense | - | - | UniProt |
RCV000492331 | p.Gly105Ser | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676056C>T | ClinVar |
RCV000492606 | p.Gly105Arg | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676056C>G | ClinVar |
COSM338570 | p.Gly105Cys | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7676056C>A | NCI-TCGA Cosmic |
RCV000785342 | p.Gly105Val | missense variant | Ovarian Neoplasms | NC_000017.11:g.7676055C>A | ClinVar |
rs587781504 | p.Gly105Asp | missense variant | - | NC_000017.11:g.7676055C>T | TOPMed,gnomAD |
RCV000727568 | p.Gly105Ter | frameshift | - | NC_000017.11:g.7676057del | ClinVar |
rs1060501195 | p.Gly105Arg | missense variant | - | NC_000017.11:g.7676056C>G | - |
rs587781504 | p.Gly105Asp | missense variant | - | NC_000017.11:g.7676055C>T | UniProt,dbSNP |
VAR_044662 | p.Gly105Asp | missense variant | - | NC_000017.11:g.7676055C>T | UniProt |
RCV000228756 | p.Gly105Asp | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676055C>T | ClinVar |
VAR_044661 | p.Gly105Cys | Missense | Li-Fraumeni syndrome (LFS) [MIM:151623] | - | UniProt |
VAR_044665 | p.Gly105Val | Missense | - | - | UniProt |
RCV000582529 | p.Ser106Arg | missense variant | - | NC_000017.11:g.7676051G>C | ClinVar |
NCI-TCGA novel | p.Ser106CysSer | insertion | - | NC_000017.11:g.7676049_7676050insAGCTGC | NCI-TCGA |
RCV000774504 | p.Ser106Ile | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676052C>A | ClinVar |
rs1555526581 | p.Ser106Arg | missense variant | - | NC_000017.11:g.7676051G>C | UniProt,dbSNP |
VAR_044667 | p.Ser106Arg | missense variant | - | NC_000017.11:g.7676051G>C | UniProt |
rs1555526581 | p.Ser106Arg | missense variant | - | NC_000017.11:g.7676051G>C | - |
VAR_044666 | p.Ser106Gly | Missense | - | - | UniProt |
rs587782447 | p.Tyr107Ser | missense variant | - | NC_000017.11:g.7676049T>G | - |
RCV000460800 | p.Tyr107Asn | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676050A>T | ClinVar |
COSM220765 | p.Tyr107Asp | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7676050A>C | NCI-TCGA Cosmic |
RCV000132052 | p.Tyr107Cys | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676049T>C | ClinVar |
RCV000473161 | p.Tyr107Ter | nonsense | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676048G>T | ClinVar |
rs587782447 | p.Tyr107Cys | missense variant | - | NC_000017.11:g.7676049T>C | UniProt,dbSNP |
VAR_044668 | p.Tyr107Cys | missense variant | - | NC_000017.11:g.7676049T>C | UniProt |
rs587782447 | p.Tyr107Cys | missense variant | - | NC_000017.11:g.7676049T>C | - |
rs368771578 | p.Tyr107His | missense variant | - | NC_000017.11:g.7676050A>G | 1000Genomes,ESP,ExAC,TOPMed,gnomAD |
rs770776262 | p.Tyr107Ter | stop gained | - | NC_000017.11:g.7676048G>T | ExAC,gnomAD |
rs368771578 | p.Tyr107Asn | missense variant | - | NC_000017.11:g.7676050A>T | 1000Genomes,ESP,ExAC,TOPMed,gnomAD |
RCV000131517 | p.Tyr107Ser | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676049T>G | ClinVar |
RCV000709408 | p.Tyr107Cys | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676049T>C | ClinVar |
RCV000588191 | p.Tyr107His | missense variant | - | NC_000017.11:g.7676050A>G | ClinVar |
RCV000411273 | p.Tyr107His | missense variant | Li-Fraumeni syndrome 1 (LFS) | NC_000017.11:g.7676050A>G | ClinVar |
VAR_044669 | p.Tyr107Asp | Missense | - | - | UniProt |
rs587782461 | p.Gly108Arg | missense variant | - | NC_000017.11:g.7676047C>G | ExAC,gnomAD |
rs587782461 | p.Gly108Ser | missense variant | - | NC_000017.11:g.7676047C>T | UniProt,dbSNP |
VAR_044672 | p.Gly108Ser | missense variant | - | NC_000017.11:g.7676047C>T | UniProt |
rs587782461 | p.Gly108Ser | missense variant | - | NC_000017.11:g.7676047C>T | ExAC,gnomAD |
RCV000679368 | p.Gly108Ser | missense variant | - | NC_000017.11:g.7676047C>T | ClinVar |
COSM437634 | p.Gly108PhePheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7676046_7676047CC>- | NCI-TCGA Cosmic |
COSM2745024 | p.Gly108ValPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7676046C>- | NCI-TCGA Cosmic |
RCV000527049 | p.Gly108Arg | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676047C>G | ClinVar |
RCV000777270 | p.Gly108Arg | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676047C>G | ClinVar |
RCV000131548 | p.Gly108Ser | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676047C>T | ClinVar |
rs587782461 | p.Gly108Cys | missense variant | - | NC_000017.11:g.7676047C>A | ExAC,gnomAD |
RCV000458425 | p.Gly108Ser | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676047C>T | ClinVar |
VAR_044671 | p.Gly108Asp | Missense | - | - | UniProt |
rs1064796722 | p.Phe109Ser | missense variant | - | NC_000017.11:g.7676043A>G | UniProt,dbSNP |
VAR_044675 | p.Phe109Ser | missense variant | - | NC_000017.11:g.7676043A>G | UniProt |
rs1064796722 | p.Phe109Ser | missense variant | - | NC_000017.11:g.7676043A>G | - |
rs1057523496 | p.Phe109Val | missense variant | - | NC_000017.11:g.7676044A>C | - |
RCV000492295 | p.Phe109Ter | frameshift | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676043delinsTTGGG | ClinVar |
RCV000484423 | p.Phe109Ser | missense variant | - | NC_000017.11:g.7676043A>G | ClinVar |
RCV000434126 | p.Phe109Val | missense variant | - | NC_000017.11:g.7676044A>C | ClinVar |
RCV000492114 | p.Phe109Ter | frameshift | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676041_7676045delinsTTTT | ClinVar |
RCV000785545 | p.Phe109Cys | missense variant | Ovarian Neoplasms | NC_000017.11:g.7676043A>C | ClinVar |
NCI-TCGA novel | p.Phe109LeuPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7676035_7676045CCAGACGGAAA>- | NCI-TCGA |
RCV000479264 | p.Phe109Ter | frameshift | - | NC_000017.11:g.7676041_7676042del | ClinVar |
VAR_044673 | p.Phe109Cys | Missense | - | - | UniProt |
VAR_044674 | p.Phe109Leu | Missense | - | - | UniProt |
RCV000473145 | p.Arg110Leu | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676040C>A | ClinVar |
RCV000122182 | p.Arg110His | missense variant | - | NC_000017.11:g.7676040C>T | ClinVar |
RCV000461586 | p.Arg110Ser | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676041G>T | ClinVar |
RCV000195648 | p.Arg110Cys | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676041G>A | ClinVar |
RCV000115718 | p.Arg110Ter | frameshift | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676042del | ClinVar |
COSM1480090 | p.Arg110SerPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7676042_7676043insAA | NCI-TCGA Cosmic |
COSM3723930 | p.Arg110TrpPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7676038_7676041GACG>- | NCI-TCGA Cosmic |
COSM1480087 | p.Arg110SerPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7676041_7676042insGA | NCI-TCGA Cosmic |
RCV000414039 | p.Arg110Cys | missense variant | - | NC_000017.11:g.7676041G>A | ClinVar |
RCV000129184 | p.Arg110Ser | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676041G>T | ClinVar |
RCV000131196 | p.Arg110Cys | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676041G>A | ClinVar |
rs587781371 | p.Arg110Ser | missense variant | - | NC_000017.11:g.7676041G>T | UniProt,dbSNP |
VAR_044678 | p.Arg110Ser | missense variant | - | NC_000017.11:g.7676041G>T | UniProt |
rs587781371 | p.Arg110Ser | missense variant | - | NC_000017.11:g.7676041G>T | ExAC,gnomAD |
rs11540654 | p.Arg110His | missense variant | - | NC_000017.11:g.7676040C>T | 1000Genomes,ExAC,TOPMed,gnomAD |
rs11540654 | p.Arg110Pro | missense variant | - | NC_000017.11:g.7676040C>G | 1000Genomes,ExAC,TOPMed,gnomAD |
rs587781371 | p.Arg110Cys | missense variant | - | NC_000017.11:g.7676041G>A | ExAC,gnomAD |
rs587781371 | p.Arg110Cys | missense variant | - | NC_000017.11:g.7676041G>A | UniProt,dbSNP |
VAR_005860 | p.Arg110Cys | missense variant | - | NC_000017.11:g.7676041G>A | UniProt |
rs587780066 | p.Arg110ValPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7676041G>- | NCI-TCGA,NCI-TCGA Cosmic |
RCV000231991 | p.Arg110Pro | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676040C>G | ClinVar |
rs11540654 | p.Arg110Leu | missense variant | - | NC_000017.11:g.7676040C>A | 1000Genomes,ExAC,TOPMed,gnomAD |
VAR_044676 | p.Arg110Gly | Missense | - | - | UniProt |
RCV000420444 | p.Leu111Arg | missense variant | Adenocarcinoma of stomach | NC_000017.11:g.7676037A>C | ClinVar |
RCV000423948 | p.Leu111Arg | missense variant | Squamous cell lung carcinoma | NC_000017.11:g.7676037A>C | ClinVar |
RCV000433045 | p.Leu111Gln | missense variant | Malignant melanoma of skin (CMM) | NC_000017.11:g.7676037A>T | ClinVar |
RCV000492097 | p.Leu111Ter | frameshift | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676042_7676048dup | ClinVar |
RCV000442091 | p.Leu111Gln | missense variant | Carcinoma of esophagus | NC_000017.11:g.7676037A>T | ClinVar |
RCV000421931 | p.Leu111Gln | missense variant | Squamous cell lung carcinoma | NC_000017.11:g.7676037A>T | ClinVar |
RCV000442462 | p.Leu111Gln | missense variant | Glioblastoma | NC_000017.11:g.7676037A>T | ClinVar |
RCV000433598 | p.Leu111Gln | missense variant | Hepatocellular carcinoma (HCC) | NC_000017.11:g.7676037A>T | ClinVar |
RCV000441661 | p.Leu111Arg | missense variant | Carcinoma of esophagus | NC_000017.11:g.7676037A>C | ClinVar |
RCV000443054 | p.Leu111Gln | missense variant | Chronic lymphocytic leukemia (CLL) | NC_000017.11:g.7676037A>T | ClinVar |
RCV000699900 | p.Leu111Ter | frameshift | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676042_7676048dup | ClinVar |
RCV000424730 | p.Leu111Gln | missense variant | Adenocarcinoma of stomach | NC_000017.11:g.7676037A>T | ClinVar |
RCV000434970 | p.Leu111Gln | missense variant | Neoplasm of the breast | NC_000017.11:g.7676037A>T | ClinVar |
RCV000423328 | p.Leu111Arg | missense variant | Chronic lymphocytic leukemia (CLL) | NC_000017.11:g.7676037A>C | ClinVar |
RCV000459042 | p.Leu111Pro | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676037A>G | ClinVar |
RCV000430499 | p.Leu111Arg | missense variant | Malignant melanoma of skin (CMM) | NC_000017.11:g.7676037A>C | ClinVar |
rs1057519997 | p.Leu111Arg | missense variant | - | NC_000017.11:g.7676037A>C | UniProt,dbSNP |
VAR_044682 | p.Leu111Arg | missense variant | - | NC_000017.11:g.7676037A>C | UniProt |
rs1057519997 | p.Leu111Pro | missense variant | - | NC_000017.11:g.7676037A>G | UniProt,dbSNP |
VAR_044680 | p.Leu111Pro | missense variant | - | NC_000017.11:g.7676037A>G | UniProt |
rs1057519997 | p.Leu111Gln | missense variant | - | NC_000017.11:g.7676037A>T | UniProt,dbSNP |
VAR_044681 | p.Leu111Gln | missense variant | - | NC_000017.11:g.7676037A>T | UniProt |
RCV000440112 | p.Leu111Arg | missense variant | Glioblastoma | NC_000017.11:g.7676037A>C | ClinVar |
RCV000435486 | p.Leu111Arg | missense variant | Neoplasm of the breast | NC_000017.11:g.7676037A>C | ClinVar |
RCV000429869 | p.Leu111Arg | missense variant | Hepatocellular carcinoma (HCC) | NC_000017.11:g.7676037A>C | ClinVar |
VAR_044679 | p.Leu111Met | Missense | - | - | UniProt |
RCV000581490 | p.Gly112Ser | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676035C>T | ClinVar |
rs1423803759 | p.Gly112Ser | missense variant | - | NC_000017.11:g.7676035C>T | UniProt,dbSNP |
VAR_044684 | p.Gly112Ser | missense variant | - | NC_000017.11:g.7676035C>T | UniProt |
rs1423803759 | p.Gly112Ser | missense variant | - | NC_000017.11:g.7676035C>T | gnomAD |
rs1390502714 | p.Gly112Ala | missense variant | - | NC_000017.11:g.7676034C>G | gnomAD |
VAR_044683 | p.Gly112Asp | Missense | - | - | UniProt |
RCV000129770 | p.Phe113Val | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676032A>C | ClinVar |
COSM4070059 | p.Phe113Leu | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7676030G>C | NCI-TCGA Cosmic |
RCV000633376 | p.Phe113Val | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676032A>C | ClinVar |
RCV000785288 | p.Phe113Cys | missense variant | Ovarian Neoplasms | NC_000017.11:g.7676031A>C | ClinVar |
rs587781642 | p.Phe113Val | missense variant | - | NC_000017.11:g.7676032A>C | - |
rs587781642 | p.Phe113Val | missense variant | - | NC_000017.11:g.7676032A>C | UniProt,dbSNP |
VAR_033033 | p.Phe113Val | missense variant | - | NC_000017.11:g.7676032A>C | UniProt |
VAR_044685 | p.Phe113Ile | Missense | - | - | UniProt |
VAR_044687 | p.Phe113Ser | Missense | - | - | UniProt |
VAR_044686 | p.Phe113Leu | Missense | - | - | UniProt |
VAR_045788 | p.Phe113Gly | Missense | - | - | UniProt |
VAR_005863 | p.Phe113Cys | Missense | - | - | UniProt |
rs781724995 | p.Leu114Ser | missense variant | - | NC_000017.11:g.7676028A>G | ExAC,TOPMed,gnomAD |
RCV000537102 | p.Leu114Ser | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676028A>G | ClinVar |
RCV000785466 | p.Leu114Ter | nonsense | Ovarian Neoplasms | NC_000017.11:g.7676028A>T | ClinVar |
COSM5230967 | p.His115IlePheSerTerUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7676026G>- | NCI-TCGA Cosmic |
rs1555526532 | p.His115Asn | missense variant | - | NC_000017.11:g.7676026G>T | - |
RCV000575197 | p.His115Arg | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676025T>C | ClinVar |
RCV000696891 | p.His115Arg | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676025T>C | ClinVar |
RCV000161021 | p.His115Arg | missense variant | - | NC_000017.11:g.7676025T>C | ClinVar |
RCV000821053 | p.His115Asn | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676026G>T | ClinVar |
rs730881996 | p.His115Arg | missense variant | - | NC_000017.11:g.7676025T>C | - |
RCV000576064 | p.His115Asn | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676026G>T | ClinVar |
VAR_044688 | p.His115Tyr | Missense | - | - | UniProt |
RCV000657463 | p.Ser116Ter | frameshift | - | NC_000017.11:g.7676023_7676029dup | ClinVar |
rs989692988 | p.Ser116Ala | missense variant | - | NC_000017.11:g.7676023A>C | gnomAD |
VAR_044689 | p.Ser116Cys | Missense | - | - | UniProt |
VAR_044690 | p.Ser116Phe | Missense | - | - | UniProt |
VAR_044691 | p.Ser116Pro | Missense | - | - | UniProt |
RCV000565337 | p.Gly117Arg | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676020C>T | ClinVar |
NCI-TCGA novel | p.Gly117AspPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7676003_7676019CACAGACTTGGCTGTCC>- | NCI-TCGA |
rs755238756 | p.Gly117Ala | missense variant | - | NC_000017.11:g.7676019C>G | ExAC,gnomAD |
rs755238756 | p.Gly117Glu | missense variant | - | NC_000017.11:g.7676019C>T | ExAC,gnomAD |
rs755238756 | p.Gly117Glu | missense variant | - | NC_000017.11:g.7676019C>T | UniProt,dbSNP |
VAR_044692 | p.Gly117Glu | missense variant | - | NC_000017.11:g.7676019C>T | UniProt |
rs1555526518 | p.Gly117Arg | missense variant | - | NC_000017.11:g.7676020C>T | - |
rs1555526518 | p.Gly117Arg | missense variant | - | NC_000017.11:g.7676020C>T | UniProt,dbSNP |
VAR_044693 | p.Gly117Arg | missense variant | - | NC_000017.11:g.7676020C>T | UniProt |
rs1064794141 | p.Thr118Ile | missense variant | - | NC_000017.11:g.7676016G>A | - |
RCV000484765 | p.Thr118Ile | missense variant | - | NC_000017.11:g.7676016G>A | ClinVar |
COSM69197 | p.Thr118AspPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7676017_7676018insC | NCI-TCGA Cosmic |
COSM2745000 | p.Thr118GlnPheSerTerUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7676018C>- | NCI-TCGA Cosmic |
RCV000526166 | p.Thr118Ile | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676016G>A | ClinVar |
RCV000569220 | p.Thr118Ile | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676016G>A | ClinVar |
VAR_044694 | p.Thr118Ala | Missense | - | - | UniProt |
VAR_044696 | p.Thr118Arg | Missense | - | - | UniProt |
RCV000567984 | p.Ala119Pro | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676014C>G | ClinVar |
rs1555526506 | p.Ala119Pro | missense variant | - | NC_000017.11:g.7676014C>G | - |
VAR_044698 | p.Ala119Thr | Missense | - | - | UniProt |
VAR_044697 | p.Ala119Asp | Missense | - | - | UniProt |
rs121912658 | p.Lys120Gln | missense variant | - | NC_000017.11:g.7676011T>G | UniProt,dbSNP |
VAR_044701 | p.Lys120Gln | missense variant | - | NC_000017.11:g.7676011T>G | UniProt |
RCV000013158 | p.Lys120Ter | nonsense | Li-Fraumeni-like syndrome (LFL) | NC_000017.11:g.7676011T>A | ClinVar |
RCV000478911 | p.Lys120Gln | missense variant | - | NC_000017.11:g.7676011T>G | ClinVar |
RCV000213049 | p.Lys120Glu | missense variant | - | NC_000017.11:g.7676011T>C | ClinVar |
COSM4384940 | p.Lys120SerPheSerTerUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7676012G>- | NCI-TCGA Cosmic |
NCI-TCGA novel | p.Lys120ThrPheSerTerUnk | stop gained | - | NC_000017.11:g.7676010_7676011insTAAG | NCI-TCGA |
rs121912658 | p.Lys120Glu | missense variant | - | NC_000017.11:g.7676011T>C | UniProt,dbSNP |
VAR_044699 | p.Lys120Glu | missense variant | - | NC_000017.11:g.7676011T>C | UniProt |
VAR_044700 | p.Lys120Met | Missense | - | - | UniProt |
VAR_044702 | p.Lys120Arg | Missense | - | - | UniProt |
COSM45223 | p.Ser121CysPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7676006_7676007AG>- | NCI-TCGA Cosmic |
NCI-TCGA novel | p.Ser121Tyr | missense variant | - | NC_000017.11:g.7676007G>T | NCI-TCGA |
RCV000785255 | p.Ser121Ter | frameshift | Ovarian Neoplasms | NC_000017.11:g.7675999_7676009del | ClinVar |
VAR_044703 | p.Ser121Phe | Missense | - | - | UniProt |
RCV000824056 | p.Val122Ter | frameshift | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676003_7676004CA[1] | ClinVar |
RCV000785538 | p.Val122Ter | frameshift | Ovarian Neoplasms | NC_000017.11:g.7676003_7676004CA[1] | ClinVar |
RCV000129460 | p.Val122Met | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676005C>T | ClinVar |
RCV000581285 | p.Val122Met | missense variant | - | NC_000017.11:g.7676005C>T | ClinVar |
RCV000115720 | p.Val122Ter | frameshift | - | NC_000017.11:g.7676003_7676004CA[1] | ClinVar |
RCV000206482 | p.Val122Met | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676005C>T | ClinVar |
NCI-TCGA novel | p.Val122CysPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7676005_7676006insA | NCI-TCGA |
NCI-TCGA novel | p.Val122LeuPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7676001_7676005GTCAC>- | NCI-TCGA |
rs587781495 | p.Val122Met | missense variant | - | NC_000017.11:g.7676005C>T | - |
rs587780067 | p.Val122AspPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7676003_7676004CA>- | NCI-TCGA,NCI-TCGA Cosmic |
RCV000494892 | p.Val122Ter | frameshift | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7676010_7676040dup | ClinVar |
VAR_044704 | p.Val122Leu | Missense | - | - | UniProt |
COSM1324764 | p.Thr123ArgPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7676001_7676002insTC | NCI-TCGA Cosmic |
RCV000572422 | p.Thr123Ile | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7676001G>A | ClinVar |
NCI-TCGA novel | p.Thr123AspPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7676002_7676003insC | NCI-TCGA |
rs1555526486 | p.Thr123Ile | missense variant | - | NC_000017.11:g.7676001G>A | - |
rs1555526486 | p.Thr123Ile | missense variant | - | NC_000017.11:g.7676001G>A | UniProt,dbSNP |
VAR_044705 | p.Thr123Ile | missense variant | - | NC_000017.11:g.7676001G>A | UniProt |
VAR_044706 | p.Thr123Asn | Missense | - | - | UniProt |
rs730881997 | p.Cys124Gly | missense variant | - | NC_000017.11:g.7675999A>C | ExAC,TOPMed,gnomAD |
RCV000785247 | p.Cys124Ter | frameshift | Ovarian Neoplasms | NC_000017.11:g.7675998dup | ClinVar |
COSM5080715 | p.Cys124PhePheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7675998_7675999insAA | NCI-TCGA Cosmic |
COSM4434421 | p.Cys124AlaPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7675999A>- | NCI-TCGA Cosmic |
COSM69020 | p.Cys124Ter | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7675997G>- | NCI-TCGA Cosmic |
COSM1268350 | p.Cys124TrpPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7675997_7675998insC | NCI-TCGA Cosmic |
RCV000541004 | p.Cys124Ter | nonsense | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675997G>T | ClinVar |
RCV000574455 | p.Cys124Ser | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7675999A>T | ClinVar |
RCV000161022 | p.Cys124Ser | missense variant | - | NC_000017.11:g.7675999A>T | ClinVar |
RCV000217878 | p.Cys124Gly | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7675999A>C | ClinVar |
rs730881997 | p.Cys124Ser | missense variant | - | NC_000017.11:g.7675999A>T | ExAC,TOPMed,gnomAD |
rs1555526478 | p.Cys124Ter | stop gained | - | NC_000017.11:g.7675997G>T | - |
VAR_044710 | p.Cys124Trp | Missense | - | - | UniProt |
VAR_044711 | p.Cys124Tyr | Missense | - | - | UniProt |
VAR_044708 | p.Cys124Arg | Missense | - | - | UniProt |
rs786201057 | p.Thr125Lys | missense variant | - | NC_000017.11:g.7675995G>T | UniProt,dbSNP |
VAR_044713 | p.Thr125Lys | missense variant | - | NC_000017.11:g.7675995G>T | UniProt |
RCV000437835 | p.Thr125Pro | missense variant | Lung adenocarcinoma | NC_000017.11:g.7675996T>G | ClinVar |
RCV000434566 | p.Thr125Pro | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7675996T>G | ClinVar |
RCV000436394 | p.Thr125Pro | missense variant | - | NC_000017.11:g.7675996T>G | ClinVar |
RCV000439813 | p.Thr125Pro | missense variant | Adrenocortical carcinoma | NC_000017.11:g.7675996T>G | ClinVar |
RCV000425049 | p.Thr125Pro | missense variant | Neoplasm of the breast | NC_000017.11:g.7675996T>G | ClinVar |
RCV000442185 | p.Thr125Pro | missense variant | Carcinoma of esophagus | NC_000017.11:g.7675996T>G | ClinVar |
RCV000422630 | p.Thr125Pro | missense variant | - | NC_000017.11:g.7675996T>G | ClinVar |
RCV000442101 | p.Thr125Pro | missense variant | Squamous cell lung carcinoma | NC_000017.11:g.7675996T>G | ClinVar |
RCV000418295 | p.Thr125Pro | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7675996T>G | ClinVar |
RCV000426486 | p.Thr125Pro | missense variant | Glioblastoma | NC_000017.11:g.7675996T>G | ClinVar |
RCV000429194 | p.Thr125Pro | missense variant | Small cell lung cancer | NC_000017.11:g.7675996T>G | ClinVar |
RCV000428307 | p.Thr125Pro | missense variant | - | NC_000017.11:g.7675996T>G | ClinVar |
RCV000417666 | p.Thr125Pro | missense variant | Neoplasm of the large intestine | NC_000017.11:g.7675996T>G | ClinVar |
RCV000434887 | p.Thr125Pro | missense variant | Hepatocellular carcinoma (HCC) | NC_000017.11:g.7675996T>G | ClinVar |
RCV000439620 | p.Thr125Pro | missense variant | Renal cell carcinoma, papillary, 1 (RCCP1) | NC_000017.11:g.7675996T>G | ClinVar |
RCV000433906 | p.Thr125Pro | missense variant | Acute myeloid leukemia (AML) | NC_000017.11:g.7675996T>G | ClinVar |
RCV000423200 | p.Thr125Pro | missense variant | Malignant melanoma of skin (CMM) | NC_000017.11:g.7675996T>G | ClinVar |
RCV000427158 | p.Thr125Pro | missense variant | Adenocarcinoma of stomach | NC_000017.11:g.7675996T>G | ClinVar |
RCV000440402 | p.Thr125Arg | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7675995G>C | ClinVar |
RCV000197507 | p.Thr125Lys | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675995G>T | ClinVar |
RCV000436286 | p.Thr125Arg | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7675995G>C | ClinVar |
RCV000424710 | p.Thr125Arg | missense variant | Small cell lung cancer | NC_000017.11:g.7675995G>C | ClinVar |
RCV000419630 | p.Thr125Arg | missense variant | Neoplasm of the breast | NC_000017.11:g.7675995G>C | ClinVar |
NCI-TCGA novel | p.Thr125AsnPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7675995_7675996insCTCGCTAGTGGGT | NCI-TCGA |
RCV000492090 | p.Thr125Arg | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7675995G>C | ClinVar |
RCV000442028 | p.Thr125Arg | missense variant | Lung adenocarcinoma | NC_000017.11:g.7675995G>C | ClinVar |
RCV000419385 | p.Thr125Arg | missense variant | Glioblastoma | NC_000017.11:g.7675995G>C | ClinVar |
RCV000425385 | p.Thr125Arg | missense variant | Hepatocellular carcinoma (HCC) | NC_000017.11:g.7675995G>C | ClinVar |
RCV000237013 | p.Thr125Met | missense variant | - | NC_000017.11:g.7675995G>A | ClinVar |
RCV000429727 | p.Thr125Arg | missense variant | Acute myeloid leukemia (AML) | NC_000017.11:g.7675995G>C | ClinVar |
rs1057520003 | p.Thr125Pro | missense variant | - | NC_000017.11:g.7675996T>G | UniProt,dbSNP |
VAR_044714 | p.Thr125Pro | missense variant | - | NC_000017.11:g.7675996T>G | UniProt |
rs1057520003 | p.Thr125Pro | missense variant | - | NC_000017.11:g.7675996T>G | - |
rs786201057 | p.Thr125Arg | missense variant | - | NC_000017.11:g.7675995G>C | UniProt,dbSNP |
VAR_044715 | p.Thr125Arg | missense variant | - | NC_000017.11:g.7675995G>C | UniProt |
rs786201057 | p.Thr125Arg | missense variant | - | NC_000017.11:g.7675995G>C | gnomAD |
rs786201057 | p.Thr125Met | missense variant | - | NC_000017.11:g.7675995G>A | UniProt,dbSNP |
VAR_005864 | p.Thr125Met | missense variant | - | NC_000017.11:g.7675995G>A | UniProt |
rs786201057 | p.Thr125Met | missense variant | - | NC_000017.11:g.7675995G>A | gnomAD |
rs786201057 | p.Thr125Lys | missense variant | - | NC_000017.11:g.7675995G>T | gnomAD |
RCV000443332 | p.Thr125Pro | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7675996T>G | ClinVar |
RCV000432449 | p.Thr125Pro | missense variant | Neoplasm of brain | NC_000017.11:g.7675996T>G | ClinVar |
RCV000434737 | p.Thr125Arg | missense variant | Squamous cell lung carcinoma | NC_000017.11:g.7675995G>C | ClinVar |
RCV000424026 | p.Thr125Arg | missense variant | - | NC_000017.11:g.7675995G>C | ClinVar |
RCV000442833 | p.Thr125Arg | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7675995G>C | ClinVar |
RCV000440628 | p.Thr125Arg | missense variant | - | NC_000017.11:g.7675995G>C | ClinVar |
RCV000436088 | p.Thr125Arg | missense variant | Malignant melanoma of skin (CMM) | NC_000017.11:g.7675995G>C | ClinVar |
RCV000436638 | p.Thr125Arg | missense variant | Adrenocortical carcinoma | NC_000017.11:g.7675995G>C | ClinVar |
RCV000423812 | p.Thr125Arg | missense variant | Renal cell carcinoma, papillary, 1 (RCCP1) | NC_000017.11:g.7675995G>C | ClinVar |
RCV000442755 | p.Thr125Arg | missense variant | - | NC_000017.11:g.7675995G>C | ClinVar |
RCV000432131 | p.Thr125Arg | missense variant | Carcinoma of esophagus | NC_000017.11:g.7675995G>C | ClinVar |
RCV000423368 | p.Thr125Arg | missense variant | Neoplasm of the large intestine | NC_000017.11:g.7675995G>C | ClinVar |
RCV000428977 | p.Thr125Arg | missense variant | Neoplasm of brain | NC_000017.11:g.7675995G>C | ClinVar |
RCV000430321 | p.Thr125Arg | missense variant | Adenocarcinoma of stomach | NC_000017.11:g.7675995G>C | ClinVar |
VAR_044712 | p.Thr125Ala | Missense | - | - | UniProt |
COSM4435839 | p.Tyr126His | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7675236A>G | NCI-TCGA Cosmic |
COSM1610875 | p.Tyr126Ser | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7675235T>G | NCI-TCGA Cosmic |
RCV000702157 | p.Tyr126Ter | nonsense | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675234G>C | ClinVar |
NCI-TCGA novel | p.Tyr126ArgPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7675994_7675995insACTCTCTCTA | NCI-TCGA |
RCV000785493 | p.Tyr126Cys | missense variant | Ovarian Neoplasms | NC_000017.11:g.7675235T>C | ClinVar |
RCV000785318 | p.Tyr126Ter | frameshift | Ovarian Neoplasms | NC_000017.11:g.7675236del | ClinVar |
rs1555526335 | p.Tyr126Cys | missense variant | - | NC_000017.11:g.7675235T>C | UniProt,dbSNP |
VAR_044716 | p.Tyr126Cys | missense variant | - | NC_000017.11:g.7675235T>C | UniProt |
RCV000785482 | p.Tyr126Asp | missense variant | Ovarian Neoplasms | NC_000017.11:g.7675236A>C | ClinVar |
RCV000492304 | p.Tyr126Asn | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7675236A>T | ClinVar |
RCV000801059 | p.Tyr126Asn | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675236A>T | ClinVar |
RCV000255685 | p.Tyr126Asp | missense variant | - | NC_000017.11:g.7675236A>C | ClinVar |
VAR_045789 | p.Tyr126Gly | Missense | - | - | UniProt |
VAR_044718 | p.Tyr126His | Missense | - | - | UniProt |
VAR_044719 | p.Tyr126Ser | Missense | - | - | UniProt |
VAR_044717 | p.Tyr126Phe | Missense | - | - | UniProt |
COSM1644270 | p.Ser127Pro | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7675233A>G | NCI-TCGA Cosmic |
COSM3403294 | p.Ser127Tyr | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7675232G>T | NCI-TCGA Cosmic |
COSM1168839 | p.Ser127Thr | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7675233A>T | NCI-TCGA Cosmic |
RCV000205404 | p.Ser127Cys | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675232G>C | ClinVar |
RCV000785332 | p.Ser127Phe | missense variant | Ovarian Neoplasms | NC_000017.11:g.7675232G>A | ClinVar |
RCV000161024 | p.Ser127Phe | missense variant | - | NC_000017.11:g.7675232G>A | ClinVar |
VAR_044722 | p.Ser127Thr | Missense | - | - | UniProt |
VAR_044721 | p.Ser127Pro | Missense | - | - | UniProt |
VAR_044723 | p.Ser127Tyr | Missense | - | - | UniProt |
COSM5198771 | p.Pro128LeuPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7675229G>- | NCI-TCGA Cosmic |
rs1555526327 | p.Pro128Thr | missense variant | - | NC_000017.11:g.7675230G>T | - |
RCV000569462 | p.Pro128Thr | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7675230G>T | ClinVar |
RCV000633349 | p.Pro128Thr | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675230G>T | ClinVar |
VAR_044724 | p.Pro128Ala | Missense | - | - | UniProt |
VAR_005868 | p.Pro128Ser | Missense | - | - | UniProt |
VAR_044725 | p.Pro128Leu | Missense | - | - | UniProt |
VAR_044726 | p.Pro128Arg | Missense | - | - | UniProt |
rs137852792 | p.Ala129Gly | missense variant | - | NC_000017.11:g.7675226G>C | TOPMed |
rs1438095083 | p.Ala129Thr | missense variant | - | NC_000017.11:g.7675227C>T | UniProt,dbSNP |
VAR_044728 | p.Ala129Thr | missense variant | - | NC_000017.11:g.7675227C>T | UniProt |
rs1438095083 | p.Ala129Thr | missense variant | - | NC_000017.11:g.7675227C>T | TOPMed |
RCV000557322 | p.Ala129Gly | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675226G>C | ClinVar |
RCV000567140 | p.Ala129Thr | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7675227C>T | ClinVar |
RCV000119793 | p.Ala129Val | missense variant | Familial cancer of breast | NC_000017.11:g.7675226G>A | ClinVar |
NCI-TCGA novel | p.Ala129ValPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7675226_7675227insA | NCI-TCGA |
rs137852792 | p.Ala129Val | missense variant | - | NC_000017.11:g.7675226G>A | UniProt,dbSNP |
VAR_044729 | p.Ala129Val | missense variant | - | NC_000017.11:g.7675226G>A | UniProt |
rs137852792 | p.Ala129Val | missense variant | - | NC_000017.11:g.7675226G>A | TOPMed |
VAR_005869 | p.Ala129Asp | Missense | - | - | UniProt |
VAR_044727 | p.Ala129Gly | Missense | - | - | UniProt |
rs863224683 | p.Leu130Val | missense variant | - | NC_000017.11:g.7675224G>C | UniProt,dbSNP |
VAR_044734 | p.Leu130Val | missense variant | - | NC_000017.11:g.7675224G>C | UniProt |
rs863224683 | p.Leu130Val | missense variant | - | NC_000017.11:g.7675224G>C | - |
RCV000492142 | p.Leu130Pro | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7675223A>G | ClinVar |
COSM69196 | p.Leu130ProPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7675223_7675224insGG | NCI-TCGA Cosmic |
COSM1610872 | p.Leu130Arg | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7675223A>C | NCI-TCGA Cosmic |
NCI-TCGA novel | p.Leu130CysPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7675224_7675225insGGCA | NCI-TCGA |
RCV000565366 | p.Leu130Val | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7675224G>C | ClinVar |
RCV000571787 | p.Leu130Phe | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7675224G>A | ClinVar |
rs1131691013 | p.Leu130Pro | missense variant | - | NC_000017.11:g.7675223A>G | - |
rs1131691013 | p.Leu130Pro | missense variant | - | NC_000017.11:g.7675223A>G | UniProt,dbSNP |
VAR_044733 | p.Leu130Pro | missense variant | - | NC_000017.11:g.7675223A>G | UniProt |
rs863224683 | p.Leu130Phe | missense variant | - | NC_000017.11:g.7675224G>A | UniProt,dbSNP |
VAR_044730 | p.Leu130Phe | missense variant | - | NC_000017.11:g.7675224G>A | UniProt |
rs863224683 | p.Leu130Phe | missense variant | - | NC_000017.11:g.7675224G>A | - |
RCV000536061 | p.Leu130Val | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675224G>C | ClinVar |
RCV000200055 | p.Leu130Phe | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675224G>A | ClinVar |
RCV000759374 | p.Leu130Val | missense variant | - | NC_000017.11:g.7675224G>C | ClinVar |
VAR_044732 | p.Leu130Ile | Missense | - | - | UniProt |
VAR_044731 | p.Leu130His | Missense | - | - | UniProt |
VAR_005870 | p.Leu130Arg | Missense | - | - | UniProt |
RCV000821569 | p.Asn131Ile | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675220T>A | ClinVar |
RCV000492741 | p.Asn131Lys | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7675219G>T | ClinVar |
COSM437612 | p.Asn131ThrPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7675220T>- | NCI-TCGA Cosmic |
COSM100015 | p.Asn131LysPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7675219G>- | NCI-TCGA Cosmic |
COSM1610869 | p.Asn131Ser | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7675220T>C | NCI-TCGA Cosmic |
RCV000130751 | p.Asn131Tyr | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7675221T>A | ClinVar |
RCV000465360 | p.Asn131Lys | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675219G>T | ClinVar |
NCI-TCGA novel | p.Asn131GlnPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7675221_7675222TG>- | NCI-TCGA |
rs769270327 | p.Asn131Lys | missense variant | - | NC_000017.11:g.7675219G>T | ExAC,TOPMed,gnomAD |
rs769270327 | p.Asn131Lys | missense variant | - | NC_000017.11:g.7675219G>T | UniProt,dbSNP |
VAR_005872 | p.Asn131Lys | missense variant | - | NC_000017.11:g.7675219G>T | UniProt |
rs1131691037 | p.Asn131Ile | missense variant | - | NC_000017.11:g.7675220T>A | - |
rs1131691037 | p.Asn131Ile | missense variant | - | NC_000017.11:g.7675220T>A | UniProt,dbSNP |
VAR_044737 | p.Asn131Ile | missense variant | - | NC_000017.11:g.7675220T>A | UniProt |
rs587782160 | p.Asn131Tyr | missense variant | - | NC_000017.11:g.7675221T>A | - |
rs587782160 | p.Asn131Tyr | missense variant | - | NC_000017.11:g.7675221T>A | UniProt,dbSNP |
VAR_044739 | p.Asn131Tyr | missense variant | - | NC_000017.11:g.7675221T>A | UniProt |
RCV000236166 | p.Asn131Lys | missense variant | - | NC_000017.11:g.7675219G>T | ClinVar |
RCV000785315 | p.Asn131Ter | frameshift | Ovarian Neoplasms | NC_000017.11:g.7675219del | ClinVar |
VAR_005871 | p.Asn131Ser | Missense | - | - | UniProt |
VAR_044736 | p.Asn131His | Missense | - | - | UniProt |
VAR_044735 | p.Asn131Asp | Missense | - | - | UniProt |
VAR_044738 | p.Asn131Thr | Missense | - | - | UniProt |
rs1057519996 | p.Lys132Met | missense variant | - | NC_000017.11:g.7675217T>A | gnomAD |
rs1057519996 | p.Lys132Met | missense variant | - | NC_000017.11:g.7675217T>A | UniProt,dbSNP |
VAR_005873 | p.Lys132Met | missense variant | - | NC_000017.11:g.7675217T>A | UniProt |
rs866775781 | p.Lys132Asn | missense variant | - | NC_000017.11:g.7675216C>G | - |
rs1057519996 | p.Lys132Arg | missense variant | - | NC_000017.11:g.7675217T>C | gnomAD |
rs866775781 | p.Lys132Asn | missense variant | - | NC_000017.11:g.7675216C>A | - |
RCV000420694 | p.Lys132Thr | missense variant | Uterine Carcinosarcoma | NC_000017.11:g.7675217T>G | ClinVar |
RCV000443063 | p.Lys132Thr | missense variant | Adrenocortical carcinoma | NC_000017.11:g.7675217T>G | ClinVar |
RCV000437675 | p.Lys132Thr | missense variant | Lung adenocarcinoma | NC_000017.11:g.7675217T>G | ClinVar |
RCV000433123 | p.Lys132Thr | missense variant | Squamous cell lung carcinoma | NC_000017.11:g.7675217T>G | ClinVar |
RCV000435461 | p.Lys132Thr | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7675217T>G | ClinVar |
RCV000471183 | p.Lys132Arg | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675217T>C | ClinVar |
RCV000424547 | p.Lys132Thr | missense variant | - | NC_000017.11:g.7675217T>G | ClinVar |
RCV000442106 | p.Lys132Thr | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7675217T>G | ClinVar |
RCV000546420 | p.Lys132Met | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675217T>A | ClinVar |
RCV000422403 | p.Lys132Thr | missense variant | Uterine cervical neoplasms | NC_000017.11:g.7675217T>G | ClinVar |
RCV000423393 | p.Lys132Thr | missense variant | Neoplasm of the large intestine | NC_000017.11:g.7675217T>G | ClinVar |
RCV000433243 | p.Lys132Thr | missense variant | Adenocarcinoma of stomach | NC_000017.11:g.7675217T>G | ClinVar |
RCV000442713 | p.Lys132Gln | missense variant | Neoplasm of the large intestine | NC_000017.11:g.7675218T>G | ClinVar |
RCV000429238 | p.Lys132Gln | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7675218T>G | ClinVar |
RCV000427528 | p.Lys132Gln | missense variant | - | NC_000017.11:g.7675218T>G | ClinVar |
RCV000432417 | p.Lys132Asn | missense variant | - | NC_000017.11:g.7675216C>G | ClinVar |
RCV000419339 | p.Lys132Asn | missense variant | Lung adenocarcinoma | NC_000017.11:g.7675216C>G | ClinVar |
RCV000430184 | p.Lys132Asn | missense variant | Uterine Carcinosarcoma | NC_000017.11:g.7675216C>G | ClinVar |
RCV000430063 | p.Lys132Asn | missense variant | Squamous cell lung carcinoma | NC_000017.11:g.7675216C>G | ClinVar |
RCV000439586 | p.Lys132Asn | missense variant | Carcinoma of esophagus | NC_000017.11:g.7675216C>G | ClinVar |
RCV000795096 | p.Lys132Asn | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675216C>A | ClinVar |
RCV000432219 | p.Lys132Asn | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7675216C>G | ClinVar |
RCV000432114 | p.Lys132Gln | missense variant | Neoplasm of brain | NC_000017.11:g.7675218T>G | ClinVar |
RCV000439934 | p.Lys132Gln | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7675218T>G | ClinVar |
RCV000422568 | p.Lys132Gln | missense variant | Carcinoma of esophagus | NC_000017.11:g.7675218T>G | ClinVar |
RCV000434062 | p.Lys132Gln | missense variant | Neoplasm of the breast | NC_000017.11:g.7675218T>G | ClinVar |
RCV000421029 | p.Lys132Gln | missense variant | Adenocarcinoma of stomach | NC_000017.11:g.7675218T>G | ClinVar |
RCV000440130 | p.Lys132Gln | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7675218T>G | ClinVar |
RCV000442639 | p.Lys132Gln | missense variant | Multiple myeloma (MM) | NC_000017.11:g.7675218T>G | ClinVar |
RCV000468362 | p.Lys132Glu | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675218T>C | ClinVar |
RCV000422634 | p.Lys132Asn | missense variant | Multiple myeloma (MM) | NC_000017.11:g.7675216C>G | ClinVar |
RCV000437720 | p.Lys132Asn | missense variant | Adrenocortical carcinoma | NC_000017.11:g.7675216C>G | ClinVar |
RCV000427056 | p.Lys132Asn | missense variant | Neoplasm of the large intestine | NC_000017.11:g.7675216C>G | ClinVar |
RCV000442346 | p.Lys132Asn | missense variant | Neoplasm of brain | NC_000017.11:g.7675216C>G | ClinVar |
RCV000442734 | p.Lys132Asn | missense variant | Uterine cervical neoplasms | NC_000017.11:g.7675216C>G | ClinVar |
rs1057519996 | p.Lys132Thr | missense variant | - | NC_000017.11:g.7675217T>G | gnomAD |
rs1057519996 | p.Lys132Thr | missense variant | - | NC_000017.11:g.7675217T>G | UniProt,dbSNP |
VAR_044743 | p.Lys132Thr | missense variant | - | NC_000017.11:g.7675217T>G | UniProt |
rs747342068 | p.Lys132Gln | missense variant | - | NC_000017.11:g.7675218T>G | ExAC,gnomAD |
rs747342068 | p.Lys132Glu | missense variant | - | NC_000017.11:g.7675218T>C | ExAC,gnomAD |
RCV000427319 | p.Lys132Gln | missense variant | Squamous cell lung carcinoma | NC_000017.11:g.7675218T>G | ClinVar |
RCV000419400 | p.Lys132Gln | missense variant | Adrenocortical carcinoma | NC_000017.11:g.7675218T>G | ClinVar |
RCV000419226 | p.Lys132Gln | missense variant | Uterine cervical neoplasms | NC_000017.11:g.7675218T>G | ClinVar |
RCV000432840 | p.Lys132Gln | missense variant | Uterine Carcinosarcoma | NC_000017.11:g.7675218T>G | ClinVar |
RCV000438684 | p.Lys132Gln | missense variant | Lung adenocarcinoma | NC_000017.11:g.7675218T>G | ClinVar |
RCV000436873 | p.Lys132Gln | missense variant | Glioblastoma | NC_000017.11:g.7675218T>G | ClinVar |
RCV000442467 | p.Lys132Thr | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7675217T>G | ClinVar |
RCV000427017 | p.Lys132Thr | missense variant | Neoplasm of the breast | NC_000017.11:g.7675217T>G | ClinVar |
RCV000437910 | p.Lys132Thr | missense variant | Neoplasm of brain | NC_000017.11:g.7675217T>G | ClinVar |
RCV000425633 | p.Lys132Thr | missense variant | Multiple myeloma (MM) | NC_000017.11:g.7675217T>G | ClinVar |
RCV000430299 | p.Lys132Thr | missense variant | Carcinoma of esophagus | NC_000017.11:g.7675217T>G | ClinVar |
RCV000419605 | p.Lys132Thr | missense variant | Glioblastoma | NC_000017.11:g.7675217T>G | ClinVar |
rs1057519996 | p.Lys132Arg | missense variant | - | NC_000017.11:g.7675217T>C | UniProt,dbSNP |
VAR_044742 | p.Lys132Arg | missense variant | - | NC_000017.11:g.7675217T>C | UniProt |
RCV000439834 | p.Lys132Asn | missense variant | Glioblastoma | NC_000017.11:g.7675216C>G | ClinVar |
RCV000440843 | p.Lys132Asn | missense variant | Adenocarcinoma of stomach | NC_000017.11:g.7675216C>G | ClinVar |
RCV000421516 | p.Lys132Asn | missense variant | Neoplasm of the breast | NC_000017.11:g.7675216C>G | ClinVar |
RCV000424592 | p.Lys132Asn | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7675216C>G | ClinVar |
RCV000166969 | p.Lys132Ter | frameshift | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7675207_7675222del | ClinVar |
RCV000434424 | p.Lys132Asn | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7675216C>G | ClinVar |
VAR_045790 | p.Lys132Leu | Missense | - | - | UniProt |
VAR_045791 | p.Lys132Trp | Missense | - | - | UniProt |
VAR_047159 | p.Lys132_Met133delinsAsnLeu | deletion_insertion | - | - | UniProt |
rs1064795139 | p.Met133Ile | missense variant | - | NC_000017.11:g.7675213C>T | gnomAD |
rs1064795139 | p.Met133Ile | missense variant | - | NC_000017.11:g.7675213C>T | UniProt,dbSNP |
VAR_044744 | p.Met133Ile | missense variant | - | NC_000017.11:g.7675213C>T | UniProt |
RCV000013151 | p.Met133Thr | missense variant | Li-Fraumeni syndrome 1 (LFS) | NC_000017.11:g.7675214A>G | ClinVar |
RCV000484833 | p.Met133Ile | missense variant | - | NC_000017.11:g.7675213C>T | ClinVar |
RCV000662907 | p.Met133Ile | missense variant | Li-Fraumeni syndrome 1 (LFS) | NC_000017.11:g.7675213C>T | ClinVar |
COSM11781 | p.Met133Lys | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7675214A>T | NCI-TCGA Cosmic |
COSM1559495 | p.Met133Arg | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7675214A>C | NCI-TCGA Cosmic |
rs1057280220 | p.Met133Val | missense variant | - | NC_000017.11:g.7675215T>C | UniProt,dbSNP |
VAR_044748 | p.Met133Val | missense variant | - | NC_000017.11:g.7675215T>C | UniProt |
rs1057280220 | p.Met133Val | missense variant | - | NC_000017.11:g.7675215T>C | TOPMed,gnomAD |
RCV000633342 | p.Met133Val | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675215T>C | ClinVar |
rs28934873 | p.Met133Thr | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675214A>G | UniProt,dbSNP |
VAR_005875 | p.Met133Thr | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675214A>G | UniProt |
rs28934873 | p.Met133Thr | missense variant | Li-fraumeni syndrome 1 (lfs1) | NC_000017.11:g.7675214A>G | - |
RCV000492130 | p.Met133Thr | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7675214A>G | ClinVar |
VAR_044746 | p.Met133Leu | Missense | - | - | UniProt |
VAR_044745 | p.Met133Lys | Missense | - | - | UniProt |
VAR_044747 | p.Met133Arg | Missense | Li-Fraumeni syndrome (LFS) [MIM:151623] | - | UniProt |
rs267605077 | p.Phe134Leu | missense variant | - | NC_000017.11:g.7675212A>G | - |
COSM249523 | p.Phe134Val | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7675212A>C | NCI-TCGA Cosmic |
COSM45167 | p.Phe134Leu | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7675210A>T | NCI-TCGA Cosmic |
rs267605077 | p.Phe134Ile | missense variant | - | NC_000017.11:g.7675212A>T | - |
rs780442292 | p.Phe134Cys | missense variant | - | NC_000017.11:g.7675211A>C | ExAC,gnomAD |
RCV000582839 | p.Phe134Ter | frameshift | - | NC_000017.11:g.7675211_7675212insC | ClinVar |
RCV000565274 | p.Phe134Ile | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7675212A>T | ClinVar |
RCV000214547 | p.Phe134Cys | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7675211A>C | ClinVar |
RCV000656580 | p.Phe134Cys | missense variant | - | NC_000017.11:g.7675211A>C | ClinVar |
VAR_044751 | p.Phe134Ser | Missense | - | - | UniProt |
VAR_044750 | p.Phe134Ile | Missense | - | - | UniProt |
VAR_044752 | p.Phe134Val | Missense | - | - | UniProt |
rs1057519976 | p.Cys135Trp | missense variant | - | NC_000017.11:g.7675207G>C | UniProt,dbSNP |
VAR_044755 | p.Cys135Trp | missense variant | - | NC_000017.11:g.7675207G>C | UniProt |
RCV000420220 | p.Cys135Trp | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7675207G>C | ClinVar |
RCV000814994 | p.Cys135Ser | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675209A>T | ClinVar |
RCV000441192 | p.Cys135Arg | missense variant | Squamous cell lung carcinoma | NC_000017.11:g.7675209A>G | ClinVar |
RCV000429841 | p.Cys135Trp | missense variant | Adrenocortical carcinoma | NC_000017.11:g.7675207G>C | ClinVar |
RCV000418091 | p.Cys135Arg | missense variant | Neoplasm of brain | NC_000017.11:g.7675209A>G | ClinVar |
RCV000440105 | p.Cys135Arg | missense variant | Adenocarcinoma of stomach | NC_000017.11:g.7675209A>G | ClinVar |
RCV000432245 | p.Cys135Trp | missense variant | Neoplasm of brain | NC_000017.11:g.7675207G>C | ClinVar |
RCV000425388 | p.Cys135Arg | missense variant | Lung adenocarcinoma | NC_000017.11:g.7675209A>G | ClinVar |
RCV000423943 | p.Cys135Arg | missense variant | Neoplasm of the breast | NC_000017.11:g.7675209A>G | ClinVar |
RCV000441628 | p.Cys135Trp | missense variant | Adenocarcinoma of stomach | NC_000017.11:g.7675207G>C | ClinVar |
RCV000417767 | p.Cys135Trp | missense variant | Carcinoma of esophagus | NC_000017.11:g.7675207G>C | ClinVar |
RCV000422903 | p.Cys135Arg | missense variant | Adenocarcinoma of prostate | NC_000017.11:g.7675209A>G | ClinVar |
RCV000423274 | p.Cys135Trp | missense variant | Hepatocellular carcinoma (HCC) | NC_000017.11:g.7675207G>C | ClinVar |
RCV000430892 | p.Cys135Trp | missense variant | Adenocarcinoma of prostate | NC_000017.11:g.7675207G>C | ClinVar |
RCV000444995 | p.Cys135Arg | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7675209A>G | ClinVar |
RCV000433604 | p.Cys135Arg | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7675209A>G | ClinVar |
RCV000432610 | p.Cys135Arg | missense variant | Hepatocellular carcinoma (HCC) | NC_000017.11:g.7675209A>G | ClinVar |
RCV000492493 | p.Cys135Ter | frameshift | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7675207_7675209delinsCC | ClinVar |
RCV000426036 | p.Cys135Arg | missense variant | Adrenocortical carcinoma | NC_000017.11:g.7675209A>G | ClinVar |
RCV000439451 | p.Cys135Trp | missense variant | - | NC_000017.11:g.7675207G>C | ClinVar |
RCV000422242 | p.Cys135Tyr | missense variant | Adenocarcinoma of prostate | NC_000017.11:g.7675208C>T | ClinVar |
RCV000426876 | p.Cys135Phe | missense variant | Neoplasm of the large intestine | NC_000017.11:g.7675208C>A | ClinVar |
RCV000435797 | p.Cys135Phe | missense variant | Adenocarcinoma of stomach | NC_000017.11:g.7675208C>A | ClinVar |
RCV000436440 | p.Cys135Phe | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7675208C>A | ClinVar |
RCV000434318 | p.Cys135Phe | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7675208C>A | ClinVar |
COSM5369713 | p.Cys135SerPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7675208C>- | NCI-TCGA Cosmic |
COSM13156 | p.Cys135AlaPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7675209A>- | NCI-TCGA Cosmic |
COSM44319 | p.Cys135Ter | stop gained | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7675207G>T | NCI-TCGA Cosmic |
RCV000439440 | p.Cys135Tyr | missense variant | Lung adenocarcinoma | NC_000017.11:g.7675208C>T | ClinVar |
RCV000425788 | p.Cys135Phe | missense variant | Adrenocortical carcinoma | NC_000017.11:g.7675208C>A | ClinVar |
RCV000431855 | p.Cys135Tyr | missense variant | Hepatocellular carcinoma (HCC) | NC_000017.11:g.7675208C>T | ClinVar |
RCV000130396 | p.Cys135Tyr | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7675208C>T | ClinVar |
RCV000423651 | p.Cys135Tyr | missense variant | Adrenocortical carcinoma | NC_000017.11:g.7675208C>T | ClinVar |
RCV000438861 | p.Cys135Phe | missense variant | Squamous cell lung carcinoma | NC_000017.11:g.7675208C>A | ClinVar |
RCV000421166 | p.Cys135Tyr | missense variant | - | NC_000017.11:g.7675208C>T | ClinVar |
RCV000418582 | p.Cys135Phe | missense variant | Adenocarcinoma of prostate | NC_000017.11:g.7675208C>A | ClinVar |
RCV000437052 | p.Cys135Tyr | missense variant | Neoplasm of the breast | NC_000017.11:g.7675208C>T | ClinVar |
RCV000438381 | p.Cys135Tyr | missense variant | Squamous cell lung carcinoma | NC_000017.11:g.7675208C>T | ClinVar |
RCV000581322 | p.Cys135Tyr | missense variant | - | NC_000017.11:g.7675208C>T | ClinVar |
RCV000428748 | p.Cys135Tyr | missense variant | Neoplasm of the large intestine | NC_000017.11:g.7675208C>T | ClinVar |
RCV000419337 | p.Cys135Tyr | missense variant | Carcinoma of esophagus | NC_000017.11:g.7675208C>T | ClinVar |
RCV000444605 | p.Cys135Phe | missense variant | - | NC_000017.11:g.7675208C>A | ClinVar |
RCV000444308 | p.Cys135Phe | missense variant | Hepatocellular carcinoma (HCC) | NC_000017.11:g.7675208C>A | ClinVar |
RCV000417503 | p.Cys135Phe | missense variant | Neoplasm of brain | NC_000017.11:g.7675208C>A | ClinVar |
RCV000427781 | p.Cys135Phe | missense variant | Carcinoma of esophagus | NC_000017.11:g.7675208C>A | ClinVar |
RCV000429447 | p.Cys135Tyr | missense variant | Adenocarcinoma of stomach | NC_000017.11:g.7675208C>T | ClinVar |
RCV000428180 | p.Cys135Phe | missense variant | Lung adenocarcinoma | NC_000017.11:g.7675208C>A | ClinVar |
NCI-TCGA novel | p.Cys135LeuPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7675208_7675209insA | NCI-TCGA |
NCI-TCGA novel | p.Cys135Ter | stop gained | - | NC_000017.11:g.7675206_7675207GG>- | NCI-TCGA |
rs1057519975 | p.Cys135Arg | missense variant | - | NC_000017.11:g.7675209A>G | UniProt,dbSNP |
VAR_044754 | p.Cys135Arg | missense variant | - | NC_000017.11:g.7675209A>G | UniProt |
rs587781991 | p.Cys135Phe | missense variant | - | NC_000017.11:g.7675208C>A | UniProt,dbSNP |
VAR_005877 | p.Cys135Phe | missense variant | - | NC_000017.11:g.7675208C>A | UniProt |
rs587781991 | p.Cys135Phe | missense variant | - | NC_000017.11:g.7675208C>A | - |
rs1057519975 | p.Cys135Ser | missense variant | - | NC_000017.11:g.7675209A>T | UniProt,dbSNP |
VAR_005876 | p.Cys135Ser | missense variant | - | NC_000017.11:g.7675209A>T | UniProt |
rs1057519975 | p.Cys135Gly | missense variant | - | NC_000017.11:g.7675209A>C | UniProt,dbSNP |
VAR_044753 | p.Cys135Gly | missense variant | - | NC_000017.11:g.7675209A>C | UniProt |
RCV000419825 | p.Cys135Tyr | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7675208C>T | ClinVar |
RCV000444676 | p.Cys135Tyr | missense variant | Neoplasm of brain | NC_000017.11:g.7675208C>T | ClinVar |
RCV000436707 | p.Cys135Phe | missense variant | Neoplasm of the breast | NC_000017.11:g.7675208C>A | ClinVar |
RCV000492398 | p.Cys135Phe | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7675208C>A | ClinVar |
RCV000430048 | p.Cys135Tyr | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7675208C>T | ClinVar |
RCV000434979 | p.Cys135Trp | missense variant | Neoplasm of the breast | NC_000017.11:g.7675207G>C | ClinVar |
RCV000424924 | p.Cys135Trp | missense variant | Lung adenocarcinoma | NC_000017.11:g.7675207G>C | ClinVar |
RCV000434656 | p.Cys135Arg | missense variant | Neoplasm of the large intestine | NC_000017.11:g.7675209A>G | ClinVar |
RCV000444209 | p.Cys135Arg | missense variant | - | NC_000017.11:g.7675209A>G | ClinVar |
RCV000435704 | p.Cys135Trp | missense variant | Neoplasm of the large intestine | NC_000017.11:g.7675207G>C | ClinVar |
RCV000440498 | p.Cys135Trp | missense variant | Squamous cell lung carcinoma | NC_000017.11:g.7675207G>C | ClinVar |
RCV000420893 | p.Cys135Trp | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7675207G>C | ClinVar |
RCV000570655 | p.Cys135Gly | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7675209A>C | ClinVar |
RCV000430504 | p.Cys135Arg | missense variant | Carcinoma of esophagus | NC_000017.11:g.7675209A>G | ClinVar |
rs587781991 | p.Cys135Tyr | missense variant | - | NC_000017.11:g.7675208C>T | UniProt,dbSNP |
VAR_044756 | p.Cys135Tyr | missense variant | - | NC_000017.11:g.7675208C>T | UniProt |
rs587781991 | p.Cys135Tyr | missense variant | - | NC_000017.11:g.7675208C>T | - |
VAR_045792 | p.Cys135Thr | Missense | - | - | UniProt |
RCV000165874 | p.Gln136His | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7675204T>G | ClinVar |
RCV000229644 | p.Gln136His | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675204T>G | ClinVar |
COSM11166 | p.Gln136Ter | stop gained | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7675206G>A | NCI-TCGA Cosmic |
RCV000572692 | p.Gln136Glu | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7675206G>C | ClinVar |
RCV000704458 | p.Gln136Pro | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675205T>G | ClinVar |
RCV000571644 | p.Gln136His | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7675204T>A | ClinVar |
rs758781593 | p.Gln136His | missense variant | - | NC_000017.11:g.7675204T>A | ExAC,TOPMed,gnomAD |
rs1555526268 | p.Gln136Glu | missense variant | - | NC_000017.11:g.7675206G>C | - |
rs1555526268 | p.Gln136Glu | missense variant | - | NC_000017.11:g.7675206G>C | UniProt,dbSNP |
VAR_005878 | p.Gln136Glu | missense variant | - | NC_000017.11:g.7675206G>C | UniProt |
rs758781593 | p.Gln136His | missense variant | - | NC_000017.11:g.7675204T>G | ExAC,TOPMed,gnomAD |
VAR_044759 | p.Gln136Arg | Missense | - | - | UniProt |
VAR_005879 | p.Gln136Lys | Missense | - | - | UniProt |
VAR_044758 | p.Gln136Pro | Missense | - | - | UniProt |
COSM1172505 | p.Leu137Gln | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7675202A>T | NCI-TCGA Cosmic |
NCI-TCGA novel | p.Leu137ProPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7675201_7675204CAGT>- | NCI-TCGA |
VAR_044762 | p.Leu137Val | Missense | - | - | UniProt |
VAR_044760 | p.Leu137Met | Missense | - | - | UniProt |
VAR_005880 | p.Leu137Gln | Missense | - | - | UniProt |
VAR_044761 | p.Leu137Pro | Missense | - | - | UniProt |
rs28934875 | p.Ala138Pro | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675200C>G | UniProt,dbSNP |
VAR_005881 | p.Ala138Pro | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675200C>G | UniProt |
RCV000813957 | p.Ala138Val | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675199G>A | ClinVar |
COSM3403284 | p.Ala138Thr | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7675200C>T | NCI-TCGA Cosmic |
RCV000164195 | p.Ala138Val | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7675199G>A | ClinVar |
NCI-TCGA novel | p.Ala138CysPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7675185_7675200CAGGGCAGGTCTTGGC>- | NCI-TCGA |
rs750600586 | p.Ala138Asp | missense variant | - | NC_000017.11:g.7675199G>T | ExAC,gnomAD |
rs750600586 | p.Ala138Val | missense variant | - | NC_000017.11:g.7675199G>A | UniProt,dbSNP |
VAR_033034 | p.Ala138Val | missense variant | - | NC_000017.11:g.7675199G>A | UniProt |
rs750600586 | p.Ala138Val | missense variant | - | NC_000017.11:g.7675199G>A | ExAC,gnomAD |
RCV000633392 | p.Ala138Asp | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675199G>T | ClinVar |
RCV000461233 | p.Ala138Pro | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675200C>G | ClinVar |
VAR_044764 | p.Ala138Ser | Missense | Li-Fraumeni syndrome (LFS) [MIM:151623] | - | UniProt |
VAR_044765 | p.Ala138Thr | Missense | - | - | UniProt |
VAR_044763 | p.Ala138Asp | Missense | - | - | UniProt |
RCV000785252 | p.Lys139Ter | nonsense | Ovarian Neoplasms | NC_000017.11:g.7675197T>A | ClinVar |
RCV000119794 | p.Lys139Ter | frameshift | Familial cancer of breast | NC_000017.11:g.7675199del | ClinVar |
COSM2151006 | p.Lys139AsnPheSerTerUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7675194_7675195TC>- | NCI-TCGA Cosmic |
COSM44110 | p.Lys139ArgPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7675196T>- | NCI-TCGA Cosmic |
COSM1303397 | p.Lys139Asn | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7675195C>G | NCI-TCGA Cosmic |
NCI-TCGA novel | p.Lys139AlaPheSerTerUnk | frameshift | - | NC_000017.11:g.7675185_7675198CAGGGCAGGTCTTG>- | NCI-TCGA |
NCI-TCGA novel | p.Lys139ProPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7675161_7675197GTGTGGAATCAACCCACAGCTGCACAGGGCAGGTCTT>- | NCI-TCGA |
NCI-TCGA novel | p.Lys139Thr | inframe deletion | - | NC_000017.11:g.7675188_7675196GGCAGGTCT>- | NCI-TCGA |
NCI-TCGA novel | p.Lys139CysPheSerTerUnk | frameshift | - | NC_000017.11:g.7675187_7675197GGGCAGGTCTT>- | NCI-TCGA |
RCV000709406 | p.Lys139Asn | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675195C>A | ClinVar |
rs1212996409 | p.Lys139Glu | missense variant | - | NC_000017.11:g.7675197T>C | TOPMed |
rs1212996409 | p.Lys139Glu | missense variant | - | NC_000017.11:g.7675197T>C | UniProt,dbSNP |
VAR_044766 | p.Lys139Glu | missense variant | - | NC_000017.11:g.7675197T>C | UniProt |
VAR_044768 | p.Lys139Arg | Missense | - | - | UniProt |
VAR_005882 | p.Lys139Asn | Missense | - | - | UniProt |
VAR_044769 | p.Lys139Thr | Missense | - | - | UniProt |
VAR_044767 | p.Lys139Gln | Missense | - | - | UniProt |
COSM69088 | p.Thr140MetPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7675187_7675193GGGCAGG>- | NCI-TCGA Cosmic |
rs786202561 | p.Thr140Asn | missense variant | - | NC_000017.11:g.7675193G>T | - |
rs786202561 | p.Thr140Asn | missense variant | - | NC_000017.11:g.7675193G>T | UniProt,dbSNP |
VAR_044772 | p.Thr140Asn | missense variant | - | NC_000017.11:g.7675193G>T | UniProt |
RCV000165423 | p.Thr140Asn | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7675193G>T | ClinVar |
VAR_044773 | p.Thr140Pro | Missense | - | - | UniProt |
VAR_044770 | p.Thr140Ala | Missense | - | - | UniProt |
VAR_044774 | p.Thr140Ser | Missense | - | - | UniProt |
VAR_044771 | p.Thr140Ile | Missense | - | - | UniProt |
rs1057519977 | p.Cys141Trp | missense variant | - | NC_000017.11:g.7675189G>C | UniProt,dbSNP |
VAR_044777 | p.Cys141Trp | missense variant | - | NC_000017.11:g.7675189G>C | UniProt |
rs587781288 | p.Cys141Tyr | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675190C>T | UniProt,dbSNP |
VAR_005886 | p.Cys141Tyr | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675190C>T | UniProt |
RCV000438636 | p.Cys141Gly | missense variant | Adenocarcinoma of prostate | NC_000017.11:g.7675191A>C | ClinVar |
RCV000467641 | p.Cys141Trp | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675189G>C | ClinVar |
RCV000433900 | p.Cys141Ser | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7675191A>T | ClinVar |
RCV000444521 | p.Cys141Gly | missense variant | Squamous cell lung carcinoma | NC_000017.11:g.7675191A>C | ClinVar |
RCV000428237 | p.Cys141Ser | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7675191A>T | ClinVar |
RCV000432969 | p.Cys141Gly | missense variant | Malignant neoplasm of body of uterus | NC_000017.11:g.7675191A>C | ClinVar |
RCV000440220 | p.Cys141Arg | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7675191A>G | ClinVar |
RCV000431037 | p.Cys141Arg | missense variant | Malignant neoplasm of body of uterus | NC_000017.11:g.7675191A>G | ClinVar |
RCV000418678 | p.Cys141Arg | missense variant | Lung adenocarcinoma | NC_000017.11:g.7675191A>G | ClinVar |
RCV000432852 | p.Cys141Ser | missense variant | Lung adenocarcinoma | NC_000017.11:g.7675191A>T | ClinVar |
RCV000438490 | p.Cys141Ser | missense variant | Neoplasm of the large intestine | NC_000017.11:g.7675191A>T | ClinVar |
RCV000437911 | p.Cys141Gly | missense variant | Renal cell carcinoma, papillary, 1 (RCCP1) | NC_000017.11:g.7675191A>C | ClinVar |
RCV000417913 | p.Cys141Ser | missense variant | Neoplasm of the breast | NC_000017.11:g.7675191A>T | ClinVar |
RCV000430556 | p.Cys141Ser | missense variant | Acute myeloid leukemia (AML) | NC_000017.11:g.7675191A>T | ClinVar |
RCV000436190 | p.Cys141Arg | missense variant | Adenocarcinoma of prostate | NC_000017.11:g.7675191A>G | ClinVar |
RCV000437414 | p.Cys141Arg | missense variant | Neoplasm of the breast | NC_000017.11:g.7675191A>G | ClinVar |
RCV000423623 | p.Cys141Arg | missense variant | Multiple myeloma (MM) | NC_000017.11:g.7675191A>G | ClinVar |
RCV000419137 | p.Cys141Gly | missense variant | Acute myeloid leukemia (AML) | NC_000017.11:g.7675191A>C | ClinVar |
RCV000432161 | p.Cys141Arg | missense variant | Renal cell carcinoma, papillary, 1 (RCCP1) | NC_000017.11:g.7675191A>G | ClinVar |
RCV000427661 | p.Cys141Gly | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7675191A>C | ClinVar |
RCV000430017 | p.Cys141Arg | missense variant | Squamous cell lung carcinoma | NC_000017.11:g.7675191A>G | ClinVar |
RCV000422574 | p.Cys141Ser | missense variant | Malignant neoplasm of body of uterus | NC_000017.11:g.7675191A>T | ClinVar |
RCV000441312 | p.Cys141Arg | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7675191A>G | ClinVar |
RCV000420961 | p.Cys141Gly | missense variant | Neoplasm of the large intestine | NC_000017.11:g.7675191A>C | ClinVar |
RCV000421892 | p.Cys141Ser | missense variant | Neoplasm of brain | NC_000017.11:g.7675191A>T | ClinVar |
RCV000442038 | p.Cys141Ser | missense variant | Multiple myeloma (MM) | NC_000017.11:g.7675191A>T | ClinVar |
RCV000426677 | p.Cys141Gly | missense variant | Multiple myeloma (MM) | NC_000017.11:g.7675191A>C | ClinVar |
RCV000427605 | p.Cys141Phe | missense variant | Adenocarcinoma of prostate | NC_000017.11:g.7675190C>A | ClinVar |
RCV000433302 | p.Cys141Phe | missense variant | Neoplasm of the breast | NC_000017.11:g.7675190C>A | ClinVar |
COSM1522477 | p.Cys141Ter | stop gained | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7675189G>T | NCI-TCGA Cosmic |
COSM293910 | p.Cys141Ser | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7675190C>G | NCI-TCGA Cosmic |
COSM69019 | p.Cys141AlaPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7675192G>- | NCI-TCGA Cosmic |
RCV000444376 | p.Cys141Phe | missense variant | Neoplasm of the large intestine | NC_000017.11:g.7675190C>A | ClinVar |
RCV000436176 | p.Cys141Phe | missense variant | Multiple myeloma (MM) | NC_000017.11:g.7675190C>A | ClinVar |
RCV000417404 | p.Cys141Phe | missense variant | Acute myeloid leukemia (AML) | NC_000017.11:g.7675190C>A | ClinVar |
RCV000435499 | p.Cys141Phe | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7675190C>A | ClinVar |
RCV000418478 | p.Cys141Phe | missense variant | Renal cell carcinoma, papillary, 1 (RCCP1) | NC_000017.11:g.7675190C>A | ClinVar |
RCV000423030 | p.Cys141Phe | missense variant | Malignant neoplasm of body of uterus | NC_000017.11:g.7675190C>A | ClinVar |
rs1057519978 | p.Cys141Arg | missense variant | - | NC_000017.11:g.7675191A>G | UniProt,dbSNP |
VAR_044775 | p.Cys141Arg | missense variant | - | NC_000017.11:g.7675191A>G | UniProt |
rs1057519978 | p.Cys141Arg | missense variant | - | NC_000017.11:g.7675191A>G | - |
RCV000504610 | p.Cys141Ter | frameshift | Neoplasm of the breast | NC_000017.11:g.7675192_7675196dup | ClinVar |
rs1057519978 | p.Cys141Gly | missense variant | - | NC_000017.11:g.7675191A>C | UniProt,dbSNP |
VAR_005884 | p.Cys141Gly | missense variant | - | NC_000017.11:g.7675191A>C | UniProt |
rs1057519978 | p.Cys141Gly | missense variant | - | NC_000017.11:g.7675191A>C | - |
rs587781288 | p.Cys141Phe | missense variant | - | NC_000017.11:g.7675190C>A | UniProt,dbSNP |
VAR_005885 | p.Cys141Phe | missense variant | - | NC_000017.11:g.7675190C>A | UniProt |
RCV000437866 | p.Cys141Phe | missense variant | Neoplasm of brain | NC_000017.11:g.7675190C>A | ClinVar |
RCV000425219 | p.Cys141Phe | missense variant | Lung adenocarcinoma | NC_000017.11:g.7675190C>A | ClinVar |
RCV000429427 | p.Cys141Phe | missense variant | Squamous cell lung carcinoma | NC_000017.11:g.7675190C>A | ClinVar |
RCV000445236 | p.Cys141Phe | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7675190C>A | ClinVar |
RCV000472876 | p.Cys141Tyr | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675190C>T | ClinVar |
RCV000128975 | p.Cys141Tyr | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7675190C>T | ClinVar |
RCV000420817 | p.Cys141Arg | missense variant | Acute myeloid leukemia (AML) | NC_000017.11:g.7675191A>G | ClinVar |
RCV000439533 | p.Cys141Ser | missense variant | Squamous cell lung carcinoma | NC_000017.11:g.7675191A>T | ClinVar |
RCV000425407 | p.Cys141Arg | missense variant | Neoplasm of the large intestine | NC_000017.11:g.7675191A>G | ClinVar |
RCV000436820 | p.Cys141Gly | missense variant | Neoplasm of the breast | NC_000017.11:g.7675191A>C | ClinVar |
RCV000439057 | p.Cys141Ser | missense variant | Adenocarcinoma of prostate | NC_000017.11:g.7675191A>T | ClinVar |
RCV000419723 | p.Cys141Arg | missense variant | Neoplasm of brain | NC_000017.11:g.7675191A>G | ClinVar |
RCV000425541 | p.Cys141Gly | missense variant | Lung adenocarcinoma | NC_000017.11:g.7675191A>C | ClinVar |
RCV000432339 | p.Cys141Gly | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7675191A>C | ClinVar |
RCV000444835 | p.Cys141Gly | missense variant | Neoplasm of brain | NC_000017.11:g.7675191A>C | ClinVar |
RCV000420314 | p.Cys141Ser | missense variant | Renal cell carcinoma, papillary, 1 (RCCP1) | NC_000017.11:g.7675191A>T | ClinVar |
rs1057519978 | p.Cys141Ser | missense variant | - | NC_000017.11:g.7675191A>T | UniProt,dbSNP |
VAR_044776 | p.Cys141Ser | missense variant | - | NC_000017.11:g.7675191A>T | UniProt |
rs1057519978 | p.Cys141Ser | missense variant | - | NC_000017.11:g.7675191A>T | - |
VAR_045793 | p.Cys141Ala | Missense | - | - | UniProt |
NCI-TCGA novel | p.Pro142LeuPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7675187G>- | NCI-TCGA |
rs779196500 | p.Pro142Leu | missense variant | - | NC_000017.11:g.7675187G>A | UniProt,dbSNP |
VAR_044780 | p.Pro142Leu | missense variant | - | NC_000017.11:g.7675187G>A | UniProt |
rs779196500 | p.Pro142Leu | missense variant | - | NC_000017.11:g.7675187G>A | ExAC,gnomAD |
VAR_044783 | p.Pro142Thr | Missense | - | - | UniProt |
VAR_045794 | p.Pro142Phe | Missense | - | - | UniProt |
VAR_044779 | p.Pro142His | Missense | - | - | UniProt |
VAR_044781 | p.Pro142Arg | Missense | - | - | UniProt |
VAR_044782 | p.Pro142Ser | Missense | - | - | UniProt |
VAR_044778 | p.Pro142Ala | Missense | - | - | UniProt |
rs587782620 | p.Val143Leu | missense variant | - | NC_000017.11:g.7675185C>A | UniProt,dbSNP |
VAR_044786 | p.Val143Leu | missense variant | - | NC_000017.11:g.7675185C>A | UniProt |
rs1555526241 | p.Val143Gly | missense variant | - | NC_000017.11:g.7675184A>C | - |
rs1555526241 | p.Val143Gly | missense variant | - | NC_000017.11:g.7675184A>C | UniProt,dbSNP |
VAR_044785 | p.Val143Gly | missense variant | - | NC_000017.11:g.7675184A>C | UniProt |
COSM11306 | p.Val143Ala | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7675184A>G | NCI-TCGA Cosmic |
COSM3522705 | p.Val143Glu | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7675184A>T | NCI-TCGA Cosmic |
RCV000413546 | p.Val143Met | missense variant | Neoplasm of the breast | NC_000017.11:g.7675185C>T | ClinVar |
RCV000165206 | p.Val143Leu | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7675185C>A | ClinVar |
NCI-TCGA novel | p.Val143AlaPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7675184_7675185insCAGGG | NCI-TCGA |
NCI-TCGA novel | p.Val143GlyPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7675184_7675185insCAGGGCAGGTCTTGGC | NCI-TCGA |
NCI-TCGA novel | p.Val143ArgPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7675159_7675186GGGTGTGGAATCAACCCACAGCTGCACA>- | NCI-TCGA |
rs587782620 | p.Val143Met | missense variant | - | NC_000017.11:g.7675185C>T | UniProt,dbSNP |
VAR_044787 | p.Val143Met | missense variant | - | NC_000017.11:g.7675185C>T | UniProt |
RCV000562247 | p.Val143Gly | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7675184A>C | ClinVar |
VAR_005887 | p.Val143Ala | Missense | - | - | UniProt |
VAR_044784 | p.Val143Glu | Missense | - | - | UniProt |
rs786201419 | p.Gln144His | missense variant | - | NC_000017.11:g.7675180C>A | TOPMed |
rs786203071 | p.Gln144Leu | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675181T>A | UniProt,dbSNP |
VAR_044790 | p.Gln144Leu | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675181T>A | UniProt |
RCV000430092 | p.Gln144His | missense variant | - | NC_000017.11:g.7675180C>A | ClinVar |
RCV000425167 | p.Gln144Leu | missense variant | Hepatocellular carcinoma (HCC) | NC_000017.11:g.7675181T>A | ClinVar |
RCV000435123 | p.Gln144Leu | missense variant | Adenocarcinoma of stomach | NC_000017.11:g.7675181T>A | ClinVar |
RCV000423654 | p.Gln144Leu | missense variant | Malignant neoplasm of body of uterus | NC_000017.11:g.7675181T>A | ClinVar |
COSM69087 | p.Gln144AlaPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7675152_7675182CGGGCGGGGGTGTGGAATCAACCCACAGCTG>- | NCI-TCGA Cosmic |
NCI-TCGA novel | p.Gln144LeuPheSerTerUnk | frameshift | - | NC_000017.11:g.7675181_7675182insA | NCI-TCGA |
NCI-TCGA novel | p.Gln144GlyPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7675177_7675183CAGCTGC>- | NCI-TCGA |
NCI-TCGA novel | p.Gln144ThrPheSerTerUnk | frameshift | - | NC_000017.11:g.7675182_7675183insT | NCI-TCGA |
RCV000785285 | p.Gln144Ter | nonsense | Ovarian Neoplasms | NC_000017.11:g.7675182G>A | ClinVar |
RCV000166212 | p.Gln144Pro | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7675181T>G | ClinVar |
RCV000441498 | p.Gln144His | missense variant | Neoplasm of the breast | NC_000017.11:g.7675180C>A | ClinVar |
RCV000434320 | p.Gln144Leu | missense variant | - | NC_000017.11:g.7675181T>A | ClinVar |
RCV000443135 | p.Gln144Leu | missense variant | Neoplasm of the breast | NC_000017.11:g.7675181T>A | ClinVar |
RCV000434521 | p.Gln144Leu | missense variant | Lung adenocarcinoma | NC_000017.11:g.7675181T>A | ClinVar |
RCV000437256 | p.Gln144His | missense variant | Adenocarcinoma of stomach | NC_000017.11:g.7675180C>A | ClinVar |
RCV000425946 | p.Gln144His | missense variant | Lung adenocarcinoma | NC_000017.11:g.7675180C>A | ClinVar |
rs786201419 | p.Gln144His | missense variant | - | NC_000017.11:g.7675180C>A | UniProt,dbSNP |
VAR_044788 | p.Gln144His | missense variant | - | NC_000017.11:g.7675180C>A | UniProt |
rs786203071 | p.Gln144Pro | missense variant | - | NC_000017.11:g.7675181T>G | UniProt,dbSNP |
VAR_005888 | p.Gln144Pro | missense variant | - | NC_000017.11:g.7675181T>G | UniProt |
rs757274881 | p.Gln144Ter | stop gained | - | NC_000017.11:g.7675182G>A | ExAC,gnomAD |
RCV000418508 | p.Gln144His | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7675180C>A | ClinVar |
RCV000435752 | p.Gln144His | missense variant | Malignant neoplasm of body of uterus | NC_000017.11:g.7675180C>A | ClinVar |
RCV000443744 | p.Gln144Leu | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7675181T>A | ClinVar |
RCV000429945 | p.Gln144His | missense variant | Hepatocellular carcinoma (HCC) | NC_000017.11:g.7675180C>A | ClinVar |
RCV000419148 | p.Gln144His | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7675180C>A | ClinVar |
RCV000443056 | p.Gln144Leu | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7675181T>A | ClinVar |
VAR_044789 | p.Gln144Lys | Missense | - | - | UniProt |
VAR_044791 | p.Gln144Arg | Missense | - | - | UniProt |
rs587782197 | p.Leu145Gln | missense variant | - | NC_000017.11:g.7675178A>T | gnomAD |
COSM1679514 | p.Leu145Arg | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7675178A>C | NCI-TCGA Cosmic |
RCV000785265 | p.Leu145Pro | missense variant | Ovarian Neoplasms | NC_000017.11:g.7675178A>G | ClinVar |
RCV000565971 | p.Leu145Gln | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7675178A>T | ClinVar |
rs587782197 | p.Leu145Pro | missense variant | - | NC_000017.11:g.7675178A>G | gnomAD |
rs587782197 | p.Leu145Pro | missense variant | - | NC_000017.11:g.7675178A>G | UniProt,dbSNP |
VAR_005889 | p.Leu145Pro | missense variant | - | NC_000017.11:g.7675178A>G | UniProt |
VAR_044793 | p.Leu145Arg | Missense | - | - | UniProt |
VAR_044794 | p.Leu145Val | Missense | - | - | UniProt |
VAR_005890 | p.Leu145Gln | Missense | - | - | UniProt |
VAR_044792 | p.Leu145Met | Missense | - | - | UniProt |
RCV000633358 | p.Trp146Ter | nonsense | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675174C>T | ClinVar |
COSM417960 | p.Trp146Ser | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7675175C>G | NCI-TCGA Cosmic |
NCI-TCGA novel | p.Trp146SerPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7675166_7675175GAATCAACCC>- | NCI-TCGA |
NCI-TCGA novel | p.Trp146ValPheSerTerUnk | frameshift | - | NC_000017.11:g.7675177_7675178insA | NCI-TCGA |
rs786203064 | p.Trp146Gly | missense variant | - | NC_000017.11:g.7675176A>C | - |
rs786203064 | p.Trp146Gly | missense variant | - | NC_000017.11:g.7675176A>C | UniProt,dbSNP |
VAR_044796 | p.Trp146Gly | missense variant | - | NC_000017.11:g.7675176A>C | UniProt |
rs1131691026 | p.Trp146Ter | stop gained | - | NC_000017.11:g.7675174C>T | - |
rs1206165503 | p.Trp146Ter | stop gained | - | NC_000017.11:g.7675175C>T | gnomAD |
RCV000785547 | p.Trp146Ter | nonsense | Ovarian Neoplasms | NC_000017.11:g.7675175C>T | ClinVar |
RCV000492181 | p.Trp146Ter | nonsense | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7675174C>T | ClinVar |
RCV000166204 | p.Trp146Gly | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7675176A>C | ClinVar |
VAR_044799 | p.Trp146Ser | Missense | - | - | UniProt |
VAR_044795 | p.Trp146Cys | Missense | - | - | UniProt |
VAR_044798 | p.Trp146Arg | Missense | - | - | UniProt |
VAR_044797 | p.Trp146Leu | Missense | - | - | UniProt |
COSM437583 | p.Val147LeuPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7675173C>- | NCI-TCGA Cosmic |
rs1453167097 | p.Val147Gly | missense variant | - | NC_000017.11:g.7675172A>C | TOPMed |
rs1453167097 | p.Val147Gly | missense variant | - | NC_000017.11:g.7675172A>C | UniProt,dbSNP |
VAR_005892 | p.Val147Gly | missense variant | - | NC_000017.11:g.7675172A>C | UniProt |
RCV000633361 | p.Val147Ile | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675173C>T | ClinVar |
rs1555526226 | p.Val147Ile | missense variant | - | NC_000017.11:g.7675173C>T | - |
rs1555526226 | p.Val147Ile | missense variant | - | NC_000017.11:g.7675173C>T | UniProt,dbSNP |
VAR_044803 | p.Val147Ile | missense variant | - | NC_000017.11:g.7675173C>T | UniProt |
RCV000785251 | p.Val147Ter | frameshift | Ovarian Neoplasms | NC_000017.11:g.7675175del | ClinVar |
VAR_044802 | p.Val147Phe | Missense | - | - | UniProt |
VAR_005891 | p.Val147Asp | Missense | - | - | UniProt |
VAR_044801 | p.Val147Glu | Missense | - | - | UniProt |
VAR_044800 | p.Val147Ala | Missense | - | - | UniProt |
rs1046611742 | p.Asp148Ala | missense variant | - | NC_000017.11:g.7675169T>G | - |
rs1131691007 | p.Asp148Tyr | missense variant | - | NC_000017.11:g.7675170C>A | gnomAD |
rs1131691007 | p.Asp148Tyr | missense variant | - | NC_000017.11:g.7675170C>A | UniProt,dbSNP |
VAR_044809 | p.Asp148Tyr | missense variant | - | NC_000017.11:g.7675170C>A | UniProt |
RCV000492685 | p.Asp148Tyr | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7675170C>A | ClinVar |
RCV000799619 | p.Asp148Tyr | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675170C>A | ClinVar |
RCV000569500 | p.Asp148Ala | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7675169T>G | ClinVar |
COSM46341 | p.Asp148IlePheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7675171A>- | NCI-TCGA Cosmic |
COSM44043 | p.Asp148Asn | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7675170C>T | NCI-TCGA Cosmic |
VAR_044806 | p.Asp148Gly | Missense | - | - | UniProt |
VAR_044805 | p.Asp148Glu | Missense | - | - | UniProt |
VAR_044808 | p.Asp148Val | Missense | - | - | UniProt |
VAR_044807 | p.Asp148Asn | Missense | - | - | UniProt |
RCV000785335 | p.Ser149Ter | frameshift | Ovarian Neoplasms | NC_000017.11:g.7675168dup | ClinVar |
RCV000785501 | p.Ser149Ter | frameshift | Ovarian Neoplasms | NC_000017.11:g.7675168del | ClinVar |
RCV000481047 | p.Ser149Ter | frameshift | - | NC_000017.11:g.7675168del | ClinVar |
COSM1324767 | p.Ser149PhePheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7675166_7675167insA | NCI-TCGA Cosmic |
COSM1163644 | p.Ser149ProPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7675167A>- | NCI-TCGA Cosmic |
rs1555526214 | p.Ser149Phe | missense variant | - | NC_000017.11:g.7675166G>A | UniProt,dbSNP |
VAR_044810 | p.Ser149Phe | missense variant | - | NC_000017.11:g.7675166G>A | UniProt |
rs1555526214 | p.Ser149Phe | missense variant | - | NC_000017.11:g.7675166G>A | - |
RCV000567597 | p.Ser149Phe | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7675166G>A | ClinVar |
VAR_044811 | p.Ser149Thr | Missense | - | - | UniProt |
VAR_005893 | p.Ser149Pro | Missense | - | - | UniProt |
RCV000582435 | p.Thr150Ter | frameshift | - | NC_000017.11:g.7675152_7675164del | ClinVar |
RCV000475282 | p.Thr150Ter | frameshift | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675152_7675164del | ClinVar |
RCV000131407 | p.Thr150Ter | frameshift | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7675154_7675166del | ClinVar |
COSM111417 | p.Thr150AlaPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7675152_7675164CGGGCGGGGGTGT>- | NCI-TCGA Cosmic |
COSM1386825 | p.Thr150Ala | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7675164T>C | NCI-TCGA Cosmic |
VAR_044816 | p.Thr150Pro | Missense | - | - | UniProt |
VAR_044814 | p.Thr150Lys | Missense | - | - | UniProt |
VAR_044813 | p.Thr150Ile | Missense | - | - | UniProt |
VAR_044817 | p.Thr150Arg | Missense | - | - | UniProt |
VAR_044812 | p.Thr150Ala | Missense | - | - | UniProt |
VAR_044815 | p.Thr150Asn | Missense | - | - | UniProt |
rs1057520000 | p.Pro151His | missense variant | - | NC_000017.11:g.7675160G>T | UniProt,dbSNP |
VAR_044818 | p.Pro151His | missense variant | - | NC_000017.11:g.7675160G>T | UniProt |
rs28934874 | p.Pro151Ser | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675161G>A | UniProt,dbSNP |
VAR_005895 | p.Pro151Ser | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675161G>A | UniProt |
rs28934874 | p.Pro151Thr | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675161G>T | UniProt,dbSNP |
VAR_005896 | p.Pro151Thr | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675161G>T | UniProt |
RCV000429847 | p.Pro151Ser | missense variant | Neoplasm of the large intestine | NC_000017.11:g.7675161G>A | ClinVar |
RCV000433689 | p.Pro151Ser | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7675161G>A | ClinVar |
RCV000440887 | p.Pro151Ser | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7675161G>A | ClinVar |
RCV000421928 | p.Pro151Ser | missense variant | Carcinoma of esophagus | NC_000017.11:g.7675161G>A | ClinVar |
RCV000423715 | p.Pro151Arg | missense variant | Hepatocellular carcinoma (HCC) | NC_000017.11:g.7675160G>C | ClinVar |
RCV000435893 | p.Pro151Arg | missense variant | Uterine Carcinosarcoma | NC_000017.11:g.7675160G>C | ClinVar |
RCV000424514 | p.Pro151Arg | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7675160G>C | ClinVar |
RCV000633371 | p.Pro151His | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675160G>T | ClinVar |
RCV000439174 | p.Pro151Arg | missense variant | Lung adenocarcinoma | NC_000017.11:g.7675160G>C | ClinVar |
RCV000435439 | p.Pro151Arg | missense variant | Malignant neoplasm of body of uterus | NC_000017.11:g.7675160G>C | ClinVar |
RCV000425600 | p.Pro151Arg | missense variant | Adenocarcinoma of stomach | NC_000017.11:g.7675160G>C | ClinVar |
RCV000767320 | p.Pro151Ter | frameshift | - | NC_000017.11:g.7675154_7675163del | ClinVar |
RCV000430235 | p.Pro151Arg | missense variant | Multiple myeloma (MM) | NC_000017.11:g.7675160G>C | ClinVar |
RCV000436541 | p.Pro151Arg | missense variant | Squamous cell lung carcinoma | NC_000017.11:g.7675160G>C | ClinVar |
RCV000419958 | p.Pro151Arg | missense variant | Neoplasm of the large intestine | NC_000017.11:g.7675160G>C | ClinVar |
RCV000418846 | p.Pro151Arg | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7675160G>C | ClinVar |
RCV000440477 | p.Pro151Arg | missense variant | Carcinoma of esophagus | NC_000017.11:g.7675160G>C | ClinVar |
RCV000119796 | p.Pro151Ter | frameshift | Sarcoma (Liposarcoma) | NC_000017.11:g.7675154_7675163del | ClinVar |
COSM44288 | p.Pro151Leu | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7675160G>A | NCI-TCGA Cosmic |
COSM5174080 | p.Pro151ArgPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7675153_7675160GGGCGGGG>- | NCI-TCGA Cosmic |
RCV000420199 | p.Pro151Ser | missense variant | Malignant melanoma of skin (CMM) | NC_000017.11:g.7675161G>A | ClinVar |
RCV000785532 | p.Pro151Ser | missense variant | Ovarian Neoplasms | NC_000017.11:g.7675161G>A | ClinVar |
RCV000440140 | p.Pro151Ser | missense variant | Neoplasm of the breast | NC_000017.11:g.7675161G>A | ClinVar |
RCV000432585 | p.Pro151Ser | missense variant | Adenoid cystic carcinoma | NC_000017.11:g.7675161G>A | ClinVar |
RCV000443020 | p.Pro151Ser | missense variant | Hepatocellular carcinoma (HCC) | NC_000017.11:g.7675161G>A | ClinVar |
RCV000438074 | p.Pro151Ser | missense variant | Squamous cell lung carcinoma | NC_000017.11:g.7675161G>A | ClinVar |
RCV000219702 | p.Pro151Ser | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7675161G>A | ClinVar |
RCV000422996 | p.Pro151Ser | missense variant | Malignant neoplasm of body of uterus | NC_000017.11:g.7675161G>A | ClinVar |
RCV000426058 | p.Pro151Ser | missense variant | Multiple myeloma (MM) | NC_000017.11:g.7675161G>A | ClinVar |
RCV000013168 | p.Pro151Thr | missense variant | Breast adenocarcinoma | NC_000017.11:g.7675161G>T | ClinVar |
rs1057520000 | p.Pro151Arg | missense variant | - | NC_000017.11:g.7675160G>C | UniProt,dbSNP |
VAR_044820 | p.Pro151Arg | missense variant | - | NC_000017.11:g.7675160G>C | UniProt |
rs28934874 | p.Pro151Ala | missense variant | - | NC_000017.11:g.7675161G>C | - |
rs28934874 | p.Pro151Ala | missense variant | - | NC_000017.11:g.7675161G>C | UniProt,dbSNP |
VAR_005894 | p.Pro151Ala | missense variant | - | NC_000017.11:g.7675161G>C | UniProt |
RCV000420869 | p.Pro151Ser | missense variant | Adenocarcinoma of stomach | NC_000017.11:g.7675161G>A | ClinVar |
RCV000443101 | p.Pro151Arg | missense variant | Neoplasm of the breast | NC_000017.11:g.7675160G>C | ClinVar |
RCV000441608 | p.Pro151Arg | missense variant | Adenoid cystic carcinoma | NC_000017.11:g.7675160G>C | ClinVar |
RCV000431352 | p.Pro151Arg | missense variant | Neoplasm of brain | NC_000017.11:g.7675160G>C | ClinVar |
RCV000434196 | p.Pro151Arg | missense variant | Malignant melanoma of skin (CMM) | NC_000017.11:g.7675160G>C | ClinVar |
RCV000419325 | p.Pro151Arg | missense variant | - | NC_000017.11:g.7675160G>C | ClinVar |
RCV000421526 | p.Pro151Arg | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7675160G>C | ClinVar |
RCV000443379 | p.Pro151Ser | missense variant | - | NC_000017.11:g.7675161G>A | ClinVar |
RCV000435681 | p.Pro151Ser | missense variant | Neoplasm of brain | NC_000017.11:g.7675161G>A | ClinVar |
RCV000427411 | p.Pro151Ser | missense variant | Lung adenocarcinoma | NC_000017.11:g.7675161G>A | ClinVar |
RCV000424996 | p.Pro151Ser | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7675161G>A | ClinVar |
RCV000459465 | p.Pro151Ala | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675161G>C | ClinVar |
RCV000431507 | p.Pro151Ser | missense variant | Uterine Carcinosarcoma | NC_000017.11:g.7675161G>A | ClinVar |
VAR_044819 | p.Pro151Leu | Missense | - | - | UniProt |
RCV000677669 | p.Pro152Leu | missense variant | Li-Fraumeni syndrome 1 (LFS) | NC_000017.11:g.7675157G>A | ClinVar |
RCV000132156 | p.Pro152Leu | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7675157G>A | ClinVar |
RCV000168122 | p.Pro152Leu | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675157G>A | ClinVar |
COSM1180849 | p.Pro152ArgPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7675157G>- | NCI-TCGA Cosmic |
COSM3970373 | p.Pro152Gln | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7675157G>T | NCI-TCGA Cosmic |
COSM1480077 | p.Pro152AlaPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7675146_7675158GGGTGCCGGGCGG>- | NCI-TCGA Cosmic |
RCV000583667 | p.Pro152Leu | missense variant | - | NC_000017.11:g.7675157G>A | ClinVar |
NCI-TCGA novel | p.Pro152TrpPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7675135_7675159GGCGCGGACGCGGGTGCCGGGCGGG>- | NCI-TCGA |
RCV000785525 | p.Pro152Ter | frameshift | Ovarian Neoplasms | NC_000017.11:g.7675161del | ClinVar |
rs767328513 | p.Pro152Ser | missense variant | - | NC_000017.11:g.7675158G>A | UniProt,dbSNP |
VAR_005898 | p.Pro152Ser | missense variant | - | NC_000017.11:g.7675158G>A | UniProt |
rs767328513 | p.Pro152Ser | missense variant | - | NC_000017.11:g.7675158G>A | ExAC,gnomAD |
rs587782705 | p.Pro152Leu | missense variant | - | NC_000017.11:g.7675157G>A | ExAC,TOPMed,gnomAD |
rs587782705 | p.Pro152Leu | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675157G>A | UniProt,dbSNP |
VAR_005897 | p.Pro152Leu | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675157G>A | UniProt |
RCV000785557 | p.Pro152Ter | frameshift | Ovarian Neoplasms | NC_000017.11:g.7675160_7675162delinsA | ClinVar |
RCV000570923 | p.Pro152Ser | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7675158G>A | ClinVar |
RCV000755703 | p.Pro152Leu | missense variant | Familial cancer of breast | NC_000017.11:g.7675157G>A | ClinVar |
RCV000220919 | p.Pro152Ter | frameshift | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7675151_7675163del | ClinVar |
RCV000785289 | p.Pro152Ter | frameshift | Ovarian Neoplasms | NC_000017.11:g.7675151_7675163del | ClinVar |
VAR_044823 | p.Pro152Arg | Missense | - | - | UniProt |
VAR_044821 | p.Pro152Ala | Missense | - | - | UniProt |
VAR_044822 | p.Pro152Gln | Missense | - | - | UniProt |
VAR_044824 | p.Pro152Thr | Missense | - | - | UniProt |
RCV000481578 | p.Pro153Ser | missense variant | - | NC_000017.11:g.7675155G>A | ClinVar |
RCV000561574 | p.Pro153Ser | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7675155G>A | ClinVar |
RCV000795252 | p.Pro153Ser | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675155G>A | ClinVar |
RCV000161060 | p.Pro153Ter | frameshift | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7675161dup | ClinVar |
RCV000013155 | p.Pro153Ter | frameshift | Li-Fraumeni syndrome 1 (LFS) | NC_000017.11:g.7675161dup | ClinVar |
NCI-TCGA novel | p.Pro153ArgPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7675156_7675157insGG | NCI-TCGA |
NCI-TCGA novel | p.Pro153AlaPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7675156_7675157insA | NCI-TCGA |
RCV000766936 | p.Pro153Ter | frameshift | - | NC_000017.11:g.7675161dup | ClinVar |
rs1064795860 | p.Pro153Ser | missense variant | - | NC_000017.11:g.7675155G>A | - |
rs1064795860 | p.Pro153Ser | missense variant | - | NC_000017.11:g.7675155G>A | UniProt,dbSNP |
VAR_044829 | p.Pro153Ser | missense variant | - | NC_000017.11:g.7675155G>A | UniProt |
rs730882019 | p.Pro153AlaPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7675156_7675157insG | NCI-TCGA,NCI-TCGA Cosmic |
VAR_044826 | p.Pro153His | Missense | - | - | UniProt |
VAR_045795 | p.Pro153Phe | Missense | - | - | UniProt |
VAR_005899 | p.Pro153Thr | Missense | - | - | UniProt |
VAR_044827 | p.Pro153Leu | Missense | - | - | UniProt |
VAR_044828 | p.Pro153Arg | Missense | - | - | UniProt |
VAR_044825 | p.Pro153Ala | Missense | - | - | UniProt |
rs762846821 | p.Gly154Val | missense variant | - | NC_000017.11:g.7675151C>A | ExAC,TOPMed,gnomAD |
rs762846821 | p.Gly154Val | missense variant | - | NC_000017.11:g.7675151C>A | UniProt,dbSNP |
VAR_005900 | p.Gly154Val | missense variant | - | NC_000017.11:g.7675151C>A | UniProt |
RCV000567683 | p.Gly154Arg | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7675152C>G | ClinVar |
RCV000690679 | p.Gly154Arg | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675152C>G | ClinVar |
RCV000119797 | p.Gly154Ser | missense variant | Sarcoma (Liposarcoma) | NC_000017.11:g.7675152C>T | ClinVar |
RCV000662397 | p.Gly154Asp | missense variant | Li-Fraumeni syndrome 1 (LFS) | NC_000017.11:g.7675151C>T | ClinVar |
COSM404850 | p.Gly154AlaPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7675153G>- | NCI-TCGA Cosmic |
COSM1640854 | p.Gly154AlaPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7675156C>- | NCI-TCGA Cosmic |
COSM5315967 | p.Gly154AlaPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7675151C>- | NCI-TCGA Cosmic |
rs137852789 | p.Gly154Arg | missense variant | - | NC_000017.11:g.7675152C>G | ExAC,TOPMed,gnomAD |
RCV000785249 | p.Gly154Ter | frameshift | Ovarian Neoplasms | NC_000017.11:g.7675149_7675152del | ClinVar |
RCV000764147 | p.Gly154Asp | missense variant | Adrenocortical carcinoma, hereditary (ADCC) | NC_000017.11:g.7675151C>T | ClinVar |
NCI-TCGA novel | p.Gly154TrpPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7675135_7675153GGCGCGGACGCGGGTGCCG>- | NCI-TCGA |
NCI-TCGA novel | p.Gly154ArgPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7675152_7675153insG | NCI-TCGA |
RCV000492535 | p.Gly154Asp | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7675151C>T | ClinVar |
RCV000231149 | p.Gly154Asp | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675151C>T | ClinVar |
rs762846821 | p.Gly154Asp | missense variant | - | NC_000017.11:g.7675151C>T | ExAC,TOPMed,gnomAD |
rs762846821 | p.Gly154Asp | missense variant | - | NC_000017.11:g.7675151C>T | UniProt,dbSNP |
VAR_044832 | p.Gly154Asp | missense variant | - | NC_000017.11:g.7675151C>T | UniProt |
rs137852789 | p.Gly154Ser | missense variant | - | NC_000017.11:g.7675152C>T | UniProt,dbSNP |
VAR_044833 | p.Gly154Ser | missense variant | - | NC_000017.11:g.7675152C>T | UniProt |
rs137852789 | p.Gly154Ser | missense variant | - | NC_000017.11:g.7675152C>T | ExAC,TOPMed,gnomAD |
VAR_045796 | p.Gly154Ile | Missense | - | - | UniProt |
VAR_044831 | p.Gly154Cys | Missense | - | - | UniProt |
VAR_044830 | p.Gly154Ala | Missense | - | - | UniProt |
rs786202752 | p.Thr155Asn | missense variant | - | NC_000017.11:g.7675148G>T | TOPMed,gnomAD |
COSM44033 | p.Thr155Ile | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7675148G>A | NCI-TCGA Cosmic |
COSM10912 | p.Thr155Pro | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7675149T>G | NCI-TCGA Cosmic |
NCI-TCGA novel | p.Thr155SerPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7675144_7675150GCGGGTG>- | NCI-TCGA |
RCV000534841 | p.Thr155Ala | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675149T>C | ClinVar |
rs772683278 | p.Thr155Ala | missense variant | - | NC_000017.11:g.7675149T>C | UniProt,dbSNP |
VAR_005901 | p.Thr155Ala | missense variant | - | NC_000017.11:g.7675149T>C | UniProt |
rs772683278 | p.Thr155Ala | missense variant | - | NC_000017.11:g.7675149T>C | ExAC,gnomAD |
rs786202752 | p.Thr155Ser | missense variant | - | NC_000017.11:g.7675148G>C | TOPMed,gnomAD |
rs786202752 | p.Thr155Asn | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675148G>T | UniProt,dbSNP |
VAR_044836 | p.Thr155Asn | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675148G>T | UniProt |
rs786202752 | p.Thr155Ser | missense variant | - | NC_000017.11:g.7675148G>C | UniProt,dbSNP |
VAR_044838 | p.Thr155Ser | missense variant | - | NC_000017.11:g.7675148G>C | UniProt |
RCV000804037 | p.Thr155Ser | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675148G>C | ClinVar |
RCV000492645 | p.Thr155Asn | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7675148G>T | ClinVar |
VAR_044837 | p.Thr155Pro | Missense | - | - | UniProt |
VAR_044834 | p.Thr155Ile | Missense | - | - | UniProt |
VAR_044835 | p.Thr155Met | Missense | - | - | UniProt |
RCV000764146 | p.Arg156Cys | missense variant | Adrenocortical carcinoma, hereditary (ADCC) | NC_000017.11:g.7675146G>A | ClinVar |
COSM45154 | p.Arg156Gly | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7675146G>C | NCI-TCGA Cosmic |
COSM44479 | p.Arg156AlaPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7675140_7675146GGACGCG>- | NCI-TCGA Cosmic |
RCV000785506 | p.Arg156Pro | missense variant | Ovarian Neoplasms | NC_000017.11:g.7675145C>G | ClinVar |
RCV000232885 | p.Arg156Cys | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675146G>A | ClinVar |
RCV000409094 | p.Arg156Cys | missense variant | Li-Fraumeni syndrome 1 (LFS) | NC_000017.11:g.7675146G>A | ClinVar |
NCI-TCGA novel | p.Arg156HisPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7675145_7675146insGGGT | NCI-TCGA |
NCI-TCGA novel | p.Arg156AlaPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7675113_7675147GTGACTGCTTGTAGATGGCCATGGCGCGGACGCGG>- | NCI-TCGA |
NCI-TCGA novel | p.Arg156ProPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7675142_7675145ACGC>- | NCI-TCGA |
rs563378859 | p.Arg156Cys | missense variant | - | NC_000017.11:g.7675146G>A | TOPMed,gnomAD |
rs371524413 | p.Arg156His | missense variant | - | NC_000017.11:g.7675145C>T | ESP,ExAC,TOPMed,gnomAD |
rs371524413 | p.Arg156His | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675145C>T | UniProt,dbSNP |
VAR_044841 | p.Arg156His | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675145C>T | UniProt |
RCV000115722 | p.Arg156His | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7675145C>T | ClinVar |
RCV000213051 | p.Arg156Cys | missense variant | - | NC_000017.11:g.7675146G>A | ClinVar |
VAR_044842 | p.Arg156Leu | Missense | - | - | UniProt |
VAR_044840 | p.Arg156Gly | Missense | - | - | UniProt |
VAR_005902 | p.Arg156Pro | Missense | - | - | UniProt |
VAR_044843 | p.Arg156Ser | Missense | - | - | UniProt |
rs1131691023 | p.Val157Asp | missense variant | - | NC_000017.11:g.7675142A>T | - |
rs121912654 | p.Val157Phe | missense variant | - | NC_000017.11:g.7675143C>A | UniProt,dbSNP |
VAR_005904 | p.Val157Phe | missense variant | - | NC_000017.11:g.7675143C>A | UniProt |
RCV000492393 | p.Val157Ala | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7675142A>G | ClinVar |
RCV000505579 | p.Val157Ala | missense variant | Adrenocortical carcinoma | NC_000017.11:g.7675142A>G | ClinVar |
RCV000785500 | p.Val157Phe | missense variant | Ovarian Neoplasms | NC_000017.11:g.7675143C>A | ClinVar |
RCV000528459 | p.Val157Ile | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675143C>T | ClinVar |
RCV000566103 | p.Val157Phe | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7675143C>A | ClinVar |
RCV000164816 | p.Val157Ile | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7675143C>T | ClinVar |
RCV000235399 | p.Val157Ile | missense variant | - | NC_000017.11:g.7675143C>T | ClinVar |
COSM45120 | p.Val157Leu | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7675143C>G | NCI-TCGA Cosmic |
COSM1480073 | p.Val157Gly | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7675142A>C | NCI-TCGA Cosmic |
COSM44490 | p.Val157HisPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7675136_7675143GCGCGGAC>- | NCI-TCGA Cosmic |
COSM4450158 | p.Val157ProPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7675143_7675144CG>- | NCI-TCGA Cosmic |
COSM3675456 | p.Val157AlaPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7675142_7675143insG | NCI-TCGA Cosmic |
COSM43710 | p.Val157SerPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7675144G>- | NCI-TCGA Cosmic |
RCV000583594 | p.Val157Ter | frameshift | - | NC_000017.11:g.7675139_7675146del | ClinVar |
rs121912654 | p.Val157Ile | missense variant | - | NC_000017.11:g.7675143C>T | ExAC,TOPMed,gnomAD |
rs121912654 | p.Val157Phe | missense variant | - | NC_000017.11:g.7675143C>A | ExAC,TOPMed,gnomAD |
rs1131691023 | p.Val157Ala | missense variant | - | NC_000017.11:g.7675142A>G | - |
rs1131691023 | p.Val157Ala | missense variant | - | NC_000017.11:g.7675142A>G | UniProt,dbSNP |
VAR_044844 | p.Val157Ala | missense variant | - | NC_000017.11:g.7675142A>G | UniProt |
rs121912654 | p.Val157Ile | missense variant | - | NC_000017.11:g.7675143C>T | UniProt,dbSNP |
VAR_012977 | p.Val157Ile | missense variant | - | NC_000017.11:g.7675143C>T | UniProt |
RCV000561132 | p.Val157Asp | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7675142A>T | ClinVar |
VAR_044845 | p.Val157Gly | Missense | - | - | UniProt |
VAR_005903 | p.Val157Asp | Missense | - | - | UniProt |
VAR_044846 | p.Val157Leu | Missense | - | - | UniProt |
RCV000255654 | p.Arg158His | missense variant | - | NC_000017.11:g.7675139C>T | ClinVar |
COSM3970360 | p.Arg158Ser | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7675140G>T | NCI-TCGA Cosmic |
COSM43781 | p.Arg158AlaPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7675140G>- | NCI-TCGA Cosmic |
COSM11087 | p.Arg158Gly | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7675140G>C | NCI-TCGA Cosmic |
RCV000533951 | p.Arg158Cys | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675140G>A | ClinVar |
RCV000688595 | p.Arg158Leu | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675138_7675139delinsAA | ClinVar |
rs587780068 | p.Arg158Cys | missense variant | - | NC_000017.11:g.7675140G>A | UniProt,dbSNP |
VAR_005905 | p.Arg158Cys | missense variant | - | NC_000017.11:g.7675140G>A | UniProt |
rs587780068 | p.Arg158Cys | missense variant | - | NC_000017.11:g.7675140G>A | ExAC,gnomAD |
rs587782144 | p.Arg158Pro | missense variant | - | NC_000017.11:g.7675139C>G | ExAC,gnomAD |
rs587782144 | p.Arg158Pro | missense variant | - | NC_000017.11:g.7675139C>G | UniProt,dbSNP |
VAR_044848 | p.Arg158Pro | missense variant | - | NC_000017.11:g.7675139C>G | UniProt |
rs587782144 | p.Arg158His | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675139C>T | UniProt,dbSNP |
VAR_005907 | p.Arg158His | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675139C>T | UniProt |
rs587782144 | p.Arg158Leu | missense variant | - | NC_000017.11:g.7675139C>A | ExAC,gnomAD |
rs587782144 | p.Arg158His | missense variant | - | NC_000017.11:g.7675139C>T | ExAC,gnomAD |
RCV000785488 | p.Arg158Ter | frameshift | Ovarian Neoplasms | NC_000017.11:g.7675138_7675141del | ClinVar |
RCV000236862 | p.Arg158Pro | missense variant | - | NC_000017.11:g.7675139C>G | ClinVar |
RCV000633348 | p.Arg158Leu | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675139C>A | ClinVar |
VAR_044849 | p.Arg158Gln | Missense | - | - | UniProt |
VAR_044850 | p.Arg158Ser | Missense | - | - | UniProt |
VAR_045797 | p.Arg158Phe | Missense | - | - | UniProt |
VAR_005906 | p.Arg158Gly | Missense | Li-Fraumeni syndrome (LFS) [MIM:151623] | - | UniProt |
VAR_044847 | p.Arg158Leu | Missense | - | - | UniProt |
VAR_045798 | p.Arg158Tyr | Missense | - | - | UniProt |
rs1555526131 | p.Ala159Val | missense variant | - | NC_000017.11:g.7675136G>A | UniProt,dbSNP |
VAR_044856 | p.Ala159Val | missense variant | - | NC_000017.11:g.7675136G>A | UniProt |
rs730882000 | p.Ala159Thr | missense variant | - | NC_000017.11:g.7675137C>T | gnomAD |
rs1555526131 | p.Ala159Val | missense variant | - | NC_000017.11:g.7675136G>A | - |
RCV000785272 | p.Ala159Pro | missense variant | Ovarian Neoplasms | NC_000017.11:g.7675137C>G | ClinVar |
RCV000527533 | p.Ala159Val | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675136G>A | ClinVar |
rs730882022 | p.Ala159Phe | missense variant | - | NC_000017.11:g.7675136_7675137delinsAA | - |
rs730882000 | p.Ala159Pro | missense variant | - | NC_000017.11:g.7675137C>G | gnomAD |
RCV000161063 | p.Ala159Phe | missense variant | - | NC_000017.11:g.7675136_7675137delinsAA | ClinVar |
VAR_044851 | p.Ala159Asp | Missense | - | - | UniProt |
VAR_044852 | p.Ala159Gly | Missense | - | - | UniProt |
VAR_044854 | p.Ala159Ser | Missense | - | - | UniProt |
rs377274728 | p.Met160Val | missense variant | - | NC_000017.11:g.7675134T>C | gnomAD |
COSM1610860 | p.Met160Ile | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7675132C>A | NCI-TCGA Cosmic |
RCV000542402 | p.Met160Ile | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675132C>T | ClinVar |
RCV000218200 | p.Met160Ile | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7675132C>T | ClinVar |
RCV000485502 | p.Met160Ile | missense variant | - | NC_000017.11:g.7675132C>T | ClinVar |
rs377274728 | p.Met160Leu | missense variant | - | NC_000017.11:g.7675134T>A | gnomAD |
rs772354334 | p.Met160Ile | missense variant | - | NC_000017.11:g.7675132C>T | ExAC,TOPMed,gnomAD |
rs772354334 | p.Met160Ile | missense variant | - | NC_000017.11:g.7675132C>T | UniProt,dbSNP |
VAR_005908 | p.Met160Ile | missense variant | - | NC_000017.11:g.7675132C>T | UniProt |
RCV000513585 | p.Met160Val | missense variant | - | NC_000017.11:g.7675134T>C | ClinVar |
VAR_047161 | p.Met160_Ala161delinsIleSer | deletion_insertion | - | - | UniProt |
VAR_044858 | p.Met160Thr | Missense | - | - | UniProt |
VAR_047162 | p.Met160_Ala161delinsIleThr | deletion_insertion | - | - | UniProt |
VAR_047160 | p.Met160_Ala161delinsIlePro | deletion_insertion | - | - | UniProt |
VAR_044857 | p.Met160Lys | Missense | - | - | UniProt |
RCV000013180 | p.Ala161Ter | frameshift | Osteosarcoma | NC_000017.11:g.7675131_7675137dup | ClinVar |
COSM43689 | p.Ala161Val | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7675130G>A | NCI-TCGA Cosmic |
COSM45501 | p.Ala161Pro | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7675131C>G | NCI-TCGA Cosmic |
COSM1610856 | p.Ala161Ser | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7675131C>A | NCI-TCGA Cosmic |
RCV000149053 | p.Ala161Thr | missense variant | Malignant tumor of prostate | NC_000017.11:g.7675131C>T | ClinVar |
RCV000473543 | p.Ala161Thr | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675131C>T | ClinVar |
NCI-TCGA novel | p.Ala161GlyPheSerTerUnk | frameshift | - | NC_000017.11:g.7675112_7675130TGTGACTGCTTGTAGATGG>- | NCI-TCGA |
rs1064795691 | p.Ala161Asp | missense variant | - | NC_000017.11:g.7675130G>T | UniProt,dbSNP |
VAR_044860 | p.Ala161Asp | missense variant | - | NC_000017.11:g.7675130G>T | UniProt |
RCV000214033 | p.Ala161Thr | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7675131C>T | ClinVar |
RCV000761073 | p.Ala161Thr | missense variant | - | NC_000017.11:g.7675131C>T | ClinVar |
RCV000552464 | p.Ala161Asp | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675130G>T | ClinVar |
RCV000013179 | p.Ala161Ter | frameshift | Choroid plexus papilloma (CPP) | NC_000017.11:g.7675131_7675137dup | ClinVar |
VAR_045800 | p.Ala161Phe | Missense | - | - | UniProt |
VAR_044861 | p.Ala161Gly | Missense | - | - | UniProt |
VAR_005909 | p.Ala161Ser | Missense | - | - | UniProt |
VAR_044862 | p.Ala161Pro | Missense | - | - | UniProt |
VAR_044864 | p.Ala161Val | Missense | - | - | UniProt |
COSM4070049 | p.Ile162Phe | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7675128T>A | NCI-TCGA Cosmic |
COSM11966 | p.Ile162Asn | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7675127A>T | NCI-TCGA Cosmic |
COSM437560 | p.Ile162Asn | inframe deletion | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7675125_7675127AGA>- | NCI-TCGA Cosmic |
COSM5195325 | p.Ile162ThrPheSerTerUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7675127A>- | NCI-TCGA Cosmic |
NCI-TCGA novel | p.Ile162TrpPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7675128_7675129insGGCCA | NCI-TCGA |
NCI-TCGA novel | p.Ile162HisPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7675110_7675129GCTGTGACTGCTTGTAGATG>- | NCI-TCGA |
rs587780069 | p.Ile162Ser | missense variant | - | NC_000017.11:g.7675127A>C | - |
rs587780069 | p.Ile162Ser | missense variant | - | NC_000017.11:g.7675127A>C | UniProt,dbSNP |
VAR_005910 | p.Ile162Ser | missense variant | - | NC_000017.11:g.7675127A>C | UniProt |
RCV000115724 | p.Ile162Ser | missense variant | - | NC_000017.11:g.7675127A>C | ClinVar |
VAR_044865 | p.Ile162Phe | Missense | - | - | UniProt |
VAR_044868 | p.Ile162Thr | Missense | - | - | UniProt |
VAR_005911 | p.Ile162Val | Missense | - | - | UniProt |
VAR_044866 | p.Ile162Met | Missense | - | - | UniProt |
VAR_044867 | p.Ile162Asn | Missense | - | - | UniProt |
rs786203436 | p.Tyr163His | missense variant | - | NC_000017.11:g.7675125A>G | UniProt,dbSNP |
VAR_005912 | p.Tyr163His | missense variant | - | NC_000017.11:g.7675125A>G | UniProt |
RCV000424864 | p.Tyr163Cys | missense variant | Small cell lung cancer | NC_000017.11:g.7675124T>C | ClinVar |
RCV000442798 | p.Tyr163Cys | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7675124T>C | ClinVar |
RCV000434251 | p.Tyr163Cys | missense variant | Malignant melanoma of skin (CMM) | NC_000017.11:g.7675124T>C | ClinVar |
RCV000443833 | p.Tyr163Cys | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7675124T>C | ClinVar |
RCV000419252 | p.Tyr163Cys | missense variant | Neoplasm of the large intestine | NC_000017.11:g.7675124T>C | ClinVar |
RCV000419946 | p.Tyr163Cys | missense variant | Hepatocellular carcinoma (HCC) | NC_000017.11:g.7675124T>C | ClinVar |
RCV000443742 | p.Tyr163Cys | missense variant | Neoplasm of brain | NC_000017.11:g.7675124T>C | ClinVar |
RCV000429510 | p.Tyr163Cys | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7675124T>C | ClinVar |
RCV000430191 | p.Tyr163Cys | missense variant | Neoplasm of the breast | NC_000017.11:g.7675124T>C | ClinVar |
RCV000435593 | p.Tyr163Cys | missense variant | Carcinoma of esophagus | NC_000017.11:g.7675124T>C | ClinVar |
RCV000434917 | p.Tyr163Cys | missense variant | Lung adenocarcinoma | NC_000017.11:g.7675124T>C | ClinVar |
RCV000427698 | p.Tyr163Cys | missense variant | Uterine Carcinosarcoma | NC_000017.11:g.7675124T>C | ClinVar |
RCV000426124 | p.Tyr163Asp | missense variant | Neoplasm of the breast | NC_000017.11:g.7675125A>C | ClinVar |
RCV000440924 | p.Tyr163His | missense variant | Hepatocellular carcinoma (HCC) | NC_000017.11:g.7675125A>G | ClinVar |
RCV000435900 | p.Tyr163His | missense variant | Neoplasm of brain | NC_000017.11:g.7675125A>G | ClinVar |
RCV000417885 | p.Tyr163Asp | missense variant | Small cell lung cancer | NC_000017.11:g.7675125A>C | ClinVar |
RCV000425235 | p.Tyr163Asp | missense variant | Malignant melanoma of skin (CMM) | NC_000017.11:g.7675125A>C | ClinVar |
RCV000420721 | p.Tyr163Asp | missense variant | Hepatocellular carcinoma (HCC) | NC_000017.11:g.7675125A>C | ClinVar |
RCV000420162 | p.Tyr163Asp | missense variant | Uterine Carcinosarcoma | NC_000017.11:g.7675125A>C | ClinVar |
COSM1324776 | p.Tyr163LeuPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7675125_7675126insG | NCI-TCGA Cosmic |
RCV000785334 | p.Tyr163Cys | missense variant | Ovarian Neoplasms | NC_000017.11:g.7675124T>C | ClinVar |
RCV000423543 | p.Tyr163Cys | missense variant | Squamous cell lung carcinoma | NC_000017.11:g.7675124T>C | ClinVar |
RCV000436926 | p.Tyr163Cys | missense variant | - | NC_000017.11:g.7675124T>C | ClinVar |
RCV000759375 | p.Tyr163Ter | nonsense | - | NC_000017.11:g.7675123G>C | ClinVar |
RCV000436639 | p.Tyr163His | missense variant | Lung adenocarcinoma | NC_000017.11:g.7675125A>G | ClinVar |
RCV000418859 | p.Tyr163His | missense variant | Squamous cell lung carcinoma | NC_000017.11:g.7675125A>G | ClinVar |
RCV000633347 | p.Tyr163Asn | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675125A>T | ClinVar |
RCV000434193 | p.Tyr163His | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7675125A>G | ClinVar |
RCV000444147 | p.Tyr163Asp | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7675125A>C | ClinVar |
RCV000423893 | p.Tyr163His | missense variant | Malignant melanoma of skin (CMM) | NC_000017.11:g.7675125A>G | ClinVar |
RCV000441262 | p.Tyr163Asp | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7675125A>C | ClinVar |
rs786203436 | p.Tyr163Asn | missense variant | - | NC_000017.11:g.7675125A>T | UniProt,dbSNP |
VAR_044871 | p.Tyr163Asn | missense variant | - | NC_000017.11:g.7675125A>T | UniProt |
rs786203436 | p.Tyr163Asp | missense variant | - | NC_000017.11:g.7675125A>C | UniProt,dbSNP |
VAR_044869 | p.Tyr163Asp | missense variant | - | NC_000017.11:g.7675125A>C | UniProt |
RCV000430982 | p.Tyr163Asp | missense variant | Neoplasm of the large intestine | NC_000017.11:g.7675125A>C | ClinVar |
RCV000443587 | p.Tyr163Asp | missense variant | Squamous cell lung carcinoma | NC_000017.11:g.7675125A>C | ClinVar |
RCV000433509 | p.Tyr163Asp | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7675125A>C | ClinVar |
RCV000424608 | p.Tyr163Asp | missense variant | Lung adenocarcinoma | NC_000017.11:g.7675125A>C | ClinVar |
RCV000425645 | p.Tyr163His | missense variant | Neoplasm of the breast | NC_000017.11:g.7675125A>G | ClinVar |
RCV000431265 | p.Tyr163His | missense variant | - | NC_000017.11:g.7675125A>G | ClinVar |
RCV000438678 | p.Tyr163His | missense variant | Neoplasm of the large intestine | NC_000017.11:g.7675125A>G | ClinVar |
RCV000418221 | p.Tyr163His | missense variant | Carcinoma of esophagus | NC_000017.11:g.7675125A>G | ClinVar |
RCV000434903 | p.Tyr163Asp | missense variant | Carcinoma of esophagus | NC_000017.11:g.7675125A>C | ClinVar |
RCV000428451 | p.Tyr163His | missense variant | Small cell lung cancer | NC_000017.11:g.7675125A>G | ClinVar |
RCV000417511 | p.Tyr163His | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7675125A>G | ClinVar |
RCV000423239 | p.Tyr163His | missense variant | Uterine Carcinosarcoma | NC_000017.11:g.7675125A>G | ClinVar |
RCV000441609 | p.Tyr163His | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7675125A>G | ClinVar |
RCV000432709 | p.Tyr163Asp | missense variant | Neoplasm of brain | NC_000017.11:g.7675125A>C | ClinVar |
RCV000435516 | p.Tyr163Asp | missense variant | - | NC_000017.11:g.7675125A>C | ClinVar |
RCV000166739 | p.Tyr163Asp | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7675125A>C | ClinVar |
VAR_044870 | p.Tyr163Phe | Missense | - | - | UniProt |
VAR_044872 | p.Tyr163Ser | Missense | - | - | UniProt |
rs1131691034 | p.Lys164Asn | missense variant | - | NC_000017.11:g.7675120C>G | UniProt,dbSNP |
VAR_005913 | p.Lys164Asn | missense variant | - | NC_000017.11:g.7675120C>G | UniProt |
RCV000492698 | p.Lys164Asn | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7675120C>G | ClinVar |
COSM1564175 | p.Lys164SerPheSerTerUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7675118_7675121TGCT>- | NCI-TCGA Cosmic |
RCV000703049 | p.Lys164AsnTer | nonsense | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675119_7675120delinsAG | ClinVar |
NCI-TCGA novel | p.Lys164SerPheSerTerUnk | frameshift | - | NC_000017.11:g.7675121T>- | NCI-TCGA |
rs879254249 | p.Lys164Glu | missense variant | - | NC_000017.11:g.7675122T>C | UniProt,dbSNP |
VAR_044873 | p.Lys164Glu | missense variant | - | NC_000017.11:g.7675122T>C | UniProt |
rs879254249 | p.Lys164Glu | missense variant | - | NC_000017.11:g.7675122T>C | - |
rs1131691034 | p.Lys164Asn | missense variant | - | NC_000017.11:g.7675120C>G | TOPMed |
RCV000235745 | p.Lys164Glu | missense variant | - | NC_000017.11:g.7675122T>C | ClinVar |
RCV000541487 | p.Lys164Glu | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675122T>C | ClinVar |
VAR_044874 | p.Lys164Met | Missense | - | - | UniProt |
VAR_005914 | p.Lys164Gln | Missense | - | - | UniProt |
VAR_044876 | p.Lys164Thr | Missense | - | - | UniProt |
VAR_044875 | p.Lys164Arg | Missense | - | - | UniProt |
RCV000785484 | p.Gln165Ter | nonsense | Ovarian Neoplasms | NC_000017.11:g.7675119G>A | ClinVar |
RCV000219202 | p.Gln165Ter | nonsense | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7675119G>A | ClinVar |
RCV000573450 | p.Gln165Lys | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7675119G>T | ClinVar |
NCI-TCGA novel | p.Gln165HisPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7675117_7675118insAGCA | NCI-TCGA |
NCI-TCGA novel | p.Gln165AlaPheSerTerUnk | frameshift | - | NC_000017.11:g.7675091_7675119CTCACAACCTCCGTCATGTGCTGTGACTG>- | NCI-TCGA |
RCV000633373 | p.Gln165Ter | nonsense | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675119G>A | ClinVar |
RCV000161028 | p.Gln165Ter | nonsense | - | NC_000017.11:g.7675119G>A | ClinVar |
VAR_044879 | p.Gln165Pro | Missense | - | - | UniProt |
VAR_044878 | p.Gln165His | Missense | - | - | UniProt |
VAR_005915 | p.Gln165Leu | Missense | - | - | UniProt |
VAR_005916 | p.Gln165Arg | Missense | - | - | UniProt |
VAR_044877 | p.Gln165Glu | Missense | - | - | UniProt |
COSM11508 | p.Ser166Ter | stop gained | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7675115G>T | NCI-TCGA Cosmic |
RCV000785317 | p.Ser166Ter | nonsense | Ovarian Neoplasms | NC_000017.11:g.7675115G>C | ClinVar |
rs1555526101 | p.Ser166Leu | missense variant | - | NC_000017.11:g.7675115G>A | UniProt,dbSNP |
VAR_005917 | p.Ser166Leu | missense variant | - | NC_000017.11:g.7675115G>A | UniProt |
rs1555526101 | p.Ser166Leu | missense variant | - | NC_000017.11:g.7675115G>A | - |
RCV000633333 | p.Ser166Leu | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675115G>A | ClinVar |
VAR_044880 | p.Ser166Ala | Missense | - | - | UniProt |
VAR_044881 | p.Ser166Gly | Missense | - | - | UniProt |
VAR_044883 | p.Ser166Thr | Missense | - | - | UniProt |
VAR_044882 | p.Ser166Pro | Missense | - | - | UniProt |
RCV000580182 | p.Gln167Pro | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7675112T>G | ClinVar |
COSM437555 | p.Gln167HisPheSerTerUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7675111C>- | NCI-TCGA Cosmic |
COSM69214 | p.Gln167ThrPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7675113_7675114insT | NCI-TCGA Cosmic |
RCV000663165 | p.Gln167Ter | nonsense | Li-Fraumeni syndrome 1 (LFS) | NC_000017.11:g.7675113G>A | ClinVar |
NCI-TCGA novel | p.Gln167ThrPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7675114_7675115insA | NCI-TCGA |
rs1319163924 | p.Gln167Pro | missense variant | - | NC_000017.11:g.7675112T>G | TOPMed,gnomAD |
RCV000686348 | p.Gln167Ter | frameshift | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675111del | ClinVar |
VAR_044885 | p.Gln167Lys | Missense | Li-Fraumeni syndrome (LFS) [MIM:151623] | - | UniProt |
VAR_044884 | p.Gln167His | Missense | - | - | UniProt |
VAR_047163 | p.Gln167_His168delinsHisAsp | deletion_insertion | - | - | UniProt |
VAR_044886 | p.Gln167Leu | Missense | - | - | UniProt |
VAR_044887 | p.Gln167Arg | Missense | - | - | UniProt |
VAR_047164 | p.Gln167_His168delinsTyrLeu | deletion_insertion | - | - | UniProt |
RCV000702915 | p.His168Arg | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675109T>C | ClinVar |
COSM1649383 | p.His168Leu | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7675109T>A | NCI-TCGA Cosmic |
COSM1480069 | p.His168Pro | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7675109T>G | NCI-TCGA Cosmic |
NCI-TCGA novel | p.His168CysPheSerTerUnk | frameshift | - | NC_000017.11:g.7675097_7675110ACCTCCGTCATGTG>- | NCI-TCGA |
VAR_045801 | p.His168Val | Missense | - | - | UniProt |
VAR_044889 | p.His168Leu | Missense | - | - | UniProt |
VAR_044888 | p.His168Asp | Missense | - | - | UniProt |
VAR_044892 | p.His168Gln | Missense | - | - | UniProt |
VAR_044893 | p.His168Tyr | Missense | - | - | UniProt |
VAR_047165 | p.His168_Met169delinsLeuIle | deletion_insertion | - | - | UniProt |
VAR_044891 | p.His168Pro | Missense | - | - | UniProt |
VAR_044890 | p.His168Asn | Missense | - | - | UniProt |
COSM357727 | p.Met169Ile | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7675105C>T | NCI-TCGA Cosmic |
COSM4070043 | p.Met169Thr | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7675106A>G | NCI-TCGA Cosmic |
RCV000689187 | p.Met169Arg | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675106A>C | ClinVar |
VAR_047166 | p.Met169_Thr170delinsIleSer | deletion_insertion | - | - | UniProt |
VAR_044895 | p.Met169Val | Missense | - | - | UniProt |
VAR_044894 | p.Met169Lys | Missense | - | - | UniProt |
VAR_005919 | p.Met169Ile | Missense | - | - | UniProt |
VAR_005920 | p.Met169Thr | Missense | - | - | UniProt |
rs779000871 | p.Thr170Met | missense variant | - | NC_000017.11:g.7675103G>A | ExAC,TOPMed,gnomAD |
rs779000871 | p.Thr170Met | missense variant | - | NC_000017.11:g.7675103G>A | UniProt,dbSNP |
VAR_005921 | p.Thr170Met | missense variant | - | NC_000017.11:g.7675103G>A | UniProt |
RCV000123097 | p.Thr170Ala | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675104T>C | ClinVar |
RCV000759376 | p.Thr170Ter | frameshift | - | NC_000017.11:g.7675102_7675105del | ClinVar |
RCV000478196 | p.Thr170Met | missense variant | - | NC_000017.11:g.7675103G>A | ClinVar |
RCV000567372 | p.Thr170Ter | frameshift | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7675102_7675105del | ClinVar |
rs779000871 | p.Thr170Arg | missense variant | - | NC_000017.11:g.7675103G>C | ExAC,TOPMed,gnomAD |
rs587780729 | p.Thr170Ala | missense variant | - | NC_000017.11:g.7675104T>C | - |
rs587780729 | p.Thr170Ala | missense variant | - | NC_000017.11:g.7675104T>C | UniProt,dbSNP |
VAR_044896 | p.Thr170Ala | missense variant | - | NC_000017.11:g.7675104T>C | UniProt |
RCV000206777 | p.Thr170Met | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675103G>A | ClinVar |
RCV000662787 | p.Thr170Met | missense variant | Li-Fraumeni syndrome 1 (LFS) | NC_000017.11:g.7675103G>A | ClinVar |
RCV000163119 | p.Thr170Met | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7675103G>A | ClinVar |
RCV000580691 | p.Thr170Arg | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7675103G>C | ClinVar |
VAR_044897 | p.Thr170Lys | Missense | - | - | UniProt |
VAR_044898 | p.Thr170Pro | Missense | - | - | UniProt |
VAR_005922 | p.Thr170Ser | Missense | - | - | UniProt |
RCV000130145 | p.Glu171Lys | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7675101C>T | ClinVar |
RCV000168226 | p.Glu171Lys | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675101C>T | ClinVar |
COSM46095 | p.Glu171ArgPheSerTerUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7675101C>- | NCI-TCGA Cosmic |
COSM437546 | p.Glu171LeuPheSerTerUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7675098_7675101CCTC>- | NCI-TCGA Cosmic |
RCV000480730 | p.Glu171Lys | missense variant | - | NC_000017.11:g.7675101C>T | ClinVar |
RCV000792928 | p.Glu171Ter | nonsense | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675101C>A | ClinVar |
RCV000785509 | p.Glu171Ter | nonsense | Ovarian Neoplasms | NC_000017.11:g.7675101C>A | ClinVar |
NCI-TCGA novel | p.Glu171GlyPheSerTerUnk | frameshift | - | NC_000017.11:g.7675100T>- | NCI-TCGA |
NCI-TCGA novel | p.Glu171GlyPheSerTerUnk | frameshift | - | NC_000017.11:g.7675100_7675101insCC | NCI-TCGA |
rs587781845 | p.Glu171Lys | missense variant | - | NC_000017.11:g.7675101C>T | - |
rs587781845 | p.Glu171Lys | missense variant | - | NC_000017.11:g.7675101C>T | UniProt,dbSNP |
VAR_044902 | p.Glu171Lys | missense variant | - | NC_000017.11:g.7675101C>T | UniProt |
VAR_044899 | p.Glu171Ala | Missense | - | - | UniProt |
VAR_044904 | p.Glu171Val | Missense | - | - | UniProt |
VAR_044903 | p.Glu171Gln | Missense | - | - | UniProt |
VAR_044900 | p.Glu171Asp | Missense | - | - | UniProt |
VAR_044901 | p.Glu171Gly | Missense | - | - | UniProt |
rs1131691043 | p.Val172Phe | missense variant | - | NC_000017.11:g.7675098C>A | - |
rs1131691043 | p.Val172Phe | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675098C>A | UniProt,dbSNP |
VAR_044906 | p.Val172Phe | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675098C>A | UniProt |
RCV000633341 | p.Val172Ala | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675097A>G | ClinVar |
RCV000492688 | p.Val172Phe | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7675098C>A | ClinVar |
COSM1161213 | p.Val172Asp | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7675097A>T | NCI-TCGA Cosmic |
COSM45906 | p.Val172LeuPheSerTerUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7675098C>- | NCI-TCGA Cosmic |
rs1131691021 | p.Val172Gly | missense variant | - | NC_000017.11:g.7675097A>C | - |
rs1131691021 | p.Val172Gly | missense variant | - | NC_000017.11:g.7675097A>C | UniProt,dbSNP |
VAR_044907 | p.Val172Gly | missense variant | - | NC_000017.11:g.7675097A>C | UniProt |
rs1131691021 | p.Val172Ala | missense variant | - | NC_000017.11:g.7675097A>G | - |
RCV000492745 | p.Val172Gly | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7675097A>C | ClinVar |
VAR_044908 | p.Val172Ile | Missense | - | - | UniProt |
VAR_005923 | p.Val172Ala | Missense | - | - | UniProt |
VAR_044905 | p.Val172Asp | Missense | - | - | UniProt |
rs876660754 | p.Val173Leu | missense variant | - | NC_000017.11:g.7675095C>A | UniProt,dbSNP |
VAR_005925 | p.Val173Leu | missense variant | - | NC_000017.11:g.7675095C>A | UniProt |
RCV000807434 | p.Val173Gly | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675094A>C | ClinVar |
RCV000438785 | p.Val173Ala | missense variant | Hepatocellular carcinoma (HCC) | NC_000017.11:g.7675094A>G | ClinVar |
RCV000439921 | p.Val173Ala | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7675094A>G | ClinVar |
RCV000432237 | p.Val173Ala | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7675094A>G | ClinVar |
RCV000582350 | p.Val173Glu | missense variant | - | NC_000017.11:g.7675094A>T | ClinVar |
RCV000430991 | p.Val173Ala | missense variant | Neoplasm of the large intestine | NC_000017.11:g.7675094A>G | ClinVar |
RCV000775880 | p.Val173Ala | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7675094A>G | ClinVar |
RCV000420735 | p.Val173Ala | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7675094A>G | ClinVar |
RCV000437348 | p.Val173Ala | missense variant | Small cell lung cancer | NC_000017.11:g.7675094A>G | ClinVar |
RCV000438619 | p.Val173Ala | missense variant | Adenocarcinoma of stomach | NC_000017.11:g.7675094A>G | ClinVar |
RCV000419648 | p.Val173Ala | missense variant | Adrenocortical carcinoma | NC_000017.11:g.7675094A>G | ClinVar |
RCV000428561 | p.Val173Ala | missense variant | Malignant neoplasm of body of uterus | NC_000017.11:g.7675094A>G | ClinVar |
RCV000426247 | p.Val173Ala | missense variant | Acute myeloid leukemia (AML) | NC_000017.11:g.7675094A>G | ClinVar |
RCV000420982 | p.Val173Ala | missense variant | Neoplasm of brain | NC_000017.11:g.7675094A>G | ClinVar |
RCV000424469 | p.Val173Met | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7675095C>T | ClinVar |
RCV000423333 | p.Val173Met | missense variant | Malignant neoplasm of body of uterus | NC_000017.11:g.7675095C>T | ClinVar |
RCV000418768 | p.Val173Met | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7675095C>T | ClinVar |
COSM298209 | p.Val173GluPheSerTerUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7675093_7675094CA>- | NCI-TCGA Cosmic |
COSM121042 | p.Val173Leu | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7675095C>G | NCI-TCGA Cosmic |
NCI-TCGA novel | p.Val173AlaPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7675079_7675094TGGGGGCAGCGCCTCA>- | NCI-TCGA |
NCI-TCGA novel | p.Val173AlaPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7675088_7675094CGCCTCA>- | NCI-TCGA |
RCV000423542 | p.Val173Met | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7675095C>T | ClinVar |
RCV000694763 | p.Val173Leu | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675095C>A | ClinVar |
RCV000435365 | p.Val173Met | missense variant | Neoplasm of brain | NC_000017.11:g.7675095C>T | ClinVar |
RCV000214341 | p.Val173Met | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7675095C>T | ClinVar |
RCV000429913 | p.Val173Met | missense variant | Lung adenocarcinoma | NC_000017.11:g.7675095C>T | ClinVar |
rs876660754 | p.Val173Met | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675095C>T | UniProt,dbSNP |
VAR_005926 | p.Val173Met | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675095C>T | UniProt |
RCV000657325 | p.Val173Ter | frameshift | - | NC_000017.11:g.7675096_7675099dup | ClinVar |
RCV000445170 | p.Val173Ala | missense variant | Lung adenocarcinoma | NC_000017.11:g.7675094A>G | ClinVar |
RCV000437553 | p.Val173Ala | missense variant | Neoplasm of the breast | NC_000017.11:g.7675094A>G | ClinVar |
RCV000436282 | p.Val173Ala | missense variant | Malignant melanoma of skin (CMM) | NC_000017.11:g.7675094A>G | ClinVar |
RCV000430804 | p.Val173Ala | missense variant | - | NC_000017.11:g.7675094A>G | ClinVar |
RCV000421990 | p.Val173Ala | missense variant | Carcinoma of esophagus | NC_000017.11:g.7675094A>G | ClinVar |
RCV000429546 | p.Val173Met | missense variant | Carcinoma of esophagus | NC_000017.11:g.7675095C>T | ClinVar |
RCV000418173 | p.Val173Met | missense variant | Neoplasm of the breast | NC_000017.11:g.7675095C>T | ClinVar |
RCV000165358 | p.Val173Ter | frameshift | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7675097_7675101dup | ClinVar |
RCV000434638 | p.Val173Met | missense variant | Adrenocortical carcinoma | NC_000017.11:g.7675095C>T | ClinVar |
RCV000435180 | p.Val173Met | missense variant | - | NC_000017.11:g.7675095C>T | ClinVar |
RCV000441217 | p.Val173Met | missense variant | Adenocarcinoma of stomach | NC_000017.11:g.7675095C>T | ClinVar |
RCV000418817 | p.Val173Met | missense variant | Hepatocellular carcinoma (HCC) | NC_000017.11:g.7675095C>T | ClinVar |
RCV000785308 | p.Val173Met | missense variant | Ovarian Neoplasms | NC_000017.11:g.7675095C>T | ClinVar |
RCV000433605 | p.Val173Met | missense variant | Neoplasm of the large intestine | NC_000017.11:g.7675095C>T | ClinVar |
RCV000439338 | p.Val173Met | missense variant | Malignant melanoma of skin (CMM) | NC_000017.11:g.7675095C>T | ClinVar |
RCV000440133 | p.Val173Met | missense variant | Small cell lung cancer | NC_000017.11:g.7675095C>T | ClinVar |
VAR_045802 | p.Val173Trp | Missense | - | - | UniProt |
RCV000478775 | p.Arg174Lys | missense variant | - | NC_000017.11:g.7675091C>T | ClinVar |
COSM131454 | p.Arg174Trp | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7675092T>A | NCI-TCGA Cosmic |
COSM44725 | p.Arg174SerPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7675090C>- | NCI-TCGA Cosmic |
NCI-TCGA novel | p.Arg174ProPheSerTerUnk | frameshift | - | NC_000017.11:g.7675085_7675092CAGCGCCT>- | NCI-TCGA |
RCV000205095 | p.Arg174Gly | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675092T>C | ClinVar |
rs1064796681 | p.Arg174Lys | missense variant | - | NC_000017.11:g.7675091C>T | - |
rs864622115 | p.Arg174Gly | missense variant | - | NC_000017.11:g.7675092T>C | - |
VAR_044915 | p.Arg174Trp | Missense | - | - | UniProt |
VAR_044913 | p.Arg174Ser | Missense | - | - | UniProt |
VAR_044912 | p.Arg174Met | Missense | - | - | UniProt |
VAR_044914 | p.Arg174Thr | Missense | - | - | UniProt |
rs28934578 | p.Arg175Leu | missense variant | Li-fraumeni syndrome 1 (lfs1) | NC_000017.11:g.7675088C>A | ExAC,TOPMed,gnomAD |
rs138729528 | p.Arg175Cys | missense variant | - | NC_000017.11:g.7675089G>A | 1000Genomes,ExAC,TOPMed,gnomAD |
rs28934578 | p.Arg175His | missense variant | Li-fraumeni syndrome 1 (lfs1) | NC_000017.11:g.7675088C>T | ExAC,TOPMed,gnomAD |
RCV000161065 | p.Arg175Leu | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7675088C>A | ClinVar |
RCV000704159 | p.Arg175Cys | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675089G>A | ClinVar |
RCV000459914 | p.Arg175Gly | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675089G>C | ClinVar |
RCV000235329 | p.Arg175Cys | missense variant | - | NC_000017.11:g.7675089G>A | ClinVar |
RCV000428918 | p.Arg175His | missense variant | Neoplasm of the breast | NC_000017.11:g.7675088C>T | ClinVar |
NCI-TCGA novel | p.Arg175ProPheSerTerUnkUnk | stop gained | - | NC_000017.11:g.7675088_7675089insGCCTCACAACCTCCGTCATGTGCTGTGACTGCTTGTAGATGGCCATG | NCI-TCGA |
rs28934578 | p.Arg175Leu | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675088C>A | UniProt,dbSNP |
VAR_005930 | p.Arg175Leu | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675088C>A | UniProt |
rs28934578 | p.Arg175His | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675088C>T | UniProt,dbSNP |
VAR_005932 | p.Arg175His | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675088C>T | UniProt |
rs138729528 | p.Arg175Cys | missense variant | - | NC_000017.11:g.7675089G>A | UniProt,dbSNP |
VAR_005928 | p.Arg175Cys | missense variant | - | NC_000017.11:g.7675089G>A | UniProt |
rs138729528 | p.Arg175Gly | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675089G>C | UniProt,dbSNP |
VAR_005929 | p.Arg175Gly | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675089G>C | UniProt |
rs138729528 | p.Arg175Gly | missense variant | - | NC_000017.11:g.7675089G>C | 1000Genomes,ExAC,TOPMed,gnomAD |
VAR_044917 | p.Arg175Ser | Missense | - | - | UniProt |
VAR_005931 | p.Arg175Pro | Missense | - | - | UniProt |
VAR_044916 | p.Arg175Gln | Missense | - | - | UniProt |
RCV000567103 | p.Cys176Trp | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7675084G>C | ClinVar |
RCV000439156 | p.Cys176Ser | missense variant | Hepatocellular carcinoma (HCC) | NC_000017.11:g.7675086A>T | ClinVar |
RCV000425147 | p.Cys176Gly | missense variant | Hepatocellular carcinoma (HCC) | NC_000017.11:g.7675086A>C | ClinVar |
RCV000426275 | p.Cys176Ser | missense variant | Neoplasm of the breast | NC_000017.11:g.7675086A>T | ClinVar |
RCV000430876 | p.Cys176Arg | missense variant | - | NC_000017.11:g.7675086A>G | ClinVar |
RCV000437830 | p.Cys176Gly | missense variant | Lung adenocarcinoma | NC_000017.11:g.7675086A>C | ClinVar |
RCV000428520 | p.Cys176Ser | missense variant | Squamous cell lung carcinoma | NC_000017.11:g.7675086A>T | ClinVar |
RCV000427160 | p.Cys176Gly | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7675086A>C | ClinVar |
RCV000433975 | p.Cys176Gly | missense variant | Acute myeloid leukemia (AML) | NC_000017.11:g.7675086A>C | ClinVar |
RCV000445223 | p.Cys176Gly | missense variant | Carcinoma of esophagus | NC_000017.11:g.7675086A>C | ClinVar |
RCV000425379 | p.Cys176Arg | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7675086A>G | ClinVar |
RCV000426543 | p.Cys176Gly | missense variant | Neoplasm of brain | NC_000017.11:g.7675086A>C | ClinVar |
RCV000420420 | p.Cys176Ser | missense variant | Lung adenocarcinoma | NC_000017.11:g.7675086A>T | ClinVar |
RCV000442242 | p.Cys176Ser | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7675086A>T | ClinVar |
RCV000432450 | p.Cys176Gly | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7675086A>C | ClinVar |
RCV000419497 | p.Cys176Arg | missense variant | Neoplasm of brain | NC_000017.11:g.7675086A>G | ClinVar |
RCV000417996 | p.Cys176Gly | missense variant | Adenocarcinoma of prostate | NC_000017.11:g.7675086A>C | ClinVar |
RCV000436082 | p.Cys176Arg | missense variant | Neoplasm of the large intestine | NC_000017.11:g.7675086A>G | ClinVar |
RCV000431070 | p.Cys176Arg | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7675086A>G | ClinVar |
RCV000436236 | p.Cys176Arg | missense variant | Hepatocellular carcinoma (HCC) | NC_000017.11:g.7675086A>G | ClinVar |
RCV000422633 | p.Cys176Gly | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7675086A>C | ClinVar |
RCV000433667 | p.Cys176Ser | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7675086A>T | ClinVar |
RCV000436945 | p.Cys176Ser | missense variant | Adenocarcinoma of prostate | NC_000017.11:g.7675086A>T | ClinVar |
RCV000434994 | p.Cys176Gly | missense variant | Renal cell carcinoma, papillary, 1 (RCCP1) | NC_000017.11:g.7675086A>C | ClinVar |
RCV000428308 | p.Cys176Ser | missense variant | Renal cell carcinoma, papillary, 1 (RCCP1) | NC_000017.11:g.7675086A>T | ClinVar |
RCV000420646 | p.Cys176Ser | missense variant | Adenocarcinoma of stomach | NC_000017.11:g.7675086A>T | ClinVar |
RCV000441815 | p.Cys176Arg | missense variant | Acute myeloid leukemia (AML) | NC_000017.11:g.7675086A>G | ClinVar |
RCV000434565 | p.Cys176Gly | missense variant | Adenocarcinoma of stomach | NC_000017.11:g.7675086A>C | ClinVar |
RCV000444511 | p.Cys176Ser | missense variant | Neoplasm of the large intestine | NC_000017.11:g.7675086A>T | ClinVar |
RCV000438958 | p.Cys176Arg | missense variant | Carcinoma of esophagus | NC_000017.11:g.7675086A>G | ClinVar |
RCV000425621 | p.Cys176Ser | missense variant | Neoplasm of brain | NC_000017.11:g.7675086A>T | ClinVar |
RCV000444713 | p.Cys176Arg | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7675086A>G | ClinVar |
RCV000417784 | p.Cys176Gly | missense variant | - | NC_000017.11:g.7675086A>C | ClinVar |
RCV000431573 | p.Cys176Arg | missense variant | Adenocarcinoma of prostate | NC_000017.11:g.7675086A>G | ClinVar |
RCV000430429 | p.Cys176Arg | missense variant | Lung adenocarcinoma | NC_000017.11:g.7675086A>G | ClinVar |
RCV000417611 | p.Cys176Ser | missense variant | Acute myeloid leukemia (AML) | NC_000017.11:g.7675086A>T | ClinVar |
RCV000439618 | p.Cys176Gly | missense variant | Squamous cell lung carcinoma | NC_000017.11:g.7675086A>C | ClinVar |
RCV000530055 | p.Cys176Trp | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675084G>C | ClinVar |
RCV000440706 | p.Cys176Phe | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7675085C>A | ClinVar |
RCV000442295 | p.Cys176Phe | missense variant | Carcinoma of esophagus | NC_000017.11:g.7675085C>A | ClinVar |
COSM44759 | p.Cys176AlaPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7675086A>- | NCI-TCGA Cosmic |
COSM179822 | p.Cys176Ter | stop gained | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7675084G>T | NCI-TCGA Cosmic |
COSM3773309 | p.Cys176Ser | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7675085C>G | NCI-TCGA Cosmic |
NCI-TCGA novel | p.Cys176Ter | stop gained | - | NC_000017.11:g.7675084_7675085insT | NCI-TCGA |
RCV000445093 | p.Cys176Phe | missense variant | Acute myeloid leukemia (AML) | NC_000017.11:g.7675085C>A | ClinVar |
RCV000423829 | p.Cys176Phe | missense variant | Neoplasm of the large intestine | NC_000017.11:g.7675085C>A | ClinVar |
RCV000429162 | p.Cys176Phe | missense variant | Renal cell carcinoma, papillary, 1 (RCCP1) | NC_000017.11:g.7675085C>A | ClinVar |
RCV000461158 | p.Cys176Tyr | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675085C>T | ClinVar |
RCV000424063 | p.Cys176Phe | missense variant | Adenocarcinoma of stomach | NC_000017.11:g.7675085C>A | ClinVar |
RCV000440448 | p.Cys176Phe | missense variant | Neoplasm of brain | NC_000017.11:g.7675085C>A | ClinVar |
rs786202962 | p.Cys176Phe | missense variant | - | NC_000017.11:g.7675085C>A | UniProt,dbSNP |
VAR_005933 | p.Cys176Phe | missense variant | - | NC_000017.11:g.7675085C>A | UniProt |
rs786202962 | p.Cys176Tyr | missense variant | - | NC_000017.11:g.7675085C>T | UniProt,dbSNP |
VAR_044921 | p.Cys176Tyr | missense variant | - | NC_000017.11:g.7675085C>T | UniProt |
rs967461896 | p.Cys176Ser | missense variant | - | NC_000017.11:g.7675086A>T | - |
rs786202962 | p.Cys176Phe | missense variant | - | NC_000017.11:g.7675085C>A | gnomAD |
rs967461896 | p.Cys176Arg | missense variant | - | NC_000017.11:g.7675086A>G | - |
rs1057519980 | p.Cys176Trp | missense variant | - | NC_000017.11:g.7675084G>C | UniProt,dbSNP |
VAR_005934 | p.Cys176Trp | missense variant | - | NC_000017.11:g.7675084G>C | UniProt |
rs1057519980 | p.Cys176Trp | missense variant | - | NC_000017.11:g.7675084G>C | gnomAD |
rs786202962 | p.Cys176Tyr | missense variant | - | NC_000017.11:g.7675085C>T | gnomAD |
RCV000785487 | p.Cys176Arg | missense variant | Ovarian Neoplasms | NC_000017.11:g.7675084_7675086delinsCCG | ClinVar |
RCV000785535 | p.Cys176Gly | missense variant | Ovarian Neoplasms | NC_000017.11:g.7675086A>C | ClinVar |
RCV000437617 | p.Cys176Ser | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7675086A>T | ClinVar |
RCV000442522 | p.Cys176Gly | missense variant | Neoplasm of the breast | NC_000017.11:g.7675086A>C | ClinVar |
RCV000423671 | p.Cys176Arg | missense variant | Adenocarcinoma of stomach | NC_000017.11:g.7675086A>G | ClinVar |
RCV000421755 | p.Cys176Arg | missense variant | Neoplasm of the breast | NC_000017.11:g.7675086A>G | ClinVar |
RCV000436752 | p.Cys176Arg | missense variant | Squamous cell lung carcinoma | NC_000017.11:g.7675086A>G | ClinVar |
RCV000427846 | p.Cys176Ser | missense variant | Carcinoma of esophagus | NC_000017.11:g.7675086A>T | ClinVar |
RCV000419681 | p.Cys176Arg | missense variant | Renal cell carcinoma, papillary, 1 (RCCP1) | NC_000017.11:g.7675086A>G | ClinVar |
RCV000423257 | p.Cys176Gly | missense variant | Neoplasm of the large intestine | NC_000017.11:g.7675086A>C | ClinVar |
RCV000439650 | p.Cys176Ser | missense variant | - | NC_000017.11:g.7675086A>T | ClinVar |
RCV000785469 | p.Cys176Arg | missense variant | Ovarian Neoplasms | NC_000017.11:g.7675086A>G | ClinVar |
RCV000423447 | p.Cys176Phe | missense variant | Adenocarcinoma of prostate | NC_000017.11:g.7675085C>A | ClinVar |
RCV000434780 | p.Cys176Phe | missense variant | Squamous cell lung carcinoma | NC_000017.11:g.7675085C>A | ClinVar |
RCV000435143 | p.Cys176Phe | missense variant | Hepatocellular carcinoma (HCC) | NC_000017.11:g.7675085C>A | ClinVar |
RCV000445073 | p.Cys176Phe | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7675085C>A | ClinVar |
RCV000424490 | p.Cys176Phe | missense variant | Lung adenocarcinoma | NC_000017.11:g.7675085C>A | ClinVar |
RCV000429805 | p.Cys176Phe | missense variant | Neoplasm of the breast | NC_000017.11:g.7675085C>A | ClinVar |
RCV000431923 | p.Cys176Phe | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7675085C>A | ClinVar |
RCV000425950 | p.Cys176Phe | missense variant | - | NC_000017.11:g.7675085C>A | ClinVar |
VAR_044918 | p.Cys176Gly | Missense | - | - | UniProt |
VAR_044919 | p.Cys176Arg | Missense | - | - | UniProt |
VAR_047167 | p.Cys176_Pro177delinsPheSer | deletion_insertion | - | - | UniProt |
rs751477326 | p.Pro177Leu | missense variant | - | NC_000017.11:g.7675082G>A | ExAC,gnomAD |
RCV000540639 | p.Pro177Arg | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675082G>C | ClinVar |
RCV000574871 | p.Pro177Thr | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7675083G>T | ClinVar |
RCV000687535 | p.Pro177Thr | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675083G>T | ClinVar |
COSM45326 | p.Pro177His | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7675082G>T | NCI-TCGA Cosmic |
RCV000477631 | p.Pro177Leu | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675082G>A | ClinVar |
rs147002414 | p.Pro177Ser | missense variant | - | NC_000017.11:g.7675083G>A | UniProt,dbSNP |
VAR_044924 | p.Pro177Ser | missense variant | - | NC_000017.11:g.7675083G>A | UniProt |
rs147002414 | p.Pro177Ser | missense variant | - | NC_000017.11:g.7675083G>A | - |
rs147002414 | p.Pro177Thr | missense variant | - | NC_000017.11:g.7675083G>T | - |
rs751477326 | p.Pro177Arg | missense variant | - | NC_000017.11:g.7675082G>C | ExAC,gnomAD |
RCV000759377 | p.Pro177Leu | missense variant | - | NC_000017.11:g.7675082G>A | ClinVar |
VAR_044922 | p.Pro177Ala | Missense | - | - | UniProt |
VAR_044923 | p.Pro177His | Missense | - | - | UniProt |
VAR_045803 | p.Pro177Phe | Missense | - | - | UniProt |
VAR_045804 | p.Pro177Ile | Missense | - | - | UniProt |
VAR_044925 | p.Pro177Thr | Missense | - | - | UniProt |
RCV000485632 | p.His178Asn | missense variant | - | NC_000017.11:g.7675080G>T | ClinVar |
RCV000575494 | p.His178Asp | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7675080G>C | ClinVar |
COSM111495 | p.His178ThrPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7675080G>- | NCI-TCGA Cosmic |
COSM44120 | p.His178Tyr | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7675080G>A | NCI-TCGA Cosmic |
COSM1630425 | p.His178ProPheSerTerUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7675079_7675080insG | NCI-TCGA Cosmic |
NCI-TCGA novel | p.His178ProPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7675079T>- | NCI-TCGA |
NCI-TCGA novel | p.His178GlnPheSerTerUnk | frameshift | - | NC_000017.11:g.7675078_7675079insT | NCI-TCGA |
NCI-TCGA novel | p.His178ProPheSerTerUnk | frameshift | - | NC_000017.11:g.7675080_7675081GG>- | NCI-TCGA |
NCI-TCGA novel | p.His178ProPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7675079_7675080insGG | NCI-TCGA |
RCV000785267 | p.His178Ter | frameshift | Ovarian Neoplasms | NC_000017.11:g.7675072_7675079del | ClinVar |
RCV000698003 | p.His178Gln | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675078G>T | ClinVar |
RCV000215848 | p.His178Ter | frameshift | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7675084del | ClinVar |
rs1555526004 | p.His178Pro | missense variant | - | NC_000017.11:g.7675079T>G | - |
rs1555526004 | p.His178Pro | missense variant | - | NC_000017.11:g.7675079T>G | UniProt,dbSNP |
VAR_044929 | p.His178Pro | missense variant | - | NC_000017.11:g.7675079T>G | UniProt |
rs1064795203 | p.His178Asn | missense variant | - | NC_000017.11:g.7675080G>T | UniProt,dbSNP |
VAR_044928 | p.His178Asn | missense variant | - | NC_000017.11:g.7675080G>T | UniProt |
RCV000562255 | p.His178Pro | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7675079T>G | ClinVar |
RCV000633339 | p.His178Asp | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675080G>C | ClinVar |
RCV000785474 | p.His178Ter | frameshift | Ovarian Neoplasms | NC_000017.11:g.7675084del | ClinVar |
RCV000013176 | p.His178Ter | frameshift | Li-Fraumeni syndrome 1 (LFS) | NC_000017.11:g.7675084del | ClinVar |
VAR_044927 | p.His178Leu | Missense | - | - | UniProt |
VAR_047168 | p.His178_His179delinsGlnSer | deletion_insertion | - | - | UniProt |
VAR_044926 | p.His178Asp | Missense | - | - | UniProt |
VAR_044932 | p.His178Tyr | Missense | - | - | UniProt |
VAR_005936 | p.His178insHisProHisPro | inframe_insertion | - | - | UniProt |
VAR_044931 | p.His178Arg | Missense | - | - | UniProt |
VAR_044930 | p.His178Gln | Missense | - | - | UniProt |
rs1057519991 | p.His179Arg | missense variant | - | NC_000017.11:g.7675076T>C | gnomAD |
rs587780070 | p.His179Asn | missense variant | - | NC_000017.11:g.7675077G>T | UniProt,dbSNP |
VAR_044935 | p.His179Asn | missense variant | - | NC_000017.11:g.7675077G>T | UniProt |
rs1057519991 | p.His179Arg | missense variant | - | NC_000017.11:g.7675076T>C | UniProt,dbSNP |
VAR_044938 | p.His179Arg | missense variant | - | NC_000017.11:g.7675076T>C | UniProt |
rs876660821 | p.His179Gln | missense variant | - | NC_000017.11:g.7675075A>T | gnomAD |
RCV000438217 | p.His179Leu | missense variant | Acute myeloid leukemia (AML) | NC_000017.11:g.7675076T>A | ClinVar |
RCV000418835 | p.His179Leu | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7675076T>A | ClinVar |
RCV000433456 | p.His179Pro | missense variant | - | NC_000017.11:g.7675076T>G | ClinVar |
RCV000421433 | p.His179Pro | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7675076T>G | ClinVar |
RCV000441519 | p.His179Pro | missense variant | Neoplasm of the large intestine | NC_000017.11:g.7675076T>G | ClinVar |
RCV000443637 | p.His179Leu | missense variant | Neoplasm of the large intestine | NC_000017.11:g.7675076T>A | ClinVar |
RCV000418129 | p.His179Leu | missense variant | Uterine Carcinosarcoma | NC_000017.11:g.7675076T>A | ClinVar |
RCV000529132 | p.His179Arg | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675076T>C | ClinVar |
RCV000420124 | p.His179Leu | missense variant | Carcinoma of gallbladder | NC_000017.11:g.7675076T>A | ClinVar |
RCV000421837 | p.His179Leu | missense variant | Glioblastoma | NC_000017.11:g.7675076T>A | ClinVar |
RCV000432547 | p.His179Pro | missense variant | Carcinoma of esophagus | NC_000017.11:g.7675076T>G | ClinVar |
RCV000438275 | p.His179Pro | missense variant | Hepatocellular carcinoma (HCC) | NC_000017.11:g.7675076T>G | ClinVar |
RCV000427941 | p.His179Leu | missense variant | Neoplasm of brain | NC_000017.11:g.7675076T>A | ClinVar |
RCV000427330 | p.His179Leu | missense variant | Hepatocellular carcinoma (HCC) | NC_000017.11:g.7675076T>A | ClinVar |
RCV000429543 | p.His179Leu | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7675076T>A | ClinVar |
RCV000427925 | p.His179Pro | missense variant | Small cell lung cancer | NC_000017.11:g.7675076T>G | ClinVar |
RCV000433134 | p.His179Leu | missense variant | Small cell lung cancer | NC_000017.11:g.7675076T>A | ClinVar |
RCV000438631 | p.His179Leu | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7675076T>A | ClinVar |
RCV000439318 | p.His179Leu | missense variant | Adenocarcinoma of stomach | NC_000017.11:g.7675076T>A | ClinVar |
RCV000443703 | p.His179Pro | missense variant | Adenocarcinoma of stomach | NC_000017.11:g.7675076T>G | ClinVar |
RCV000435347 | p.His179Leu | missense variant | Squamous cell lung carcinoma | NC_000017.11:g.7675076T>A | ClinVar |
RCV000444683 | p.His179Leu | missense variant | Lung adenocarcinoma | NC_000017.11:g.7675076T>A | ClinVar |
RCV000421224 | p.His179Pro | missense variant | Squamous cell lung carcinoma | NC_000017.11:g.7675076T>G | ClinVar |
RCV000432531 | p.His179Leu | missense variant | - | NC_000017.11:g.7675076T>A | ClinVar |
RCV000428125 | p.His179Pro | missense variant | Acute myeloid leukemia (AML) | NC_000017.11:g.7675076T>G | ClinVar |
RCV000431234 | p.His179Pro | missense variant | Neoplasm of brain | NC_000017.11:g.7675076T>G | ClinVar |
RCV000444694 | p.His179Pro | missense variant | Lung adenocarcinoma | NC_000017.11:g.7675076T>G | ClinVar |
RCV000431709 | p.His179Asp | missense variant | Carcinoma of gallbladder | NC_000017.11:g.7675077G>C | ClinVar |
RCV000437679 | p.His179Asp | missense variant | Acute myeloid leukemia (AML) | NC_000017.11:g.7675077G>C | ClinVar |
RCV000428854 | p.His179Tyr | missense variant | Acute myeloid leukemia (AML) | NC_000017.11:g.7675077G>A | ClinVar |
RCV000427283 | p.His179Tyr | missense variant | Neoplasm of brain | NC_000017.11:g.7675077G>A | ClinVar |
RCV000424030 | p.His179Asp | missense variant | Uterine Carcinosarcoma | NC_000017.11:g.7675077G>C | ClinVar |
RCV000421694 | p.His179Asp | missense variant | Neoplasm of the large intestine | NC_000017.11:g.7675077G>C | ClinVar |
RCV000430072 | p.His179Asp | missense variant | Adenocarcinoma of stomach | NC_000017.11:g.7675077G>C | ClinVar |
RCV000434725 | p.His179Tyr | missense variant | Malignant melanoma of skin (CMM) | NC_000017.11:g.7675077G>A | ClinVar |
RCV000425288 | p.His179Asp | missense variant | Lung adenocarcinoma | NC_000017.11:g.7675077G>C | ClinVar |
RCV000420116 | p.His179Asp | missense variant | Malignant melanoma of skin (CMM) | NC_000017.11:g.7675077G>C | ClinVar |
RCV000419821 | p.His179Asp | missense variant | Small cell lung cancer | NC_000017.11:g.7675077G>C | ClinVar |
RCV000695193 | p.His179Asn | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675077G>T | ClinVar |
RCV000424007 | p.His179Tyr | missense variant | Small cell lung cancer | NC_000017.11:g.7675077G>A | ClinVar |
RCV000436095 | p.His179Tyr | missense variant | Carcinoma of gallbladder | NC_000017.11:g.7675077G>A | ClinVar |
RCV000464573 | p.His179Gln | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675075A>T | ClinVar |
RCV000444860 | p.His179Asp | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7675077G>C | ClinVar |
RCV000424716 | p.His179Tyr | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7675077G>A | ClinVar |
RCV000434379 | p.His179Tyr | missense variant | Neoplasm of the large intestine | NC_000017.11:g.7675077G>A | ClinVar |
RCV000426383 | p.His179Asp | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7675077G>C | ClinVar |
RCV000419735 | p.His179Tyr | missense variant | Glioblastoma | NC_000017.11:g.7675077G>A | ClinVar |
RCV000423688 | p.His179Tyr | missense variant | Adenocarcinoma of stomach | NC_000017.11:g.7675077G>A | ClinVar |
RCV000663095 | p.His179Tyr | missense variant | Li-Fraumeni syndrome 1 (LFS) | NC_000017.11:g.7675077G>A | ClinVar |
RCV000419024 | p.His179Tyr | missense variant | - | NC_000017.11:g.7675077G>A | ClinVar |
RCV000440707 | p.His179Asp | missense variant | Neoplasm of brain | NC_000017.11:g.7675077G>C | ClinVar |
RCV000785312 | p.His179Tyr | missense variant | Ovarian Neoplasms | NC_000017.11:g.7675077G>A | ClinVar |
RCV000430612 | p.His179Asp | missense variant | - | NC_000017.11:g.7675077G>C | ClinVar |
RCV000431956 | p.His179Asp | missense variant | Hepatocellular carcinoma (HCC) | NC_000017.11:g.7675077G>C | ClinVar |
RCV000444364 | p.His179Tyr | missense variant | Neoplasm of the breast | NC_000017.11:g.7675077G>A | ClinVar |
RCV000444992 | p.His179Asp | missense variant | Carcinoma of esophagus | NC_000017.11:g.7675077G>C | ClinVar |
RCV000436443 | p.His179Asp | missense variant | Squamous cell lung carcinoma | NC_000017.11:g.7675077G>C | ClinVar |
RCV000430411 | p.His179Tyr | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7675077G>A | ClinVar |
rs587780070 | p.His179Tyr | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675077G>A | UniProt,dbSNP |
VAR_044939 | p.His179Tyr | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675077G>A | UniProt |
rs876660821 | p.His179Gln | missense variant | - | NC_000017.11:g.7675075A>C | UniProt,dbSNP |
VAR_044937 | p.His179Gln | missense variant | - | NC_000017.11:g.7675075A>C | UniProt |
rs587780070 | p.His179Asp | missense variant | - | NC_000017.11:g.7675077G>C | UniProt,dbSNP |
VAR_044933 | p.His179Asp | missense variant | - | NC_000017.11:g.7675077G>C | UniProt |
rs587780070 | p.His179Asp | missense variant | - | NC_000017.11:g.7675077G>C | gnomAD |
rs876660821 | p.His179Gln | missense variant | - | NC_000017.11:g.7675075A>C | gnomAD |
rs587780070 | p.His179Asn | missense variant | - | NC_000017.11:g.7675077G>T | gnomAD |
rs1057519991 | p.His179Leu | missense variant | - | NC_000017.11:g.7675076T>A | UniProt,dbSNP |
VAR_044934 | p.His179Leu | missense variant | - | NC_000017.11:g.7675076T>A | UniProt |
rs1057519991 | p.His179Pro | missense variant | - | NC_000017.11:g.7675076T>G | gnomAD |
rs587780070 | p.His179Tyr | missense variant | - | NC_000017.11:g.7675077G>A | gnomAD |
rs1057519991 | p.His179Pro | missense variant | - | NC_000017.11:g.7675076T>G | UniProt,dbSNP |
VAR_044936 | p.His179Pro | missense variant | - | NC_000017.11:g.7675076T>G | UniProt |
RCV000441771 | p.His179Asp | missense variant | Glioblastoma | NC_000017.11:g.7675077G>C | ClinVar |
RCV000443866 | p.His179Asp | missense variant | Malignant neoplasm of body of uterus | NC_000017.11:g.7675077G>C | ClinVar |
RCV000431087 | p.His179Tyr | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7675077G>A | ClinVar |
RCV000440222 | p.His179Tyr | missense variant | Carcinoma of esophagus | NC_000017.11:g.7675077G>A | ClinVar |
RCV000441827 | p.His179Tyr | missense variant | Hepatocellular carcinoma (HCC) | NC_000017.11:g.7675077G>A | ClinVar |
RCV000436304 | p.His179Tyr | missense variant | Uterine Carcinosarcoma | NC_000017.11:g.7675077G>A | ClinVar |
RCV000435360 | p.His179Tyr | missense variant | Malignant neoplasm of body of uterus | NC_000017.11:g.7675077G>A | ClinVar |
RCV000423020 | p.His179Tyr | missense variant | Squamous cell lung carcinoma | NC_000017.11:g.7675077G>A | ClinVar |
RCV000423899 | p.His179Asp | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7675077G>C | ClinVar |
RCV000436622 | p.His179Asp | missense variant | Neoplasm of the breast | NC_000017.11:g.7675077G>C | ClinVar |
RCV000444227 | p.His179Tyr | missense variant | Lung adenocarcinoma | NC_000017.11:g.7675077G>A | ClinVar |
RCV000439058 | p.His179Pro | missense variant | Carcinoma of gallbladder | NC_000017.11:g.7675076T>G | ClinVar |
RCV000422328 | p.His179Pro | missense variant | Uterine Carcinosarcoma | NC_000017.11:g.7675076T>G | ClinVar |
RCV000427172 | p.His179Pro | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7675076T>G | ClinVar |
RCV000427517 | p.His179Leu | missense variant | Neoplasm of the breast | NC_000017.11:g.7675076T>A | ClinVar |
RCV000420510 | p.His179Pro | missense variant | Malignant neoplasm of body of uterus | NC_000017.11:g.7675076T>G | ClinVar |
RCV000426919 | p.His179Pro | missense variant | Glioblastoma | NC_000017.11:g.7675076T>G | ClinVar |
RCV000444604 | p.His179Pro | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7675076T>G | ClinVar |
RCV000437164 | p.His179Pro | missense variant | Neoplasm of the breast | NC_000017.11:g.7675076T>G | ClinVar |
RCV000432746 | p.His179Leu | missense variant | Malignant melanoma of skin (CMM) | NC_000017.11:g.7675076T>A | ClinVar |
RCV000439930 | p.His179Leu | missense variant | Malignant neoplasm of body of uterus | NC_000017.11:g.7675076T>A | ClinVar |
RCV000434884 | p.His179Pro | missense variant | Malignant melanoma of skin (CMM) | NC_000017.11:g.7675076T>G | ClinVar |
RCV000426806 | p.His179Leu | missense variant | Carcinoma of esophagus | NC_000017.11:g.7675076T>A | ClinVar |
rs1057519991 | p.His179Leu | missense variant | - | NC_000017.11:g.7675076T>A | gnomAD |
RCV000815181 | p.His179Gln | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675075A>C | ClinVar |
RCV000704693 | p.His179Ter | frameshift | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675077_7675095dup | ClinVar |
RCV000235571 | p.Glu180Lys | missense variant | - | NC_000017.11:g.7675074C>T | ClinVar |
RCV000785283 | p.Glu180Ter | nonsense | Ovarian Neoplasms | NC_000017.11:g.7675074C>A | ClinVar |
rs879253911 | p.Glu180Lys | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675074C>T | UniProt,dbSNP |
VAR_044943 | p.Glu180Lys | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675074C>T | UniProt |
rs879253911 | p.Glu180Lys | missense variant | - | NC_000017.11:g.7675074C>T | - |
RCV000544036 | p.Glu180Lys | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675074C>T | ClinVar |
RCV000492319 | p.Glu180Lys | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7675074C>T | ClinVar |
VAR_044942 | p.Glu180Gly | Missense | - | - | UniProt |
VAR_044941 | p.Glu180Asp | Missense | - | - | UniProt |
VAR_044945 | p.Glu180Val | Missense | - | - | UniProt |
VAR_044944 | p.Glu180Gln | Missense | - | - | UniProt |
VAR_044940 | p.Glu180Ala | Missense | - | - | UniProt |
rs397514495 | p.Arg181Leu | missense variant | Glioma susceptibility 1 (glm1) | NC_000017.11:g.7675070C>A | ExAC,TOPMed,gnomAD |
RCV000692266 | p.Arg181Leu | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675070C>A | ClinVar |
RCV000255239 | p.Arg181His | missense variant | - | NC_000017.11:g.7675070C>T | ClinVar |
RCV000222957 | p.Arg181Ser | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7675071G>T | ClinVar |
RCV000576528 | p.Arg181His | missense variant | Li-Fraumeni syndrome 1 (LFS) | NC_000017.11:g.7675070C>T | ClinVar |
COSM45046 | p.Arg181Pro | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7675070C>G | NCI-TCGA Cosmic |
COSM5369730 | p.Arg181LeuPheSerTerUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7675069_7675070GC>- | NCI-TCGA Cosmic |
RCV000799329 | p.Arg181Ser | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675071G>T | ClinVar |
rs397514495 | p.Arg181His | missense variant | Glioma susceptibility 1 (glm1) | NC_000017.11:g.7675070C>T | ExAC,TOPMed,gnomAD |
rs587782596 | p.Arg181Ser | missense variant | - | NC_000017.11:g.7675071G>T | UniProt,dbSNP |
VAR_044950 | p.Arg181Ser | missense variant | - | NC_000017.11:g.7675071G>T | UniProt |
rs587782596 | p.Arg181Ser | missense variant | - | NC_000017.11:g.7675071G>T | TOPMed |
rs397514495 | p.Arg181His | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675070C>T | UniProt,dbSNP |
VAR_044948 | p.Arg181His | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675070C>T | UniProt |
rs397514495 | p.Arg181Leu | missense variant | - | NC_000017.11:g.7675070C>A | UniProt,dbSNP |
VAR_005937 | p.Arg181Leu | missense variant | - | NC_000017.11:g.7675070C>A | UniProt |
RCV000131382 | p.Arg181His | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7675070C>T | ClinVar |
RCV000236276 | p.Arg181Cys | missense variant | - | NC_000017.11:g.7675071G>A | ClinVar |
rs587782596 | p.Arg181Cys | missense variant | - | NC_000017.11:g.7675071G>A | TOPMed |
rs587782596 | p.Arg181Cys | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675071G>A | UniProt,dbSNP |
VAR_044946 | p.Arg181Cys | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675071G>A | UniProt |
VAR_044947 | p.Arg181Gly | Missense | - | - | UniProt |
VAR_044949 | p.Arg181Pro | Missense | - | - | UniProt |
RCV000785517 | p.Cys182Ter | frameshift | Ovarian Neoplasms | NC_000017.11:g.7675067del | ClinVar |
RCV000485383 | p.Cys182Trp | missense variant | - | NC_000017.11:g.7675066G>C | ClinVar |
rs1064796257 | p.Cys182Trp | missense variant | - | NC_000017.11:g.7675066G>C | - |
VAR_044952 | p.Cys182Tyr | Missense | - | - | UniProt |
VAR_044951 | p.Cys182Arg | Missense | - | - | UniProt |
VAR_005938 | p.Cys182Ser | Missense | - | - | UniProt |
COSM11717 | p.Ser183Ter | stop gained | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7675064G>T | NCI-TCGA Cosmic |
RCV000565655 | p.Ser183Leu | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7675064G>A | ClinVar |
rs1555525970 | p.Ser183Leu | missense variant | - | NC_000017.11:g.7675064G>A | - |
rs1555525970 | p.Ser183Leu | missense variant | - | NC_000017.11:g.7675064G>A | UniProt,dbSNP |
VAR_044953 | p.Ser183Leu | missense variant | - | NC_000017.11:g.7675064G>A | UniProt |
RCV000785319 | p.Ser183Ter | nonsense | Ovarian Neoplasms | NC_000017.11:g.7675064G>C | ClinVar |
VAR_044954 | p.Ser183Pro | Missense | - | - | UniProt |
COSM44179 | p.Asp184AlaPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7675058_7675061CTAT>- | NCI-TCGA Cosmic |
rs1060501209 | p.Asp184Gly | missense variant | - | NC_000017.11:g.7675061T>C | - |
RCV000785502 | p.Asp184Ter | frameshift | Ovarian Neoplasms | NC_000017.11:g.7675061del | ClinVar |
RCV000462657 | p.Asp184Gly | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675061T>C | ClinVar |
VAR_005939 | p.Asp184Tyr | Missense | - | - | UniProt |
VAR_044957 | p.Asp184Val | Missense | - | - | UniProt |
VAR_044956 | p.Asp184His | Missense | - | - | UniProt |
RCV000129849 | p.Ser185Asn | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7675058C>T | ClinVar |
RCV000662659 | p.Ser185Asn | missense variant | Li-Fraumeni syndrome 1 (LFS) | NC_000017.11:g.7675058C>T | ClinVar |
RCV000233843 | p.Ser185Asn | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675058C>T | ClinVar |
rs150607408 | p.Ser185Asn | missense variant | - | NC_000017.11:g.7675058C>T | UniProt,dbSNP |
VAR_044961 | p.Ser185Asn | missense variant | - | NC_000017.11:g.7675058C>T | UniProt |
rs150607408 | p.Ser185Asn | missense variant | - | NC_000017.11:g.7675058C>T | ESP,ExAC,TOPMed,gnomAD |
VAR_044960 | p.Ser185Ile | Missense | - | - | UniProt |
VAR_044963 | p.Ser185Thr | Missense | - | - | UniProt |
VAR_044962 | p.Ser185Arg | Missense | - | - | UniProt |
VAR_044958 | p.Ser185Cys | Missense | - | - | UniProt |
VAR_044959 | p.Ser185Gly | Missense | - | - | UniProt |
RCV000467183 | p.Asp186Asn | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675056C>T | ClinVar |
RCV000571882 | p.Asp186Asn | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7675056C>T | ClinVar |
NCI-TCGA novel | p.Asp186ValPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7675055T>- | NCI-TCGA |
rs1060501206 | p.Asp186Asn | missense variant | - | NC_000017.11:g.7675056C>T | gnomAD |
rs375275361 | p.Asp186Glu | missense variant | - | NC_000017.11:g.7675054A>T | ESP,ExAC,TOPMed,gnomAD |
RCV000470622 | p.Asp186Glu | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7675054A>T | ClinVar |
RCV000481372 | p.Asp186Asn | missense variant | - | NC_000017.11:g.7675056C>T | ClinVar |
RCV000235477 | p.Asp186Glu | missense variant | - | NC_000017.11:g.7675054A>T | ClinVar |
VAR_005940 | p.Asp186Tyr | Missense | - | - | UniProt |
VAR_044968 | p.Asp186Val | Missense | - | - | UniProt |
VAR_044966 | p.Asp186His | Missense | - | - | UniProt |
VAR_044965 | p.Asp186Gly | Missense | - | - | UniProt |
RCV000483175 | p.Gly187Asp | missense variant | - | NC_000017.11:g.7674971C>T | ClinVar |
rs776167460 | p.Gly187Ser | missense variant | - | NC_000017.11:g.7675053C>T | UniProt,dbSNP |
VAR_005942 | p.Gly187Ser | missense variant | - | NC_000017.11:g.7675053C>T | UniProt |
rs776167460 | p.Gly187Ser | missense variant | - | NC_000017.11:g.7675053C>T | ExAC |
rs1064795841 | p.Gly187Asp | missense variant | - | NC_000017.11:g.7674971C>T | - |
VAR_044969 | p.Gly187Asp | Missense | - | - | UniProt |
VAR_044970 | p.Gly187Arg | Missense | - | - | UniProt |
VAR_044971 | p.Gly187Val | Missense | - | - | UniProt |
VAR_045805 | p.Gly187Asn | Missense | - | - | UniProt |
VAR_005941 | p.Gly187Cys | Missense | - | - | UniProt |
rs1199893366 | p.Leu188Pro | missense variant | - | NC_000017.11:g.7674968A>G | TOPMed |
rs1199893366 | p.Leu188Pro | missense variant | - | NC_000017.11:g.7674968A>G | UniProt,dbSNP |
VAR_044972 | p.Leu188Pro | missense variant | - | NC_000017.11:g.7674968A>G | UniProt |
COSM1324790 | p.Leu188ThrPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7674969_7674970insT | NCI-TCGA Cosmic |
NCI-TCGA novel | p.Leu188GlyPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7674968_7674969AG>- | NCI-TCGA |
VAR_044973 | p.Leu188Val | Missense | - | - | UniProt |
rs1555525921 | p.Ala189Ser | missense variant | - | NC_000017.11:g.7674966C>A | - |
rs1555525921 | p.Ala189Ser | missense variant | - | NC_000017.11:g.7674966C>A | UniProt,dbSNP |
VAR_044976 | p.Ala189Ser | missense variant | - | NC_000017.11:g.7674966C>A | UniProt |
rs121912665 | p.Ala189Val | missense variant | - | NC_000017.11:g.7674965G>A | UniProt,dbSNP |
VAR_044978 | p.Ala189Val | missense variant | - | NC_000017.11:g.7674965G>A | UniProt |
rs121912665 | p.Ala189Val | missense variant | - | NC_000017.11:g.7674965G>A | ExAC,TOPMed,gnomAD |
RCV000013182 | p.Ala189Val | missense variant | Familial colorectal cancer (CRC) | NC_000017.11:g.7674965G>A | ClinVar |
COSM45750 | p.Ala189ProPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7674966C>- | NCI-TCGA Cosmic |
NCI-TCGA novel | p.Ala189AspPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7674949_7674965AAGATGCTGAGGAGGGG>- | NCI-TCGA |
RCV000633369 | p.Ala189Ser | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674966C>A | ClinVar |
VAR_005943 | p.Ala189Pro | Missense | - | - | UniProt |
VAR_044975 | p.Ala189Gly | Missense | - | - | UniProt |
VAR_044974 | p.Ala189Asp | Missense | - | - | UniProt |
VAR_044977 | p.Ala189Thr | Missense | - | - | UniProt |
rs876660825 | p.Pro190Leu | missense variant | - | NC_000017.11:g.7674962G>A | UniProt,dbSNP |
VAR_005944 | p.Pro190Leu | missense variant | - | NC_000017.11:g.7674962G>A | UniProt |
rs876660825 | p.Pro190Leu | missense variant | - | NC_000017.11:g.7674962G>A | - |
rs876660825 | p.Pro190Arg | missense variant | - | NC_000017.11:g.7674962G>C | - |
rs876660825 | p.Pro190Arg | missense variant | - | NC_000017.11:g.7674962G>C | UniProt,dbSNP |
VAR_044981 | p.Pro190Arg | missense variant | - | NC_000017.11:g.7674962G>C | UniProt |
RCV000551566 | p.Pro190Leu | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674962G>A | ClinVar |
RCV000484792 | p.Pro190Leu | missense variant | - | NC_000017.11:g.7674962G>A | ClinVar |
rs876660254 | p.Pro190Thr | missense variant | - | NC_000017.11:g.7674963G>T | UniProt,dbSNP |
VAR_044983 | p.Pro190Thr | missense variant | - | NC_000017.11:g.7674963G>T | UniProt |
rs876660254 | p.Pro190Thr | missense variant | - | NC_000017.11:g.7674963G>T | - |
RCV000213384 | p.Pro190Thr | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7674963G>T | ClinVar |
RCV000222080 | p.Pro190Arg | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7674962G>C | ClinVar |
VAR_044980 | p.Pro190His | Missense | - | - | UniProt |
VAR_044979 | p.Pro190Ala | Missense | - | - | UniProt |
VAR_044982 | p.Pro190Ser | Missense | - | - | UniProt |
rs587778718 | p.Pro191Arg | missense variant | - | NC_000017.11:g.7674959G>C | ExAC,TOPMed,gnomAD |
rs587778718 | p.Pro191Leu | missense variant | - | NC_000017.11:g.7674959G>A | UniProt,dbSNP |
VAR_044985 | p.Pro191Leu | missense variant | - | NC_000017.11:g.7674959G>A | UniProt |
RCV000662561 | p.Pro191Arg | missense variant | Li-Fraumeni syndrome 1 (LFS) | NC_000017.11:g.7674959G>C | ClinVar |
RCV000219468 | p.Pro191Arg | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7674959G>C | ClinVar |
COSM1480064 | p.Pro191SerPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7674960_7674961insA | NCI-TCGA Cosmic |
RCV000205751 | p.Pro191Arg | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674959G>C | ClinVar |
RCV000766937 | p.Pro191Arg | missense variant | - | NC_000017.11:g.7674959G>C | ClinVar |
NCI-TCGA novel | p.Pro191GlnPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7674944_7674959CGGATAAGATGCTGAG>- | NCI-TCGA |
rs587778718 | p.Pro191Leu | missense variant | - | NC_000017.11:g.7674959G>A | ExAC,TOPMed,gnomAD |
rs587778718 | p.Pro191His | missense variant | - | NC_000017.11:g.7674959G>T | UniProt,dbSNP |
VAR_044984 | p.Pro191His | missense variant | - | NC_000017.11:g.7674959G>T | UniProt |
rs587778718 | p.Pro191Arg | missense variant | - | NC_000017.11:g.7674959G>C | UniProt,dbSNP |
VAR_044986 | p.Pro191Arg | missense variant | - | NC_000017.11:g.7674959G>C | UniProt |
rs587778718 | p.Pro191His | missense variant | - | NC_000017.11:g.7674959G>T | ExAC,TOPMed,gnomAD |
VAR_005945 | p.Pro191Thr | Missense | - | - | UniProt |
rs866380588 | p.Gln192Ter | stop gained | - | NC_000017.11:g.7674957G>A | - |
RCV000161029 | p.Gln192Arg | missense variant | - | NC_000017.11:g.7674956T>C | ClinVar |
NCI-TCGA novel | p.Gln192SerPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7674957G>- | NCI-TCGA |
rs730882002 | p.Gln192Arg | missense variant | - | NC_000017.11:g.7674956T>C | - |
RCV000472712 | p.Gln192Ter | nonsense | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674957G>A | ClinVar |
VAR_044991 | p.Gln192Pro | Missense | - | - | UniProt |
VAR_047171 | p.Gln192_His193delinsHisTyr | deletion_insertion | - | - | UniProt |
VAR_044988 | p.Gln192His | Missense | - | - | UniProt |
VAR_044990 | p.Gln192Leu | Missense | - | - | UniProt |
VAR_047170 | p.Gln192_His193delinsHisAsn | deletion_insertion | - | - | UniProt |
VAR_044989 | p.Gln192Lys | Missense | - | - | UniProt |
rs876658468 | p.His193Asn | missense variant | - | NC_000017.11:g.7674954G>T | UniProt,dbSNP |
VAR_044993 | p.His193Asn | missense variant | - | NC_000017.11:g.7674954G>T | UniProt |
rs876658468 | p.His193Asn | missense variant | - | NC_000017.11:g.7674954G>T | - |
rs876658468 | p.His193Tyr | missense variant | - | NC_000017.11:g.7674954G>A | UniProt,dbSNP |
VAR_044996 | p.His193Tyr | missense variant | - | NC_000017.11:g.7674954G>A | UniProt |
rs876658468 | p.His193Tyr | missense variant | - | NC_000017.11:g.7674954G>A | - |
RCV000420192 | p.His193Asn | missense variant | Lung adenocarcinoma | NC_000017.11:g.7674954G>T | ClinVar |
RCV000438671 | p.His193Asn | missense variant | Malignant neoplasm of body of uterus | NC_000017.11:g.7674954G>T | ClinVar |
RCV000419469 | p.His193Tyr | missense variant | Papillary renal cell carcinoma, sporadic | NC_000017.11:g.7674954G>A | ClinVar |
RCV000425552 | p.His193Asp | missense variant | Lung adenocarcinoma | NC_000017.11:g.7674954G>C | ClinVar |
RCV000418086 | p.His193Arg | missense variant | Neoplasm of the breast | NC_000017.11:g.7674953T>C | ClinVar |
RCV000418288 | p.His193Arg | missense variant | Adenocarcinoma of stomach | NC_000017.11:g.7674953T>C | ClinVar |
RCV000423052 | p.His193Arg | missense variant | Carcinoma of esophagus | NC_000017.11:g.7674953T>C | ClinVar |
RCV000444985 | p.His193Pro | missense variant | Hepatocellular carcinoma (HCC) | NC_000017.11:g.7674953T>G | ClinVar |
RCV000444677 | p.His193Asn | missense variant | Squamous cell lung carcinoma | NC_000017.11:g.7674954G>T | ClinVar |
RCV000419839 | p.His193Tyr | missense variant | Hepatocellular carcinoma (HCC) | NC_000017.11:g.7674954G>A | ClinVar |
RCV000441502 | p.His193Tyr | missense variant | Small cell lung cancer | NC_000017.11:g.7674954G>A | ClinVar |
RCV000434549 | p.His193Arg | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7674953T>C | ClinVar |
RCV000435870 | p.His193Arg | missense variant | Neoplasm of the large intestine | NC_000017.11:g.7674953T>C | ClinVar |
RCV000437380 | p.His193Tyr | missense variant | Acute myeloid leukemia (AML) | NC_000017.11:g.7674954G>A | ClinVar |
RCV000425919 | p.His193Asp | missense variant | - | NC_000017.11:g.7674954G>C | ClinVar |
RCV000445029 | p.His193Arg | missense variant | Squamous cell lung carcinoma | NC_000017.11:g.7674953T>C | ClinVar |
RCV000439568 | p.His193Pro | missense variant | Uterine Carcinosarcoma | NC_000017.11:g.7674953T>G | ClinVar |
RCV000437710 | p.His193Asn | missense variant | Adenocarcinoma of prostate | NC_000017.11:g.7674954G>T | ClinVar |
RCV000422815 | p.His193Asn | missense variant | Papillary renal cell carcinoma, sporadic | NC_000017.11:g.7674954G>T | ClinVar |
RCV000432878 | p.His193Asn | missense variant | Chronic lymphocytic leukemia (CLL) | NC_000017.11:g.7674954G>T | ClinVar |
RCV000422912 | p.His193Pro | missense variant | Small cell lung cancer | NC_000017.11:g.7674953T>G | ClinVar |
RCV000419924 | p.His193Asp | missense variant | Neoplasm of the large intestine | NC_000017.11:g.7674954G>C | ClinVar |
RCV000221478 | p.His193Tyr | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7674954G>A | ClinVar |
RCV000436284 | p.His193Tyr | missense variant | Uterine Carcinosarcoma | NC_000017.11:g.7674954G>A | ClinVar |
RCV000423524 | p.His193Tyr | missense variant | - | NC_000017.11:g.7674954G>A | ClinVar |
RCV000423516 | p.His193Pro | missense variant | Squamous cell lung carcinoma | NC_000017.11:g.7674953T>G | ClinVar |
RCV000429618 | p.His193Arg | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7674953T>C | ClinVar |
RCV000444740 | p.His193Tyr | missense variant | - | NC_000017.11:g.7674954G>A | ClinVar |
RCV000441340 | p.His193Asp | missense variant | Papillary renal cell carcinoma, sporadic | NC_000017.11:g.7674954G>C | ClinVar |
RCV000440903 | p.His193Arg | missense variant | Acute myeloid leukemia (AML) | NC_000017.11:g.7674953T>C | ClinVar |
RCV000422179 | p.His193Asn | missense variant | - | NC_000017.11:g.7674954G>T | ClinVar |
RCV000428079 | p.His193Asn | missense variant | - | NC_000017.11:g.7674954G>T | ClinVar |
RCV000445148 | p.His193Arg | missense variant | Malignant neoplasm of body of uterus | NC_000017.11:g.7674953T>C | ClinVar |
RCV000427668 | p.His193Pro | missense variant | Acute myeloid leukemia (AML) | NC_000017.11:g.7674953T>G | ClinVar |
RCV000419005 | p.His193Asp | missense variant | Adenocarcinoma of stomach | NC_000017.11:g.7674954G>C | ClinVar |
RCV000164329 | p.His193Arg | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7674953T>C | ClinVar |
RCV000460847 | p.His193Arg | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674953T>C | ClinVar |
RCV000424851 | p.His193Pro | missense variant | Papillary renal cell carcinoma, sporadic | NC_000017.11:g.7674953T>G | ClinVar |
RCV000428197 | p.His193Pro | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7674953T>G | ClinVar |
RCV000425273 | p.His193Asp | missense variant | - | NC_000017.11:g.7674954G>C | ClinVar |
RCV000429577 | p.His193Pro | missense variant | Adenocarcinoma of stomach | NC_000017.11:g.7674953T>G | ClinVar |
RCV000432133 | p.His193Asn | missense variant | Neoplasm of the breast | NC_000017.11:g.7674954G>T | ClinVar |
RCV000417520 | p.His193Pro | missense variant | Neoplasm of the large intestine | NC_000017.11:g.7674953T>G | ClinVar |
RCV000421204 | p.His193Tyr | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7674954G>A | ClinVar |
RCV000433342 | p.His193Arg | missense variant | Small cell lung cancer | NC_000017.11:g.7674953T>C | ClinVar |
RCV000431849 | p.His193Asp | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7674954G>C | ClinVar |
RCV000429902 | p.His193Tyr | missense variant | Neoplasm of the large intestine | NC_000017.11:g.7674954G>A | ClinVar |
RCV000417979 | p.His193Arg | missense variant | Chronic lymphocytic leukemia (CLL) | NC_000017.11:g.7674953T>C | ClinVar |
RCV000432551 | p.His193Tyr | missense variant | Lung adenocarcinoma | NC_000017.11:g.7674954G>A | ClinVar |
RCV000435651 | p.His193Arg | missense variant | Hepatocellular carcinoma (HCC) | NC_000017.11:g.7674953T>C | ClinVar |
RCV000425611 | p.His193Arg | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7674953T>C | ClinVar |
RCV000433585 | p.His193Pro | missense variant | Lung adenocarcinoma | NC_000017.11:g.7674953T>G | ClinVar |
RCV000424900 | p.His193Tyr | missense variant | Chronic lymphocytic leukemia (CLL) | NC_000017.11:g.7674954G>A | ClinVar |
RCV000420894 | p.His193Asn | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7674954G>T | ClinVar |
RCV000430089 | p.His193Tyr | missense variant | Neoplasm of brain | NC_000017.11:g.7674954G>A | ClinVar |
RCV000432462 | p.His193Asp | missense variant | Chronic lymphocytic leukemia (CLL) | NC_000017.11:g.7674954G>C | ClinVar |
RCV000434647 | p.His193Tyr | missense variant | Squamous cell lung carcinoma | NC_000017.11:g.7674954G>A | ClinVar |
RCV000809571 | p.His193Tyr | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674954G>A | ClinVar |
RCV000435420 | p.His193Pro | missense variant | Chronic lymphocytic leukemia (CLL) | NC_000017.11:g.7674953T>G | ClinVar |
RCV000426753 | p.His193Asn | missense variant | Small cell lung cancer | NC_000017.11:g.7674954G>T | ClinVar |
RCV000437420 | p.His193Asn | missense variant | Acute myeloid leukemia (AML) | NC_000017.11:g.7674954G>T | ClinVar |
RCV000427767 | p.His193Arg | missense variant | Adenocarcinoma of prostate | NC_000017.11:g.7674953T>C | ClinVar |
RCV000422374 | p.His193Pro | missense variant | Carcinoma of esophagus | NC_000017.11:g.7674953T>G | ClinVar |
RCV000441629 | p.His193Asn | missense variant | Neoplasm of brain | NC_000017.11:g.7674954G>T | ClinVar |
RCV000431464 | p.His193Tyr | missense variant | Adenocarcinoma of prostate | NC_000017.11:g.7674954G>A | ClinVar |
rs786201838 | p.His193Pro | missense variant | - | NC_000017.11:g.7674953T>G | UniProt,dbSNP |
VAR_044994 | p.His193Pro | missense variant | - | NC_000017.11:g.7674953T>G | UniProt |
rs876658468 | p.His193Asp | missense variant | - | NC_000017.11:g.7674954G>C | UniProt,dbSNP |
VAR_005947 | p.His193Asp | missense variant | - | NC_000017.11:g.7674954G>C | UniProt |
rs786201838 | p.His193Leu | missense variant | - | NC_000017.11:g.7674953T>A | UniProt,dbSNP |
VAR_044992 | p.His193Leu | missense variant | - | NC_000017.11:g.7674953T>A | UniProt |
rs876658468 | p.His193Asp | missense variant | - | NC_000017.11:g.7674954G>C | - |
rs786201838 | p.His193Arg | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674953T>C | UniProt,dbSNP |
VAR_005948 | p.His193Arg | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674953T>C | UniProt |
RCV000439827 | p.His193Arg | missense variant | Papillary renal cell carcinoma, sporadic | NC_000017.11:g.7674953T>C | ClinVar |
RCV000445292 | p.His193Pro | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7674953T>G | ClinVar |
RCV000255425 | p.His193Arg | missense variant | - | NC_000017.11:g.7674953T>C | ClinVar |
RCV000434933 | p.His193Pro | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7674953T>G | ClinVar |
RCV000424475 | p.His193Arg | missense variant | Uterine Carcinosarcoma | NC_000017.11:g.7674953T>C | ClinVar |
RCV000441851 | p.His193Asn | missense variant | Adenocarcinoma of stomach | NC_000017.11:g.7674954G>T | ClinVar |
RCV000438391 | p.His193Asp | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7674954G>C | ClinVar |
RCV000430614 | p.His193Asp | missense variant | Carcinoma of esophagus | NC_000017.11:g.7674954G>C | ClinVar |
RCV000423999 | p.His193Asp | missense variant | Hepatocellular carcinoma (HCC) | NC_000017.11:g.7674954G>C | ClinVar |
RCV000445008 | p.His193Tyr | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7674954G>A | ClinVar |
RCV000421458 | p.His193Asn | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7674954G>T | ClinVar |
RCV000433595 | p.His193Asn | missense variant | Hepatocellular carcinoma (HCC) | NC_000017.11:g.7674954G>T | ClinVar |
RCV000418378 | p.His193Asp | missense variant | Uterine Carcinosarcoma | NC_000017.11:g.7674954G>C | ClinVar |
RCV000430888 | p.His193Asn | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7674954G>T | ClinVar |
RCV000426264 | p.His193Tyr | missense variant | Malignant neoplasm of body of uterus | NC_000017.11:g.7674954G>A | ClinVar |
RCV000412758 | p.His193Tyr | missense variant | - | NC_000017.11:g.7674954G>A | ClinVar |
RCV000419544 | p.His193Asn | missense variant | Uterine Carcinosarcoma | NC_000017.11:g.7674954G>T | ClinVar |
RCV000439335 | p.His193Asn | missense variant | Neoplasm of the large intestine | NC_000017.11:g.7674954G>T | ClinVar |
RCV000421156 | p.His193Asp | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7674954G>C | ClinVar |
RCV000434205 | p.His193Pro | missense variant | - | NC_000017.11:g.7674953T>G | ClinVar |
RCV000423280 | p.His193Arg | missense variant | Lung adenocarcinoma | NC_000017.11:g.7674953T>C | ClinVar |
RCV000428340 | p.His193Arg | missense variant | - | NC_000017.11:g.7674953T>C | ClinVar |
RCV000439433 | p.His193Arg | missense variant | Neoplasm of brain | NC_000017.11:g.7674953T>C | ClinVar |
RCV000785346 | p.His193Arg | missense variant | Ovarian Neoplasms | NC_000017.11:g.7674953T>C | ClinVar |
RCV000418213 | p.His193Pro | missense variant | Adenocarcinoma of prostate | NC_000017.11:g.7674953T>G | ClinVar |
RCV000435566 | p.His193Pro | missense variant | Neoplasm of brain | NC_000017.11:g.7674953T>G | ClinVar |
RCV000697802 | p.His193Leu | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674953T>A | ClinVar |
RCV000442541 | p.His193Pro | missense variant | Malignant neoplasm of body of uterus | NC_000017.11:g.7674953T>G | ClinVar |
RCV000428877 | p.His193Pro | missense variant | - | NC_000017.11:g.7674953T>G | ClinVar |
RCV000434391 | p.His193Arg | missense variant | - | NC_000017.11:g.7674953T>C | ClinVar |
RCV000425998 | p.His193Tyr | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7674954G>A | ClinVar |
RCV000442175 | p.His193Asp | missense variant | Squamous cell lung carcinoma | NC_000017.11:g.7674954G>C | ClinVar |
RCV000427057 | p.His193Asn | missense variant | Carcinoma of esophagus | NC_000017.11:g.7674954G>T | ClinVar |
RCV000436620 | p.His193Asp | missense variant | Acute myeloid leukemia (AML) | NC_000017.11:g.7674954G>C | ClinVar |
RCV000440641 | p.His193Asp | missense variant | Malignant neoplasm of body of uterus | NC_000017.11:g.7674954G>C | ClinVar |
RCV000429967 | p.His193Asp | missense variant | Small cell lung cancer | NC_000017.11:g.7674954G>C | ClinVar |
RCV000444718 | p.His193Asp | missense variant | Adenocarcinoma of prostate | NC_000017.11:g.7674954G>C | ClinVar |
RCV000434704 | p.His193Asp | missense variant | Neoplasm of the breast | NC_000017.11:g.7674954G>C | ClinVar |
RCV000440111 | p.His193Tyr | missense variant | Carcinoma of esophagus | NC_000017.11:g.7674954G>A | ClinVar |
RCV000441207 | p.His193Tyr | missense variant | Neoplasm of the breast | NC_000017.11:g.7674954G>A | ClinVar |
RCV000418749 | p.His193Tyr | missense variant | Adenocarcinoma of stomach | NC_000017.11:g.7674954G>A | ClinVar |
RCV000436250 | p.His193Asp | missense variant | Neoplasm of brain | NC_000017.11:g.7674954G>C | ClinVar |
RCV000440128 | p.His193Pro | missense variant | Neoplasm of the breast | NC_000017.11:g.7674953T>G | ClinVar |
VAR_044995 | p.His193Gln | Missense | - | - | UniProt |
rs1057519998 | p.Leu194His | missense variant | - | NC_000017.11:g.7674950A>T | UniProt,dbSNP |
VAR_044998 | p.Leu194His | missense variant | - | NC_000017.11:g.7674950A>T | UniProt |
RCV000441887 | p.Leu194Pro | missense variant | Neoplasm of the large intestine | NC_000017.11:g.7674950A>G | ClinVar |
RCV000535418 | p.Leu194Arg | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674950A>C | ClinVar |
RCV000424516 | p.Leu194Pro | missense variant | Hepatocellular carcinoma (HCC) | NC_000017.11:g.7674950A>G | ClinVar |
RCV000442808 | p.Leu194Pro | missense variant | Lung adenocarcinoma | NC_000017.11:g.7674950A>G | ClinVar |
RCV000441162 | p.Leu194Pro | missense variant | Glioblastoma | NC_000017.11:g.7674950A>G | ClinVar |
RCV000423937 | p.Leu194Pro | missense variant | Uterine cervical neoplasms | NC_000017.11:g.7674950A>G | ClinVar |
RCV000433582 | p.Leu194Pro | missense variant | Neoplasm of brain | NC_000017.11:g.7674950A>G | ClinVar |
RCV000565549 | p.Leu194His | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7674950A>T | ClinVar |
RCV000429595 | p.Leu194Phe | missense variant | Neoplasm of brain | NC_000017.11:g.7674951G>A | ClinVar |
RCV000439843 | p.Leu194Phe | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7674951G>A | ClinVar |
RCV000436065 | p.Leu194Phe | missense variant | - | NC_000017.11:g.7674951G>A | ClinVar |
RCV000421548 | p.Leu194Phe | missense variant | Uterine cervical neoplasms | NC_000017.11:g.7674951G>A | ClinVar |
RCV000417813 | p.Leu194Phe | missense variant | Neoplasm of the breast | NC_000017.11:g.7674951G>A | ClinVar |
RCV000419908 | p.Leu194Phe | missense variant | Glioblastoma | NC_000017.11:g.7674951G>A | ClinVar |
RCV000439186 | p.Leu194Phe | missense variant | Neoplasm of the large intestine | NC_000017.11:g.7674951G>A | ClinVar |
RCV000428029 | p.Leu194Phe | missense variant | Lung adenocarcinoma | NC_000017.11:g.7674951G>A | ClinVar |
RCV000418414 | p.Leu194Phe | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7674951G>A | ClinVar |
RCV000426684 | p.Leu194Phe | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7674951G>A | ClinVar |
RCV000115728 | p.Leu194Phe | missense variant | - | NC_000017.11:g.7674951G>A | ClinVar |
NCI-TCGA novel | p.Leu194ProPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7674946_7674950GATAA>- | NCI-TCGA |
NCI-TCGA novel | p.Leu194GluPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7674946_7674952GATAAGA>- | NCI-TCGA |
rs587780071 | p.Leu194Phe | missense variant | - | NC_000017.11:g.7674951G>A | - |
rs587780071 | p.Leu194Phe | missense variant | - | NC_000017.11:g.7674951G>A | UniProt,dbSNP |
VAR_044997 | p.Leu194Phe | missense variant | - | NC_000017.11:g.7674951G>A | UniProt |
rs1057519998 | p.Leu194Pro | missense variant | - | NC_000017.11:g.7674950A>G | gnomAD |
rs1057519998 | p.Leu194His | missense variant | - | NC_000017.11:g.7674950A>T | gnomAD |
rs1057519998 | p.Leu194Arg | missense variant | - | NC_000017.11:g.7674950A>C | gnomAD |
rs1057519998 | p.Leu194Arg | missense variant | - | NC_000017.11:g.7674950A>C | UniProt,dbSNP |
VAR_005950 | p.Leu194Arg | missense variant | - | NC_000017.11:g.7674950A>C | UniProt |
rs1057519998 | p.Leu194Pro | missense variant | - | NC_000017.11:g.7674950A>G | UniProt,dbSNP |
VAR_005949 | p.Leu194Pro | missense variant | - | NC_000017.11:g.7674950A>G | UniProt |
RCV000434383 | p.Leu194Phe | missense variant | Hepatocellular carcinoma (HCC) | NC_000017.11:g.7674951G>A | ClinVar |
RCV000561306 | p.Leu194Arg | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7674950A>C | ClinVar |
RCV000425646 | p.Leu194Pro | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7674950A>G | ClinVar |
RCV000426810 | p.Leu194Pro | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7674950A>G | ClinVar |
RCV000433343 | p.Leu194Pro | missense variant | - | NC_000017.11:g.7674950A>G | ClinVar |
RCV000419057 | p.Leu194Pro | missense variant | Neoplasm of the breast | NC_000017.11:g.7674950A>G | ClinVar |
RCV000436323 | p.Leu194Pro | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7674950A>G | ClinVar |
VAR_045000 | p.Leu194Val | Missense | - | - | UniProt |
VAR_044999 | p.Leu194Ile | Missense | - | - | UniProt |
rs760043106 | p.Ile195Thr | missense variant | - | NC_000017.11:g.7674947A>G | ExAC,gnomAD |
rs760043106 | p.Ile195Thr | missense variant | - | NC_000017.11:g.7674947A>G | UniProt,dbSNP |
VAR_005951 | p.Ile195Thr | missense variant | - | NC_000017.11:g.7674947A>G | UniProt |
RCV000426791 | p.Ile195Phe | missense variant | Lung adenocarcinoma | NC_000017.11:g.7674948T>A | ClinVar |
RCV000420717 | p.Ile195Phe | missense variant | Neoplasm of the breast | NC_000017.11:g.7674948T>A | ClinVar |
RCV000423573 | p.Ile195Phe | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7674948T>A | ClinVar |
RCV000417891 | p.Ile195Phe | missense variant | Acute myeloid leukemia (AML) | NC_000017.11:g.7674948T>A | ClinVar |
RCV000436319 | p.Ile195Phe | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7674948T>A | ClinVar |
RCV000433525 | p.Ile195Phe | missense variant | Carcinoma of esophagus | NC_000017.11:g.7674948T>A | ClinVar |
RCV000426094 | p.Ile195Phe | missense variant | Uterine Carcinosarcoma | NC_000017.11:g.7674948T>A | ClinVar |
RCV000441219 | p.Ile195Phe | missense variant | Chronic lymphocytic leukemia (CLL) | NC_000017.11:g.7674948T>A | ClinVar |
RCV000425266 | p.Ile195Phe | missense variant | Glioblastoma | NC_000017.11:g.7674948T>A | ClinVar |
RCV000428137 | p.Ile195Phe | missense variant | Hepatocellular carcinoma (HCC) | NC_000017.11:g.7674948T>A | ClinVar |
RCV000433861 | p.Ile195Phe | missense variant | Adenocarcinoma of stomach | NC_000017.11:g.7674948T>A | ClinVar |
RCV000435534 | p.Ile195Phe | missense variant | Multiple myeloma (MM) | NC_000017.11:g.7674948T>A | ClinVar |
RCV000438337 | p.Ile195Phe | missense variant | Squamous cell lung carcinoma | NC_000017.11:g.7674948T>A | ClinVar |
RCV000444892 | p.Ile195Phe | missense variant | Neoplasm of the large intestine | NC_000017.11:g.7674948T>A | ClinVar |
RCV000633400 | p.Ile195Met | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674946G>C | ClinVar |
RCV000427622 | p.Ile195Ser | missense variant | Uterine Carcinosarcoma | NC_000017.11:g.7674947A>C | ClinVar |
RCV000445057 | p.Ile195Ser | missense variant | Neoplasm of the large intestine | NC_000017.11:g.7674947A>C | ClinVar |
RCV000431547 | p.Ile195Ser | missense variant | Hepatocellular carcinoma (HCC) | NC_000017.11:g.7674947A>C | ClinVar |
RCV000442296 | p.Ile195Ser | missense variant | Carcinoma of esophagus | NC_000017.11:g.7674947A>C | ClinVar |
RCV000421312 | p.Ile195Ser | missense variant | Neoplasm of the breast | NC_000017.11:g.7674947A>C | ClinVar |
RCV000422467 | p.Ile195Ser | missense variant | Chronic lymphocytic leukemia (CLL) | NC_000017.11:g.7674947A>C | ClinVar |
COSM5430897 | p.Ile195LeuPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7674949_7674950insAG | NCI-TCGA Cosmic |
COSM295517 | p.Ile195AsnPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7674947_7674948insT | NCI-TCGA Cosmic |
COSM308341 | p.Ile195SerPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7674949A>- | NCI-TCGA Cosmic |
RCV000437865 | p.Ile195Ser | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7674947A>C | ClinVar |
NCI-TCGA novel | p.Ile195TyrPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7674948_7674949insA | NCI-TCGA |
RCV000421805 | p.Ile195Ser | missense variant | Glioblastoma | NC_000017.11:g.7674947A>C | ClinVar |
RCV000429226 | p.Ile195Ser | missense variant | Squamous cell lung carcinoma | NC_000017.11:g.7674947A>C | ClinVar |
RCV000692717 | p.Ile195Asn | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674947A>T | ClinVar |
RCV000439461 | p.Ile195Ser | missense variant | Lung adenocarcinoma | NC_000017.11:g.7674947A>C | ClinVar |
RCV000426991 | p.Ile195Ser | missense variant | Neoplasm of brain | NC_000017.11:g.7674947A>C | ClinVar |
RCV000442729 | p.Ile195Ser | missense variant | Multiple myeloma (MM) | NC_000017.11:g.7674947A>C | ClinVar |
RCV000437242 | p.Ile195Ser | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7674947A>C | ClinVar |
RCV000429901 | p.Ile195Ser | missense variant | Acute myeloid leukemia (AML) | NC_000017.11:g.7674947A>C | ClinVar |
RCV000785262 | p.Ile195Ter | frameshift | Ovarian Neoplasms | NC_000017.11:g.7674950del | ClinVar |
rs760043106 | p.Ile195Asn | missense variant | - | NC_000017.11:g.7674947A>T | ExAC,gnomAD |
rs760043106 | p.Ile195Asn | missense variant | - | NC_000017.11:g.7674947A>T | UniProt,dbSNP |
VAR_045002 | p.Ile195Asn | missense variant | - | NC_000017.11:g.7674947A>T | UniProt |
rs760043106 | p.Ile195Ser | missense variant | - | NC_000017.11:g.7674947A>C | ExAC,gnomAD |
rs760043106 | p.Ile195Ser | missense variant | - | NC_000017.11:g.7674947A>C | UniProt,dbSNP |
VAR_045003 | p.Ile195Ser | missense variant | - | NC_000017.11:g.7674947A>C | UniProt |
rs942158624 | p.Ile195Phe | missense variant | - | NC_000017.11:g.7674948T>A | - |
RCV000432185 | p.Ile195Ser | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7674947A>C | ClinVar |
RCV000487386 | p.Ile195Thr | missense variant | - | NC_000017.11:g.7674947A>G | ClinVar |
RCV000440129 | p.Ile195Ser | missense variant | Adenocarcinoma of stomach | NC_000017.11:g.7674947A>C | ClinVar |
RCV000198789 | p.Ile195Thr | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674947A>G | ClinVar |
RCV000418677 | p.Ile195Phe | missense variant | Neoplasm of brain | NC_000017.11:g.7674948T>A | ClinVar |
RCV000430955 | p.Ile195Phe | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7674948T>A | ClinVar |
VAR_047172 | p.Ile195Leu | Missense | - | - | UniProt |
VAR_045004 | p.Ile195Val | Missense | - | - | UniProt |
VAR_045806 | p.Ile195Tyr | Missense | - | - | UniProt |
rs483352697 | p.Arg196Pro | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674944C>G | UniProt,dbSNP |
VAR_045007 | p.Arg196Pro | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674944C>G | UniProt |
rs483352697 | p.Arg196Pro | missense variant | - | NC_000017.11:g.7674944C>G | gnomAD |
RCV000230517 | p.Arg196Gly | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674945G>C | ClinVar |
RCV000440531 | p.Arg196Pro | missense variant | Adenocarcinoma of stomach | NC_000017.11:g.7674944C>G | ClinVar |
RCV000435372 | p.Arg196Pro | missense variant | Malignant melanoma of skin (CMM) | NC_000017.11:g.7674944C>G | ClinVar |
RCV000431695 | p.Arg196Pro | missense variant | Carcinoma of esophagus | NC_000017.11:g.7674944C>G | ClinVar |
RCV000443813 | p.Arg196Pro | missense variant | Squamous cell lung carcinoma | NC_000017.11:g.7674944C>G | ClinVar |
RCV000440866 | p.Arg196Pro | missense variant | Glioblastoma | NC_000017.11:g.7674944C>G | ClinVar |
RCV000436292 | p.Arg196Pro | missense variant | Multiple myeloma (MM) | NC_000017.11:g.7674944C>G | ClinVar |
RCV000426017 | p.Arg196Pro | missense variant | - | NC_000017.11:g.7674944C>G | ClinVar |
RCV000423798 | p.Arg196Pro | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7674944C>G | ClinVar |
RCV000434064 | p.Arg196Pro | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7674944C>G | ClinVar |
RCV000196467 | p.Arg196Gln | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674944C>T | ClinVar |
RCV000216410 | p.Arg196Pro | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7674944C>G | ClinVar |
RCV000205265 | p.Arg196Ter | nonsense | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674945G>A | ClinVar |
RCV000425092 | p.Arg196Pro | missense variant | Neoplasm of the breast | NC_000017.11:g.7674944C>G | ClinVar |
RCV000419494 | p.Arg196Pro | missense variant | Small cell lung cancer | NC_000017.11:g.7674944C>G | ClinVar |
RCV000443927 | p.Arg196Pro | missense variant | Neoplasm of brain | NC_000017.11:g.7674944C>G | ClinVar |
RCV000087172 | p.Arg196Leu | missense variant | - | NC_000017.11:g.7674944C>A | ClinVar |
RCV000131510 | p.Arg196Ter | nonsense | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7674945G>A | ClinVar |
rs483352697 | p.Arg196Leu | missense variant | - | NC_000017.11:g.7674944C>A | gnomAD |
rs483352697 | p.Arg196Gln | missense variant | - | NC_000017.11:g.7674944C>T | UniProt,dbSNP |
VAR_045008 | p.Arg196Gln | missense variant | - | NC_000017.11:g.7674944C>T | UniProt |
rs397516435 | p.Arg196Ter | stop gained | - | NC_000017.11:g.7674945G>A | ExAC,TOPMed,gnomAD |
rs483352697 | p.Arg196Gln | missense variant | - | NC_000017.11:g.7674944C>T | gnomAD |
rs397516435 | p.Arg196Gly | missense variant | - | NC_000017.11:g.7674945G>C | ExAC,TOPMed,gnomAD |
rs397516435 | p.Arg196Gly | missense variant | - | NC_000017.11:g.7674945G>C | UniProt,dbSNP |
VAR_045005 | p.Arg196Gly | missense variant | - | NC_000017.11:g.7674945G>C | UniProt |
rs483352697 | p.Arg196Leu | missense variant | - | NC_000017.11:g.7674944C>A | UniProt,dbSNP |
VAR_045006 | p.Arg196Leu | missense variant | - | NC_000017.11:g.7674944C>A | UniProt |
RCV000418400 | p.Arg196Pro | missense variant | Neoplasm of the large intestine | NC_000017.11:g.7674944C>G | ClinVar |
RCV000412710 | p.Arg196Ter | nonsense | - | NC_000017.11:g.7674945G>A | ClinVar |
RCV000429772 | p.Arg196Pro | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7674944C>G | ClinVar |
RCV000427483 | p.Arg196Pro | missense variant | Renal cell carcinoma, papillary, 1 (RCCP1) | NC_000017.11:g.7674944C>G | ClinVar |
RCV000235733 | p.Arg196Gln | missense variant | - | NC_000017.11:g.7674944C>T | ClinVar |
RCV000785329 | p.Arg196Ter | nonsense | Ovarian Neoplasms | NC_000017.11:g.7674945G>A | ClinVar |
RCV000433800 | p.Arg196Pro | missense variant | Lung adenocarcinoma | NC_000017.11:g.7674944C>G | ClinVar |
RCV000580263 | p.Arg196Gln | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7674944C>T | ClinVar |
RCV000217052 | p.Arg196Gly | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7674945G>C | ClinVar |
VAR_045009 | p.Arg196Ser | Missense | - | - | UniProt |
COSM437521 | p.Val197Gly | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7674941A>C | NCI-TCGA Cosmic |
NCI-TCGA novel | p.Val197IlePheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7674919_7674943CTCCACACGCAAATTTCCTTCCACT>- | NCI-TCGA |
RCV000785480 | p.Val197Glu | missense variant | Ovarian Neoplasms | NC_000017.11:g.7674941A>T | ClinVar |
RCV000167874 | p.Val197Met | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674942C>T | ClinVar |
RCV000566652 | p.Val197Leu | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7674942C>G | ClinVar |
rs786204041 | p.Val197Met | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674942C>T | UniProt,dbSNP |
VAR_045013 | p.Val197Met | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674942C>T | UniProt |
rs786204041 | p.Val197Met | missense variant | - | NC_000017.11:g.7674942C>T | gnomAD |
rs786204041 | p.Val197Leu | missense variant | - | NC_000017.11:g.7674942C>A | gnomAD |
rs786204041 | p.Val197Leu | missense variant | - | NC_000017.11:g.7674942C>G | gnomAD |
rs786204041 | p.Val197Leu | missense variant | - | NC_000017.11:g.7674942C>G | UniProt,dbSNP |
VAR_045012 | p.Val197Leu | missense variant | - | NC_000017.11:g.7674942C>G | UniProt |
RCV000811803 | p.Val197Glu | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674941A>T | ClinVar |
RCV000198322 | p.Val197Leu | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674942C>A | ClinVar |
VAR_045010 | p.Val197Glu | Missense | - | - | UniProt |
VAR_045011 | p.Val197Gly | Missense | - | - | UniProt |
RCV000492785 | p.Glu198Ter | frameshift | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7674940del | ClinVar |
COSM1386746 | p.Glu198GlyPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7674938_7674939insC | NCI-TCGA Cosmic |
RCV000785326 | p.Glu198Ter | nonsense | Ovarian Neoplasms | NC_000017.11:g.7674939C>A | ClinVar |
VAR_005952 | p.Glu198Lys | Missense | - | - | UniProt |
VAR_045015 | p.Glu198Gly | Missense | - | - | UniProt |
VAR_045016 | p.Glu198Gln | Missense | - | - | UniProt |
VAR_045014 | p.Glu198Asp | Missense | - | - | UniProt |
VAR_045017 | p.Glu198Val | Missense | - | - | UniProt |
COSM100022 | p.Gly199GluPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7674937T>- | NCI-TCGA Cosmic |
RCV000522967 | p.Gly199Val | missense variant | - | NC_000017.11:g.7674935C>A | ClinVar |
NCI-TCGA novel | p.Gly199IlePheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7674933_7674936TTCC>- | NCI-TCGA |
RCV000785258 | p.Gly199Ter | nonsense | Ovarian Neoplasms | NC_000017.11:g.7674936C>A | ClinVar |
rs1555525857 | p.Gly199Val | missense variant | - | NC_000017.11:g.7674935C>A | - |
rs1555525857 | p.Gly199Val | missense variant | - | NC_000017.11:g.7674935C>A | UniProt,dbSNP |
VAR_045021 | p.Gly199Val | missense variant | - | NC_000017.11:g.7674935C>A | UniProt |
RCV000706290 | p.Gly199Glu | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674935C>T | ClinVar |
VAR_045020 | p.Gly199Arg | Missense | - | - | UniProt |
VAR_045018 | p.Gly199Ala | Missense | - | - | UniProt |
VAR_045019 | p.Gly199Glu | Missense | - | - | UniProt |
RCV000492564 | p.Asn200Ter | frameshift | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7674934del | ClinVar |
COSM255157 | p.Asn200IlePheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7674932T>- | NCI-TCGA Cosmic |
NCI-TCGA novel | p.Asn200ValPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7674933_7674934insGCCAATATGTATGAATAGCTATGTAGTTATATAC | NCI-TCGA |
VAR_045807 | p.Asn200Pro | Missense | - | - | UniProt |
VAR_045023 | p.Asn200Ile | Missense | - | - | UniProt |
VAR_045025 | p.Asn200Ser | Missense | - | - | UniProt |
VAR_045024 | p.Asn200Lys | Missense | - | - | UniProt |
VAR_045022 | p.Asn200Asp | Missense | - | - | UniProt |
VAR_045026 | p.Asn200Thr | Missense | - | - | UniProt |
COSM3742467 | p.Leu201Ter | stop gained | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7674929A>T | NCI-TCGA Cosmic |
COSM5215175 | p.Leu201PhePheSerTerUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7674928_7674929insA | NCI-TCGA Cosmic |
rs730882024 | p.Leu201Phe | missense variant | - | NC_000017.11:g.7674928C>A | TOPMed |
VAR_045029 | p.Leu201Ser | Missense | - | - | UniProt |
VAR_045028 | p.Leu201Pro | Missense | - | - | UniProt |
VAR_047173 | p.Leu201_Arg202delinsPheCys | deletion_insertion | - | - | UniProt |
rs587778719 | p.Arg202Leu | missense variant | - | NC_000017.11:g.7674926C>A | UniProt,dbSNP |
VAR_045033 | p.Arg202Leu | missense variant | - | NC_000017.11:g.7674926C>A | UniProt |
RCV000563913 | p.Arg202Cys | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7674927G>A | ClinVar |
RCV000218191 | p.Arg202Gly | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7674927G>C | ClinVar |
RCV000161030 | p.Arg202Leu | missense variant | - | NC_000017.11:g.7674926C>A | ClinVar |
rs587780072 | p.Arg202Cys | missense variant | - | NC_000017.11:g.7674927G>A | UniProt,dbSNP |
VAR_045030 | p.Arg202Cys | missense variant | - | NC_000017.11:g.7674927G>A | UniProt |
rs587780072 | p.Arg202Cys | missense variant | - | NC_000017.11:g.7674927G>A | ExAC,gnomAD |
rs587780072 | p.Arg202Gly | missense variant | - | NC_000017.11:g.7674927G>C | ExAC,gnomAD |
rs587778719 | p.Arg202His | missense variant | - | NC_000017.11:g.7674926C>T | TOPMed |
rs587780072 | p.Arg202Gly | missense variant | - | NC_000017.11:g.7674927G>C | UniProt,dbSNP |
VAR_045031 | p.Arg202Gly | missense variant | - | NC_000017.11:g.7674927G>C | UniProt |
rs587778719 | p.Arg202His | missense variant | - | NC_000017.11:g.7674926C>T | UniProt,dbSNP |
VAR_045032 | p.Arg202His | missense variant | - | NC_000017.11:g.7674926C>T | UniProt |
rs587778719 | p.Arg202Leu | missense variant | - | NC_000017.11:g.7674926C>A | TOPMed |
RCV000459232 | p.Arg202His | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674926C>T | ClinVar |
VAR_045035 | p.Arg202Ser | Missense | - | - | UniProt |
VAR_045034 | p.Arg202Pro | Missense | - | - | UniProt |
rs730882003 | p.Val203Leu | missense variant | - | NC_000017.11:g.7674924C>A | - |
RCV000460914 | p.Val203Met | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674924C>T | ClinVar |
COSM45308 | p.Val203TrpPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7674924C>- | NCI-TCGA Cosmic |
COSM1386715 | p.Val203GlyPheSerTerUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7674922_7674923CA>- | NCI-TCGA Cosmic |
RCV000695145 | p.Val203Leu | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674924C>A | ClinVar |
RCV000564049 | p.Val203Leu | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7674924C>G | ClinVar |
rs730882003 | p.Val203Met | missense variant | - | NC_000017.11:g.7674924C>T | - |
rs730882003 | p.Val203Leu | missense variant | - | NC_000017.11:g.7674924C>G | - |
RCV000564461 | p.Val203Leu | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7674924C>A | ClinVar |
RCV000161031 | p.Val203Met | missense variant | - | NC_000017.11:g.7674924C>T | ClinVar |
RCV000492177 | p.Val203Met | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7674924C>T | ClinVar |
RCV000696578 | p.Val203Leu | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674924C>G | ClinVar |
VAR_047174 | p.Val203_Glu204delinsLeuVal | deletion_insertion | - | - | UniProt |
VAR_045037 | p.Val203Glu | Missense | - | - | UniProt |
VAR_045038 | p.Val203Leu | Missense | - | - | UniProt |
VAR_045036 | p.Val203Ala | Missense | - | - | UniProt |
VAR_045808 | p.Val203Trp | Missense | - | - | UniProt |
COSM46471 | p.Glu204Asp | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7674919C>G | NCI-TCGA Cosmic |
COSM437512 | p.Glu204SerPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7674921C>- | NCI-TCGA Cosmic |
COSM45782 | p.Glu204Gln | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7674921C>G | NCI-TCGA Cosmic |
COSM10804 | p.Glu204Ter | stop gained | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7674921C>A | NCI-TCGA Cosmic |
NCI-TCGA novel | p.Glu204ValPheSerTerUnk | frameshift | - | NC_000017.11:g.7674919_7674920CT>- | NCI-TCGA |
rs1260903787 | p.Glu204Gly | missense variant | - | NC_000017.11:g.7674920T>C | TOPMed,gnomAD |
RCV000785499 | p.Glu204Ter | nonsense | Ovarian Neoplasms | NC_000017.11:g.7674921_7674922delinsAG | ClinVar |
VAR_045040 | p.Glu204Ala | Missense | - | - | UniProt |
VAR_045045 | p.Glu204Val | Missense | - | - | UniProt |
VAR_045044 | p.Glu204Gln | Missense | - | - | UniProt |
VAR_045041 | p.Glu204Asp | Missense | - | - | UniProt |
VAR_045043 | p.Glu204Lys | Missense | - | - | UniProt |
rs1057520008 | p.Tyr205Asn | missense variant | - | NC_000017.11:g.7674918A>T | UniProt,dbSNP |
VAR_045047 | p.Tyr205Asn | missense variant | - | NC_000017.11:g.7674918A>T | UniProt |
RCV000436627 | p.Tyr205Phe | missense variant | Multiple myeloma (MM) | NC_000017.11:g.7674917T>A | ClinVar |
RCV000419588 | p.Tyr205Phe | missense variant | Renal cell carcinoma, papillary, 1 (RCCP1) | NC_000017.11:g.7674917T>A | ClinVar |
RCV000429897 | p.Tyr205Phe | missense variant | Squamous cell lung carcinoma | NC_000017.11:g.7674917T>A | ClinVar |
RCV000443239 | p.Tyr205Ser | missense variant | Neoplasm of the large intestine | NC_000017.11:g.7674917T>G | ClinVar |
RCV000417872 | p.Tyr205Ser | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7674917T>G | ClinVar |
RCV000462351 | p.Tyr205Asp | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674918A>C | ClinVar |
RCV000418952 | p.Tyr205Phe | missense variant | Non-Hodgkin lymphoma (NHL) | NC_000017.11:g.7674917T>A | ClinVar |
RCV000440667 | p.Tyr205Cys | missense variant | Multiple myeloma (MM) | NC_000017.11:g.7674917T>C | ClinVar |
RCV000439980 | p.Tyr205Cys | missense variant | Neoplasm of the large intestine | NC_000017.11:g.7674917T>C | ClinVar |
RCV000433474 | p.Tyr205Asn | missense variant | Glioblastoma | NC_000017.11:g.7674918A>T | ClinVar |
RCV000438926 | p.Tyr205Phe | missense variant | Carcinoma of esophagus | NC_000017.11:g.7674917T>A | ClinVar |
RCV000443828 | p.Tyr205Cys | missense variant | Neoplasm of brain | NC_000017.11:g.7674917T>C | ClinVar |
RCV000436591 | p.Tyr205Ser | missense variant | Neoplasm of brain | NC_000017.11:g.7674917T>G | ClinVar |
RCV000704312 | p.Tyr205Cys | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674917T>C | ClinVar |
RCV000431494 | p.Tyr205Phe | missense variant | Glioblastoma | NC_000017.11:g.7674917T>A | ClinVar |
RCV000424901 | p.Tyr205Cys | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7674917T>C | ClinVar |
RCV000439588 | p.Tyr205Phe | missense variant | Hepatocellular carcinoma (HCC) | NC_000017.11:g.7674917T>A | ClinVar |
RCV000433236 | p.Tyr205Cys | missense variant | Malignant neoplasm of body of uterus | NC_000017.11:g.7674917T>C | ClinVar |
RCV000442863 | p.Tyr205Cys | missense variant | Lung adenocarcinoma | NC_000017.11:g.7674917T>C | ClinVar |
RCV000443687 | p.Tyr205Cys | missense variant | Carcinoma of esophagus | NC_000017.11:g.7674917T>C | ClinVar |
RCV000430294 | p.Tyr205Asn | missense variant | Neoplasm of the large intestine | NC_000017.11:g.7674918A>T | ClinVar |
RCV000441249 | p.Tyr205Ser | missense variant | Uterine Carcinosarcoma | NC_000017.11:g.7674917T>G | ClinVar |
RCV000663307 | p.Tyr205Asp | missense variant | Li-Fraumeni syndrome 1 (LFS) | NC_000017.11:g.7674918A>C | ClinVar |
RCV000418906 | p.Tyr205Ser | missense variant | Glioblastoma | NC_000017.11:g.7674917T>G | ClinVar |
RCV000444287 | p.Tyr205Asn | missense variant | Squamous cell lung carcinoma | NC_000017.11:g.7674918A>T | ClinVar |
RCV000430410 | p.Tyr205Cys | missense variant | Uterine Carcinosarcoma | NC_000017.11:g.7674917T>C | ClinVar |
RCV000424047 | p.Tyr205Phe | missense variant | Neoplasm of the breast | NC_000017.11:g.7674917T>A | ClinVar |
RCV000443993 | p.Tyr205Phe | missense variant | Neoplasm of the large intestine | NC_000017.11:g.7674917T>A | ClinVar |
RCV000429233 | p.Tyr205Phe | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7674917T>A | ClinVar |
RCV000421916 | p.Tyr205Phe | missense variant | Lung adenocarcinoma | NC_000017.11:g.7674917T>A | ClinVar |
RCV000434394 | p.Tyr205Phe | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7674917T>A | ClinVar |
RCV000426974 | p.Tyr205Phe | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7674917T>A | ClinVar |
RCV000432320 | p.Tyr205Cys | missense variant | Neoplasm of the breast | NC_000017.11:g.7674917T>C | ClinVar |
RCV000428760 | p.Tyr205Ser | missense variant | Lung adenocarcinoma | NC_000017.11:g.7674917T>G | ClinVar |
RCV000444368 | p.Tyr205Asn | missense variant | Lung adenocarcinoma | NC_000017.11:g.7674918A>T | ClinVar |
RCV000437249 | p.Tyr205Ser | missense variant | Hepatocellular carcinoma (HCC) | NC_000017.11:g.7674917T>G | ClinVar |
RCV000426051 | p.Tyr205Asn | missense variant | Hepatocellular carcinoma (HCC) | NC_000017.11:g.7674918A>T | ClinVar |
RCV000433698 | p.Tyr205Ser | missense variant | Non-Hodgkin lymphoma (NHL) | NC_000017.11:g.7674917T>G | ClinVar |
RCV000424892 | p.Tyr205Asn | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7674918A>T | ClinVar |
RCV000430958 | p.Tyr205Ser | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7674917T>G | ClinVar |
RCV000421235 | p.Tyr205Phe | missense variant | Malignant neoplasm of body of uterus | NC_000017.11:g.7674917T>A | ClinVar |
RCV000420753 | p.Tyr205Asn | missense variant | Neoplasm of the breast | NC_000017.11:g.7674918A>T | ClinVar |
RCV000443853 | p.Tyr205Phe | missense variant | Uterine Carcinosarcoma | NC_000017.11:g.7674917T>A | ClinVar |
RCV000423862 | p.Tyr205Ser | missense variant | Renal cell carcinoma, papillary, 1 (RCCP1) | NC_000017.11:g.7674917T>G | ClinVar |
RCV000430575 | p.Tyr205Asn | missense variant | Multiple myeloma (MM) | NC_000017.11:g.7674918A>T | ClinVar |
RCV000437254 | p.Tyr205Cys | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7674917T>C | ClinVar |
RCV000422077 | p.Tyr205Cys | missense variant | Hepatocellular carcinoma (HCC) | NC_000017.11:g.7674917T>C | ClinVar |
RCV000417461 | p.Tyr205Asn | missense variant | Carcinoma of esophagus | NC_000017.11:g.7674918A>T | ClinVar |
RCV000440868 | p.Tyr205Ser | missense variant | Squamous cell lung carcinoma | NC_000017.11:g.7674917T>G | ClinVar |
RCV000431652 | p.Tyr205Cys | missense variant | Glioblastoma | NC_000017.11:g.7674917T>C | ClinVar |
RCV000428672 | p.Tyr205Phe | missense variant | Neoplasm of brain | NC_000017.11:g.7674917T>A | ClinVar |
RCV000422980 | p.Tyr205Cys | missense variant | Renal cell carcinoma, papillary, 1 (RCCP1) | NC_000017.11:g.7674917T>C | ClinVar |
RCV000437987 | p.Tyr205Asn | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7674918A>T | ClinVar |
RCV000437968 | p.Tyr205Cys | missense variant | Squamous cell lung carcinoma | NC_000017.11:g.7674917T>C | ClinVar |
RCV000424176 | p.Tyr205Ser | missense variant | Malignant neoplasm of body of uterus | NC_000017.11:g.7674917T>G | ClinVar |
RCV000427034 | p.Tyr205Cys | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7674917T>C | ClinVar |
RCV000422784 | p.Tyr205Asn | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7674918A>T | ClinVar |
RCV000427749 | p.Tyr205Cys | missense variant | Non-Hodgkin lymphoma (NHL) | NC_000017.11:g.7674917T>C | ClinVar |
rs1057520008 | p.Tyr205Asp | missense variant | - | NC_000017.11:g.7674918A>C | UniProt,dbSNP |
VAR_005954 | p.Tyr205Asp | missense variant | - | NC_000017.11:g.7674918A>C | UniProt |
rs1057520008 | p.Tyr205His | missense variant | - | NC_000017.11:g.7674918A>G | gnomAD |
NCI-TCGA novel | p.Tyr205Ter | stop gained | - | NC_000017.11:g.7674916_7674917insT | NCI-TCGA |
RCV000164938 | p.Tyr205Ter | nonsense | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7674916A>T | ClinVar |
rs1057520007 | p.Tyr205Cys | missense variant | - | NC_000017.11:g.7674917T>C | UniProt,dbSNP |
VAR_005953 | p.Tyr205Cys | missense variant | - | NC_000017.11:g.7674917T>C | UniProt |
rs1057520007 | p.Tyr205Cys | missense variant | - | NC_000017.11:g.7674917T>C | - |
rs786202222 | p.Tyr205Ter | stop gained | - | NC_000017.11:g.7674916A>T | gnomAD |
rs1057520008 | p.Tyr205Asn | missense variant | - | NC_000017.11:g.7674918A>T | gnomAD |
rs1057520007 | p.Tyr205Ser | missense variant | - | NC_000017.11:g.7674917T>G | UniProt,dbSNP |
VAR_045048 | p.Tyr205Ser | missense variant | - | NC_000017.11:g.7674917T>G | UniProt |
rs1057520007 | p.Tyr205Ser | missense variant | - | NC_000017.11:g.7674917T>G | - |
rs1057520008 | p.Tyr205His | missense variant | - | NC_000017.11:g.7674918A>G | UniProt,dbSNP |
VAR_045046 | p.Tyr205His | missense variant | - | NC_000017.11:g.7674918A>G | UniProt |
rs1057520007 | p.Tyr205Phe | missense variant | - | NC_000017.11:g.7674917T>A | UniProt,dbSNP |
VAR_047175 | p.Tyr205Phe | missense variant | - | NC_000017.11:g.7674917T>A | UniProt |
rs1057520007 | p.Tyr205Phe | missense variant | - | NC_000017.11:g.7674917T>A | - |
rs1057520008 | p.Tyr205Asp | missense variant | - | NC_000017.11:g.7674918A>C | gnomAD |
RCV000435608 | p.Tyr205Asn | missense variant | Non-Hodgkin lymphoma (NHL) | NC_000017.11:g.7674918A>T | ClinVar |
RCV000428105 | p.Tyr205Ser | missense variant | Neoplasm of the breast | NC_000017.11:g.7674917T>G | ClinVar |
RCV000424682 | p.Tyr205Asn | missense variant | Neoplasm of brain | NC_000017.11:g.7674918A>T | ClinVar |
RCV000419577 | p.Tyr205Asn | missense variant | Renal cell carcinoma, papillary, 1 (RCCP1) | NC_000017.11:g.7674918A>T | ClinVar |
RCV000819983 | p.Tyr205His | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674918A>G | ClinVar |
RCV000438368 | p.Tyr205Ser | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7674917T>G | ClinVar |
RCV000435531 | p.Tyr205Ser | missense variant | Multiple myeloma (MM) | NC_000017.11:g.7674917T>G | ClinVar |
RCV000426347 | p.Tyr205Ser | missense variant | Carcinoma of esophagus | NC_000017.11:g.7674917T>G | ClinVar |
RCV000441202 | p.Tyr205Asn | missense variant | Uterine Carcinosarcoma | NC_000017.11:g.7674918A>T | ClinVar |
RCV000775886 | p.Tyr205His | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7674918A>G | ClinVar |
RCV000432365 | p.Tyr205Asn | missense variant | Malignant neoplasm of body of uterus | NC_000017.11:g.7674918A>T | ClinVar |
COSM1610844 | p.Leu206TrpPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7674914A>- | NCI-TCGA Cosmic |
RCV000507226 | p.Leu206Ser | missense variant | - | NC_000017.11:g.7674914A>G | ClinVar |
VAR_045050 | p.Leu206Met | Missense | - | - | UniProt |
VAR_045049 | p.Leu206Phe | Missense | - | - | UniProt |
NCI-TCGA novel | p.Asp207PhePheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7674897_7674912AAGTGTTTCTGTCATC>- | NCI-TCGA |
VAR_045052 | p.Asp207Gly | Missense | - | - | UniProt |
VAR_045056 | p.Asp207Tyr | Missense | - | - | UniProt |
VAR_047176 | p.Asp207_Asp208delinsGluTyr | deletion_insertion | - | - | UniProt |
VAR_045053 | p.Asp207His | Missense | - | - | UniProt |
VAR_045051 | p.Asp207Glu | Missense | - | - | UniProt |
VAR_045055 | p.Asp207Val | Missense | - | - | UniProt |
RCV000709405 | p.Asp208Gly | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674908T>C | ClinVar |
COSM43987 | p.Asp208Asn | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7674909C>T | NCI-TCGA Cosmic |
rs1464727668 | p.Asp208Val | missense variant | - | NC_000017.11:g.7674908T>A | - |
rs1464727668 | p.Asp208Val | missense variant | - | NC_000017.11:g.7674908T>A | UniProt,dbSNP |
VAR_045061 | p.Asp208Val | missense variant | - | NC_000017.11:g.7674908T>A | UniProt |
VAR_045059 | p.Asp208His | Missense | - | - | UniProt |
VAR_045062 | p.Asp208Tyr | Missense | - | - | UniProt |
VAR_045057 | p.Asp208Glu | Missense | - | - | UniProt |
VAR_045060 | p.Asp208Asn | Missense | - | - | UniProt |
VAR_045058 | p.Asp208Gly | Missense | - | - | UniProt |
VAR_045809 | p.Asp208Ile | Missense | - | - | UniProt |
RCV000492427 | p.Arg209Ter | frameshift | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7674905_7674906del | ClinVar |
RCV000414120 | p.Arg209Ter | frameshift | - | NC_000017.11:g.7674905_7674906del | ClinVar |
RCV000539085 | p.Arg209Ter | frameshift | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674905_7674906del | ClinVar |
RCV000771676 | p.Arg209Gly | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7674906T>C | ClinVar |
COSM69086 | p.Arg209HisPheSerTerUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7674902_7674906TTTCT>- | NCI-TCGA Cosmic |
COSM13120 | p.Arg209LysPheSerTerUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7674904_7674905TC>- | NCI-TCGA Cosmic |
COSM46120 | p.Arg209Ile | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7674905C>A | NCI-TCGA Cosmic |
COSM308314 | p.Arg209Lys | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7674905C>T | NCI-TCGA Cosmic |
rs1429743956 | p.Arg209Ter | stop gained | - | NC_000017.11:g.7674906T>A | - |
RCV000785270 | p.Arg209Ter | frameshift | Ovarian Neoplasms | NC_000017.11:g.7674905_7674906del | ClinVar |
VAR_045064 | p.Arg209Lys | Missense | - | - | UniProt |
VAR_045066 | p.Arg209Thr | Missense | - | - | UniProt |
VAR_045063 | p.Arg209Ile | Missense | - | - | UniProt |
VAR_045065 | p.Arg209Ser | Missense | - | - | UniProt |
RCV000466733 | p.Asn210Tyr | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674903T>A | ClinVar |
RCV000013156 | p.Asn210Ter | frameshift | Li-Fraumeni syndrome 1 (LFS) | NC_000017.11:g.7674903_7674904del | ClinVar |
NCI-TCGA novel | p.Asn210ThrPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7674902T>- | NCI-TCGA |
NCI-TCGA novel | p.Asn210PhePheSerTerUnk | frameshift | - | NC_000017.11:g.7674899_7674903GTGTT>- | NCI-TCGA |
rs1060501200 | p.Asn210Tyr | missense variant | - | NC_000017.11:g.7674903T>A | - |
VAR_045068 | p.Asn210His | Missense | - | - | UniProt |
VAR_045071 | p.Asn210Ser | Missense | - | - | UniProt |
VAR_045070 | p.Asn210Lys | Missense | - | - | UniProt |
VAR_045072 | p.Asn210Thr | Missense | - | - | UniProt |
VAR_045069 | p.Asn210Ile | Missense | - | - | UniProt |
VAR_045067 | p.Asn210Asp | Missense | - | - | UniProt |
RCV000469438 | p.Thr211Ala | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674900T>C | ClinVar |
RCV000633327 | p.Thr211Pro | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674900T>G | ClinVar |
COSM1636913 | p.Thr211LeuPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7674900T>- | NCI-TCGA Cosmic |
COSM1386676 | p.Thr211Ile | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7674899G>A | NCI-TCGA Cosmic |
COSM45222 | p.Thr211PhePheSerTerUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7674899_7674900GT>- | NCI-TCGA Cosmic |
rs1060501198 | p.Thr211Pro | missense variant | - | NC_000017.11:g.7674900T>G | - |
rs1060501198 | p.Thr211Ala | missense variant | - | NC_000017.11:g.7674900T>C | - |
VAR_045077 | p.Thr211Pro | Missense | - | - | UniProt |
VAR_045076 | p.Thr211Asn | Missense | - | - | UniProt |
VAR_045078 | p.Thr211Ser | Missense | - | - | UniProt |
VAR_045075 | p.Thr211Ile | Missense | - | - | UniProt |
RCV000486339 | p.Phe212Ile | missense variant | - | NC_000017.11:g.7674897A>T | ClinVar |
RCV000687495 | p.Phe212Ile | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674897A>T | ClinVar |
COSM1735835 | p.Phe212SerPheSerTerUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7674895_7674896AA>- | NCI-TCGA Cosmic |
NCI-TCGA novel | p.Phe212TyrPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7674893_7674896CGAA>- | NCI-TCGA |
RCV000492303 | p.Phe212Ter | frameshift | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7674897_7674898del | ClinVar |
rs1064795766 | p.Phe212Ile | missense variant | - | NC_000017.11:g.7674897A>T | - |
rs1064795766 | p.Phe212Ile | missense variant | - | NC_000017.11:g.7674897A>T | UniProt,dbSNP |
VAR_045079 | p.Phe212Ile | missense variant | - | NC_000017.11:g.7674897A>T | UniProt |
RCV000492242 | p.Phe212Ile | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7674897A>T | ClinVar |
RCV000785471 | p.Phe212Ter | frameshift | Ovarian Neoplasms | NC_000017.11:g.7674897_7674898del | ClinVar |
VAR_045083 | p.Phe212Tyr | Missense | - | - | UniProt |
VAR_045081 | p.Phe212Ser | Missense | - | - | UniProt |
VAR_045082 | p.Phe212Val | Missense | - | - | UniProt |
VAR_045080 | p.Phe212Leu | Missense | - | - | UniProt |
rs587778720 | p.Arg213Leu | missense variant | - | NC_000017.11:g.7674893C>A | UniProt,dbSNP |
VAR_045085 | p.Arg213Leu | missense variant | - | NC_000017.11:g.7674893C>A | UniProt |
rs587778720 | p.Arg213Pro | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674893C>G | UniProt,dbSNP |
VAR_036506 | p.Arg213Pro | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674893C>G | UniProt |
rs587778720 | p.Arg213Pro | missense variant | - | NC_000017.11:g.7674893C>G | ExAC,gnomAD |
rs587778720 | p.Arg213Gln | missense variant | - | NC_000017.11:g.7674893C>T | ExAC,gnomAD |
RCV000444193 | p.Arg213Gly | missense variant | Lung adenocarcinoma | NC_000017.11:g.7674894G>C | ClinVar |
RCV000432206 | p.Arg213Gly | missense variant | Adenocarcinoma of stomach | NC_000017.11:g.7674894G>C | ClinVar |
RCV000417479 | p.Arg213Gly | missense variant | Hepatocellular carcinoma (HCC) | NC_000017.11:g.7674894G>C | ClinVar |
RCV000428146 | p.Arg213Gly | missense variant | Renal cell carcinoma, papillary, 1 (RCCP1) | NC_000017.11:g.7674894G>C | ClinVar |
RCV000438186 | p.Arg213Gly | missense variant | Uterine Carcinosarcoma | NC_000017.11:g.7674894G>C | ClinVar |
RCV000430949 | p.Arg213Gly | missense variant | Neoplasm of brain | NC_000017.11:g.7674894G>C | ClinVar |
RCV000428841 | p.Arg213Leu | missense variant | Carcinoma of esophagus | NC_000017.11:g.7674893C>A | ClinVar |
RCV000433789 | p.Arg213Leu | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7674893C>A | ClinVar |
RCV000785330 | p.Arg213Ter | nonsense | Ovarian Neoplasms | NC_000017.11:g.7674894G>A | ClinVar |
RCV000421737 | p.Arg213Leu | missense variant | Neoplasm of brain | NC_000017.11:g.7674893C>A | ClinVar |
RCV000422684 | p.Arg213Leu | missense variant | Hepatocellular carcinoma (HCC) | NC_000017.11:g.7674893C>A | ClinVar |
RCV000435387 | p.Arg213Leu | missense variant | Squamous cell lung carcinoma | NC_000017.11:g.7674893C>A | ClinVar |
RCV000439979 | p.Arg213Leu | missense variant | Lung adenocarcinoma | NC_000017.11:g.7674893C>A | ClinVar |
RCV000437481 | p.Arg213Leu | missense variant | - | NC_000017.11:g.7674893C>A | ClinVar |
RCV000436862 | p.Arg213Gly | missense variant | - | NC_000017.11:g.7674894G>C | ClinVar |
RCV000437472 | p.Arg213Gly | missense variant | Nasopharyngeal Neoplasms | NC_000017.11:g.7674894G>C | ClinVar |
RCV000115730 | p.Arg213Ter | nonsense | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7674894G>A | ClinVar |
RCV000626448 | p.Arg213Gln | missense variant | - | NC_000017.11:g.7674893C>T | ClinVar |
RCV000213050 | p.Arg213Ter | nonsense | - | NC_000017.11:g.7674894G>A | ClinVar |
RCV000420272 | p.Arg213Gly | missense variant | Glioblastoma | NC_000017.11:g.7674894G>C | ClinVar |
RCV000444980 | p.Arg213Gly | missense variant | Neoplasm of the breast | NC_000017.11:g.7674894G>C | ClinVar |
RCV000428488 | p.Arg213Leu | missense variant | Renal cell carcinoma, papillary, 1 (RCCP1) | NC_000017.11:g.7674893C>A | ClinVar |
RCV000144672 | p.Arg213Ter | nonsense | Li-Fraumeni syndrome 1 (LFS) | NC_000017.11:g.7674894G>A | ClinVar |
RCV000780783 | p.Arg213Ter | nonsense | - | NC_000017.11:g.7674894G>A | ClinVar |
RCV000438469 | p.Arg213Leu | missense variant | Adenoid cystic carcinoma | NC_000017.11:g.7674893C>A | ClinVar |
RCV000426799 | p.Arg213Gly | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7674894G>C | ClinVar |
RCV000419627 | p.Arg213Gly | missense variant | Malignant neoplasm of body of uterus | NC_000017.11:g.7674894G>C | ClinVar |
RCV000036532 | p.Arg213Ter | nonsense | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674894G>A | ClinVar |
RCV000438834 | p.Arg213Gly | missense variant | Squamous cell lung carcinoma | NC_000017.11:g.7674894G>C | ClinVar |
RCV000431481 | p.Arg213Gly | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7674894G>C | ClinVar |
RCV000421648 | p.Arg213Gly | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7674894G>C | ClinVar |
RCV000418814 | p.Arg213Leu | missense variant | Malignant melanoma of skin (CMM) | NC_000017.11:g.7674893C>A | ClinVar |
RCV000445195 | p.Arg213Leu | missense variant | Malignant neoplasm of body of uterus | NC_000017.11:g.7674893C>A | ClinVar |
RCV000444469 | p.Arg213Leu | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7674893C>A | ClinVar |
RCV000439587 | p.Arg213Leu | missense variant | Adenocarcinoma of prostate | NC_000017.11:g.7674893C>A | ClinVar |
RCV000443648 | p.Arg213Leu | missense variant | Nasopharyngeal Neoplasms | NC_000017.11:g.7674893C>A | ClinVar |
RCV000427500 | p.Arg213Leu | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7674893C>A | ClinVar |
RCV000432738 | p.Arg213Leu | missense variant | - | NC_000017.11:g.7674893C>A | ClinVar |
RCV000417467 | p.Arg213Leu | missense variant | Adrenocortical carcinoma | NC_000017.11:g.7674893C>A | ClinVar |
RCV000435132 | p.Arg213Leu | missense variant | Adenocarcinoma of stomach | NC_000017.11:g.7674893C>A | ClinVar |
RCV000422458 | p.Arg213Leu | missense variant | Neoplasm of the large intestine | NC_000017.11:g.7674893C>A | ClinVar |
RCV000421524 | p.Arg213Gly | missense variant | Malignant melanoma of skin (CMM) | NC_000017.11:g.7674894G>C | ClinVar |
RCV000202592 | p.Arg213Ter | frameshift | Acute megakaryoblastic leukemia | NC_000017.11:g.7674898del | ClinVar |
rs864309495 | p.Arg213AspPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7674895A>- | NCI-TCGA,NCI-TCGA Cosmic |
rs587778720 | p.Arg213Leu | missense variant | - | NC_000017.11:g.7674893C>A | ExAC,gnomAD |
rs397516436 | p.Arg213Gly | missense variant | - | NC_000017.11:g.7674894G>C | ExAC |
rs397516436 | p.Arg213Gly | missense variant | - | NC_000017.11:g.7674894G>C | UniProt,dbSNP |
VAR_045084 | p.Arg213Gly | missense variant | - | NC_000017.11:g.7674894G>C | UniProt |
rs397516436 | p.Arg213Ter | stop gained | - | NC_000017.11:g.7674894G>A | ExAC |
rs587778720 | p.Arg213Gln | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674893C>T | UniProt,dbSNP |
VAR_005955 | p.Arg213Gln | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674893C>T | UniProt |
RCV000428823 | p.Arg213Gly | missense variant | Adrenocortical carcinoma | NC_000017.11:g.7674894G>C | ClinVar |
RCV000418608 | p.Arg213Leu | missense variant | Uterine Carcinosarcoma | NC_000017.11:g.7674893C>A | ClinVar |
RCV000428624 | p.Arg213Leu | missense variant | Neoplasm of the breast | NC_000017.11:g.7674893C>A | ClinVar |
RCV000427240 | p.Arg213Leu | missense variant | Glioblastoma | NC_000017.11:g.7674893C>A | ClinVar |
RCV000220461 | p.Arg213Pro | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7674893C>G | ClinVar |
RCV000432863 | p.Arg213Gly | missense variant | - | NC_000017.11:g.7674894G>C | ClinVar |
RCV000438677 | p.Arg213Gly | missense variant | Adenocarcinoma of prostate | NC_000017.11:g.7674894G>C | ClinVar |
RCV000424254 | p.Arg213Gly | missense variant | Carcinoma of esophagus | NC_000017.11:g.7674894G>C | ClinVar |
RCV000426157 | p.Arg213Gly | missense variant | Adenoid cystic carcinoma | NC_000017.11:g.7674894G>C | ClinVar |
RCV000425630 | p.Arg213Gly | missense variant | Neoplasm of the large intestine | NC_000017.11:g.7674894G>C | ClinVar |
VAR_045086 | p.Arg213Trp | Missense | - | - | UniProt |
rs587781386 | p.His214Gln | missense variant | - | NC_000017.11:g.7674889A>C | UniProt,dbSNP |
VAR_047177 | p.His214Gln | missense variant | - | NC_000017.11:g.7674889A>C | UniProt |
rs876658466 | p.His214Asn | missense variant | - | NC_000017.11:g.7674891G>T | - |
RCV000427039 | p.His214Leu | missense variant | Chronic lymphocytic leukemia (CLL) | NC_000017.11:g.7674890T>A | ClinVar |
RCV000423188 | p.His214Leu | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7674890T>A | ClinVar |
RCV000444957 | p.His214Leu | missense variant | Renal cell carcinoma, papillary, 1 (RCCP1) | NC_000017.11:g.7674890T>A | ClinVar |
RCV000477234 | p.His214Arg | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674890T>C | ClinVar |
RCV000440391 | p.His214Leu | missense variant | Neoplasm of the large intestine | NC_000017.11:g.7674890T>A | ClinVar |
RCV000445284 | p.His214Leu | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7674890T>A | ClinVar |
RCV000431675 | p.His214Leu | missense variant | Glioblastoma | NC_000017.11:g.7674890T>A | ClinVar |
RCV000421427 | p.His214Leu | missense variant | Squamous cell lung carcinoma | NC_000017.11:g.7674890T>A | ClinVar |
RCV000442701 | p.His214Leu | missense variant | - | NC_000017.11:g.7674890T>A | ClinVar |
COSM4422060 | p.His214GlnPheSerTerUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7674888_7674889TA>- | NCI-TCGA Cosmic |
NCI-TCGA novel | p.His214LeuPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7674890_7674891insGCCGAAAA | NCI-TCGA |
NCI-TCGA novel | p.His214GlnPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7674889A>- | NCI-TCGA |
rs1057519992 | p.His214Leu | missense variant | - | NC_000017.11:g.7674890T>A | gnomAD |
rs1057519992 | p.His214Pro | missense variant | - | NC_000017.11:g.7674890T>G | gnomAD |
rs1057519992 | p.His214Arg | missense variant | - | NC_000017.11:g.7674890T>C | gnomAD |
rs1057519992 | p.His214Arg | missense variant | - | NC_000017.11:g.7674890T>C | UniProt,dbSNP |
VAR_045089 | p.His214Arg | missense variant | - | NC_000017.11:g.7674890T>C | UniProt |
rs587781386 | p.His214Gln | missense variant | - | NC_000017.11:g.7674889A>C | ExAC,TOPMed,gnomAD |
rs1057519992 | p.His214Pro | missense variant | - | NC_000017.11:g.7674890T>G | UniProt,dbSNP |
VAR_045088 | p.His214Pro | missense variant | - | NC_000017.11:g.7674890T>G | UniProt |
RCV000410083 | p.His214Gln | missense variant | Li-Fraumeni syndrome 1 (LFS) | NC_000017.11:g.7674889A>C | ClinVar |
RCV000427702 | p.His214Leu | missense variant | Hepatocellular carcinoma (HCC) | NC_000017.11:g.7674890T>A | ClinVar |
RCV000433885 | p.His214Leu | missense variant | Carcinoma of esophagus | NC_000017.11:g.7674890T>A | ClinVar |
RCV000437948 | p.His214Leu | missense variant | Adenocarcinoma of stomach | NC_000017.11:g.7674890T>A | ClinVar |
RCV000214223 | p.His214Asn | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7674891G>T | ClinVar |
RCV000803678 | p.His214Asn | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674891G>T | ClinVar |
VAR_045087 | p.His214Asp | Missense | - | - | UniProt |
VAR_045090 | p.His214Tyr | Missense | - | - | UniProt |
RCV000422178 | p.Ser215Arg | missense variant | Neoplasm of the breast | NC_000017.11:g.7674886A>C | ClinVar |
RCV000785463 | p.Ser215Arg | missense variant | Ovarian Neoplasms | NC_000017.11:g.7674886A>C | ClinVar |
RCV000425174 | p.Ser215Arg | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7674886A>C | ClinVar |
RCV000437603 | p.Ser215Arg | missense variant | Hepatocellular carcinoma (HCC) | NC_000017.11:g.7674886A>C | ClinVar |
RCV000432876 | p.Ser215Arg | missense variant | Small cell lung cancer | NC_000017.11:g.7674886A>C | ClinVar |
RCV000421044 | p.Ser215Arg | missense variant | Adenocarcinoma of stomach | NC_000017.11:g.7674886A>C | ClinVar |
RCV000422423 | p.Ser215Asn | missense variant | Hepatocellular carcinoma (HCC) | NC_000017.11:g.7674887C>T | ClinVar |
RCV000441630 | p.Ser215Ile | missense variant | Carcinoma of esophagus | NC_000017.11:g.7674887C>A | ClinVar |
RCV000432107 | p.Ser215Asn | missense variant | Carcinoma of esophagus | NC_000017.11:g.7674887C>T | ClinVar |
RCV000423774 | p.Ser215Asn | missense variant | Acute myeloid leukemia (AML) | NC_000017.11:g.7674887C>T | ClinVar |
RCV000785347 | p.Ser215Ile | missense variant | Ovarian Neoplasms | NC_000017.11:g.7674887C>A | ClinVar |
RCV000429840 | p.Ser215Ile | missense variant | Acute myeloid leukemia (AML) | NC_000017.11:g.7674887C>A | ClinVar |
RCV000772138 | p.Ser215Gly | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7674888T>C | ClinVar |
COSM1268353 | p.Ser215Arg | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7674886A>T | NCI-TCGA Cosmic |
RCV000433950 | p.Ser215Ile | missense variant | Adenocarcinoma of stomach | NC_000017.11:g.7674887C>A | ClinVar |
RCV000434496 | p.Ser215Asn | missense variant | Neoplasm of the breast | NC_000017.11:g.7674887C>T | ClinVar |
RCV000423272 | p.Ser215Ile | missense variant | Lung adenocarcinoma | NC_000017.11:g.7674887C>A | ClinVar |
RCV000438643 | p.Ser215Asn | missense variant | Small cell lung cancer | NC_000017.11:g.7674887C>T | ClinVar |
RCV000435696 | p.Ser215Ile | missense variant | Neoplasm of the breast | NC_000017.11:g.7674887C>A | ClinVar |
RCV000420217 | p.Ser215Ile | missense variant | Small cell lung cancer | NC_000017.11:g.7674887C>A | ClinVar |
RCV000492171 | p.Ser215Asn | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7674887C>T | ClinVar |
RCV000427974 | p.Ser215Asn | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7674887C>T | ClinVar |
RCV000443221 | p.Ser215Asn | missense variant | Adenocarcinoma of stomach | NC_000017.11:g.7674887C>T | ClinVar |
RCV000785298 | p.Ser215Ter | frameshift | Ovarian Neoplasms | NC_000017.11:g.7674888dup | ClinVar |
NCI-TCGA novel | p.Ser215LysPheSerTerUnk | frameshift | - | NC_000017.11:g.7674887_7674888insT | NCI-TCGA |
RCV000581621 | p.Ser215Ter | frameshift | - | NC_000017.11:g.7674887_7674888dup | ClinVar |
rs1057520001 | p.Ser215Arg | missense variant | - | NC_000017.11:g.7674886A>C | UniProt,dbSNP |
VAR_045095 | p.Ser215Arg | missense variant | - | NC_000017.11:g.7674886A>C | UniProt |
rs587782177 | p.Ser215Asn | missense variant | - | NC_000017.11:g.7674887C>T | UniProt,dbSNP |
VAR_045094 | p.Ser215Asn | missense variant | - | NC_000017.11:g.7674887C>T | UniProt |
rs587782177 | p.Ser215Thr | missense variant | - | NC_000017.11:g.7674887C>G | UniProt,dbSNP |
VAR_045096 | p.Ser215Thr | missense variant | - | NC_000017.11:g.7674887C>G | UniProt |
rs587782177 | p.Ser215Ile | missense variant | - | NC_000017.11:g.7674887C>A | UniProt,dbSNP |
VAR_045093 | p.Ser215Ile | missense variant | - | NC_000017.11:g.7674887C>A | UniProt |
RCV000421424 | p.Ser215Asn | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7674887C>T | ClinVar |
RCV000420881 | p.Ser215Ile | missense variant | Hepatocellular carcinoma (HCC) | NC_000017.11:g.7674887C>A | ClinVar |
RCV000430889 | p.Ser215Ile | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7674887C>A | ClinVar |
RCV000440493 | p.Ser215Ile | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7674887C>A | ClinVar |
RCV000130796 | p.Ser215Thr | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7674887C>G | ClinVar |
RCV000442434 | p.Ser215Asn | missense variant | Lung adenocarcinoma | NC_000017.11:g.7674887C>T | ClinVar |
RCV000442610 | p.Ser215Arg | missense variant | Acute myeloid leukemia (AML) | NC_000017.11:g.7674886A>C | ClinVar |
RCV000439391 | p.Ser215Arg | missense variant | Carcinoma of esophagus | NC_000017.11:g.7674886A>C | ClinVar |
RCV000431745 | p.Ser215Arg | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7674886A>C | ClinVar |
RCV000442691 | p.Ser215Arg | missense variant | Lung adenocarcinoma | NC_000017.11:g.7674886A>C | ClinVar |
RCV000492567 | p.Ser215Arg | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7674888T>G | ClinVar |
RCV000700891 | p.Ser215Gly | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674888T>C | ClinVar |
VAR_045091 | p.Ser215Cys | Missense | - | - | UniProt |
VAR_045810 | p.Ser215Lys | Missense | - | - | UniProt |
rs1057520004 | p.Val216Glu | missense variant | - | NC_000017.11:g.7674884A>T | - |
rs1057520004 | p.Val216Glu | missense variant | - | NC_000017.11:g.7674884A>T | UniProt,dbSNP |
VAR_045098 | p.Val216Glu | missense variant | - | NC_000017.11:g.7674884A>T | UniProt |
RCV000439990 | p.Val216Gly | missense variant | Neoplasm of the breast | NC_000017.11:g.7674884A>C | ClinVar |
RCV000429825 | p.Val216Glu | missense variant | Glioblastoma | NC_000017.11:g.7674884A>T | ClinVar |
RCV000423344 | p.Val216Gly | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7674884A>C | ClinVar |
RCV000442920 | p.Val216Gly | missense variant | Lung adenocarcinoma | NC_000017.11:g.7674884A>C | ClinVar |
RCV000433620 | p.Val216Gly | missense variant | Carcinoma of esophagus | NC_000017.11:g.7674884A>C | ClinVar |
RCV000442891 | p.Val216Gly | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7674884A>C | ClinVar |
RCV000436131 | p.Val216Glu | missense variant | Squamous cell lung carcinoma | NC_000017.11:g.7674884A>T | ClinVar |
RCV000423283 | p.Val216Glu | missense variant | Uterine Carcinosarcoma | NC_000017.11:g.7674884A>T | ClinVar |
RCV000439819 | p.Val216Glu | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7674884A>T | ClinVar |
RCV000418474 | p.Val216Glu | missense variant | - | NC_000017.11:g.7674884A>T | ClinVar |
RCV000424582 | p.Val216Gly | missense variant | Uterine Carcinosarcoma | NC_000017.11:g.7674884A>C | ClinVar |
RCV000434860 | p.Val216Glu | missense variant | Neoplasm of the breast | NC_000017.11:g.7674884A>T | ClinVar |
RCV000440155 | p.Val216Gly | missense variant | Neoplasm of brain | NC_000017.11:g.7674884A>C | ClinVar |
RCV000424832 | p.Val216Glu | missense variant | Carcinoma of esophagus | NC_000017.11:g.7674884A>T | ClinVar |
RCV000419558 | p.Val216Glu | missense variant | Lung adenocarcinoma | NC_000017.11:g.7674884A>T | ClinVar |
RCV000418104 | p.Val216Glu | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7674884A>T | ClinVar |
RCV000429571 | p.Val216Glu | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7674884A>T | ClinVar |
RCV000427972 | p.Val216Leu | missense variant | Lung adenocarcinoma | NC_000017.11:g.7674885C>A | ClinVar |
RCV000437749 | p.Val216Leu | missense variant | Uterine Carcinosarcoma | NC_000017.11:g.7674885C>A | ClinVar |
RCV000785309 | p.Val216Leu | missense variant | Ovarian Neoplasms | NC_000017.11:g.7674885C>A | ClinVar |
RCV000420083 | p.Val216Leu | missense variant | Neoplasm of brain | NC_000017.11:g.7674885C>A | ClinVar |
RCV000583984 | p.Val216Met | missense variant | - | NC_000017.11:g.7674885C>T | ClinVar |
RCV000442710 | p.Val216Leu | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7674885C>A | ClinVar |
RCV000663213 | p.Val216Met | missense variant | Li-Fraumeni syndrome 1 (LFS) | NC_000017.11:g.7674885C>T | ClinVar |
RCV000431215 | p.Val216Leu | missense variant | Neoplasm of the breast | NC_000017.11:g.7674885C>A | ClinVar |
rs1057520004 | p.Val216Gly | missense variant | - | NC_000017.11:g.7674884A>C | UniProt,dbSNP |
VAR_045099 | p.Val216Gly | missense variant | - | NC_000017.11:g.7674884A>C | UniProt |
rs1057520004 | p.Val216Gly | missense variant | - | NC_000017.11:g.7674884A>C | - |
RCV000439081 | p.Val216Leu | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7674885C>A | ClinVar |
RCV000426649 | p.Val216Leu | missense variant | Glioblastoma | NC_000017.11:g.7674885C>A | ClinVar |
RCV000422099 | p.Val216Leu | missense variant | Carcinoma of esophagus | NC_000017.11:g.7674885C>A | ClinVar |
RCV000428855 | p.Val216Leu | missense variant | - | NC_000017.11:g.7674885C>A | ClinVar |
RCV000437980 | p.Val216Leu | missense variant | Squamous cell lung carcinoma | NC_000017.11:g.7674885C>A | ClinVar |
RCV000466409 | p.Val216Leu | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674885C>G | ClinVar |
RCV000417716 | p.Val216Leu | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7674885C>A | ClinVar |
RCV000440944 | p.Val216Glu | missense variant | Neoplasm of brain | NC_000017.11:g.7674884A>T | ClinVar |
RCV000434681 | p.Val216Gly | missense variant | - | NC_000017.11:g.7674884A>C | ClinVar |
RCV000433417 | p.Val216Gly | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7674884A>C | ClinVar |
RCV000427043 | p.Val216Gly | missense variant | Squamous cell lung carcinoma | NC_000017.11:g.7674884A>C | ClinVar |
RCV000422282 | p.Val216Gly | missense variant | Glioblastoma | NC_000017.11:g.7674884A>C | ClinVar |
VAR_045811 | p.Val216Trp | Missense | - | - | UniProt |
VAR_045097 | p.Val216Ala | Missense | - | - | UniProt |
NCI-TCGA novel | p.Val217GlyPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7674881_7674882insCC | NCI-TCGA |
rs35163653 | p.Val217Met | missense variant | - | NC_000017.11:g.7674882C>T | ExAC,gnomAD |
rs35163653 | p.Val217Met | missense variant | - | NC_000017.11:g.7674882C>T | UniProt,dbSNP |
VAR_047178 | p.Val217Met | missense variant | - | NC_000017.11:g.7674882C>T | UniProt |
RCV000161936 | p.Val217Met | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674882C>T | ClinVar |
VAR_045102 | p.Val217Glu | Missense | - | - | UniProt |
VAR_045104 | p.Val217Ile | Missense | - | - | UniProt |
VAR_045105 | p.Val217Leu | Missense | - | - | UniProt |
VAR_045103 | p.Val217Gly | Missense | - | - | UniProt |
VAR_045101 | p.Val217Ala | Missense | - | - | UniProt |
COSM1324795 | p.Val218CysPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7674879C>- | NCI-TCGA Cosmic |
RCV000785273 | p.Val218Ter | frameshift | Ovarian Neoplasms | NC_000017.11:g.7674883_7674887dup | ClinVar |
RCV000633350 | p.Val218Gly | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674878A>C | ClinVar |
rs1555525743 | p.Val218Gly | missense variant | - | NC_000017.11:g.7674878A>C | - |
rs1555525743 | p.Val218Gly | missense variant | - | NC_000017.11:g.7674878A>C | UniProt,dbSNP |
VAR_045108 | p.Val218Gly | missense variant | - | NC_000017.11:g.7674878A>C | UniProt |
rs878854072 | p.Val218Met | missense variant | - | NC_000017.11:g.7674879C>T | - |
rs878854072 | p.Val218Met | missense variant | - | NC_000017.11:g.7674879C>T | UniProt,dbSNP |
VAR_045110 | p.Val218Met | missense variant | - | NC_000017.11:g.7674879C>T | UniProt |
RCV000228072 | p.Val218Met | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674879C>T | ClinVar |
RCV000165061 | p.Val218Ter | frameshift | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7674865_7674880del | ClinVar |
VAR_045106 | p.Val218Ala | Missense | - | - | UniProt |
VAR_045109 | p.Val218Leu | Missense | - | - | UniProt |
VAR_045107 | p.Val218Glu | Missense | - | - | UniProt |
rs879253894 | p.Pro219Ser | missense variant | - | NC_000017.11:g.7674876G>A | UniProt,dbSNP |
VAR_045114 | p.Pro219Ser | missense variant | - | NC_000017.11:g.7674876G>A | UniProt |
NCI-TCGA novel | p.Pro219LeuPheSerTerUnk | frameshift | - | NC_000017.11:g.7674874_7674875GG>- | NCI-TCGA |
NCI-TCGA novel | p.Pro219AlaPheSerTerUnk | frameshift | - | NC_000017.11:g.7674876_7674877insC | NCI-TCGA |
RCV000569731 | p.Pro219Ter | frameshift | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7674863_7674878del | ClinVar |
RCV000236313 | p.Pro219Ser | missense variant | - | NC_000017.11:g.7674876G>A | ClinVar |
rs879253894 | p.Pro219Ser | missense variant | - | NC_000017.11:g.7674876G>A | gnomAD |
rs1420675064 | p.Pro219Leu | missense variant | - | NC_000017.11:g.7674875G>A | gnomAD |
rs1420675064 | p.Pro219Leu | missense variant | - | NC_000017.11:g.7674875G>A | UniProt,dbSNP |
VAR_045112 | p.Pro219Leu | missense variant | - | NC_000017.11:g.7674875G>A | UniProt |
VAR_045111 | p.Pro219His | Missense | - | - | UniProt |
VAR_045812 | p.Pro219Cys | Missense | - | - | UniProt |
VAR_045113 | p.Pro219Arg | Missense | - | - | UniProt |
VAR_045115 | p.Pro219Thr | Missense | - | - | UniProt |
rs530941076 | p.Tyr220Asn | missense variant | - | NC_000017.11:g.7674873A>T | UniProt,dbSNP |
VAR_045118 | p.Tyr220Asn | missense variant | - | NC_000017.11:g.7674873A>T | UniProt |
rs530941076 | p.Tyr220Asp | missense variant | - | NC_000017.11:g.7674873A>C | UniProt,dbSNP |
VAR_045116 | p.Tyr220Asp | missense variant | - | NC_000017.11:g.7674873A>C | UniProt |
rs530941076 | p.Tyr220Asp | missense variant | - | NC_000017.11:g.7674873A>C | 1000Genomes,ExAC,gnomAD |
rs121912666 | p.Tyr220Cys | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674872T>C | UniProt,dbSNP |
VAR_005957 | p.Tyr220Cys | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674872T>C | UniProt |
RCV000418951 | p.Tyr220Cys | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7674872T>C | ClinVar |
RCV000425193 | p.Tyr220Cys | missense variant | Squamous cell lung carcinoma | NC_000017.11:g.7674872T>C | ClinVar |
RCV000423111 | p.Tyr220Cys | missense variant | Malignant neoplasm of body of uterus | NC_000017.11:g.7674872T>C | ClinVar |
RCV000428791 | p.Tyr220Cys | missense variant | Papillary renal cell carcinoma, sporadic | NC_000017.11:g.7674872T>C | ClinVar |
RCV000435063 | p.Tyr220Cys | missense variant | Neoplasm of brain | NC_000017.11:g.7674872T>C | ClinVar |
RCV000436553 | p.Tyr220Cys | missense variant | Uterine Carcinosarcoma | NC_000017.11:g.7674872T>C | ClinVar |
RCV000440244 | p.Tyr220Cys | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7674872T>C | ClinVar |
RCV000438068 | p.Tyr220Asn | missense variant | Renal cell carcinoma, papillary, 1 (RCCP1) | NC_000017.11:g.7674873A>T | ClinVar |
RCV000419021 | p.Tyr220Asn | missense variant | Adenocarcinoma of prostate | NC_000017.11:g.7674873A>T | ClinVar |
RCV000570507 | p.Tyr220Asn | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7674873A>T | ClinVar |
RCV000443812 | p.Tyr220Asn | missense variant | Hepatocellular carcinoma (HCC) | NC_000017.11:g.7674873A>T | ClinVar |
RCV000432093 | p.Tyr220Asn | missense variant | Uterine Carcinosarcoma | NC_000017.11:g.7674873A>T | ClinVar |
RCV000419702 | p.Tyr220Asn | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7674873A>T | ClinVar |
RCV000418575 | p.Tyr220Asp | missense variant | Neoplasm of the large intestine | NC_000017.11:g.7674873A>C | ClinVar |
RCV000444073 | p.Tyr220Asp | missense variant | Lung adenocarcinoma | NC_000017.11:g.7674873A>C | ClinVar |
RCV000418779 | p.Tyr220Asp | missense variant | Malignant melanoma of skin (CMM) | NC_000017.11:g.7674873A>C | ClinVar |
RCV000434918 | p.Tyr220Asp | missense variant | Renal cell carcinoma, papillary, 1 (RCCP1) | NC_000017.11:g.7674873A>C | ClinVar |
RCV000785544 | p.Tyr220Cys | missense variant | Ovarian Neoplasms | NC_000017.11:g.7674872T>C | ClinVar |
RCV000444814 | p.Tyr220Cys | missense variant | Small cell lung cancer | NC_000017.11:g.7674872T>C | ClinVar |
RCV000428097 | p.Tyr220Cys | missense variant | - | NC_000017.11:g.7674872T>C | ClinVar |
RCV000444717 | p.Tyr220Cys | missense variant | Neoplasm of the large intestine | NC_000017.11:g.7674872T>C | ClinVar |
RCV000434300 | p.Tyr220Cys | missense variant | Adenocarcinoma of stomach | NC_000017.11:g.7674872T>C | ClinVar |
RCV000013183 | p.Tyr220Ser | missense variant | Li-Fraumeni syndrome 1 (LFS) | NC_000017.11:g.7674872T>G | ClinVar |
RCV000434614 | p.Tyr220Cys | missense variant | Adenocarcinoma of prostate | NC_000017.11:g.7674872T>C | ClinVar |
RCV000439456 | p.Tyr220Cys | missense variant | Hepatocellular carcinoma (HCC) | NC_000017.11:g.7674872T>C | ClinVar |
RCV000423624 | p.Tyr220Cys | missense variant | Neoplasm of the breast | NC_000017.11:g.7674872T>C | ClinVar |
RCV000417417 | p.Tyr220Cys | missense variant | Glioblastoma | NC_000017.11:g.7674872T>C | ClinVar |
RCV000425869 | p.Tyr220Cys | missense variant | Malignant melanoma of skin (CMM) | NC_000017.11:g.7674872T>C | ClinVar |
RCV000472593 | p.Tyr220Ser | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674872T>G | ClinVar |
RCV000442230 | p.Tyr220Cys | missense variant | Lung adenocarcinoma | NC_000017.11:g.7674872T>C | ClinVar |
RCV000423029 | p.Tyr220Cys | missense variant | Renal cell carcinoma, papillary, 1 (RCCP1) | NC_000017.11:g.7674872T>C | ClinVar |
RCV000433936 | p.Tyr220Cys | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7674872T>C | ClinVar |
RCV000439645 | p.Tyr220Cys | missense variant | Acute myeloid leukemia (AML) | NC_000017.11:g.7674872T>C | ClinVar |
COSM5625799 | p.Tyr220MetPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7674874G>- | NCI-TCGA Cosmic |
RCV000427506 | p.Tyr220Asp | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7674873A>C | ClinVar |
RCV000430837 | p.Tyr220Asp | missense variant | Adenocarcinoma of stomach | NC_000017.11:g.7674873A>C | ClinVar |
RCV000428144 | p.Tyr220Asp | missense variant | Hepatocellular carcinoma (HCC) | NC_000017.11:g.7674873A>C | ClinVar |
RCV000438838 | p.Tyr220Asn | missense variant | Papillary renal cell carcinoma, sporadic | NC_000017.11:g.7674873A>T | ClinVar |
RCV000444915 | p.Tyr220Asp | missense variant | Adenocarcinoma of prostate | NC_000017.11:g.7674873A>C | ClinVar |
RCV000424584 | p.Tyr220Asn | missense variant | Glioblastoma | NC_000017.11:g.7674873A>T | ClinVar |
RCV000439357 | p.Tyr220Asn | missense variant | Malignant neoplasm of body of uterus | NC_000017.11:g.7674873A>T | ClinVar |
RCV000566866 | p.Tyr220His | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7674873A>G | ClinVar |
RCV000433449 | p.Tyr220Asp | missense variant | Papillary renal cell carcinoma, sporadic | NC_000017.11:g.7674873A>C | ClinVar |
RCV000426793 | p.Tyr220Asp | missense variant | Small cell lung cancer | NC_000017.11:g.7674873A>C | ClinVar |
RCV000440413 | p.Tyr220Asp | missense variant | Malignant neoplasm of body of uterus | NC_000017.11:g.7674873A>C | ClinVar |
RCV000425315 | p.Tyr220Asp | missense variant | Glioblastoma | NC_000017.11:g.7674873A>C | ClinVar |
RCV000427847 | p.Tyr220Asn | missense variant | Neoplasm of brain | NC_000017.11:g.7674873A>T | ClinVar |
RCV000434427 | p.Tyr220Asn | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7674873A>T | ClinVar |
RCV000438679 | p.Tyr220Asn | missense variant | - | NC_000017.11:g.7674873A>T | ClinVar |
RCV000419523 | p.Tyr220Asn | missense variant | Squamous cell lung carcinoma | NC_000017.11:g.7674873A>T | ClinVar |
RCV000429130 | p.Tyr220Asn | missense variant | Neoplasm of the breast | NC_000017.11:g.7674873A>T | ClinVar |
RCV000423767 | p.Tyr220Asn | missense variant | Small cell lung cancer | NC_000017.11:g.7674873A>T | ClinVar |
RCV000431034 | p.Tyr220Asp | missense variant | Uterine Carcinosarcoma | NC_000017.11:g.7674873A>C | ClinVar |
RCV000437034 | p.Tyr220Asp | missense variant | Neoplasm of brain | NC_000017.11:g.7674873A>C | ClinVar |
RCV000424311 | p.Tyr220Asp | missense variant | Squamous cell lung carcinoma | NC_000017.11:g.7674873A>C | ClinVar |
RCV000436457 | p.Tyr220Asp | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7674873A>C | ClinVar |
NCI-TCGA novel | p.Tyr220Ter | frameshift | - | NC_000017.11:g.7674862_7674872AGGCGGCTCAT>- | NCI-TCGA |
rs530941076 | p.Tyr220Asn | missense variant | - | NC_000017.11:g.7674873A>T | 1000Genomes,ExAC,gnomAD |
rs530941076 | p.Tyr220His | missense variant | - | NC_000017.11:g.7674873A>G | 1000Genomes,ExAC,gnomAD |
rs121912666 | p.Tyr220Cys | missense variant | Li-fraumeni syndrome 1 (lfs1) | NC_000017.11:g.7674872T>C | ExAC,TOPMed,gnomAD |
rs121912666 | p.Tyr220Ser | missense variant | Li-fraumeni syndrome 1 (lfs1) | NC_000017.11:g.7674872T>G | ExAC,TOPMed,gnomAD |
rs121912666 | p.Tyr220Ser | missense variant | - | NC_000017.11:g.7674872T>G | UniProt,dbSNP |
VAR_005959 | p.Tyr220Ser | missense variant | - | NC_000017.11:g.7674872T>G | UniProt |
rs530941076 | p.Tyr220His | missense variant | - | NC_000017.11:g.7674873A>G | UniProt,dbSNP |
VAR_005958 | p.Tyr220His | missense variant | - | NC_000017.11:g.7674873A>G | UniProt |
RCV000434035 | p.Tyr220Asn | missense variant | Malignant melanoma of skin (CMM) | NC_000017.11:g.7674873A>T | ClinVar |
RCV000437403 | p.Tyr220Asn | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7674873A>T | ClinVar |
RCV000441127 | p.Tyr220Asp | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7674873A>C | ClinVar |
RCV000417982 | p.Tyr220Asp | missense variant | Neoplasm of the breast | NC_000017.11:g.7674873A>C | ClinVar |
RCV000422783 | p.Tyr220Asp | missense variant | - | NC_000017.11:g.7674873A>C | ClinVar |
RCV000426310 | p.Tyr220Asn | missense variant | Lung adenocarcinoma | NC_000017.11:g.7674873A>T | ClinVar |
RCV000429300 | p.Tyr220Asn | missense variant | Neoplasm of the large intestine | NC_000017.11:g.7674873A>T | ClinVar |
RCV000421037 | p.Tyr220Asn | missense variant | Adenocarcinoma of stomach | NC_000017.11:g.7674873A>T | ClinVar |
RCV000785516 | p.Tyr220Ter | nonsense | Ovarian Neoplasms | NC_000017.11:g.7674871A>T | ClinVar |
VAR_045117 | p.Tyr220Phe | Missense | - | - | UniProt |
rs786201592 | p.Glu221Lys | missense variant | - | NC_000017.11:g.7674870C>T | UniProt,dbSNP |
VAR_045122 | p.Glu221Lys | missense variant | - | NC_000017.11:g.7674870C>T | UniProt |
rs786201592 | p.Glu221Lys | missense variant | - | NC_000017.11:g.7674870C>T | gnomAD |
RCV000492096 | p.Glu221Ter | frameshift | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7674869del | ClinVar |
RCV000234225 | p.Glu221Ter | frameshift | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674869del | ClinVar |
NCI-TCGA novel | p.Glu221AlaPheSerTerUnk | frameshift | - | NC_000017.11:g.7674865_7674869CGGCT>- | NCI-TCGA |
rs786201592 | p.Glu221Ter | stop gained | - | NC_000017.11:g.7674870C>A | gnomAD |
RCV000695405 | p.Glu221Ala | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674869T>G | ClinVar |
RCV000785468 | p.Glu221Ter | nonsense | Ovarian Neoplasms | NC_000017.11:g.7674870C>A | ClinVar |
RCV000528158 | p.Glu221Lys | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674870C>T | ClinVar |
RCV000163935 | p.Glu221Lys | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7674870C>T | ClinVar |
RCV000794857 | p.Glu221Ter | nonsense | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674870C>A | ClinVar |
VAR_045119 | p.Glu221Ala | Missense | - | - | UniProt |
VAR_045121 | p.Glu221Gly | Missense | - | - | UniProt |
VAR_045123 | p.Glu221Gln | Missense | - | - | UniProt |
VAR_045120 | p.Glu221Asp | Missense | - | - | UniProt |
RCV000564109 | p.Pro222Ser | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7674867G>A | ClinVar |
RCV000213056 | p.Pro222Leu | missense variant | - | NC_000017.11:g.7674866G>A | ClinVar |
RCV000411498 | p.Pro222Leu | missense variant | Li-Fraumeni syndrome 1 (LFS) | NC_000017.11:g.7674866G>A | ClinVar |
RCV000148907 | p.Pro222Leu | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674866G>A | ClinVar |
RCV000161032 | p.Pro222Leu | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7674866G>A | ClinVar |
rs146340390 | p.Pro222Leu | missense variant | - | NC_000017.11:g.7674866G>A | UniProt,dbSNP |
VAR_045125 | p.Pro222Leu | missense variant | - | NC_000017.11:g.7674866G>A | UniProt |
rs146340390 | p.Pro222Leu | missense variant | - | NC_000017.11:g.7674866G>A | ESP,ExAC,TOPMed,gnomAD |
rs1060501203 | p.Pro222Ser | missense variant | - | NC_000017.11:g.7674867G>A | TOPMed |
RCV000785327 | p.Pro222Ter | frameshift | Ovarian Neoplasms | NC_000017.11:g.7674867del | ClinVar |
VAR_045127 | p.Pro222Arg | Missense | - | - | UniProt |
VAR_045124 | p.Pro222Ala | Missense | - | - | UniProt |
VAR_045129 | p.Pro222Thr | Missense | - | - | UniProt |
VAR_045126 | p.Pro222Gln | Missense | - | - | UniProt |
RCV000223388 | p.Pro223Leu | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7674863G>A | ClinVar |
RCV000633401 | p.Pro223Leu | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674863G>A | ClinVar |
COSM1318439 | p.Pro223ArgPheSerTerUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7674863_7674864insGCGGCTC | NCI-TCGA Cosmic |
COSM111639 | p.Pro223Ter | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7674864_7674865GC>- | NCI-TCGA Cosmic |
NCI-TCGA novel | p.Pro223AlaPheSerTerUnk | frameshift | - | NC_000017.11:g.7674865_7674866insGGCT | NCI-TCGA |
rs138983188 | p.Pro223His | missense variant | - | NC_000017.11:g.7674863G>T | ESP |
rs138983188 | p.Pro223His | missense variant | - | NC_000017.11:g.7674863G>T | UniProt,dbSNP |
VAR_045130 | p.Pro223His | missense variant | - | NC_000017.11:g.7674863G>T | UniProt |
rs138983188 | p.Pro223Leu | missense variant | - | NC_000017.11:g.7674863G>A | UniProt,dbSNP |
VAR_045131 | p.Pro223Leu | missense variant | - | NC_000017.11:g.7674863G>A | UniProt |
rs138983188 | p.Pro223Leu | missense variant | - | NC_000017.11:g.7674863G>A | ESP |
VAR_045134 | p.Pro223Thr | Missense | - | - | UniProt |
VAR_045132 | p.Pro223Arg | Missense | - | - | UniProt |
VAR_045133 | p.Pro223Ser | Missense | - | - | UniProt |
VAR_047179 | p.Pro223Ala | Missense | - | - | UniProt |
rs267605076 | p.Glu224Asp | missense variant | - | NC_000017.11:g.7674859C>A | gnomAD |
RCV000492340 | p.Glu224Ala | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7674860T>G | ClinVar |
COSM2744697 | p.Glu224Ter | stop gained | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7674861C>A | NCI-TCGA Cosmic |
COSM69018 | p.Glu224GlyPheSerTerUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7674861_7674862CA>- | NCI-TCGA Cosmic |
COSM1646847 | p.Glu224Asp | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7674859C>G | NCI-TCGA Cosmic |
RCV000573879 | p.Glu224Lys | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7674861C>T | ClinVar |
NCI-TCGA novel | p.Glu224Ter | frameshift | - | NC_000017.11:g.7674862_7674863insT | NCI-TCGA |
rs1131691028 | p.Glu224Ala | missense variant | - | NC_000017.11:g.7674860T>G | - |
rs1555525707 | p.Glu224Lys | missense variant | - | NC_000017.11:g.7674861C>T | - |
rs1555525707 | p.Glu224Lys | missense variant | - | NC_000017.11:g.7674861C>T | UniProt,dbSNP |
VAR_045137 | p.Glu224Lys | missense variant | - | NC_000017.11:g.7674861C>T | UniProt |
VAR_045136 | p.Glu224Gly | Missense | - | - | UniProt |
VAR_045138 | p.Glu224Val | Missense | - | - | UniProt |
rs746504075 | p.Val225Ile | missense variant | - | NC_000017.11:g.7674290C>T | ExAC,gnomAD |
RCV000571914 | p.Val225Ile | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7674290C>T | ClinVar |
NCI-TCGA novel | p.Val225ArgPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7674858_7674859insCT | NCI-TCGA |
rs746504075 | p.Val225Leu | missense variant | - | NC_000017.11:g.7674290C>G | UniProt,dbSNP |
VAR_045144 | p.Val225Leu | missense variant | - | NC_000017.11:g.7674290C>G | UniProt |
rs746504075 | p.Val225Leu | missense variant | - | NC_000017.11:g.7674290C>G | ExAC,gnomAD |
VAR_045140 | p.Val225Asp | Missense | - | - | UniProt |
VAR_045143 | p.Val225Ile | Missense | - | - | UniProt |
VAR_045139 | p.Val225Ala | Missense | - | - | UniProt |
VAR_045141 | p.Val225Phe | Missense | - | - | UniProt |
VAR_045142 | p.Val225Gly | Missense | - | - | UniProt |
RCV000542075 | p.Gly226Val | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674286C>A | ClinVar |
NCI-TCGA novel | p.Gly226AlaPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7674288A>- | NCI-TCGA |
rs970212462 | p.Gly226Val | missense variant | - | NC_000017.11:g.7674286C>A | TOPMed |
RCV000572327 | p.Gly226Val | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7674286C>A | ClinVar |
RCV000785269 | p.Gly226Ter | frameshift | Ovarian Neoplasms | NC_000017.11:g.7674289del | ClinVar |
VAR_045146 | p.Gly226Ser | Missense | - | - | UniProt |
VAR_047180 | p.Gly226Asp | Missense | - | - | UniProt |
VAR_045844 | p.Gly226Asn | Missense | - | - | UniProt |
VAR_045145 | p.Gly226Ala | Missense | - | - | UniProt |
COSM4387403 | p.Ser227Tyr | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7674283G>T | NCI-TCGA Cosmic |
RCV000785280 | p.Ser227Ter | frameshift | Ovarian Neoplasms | NC_000017.11:g.7674283del | ClinVar |
VAR_045151 | p.Ser227Thr | Missense | Li-Fraumeni syndrome (LFS) [MIM:151623] | - | UniProt |
VAR_045149 | p.Ser227Phe | Missense | - | - | UniProt |
VAR_045150 | p.Ser227Pro | Missense | - | - | UniProt |
VAR_045148 | p.Ser227Cys | Missense | - | - | UniProt |
COSM69213 | p.Asp228Ter | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7674281_7674282insA | NCI-TCGA Cosmic |
COSM43853 | p.Asp228Glu | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7674279G>C | NCI-TCGA Cosmic |
COSM44398 | p.Asp228Asn | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7674281C>T | NCI-TCGA Cosmic |
COSM5025058 | p.Asp228ValPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7674277_7674280CAGT>- | NCI-TCGA Cosmic |
RCV000785306 | p.Asp228Ter | nonsense | Ovarian Neoplasms | NC_000017.11:g.7674282dup | ClinVar |
VAR_005960 | p.Asp228Glu | Missense | - | - | UniProt |
VAR_045153 | p.Asp228Gly | Missense | - | - | UniProt |
VAR_045845 | p.Asp228Pro | Missense | - | - | UniProt |
VAR_045157 | p.Asp228Tyr | Missense | - | - | UniProt |
VAR_045154 | p.Asp228His | Missense | - | - | UniProt |
VAR_045155 | p.Asp228Asn | Missense | - | - | UniProt |
VAR_045156 | p.Asp228Val | Missense | - | - | UniProt |
VAR_045152 | p.Asp228Ala | Missense | - | - | UniProt |
RCV000775944 | p.Cys229Tyr | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7674277C>T | ClinVar |
RCV000633388 | p.Cys229Arg | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674278A>G | ClinVar |
COSM45394 | p.Cys229Ter | stop gained | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7674276A>T | NCI-TCGA Cosmic |
COSM5045719 | p.Cys229LeuPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7674277C>- | NCI-TCGA Cosmic |
COSM111635 | p.Cys229TyrPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7674276_7674277AC>- | NCI-TCGA Cosmic |
rs1064793603 | p.Cys229Tyr | missense variant | - | NC_000017.11:g.7674277C>T | - |
rs1064794312 | p.Cys229Arg | missense variant | - | NC_000017.11:g.7674278A>G | gnomAD |
rs1064794312 | p.Cys229Arg | missense variant | - | NC_000017.11:g.7674278A>G | UniProt,dbSNP |
VAR_045159 | p.Cys229Arg | missense variant | - | NC_000017.11:g.7674278A>G | UniProt |
RCV000161057 | p.Cys229Ter | frameshift | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7674273_7674280del | ClinVar |
RCV000482930 | p.Cys229Arg | missense variant | - | NC_000017.11:g.7674278A>G | ClinVar |
RCV000482575 | p.Cys229Tyr | missense variant | - | NC_000017.11:g.7674277C>T | ClinVar |
RCV000492777 | p.Cys229Arg | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7674278A>G | ClinVar |
VAR_045158 | p.Cys229Gly | Missense | - | - | UniProt |
VAR_045160 | p.Cys229Ser | Missense | - | - | UniProt |
VAR_045846 | p.Cys229Asn | Missense | - | - | UniProt |
COSM44223 | p.Thr230HisPheSerTerUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7674275_7674276TA>- | NCI-TCGA Cosmic |
COSM1637323 | p.Thr230Pro | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7674275T>G | NCI-TCGA Cosmic |
VAR_045163 | p.Thr230Asn | Missense | - | - | UniProt |
VAR_045162 | p.Thr230Ala | Missense | - | - | UniProt |
VAR_045164 | p.Thr230Pro | Missense | - | - | UniProt |
VAR_005961 | p.Thr230Ile | Missense | - | - | UniProt |
VAR_045165 | p.Thr230Ser | Missense | - | - | UniProt |
rs1555525564 | p.Thr231Ile | missense variant | - | NC_000017.11:g.7674271G>A | UniProt,dbSNP |
VAR_045167 | p.Thr231Ile | missense variant | - | NC_000017.11:g.7674271G>A | UniProt |
rs1555525564 | p.Thr231Ile | missense variant | - | NC_000017.11:g.7674271G>A | - |
RCV000552433 | p.Thr231Ile | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674271G>A | ClinVar |
VAR_045169 | p.Thr231Ser | Missense | - | - | UniProt |
VAR_045166 | p.Thr231Ala | Missense | - | - | UniProt |
VAR_045168 | p.Thr231Asn | Missense | - | - | UniProt |
COSM10715 | p.Ile232Asn | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7674268A>T | NCI-TCGA Cosmic |
COSM43550 | p.Ile232Phe | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7674269T>A | NCI-TCGA Cosmic |
RCV000129637 | p.Ile232Thr | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7674268A>G | ClinVar |
RCV000785478 | p.Ile232Ser | missense variant | Ovarian Neoplasms | NC_000017.11:g.7674268A>C | ClinVar |
RCV000567074 | p.Ile232Leu | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7674269T>G | ClinVar |
rs1555525562 | p.Ile232Leu | missense variant | - | NC_000017.11:g.7674269T>G | - |
rs1555525562 | p.Ile232Leu | missense variant | - | NC_000017.11:g.7674269T>G | UniProt,dbSNP |
VAR_045171 | p.Ile232Leu | missense variant | - | NC_000017.11:g.7674269T>G | UniProt |
rs587781589 | p.Ile232Thr | missense variant | - | NC_000017.11:g.7674268A>G | UniProt,dbSNP |
VAR_005962 | p.Ile232Thr | missense variant | - | NC_000017.11:g.7674268A>G | UniProt |
RCV000759379 | p.Ile232Leu | missense variant | - | NC_000017.11:g.7674269T>G | ClinVar |
VAR_045174 | p.Ile232Val | Missense | - | - | UniProt |
VAR_045172 | p.Ile232Asn | Missense | - | - | UniProt |
VAR_045173 | p.Ile232Ser | Missense | - | - | UniProt |
VAR_045170 | p.Ile232Phe | Missense | - | - | UniProt |
rs879254233 | p.His233Arg | missense variant | - | NC_000017.11:g.7674265T>C | UniProt,dbSNP |
VAR_047181 | p.His233Arg | missense variant | - | NC_000017.11:g.7674265T>C | UniProt |
rs879254233 | p.His233Arg | missense variant | - | NC_000017.11:g.7674265T>C | - |
RCV000235730 | p.His233Arg | missense variant | - | NC_000017.11:g.7674265T>C | ClinVar |
RCV000696660 | p.His233Ter | nonsense | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674249_7674261del | ClinVar |
RCV000569303 | p.His233Arg | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7674265T>C | ClinVar |
VAR_045176 | p.His233Leu | Missense | - | - | UniProt |
VAR_045177 | p.His233Pro | Missense | - | - | UniProt |
VAR_045178 | p.His233Gln | Missense | - | - | UniProt |
VAR_045175 | p.His233Asp | Missense | Li-Fraumeni syndrome (LFS) [MIM:151623] | - | UniProt |
VAR_045179 | p.His233Tyr | Missense | - | - | UniProt |
rs587780073 | p.Tyr234Ser | missense variant | - | NC_000017.11:g.7674262T>G | ExAC,gnomAD |
rs587780073 | p.Tyr234Cys | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674262T>C | UniProt,dbSNP |
VAR_005963 | p.Tyr234Cys | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674262T>C | UniProt |
RCV000427293 | p.Tyr234Ser | missense variant | Squamous cell lung carcinoma | NC_000017.11:g.7674262T>G | ClinVar |
RCV000443862 | p.Tyr234Ser | missense variant | Small cell lung cancer | NC_000017.11:g.7674262T>G | ClinVar |
RCV000421263 | p.Tyr234Ser | missense variant | Carcinoma of esophagus | NC_000017.11:g.7674262T>G | ClinVar |
RCV000436336 | p.Tyr234Asn | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7674263A>T | ClinVar |
RCV000424345 | p.Tyr234Asp | missense variant | Adenocarcinoma of stomach | NC_000017.11:g.7674263A>C | ClinVar |
RCV000439167 | p.Tyr234Asn | missense variant | Adenocarcinoma of stomach | NC_000017.11:g.7674263A>T | ClinVar |
RCV000440475 | p.Tyr234Asp | missense variant | Neoplasm of the breast | NC_000017.11:g.7674263A>C | ClinVar |
COSM1626221 | p.Tyr234ThrPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7674258_7674264GTTGTAG>- | NCI-TCGA Cosmic |
COSM1564201 | p.Tyr234ProPheSerTerUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7674264_7674265insTGGA | NCI-TCGA Cosmic |
COSM1324800 | p.Tyr234Ter | stop gained | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7674261G>C | NCI-TCGA Cosmic |
RCV000430039 | p.Tyr234Ser | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7674262T>G | ClinVar |
RCV000115732 | p.Tyr234Cys | missense variant | - | NC_000017.11:g.7674262T>C | ClinVar |
RCV000431511 | p.Tyr234Ser | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7674262T>G | ClinVar |
RCV000440245 | p.Tyr234Ser | missense variant | Neoplasm of the large intestine | NC_000017.11:g.7674262T>G | ClinVar |
RCV000444596 | p.Tyr234Ser | missense variant | Hepatocellular carcinoma (HCC) | NC_000017.11:g.7674262T>G | ClinVar |
RCV000444569 | p.Tyr234Ser | missense variant | Adenocarcinoma of prostate | NC_000017.11:g.7674262T>G | ClinVar |
RCV000423467 | p.Tyr234Ser | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7674262T>G | ClinVar |
RCV000439556 | p.Tyr234Ser | missense variant | - | NC_000017.11:g.7674262T>G | ClinVar |
NCI-TCGA novel | p.Tyr234Ter | stop gained | - | NC_000017.11:g.7674261_7674262insT | NCI-TCGA |
RCV000445176 | p.Tyr234Asp | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7674263A>C | ClinVar |
RCV000426109 | p.Tyr234Asn | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7674263A>T | ClinVar |
RCV000418073 | p.Tyr234Asp | missense variant | Adenocarcinoma of prostate | NC_000017.11:g.7674263A>C | ClinVar |
RCV000444101 | p.Tyr234Asn | missense variant | Small cell lung cancer | NC_000017.11:g.7674263A>T | ClinVar |
RCV000423653 | p.Tyr234Asn | missense variant | - | NC_000017.11:g.7674263A>T | ClinVar |
RCV000441597 | p.Tyr234Asp | missense variant | - | NC_000017.11:g.7674263A>C | ClinVar |
RCV000444893 | p.Tyr234Asn | missense variant | Neoplasm of the large intestine | NC_000017.11:g.7674263A>T | ClinVar |
RCV000417830 | p.Tyr234Asn | missense variant | Neoplasm of the breast | NC_000017.11:g.7674263A>T | ClinVar |
rs587780073 | p.Tyr234Ser | missense variant | - | NC_000017.11:g.7674262T>G | UniProt,dbSNP |
VAR_045183 | p.Tyr234Ser | missense variant | - | NC_000017.11:g.7674262T>G | UniProt |
rs587780073 | p.Tyr234Cys | missense variant | - | NC_000017.11:g.7674262T>C | ExAC,gnomAD |
RCV000430207 | p.Tyr234Ser | missense variant | Glioblastoma | NC_000017.11:g.7674262T>G | ClinVar |
RCV000437540 | p.Tyr234Ser | missense variant | Neoplasm of the breast | NC_000017.11:g.7674262T>G | ClinVar |
RCV000433051 | p.Tyr234Ser | missense variant | Adrenocortical carcinoma | NC_000017.11:g.7674262T>G | ClinVar |
RCV000421924 | p.Tyr234Ser | missense variant | Adenocarcinoma of stomach | NC_000017.11:g.7674262T>G | ClinVar |
RCV000426723 | p.Tyr234Asn | missense variant | Squamous cell lung carcinoma | NC_000017.11:g.7674263A>T | ClinVar |
RCV000492782 | p.Tyr234His | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7674263A>G | ClinVar |
RCV000433276 | p.Tyr234Asn | missense variant | Hepatocellular carcinoma (HCC) | NC_000017.11:g.7674263A>T | ClinVar |
RCV000426512 | p.Tyr234Asn | missense variant | Adenocarcinoma of prostate | NC_000017.11:g.7674263A>T | ClinVar |
RCV000424462 | p.Tyr234Asp | missense variant | Neoplasm of the large intestine | NC_000017.11:g.7674263A>C | ClinVar |
RCV000423238 | p.Tyr234Asp | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7674263A>C | ClinVar |
RCV000445265 | p.Tyr234Asp | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7674263A>C | ClinVar |
RCV000433328 | p.Tyr234Asp | missense variant | Glioblastoma | NC_000017.11:g.7674263A>C | ClinVar |
RCV000432845 | p.Tyr234Asp | missense variant | Small cell lung cancer | NC_000017.11:g.7674263A>C | ClinVar |
RCV000492197 | p.Tyr234Asp | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7674263A>C | ClinVar |
RCV000418444 | p.Tyr234Asn | missense variant | Adrenocortical carcinoma | NC_000017.11:g.7674263A>T | ClinVar |
RCV000428072 | p.Tyr234Asn | missense variant | Carcinoma of esophagus | NC_000017.11:g.7674263A>T | ClinVar |
RCV000430896 | p.Tyr234Asp | missense variant | Hepatocellular carcinoma (HCC) | NC_000017.11:g.7674263A>C | ClinVar |
RCV000434769 | p.Tyr234Asn | missense variant | Glioblastoma | NC_000017.11:g.7674263A>T | ClinVar |
RCV000436114 | p.Tyr234Asn | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7674263A>T | ClinVar |
RCV000435222 | p.Tyr234Asp | missense variant | Adrenocortical carcinoma | NC_000017.11:g.7674263A>C | ClinVar |
RCV000425587 | p.Tyr234Asp | missense variant | Carcinoma of esophagus | NC_000017.11:g.7674263A>C | ClinVar |
RCV000433956 | p.Tyr234Asp | missense variant | Squamous cell lung carcinoma | NC_000017.11:g.7674263A>C | ClinVar |
VAR_045848 | p.Tyr234Gln | Missense | - | - | UniProt |
VAR_045181 | p.Tyr234Phe | Missense | - | - | UniProt |
VAR_045847 | p.Tyr234Lys | Missense | - | - | UniProt |
RCV000115733 | p.Asn235Ser | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7674259T>C | ClinVar |
rs786204145 | p.Asn235Tyr | missense variant | - | NC_000017.11:g.7674260T>A | UniProt,dbSNP |
VAR_045188 | p.Asn235Tyr | missense variant | - | NC_000017.11:g.7674260T>A | UniProt |
rs786204145 | p.Asn235Tyr | missense variant | - | NC_000017.11:g.7674260T>A | - |
rs144340710 | p.Asn235Ser | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674259T>C | UniProt,dbSNP |
VAR_045186 | p.Asn235Ser | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674259T>C | UniProt |
rs144340710 | p.Asn235Ile | missense variant | - | NC_000017.11:g.7674259T>A | ESP,ExAC,TOPMed,gnomAD |
rs144340710 | p.Asn235Ser | missense variant | - | NC_000017.11:g.7674259T>C | ESP,ExAC,TOPMed,gnomAD |
rs144340710 | p.Asn235Ile | missense variant | - | NC_000017.11:g.7674259T>A | UniProt,dbSNP |
VAR_045185 | p.Asn235Ile | missense variant | - | NC_000017.11:g.7674259T>A | UniProt |
RCV000168131 | p.Asn235Tyr | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674260T>A | ClinVar |
VAR_045184 | p.Asn235His | Missense | - | - | UniProt |
VAR_045187 | p.Asn235Thr | Missense | - | - | UniProt |
VAR_045849 | p.Asn235Met | Missense | - | - | UniProt |
VAR_047182 | p.Asn235Asp | Missense | - | - | UniProt |
rs587782289 | p.Tyr236Asp | missense variant | - | NC_000017.11:g.7674257A>C | UniProt,dbSNP |
VAR_045190 | p.Tyr236Asp | missense variant | - | NC_000017.11:g.7674257A>C | UniProt |
rs587782289 | p.Tyr236His | missense variant | - | NC_000017.11:g.7674257A>G | UniProt,dbSNP |
VAR_045192 | p.Tyr236His | missense variant | - | NC_000017.11:g.7674257A>G | UniProt |
RCV000439518 | p.Tyr236Asn | missense variant | Neoplasm of the breast | NC_000017.11:g.7674257A>T | ClinVar |
RCV000443891 | p.Tyr236Asn | missense variant | Neoplasm of brain | NC_000017.11:g.7674257A>T | ClinVar |
RCV000431852 | p.Tyr236Asn | missense variant | Squamous cell lung carcinoma | NC_000017.11:g.7674257A>T | ClinVar |
RCV000429935 | p.Tyr236Cys | missense variant | Lung adenocarcinoma | NC_000017.11:g.7674256T>C | ClinVar |
RCV000438183 | p.Tyr236Cys | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7674256T>C | ClinVar |
RCV000420300 | p.Tyr236Cys | missense variant | Neoplasm of brain | NC_000017.11:g.7674256T>C | ClinVar |
RCV000444464 | p.Tyr236Cys | missense variant | Neoplasm of the breast | NC_000017.11:g.7674256T>C | ClinVar |
RCV000428749 | p.Tyr236Cys | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7674256T>C | ClinVar |
RCV000437595 | p.Tyr236Cys | missense variant | - | NC_000017.11:g.7674256T>C | ClinVar |
RCV000419208 | p.Tyr236Cys | missense variant | Adenocarcinoma of prostate | NC_000017.11:g.7674256T>C | ClinVar |
COSM1522505 | p.Tyr236Ter | stop gained | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7674255G>T | NCI-TCGA Cosmic |
COSM44960 | p.Tyr236Ter | stop gained | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7674255G>C | NCI-TCGA Cosmic |
RCV000198628 | p.Tyr236His | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674257A>G | ClinVar |
RCV000438979 | p.Tyr236Asp | missense variant | Adenocarcinoma of prostate | NC_000017.11:g.7674257A>C | ClinVar |
RCV000418648 | p.Tyr236Asp | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7674257A>C | ClinVar |
RCV000421570 | p.Tyr236Asp | missense variant | Adenocarcinoma of stomach | NC_000017.11:g.7674257A>C | ClinVar |
RCV000438025 | p.Tyr236Asn | missense variant | Adenocarcinoma of prostate | NC_000017.11:g.7674257A>T | ClinVar |
RCV000421176 | p.Tyr236Asn | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7674257A>T | ClinVar |
RCV000427088 | p.Tyr236Asn | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7674257A>T | ClinVar |
RCV000429365 | p.Tyr236Asp | missense variant | Neoplasm of brain | NC_000017.11:g.7674257A>C | ClinVar |
RCV000426248 | p.Tyr236Asn | missense variant | Adenocarcinoma of stomach | NC_000017.11:g.7674257A>T | ClinVar |
RCV000430428 | p.Tyr236Asp | missense variant | Neoplasm of the large intestine | NC_000017.11:g.7674257A>C | ClinVar |
RCV000785279 | p.Tyr236Cys | missense variant | Ovarian Neoplasms | NC_000017.11:g.7674256T>C | ClinVar |
RCV000423298 | p.Tyr236Cys | missense variant | Adenocarcinoma of stomach | NC_000017.11:g.7674256T>C | ClinVar |
RCV000430980 | p.Tyr236Cys | missense variant | Squamous cell lung carcinoma | NC_000017.11:g.7674256T>C | ClinVar |
RCV000425130 | p.Tyr236Cys | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7674256T>C | ClinVar |
rs587782289 | p.Tyr236Asn | missense variant | - | NC_000017.11:g.7674257A>T | - |
rs587782289 | p.Tyr236Asn | missense variant | - | NC_000017.11:g.7674257A>T | UniProt,dbSNP |
VAR_045193 | p.Tyr236Asn | missense variant | - | NC_000017.11:g.7674257A>T | UniProt |
RCV000440629 | p.Tyr236Cys | missense variant | Neoplasm of the large intestine | NC_000017.11:g.7674256T>C | ClinVar |
RCV000161069 | p.Tyr236Ser | missense variant | - | NC_000017.11:g.7674256T>G | ClinVar |
RCV000421075 | p.Tyr236Asp | missense variant | Lung adenocarcinoma | NC_000017.11:g.7674257A>C | ClinVar |
RCV000440030 | p.Tyr236Asp | missense variant | Squamous cell lung carcinoma | NC_000017.11:g.7674257A>C | ClinVar |
RCV000444665 | p.Tyr236Asn | missense variant | - | NC_000017.11:g.7674257A>T | ClinVar |
RCV000432981 | p.Tyr236Asn | missense variant | Lung adenocarcinoma | NC_000017.11:g.7674257A>T | ClinVar |
RCV000428270 | p.Tyr236Asp | missense variant | - | NC_000017.11:g.7674257A>C | ClinVar |
RCV000419715 | p.Tyr236Asp | missense variant | Neoplasm of the breast | NC_000017.11:g.7674257A>C | ClinVar |
RCV000436923 | p.Tyr236Asp | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7674257A>C | ClinVar |
RCV000422301 | p.Tyr236Asn | missense variant | Neoplasm of the large intestine | NC_000017.11:g.7674257A>T | ClinVar |
RCV000444573 | p.Tyr236Asn | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7674257A>T | ClinVar |
RCV000435853 | p.Tyr236Asp | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7674257A>C | ClinVar |
VAR_045191 | p.Tyr236Phe | Missense | - | - | UniProt |
rs587782664 | p.Met237Ile | missense variant | - | NC_000017.11:g.7674252C>G | ExAC,TOPMed,gnomAD |
rs765848205 | p.Met237Lys | missense variant | - | NC_000017.11:g.7674253A>T | ExAC,gnomAD |
RCV000482236 | p.Met237Arg | missense variant | - | NC_000017.11:g.7674253A>C | ClinVar |
RCV000443369 | p.Met237Lys | missense variant | Neoplasm of the large intestine | NC_000017.11:g.7674253A>T | ClinVar |
RCV000442966 | p.Met237Lys | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7674253A>T | ClinVar |
RCV000200500 | p.Met237Val | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674254T>C | ClinVar |
COSM220792 | p.Met237Leu | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7674254T>A | NCI-TCGA Cosmic |
COSM45162 | p.Met237CysPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7674254T>- | NCI-TCGA Cosmic |
RCV000464261 | p.Met237Ile | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674252C>T | ClinVar |
RCV000581940 | p.Met237Ile | missense variant | - | NC_000017.11:g.7674252C>T | ClinVar |
RCV000424589 | p.Met237Lys | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7674253A>T | ClinVar |
RCV000437739 | p.Met237Lys | missense variant | - | NC_000017.11:g.7674253A>T | ClinVar |
RCV000422293 | p.Met237Lys | missense variant | Malignant neoplasm of body of uterus | NC_000017.11:g.7674253A>T | ClinVar |
RCV000161033 | p.Met237Val | missense variant | - | NC_000017.11:g.7674254T>C | ClinVar |
RCV000435309 | p.Met237Lys | missense variant | Lung adenocarcinoma | NC_000017.11:g.7674253A>T | ClinVar |
RCV000699909 | p.Met237Thr | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674253A>G | ClinVar |
RCV000568529 | p.Met237Thr | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7674253A>G | ClinVar |
NCI-TCGA novel | p.Met237GlyPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7674236_7674255TGCAGGAACTGTTACACATG>- | NCI-TCGA |
RCV000432913 | p.Met237Lys | missense variant | Neoplasm of brain | NC_000017.11:g.7674253A>T | ClinVar |
RCV000427086 | p.Met237Lys | missense variant | Adenocarcinoma of stomach | NC_000017.11:g.7674253A>T | ClinVar |
RCV000436968 | p.Met237Lys | missense variant | Neoplasm of the breast | NC_000017.11:g.7674253A>T | ClinVar |
RCV000429783 | p.Met237Lys | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7674253A>T | ClinVar |
rs587782664 | p.Met237Ile | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674252C>T | UniProt,dbSNP |
VAR_005965 | p.Met237Ile | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674252C>T | UniProt |
rs765848205 | p.Met237Arg | missense variant | - | NC_000017.11:g.7674253A>C | ExAC,gnomAD |
rs765848205 | p.Met237Thr | missense variant | - | NC_000017.11:g.7674253A>G | ExAC,gnomAD |
rs587782664 | p.Met237Ile | missense variant | - | NC_000017.11:g.7674252C>T | ExAC,TOPMed,gnomAD |
rs765848205 | p.Met237Lys | missense variant | - | NC_000017.11:g.7674253A>T | UniProt,dbSNP |
VAR_045195 | p.Met237Lys | missense variant | - | NC_000017.11:g.7674253A>T | UniProt |
rs587782664 | p.Met237Ile | missense variant | - | NC_000017.11:g.7674252C>A | ExAC,TOPMed,gnomAD |
rs765848205 | p.Met237Arg | missense variant | - | NC_000017.11:g.7674253A>C | UniProt,dbSNP |
VAR_045197 | p.Met237Arg | missense variant | - | NC_000017.11:g.7674253A>C | UniProt |
RCV000420529 | p.Met237Lys | missense variant | Squamous cell lung carcinoma | NC_000017.11:g.7674253A>T | ClinVar |
RCV000442354 | p.Met237Lys | missense variant | Carcinoma of esophagus | NC_000017.11:g.7674253A>T | ClinVar |
RCV000785508 | p.Met237Ile | missense variant | Ovarian Neoplasms | NC_000017.11:g.7674252C>A | ClinVar |
RCV000572072 | p.Met237Ter | nonsense | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7674249del | ClinVar |
RCV000574740 | p.Met237Ter | nonsense | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7674250_7674251CA[1] | ClinVar |
VAR_045196 | p.Met237Leu | Missense | - | - | UniProt |
VAR_045198 | p.Met237Thr | Missense | - | - | UniProt |
RCV000431946 | p.Cys238Arg | missense variant | Neoplasm of brain | NC_000017.11:g.7674251A>G | ClinVar |
RCV000428804 | p.Cys238Gly | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7674251A>C | ClinVar |
RCV000420677 | p.Cys238Gly | missense variant | Uterine Carcinosarcoma | NC_000017.11:g.7674251A>C | ClinVar |
RCV000423396 | p.Cys238Gly | missense variant | - | NC_000017.11:g.7674251A>C | ClinVar |
RCV000438447 | p.Cys238Arg | missense variant | Carcinoma of esophagus | NC_000017.11:g.7674251A>G | ClinVar |
RCV000437476 | p.Cys238Gly | missense variant | Neoplasm of the breast | NC_000017.11:g.7674251A>C | ClinVar |
RCV000424052 | p.Cys238Arg | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7674251A>G | ClinVar |
RCV000433046 | p.Cys238Arg | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7674251A>G | ClinVar |
RCV000433478 | p.Cys238Gly | missense variant | Multiple myeloma (MM) | NC_000017.11:g.7674251A>C | ClinVar |
RCV000437321 | p.Cys238Gly | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7674251A>C | ClinVar |
RCV000428630 | p.Cys238Gly | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7674251A>C | ClinVar |
RCV000422283 | p.Cys238Gly | missense variant | Uterine cervical neoplasms | NC_000017.11:g.7674251A>C | ClinVar |
RCV000417486 | p.Cys238Gly | missense variant | Lung adenocarcinoma | NC_000017.11:g.7674251A>C | ClinVar |
RCV000785550 | p.Cys238Gly | missense variant | Ovarian Neoplasms | NC_000017.11:g.7674251A>C | ClinVar |
RCV000427246 | p.Cys238Gly | missense variant | Neoplasm of the large intestine | NC_000017.11:g.7674251A>C | ClinVar |
RCV000421679 | p.Cys238Arg | missense variant | Multiple myeloma (MM) | NC_000017.11:g.7674251A>G | ClinVar |
RCV000441834 | p.Cys238Arg | missense variant | Lung adenocarcinoma | NC_000017.11:g.7674251A>G | ClinVar |
RCV000422044 | p.Cys238Gly | missense variant | Carcinoma of esophagus | NC_000017.11:g.7674251A>C | ClinVar |
RCV000426193 | p.Cys238Arg | missense variant | Adenocarcinoma of stomach | NC_000017.11:g.7674251A>G | ClinVar |
RCV000442237 | p.Cys238Arg | missense variant | - | NC_000017.11:g.7674251A>G | ClinVar |
RCV000435170 | p.Cys238Gly | missense variant | Malignant neoplasm of body of uterus | NC_000017.11:g.7674251A>C | ClinVar |
RCV000444792 | p.Cys238Gly | missense variant | Hepatocellular carcinoma (HCC) | NC_000017.11:g.7674251A>C | ClinVar |
RCV000441879 | p.Cys238Arg | missense variant | Neoplasm of the breast | NC_000017.11:g.7674251A>G | ClinVar |
RCV000439946 | p.Cys238Gly | missense variant | Adenocarcinoma of stomach | NC_000017.11:g.7674251A>C | ClinVar |
RCV000434344 | p.Cys238Ser | missense variant | Neoplasm of the breast | NC_000017.11:g.7674250C>G | ClinVar |
RCV000418923 | p.Cys238Ser | missense variant | Neoplasm of brain | NC_000017.11:g.7674250C>G | ClinVar |
RCV000429749 | p.Cys238Ser | missense variant | Uterine Carcinosarcoma | NC_000017.11:g.7674250C>G | ClinVar |
RCV000442527 | p.Cys238Ser | missense variant | Multiple myeloma (MM) | NC_000017.11:g.7674250C>G | ClinVar |
RCV000424531 | p.Cys238Ser | missense variant | Adenocarcinoma of stomach | NC_000017.11:g.7674250C>G | ClinVar |
COSM4425176 | p.Cys238Ter | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7674249_7674250AC>- | NCI-TCGA Cosmic |
RCV000425867 | p.Cys238Ser | missense variant | - | NC_000017.11:g.7674250C>G | ClinVar |
RCV000439773 | p.Cys238Ser | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7674250C>G | ClinVar |
RCV000435732 | p.Cys238Ser | missense variant | Hepatocellular carcinoma (HCC) | NC_000017.11:g.7674250C>G | ClinVar |
RCV000424302 | p.Cys238Ser | missense variant | Glioblastoma | NC_000017.11:g.7674250C>G | ClinVar |
NCI-TCGA novel | p.Cys238LeuPheSerTerUnk | frameshift | - | NC_000017.11:g.7674250C>- | NCI-TCGA |
RCV000161034 | p.Cys238Tyr | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7674250C>T | ClinVar |
RCV000434584 | p.Cys238Ser | missense variant | Carcinoma of esophagus | NC_000017.11:g.7674250C>G | ClinVar |
RCV000432222 | p.Cys238Ser | missense variant | Neoplasm of the large intestine | NC_000017.11:g.7674250C>G | ClinVar |
RCV000423226 | p.Cys238Ser | missense variant | Malignant neoplasm of body of uterus | NC_000017.11:g.7674250C>G | ClinVar |
RCV000425465 | p.Cys238Ser | missense variant | Chronic lymphocytic leukemia (CLL) | NC_000017.11:g.7674250C>G | ClinVar |
rs730882005 | p.Cys238Ser | missense variant | - | NC_000017.11:g.7674250C>G | ExAC,TOPMed,gnomAD |
rs1057519981 | p.Cys238Arg | missense variant | - | NC_000017.11:g.7674251A>G | UniProt,dbSNP |
VAR_045201 | p.Cys238Arg | missense variant | - | NC_000017.11:g.7674251A>G | UniProt |
rs730882005 | p.Cys238Phe | missense variant | - | NC_000017.11:g.7674250C>A | ExAC,TOPMed,gnomAD |
rs1057519981 | p.Cys238Gly | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674251A>C | UniProt,dbSNP |
VAR_045200 | p.Cys238Gly | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674251A>C | UniProt |
rs730882005 | p.Cys238Tyr | missense variant | - | NC_000017.11:g.7674250C>T | ExAC,TOPMed,gnomAD |
RCV000442617 | p.Cys238Ser | missense variant | Lung adenocarcinoma | NC_000017.11:g.7674250C>G | ClinVar |
RCV000473420 | p.Cys238Phe | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674250C>A | ClinVar |
RCV000419485 | p.Cys238Ser | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7674250C>G | ClinVar |
RCV000441115 | p.Cys238Ser | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7674250C>G | ClinVar |
RCV000440842 | p.Cys238Ser | missense variant | Uterine cervical neoplasms | NC_000017.11:g.7674250C>G | ClinVar |
RCV000437199 | p.Cys238Arg | missense variant | Neoplasm of the large intestine | NC_000017.11:g.7674251A>G | ClinVar |
RCV000438876 | p.Cys238Gly | missense variant | Glioblastoma | NC_000017.11:g.7674251A>C | ClinVar |
RCV000420409 | p.Cys238Arg | missense variant | Uterine cervical neoplasms | NC_000017.11:g.7674251A>G | ClinVar |
RCV000443356 | p.Cys238Gly | missense variant | Neoplasm of brain | NC_000017.11:g.7674251A>C | ClinVar |
RCV000565464 | p.Cys238Ser | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7674251A>T | ClinVar |
RCV000430482 | p.Cys238Arg | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7674251A>G | ClinVar |
RCV000430655 | p.Cys238Arg | missense variant | Uterine Carcinosarcoma | NC_000017.11:g.7674251A>G | ClinVar |
RCV000428210 | p.Cys238Arg | missense variant | Hepatocellular carcinoma (HCC) | NC_000017.11:g.7674251A>G | ClinVar |
RCV000437018 | p.Cys238Arg | missense variant | Malignant neoplasm of body of uterus | NC_000017.11:g.7674251A>G | ClinVar |
RCV000430919 | p.Cys238Gly | missense variant | Chronic lymphocytic leukemia (CLL) | NC_000017.11:g.7674251A>C | ClinVar |
RCV000421933 | p.Cys238Arg | missense variant | Chronic lymphocytic leukemia (CLL) | NC_000017.11:g.7674251A>G | ClinVar |
RCV000419348 | p.Cys238Arg | missense variant | Glioblastoma | NC_000017.11:g.7674251A>G | ClinVar |
rs193920789 | p.Cys238Trp | missense variant | - | NC_000017.11:g.7674249A>C | UniProt,dbSNP |
VAR_045203 | p.Cys238Trp | missense variant | - | NC_000017.11:g.7674249A>C | UniProt |
RCV000203823 | p.Cys238Trp | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674249A>C | ClinVar |
VAR_045850 | p.Cys238His | Missense | - | - | UniProt |
rs1057519999 | p.Asn239Ser | missense variant | - | NC_000017.11:g.7674247T>C | UniProt,dbSNP |
VAR_045208 | p.Asn239Ser | missense variant | - | NC_000017.11:g.7674247T>C | UniProt |
RCV000420011 | p.Asn239Ser | missense variant | Renal cell carcinoma, papillary, 1 (RCCP1) | NC_000017.11:g.7674247T>C | ClinVar |
RCV000442626 | p.Asn239Ser | missense variant | Adenocarcinoma of prostate | NC_000017.11:g.7674247T>C | ClinVar |
RCV000429581 | p.Asn239Ser | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7674247T>C | ClinVar |
RCV000431317 | p.Asn239Lys | missense variant | - | NC_000017.11:g.7674246G>C | ClinVar |
RCV000436108 | p.Asn239Ser | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7674247T>C | ClinVar |
RCV000426368 | p.Asn239Ser | missense variant | Malignant neoplasm of body of uterus | NC_000017.11:g.7674247T>C | ClinVar |
RCV000427640 | p.Asn239Ser | missense variant | Lung adenocarcinoma | NC_000017.11:g.7674247T>C | ClinVar |
RCV000418854 | p.Asn239Ser | missense variant | Neoplasm of the large intestine | NC_000017.11:g.7674247T>C | ClinVar |
RCV000438332 | p.Asn239Ser | missense variant | Adenocarcinoma of stomach | NC_000017.11:g.7674247T>C | ClinVar |
RCV000460136 | p.Asn239Ter | frameshift | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674248del | ClinVar |
RCV000438482 | p.Asn239Ser | missense variant | Hepatocellular carcinoma (HCC) | NC_000017.11:g.7674247T>C | ClinVar |
RCV000529909 | p.Asn239Lys | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674246G>C | ClinVar |
RCV000437044 | p.Asn239Ser | missense variant | Uterine Carcinosarcoma | NC_000017.11:g.7674247T>C | ClinVar |
RCV000428926 | p.Asn239Ser | missense variant | Neoplasm of the breast | NC_000017.11:g.7674247T>C | ClinVar |
RCV000560536 | p.Asn239Asp | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674248T>C | ClinVar |
COSM112003 | p.Asn239Ter | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7674248_7674249insA | NCI-TCGA Cosmic |
rs876660807 | p.Asn239Asp | missense variant | - | NC_000017.11:g.7674248T>C | UniProt,dbSNP |
VAR_045204 | p.Asn239Asp | missense variant | - | NC_000017.11:g.7674248T>C | UniProt |
rs876660807 | p.Asn239Asp | missense variant | - | NC_000017.11:g.7674248T>C | - |
NCI-TCGA novel | p.Asn239GlnPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7674247_7674248TT>- | NCI-TCGA |
rs1057519999 | p.Asn239Thr | missense variant | - | NC_000017.11:g.7674247T>G | UniProt,dbSNP |
VAR_045209 | p.Asn239Thr | missense variant | - | NC_000017.11:g.7674247T>G | UniProt |
RCV000785512 | p.Asn239Ter | nonsense | Ovarian Neoplasms | NC_000017.11:g.7674249dup | ClinVar |
RCV000545435 | p.Asn239Ter | frameshift | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674240_7674249del | ClinVar |
RCV000567507 | p.Asn239Ser | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7674247T>C | ClinVar |
RCV000633336 | p.Asn239Thr | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674247T>G | ClinVar |
VAR_045205 | p.Asn239His | Missense | - | - | UniProt |
VAR_045206 | p.Asn239Ile | Missense | - | - | UniProt |
VAR_045210 | p.Asn239Tyr | Missense | - | - | UniProt |
rs764342812 | p.Ser240Arg | missense variant | - | NC_000017.11:g.7674243A>C | ExAC,gnomAD |
RCV000709404 | p.Ser240Gly | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674245T>C | ClinVar |
RCV000544531 | p.Ser240Arg | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674243A>C | ClinVar |
NCI-TCGA novel | p.Ser240GlyPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7674236_7674246TGCAGGAACTG>- | NCI-TCGA |
NCI-TCGA novel | p.Ser240LysPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7674244_7674245insT | NCI-TCGA |
RCV000493285 | p.Ser240Ter | frameshift | - | NC_000017.11:g.7674246_7674247insA | ClinVar |
VAR_005968 | p.Ser240Ile | Missense | - | - | UniProt |
VAR_045214 | p.Ser240Pro | Missense | - | - | UniProt |
VAR_045216 | p.Ser240Thr | Missense | - | - | UniProt |
VAR_045215 | p.Ser240Arg | Missense | - | - | UniProt |
VAR_045212 | p.Ser240Gly | Missense | - | - | UniProt |
VAR_045211 | p.Ser240Cys | Missense | - | - | UniProt |
VAR_045213 | p.Ser240Asn | Missense | - | - | UniProt |
rs28934573 | p.Ser241Cys | missense variant | - | NC_000017.11:g.7674241G>C | ExAC,gnomAD |
rs28934573 | p.Ser241Tyr | missense variant | - | NC_000017.11:g.7674241G>T | ExAC,gnomAD |
rs28934573 | p.Ser241Phe | missense variant | - | NC_000017.11:g.7674241G>A | ExAC,gnomAD |
RCV000441261 | p.Ser241Tyr | missense variant | Carcinoma of gallbladder | NC_000017.11:g.7674241G>T | ClinVar |
RCV000425344 | p.Ser241Tyr | missense variant | Malignant melanoma of skin (CMM) | NC_000017.11:g.7674241G>T | ClinVar |
RCV000439590 | p.Ser241Cys | missense variant | Neoplasm of the breast | NC_000017.11:g.7674241G>C | ClinVar |
RCV000431755 | p.Ser241Tyr | missense variant | Non-Hodgkin lymphoma (NHL) | NC_000017.11:g.7674241G>T | ClinVar |
RCV000431373 | p.Ser241Cys | missense variant | Malignant neoplasm of body of uterus | NC_000017.11:g.7674241G>C | ClinVar |
RCV000236210 | p.Ser241Cys | missense variant | - | NC_000017.11:g.7674241G>C | ClinVar |
RCV000421131 | p.Ser241Tyr | missense variant | Malignant neoplasm of body of uterus | NC_000017.11:g.7674241G>T | ClinVar |
RCV000442642 | p.Ser241Cys | missense variant | Malignant melanoma of skin (CMM) | NC_000017.11:g.7674241G>C | ClinVar |
RCV000785454 | p.Ser241Tyr | missense variant | Ovarian Neoplasms | NC_000017.11:g.7674241G>T | ClinVar |
RCV000439098 | p.Ser241Cys | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7674241G>C | ClinVar |
RCV000443312 | p.Ser241Pro | missense variant | Neoplasm of the large intestine | NC_000017.11:g.7674242A>G | ClinVar |
RCV000429092 | p.Ser241Pro | missense variant | - | NC_000017.11:g.7674242A>G | ClinVar |
RCV000427437 | p.Ser241Pro | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7674242A>G | ClinVar |
RCV000440449 | p.Ser241Ala | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7674242A>C | ClinVar |
RCV000437125 | p.Ser241Ala | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7674242A>C | ClinVar |
RCV000433139 | p.Ser241Pro | missense variant | Uterine Carcinosarcoma | NC_000017.11:g.7674242A>G | ClinVar |
RCV000417799 | p.Ser241Pro | missense variant | Non-Hodgkin lymphoma (NHL) | NC_000017.11:g.7674242A>G | ClinVar |
RCV000441961 | p.Ser241Ala | missense variant | Papillary renal cell carcinoma, sporadic | NC_000017.11:g.7674242A>C | ClinVar |
RCV000443160 | p.Ser241Ala | missense variant | - | NC_000017.11:g.7674242A>C | ClinVar |
RCV000439326 | p.Ser241Pro | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7674242A>G | ClinVar |
RCV000418366 | p.Ser241Ala | missense variant | Carcinoma of esophagus | NC_000017.11:g.7674242A>C | ClinVar |
RCV000430183 | p.Ser241Pro | missense variant | Carcinoma of esophagus | NC_000017.11:g.7674242A>G | ClinVar |
RCV000423390 | p.Ser241Pro | missense variant | Papillary renal cell carcinoma, sporadic | NC_000017.11:g.7674242A>G | ClinVar |
RCV000441931 | p.Ser241Ala | missense variant | Lung adenocarcinoma | NC_000017.11:g.7674242A>C | ClinVar |
RCV000437871 | p.Ser241Pro | missense variant | Carcinoma of gallbladder | NC_000017.11:g.7674242A>G | ClinVar |
RCV000441702 | p.Ser241Ala | missense variant | - | NC_000017.11:g.7674242A>C | ClinVar |
RCV000418899 | p.Ser241Pro | missense variant | Renal cell carcinoma, papillary, 1 (RCCP1) | NC_000017.11:g.7674242A>G | ClinVar |
RCV000435947 | p.Ser241Ala | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7674242A>C | ClinVar |
RCV000429686 | p.Ser241Ala | missense variant | Malignant neoplasm of body of uterus | NC_000017.11:g.7674242A>C | ClinVar |
RCV000434790 | p.Ser241Ala | missense variant | Glioblastoma | NC_000017.11:g.7674242A>C | ClinVar |
RCV000442139 | p.Ser241Pro | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7674242A>G | ClinVar |
RCV000423557 | p.Ser241Ala | missense variant | Carcinoma of gallbladder | NC_000017.11:g.7674242A>C | ClinVar |
RCV000434877 | p.Ser241Ala | missense variant | Renal cell carcinoma, papillary, 1 (RCCP1) | NC_000017.11:g.7674242A>C | ClinVar |
RCV000433946 | p.Ser241Pro | missense variant | Glioblastoma | NC_000017.11:g.7674242A>G | ClinVar |
RCV000785263 | p.Ser241Pro | missense variant | Ovarian Neoplasms | NC_000017.11:g.7674242A>G | ClinVar |
RCV000436563 | p.Ser241Pro | missense variant | Malignant melanoma of skin (CMM) | NC_000017.11:g.7674242A>G | ClinVar |
COSM43645 | p.Ser241ProPheSerTerUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7674242A>- | NCI-TCGA Cosmic |
RCV000426195 | p.Ser241Cys | missense variant | Renal cell carcinoma, papillary, 1 (RCCP1) | NC_000017.11:g.7674241G>C | ClinVar |
RCV000492778 | p.Ser241Cys | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7674241G>C | ClinVar |
RCV000428236 | p.Ser241Cys | missense variant | - | NC_000017.11:g.7674241G>C | ClinVar |
RCV000436296 | p.Ser241Tyr | missense variant | Neoplasm of the breast | NC_000017.11:g.7674241G>T | ClinVar |
RCV000154419 | p.Ser241Cys | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674241G>C | ClinVar |
RCV000426095 | p.Ser241Tyr | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7674241G>T | ClinVar |
RCV000425780 | p.Ser241Cys | missense variant | Lung adenocarcinoma | NC_000017.11:g.7674241G>C | ClinVar |
RCV000430014 | p.Ser241Tyr | missense variant | Neoplasm of brain | NC_000017.11:g.7674241G>T | ClinVar |
RCV000013154 | p.Ser241Phe | missense variant | Osteosarcoma | NC_000017.11:g.7674241G>A | ClinVar |
RCV000437089 | p.Ser241Cys | missense variant | Carcinoma of esophagus | NC_000017.11:g.7674241G>C | ClinVar |
RCV000420364 | p.Ser241Cys | missense variant | Neoplasm of brain | NC_000017.11:g.7674241G>C | ClinVar |
rs1057520002 | p.Ser241Ala | missense variant | - | NC_000017.11:g.7674242A>C | UniProt,dbSNP |
VAR_033036 | p.Ser241Ala | missense variant | - | NC_000017.11:g.7674242A>C | UniProt |
rs1057520002 | p.Ser241Ala | missense variant | - | NC_000017.11:g.7674242A>C | gnomAD |
rs28934573 | p.Ser241Phe | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674241G>A | UniProt,dbSNP |
VAR_005969 | p.Ser241Phe | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674241G>A | UniProt |
rs28934573 | p.Ser241Tyr | missense variant | - | NC_000017.11:g.7674241G>T | UniProt,dbSNP |
VAR_045219 | p.Ser241Tyr | missense variant | - | NC_000017.11:g.7674241G>T | UniProt |
rs28934573 | p.Ser241Cys | missense variant | - | NC_000017.11:g.7674241G>C | UniProt,dbSNP |
VAR_045217 | p.Ser241Cys | missense variant | - | NC_000017.11:g.7674241G>C | UniProt |
RCV000417965 | p.Ser241Cys | missense variant | Glioblastoma | NC_000017.11:g.7674241G>C | ClinVar |
RCV000437363 | p.Ser241Tyr | missense variant | Papillary renal cell carcinoma, sporadic | NC_000017.11:g.7674241G>T | ClinVar |
RCV000422573 | p.Ser241Cys | missense variant | Carcinoma of gallbladder | NC_000017.11:g.7674241G>C | ClinVar |
RCV000429339 | p.Ser241Cys | missense variant | Neoplasm of the large intestine | NC_000017.11:g.7674241G>C | ClinVar |
RCV000438178 | p.Ser241Cys | missense variant | Uterine Carcinosarcoma | NC_000017.11:g.7674241G>C | ClinVar |
RCV000419713 | p.Ser241Tyr | missense variant | Glioblastoma | NC_000017.11:g.7674241G>T | ClinVar |
RCV000432092 | p.Ser241Tyr | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7674241G>T | ClinVar |
RCV000013153 | p.Ser241Phe | missense variant | Hepatoblastoma | NC_000017.11:g.7674241G>A | ClinVar |
RCV000419457 | p.Ser241Ala | missense variant | Neoplasm of the large intestine | NC_000017.11:g.7674242A>C | ClinVar |
RCV000420564 | p.Ser241Ala | missense variant | Uterine Carcinosarcoma | NC_000017.11:g.7674242A>C | ClinVar |
RCV000425213 | p.Ser241Pro | missense variant | Neoplasm of brain | NC_000017.11:g.7674242A>G | ClinVar |
RCV000428035 | p.Ser241Pro | missense variant | - | NC_000017.11:g.7674242A>G | ClinVar |
RCV000421946 | p.Ser241Pro | missense variant | Lung adenocarcinoma | NC_000017.11:g.7674242A>G | ClinVar |
RCV000435497 | p.Ser241Pro | missense variant | Neoplasm of the breast | NC_000017.11:g.7674242A>G | ClinVar |
RCV000432077 | p.Ser241Ala | missense variant | Neoplasm of the breast | NC_000017.11:g.7674242A>C | ClinVar |
RCV000425684 | p.Ser241Ala | missense variant | Non-Hodgkin lymphoma (NHL) | NC_000017.11:g.7674242A>C | ClinVar |
RCV000422882 | p.Ser241Pro | missense variant | - | NC_000017.11:g.7674242A>G | ClinVar |
RCV000426866 | p.Ser241Ala | missense variant | - | NC_000017.11:g.7674242A>C | ClinVar |
RCV000422775 | p.Ser241Ala | missense variant | Neoplasm of brain | NC_000017.11:g.7674242A>C | ClinVar |
RCV000442103 | p.Ser241Pro | missense variant | Malignant neoplasm of body of uterus | NC_000017.11:g.7674242A>G | ClinVar |
RCV000424609 | p.Ser241Ala | missense variant | Malignant melanoma of skin (CMM) | NC_000017.11:g.7674242A>C | ClinVar |
rs1057520002 | p.Ser241Pro | missense variant | - | NC_000017.11:g.7674242A>G | UniProt,dbSNP |
VAR_045218 | p.Ser241Pro | missense variant | - | NC_000017.11:g.7674242A>G | UniProt |
rs1057520002 | p.Ser241Pro | missense variant | - | NC_000017.11:g.7674242A>G | gnomAD |
RCV000785321 | p.Ser241Cys | missense variant | Ovarian Neoplasms | NC_000017.11:g.7674241G>C | ClinVar |
RCV000424972 | p.Ser241Tyr | missense variant | - | NC_000017.11:g.7674241G>T | ClinVar |
RCV000438864 | p.Ser241Tyr | missense variant | Neoplasm of the large intestine | NC_000017.11:g.7674241G>T | ClinVar |
RCV000430604 | p.Ser241Cys | missense variant | - | NC_000017.11:g.7674241G>C | ClinVar |
RCV000430987 | p.Ser241Tyr | missense variant | Lung adenocarcinoma | NC_000017.11:g.7674241G>T | ClinVar |
RCV000438488 | p.Ser241Cys | missense variant | Non-Hodgkin lymphoma (NHL) | NC_000017.11:g.7674241G>C | ClinVar |
RCV000419417 | p.Ser241Cys | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7674241G>C | ClinVar |
RCV000418625 | p.Ser241Tyr | missense variant | Carcinoma of esophagus | NC_000017.11:g.7674241G>T | ClinVar |
RCV000441902 | p.Ser241Tyr | missense variant | Renal cell carcinoma, papillary, 1 (RCCP1) | NC_000017.11:g.7674241G>T | ClinVar |
RCV000423572 | p.Ser241Tyr | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7674241G>T | ClinVar |
RCV000442616 | p.Ser241Cys | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7674241G>C | ClinVar |
RCV000420813 | p.Ser241Tyr | missense variant | Uterine Carcinosarcoma | NC_000017.11:g.7674241G>T | ClinVar |
RCV000426900 | p.Ser241Cys | missense variant | Papillary renal cell carcinoma, sporadic | NC_000017.11:g.7674241G>C | ClinVar |
RCV000440216 | p.Ser241Tyr | missense variant | - | NC_000017.11:g.7674241G>T | ClinVar |
RCV000441922 | p.Ser241Tyr | missense variant | - | NC_000017.11:g.7674241G>T | ClinVar |
RCV000432564 | p.Ser241Cys | missense variant | - | NC_000017.11:g.7674241G>C | ClinVar |
VAR_047183 | p.Ser241Thr | Missense | Li-Fraumeni syndrome (LFS) [MIM:151623] | - | UniProt |
rs375874539 | p.Cys242Trp | missense variant | - | NC_000017.11:g.7674237G>C | ESP,ExAC,TOPMed |
rs1057519982 | p.Cys242Gly | missense variant | - | NC_000017.11:g.7674239A>C | UniProt,dbSNP |
VAR_045220 | p.Cys242Gly | missense variant | - | NC_000017.11:g.7674239A>C | UniProt |
rs121912655 | p.Cys242Ser | missense variant | - | NC_000017.11:g.7674238C>G | UniProt,dbSNP |
VAR_045222 | p.Cys242Ser | missense variant | - | NC_000017.11:g.7674238C>G | UniProt |
rs121912655 | p.Cys242Phe | missense variant | - | NC_000017.11:g.7674238C>A | ExAC,TOPMed,gnomAD |
rs121912655 | p.Cys242Phe | missense variant | - | NC_000017.11:g.7674238C>A | UniProt,dbSNP |
VAR_005970 | p.Cys242Phe | missense variant | - | NC_000017.11:g.7674238C>A | UniProt |
RCV000424935 | p.Cys242Tyr | missense variant | - | NC_000017.11:g.7674238C>T | ClinVar |
RCV000461418 | p.Cys242Gly | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674239A>C | ClinVar |
RCV000662594 | p.Cys242Ser | missense variant | Li-Fraumeni syndrome 1 (LFS) | NC_000017.11:g.7674239A>T | ClinVar |
RCV000419041 | p.Cys242Tyr | missense variant | Squamous cell lung carcinoma | NC_000017.11:g.7674238C>T | ClinVar |
RCV000523905 | p.Cys242Arg | missense variant | - | NC_000017.11:g.7674239A>G | ClinVar |
RCV000440992 | p.Cys242Tyr | missense variant | Carcinoma of esophagus | NC_000017.11:g.7674238C>T | ClinVar |
RCV000688366 | p.Cys242Phe | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674238C>A | ClinVar |
RCV000785282 | p.Cys242Tyr | missense variant | Ovarian Neoplasms | NC_000017.11:g.7674238C>T | ClinVar |
RCV000425602 | p.Cys242Tyr | missense variant | Lung adenocarcinoma | NC_000017.11:g.7674238C>T | ClinVar |
RCV000430302 | p.Cys242Tyr | missense variant | Uterine Carcinosarcoma | NC_000017.11:g.7674238C>T | ClinVar |
RCV000436867 | p.Cys242Tyr | missense variant | Hepatocellular carcinoma (HCC) | NC_000017.11:g.7674238C>T | ClinVar |
RCV000442015 | p.Cys242Tyr | missense variant | Glioblastoma | NC_000017.11:g.7674238C>T | ClinVar |
RCV000426292 | p.Cys242Tyr | missense variant | Chronic lymphocytic leukemia (CLL) | NC_000017.11:g.7674238C>T | ClinVar |
RCV000419614 | p.Cys242Tyr | missense variant | Adenocarcinoma of stomach | NC_000017.11:g.7674238C>T | ClinVar |
RCV000436295 | p.Cys242Tyr | missense variant | Neoplasm of the breast | NC_000017.11:g.7674238C>T | ClinVar |
RCV000432119 | p.Cys242Tyr | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7674238C>T | ClinVar |
COSM2744618 | p.Cys242AlaPheSerTerUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7674240G>- | NCI-TCGA Cosmic |
COSM44378 | p.Cys242Ter | stop gained | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7674237G>T | NCI-TCGA Cosmic |
RCV000438862 | p.Cys242Trp | missense variant | Adenocarcinoma of stomach | NC_000017.11:g.7674237G>C | ClinVar |
RCV000421654 | p.Cys242Trp | missense variant | Lung adenocarcinoma | NC_000017.11:g.7674237G>C | ClinVar |
RCV000432344 | p.Cys242Trp | missense variant | Uterine Carcinosarcoma | NC_000017.11:g.7674237G>C | ClinVar |
RCV000441640 | p.Cys242Trp | missense variant | - | NC_000017.11:g.7674237G>C | ClinVar |
RCV000431682 | p.Cys242Trp | missense variant | Chronic lymphocytic leukemia (CLL) | NC_000017.11:g.7674237G>C | ClinVar |
rs121912655 | p.Cys242Ser | missense variant | - | NC_000017.11:g.7674238C>G | ExAC,TOPMed,gnomAD |
rs121912655 | p.Cys242Tyr | missense variant | - | NC_000017.11:g.7674238C>T | UniProt,dbSNP |
VAR_045224 | p.Cys242Tyr | missense variant | - | NC_000017.11:g.7674238C>T | UniProt |
rs121912655 | p.Cys242Tyr | missense variant | - | NC_000017.11:g.7674238C>T | ExAC,TOPMed,gnomAD |
RCV000432990 | p.Cys242Trp | missense variant | Carcinoma of esophagus | NC_000017.11:g.7674237G>C | ClinVar |
RCV000422298 | p.Cys242Trp | missense variant | Glioblastoma | NC_000017.11:g.7674237G>C | ClinVar |
RCV000420256 | p.Cys242Trp | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7674237G>C | ClinVar |
RCV000442778 | p.Cys242Trp | missense variant | Neoplasm of the breast | NC_000017.11:g.7674237G>C | ClinVar |
RCV000430938 | p.Cys242Trp | missense variant | Squamous cell lung carcinoma | NC_000017.11:g.7674237G>C | ClinVar |
RCV000420917 | p.Cys242Trp | missense variant | Hepatocellular carcinoma (HCC) | NC_000017.11:g.7674237G>C | ClinVar |
VAR_045221 | p.Cys242Arg | Missense | - | - | UniProt |
rs730882006 | p.Met243Thr | missense variant | - | NC_000017.11:g.7674235A>G | - |
RCV000464185 | p.Met243Val | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674236T>C | ClinVar |
RCV000562254 | p.Met243Val | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7674236T>C | ClinVar |
RCV000166281 | p.Met243Leu | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7674236T>G | ClinVar |
RCV000222280 | p.Met243Thr | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7674235A>G | ClinVar |
NCI-TCGA novel | p.Met243Ter | frameshift | - | NC_000017.11:g.7674227_7674236TGCCGCCCAT>- | NCI-TCGA |
rs786203117 | p.Met243Leu | missense variant | - | NC_000017.11:g.7674236T>G | TOPMed |
rs786203117 | p.Met243Val | missense variant | - | NC_000017.11:g.7674236T>C | UniProt,dbSNP |
VAR_045230 | p.Met243Val | missense variant | - | NC_000017.11:g.7674236T>C | UniProt |
rs786203117 | p.Met243Val | missense variant | - | NC_000017.11:g.7674236T>C | TOPMed |
rs786203117 | p.Met243Leu | missense variant | - | NC_000017.11:g.7674236T>A | UniProt,dbSNP |
VAR_045227 | p.Met243Leu | missense variant | - | NC_000017.11:g.7674236T>A | UniProt |
rs786203117 | p.Met243Leu | missense variant | - | NC_000017.11:g.7674236T>A | TOPMed |
VAR_045225 | p.Met243Ile | Missense | - | - | UniProt |
VAR_045226 | p.Met243Lys | Missense | - | - | UniProt |
VAR_047184 | p.Met243_Gly244delinsIleCys | deletion_insertion | - | - | UniProt |
VAR_047185 | p.Met243_Gly244delinsIleSer | deletion_insertion | - | - | UniProt |
VAR_045228 | p.Met243Arg | Missense | - | - | UniProt |
rs985033810 | p.Gly244Ala | missense variant | - | NC_000017.11:g.7674232C>G | - |
RCV000428522 | p.Gly244Val | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7674232C>A | ClinVar |
RCV000443964 | p.Gly244Val | missense variant | Carcinoma of esophagus | NC_000017.11:g.7674232C>A | ClinVar |
RCV000424520 | p.Gly244Arg | missense variant | Neoplasm of the large intestine | NC_000017.11:g.7674233C>G | ClinVar |
RCV000418001 | p.Gly244Arg | missense variant | Glioblastoma | NC_000017.11:g.7674233C>G | ClinVar |
RCV000423073 | p.Gly244Val | missense variant | Squamous cell lung carcinoma | NC_000017.11:g.7674232C>A | ClinVar |
RCV000432729 | p.Gly244Arg | missense variant | Malignant neoplasm of body of uterus | NC_000017.11:g.7674233C>G | ClinVar |
RCV000434977 | p.Gly244Val | missense variant | Small cell lung cancer | NC_000017.11:g.7674232C>A | ClinVar |
RCV000417831 | p.Gly244Val | missense variant | Neoplasm of brain | NC_000017.11:g.7674232C>A | ClinVar |
RCV000435229 | p.Gly244Arg | missense variant | Uterine Carcinosarcoma | NC_000017.11:g.7674233C>G | ClinVar |
RCV000443153 | p.Gly244Arg | missense variant | Small cell lung cancer | NC_000017.11:g.7674233C>G | ClinVar |
RCV000419267 | p.Gly244Arg | missense variant | Adenocarcinoma of stomach | NC_000017.11:g.7674233C>G | ClinVar |
RCV000785338 | p.Gly244Val | missense variant | Ovarian Neoplasms | NC_000017.11:g.7674232C>A | ClinVar |
RCV000424338 | p.Gly244Val | missense variant | Glioblastoma | NC_000017.11:g.7674232C>A | ClinVar |
RCV000431028 | p.Gly244Arg | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7674233C>G | ClinVar |
RCV000433805 | p.Gly244Val | missense variant | Malignant neoplasm of body of uterus | NC_000017.11:g.7674232C>A | ClinVar |
RCV000420351 | p.Gly244Arg | missense variant | Neoplasm of brain | NC_000017.11:g.7674233C>G | ClinVar |
RCV000548437 | p.Gly244Ala | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674232C>G | ClinVar |
RCV000433321 | p.Gly244Val | missense variant | Adenocarcinoma of stomach | NC_000017.11:g.7674232C>A | ClinVar |
RCV000438254 | p.Gly244Arg | missense variant | Squamous cell lung carcinoma | NC_000017.11:g.7674233C>G | ClinVar |
RCV000439173 | p.Gly244Val | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7674232C>A | ClinVar |
RCV000440310 | p.Gly244Val | missense variant | Lung adenocarcinoma | NC_000017.11:g.7674232C>A | ClinVar |
RCV000420188 | p.Gly244Val | missense variant | Hepatocellular carcinoma (HCC) | NC_000017.11:g.7674232C>A | ClinVar |
RCV000430897 | p.Gly244Val | missense variant | Neoplasm of the large intestine | NC_000017.11:g.7674232C>A | ClinVar |
RCV000633372 | p.Gly244Ser | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674233C>T | ClinVar |
RCV000430145 | p.Gly244Arg | missense variant | Carcinoma of esophagus | NC_000017.11:g.7674233C>G | ClinVar |
RCV000437599 | p.Gly244Arg | missense variant | Hepatocellular carcinoma (HCC) | NC_000017.11:g.7674233C>G | ClinVar |
RCV000538079 | p.Gly244Cys | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674233C>A | ClinVar |
COSM4603840 | p.Gly244AlaPheSerTerUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7674232C>- | NCI-TCGA Cosmic |
COSM111715 | p.Gly244Val | inframe deletion | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7674227_7674232TGCCGC>- | NCI-TCGA Cosmic |
rs985033810 | p.Gly244Asp | missense variant | - | NC_000017.11:g.7674232C>T | - |
NCI-TCGA novel | p.Gly244Ter | frameshift | - | NC_000017.11:g.7674227_7674233TGCCGCC>- | NCI-TCGA |
rs1057519989 | p.Gly244Cys | missense variant | - | NC_000017.11:g.7674233C>A | UniProt,dbSNP |
VAR_045231 | p.Gly244Cys | missense variant | - | NC_000017.11:g.7674233C>A | UniProt |
rs1057519989 | p.Gly244Arg | missense variant | - | NC_000017.11:g.7674233C>G | UniProt,dbSNP |
VAR_045234 | p.Gly244Arg | missense variant | - | NC_000017.11:g.7674233C>G | UniProt |
rs1057519989 | p.Gly244Ser | missense variant | - | NC_000017.11:g.7674233C>T | UniProt,dbSNP |
VAR_045235 | p.Gly244Ser | missense variant | - | NC_000017.11:g.7674233C>T | UniProt |
RCV000425485 | p.Gly244Arg | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7674233C>G | ClinVar |
RCV000425133 | p.Gly244Arg | missense variant | Lung adenocarcinoma | NC_000017.11:g.7674233C>G | ClinVar |
RCV000477083 | p.Gly244Asp | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674232C>T | ClinVar |
RCV000441607 | p.Gly244Val | missense variant | Uterine Carcinosarcoma | NC_000017.11:g.7674232C>A | ClinVar |
VAR_045233 | p.Gly244Glu | Missense | - | - | UniProt |
rs28934575 | p.Gly245Ser | missense variant | Li-fraumeni syndrome 1 (lfs1) | NC_000017.11:g.7674230C>T | ESP,ExAC,TOPMed,gnomAD |
rs28934575 | p.Gly245Cys | missense variant | - | NC_000017.11:g.7674230C>A | ESP,ExAC,TOPMed,gnomAD |
rs121912656 | p.Gly245Asp | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674229C>T | UniProt,dbSNP |
VAR_005973 | p.Gly245Asp | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674229C>T | UniProt |
rs121912656 | p.Gly245Asp | missense variant | Li-fraumeni syndrome 1 (lfs1) | NC_000017.11:g.7674229C>T | ExAC,gnomAD |
rs28934575 | p.Gly245Arg | missense variant | Li-fraumeni syndrome 1 (lfs1) | NC_000017.11:g.7674230C>G | ESP,ExAC,TOPMed,gnomAD |
RCV000443435 | p.Gly245Cys | missense variant | Neoplasm of the large intestine | NC_000017.11:g.7674230C>A | ClinVar |
RCV000436979 | p.Gly245Ser | missense variant | Neoplasm of the breast | NC_000017.11:g.7674230C>T | ClinVar |
RCV000419737 | p.Gly245Cys | missense variant | Neoplasm of the breast | NC_000017.11:g.7674230C>A | ClinVar |
RCV000425581 | p.Gly245Ser | missense variant | Neoplasm | NC_000017.11:g.7674230C>T | ClinVar |
RCV000420452 | p.Gly245Ser | missense variant | Glioblastoma | NC_000017.11:g.7674230C>T | ClinVar |
RCV000423577 | p.Gly245Cys | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7674230C>A | ClinVar |
RCV000432898 | p.Gly245Ser | missense variant | - | NC_000017.11:g.7674230C>T | ClinVar |
RCV000428537 | p.Gly245Ala | missense variant | - | NC_000017.11:g.7674229C>G | ClinVar |
RCV000418643 | p.Gly245Val | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7674229C>A | ClinVar |
RCV000432804 | p.Gly245Ala | missense variant | Carcinoma of esophagus | NC_000017.11:g.7674229C>G | ClinVar |
RCV000436773 | p.Gly245Ala | missense variant | Squamous cell lung carcinoma | NC_000017.11:g.7674229C>G | ClinVar |
RCV000438982 | p.Gly245Val | missense variant | Lung adenocarcinoma | NC_000017.11:g.7674229C>A | ClinVar |
RCV000431752 | p.Gly245Ala | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7674229C>G | ClinVar |
RCV000420237 | p.Gly245Ala | missense variant | Hepatocellular carcinoma (HCC) | NC_000017.11:g.7674229C>G | ClinVar |
RCV000426521 | p.Gly245Ala | missense variant | Glioblastoma | NC_000017.11:g.7674229C>G | ClinVar |
RCV000435854 | p.Gly245Val | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7674229C>A | ClinVar |
RCV000434145 | p.Gly245Val | missense variant | Carcinoma of esophagus | NC_000017.11:g.7674229C>A | ClinVar |
RCV000438479 | p.Gly245Ala | missense variant | Adenocarcinoma of prostate | NC_000017.11:g.7674229C>G | ClinVar |
RCV000422531 | p.Gly245Ala | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7674229C>G | ClinVar |
RCV000430431 | p.Gly245Val | missense variant | - | NC_000017.11:g.7674229C>A | ClinVar |
RCV000443789 | p.Gly245Ala | missense variant | Uterine Carcinosarcoma | NC_000017.11:g.7674229C>G | ClinVar |
RCV000443716 | p.Gly245Val | missense variant | Squamous cell lung carcinoma | NC_000017.11:g.7674229C>A | ClinVar |
RCV000439974 | p.Gly245Val | missense variant | Neoplasm of the breast | NC_000017.11:g.7674229C>A | ClinVar |
RCV000013149 | p.Gly245Asp | missense variant | Li-Fraumeni syndrome 1 (LFS) | NC_000017.11:g.7674229C>T | ClinVar |
RCV000164465 | p.Gly245Asp | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7674229C>T | ClinVar |
RCV000421477 | p.Gly245Ala | missense variant | Neoplasm of brain | NC_000017.11:g.7674229C>G | ClinVar |
RCV000206683 | p.Gly245Asp | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674229C>T | ClinVar |
RCV000437884 | p.Gly245Ala | missense variant | Adenocarcinoma of stomach | NC_000017.11:g.7674229C>G | ClinVar |
RCV000444483 | p.Gly245Val | missense variant | - | NC_000017.11:g.7674229C>A | ClinVar |
RCV000434833 | p.Gly245Val | missense variant | Adenocarcinoma of prostate | NC_000017.11:g.7674229C>A | ClinVar |
RCV000428216 | p.Gly245Val | missense variant | Neoplasm of the large intestine | NC_000017.11:g.7674229C>A | ClinVar |
RCV000558455 | p.Gly245Val | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674229C>A | ClinVar |
RCV000427619 | p.Gly245Ala | missense variant | - | NC_000017.11:g.7674229C>G | ClinVar |
RCV000429303 | p.Gly245Val | missense variant | Uterine Carcinosarcoma | NC_000017.11:g.7674229C>A | ClinVar |
RCV000425368 | p.Gly245Ala | missense variant | Neoplasm of the breast | NC_000017.11:g.7674229C>G | ClinVar |
RCV000255018 | p.Gly245Ala | missense variant | - | NC_000017.11:g.7674229C>G | ClinVar |
RCV000443845 | p.Gly245Ala | missense variant | Neoplasm of the large intestine | NC_000017.11:g.7674229C>G | ClinVar |
RCV000421739 | p.Gly245Val | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7674229C>A | ClinVar |
RCV000426568 | p.Gly245Val | missense variant | Glioblastoma | NC_000017.11:g.7674229C>A | ClinVar |
RCV000437258 | p.Gly245Val | missense variant | Hepatocellular carcinoma (HCC) | NC_000017.11:g.7674229C>A | ClinVar |
RCV000421020 | p.Gly245Val | missense variant | Adenocarcinoma of stomach | NC_000017.11:g.7674229C>A | ClinVar |
RCV000442824 | p.Gly245Ala | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7674229C>G | ClinVar |
RCV000424123 | p.Gly245Val | missense variant | Neoplasm of brain | NC_000017.11:g.7674229C>A | ClinVar |
RCV000433958 | p.Gly245Ala | missense variant | Lung adenocarcinoma | NC_000017.11:g.7674229C>G | ClinVar |
RCV000441334 | p.Gly245Cys | missense variant | Hepatocellular carcinoma (HCC) | NC_000017.11:g.7674230C>A | ClinVar |
RCV000428113 | p.Gly245Ser | missense variant | Carcinoma of esophagus | NC_000017.11:g.7674230C>T | ClinVar |
RCV000438801 | p.Gly245Ser | missense variant | Hepatocellular carcinoma (HCC) | NC_000017.11:g.7674230C>T | ClinVar |
RCV000434535 | p.Gly245Cys | missense variant | - | NC_000017.11:g.7674230C>A | ClinVar |
RCV000633351 | p.Gly245Arg | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674230C>G | ClinVar |
RCV000417419 | p.Gly245Ser | missense variant | Adenocarcinoma of prostate | NC_000017.11:g.7674230C>T | ClinVar |
RCV000426990 | p.Gly245Ser | missense variant | Squamous cell lung carcinoma | NC_000017.11:g.7674230C>T | ClinVar |
RCV000430002 | p.Gly245Cys | missense variant | Adenocarcinoma of prostate | NC_000017.11:g.7674230C>A | ClinVar |
rs28934575 | p.Gly245Ser | missense variant | - | NC_000017.11:g.7674230C>T | ESP,ExAC,TOPMed,gnomAD |
rs121912656 | p.Gly245Ala | missense variant | Li-fraumeni syndrome 1 (lfs1) | NC_000017.11:g.7674229C>G | ExAC,gnomAD |
rs28934575 | p.Gly245Cys | missense variant | Li-fraumeni syndrome 1 (lfs1) | NC_000017.11:g.7674230C>A | ESP,ExAC,TOPMed,gnomAD |
rs28934575 | p.Gly245Cys | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674230C>A | UniProt,dbSNP |
VAR_005972 | p.Gly245Cys | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674230C>A | UniProt |
rs121912656 | p.Gly245Ala | missense variant | - | NC_000017.11:g.7674229C>G | UniProt,dbSNP |
VAR_005971 | p.Gly245Ala | missense variant | - | NC_000017.11:g.7674229C>G | UniProt |
rs28934575 | p.Gly245Arg | missense variant | - | NC_000017.11:g.7674230C>G | ESP,ExAC,TOPMed,gnomAD |
rs28934575 | p.Gly245Arg | missense variant | - | NC_000017.11:g.7674230C>G | UniProt,dbSNP |
VAR_045238 | p.Gly245Arg | missense variant | - | NC_000017.11:g.7674230C>G | UniProt |
rs121912656 | p.Gly245Val | missense variant | Li-fraumeni syndrome 1 (lfs1) | NC_000017.11:g.7674229C>A | ExAC,gnomAD |
rs28934575 | p.Gly245Ser | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674230C>T | UniProt,dbSNP |
VAR_005974 | p.Gly245Ser | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674230C>T | UniProt |
RCV000419767 | p.Gly245Ser | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7674230C>T | ClinVar |
RCV000426307 | p.Gly245Ser | missense variant | Uterine Carcinosarcoma | NC_000017.11:g.7674230C>T | ClinVar |
RCV000440886 | p.Gly245Cys | missense variant | Neoplasm of brain | NC_000017.11:g.7674230C>A | ClinVar |
RCV000148909 | p.Gly245Ser | missense variant | Adenocarcinoma | NC_000017.11:g.7674230C>T | ClinVar |
RCV000425471 | p.Gly245Cys | missense variant | Glioblastoma | NC_000017.11:g.7674230C>A | ClinVar |
RCV000418673 | p.Gly245Cys | missense variant | Lung adenocarcinoma | NC_000017.11:g.7674230C>A | ClinVar |
RCV000417593 | p.Gly245Cys | missense variant | Uterine Carcinosarcoma | NC_000017.11:g.7674230C>A | ClinVar |
RCV000785316 | p.Gly245Ser | missense variant | Ovarian Neoplasms | NC_000017.11:g.7674230C>T | ClinVar |
rs121912656 | p.Gly245Val | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674229C>A | UniProt,dbSNP |
VAR_005975 | p.Gly245Val | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674229C>A | UniProt |
RCV000421457 | p.Gly245Ser | missense variant | Lung adenocarcinoma | NC_000017.11:g.7674230C>T | ClinVar |
RCV000426090 | p.Gly245Cys | missense variant | - | NC_000017.11:g.7674230C>A | ClinVar |
RCV000442506 | p.Gly245Ser | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7674230C>T | ClinVar |
RCV000440197 | p.Gly245Cys | missense variant | Carcinoma of esophagus | NC_000017.11:g.7674230C>A | ClinVar |
RCV000442529 | p.Gly245Ser | missense variant | Neoplasm of the large intestine | NC_000017.11:g.7674230C>T | ClinVar |
RCV000424262 | p.Gly245Cys | missense variant | Adenocarcinoma of stomach | NC_000017.11:g.7674230C>A | ClinVar |
RCV000428895 | p.Gly245Cys | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7674230C>A | ClinVar |
RCV000430925 | p.Gly245Ser | missense variant | Neoplasm of brain | NC_000017.11:g.7674230C>T | ClinVar |
RCV000437643 | p.Gly245Ser | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7674230C>T | ClinVar |
RCV000436330 | p.Gly245Cys | missense variant | Squamous cell lung carcinoma | NC_000017.11:g.7674230C>A | ClinVar |
RCV000436186 | p.Gly245Cys | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7674230C>A | ClinVar |
RCV000432120 | p.Gly245Ser | missense variant | Adenocarcinoma of stomach | NC_000017.11:g.7674230C>T | ClinVar |
RCV000438107 | p.Gly245Ser | missense variant | - | NC_000017.11:g.7674230C>T | ClinVar |
VAR_045851 | p.Gly245Phe | Missense | - | - | UniProt |
VAR_045853 | p.Gly245Leu | Missense | - | - | UniProt |
VAR_045854 | p.Gly245Asn | Missense | - | - | UniProt |
VAR_045852 | p.Gly245His | Missense | - | - | UniProt |
VAR_045237 | p.Gly245Glu | Missense | - | - | UniProt |
rs1019340046 | p.Met246Ile | missense variant | - | NC_000017.11:g.7674225C>T | TOPMed |
RCV000561491 | p.Met246Ile | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7674225C>T | ClinVar |
COSM10757 | p.Met246Ile | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7674225C>G | NCI-TCGA Cosmic |
COSM46136 | p.Met246Ile | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7674225C>A | NCI-TCGA Cosmic |
RCV000492075 | p.Met246Thr | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7674226A>G | ClinVar |
RCV000797952 | p.Met246Lys | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674226A>T | ClinVar |
RCV000166380 | p.Met246Leu | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7674227T>G | ClinVar |
rs587780074 | p.Met246Thr | missense variant | - | NC_000017.11:g.7674226A>G | UniProt,dbSNP |
VAR_005977 | p.Met246Thr | missense variant | - | NC_000017.11:g.7674226A>G | UniProt |
rs483352695 | p.Met246Leu | missense variant | - | NC_000017.11:g.7674227T>G | UniProt,dbSNP |
VAR_044020 | p.Met246Leu | missense variant | - | NC_000017.11:g.7674227T>G | UniProt |
rs483352695 | p.Met246Val | missense variant | - | NC_000017.11:g.7674227T>C | - |
rs483352695 | p.Met246Val | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674227T>C | UniProt,dbSNP |
VAR_005978 | p.Met246Val | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674227T>C | UniProt |
rs587780074 | p.Met246Arg | missense variant | - | NC_000017.11:g.7674226A>C | UniProt,dbSNP |
VAR_005976 | p.Met246Arg | missense variant | - | NC_000017.11:g.7674226A>C | UniProt |
RCV000470073 | p.Met246Leu | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674227T>A | ClinVar |
RCV000161036 | p.Met246Val | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7674227T>C | ClinVar |
RCV000574219 | p.Met246Lys | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7674226A>T | ClinVar |
RCV000785245 | p.Met246Thr | missense variant | Ovarian Neoplasms | NC_000017.11:g.7674226A>G | ClinVar |
RCV000115734 | p.Met246Arg | missense variant | - | NC_000017.11:g.7674226A>C | ClinVar |
VAR_045240 | p.Met246Lys | Missense | - | - | UniProt |
rs786201762 | p.Asn247Ser | missense variant | - | NC_000017.11:g.7674223T>C | UniProt,dbSNP |
VAR_045243 | p.Asn247Ser | missense variant | - | NC_000017.11:g.7674223T>C | UniProt |
RCV000457243 | p.Asn247Ser | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674223T>C | ClinVar |
RCV000785503 | p.Asn247Ile | missense variant | Ovarian Neoplasms | NC_000017.11:g.7674223T>A | ClinVar |
rs786201762 | p.Asn247Ile | missense variant | - | NC_000017.11:g.7674223T>A | UniProt,dbSNP |
VAR_005980 | p.Asn247Ile | missense variant | - | NC_000017.11:g.7674223T>A | UniProt |
rs1555525498 | p.AsnArg247AsnTrp | missense variant | - | NC_000017.11:g.7674221_7674222delinsAA | - |
VAR_045855 | p.Asn247Phe | Missense | - | - | UniProt |
VAR_047187 | p.Asn247_Arg248delinsIlePro | deletion_insertion | - | - | UniProt |
VAR_047188 | p.Asn247_Arg248delinsLysTrp | deletion_insertion | - | - | UniProt |
VAR_045242 | p.Asn247Lys | Missense | - | - | UniProt |
VAR_047189 | p.Asn247Thr | Missense | - | - | UniProt |
VAR_045244 | p.Asn247Tyr | Missense | - | - | UniProt |
rs121912651 | p.Arg248Gly | missense variant | - | NC_000017.11:g.7674221G>C | UniProt,dbSNP |
VAR_005981 | p.Arg248Gly | missense variant | - | NC_000017.11:g.7674221G>C | UniProt |
rs11540652 | p.Arg248Leu | missense variant | Li-fraumeni syndrome 1 (lfs1) | NC_000017.11:g.7674220C>A | ESP,ExAC,TOPMed,gnomAD |
rs11540652 | p.Arg248Gln | missense variant | Li-fraumeni syndrome 1 (lfs1) | NC_000017.11:g.7674220C>T | ESP,ExAC,TOPMed,gnomAD |
RCV000424308 | p.Arg248Trp | missense variant | - | NC_000017.11:g.7674221G>A | ClinVar |
RCV000418495 | p.Arg248Trp | missense variant | Acute myeloid leukemia (AML) | NC_000017.11:g.7674221G>A | ClinVar |
RCV000418894 | p.Arg248Pro | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7674220C>G | ClinVar |
RCV000420292 | p.Arg248Pro | missense variant | Adenocarcinoma of stomach | NC_000017.11:g.7674220C>G | ClinVar |
RCV000425782 | p.Arg248Gly | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7674221G>C | ClinVar |
RCV000422821 | p.Arg248Leu | missense variant | Squamous cell lung carcinoma | NC_000017.11:g.7674220C>A | ClinVar |
RCV000437940 | p.Arg248Leu | missense variant | Neoplasm of the breast | NC_000017.11:g.7674220C>A | ClinVar |
RCV000423159 | p.Arg248Leu | missense variant | - | NC_000017.11:g.7674220C>A | ClinVar |
RCV000443712 | p.Arg248Leu | missense variant | Malignant melanoma of skin (CMM) | NC_000017.11:g.7674220C>A | ClinVar |
RCV000434177 | p.Arg248Leu | missense variant | Small cell lung cancer | NC_000017.11:g.7674220C>A | ClinVar |
RCV000430964 | p.Arg248Pro | missense variant | - | NC_000017.11:g.7674220C>G | ClinVar |
RCV000423468 | p.Arg248Leu | missense variant | Medulloblastoma (MDB) | NC_000017.11:g.7674220C>A | ClinVar |
RCV000432999 | p.Arg248Pro | missense variant | Neoplasm of the large intestine | NC_000017.11:g.7674220C>G | ClinVar |
RCV000438849 | p.Arg248Pro | missense variant | Chronic lymphocytic leukemia (CLL) | NC_000017.11:g.7674220C>G | ClinVar |
RCV000445077 | p.Arg248Pro | missense variant | Hepatocellular carcinoma (HCC) | NC_000017.11:g.7674220C>G | ClinVar |
RCV000444130 | p.Arg248Pro | missense variant | Lung adenocarcinoma | NC_000017.11:g.7674220C>G | ClinVar |
RCV000420936 | p.Arg248Pro | missense variant | Uterine Carcinosarcoma | NC_000017.11:g.7674220C>G | ClinVar |
RCV000115736 | p.Arg248Gln | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7674220C>T | ClinVar |
RCV000435488 | p.Arg248Pro | missense variant | Squamous cell lung carcinoma | NC_000017.11:g.7674220C>G | ClinVar |
RCV000428586 | p.Arg248Leu | missense variant | Lung adenocarcinoma | NC_000017.11:g.7674220C>A | ClinVar |
RCV000424394 | p.Arg248Leu | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7674220C>A | ClinVar |
RCV000443630 | p.Arg248Leu | missense variant | Glioblastoma | NC_000017.11:g.7674220C>A | ClinVar |
RCV000441018 | p.Arg248Pro | missense variant | Acute myeloid leukemia (AML) | NC_000017.11:g.7674220C>G | ClinVar |
RCV000439516 | p.Arg248Leu | missense variant | Carcinoma of esophagus | NC_000017.11:g.7674220C>A | ClinVar |
RCV000424119 | p.Arg248Leu | missense variant | Myelodysplastic syndrome (MDS) | NC_000017.11:g.7674220C>A | ClinVar |
RCV000432304 | p.Arg248Pro | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7674220C>G | ClinVar |
RCV000441674 | p.Arg248Pro | missense variant | Carcinoma of esophagus | NC_000017.11:g.7674220C>G | ClinVar |
RCV000444805 | p.Arg248Pro | missense variant | Small cell lung cancer | NC_000017.11:g.7674220C>G | ClinVar |
RCV000419857 | p.Arg248Trp | missense variant | Small cell lung cancer | NC_000017.11:g.7674221G>A | ClinVar |
RCV000419032 | p.Arg248Trp | missense variant | Lung adenocarcinoma | NC_000017.11:g.7674221G>A | ClinVar |
RCV000633396 | p.Arg248Gly | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674221G>C | ClinVar |
RCV000425773 | p.Arg248Pro | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7674220C>G | ClinVar |
RCV000229442 | p.Arg248Pro | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674220C>G | ClinVar |
RCV000419610 | p.Arg248Pro | missense variant | Multiple myeloma (MM) | NC_000017.11:g.7674220C>G | ClinVar |
RCV000426089 | p.Arg248Pro | missense variant | Neoplasm of brain | NC_000017.11:g.7674220C>G | ClinVar |
RCV000433865 | p.Arg248Leu | missense variant | Adenocarcinoma of stomach | NC_000017.11:g.7674220C>A | ClinVar |
RCV000440422 | p.Arg248Trp | missense variant | Neoplasm of the large intestine | NC_000017.11:g.7674221G>A | ClinVar |
RCV000438698 | p.Arg248Trp | missense variant | Neoplasm | NC_000017.11:g.7674221G>A | ClinVar |
RCV000444356 | p.Arg248Gly | missense variant | Glioblastoma | NC_000017.11:g.7674221G>C | ClinVar |
RCV000418531 | p.Arg248Leu | missense variant | - | NC_000017.11:g.7674220C>A | ClinVar |
RCV000435803 | p.Arg248Trp | missense variant | Hepatocellular carcinoma (HCC) | NC_000017.11:g.7674221G>A | ClinVar |
RCV000425394 | p.Arg248Gly | missense variant | - | NC_000017.11:g.7674221G>C | ClinVar |
RCV000445145 | p.Arg248Leu | missense variant | Adenocarcinoma of prostate | NC_000017.11:g.7674220C>A | ClinVar |
RCV000429221 | p.Arg248Leu | missense variant | Acute myeloid leukemia (AML) | NC_000017.11:g.7674220C>A | ClinVar |
RCV000443867 | p.Arg248Pro | missense variant | - | NC_000017.11:g.7674220C>G | ClinVar |
RCV000434831 | p.Arg248Pro | missense variant | Neoplasm of the breast | NC_000017.11:g.7674220C>G | ClinVar |
RCV000424795 | p.Arg248Pro | missense variant | Myelodysplastic syndrome (MDS) | NC_000017.11:g.7674220C>G | ClinVar |
RCV000430044 | p.Arg248Leu | missense variant | Chronic lymphocytic leukemia (CLL) | NC_000017.11:g.7674220C>A | ClinVar |
RCV000219834 | p.Arg248Leu | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7674220C>A | ClinVar |
RCV000440686 | p.Arg248Leu | missense variant | Neoplasm of the large intestine | NC_000017.11:g.7674220C>A | ClinVar |
RCV000431663 | p.Arg248Pro | missense variant | Glioblastoma | NC_000017.11:g.7674220C>G | ClinVar |
RCV000444845 | p.Arg248Trp | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7674221G>A | ClinVar |
RCV000433611 | p.Arg248Gly | missense variant | Small cell lung cancer | NC_000017.11:g.7674221G>C | ClinVar |
RCV000445266 | p.Arg248Leu | missense variant | Malignant neoplasm of body of uterus | NC_000017.11:g.7674220C>A | ClinVar |
RCV000441010 | p.Arg248Gly | missense variant | Hepatocellular carcinoma (HCC) | NC_000017.11:g.7674221G>C | ClinVar |
RCV000436398 | p.Arg248Trp | missense variant | - | NC_000017.11:g.7674221G>A | ClinVar |
RCV000431689 | p.Arg248Trp | missense variant | Uterine Carcinosarcoma | NC_000017.11:g.7674221G>A | ClinVar |
RCV000427948 | p.Arg248Gly | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7674221G>C | ClinVar |
RCV000430543 | p.Arg248Trp | missense variant | Adenocarcinoma of stomach | NC_000017.11:g.7674221G>A | ClinVar |
RCV000431508 | p.Arg248Trp | missense variant | Multiple myeloma (MM) | NC_000017.11:g.7674221G>A | ClinVar |
RCV000434504 | p.Arg248Trp | missense variant | Squamous cell lung carcinoma | NC_000017.11:g.7674221G>A | ClinVar |
RCV000422668 | p.Arg248Gly | missense variant | Neoplasm of the large intestine | NC_000017.11:g.7674221G>C | ClinVar |
RCV000442243 | p.Arg248Trp | missense variant | Malignant melanoma of skin (CMM) | NC_000017.11:g.7674221G>A | ClinVar |
RCV000440560 | p.Arg248Trp | missense variant | Medulloblastoma (MDB) | NC_000017.11:g.7674221G>A | ClinVar |
RCV000440334 | p.Arg248Gly | missense variant | Medulloblastoma (MDB) | NC_000017.11:g.7674221G>C | ClinVar |
RCV000425100 | p.Arg248Gly | missense variant | Chronic lymphocytic leukemia (CLL) | NC_000017.11:g.7674221G>C | ClinVar |
RCV000424776 | p.Arg248Gly | missense variant | Multiple myeloma (MM) | NC_000017.11:g.7674221G>C | ClinVar |
RCV000419150 | p.Arg248Trp | missense variant | Glioblastoma | NC_000017.11:g.7674221G>A | ClinVar |
RCV000436038 | p.Arg248Gly | missense variant | Neoplasm of brain | NC_000017.11:g.7674221G>C | ClinVar |
RCV000425083 | p.Arg248Trp | missense variant | Myelodysplastic syndrome (MDS) | NC_000017.11:g.7674221G>A | ClinVar |
RCV000423804 | p.Arg248Trp | missense variant | Chronic lymphocytic leukemia (CLL) | NC_000017.11:g.7674221G>A | ClinVar |
RCV000433905 | p.Arg248Trp | missense variant | Neoplasm of brain | NC_000017.11:g.7674221G>A | ClinVar |
RCV000435050 | p.Arg248Gly | missense variant | Acute myeloid leukemia (AML) | NC_000017.11:g.7674221G>C | ClinVar |
RCV000432931 | p.Arg248Gly | missense variant | Myelodysplastic syndrome (MDS) | NC_000017.11:g.7674221G>C | ClinVar |
RCV000444427 | p.Arg248Gly | missense variant | - | NC_000017.11:g.7674221G>C | ClinVar |
RCV000437882 | p.Arg248Gly | missense variant | Adenocarcinoma of prostate | NC_000017.11:g.7674221G>C | ClinVar |
RCV000441557 | p.Arg248Trp | missense variant | - | NC_000017.11:g.7674221G>A | ClinVar |
RCV000444519 | p.Arg248Gly | missense variant | Lung adenocarcinoma | NC_000017.11:g.7674221G>C | ClinVar |
RCV000441091 | p.Arg248Trp | missense variant | Malignant neoplasm of body of uterus | NC_000017.11:g.7674221G>A | ClinVar |
RCV000430735 | p.Arg248Gly | missense variant | - | NC_000017.11:g.7674221G>C | ClinVar |
RCV000432207 | p.Arg248Gly | missense variant | Malignant neoplasm of body of uterus | NC_000017.11:g.7674221G>C | ClinVar |
RCV000424415 | p.Arg248Trp | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7674221G>A | ClinVar |
RCV000420498 | p.Arg248Gly | missense variant | Neoplasm of the breast | NC_000017.11:g.7674221G>C | ClinVar |
RCV000425682 | p.Arg248Trp | missense variant | Adenocarcinoma of prostate | NC_000017.11:g.7674221G>A | ClinVar |
RCV000429777 | p.Arg248Trp | missense variant | Neoplasm of the breast | NC_000017.11:g.7674221G>A | ClinVar |
RCV000423184 | p.Arg248Trp | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7674221G>A | ClinVar |
RCV000626118 | p.Arg248Gly | missense variant | Carcinoma of colon (CRC) | NC_000017.11:g.7674221G>C | ClinVar |
RCV000435353 | p.Arg248Gly | missense variant | Carcinoma of esophagus | NC_000017.11:g.7674221G>C | ClinVar |
RCV000441711 | p.Arg248Gly | missense variant | Adenocarcinoma of stomach | NC_000017.11:g.7674221G>C | ClinVar |
RCV000785485 | p.Arg248Trp | missense variant | Ovarian Neoplasms | NC_000017.11:g.7674221G>A | ClinVar |
RCV000423297 | p.Arg248Gly | missense variant | Squamous cell lung carcinoma | NC_000017.11:g.7674221G>C | ClinVar |
RCV000429884 | p.Arg248Trp | missense variant | Carcinoma of esophagus | NC_000017.11:g.7674221G>A | ClinVar |
RCV000417693 | p.Arg248Gly | missense variant | Uterine Carcinosarcoma | NC_000017.11:g.7674221G>C | ClinVar |
RCV000418362 | p.Arg248Gly | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7674221G>C | ClinVar |
RCV000427544 | p.Arg248Gly | missense variant | Malignant melanoma of skin (CMM) | NC_000017.11:g.7674221G>C | ClinVar |
rs121912651 | p.Arg248Trp | missense variant | Li-fraumeni syndrome 1 (lfs1) | NC_000017.11:g.7674221G>A | ExAC,gnomAD |
NCI-TCGA novel | p.Arg248HisPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7674213_7674220GGGCCTCC>- | NCI-TCGA |
rs11540652 | p.Arg248Pro | missense variant | Li-fraumeni syndrome 1 (lfs1) | NC_000017.11:g.7674220C>G | ESP,ExAC,TOPMed,gnomAD |
rs121912651 | p.Arg248Trp | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674221G>A | UniProt,dbSNP |
VAR_005984 | p.Arg248Trp | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674221G>A | UniProt |
rs121912651 | p.Arg248Gly | missense variant | Li-fraumeni syndrome 1 (lfs1) | NC_000017.11:g.7674221G>C | ExAC,gnomAD |
RCV000417894 | p.Arg248Leu | missense variant | Uterine Carcinosarcoma | NC_000017.11:g.7674220C>A | ClinVar |
RCV000436124 | p.Arg248Pro | missense variant | - | NC_000017.11:g.7674220C>G | ClinVar |
RCV000422303 | p.Arg248Leu | missense variant | Neoplasm of brain | NC_000017.11:g.7674220C>A | ClinVar |
RCV000433237 | p.Arg248Leu | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7674220C>A | ClinVar |
RCV000421633 | p.Arg248Pro | missense variant | Malignant neoplasm of body of uterus | NC_000017.11:g.7674220C>G | ClinVar |
RCV000439901 | p.Arg248Leu | missense variant | Multiple myeloma (MM) | NC_000017.11:g.7674220C>A | ClinVar |
RCV000430314 | p.Arg248Pro | missense variant | Malignant melanoma of skin (CMM) | NC_000017.11:g.7674220C>G | ClinVar |
RCV000435726 | p.Arg248Leu | missense variant | Hepatocellular carcinoma (HCC) | NC_000017.11:g.7674220C>A | ClinVar |
RCV000435101 | p.Arg248Leu | missense variant | - | NC_000017.11:g.7674220C>A | ClinVar |
RCV000425414 | p.Arg248Pro | missense variant | Adenocarcinoma of prostate | NC_000017.11:g.7674220C>G | ClinVar |
RCV000427307 | p.Arg248Leu | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7674220C>A | ClinVar |
RCV000436850 | p.Arg248Pro | missense variant | Medulloblastoma (MDB) | NC_000017.11:g.7674220C>G | ClinVar |
RCV000499534 | p.Arg248Trp | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674221_7674222delinsAA | ClinVar |
VAR_045245 | p.Arg248Cys | Missense | - | - | UniProt |
rs587782082 | p.Arg249Trp | missense variant | - | NC_000017.11:g.7674218T>A | UniProt,dbSNP |
VAR_045250 | p.Arg249Trp | missense variant | - | NC_000017.11:g.7674218T>A | UniProt |
rs587782329 | p.Arg249Thr | missense variant | - | NC_000017.11:g.7674217C>G | UniProt,dbSNP |
VAR_045249 | p.Arg249Thr | missense variant | - | NC_000017.11:g.7674217C>G | UniProt |
rs587782329 | p.Arg249Thr | missense variant | - | NC_000017.11:g.7674217C>G | - |
rs587782329 | p.Arg249Lys | missense variant | - | NC_000017.11:g.7674217C>T | UniProt,dbSNP |
VAR_045248 | p.Arg249Lys | missense variant | - | NC_000017.11:g.7674217C>T | UniProt |
RCV000130578 | p.Arg249Trp | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7674218T>A | ClinVar |
COSM6019373 | p.Arg249GlyPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7674219C>- | NCI-TCGA Cosmic |
RCV000782360 | p.Arg249Met | missense variant | Neoplasm of ovary | NC_000017.11:g.7674217C>A | ClinVar |
RCV000467567 | p.Arg249Gly | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674218T>C | ClinVar |
RCV000426063 | p.Arg249Thr | missense variant | Neoplasm of the breast | NC_000017.11:g.7674217C>G | ClinVar |
RCV000785491 | p.Arg249Ser | missense variant | Ovarian Neoplasms | NC_000017.11:g.7674216C>A | ClinVar |
rs587782329 | p.Arg249Met | missense variant | - | NC_000017.11:g.7674217C>A | UniProt,dbSNP |
VAR_033037 | p.Arg249Met | missense variant | - | NC_000017.11:g.7674217C>A | UniProt |
rs587782082 | p.Arg249Gly | missense variant | - | NC_000017.11:g.7674218T>C | UniProt,dbSNP |
VAR_005985 | p.Arg249Gly | missense variant | - | NC_000017.11:g.7674218T>C | UniProt |
rs28934571 | p.Arg249Ser | missense variant | - | NC_000017.11:g.7674216C>A | UniProt,dbSNP |
VAR_005986 | p.Arg249Ser | missense variant | - | NC_000017.11:g.7674216C>A | UniProt |
RCV000465003 | p.Arg249Ser | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674216C>G | ClinVar |
RCV000131246 | p.Arg249Lys | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7674217C>T | ClinVar |
RCV000724753 | p.Arg249Lys | missense variant | - | NC_000017.11:g.7674217C>T | ClinVar |
VAR_047191 | p.Arg249_Pro250delinsSerSer | deletion_insertion | - | - | UniProt |
VAR_045247 | p.Arg249Ile | Missense | - | - | UniProt |
VAR_045856 | p.Arg249Asn | Missense | - | - | UniProt |
VAR_047190 | p.Arg249_Pro250delinsSerAla | deletion_insertion | - | - | UniProt |
COSM43695 | p.Pro250Ser | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7674215G>A | NCI-TCGA Cosmic |
NCI-TCGA novel | p.Pro250HisPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7674213_7674214GG>- | NCI-TCGA |
NCI-TCGA novel | p.Pro250Leu | inframe deletion | - | NC_000017.11:g.7674212_7674214TGG>- | NCI-TCGA |
NCI-TCGA novel | p.Pro250Arg | missense variant | - | NC_000017.11:g.7674214G>C | NCI-TCGA |
rs1064794311 | p.Pro250Leu | missense variant | - | NC_000017.11:g.7674214G>A | UniProt,dbSNP |
VAR_047192 | p.Pro250Leu | missense variant | - | NC_000017.11:g.7674214G>A | UniProt |
RCV000479937 | p.Pro250Leu | missense variant | - | NC_000017.11:g.7674214G>A | ClinVar |
VAR_045252 | p.Pro250His | Missense | - | - | UniProt |
VAR_045254 | p.Pro250Ser | Missense | - | - | UniProt |
VAR_045253 | p.Pro250Gln | Missense | - | - | UniProt |
VAR_045857 | p.Pro250Phe | Missense | - | - | UniProt |
VAR_045255 | p.Pro250Thr | Missense | - | - | UniProt |
VAR_045251 | p.Pro250Ala | Missense | - | - | UniProt |
VAR_045858 | p.Pro250Asn | Missense | - | - | UniProt |
rs730882027 | p.Ile251Ser | missense variant | - | NC_000017.11:g.7674211A>C | ExAC,gnomAD |
RCV000161070 | p.Ile251Ser | missense variant | - | NC_000017.11:g.7674211A>C | ClinVar |
RCV000785277 | p.Ile251Leu | missense variant | Ovarian Neoplasms | NC_000017.11:g.7674212T>G | ClinVar |
RCV000564022 | p.Ile251Met | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7674210G>C | ClinVar |
COSM43967 | p.Ile251Phe | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7674212T>A | NCI-TCGA Cosmic |
COSM437492 | p.Ile251SerPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7674213G>- | NCI-TCGA Cosmic |
RCV000633360 | p.Ile251Asn | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674211A>T | ClinVar |
RCV000492548 | p.Ile251Leu | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7674212T>G | ClinVar |
rs878854074 | p.Ile251Met | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674210G>C | UniProt,dbSNP |
VAR_045258 | p.Ile251Met | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674210G>C | UniProt |
rs730882027 | p.Ile251Asn | missense variant | - | NC_000017.11:g.7674211A>T | ExAC,gnomAD |
rs730882027 | p.Ile251Thr | missense variant | - | NC_000017.11:g.7674211A>G | ExAC,gnomAD |
RCV000785350 | p.Ile251Ter | frameshift | Ovarian Neoplasms | NC_000017.11:g.7674215del | ClinVar |
RCV000506798 | p.Ile251Thr | missense variant | - | NC_000017.11:g.7674211A>G | ClinVar |
RCV000633326 | p.Ile251Met | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674210G>C | ClinVar |
VAR_005987 | p.Ile251Asn | Missense | - | - | UniProt |
VAR_045260 | p.Ile251Val | Missense | - | - | UniProt |
VAR_045256 | p.Ile251Phe | Missense | - | - | UniProt |
VAR_045259 | p.Ile251Thr | Missense | - | - | UniProt |
RCV000013143 | p.Leu252Pro | missense variant | Li-Fraumeni syndrome 1 (LFS) | NC_000017.11:g.7674208A>G | ClinVar |
COSM44541 | p.Leu252SerPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7674209G>- | NCI-TCGA Cosmic |
NCI-TCGA novel | p.Leu252Pro | inframe deletion | - | NC_000017.11:g.7674206_7674208TGA>- | NCI-TCGA |
rs121912653 | p.Leu252Pro | missense variant | Li-fraumeni syndrome 1 (lfs1) | NC_000017.11:g.7674208A>G | - |
rs121912653 | p.Leu252Pro | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674208A>G | UniProt,dbSNP |
VAR_005988 | p.Leu252Pro | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674208A>G | UniProt |
RCV000575325 | p.Leu252Ter | frameshift | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7674210del | ClinVar |
VAR_045262 | p.Leu252His | Missense | - | - | UniProt |
VAR_045264 | p.Leu252Val | Missense | - | - | UniProt |
VAR_045263 | p.Leu252Ile | Missense | - | - | UniProt |
VAR_045261 | p.Leu252Phe | Missense | - | - | UniProt |
rs1555525465 | p.Thr253Asn | missense variant | - | NC_000017.11:g.7674205G>T | - |
rs1555525465 | p.Thr253Asn | missense variant | - | NC_000017.11:g.7674205G>T | UniProt,dbSNP |
VAR_045267 | p.Thr253Asn | missense variant | - | NC_000017.11:g.7674205G>T | UniProt |
COSM43881 | p.Thr253Ser | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7674206T>A | NCI-TCGA Cosmic |
COSM45322 | p.Thr253Ala | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7674206T>C | NCI-TCGA Cosmic |
COSM4070036 | p.Thr253Ile | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7674205G>A | NCI-TCGA Cosmic |
NCI-TCGA novel | p.Thr253HisPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7674207_7674208insA | NCI-TCGA |
RCV000601887 | p.Thr253Asn | missense variant | - | NC_000017.11:g.7674205G>T | ClinVar |
VAR_045268 | p.Thr253Ser | Missense | - | - | UniProt |
VAR_045265 | p.Thr253Ala | Missense | - | - | UniProt |
VAR_047193 | p.Thr253Pro | Missense | - | - | UniProt |
VAR_045266 | p.Thr253Ile | Missense | - | - | UniProt |
rs1330865474 | p.Ile254Ser | missense variant | - | NC_000017.11:g.7674202A>C | UniProt,dbSNP |
VAR_045272 | p.Ile254Ser | missense variant | - | NC_000017.11:g.7674202A>C | UniProt |
rs1330865474 | p.Ile254Ser | missense variant | - | NC_000017.11:g.7674202A>C | gnomAD |
RCV000485986 | p.Ile254Val | missense variant | - | NC_000017.11:g.7674203T>C | ClinVar |
RCV000785554 | p.Ile254Ter | frameshift | Ovarian Neoplasms | NC_000017.11:g.7674205del | ClinVar |
RCV000573924 | p.Ile254Val | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7674203T>C | ClinVar |
RCV000765398 | p.Ile254Val | missense variant | Adrenocortical carcinoma, hereditary (ADCC) | NC_000017.11:g.7674203T>C | ClinVar |
NCI-TCGA novel | p.Ile254SerPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7674201_7674204GATG>- | NCI-TCGA |
RCV000477424 | p.Ile254Val | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674203T>C | ClinVar |
rs746601313 | p.Ile254Val | missense variant | - | NC_000017.11:g.7674203T>C | ExAC,gnomAD |
rs746601313 | p.Ile254Val | missense variant | - | NC_000017.11:g.7674203T>C | UniProt,dbSNP |
VAR_045273 | p.Ile254Val | missense variant | - | NC_000017.11:g.7674203T>C | UniProt |
VAR_045271 | p.Ile254Met | Missense | - | - | UniProt |
VAR_045859 | p.Ile254Asp | Missense | - | - | UniProt |
VAR_045269 | p.Ile254Phe | Missense | - | - | UniProt |
VAR_045270 | p.Ile254Leu | Missense | - | - | UniProt |
VAR_017909 | p.Ile254Thr | Missense | - | - | UniProt |
VAR_017908 | p.Ile254Asn | Missense | - | - | UniProt |
RCV000436027 | p.Ile255Phe | missense variant | Carcinoma of esophagus | NC_000017.11:g.7674200T>A | ClinVar |
RCV000435616 | p.Ile255Phe | missense variant | Glioblastoma | NC_000017.11:g.7674200T>A | ClinVar |
RCV000418615 | p.Ile255Phe | missense variant | Neoplasm of brain | NC_000017.11:g.7674200T>A | ClinVar |
RCV000436676 | p.Ile255Phe | missense variant | Chronic lymphocytic leukemia (CLL) | NC_000017.11:g.7674200T>A | ClinVar |
RCV000428426 | p.Ile255Phe | missense variant | Neoplasm of the breast | NC_000017.11:g.7674200T>A | ClinVar |
RCV000425759 | p.Ile255Phe | missense variant | Lung adenocarcinoma | NC_000017.11:g.7674200T>A | ClinVar |
RCV000441504 | p.Ile255Ser | missense variant | Neoplasm of brain | NC_000017.11:g.7674199A>C | ClinVar |
RCV000428170 | p.Ile255Ser | missense variant | Lung adenocarcinoma | NC_000017.11:g.7674199A>C | ClinVar |
RCV000633370 | p.Ile255Asn | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674199A>T | ClinVar |
RCV000420747 | p.Ile255Ser | missense variant | Carcinoma of esophagus | NC_000017.11:g.7674199A>C | ClinVar |
rs876659675 | p.Ile255Ser | missense variant | - | NC_000017.11:g.7674199A>C | UniProt,dbSNP |
VAR_045277 | p.Ile255Ser | missense variant | - | NC_000017.11:g.7674199A>C | UniProt |
rs876659675 | p.Ile255Asn | missense variant | - | NC_000017.11:g.7674199A>T | UniProt,dbSNP |
VAR_045276 | p.Ile255Asn | missense variant | - | NC_000017.11:g.7674199A>T | UniProt |
rs1057519995 | p.Ile255Phe | missense variant | - | NC_000017.11:g.7674200T>A | - |
rs1057519995 | p.Ile255Phe | missense variant | - | NC_000017.11:g.7674200T>A | UniProt,dbSNP |
VAR_045274 | p.Ile255Phe | missense variant | - | NC_000017.11:g.7674200T>A | UniProt |
rs876659675 | p.Ile255Thr | missense variant | - | NC_000017.11:g.7674199A>G | UniProt,dbSNP |
VAR_045278 | p.Ile255Thr | missense variant | - | NC_000017.11:g.7674199A>G | UniProt |
RCV000444896 | p.Ile255Phe | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7674200T>A | ClinVar |
RCV000785451 | p.Ile255Phe | missense variant | Ovarian Neoplasms | NC_000017.11:g.7674200T>A | ClinVar |
RCV000221023 | p.Ile255Asn | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7674199A>T | ClinVar |
RCV000458707 | p.Ile255Thr | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674199A>G | ClinVar |
RCV000441277 | p.Ile255Ser | missense variant | Glioblastoma | NC_000017.11:g.7674199A>C | ClinVar |
RCV000430544 | p.Ile255Ser | missense variant | Neoplasm of the breast | NC_000017.11:g.7674199A>C | ClinVar |
RCV000417507 | p.Ile255Ser | missense variant | Chronic lymphocytic leukemia (CLL) | NC_000017.11:g.7674199A>C | ClinVar |
RCV000423148 | p.Ile255Ser | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7674199A>C | ClinVar |
VAR_045279 | p.Ile255Val | Missense | - | - | UniProt |
VAR_045275 | p.Ile255Met | Missense | - | - | UniProt |
COSM4429608 | p.Thr256Ile | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7674196G>A | NCI-TCGA Cosmic |
COSM5229649 | p.Thr256AsnPheSerTerUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7674196_7674197insT | NCI-TCGA Cosmic |
RCV000633389 | p.Thr256Pro | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674197T>G | ClinVar |
RCV000172827 | p.Thr256Ala | missense variant | Li-Fraumeni syndrome 1 (LFS) | NC_000017.11:g.7674197T>C | ClinVar |
NCI-TCGA novel | p.Thr256IlePheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7674196_7674197insTA | NCI-TCGA |
NCI-TCGA novel | p.Thr256HisPheSerTerUnk | frameshift | - | NC_000017.11:g.7674198_7674199insA | NCI-TCGA |
RCV000688741 | p.Thr256Ala | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674197T>C | ClinVar |
RCV000219279 | p.Thr256Ter | frameshift | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7674193_7674197delinsTGGATGTCCTGACCTG | ClinVar |
VAR_045280 | p.Thr256Ile | Missense | - | - | UniProt |
VAR_045283 | p.Thr256Ser | Missense | - | - | UniProt |
VAR_045282 | p.Thr256Pro | Missense | - | - | UniProt |
VAR_045281 | p.Thr256Lys | Missense | - | - | UniProt |
rs28934577 | p.Leu257Gln | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674193A>T | UniProt,dbSNP |
VAR_045284 | p.Leu257Gln | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674193A>T | UniProt |
RCV000469142 | p.Leu257Gln | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674193A>T | ClinVar |
NCI-TCGA novel | p.Leu257ProPheSerTerUnk | frameshift | - | NC_000017.11:g.7674193_7674194insG | NCI-TCGA |
rs28934577 | p.Leu257Arg | missense variant | - | NC_000017.11:g.7674193A>C | UniProt,dbSNP |
VAR_045285 | p.Leu257Arg | missense variant | - | NC_000017.11:g.7674193A>C | UniProt |
RCV000130981 | p.Leu257Arg | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7674193A>C | ClinVar |
RCV000540536 | p.Leu257Pro | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674193A>G | ClinVar |
VAR_005989 | p.Leu257Pro | Missense | - | - | UniProt |
VAR_045286 | p.Leu257Val | Missense | - | - | UniProt |
RCV000459389 | p.Glu258Gly | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674190T>C | ClinVar |
RCV000551157 | p.Glu258Ala | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674190T>G | ClinVar |
RCV000785351 | p.Glu258Ter | nonsense | Ovarian Neoplasms | NC_000017.11:g.7674191C>A | ClinVar |
RCV000582699 | p.Glu258Lys | missense variant | - | NC_000017.11:g.7674191C>T | ClinVar |
RCV000565601 | p.Glu258Ter | nonsense | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7674191C>A | ClinVar |
COSM10751 | p.Glu258Gln | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7674191C>G | NCI-TCGA Cosmic |
COSM1522508 | p.Glu258Asp | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7674189T>A | NCI-TCGA Cosmic |
rs1060501201 | p.Glu258Ala | missense variant | - | NC_000017.11:g.7674190T>G | - |
NCI-TCGA novel | p.Glu258GlnPheSerTerUnk | frameshift | - | NC_000017.11:g.7674185_7674192AGTCTTCC>- | NCI-TCGA |
rs121912652 | p.Glu258Lys | missense variant | Li-fraumeni syndrome 1 (lfs1) | NC_000017.11:g.7674191C>T | ExAC,gnomAD |
rs121912652 | p.Glu258Lys | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674191C>T | UniProt,dbSNP |
VAR_005991 | p.Glu258Lys | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674191C>T | UniProt |
rs1060501201 | p.Glu258Gly | missense variant | - | NC_000017.11:g.7674190T>C | - |
rs121912652 | p.Glu258Ter | stop gained | Li-fraumeni syndrome 1 (lfs1) | NC_000017.11:g.7674191C>A | ExAC,gnomAD |
VAR_045290 | p.Glu258Val | Missense | - | - | UniProt |
VAR_045287 | p.Glu258Ala | Missense | - | - | UniProt |
VAR_005990 | p.Glu258Asp | Missense | - | - | UniProt |
VAR_045860 | p.Glu258Leu | Missense | - | - | UniProt |
VAR_045289 | p.Glu258Gln | Missense | - | - | UniProt |
RCV000774788 | p.Asp259Gly | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7674187T>C | ClinVar |
COSM44459 | p.Asp259Glu | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7674186G>T | NCI-TCGA Cosmic |
COSM44117 | p.Asp259Asn | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7674188C>T | NCI-TCGA Cosmic |
RCV000663222 | p.Asp259Val | missense variant | Li-Fraumeni syndrome 1 (LFS) | NC_000017.11:g.7674187T>A | ClinVar |
rs745425759 | p.Asp259Gly | missense variant | - | NC_000017.11:g.7674187T>C | UniProt,dbSNP |
VAR_045292 | p.Asp259Gly | missense variant | - | NC_000017.11:g.7674187T>C | UniProt |
rs745425759 | p.Asp259Gly | missense variant | - | NC_000017.11:g.7674187T>C | ExAC,gnomAD |
rs745425759 | p.Asp259Val | missense variant | - | NC_000017.11:g.7674187T>A | ExAC,gnomAD |
RCV000785271 | p.Asp259Tyr | missense variant | Ovarian Neoplasms | NC_000017.11:g.7674188C>A | ClinVar |
RCV000168379 | p.Asp259Gly | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674187T>C | ClinVar |
RCV000563029 | p.Asp259Val | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7674187T>A | ClinVar |
VAR_033039 | p.Asp259Tyr | Missense | - | - | UniProt |
VAR_045293 | p.Asp259His | Missense | - | - | UniProt |
VAR_045294 | p.Asp259Asn | Missense | - | - | UniProt |
VAR_045861 | p.Asp259Pro | Missense | - | - | UniProt |
VAR_045862 | p.Asp259Ser | Missense | - | - | UniProt |
VAR_047194 | p.Asp259Ala | Missense | - | - | UniProt |
VAR_045291 | p.Asp259Glu | Missense | - | - | UniProt |
VAR_045295 | p.Asp259Val | Missense | - | - | UniProt |
RCV000701990 | p.Ser260Tyr | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7674184G>T | ClinVar |
COSM44819 | p.Ser260ProPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7674185A>- | NCI-TCGA Cosmic |
COSM44587 | p.Ser260Pro | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7674185A>G | NCI-TCGA Cosmic |
NCI-TCGA novel | p.Ser260ProPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7674185_7674186insGTCTTCCAGTGTGATGATGGTGAGGATGG | NCI-TCGA |
RCV000213232 | p.Ser260Tyr | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7674184G>T | ClinVar |
rs876658916 | p.Ser260Tyr | missense variant | - | NC_000017.11:g.7674184G>T | UniProt,dbSNP |
VAR_045301 | p.Ser260Tyr | missense variant | - | NC_000017.11:g.7674184G>T | UniProt |
rs876658916 | p.Ser260Tyr | missense variant | - | NC_000017.11:g.7674184G>T | - |
VAR_045299 | p.Ser260Pro | Missense | - | - | UniProt |
VAR_045300 | p.Ser260Thr | Missense | - | - | UniProt |
VAR_045298 | p.Ser260Phe | Missense | - | - | UniProt |
VAR_045297 | p.Ser260Cys | Missense | - | - | UniProt |
VAR_045296 | p.Ser260Ala | Missense | - | - | UniProt |
COSM45668 | p.Ser261ValPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7674183G>- | NCI-TCGA Cosmic |
COSM5833416 | p.Ser261Ter | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7674182_7674183insA | NCI-TCGA Cosmic |
rs786203396 | p.Ser261Thr | missense variant | - | NC_000017.11:g.7674181C>G | - |
RCV000786823 | p.Ser261Thr | missense variant | - | NC_000017.11:g.7674181C>G | ClinVar |
VAR_045302 | p.Ser261Cys | Missense | - | - | UniProt |
VAR_045303 | p.Ser261Gly | Missense | - | - | UniProt |
VAR_045306 | p.Ser261Arg | Missense | - | - | UniProt |
VAR_045304 | p.Ser261Ile | Missense | - | - | UniProt |
VAR_045305 | p.Ser261Asn | Missense | - | - | UniProt |
RCV000492458 | p.Gly262Val | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7673835C>A | ClinVar |
COSM45527 | p.Gly262ValPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7673835C>- | NCI-TCGA Cosmic |
RCV000463102 | p.Gly262Ser | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673836C>T | ClinVar |
NCI-TCGA novel | p.Gly262AlaPheSerTerUnk | frameshift | - | NC_000017.11:g.7673822_7673835TCCCAGTAGATTAC>- | NCI-TCGA |
rs1131691025 | p.Gly262Val | missense variant | - | NC_000017.11:g.7673835C>A | UniProt,dbSNP |
VAR_045309 | p.Gly262Val | missense variant | - | NC_000017.11:g.7673835C>A | UniProt |
rs1131691025 | p.Gly262Val | missense variant | - | NC_000017.11:g.7673835C>A | - |
rs200579969 | p.Gly262Ser | missense variant | - | NC_000017.11:g.7673836C>T | ExAC,TOPMed,gnomAD |
rs200579969 | p.Gly262Cys | missense variant | - | NC_000017.11:g.7673836C>A | ExAC,TOPMed,gnomAD |
RCV000590725 | p.Gly262Ser | missense variant | - | NC_000017.11:g.7673836C>T | ClinVar |
RCV000685621 | p.Gly262Val | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673835C>A | ClinVar |
RCV000236733 | p.Gly262Ter | frameshift | - | NC_000017.11:g.7673836del | ClinVar |
RCV000129643 | p.Gly262Ser | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7673836C>T | ClinVar |
RCV000492279 | p.Gly262Ter | frameshift | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7673836del | ClinVar |
VAR_047196 | p.Gly262Asp | Missense | - | - | UniProt |
VAR_047195 | p.Gly262_Asn263delinsProAsp | deletion_insertion | - | - | UniProt |
VAR_045863 | p.Gly262His | Missense | - | - | UniProt |
rs72661119 | p.Asn263His | missense variant | - | NC_000017.11:g.7673833T>G | 1000Genomes,ExAC,gnomAD |
RCV000569163 | p.Asn263Lys | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7673831A>T | ClinVar |
RCV000663318 | p.Asn263Asp | missense variant | Li-Fraumeni syndrome 1 (LFS) | NC_000017.11:g.7673833T>C | ClinVar |
NCI-TCGA novel | p.Asn263IlePheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7673832T>- | NCI-TCGA |
NCI-TCGA novel | p.Asn263LysPheSerTerUnk | frameshift | - | NC_000017.11:g.7673831_7673832insC | NCI-TCGA |
NCI-TCGA novel | p.Asn263SerPheSerTerUnk | frameshift | - | NC_000017.11:g.7673832_7673833TT>- | NCI-TCGA |
rs72661119 | p.Asn263Asp | missense variant | - | NC_000017.11:g.7673833T>C | 1000Genomes,ExAC,gnomAD |
RCV000633354 | p.Asn263His | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673833T>G | ClinVar |
rs770598448 | p.Asn263Lys | missense variant | - | NC_000017.11:g.7673831A>T | ExAC,gnomAD |
VAR_045314 | p.Asn263Ser | Missense | - | - | UniProt |
VAR_045311 | p.Asn263His | Missense | - | - | UniProt |
VAR_045313 | p.Asn263Lys | Missense | - | - | UniProt |
VAR_045312 | p.Asn263Ile | Missense | - | - | UniProt |
RCV000472594 | p.Leu264Ter | frameshift | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673830del | ClinVar |
RCV000506102 | p.Leu264Ter | frameshift | - | NC_000017.11:g.7673830del | ClinVar |
COSM5629555 | p.Leu264TyrPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7673831A>- | NCI-TCGA Cosmic |
RCV000575862 | p.Leu264Pro | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7673829A>G | ClinVar |
rs1555525353 | p.Leu264Pro | missense variant | - | NC_000017.11:g.7673829A>G | - |
rs1555525353 | p.Leu264Pro | missense variant | - | NC_000017.11:g.7673829A>G | UniProt,dbSNP |
VAR_045316 | p.Leu264Pro | missense variant | - | NC_000017.11:g.7673829A>G | UniProt |
RCV000633364 | p.Leu264Pro | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673829A>G | ClinVar |
VAR_045318 | p.Leu264Arg | Missense | - | - | UniProt |
VAR_045315 | p.Leu264Ile | Missense | - | - | UniProt |
VAR_045317 | p.Leu264Gln | Missense | - | - | UniProt |
VAR_045319 | p.Leu264Val | Missense | - | - | UniProt |
COSM3970345 | p.Leu265Arg | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7673826A>C | NCI-TCGA Cosmic |
COSM6005483 | p.Leu265ThrPheSerTerUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7673827_7673828insT | NCI-TCGA Cosmic |
rs1555525344 | p.LeuGly265LeuTer | stop gained | - | NC_000017.11:g.7673824_7673825delinsAG | - |
rs879253942 | p.Leu265Pro | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673826A>G | UniProt,dbSNP |
VAR_045321 | p.Leu265Pro | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673826A>G | UniProt |
RCV000662855 | p.Leu265Pro | missense variant | Li-Fraumeni syndrome 1 (LFS) | NC_000017.11:g.7673826A>G | ClinVar |
VAR_045320 | p.Leu265Met | Missense | - | - | UniProt |
VAR_045322 | p.Leu265Gln | Missense | - | - | UniProt |
VAR_047197 | p.Leu265Arg | Missense | - | - | UniProt |
rs193920774 | p.Gly266Glu | missense variant | - | NC_000017.11:g.7673823C>T | UniProt,dbSNP |
VAR_045324 | p.Gly266Glu | missense variant | - | NC_000017.11:g.7673823C>T | UniProt |
rs193920774 | p.Gly266Glu | missense variant | - | NC_000017.11:g.7673823C>T | gnomAD |
COSM44187 | p.Gly266AspPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7673823C>- | NCI-TCGA Cosmic |
COSM48975 | p.Gly266GluPheSerTerUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7673819_7673823CCGTC>- | NCI-TCGA Cosmic |
RCV000422392 | p.Gly266Val | missense variant | Lung adenocarcinoma | NC_000017.11:g.7673823C>A | ClinVar |
RCV000434911 | p.Gly266Val | missense variant | Squamous cell lung carcinoma | NC_000017.11:g.7673823C>A | ClinVar |
RCV000427379 | p.Gly266Val | missense variant | - | NC_000017.11:g.7673823C>A | ClinVar |
RCV000439374 | p.Gly266Val | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7673823C>A | ClinVar |
RCV000444359 | p.Gly266Val | missense variant | Malignant melanoma of skin (CMM) | NC_000017.11:g.7673823C>A | ClinVar |
RCV000429134 | p.Gly266Val | missense variant | Small cell lung cancer | NC_000017.11:g.7673823C>A | ClinVar |
RCV000417840 | p.Gly266Val | missense variant | - | NC_000017.11:g.7673823C>A | ClinVar |
RCV000424659 | p.Gly266Val | missense variant | Neoplasm of brain | NC_000017.11:g.7673823C>A | ClinVar |
RCV000709403 | p.Gly266Glu | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673823C>T | ClinVar |
RCV000785518 | p.Gly266Ter | frameshift | Ovarian Neoplasms | NC_000017.11:g.7673825del | ClinVar |
RCV000584005 | p.Gly266Ter | nonsense | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7673824_7673825delinsAG | ClinVar |
rs1057519990 | p.Gly266Arg | missense variant | - | NC_000017.11:g.7673824C>T | gnomAD |
rs1057519990 | p.Gly266Arg | missense variant | - | NC_000017.11:g.7673824C>T | UniProt,dbSNP |
VAR_045325 | p.Gly266Arg | missense variant | - | NC_000017.11:g.7673824C>T | UniProt |
rs193920774 | p.Gly266Val | missense variant | - | NC_000017.11:g.7673823C>A | gnomAD |
rs193920774 | p.Gly266Val | missense variant | - | NC_000017.11:g.7673823C>A | UniProt,dbSNP |
VAR_045326 | p.Gly266Val | missense variant | - | NC_000017.11:g.7673823C>A | UniProt |
rs1057519990 | p.Gly266Ter | stop gained | - | NC_000017.11:g.7673824C>A | gnomAD |
rs1057519990 | p.Gly266Arg | missense variant | - | NC_000017.11:g.7673824C>G | gnomAD |
RCV000437591 | p.Gly266Val | missense variant | Uterine Carcinosarcoma | NC_000017.11:g.7673823C>A | ClinVar |
RCV000445304 | p.Gly266Val | missense variant | Malignant neoplasm of body of uterus | NC_000017.11:g.7673823C>A | ClinVar |
RCV000803659 | p.Gly266Arg | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673824C>G | ClinVar |
RCV000528667 | p.Gly266Arg | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673824C>T | ClinVar |
RCV000422798 | p.Gly266Val | missense variant | Glioblastoma | NC_000017.11:g.7673823C>A | ClinVar |
RCV000428065 | p.Gly266Val | missense variant | Neoplasm of the breast | NC_000017.11:g.7673823C>A | ClinVar |
RCV000423426 | p.Gly266Val | missense variant | Neoplasm of the large intestine | NC_000017.11:g.7673823C>A | ClinVar |
RCV000433685 | p.Gly266Val | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7673823C>A | ClinVar |
RCV000444283 | p.Gly266Val | missense variant | Chronic lymphocytic leukemia (CLL) | NC_000017.11:g.7673823C>A | ClinVar |
RCV000440058 | p.Gly266Val | missense variant | Carcinoma of esophagus | NC_000017.11:g.7673823C>A | ClinVar |
RCV000435298 | p.Gly266Val | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7673823C>A | ClinVar |
RCV000434748 | p.Gly266Val | missense variant | Hepatocellular carcinoma (HCC) | NC_000017.11:g.7673823C>A | ClinVar |
RCV000258052 | p.Gly266Ter | frameshift | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7673812_7673824del | ClinVar |
VAR_045323 | p.Gly266Ala | Missense | - | - | UniProt |
rs55832599 | p.Arg267Trp | missense variant | - | NC_000017.11:g.7673821G>A | TOPMed,gnomAD |
rs55832599 | p.Arg267Trp | missense variant | - | NC_000017.11:g.7673821G>A | UniProt,dbSNP |
VAR_036507 | p.Arg267Trp | missense variant | - | NC_000017.11:g.7673821G>A | UniProt |
rs587780075 | p.Arg267Gln | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673820C>T | UniProt,dbSNP |
VAR_045330 | p.Arg267Gln | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673820C>T | UniProt |
rs587780075 | p.Arg267Gln | missense variant | - | NC_000017.11:g.7673820C>T | ExAC,gnomAD |
RCV000130398 | p.Arg267Trp | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7673821G>A | ClinVar |
RCV000413074 | p.Arg267Trp | missense variant | - | NC_000017.11:g.7673821G>A | ClinVar |
RCV000213058 | p.Arg267Gln | missense variant | - | NC_000017.11:g.7673820C>T | ClinVar |
COSM45822 | p.Arg267Gly | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7673821G>C | NCI-TCGA Cosmic |
COSM13165 | p.Arg267Leu | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7673820C>A | NCI-TCGA Cosmic |
RCV000538977 | p.Arg267Trp | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673821G>A | ClinVar |
RCV000492273 | p.Arg267Pro | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7673820C>G | ClinVar |
RCV000205433 | p.Arg267Gln | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673820C>T | ClinVar |
RCV000115737 | p.Arg267Gln | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7673820C>T | ClinVar |
NCI-TCGA novel | p.Arg267Ter | stop gained | - | NC_000017.11:g.7673821_7673822insTCCCAGTAGATTACCACTACTCA | NCI-TCGA |
NCI-TCGA novel | p.Arg267LeuPheSerTerUnk | frameshift | - | NC_000017.11:g.7673813_7673820GCTGTTCC>- | NCI-TCGA |
rs587780075 | p.Arg267Pro | missense variant | - | NC_000017.11:g.7673820C>G | ExAC,gnomAD |
rs587780075 | p.Arg267Pro | missense variant | - | NC_000017.11:g.7673820C>G | UniProt,dbSNP |
VAR_045329 | p.Arg267Pro | missense variant | - | NC_000017.11:g.7673820C>G | UniProt |
RCV000662441 | p.Arg267Gln | missense variant | Li-Fraumeni syndrome 1 (LFS) | NC_000017.11:g.7673820C>T | ClinVar |
RCV000763416 | p.Arg267Trp | missense variant | Adrenocortical carcinoma, hereditary (ADCC) | NC_000017.11:g.7673821G>A | ClinVar |
VAR_045327 | p.Arg267Gly | Missense | - | - | UniProt |
VAR_045328 | p.Arg267His | Missense | - | - | UniProt |
COSM6583 | p.Asn268ThrPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7673819C>- | NCI-TCGA Cosmic |
NCI-TCGA novel | p.Asn268IlePheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7673817_7673818insTCCGTCCCAGTAGATTACCACTA | NCI-TCGA |
VAR_045332 | p.Asn268Ile | Missense | - | - | UniProt |
VAR_045333 | p.Asn268Lys | Missense | - | - | UniProt |
VAR_045864 | p.Asn268Phe | Missense | - | - | UniProt |
VAR_045335 | p.Asn268Tyr | Missense | - | - | UniProt |
VAR_045331 | p.Asn268His | Missense | - | - | UniProt |
VAR_045334 | p.Asn268Ser | Missense | - | - | UniProt |
NCI-TCGA novel | p.Ser269Lys | inframe deletion | - | NC_000017.11:g.7673809_7673814CAAAGC>- | NCI-TCGA |
NCI-TCGA novel | p.Ser269IlePheSerTerUnk | frameshift | - | NC_000017.11:g.7673813_7673814GC>- | NCI-TCGA |
VAR_045340 | p.Ser269Thr | Missense | - | - | UniProt |
VAR_047198 | p.Ser269Ile | Missense | - | - | UniProt |
VAR_045339 | p.Ser269Arg | Missense | - | - | UniProt |
VAR_045336 | p.Ser269Cys | Missense | - | - | UniProt |
VAR_045338 | p.Ser269Asn | Missense | - | - | UniProt |
VAR_045337 | p.Ser269Gly | Missense | - | - | UniProt |
rs1057519986 | p.Phe270Ser | missense variant | - | NC_000017.11:g.7673811A>G | UniProt,dbSNP |
VAR_045344 | p.Phe270Ser | missense variant | - | NC_000017.11:g.7673811A>G | UniProt |
rs1057519986 | p.Phe270Ser | missense variant | - | NC_000017.11:g.7673811A>G | - |
RCV000425994 | p.Phe270Ile | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7673812A>T | ClinVar |
RCV000423824 | p.Phe270Leu | missense variant | Neoplasm of the breast | NC_000017.11:g.7673810A>C | ClinVar |
RCV000418371 | p.Phe270Ile | missense variant | Squamous cell lung carcinoma | NC_000017.11:g.7673812A>T | ClinVar |
RCV000425855 | p.Phe270Val | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7673812A>C | ClinVar |
RCV000443210 | p.Phe270Val | missense variant | Neoplasm of the breast | NC_000017.11:g.7673812A>C | ClinVar |
RCV000436003 | p.Phe270Ile | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7673812A>T | ClinVar |
RCV000422121 | p.Phe270Cys | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7673811A>C | ClinVar |
RCV000435260 | p.Phe270Val | missense variant | Lung adenocarcinoma | NC_000017.11:g.7673812A>C | ClinVar |
RCV000425222 | p.Phe270Val | missense variant | - | NC_000017.11:g.7673812A>C | ClinVar |
RCV000443062 | p.Phe270Val | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7673812A>C | ClinVar |
RCV000438306 | p.Phe270Val | missense variant | Neoplasm of brain | NC_000017.11:g.7673812A>C | ClinVar |
RCV000440467 | p.Phe270Cys | missense variant | Squamous cell lung carcinoma | NC_000017.11:g.7673811A>C | ClinVar |
RCV000427865 | p.Phe270Ile | missense variant | Adenocarcinoma of stomach | NC_000017.11:g.7673812A>T | ClinVar |
RCV000434574 | p.Phe270Cys | missense variant | Neoplasm of the breast | NC_000017.11:g.7673811A>C | ClinVar |
RCV000785520 | p.Phe270Leu | missense variant | Ovarian Neoplasms | NC_000017.11:g.7673812A>G | ClinVar |
RCV000422786 | p.Phe270Cys | missense variant | Lung adenocarcinoma | NC_000017.11:g.7673811A>C | ClinVar |
RCV000443933 | p.Phe270Cys | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7673811A>C | ClinVar |
RCV000432351 | p.Phe270Cys | missense variant | - | NC_000017.11:g.7673811A>C | ClinVar |
RCV000432152 | p.Phe270Leu | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7673810A>C | ClinVar |
RCV000441020 | p.Phe270Cys | missense variant | Carcinoma of esophagus | NC_000017.11:g.7673811A>C | ClinVar |
RCV000824076 | p.Phe270Ser | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673811A>G | ClinVar |
RCV000417883 | p.Phe270Ile | missense variant | Carcinoma of esophagus | NC_000017.11:g.7673812A>T | ClinVar |
RCV000442796 | p.Phe270Leu | missense variant | - | NC_000017.11:g.7673810A>C | ClinVar |
RCV000435460 | p.Phe270Val | missense variant | Adenocarcinoma of stomach | NC_000017.11:g.7673812A>C | ClinVar |
RCV000434093 | p.Phe270Leu | missense variant | Adenocarcinoma of stomach | NC_000017.11:g.7673810A>C | ClinVar |
RCV000430671 | p.Phe270Val | missense variant | Carcinoma of esophagus | NC_000017.11:g.7673812A>C | ClinVar |
RCV000420461 | p.Phe270Val | missense variant | Squamous cell lung carcinoma | NC_000017.11:g.7673812A>C | ClinVar |
RCV000433231 | p.Phe270Leu | missense variant | Squamous cell lung carcinoma | NC_000017.11:g.7673810A>C | ClinVar |
RCV000424190 | p.Phe270Cys | missense variant | Adenocarcinoma of stomach | NC_000017.11:g.7673811A>C | ClinVar |
RCV000438906 | p.Phe270Leu | missense variant | Lung adenocarcinoma | NC_000017.11:g.7673810A>C | ClinVar |
RCV000426634 | p.Phe270Leu | missense variant | Carcinoma of esophagus | NC_000017.11:g.7673810A>C | ClinVar |
RCV000436185 | p.Phe270Ile | missense variant | Neoplasm of brain | NC_000017.11:g.7673812A>T | ClinVar |
COSM1651732 | p.Phe270LeuPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7673801_7673810ACGCACCTCA>- | NCI-TCGA Cosmic |
RCV000130388 | p.Phe270Ter | frameshift | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7673805_7673814del | ClinVar |
rs1057519987 | p.Phe270Leu | missense variant | - | NC_000017.11:g.7673810A>C | - |
rs1057519987 | p.Phe270Leu | missense variant | - | NC_000017.11:g.7673810A>C | UniProt,dbSNP |
VAR_045343 | p.Phe270Leu | missense variant | - | NC_000017.11:g.7673810A>C | UniProt |
rs1057519988 | p.Phe270Ile | missense variant | - | NC_000017.11:g.7673812A>T | - |
rs1057519988 | p.Phe270Ile | missense variant | - | NC_000017.11:g.7673812A>T | UniProt,dbSNP |
VAR_045342 | p.Phe270Ile | missense variant | - | NC_000017.11:g.7673812A>T | UniProt |
rs1057519986 | p.Phe270Cys | missense variant | - | NC_000017.11:g.7673811A>C | UniProt,dbSNP |
VAR_045341 | p.Phe270Cys | missense variant | - | NC_000017.11:g.7673811A>C | UniProt |
rs1057519986 | p.Phe270Cys | missense variant | - | NC_000017.11:g.7673811A>C | - |
rs1057519988 | p.Phe270Val | missense variant | - | NC_000017.11:g.7673812A>C | UniProt,dbSNP |
VAR_045345 | p.Phe270Val | missense variant | - | NC_000017.11:g.7673812A>C | UniProt |
rs1057519988 | p.Phe270Val | missense variant | - | NC_000017.11:g.7673812A>C | - |
RCV000785457 | p.Phe270Ter | frameshift | Ovarian Neoplasms | NC_000017.11:g.7673812del | ClinVar |
RCV000785257 | p.Phe270Ile | missense variant | Ovarian Neoplasms | NC_000017.11:g.7673812A>T | ClinVar |
RCV000426445 | p.Phe270Leu | missense variant | Neoplasm of brain | NC_000017.11:g.7673810A>C | ClinVar |
RCV000430718 | p.Phe270Ile | missense variant | Neoplasm of the breast | NC_000017.11:g.7673812A>T | ClinVar |
RCV000433925 | p.Phe270Cys | missense variant | Neoplasm of brain | NC_000017.11:g.7673811A>C | ClinVar |
RCV000438999 | p.Phe270Ile | missense variant | - | NC_000017.11:g.7673812A>T | ClinVar |
RCV000443660 | p.Phe270Leu | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7673810A>C | ClinVar |
RCV000417655 | p.Phe270Ile | missense variant | Lung adenocarcinoma | NC_000017.11:g.7673812A>T | ClinVar |
VAR_045346 | p.Phe270Tyr | Missense | - | - | UniProt |
RCV000457572 | p.Glu271Lys | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673809C>T | ClinVar |
RCV000775714 | p.Glu271Lys | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7673809C>T | ClinVar |
COSM165082 | p.Glu271Gln | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7673809C>G | NCI-TCGA Cosmic |
COSM131516 | p.Glu271Ter | stop gained | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7673809C>A | NCI-TCGA Cosmic |
COSM1610828 | p.Glu271Val | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7673808T>A | NCI-TCGA Cosmic |
NCI-TCGA novel | p.Glu271Gly | inframe deletion | - | NC_000017.11:g.7673752_7673808GGAGATTCTCTTCCTCTGTGCGCCGGTCTCTCCCAGGACAGGCACAAACACGCACCT>- | NCI-TCGA |
NCI-TCGA novel | p.Glu271Ter | frameshift | - | NC_000017.11:g.7673809_7673810insA | NCI-TCGA |
rs1060501191 | p.Glu271Lys | missense variant | - | NC_000017.11:g.7673809C>T | - |
rs1555525303 | p.GluVal271AspMet | missense variant | - | NC_000017.11:g.7673806_7673807delinsTA | - |
RCV000570036 | p.Glu271AspMet | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7673806_7673807delinsTA | ClinVar |
RCV000689318 | p.Glu271Leu | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673808_7673809delinsAA | ClinVar |
VAR_045347 | p.Glu271Ala | Missense | - | - | UniProt |
VAR_045348 | p.Glu271Asp | Missense | - | - | UniProt |
VAR_047199 | p.Glu271Val | Missense | - | - | UniProt |
VAR_045865 | p.Glu271Pro | Missense | - | - | UniProt |
VAR_045349 | p.Glu271Gly | Missense | - | - | UniProt |
VAR_045866 | p.Glu271Arg | Missense | - | - | UniProt |
VAR_045350 | p.Glu271Gln | Missense | - | - | UniProt |
rs121912657 | p.Val272Leu | missense variant | Li-fraumeni syndrome 1 (lfs1) | NC_000017.11:g.7673806C>A | ExAC,gnomAD |
rs876660333 | p.Val272Gly | missense variant | - | NC_000017.11:g.7673805A>C | UniProt,dbSNP |
VAR_045353 | p.Val272Gly | missense variant | - | NC_000017.11:g.7673805A>C | UniProt |
RCV000437100 | p.Val272Leu | missense variant | Renal cell carcinoma, papillary, 1 (RCCP1) | NC_000017.11:g.7673806C>A | ClinVar |
RCV000434621 | p.Val272Met | missense variant | Malignant neoplasm of body of uterus | NC_000017.11:g.7673806C>T | ClinVar |
RCV000436402 | p.Val272Met | missense variant | Lung adenocarcinoma | NC_000017.11:g.7673806C>T | ClinVar |
RCV000428361 | p.Val272Leu | missense variant | - | NC_000017.11:g.7673806C>A | ClinVar |
RCV000424351 | p.Val272Met | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7673806C>T | ClinVar |
RCV000164988 | p.Val272Leu | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7673806C>A | ClinVar |
RCV000426406 | p.Val272Met | missense variant | - | NC_000017.11:g.7673806C>T | ClinVar |
RCV000420507 | p.Val272Leu | missense variant | Neoplasm of the breast | NC_000017.11:g.7673806C>A | ClinVar |
RCV000417682 | p.Val272Leu | missense variant | Adenocarcinoma of stomach | NC_000017.11:g.7673806C>A | ClinVar |
RCV000418746 | p.Val272Met | missense variant | Renal cell carcinoma, papillary, 1 (RCCP1) | NC_000017.11:g.7673806C>T | ClinVar |
RCV000431193 | p.Val272Leu | missense variant | Neoplasm of the large intestine | NC_000017.11:g.7673806C>A | ClinVar |
RCV000443071 | p.Val272Met | missense variant | Neoplasm of the large intestine | NC_000017.11:g.7673806C>T | ClinVar |
RCV000434905 | p.Val272Leu | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7673806C>A | ClinVar |
RCV000443570 | p.Val272Leu | missense variant | Malignant neoplasm of body of uterus | NC_000017.11:g.7673806C>A | ClinVar |
RCV000443052 | p.Val272Met | missense variant | Neoplasm of the breast | NC_000017.11:g.7673806C>T | ClinVar |
RCV000432177 | p.Val272Met | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7673806C>T | ClinVar |
RCV000432989 | p.Val272Leu | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7673806C>A | ClinVar |
RCV000443589 | p.Val272Leu | missense variant | Multiple myeloma (MM) | NC_000017.11:g.7673806C>A | ClinVar |
RCV000785341 | p.Val272Met | missense variant | Ovarian Neoplasms | NC_000017.11:g.7673806C>T | ClinVar |
RCV000436602 | p.Val272Met | missense variant | Medulloblastoma (MDB) | NC_000017.11:g.7673806C>T | ClinVar |
RCV000439021 | p.Val272Leu | missense variant | Lung adenocarcinoma | NC_000017.11:g.7673806C>A | ClinVar |
RCV000441086 | p.Val272Met | missense variant | Multiple myeloma (MM) | NC_000017.11:g.7673806C>T | ClinVar |
RCV000425268 | p.Val272Met | missense variant | - | NC_000017.11:g.7673806C>T | ClinVar |
RCV000426429 | p.Val272Leu | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7673806C>A | ClinVar |
RCV000427077 | p.Val272Leu | missense variant | - | NC_000017.11:g.7673806C>A | ClinVar |
RCV000437706 | p.Val272Leu | missense variant | Medulloblastoma (MDB) | NC_000017.11:g.7673806C>A | ClinVar |
RCV000424542 | p.Val272Met | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7673806C>T | ClinVar |
RCV000434295 | p.Val272Met | missense variant | Adenocarcinoma of stomach | NC_000017.11:g.7673806C>T | ClinVar |
RCV000429369 | p.Val272Glu | missense variant | Lung adenocarcinoma | NC_000017.11:g.7673805A>T | ClinVar |
RCV000442761 | p.Val272Glu | missense variant | Neoplasm of the breast | NC_000017.11:g.7673805A>T | ClinVar |
RCV000442953 | p.Val272Glu | missense variant | Medulloblastoma (MDB) | NC_000017.11:g.7673805A>T | ClinVar |
RCV000441216 | p.Val272Gly | missense variant | - | NC_000017.11:g.7673805A>C | ClinVar |
RCV000439065 | p.Val272Gly | missense variant | Renal cell carcinoma, papillary, 1 (RCCP1) | NC_000017.11:g.7673805A>C | ClinVar |
RCV000421804 | p.Val272Glu | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7673805A>T | ClinVar |
RCV000434183 | p.Val272Glu | missense variant | Neoplasm of the large intestine | NC_000017.11:g.7673805A>T | ClinVar |
RCV000430105 | p.Val272Gly | missense variant | Neoplasm of the large intestine | NC_000017.11:g.7673805A>C | ClinVar |
RCV000419845 | p.Val272Gly | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7673805A>C | ClinVar |
RCV000422825 | p.Val272Glu | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7673805A>T | ClinVar |
RCV000433521 | p.Val272Glu | missense variant | Renal cell carcinoma, papillary, 1 (RCCP1) | NC_000017.11:g.7673805A>T | ClinVar |
COSM44294 | p.Val272Ala | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7673805A>G | NCI-TCGA Cosmic |
COSM13421 | p.Val272CysPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7673806C>- | NCI-TCGA Cosmic |
RCV000444129 | p.Val272Gly | missense variant | Medulloblastoma (MDB) | NC_000017.11:g.7673805A>C | ClinVar |
RCV000423493 | p.Val272Glu | missense variant | - | NC_000017.11:g.7673805A>T | ClinVar |
rs121912657 | p.Val272Leu | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673806C>A | UniProt,dbSNP |
VAR_005992 | p.Val272Leu | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673806C>A | UniProt |
rs121912657 | p.Val272Met | missense variant | - | NC_000017.11:g.7673806C>T | UniProt,dbSNP |
VAR_045354 | p.Val272Met | missense variant | - | NC_000017.11:g.7673806C>T | UniProt |
rs121912657 | p.Val272Met | missense variant | Li-fraumeni syndrome 1 (lfs1) | NC_000017.11:g.7673806C>T | ExAC,gnomAD |
rs876660333 | p.Val272Glu | missense variant | - | NC_000017.11:g.7673805A>T | UniProt,dbSNP |
VAR_045352 | p.Val272Glu | missense variant | - | NC_000017.11:g.7673805A>T | UniProt |
RCV000427639 | p.Val272Glu | missense variant | Multiple myeloma (MM) | NC_000017.11:g.7673805A>T | ClinVar |
RCV000432569 | p.Val272Gly | missense variant | Lung adenocarcinoma | NC_000017.11:g.7673805A>C | ClinVar |
RCV000421439 | p.Val272Gly | missense variant | - | NC_000017.11:g.7673805A>C | ClinVar |
RCV000427960 | p.Val272Gly | missense variant | Multiple myeloma (MM) | NC_000017.11:g.7673805A>C | ClinVar |
RCV000424786 | p.Val272Glu | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7673805A>T | ClinVar |
RCV000421184 | p.Val272Gly | missense variant | Malignant neoplasm of body of uterus | NC_000017.11:g.7673805A>C | ClinVar |
RCV000438331 | p.Val272Glu | missense variant | Malignant neoplasm of body of uterus | NC_000017.11:g.7673805A>T | ClinVar |
RCV000441467 | p.Val272Gly | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7673805A>C | ClinVar |
RCV000422297 | p.Val272Gly | missense variant | Neoplasm of the breast | NC_000017.11:g.7673805A>C | ClinVar |
RCV000444340 | p.Val272Glu | missense variant | Adenocarcinoma of stomach | NC_000017.11:g.7673805A>T | ClinVar |
RCV000420090 | p.Val272Gly | missense variant | Adenocarcinoma of stomach | NC_000017.11:g.7673805A>C | ClinVar |
RCV000431226 | p.Val272Gly | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7673805A>C | ClinVar |
RCV000440060 | p.Val272Glu | missense variant | - | NC_000017.11:g.7673805A>T | ClinVar |
VAR_045351 | p.Val272Ala | Missense | - | - | UniProt |
rs28934576 | p.Arg273Pro | missense variant | - | NC_000017.11:g.7673802C>G | 1000Genomes,ExAC,TOPMed,gnomAD |
rs121913343 | p.Arg273Cys | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673803G>A | UniProt,dbSNP |
VAR_005993 | p.Arg273Cys | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673803G>A | UniProt |
rs28934576 | p.Arg273Leu | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673802C>A | UniProt,dbSNP |
VAR_036509 | p.Arg273Leu | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673802C>A | UniProt |
rs121913343 | p.Arg273Ser | missense variant | - | NC_000017.11:g.7673803G>T | UniProt,dbSNP |
VAR_045357 | p.Arg273Ser | missense variant | - | NC_000017.11:g.7673803G>T | UniProt |
rs28934576 | p.Arg273Leu | missense variant | Li-fraumeni syndrome 1 (lfs1) | NC_000017.11:g.7673802C>A | 1000Genomes,ExAC,TOPMed,gnomAD |
RCV000553607 | p.Arg273Pro | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673802C>G | ClinVar |
RCV000561782 | p.Arg273Ser | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7673803G>T | ClinVar |
RCV000814073 | p.Arg273Gly | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673803G>C | ClinVar |
RCV000785275 | p.Arg273Gly | missense variant | Ovarian Neoplasms | NC_000017.11:g.7673803G>C | ClinVar |
RCV000205625 | p.Arg273Cys | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673803G>A | ClinVar |
COSM44440 | p.Arg273LeuPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7673802C>- | NCI-TCGA Cosmic |
rs28934576 | p.Arg273His | missense variant | Li-fraumeni syndrome 1 (lfs1) | NC_000017.11:g.7673802C>T | 1000Genomes,ExAC,TOPMed,gnomAD |
rs28934576 | p.Arg273Pro | missense variant | Li-fraumeni syndrome 1 (lfs1) | NC_000017.11:g.7673802C>G | 1000Genomes,ExAC,TOPMed,gnomAD |
rs121913343 | p.Arg273Cys | missense variant | - | NC_000017.11:g.7673803G>A | ExAC,gnomAD |
rs28934576 | p.Arg273His | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673802C>T | UniProt,dbSNP |
VAR_005995 | p.Arg273His | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673802C>T | UniProt |
rs121913343 | p.Arg273Ser | missense variant | - | NC_000017.11:g.7673803G>T | ExAC,gnomAD |
rs28934576 | p.Arg273His | missense variant | - | NC_000017.11:g.7673802C>T | 1000Genomes,ExAC,TOPMed,gnomAD |
RCV000115738 | p.Arg273His | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7673802C>T | ClinVar |
RCV000822080 | p.Arg273Leu | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673802C>A | ClinVar |
rs28934576 | p.Arg273Pro | missense variant | - | NC_000017.11:g.7673802C>G | UniProt,dbSNP |
VAR_045355 | p.Arg273Pro | missense variant | - | NC_000017.11:g.7673802C>G | UniProt |
rs28934576 | p.Arg273Leu | missense variant | - | NC_000017.11:g.7673802C>A | 1000Genomes,ExAC,TOPMed,gnomAD |
RCV000568814 | p.Arg273Leu | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7673802C>A | ClinVar |
VAR_045867 | p.Arg273Asn | Missense | - | - | UniProt |
VAR_045868 | p.Arg273Tyr | Missense | - | - | UniProt |
VAR_045356 | p.Arg273Gln | Missense | - | - | UniProt |
VAR_005994 | p.Arg273Gly | Missense | Li-Fraumeni syndrome (LFS) [MIM:151623] | - | UniProt |
rs1057520006 | p.Val274Gly | missense variant | - | NC_000017.11:g.7673799A>C | UniProt,dbSNP |
VAR_047200 | p.Val274Gly | missense variant | - | NC_000017.11:g.7673799A>C | UniProt |
rs1057520006 | p.Val274Asp | missense variant | - | NC_000017.11:g.7673799A>T | UniProt,dbSNP |
VAR_045359 | p.Val274Asp | missense variant | - | NC_000017.11:g.7673799A>T | UniProt |
RCV000440120 | p.Val274Phe | missense variant | Neoplasm of brain | NC_000017.11:g.7673800C>A | ClinVar |
RCV000424885 | p.Val274Asp | missense variant | Adenocarcinoma of stomach | NC_000017.11:g.7673799A>T | ClinVar |
RCV000440773 | p.Val274Phe | missense variant | Neoplasm of the breast | NC_000017.11:g.7673800C>A | ClinVar |
RCV000421122 | p.Val274Gly | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7673799A>C | ClinVar |
RCV000423526 | p.Val274Phe | missense variant | Hepatocellular carcinoma (HCC) | NC_000017.11:g.7673800C>A | ClinVar |
RCV000424200 | p.Val274Asp | missense variant | Neoplasm of brain | NC_000017.11:g.7673799A>T | ClinVar |
RCV000430114 | p.Val274Phe | missense variant | Adenocarcinoma of stomach | NC_000017.11:g.7673800C>A | ClinVar |
RCV000429450 | p.Val274Phe | missense variant | Malignant melanoma of skin (CMM) | NC_000017.11:g.7673800C>A | ClinVar |
RCV000419239 | p.Val274Asp | missense variant | Malignant melanoma of skin (CMM) | NC_000017.11:g.7673799A>T | ClinVar |
RCV000419865 | p.Val274Gly | missense variant | Hepatocellular carcinoma (HCC) | NC_000017.11:g.7673799A>C | ClinVar |
RCV000701251 | p.Val274Leu | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673800C>G | ClinVar |
RCV000438006 | p.Val274Ala | missense variant | Adenocarcinoma of stomach | NC_000017.11:g.7673799A>G | ClinVar |
RCV000421817 | p.Val274Ala | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7673799A>G | ClinVar |
RCV000437117 | p.Val274Gly | missense variant | Neoplasm of brain | NC_000017.11:g.7673799A>C | ClinVar |
RCV000443884 | p.Val274Asp | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7673799A>T | ClinVar |
RCV000441279 | p.Val274Gly | missense variant | Neoplasm of the breast | NC_000017.11:g.7673799A>C | ClinVar |
RCV000436477 | p.Val274Asp | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7673799A>T | ClinVar |
RCV000426067 | p.Val274Ala | missense variant | Hepatocellular carcinoma (HCC) | NC_000017.11:g.7673799A>G | ClinVar |
RCV000426772 | p.Val274Ala | missense variant | Adenocarcinoma of prostate | NC_000017.11:g.7673799A>G | ClinVar |
RCV000419355 | p.Val274Phe | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7673800C>A | ClinVar |
RCV000420150 | p.Val274Ala | missense variant | Malignant melanoma of skin (CMM) | NC_000017.11:g.7673799A>G | ClinVar |
RCV000418736 | p.Val274Phe | missense variant | Neoplasm of the large intestine | NC_000017.11:g.7673800C>A | ClinVar |
RCV000492506 | p.Val274Gly | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7673799A>C | ClinVar |
RCV000427353 | p.Val274Ala | missense variant | Neoplasm of the large intestine | NC_000017.11:g.7673799A>G | ClinVar |
RCV000432482 | p.Val274Ala | missense variant | Lung adenocarcinoma | NC_000017.11:g.7673799A>G | ClinVar |
RCV000431168 | p.Val274Gly | missense variant | Neoplasm of the large intestine | NC_000017.11:g.7673799A>C | ClinVar |
RCV000437438 | p.Val274Ala | missense variant | Small cell lung cancer | NC_000017.11:g.7673799A>G | ClinVar |
RCV000439046 | p.Val274Gly | missense variant | Adenocarcinoma of stomach | NC_000017.11:g.7673799A>C | ClinVar |
RCV000438367 | p.Val274Gly | missense variant | Small cell lung cancer | NC_000017.11:g.7673799A>C | ClinVar |
RCV000436116 | p.Val274Phe | missense variant | Small cell lung cancer | NC_000017.11:g.7673800C>A | ClinVar |
RCV000425563 | p.Val274Asp | missense variant | Small cell lung cancer | NC_000017.11:g.7673799A>T | ClinVar |
RCV000431803 | p.Val274Gly | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7673799A>C | ClinVar |
RCV000431443 | p.Val274Asp | missense variant | Neoplasm of the large intestine | NC_000017.11:g.7673799A>T | ClinVar |
RCV000420544 | p.Val274Gly | missense variant | Lung adenocarcinoma | NC_000017.11:g.7673799A>C | ClinVar |
RCV000441480 | p.Val274Asp | missense variant | Lung adenocarcinoma | NC_000017.11:g.7673799A>T | ClinVar |
rs1057520006 | p.Val274Ala | missense variant | - | NC_000017.11:g.7673799A>G | UniProt,dbSNP |
VAR_045358 | p.Val274Ala | missense variant | - | NC_000017.11:g.7673799A>G | UniProt |
rs1057520005 | p.Val274Phe | missense variant | - | NC_000017.11:g.7673800C>A | - |
rs1057520005 | p.Val274Phe | missense variant | - | NC_000017.11:g.7673800C>A | UniProt,dbSNP |
VAR_005997 | p.Val274Phe | missense variant | - | NC_000017.11:g.7673800C>A | UniProt |
rs1057520005 | p.Val274Leu | missense variant | - | NC_000017.11:g.7673800C>G | UniProt,dbSNP |
VAR_045361 | p.Val274Leu | missense variant | - | NC_000017.11:g.7673800C>G | UniProt |
rs1057520005 | p.Val274Leu | missense variant | - | NC_000017.11:g.7673800C>G | - |
RCV000426446 | p.Val274Gly | missense variant | Adenocarcinoma of prostate | NC_000017.11:g.7673799A>C | ClinVar |
RCV000432106 | p.Val274Asp | missense variant | Hepatocellular carcinoma (HCC) | NC_000017.11:g.7673799A>T | ClinVar |
RCV000434236 | p.Val274Asp | missense variant | Adenocarcinoma of prostate | NC_000017.11:g.7673799A>T | ClinVar |
RCV000444136 | p.Val274Ala | missense variant | Neoplasm of the breast | NC_000017.11:g.7673799A>G | ClinVar |
RCV000435470 | p.Val274Phe | missense variant | Adenocarcinoma of prostate | NC_000017.11:g.7673800C>A | ClinVar |
RCV000430539 | p.Val274Gly | missense variant | Malignant melanoma of skin (CMM) | NC_000017.11:g.7673799A>C | ClinVar |
RCV000428932 | p.Val274Phe | missense variant | Lung adenocarcinoma | NC_000017.11:g.7673800C>A | ClinVar |
RCV000443016 | p.Val274Asp | missense variant | Neoplasm of the breast | NC_000017.11:g.7673799A>T | ClinVar |
RCV000418237 | p.Val274Phe | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7673800C>A | ClinVar |
RCV000443517 | p.Val274Ala | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7673799A>G | ClinVar |
RCV000433292 | p.Val274Ala | missense variant | Neoplasm of brain | NC_000017.11:g.7673799A>G | ClinVar |
RCV000697629 | p.Val274Ter | frameshift | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673799_7673800AC[1] | ClinVar |
VAR_045360 | p.Val274Ile | Missense | - | - | UniProt |
RCV000441393 | p.Cys275Arg | missense variant | Chronic lymphocytic leukemia (CLL) | NC_000017.11:g.7673797A>G | ClinVar |
RCV000431136 | p.Cys275Arg | missense variant | Renal cell carcinoma, papillary, 1 (RCCP1) | NC_000017.11:g.7673797A>G | ClinVar |
RCV000425483 | p.Cys275Arg | missense variant | Neoplasm of the large intestine | NC_000017.11:g.7673797A>G | ClinVar |
RCV000430390 | p.Cys275Arg | missense variant | - | NC_000017.11:g.7673797A>G | ClinVar |
RCV000426139 | p.Cys275Arg | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7673797A>G | ClinVar |
RCV000443110 | p.Cys275Arg | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7673797A>G | ClinVar |
RCV000424757 | p.Cys275Arg | missense variant | Multiple myeloma (MM) | NC_000017.11:g.7673797A>G | ClinVar |
RCV000432909 | p.Cys275Arg | missense variant | Lung adenocarcinoma | NC_000017.11:g.7673797A>G | ClinVar |
RCV000785323 | p.Cys275Phe | missense variant | Ovarian Neoplasms | NC_000017.11:g.7673796C>A | ClinVar |
RCV000423743 | p.Cys275Phe | missense variant | Neoplasm of brain | NC_000017.11:g.7673796C>A | ClinVar |
RCV000428868 | p.Cys275Phe | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7673796C>A | ClinVar |
RCV000434455 | p.Cys275Phe | missense variant | Carcinoma of esophagus | NC_000017.11:g.7673796C>A | ClinVar |
RCV000235315 | p.Cys275Tyr | missense variant | - | NC_000017.11:g.7673796C>T | ClinVar |
RCV000418840 | p.Cys275Phe | missense variant | Lung adenocarcinoma | NC_000017.11:g.7673796C>A | ClinVar |
RCV000423016 | p.Cys275Phe | missense variant | Renal cell carcinoma, papillary, 1 (RCCP1) | NC_000017.11:g.7673796C>A | ClinVar |
RCV000580293 | p.Cys275Ser | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7673796C>G | ClinVar |
COSM11501 | p.Cys275Gly | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7673797A>C | NCI-TCGA Cosmic |
COSM318164 | p.Cys275LeuPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7673796C>- | NCI-TCGA Cosmic |
COSM1268366 | p.Cys275Ter | stop gained | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7673795A>T | NCI-TCGA Cosmic |
COSM45251 | p.Cys275ValPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7673797A>- | NCI-TCGA Cosmic |
NCI-TCGA novel | p.Cys275Trp | inframe deletion | - | NC_000017.11:g.7673775_7673795CGGTCTCTCCCAGGACAGGCA>- | NCI-TCGA |
NCI-TCGA novel | p.Cys275LeuPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7673789_7673798ACAGGCACAA>- | NCI-TCGA |
NCI-TCGA novel | p.Cys275Ter | frameshift | - | NC_000017.11:g.7673783_7673796CCCAGGACAGGCAC>- | NCI-TCGA |
RCV000785448 | p.Cys275Trp | missense variant | Ovarian Neoplasms | NC_000017.11:g.7673795A>C | ClinVar |
RCV000436058 | p.Cys275Phe | missense variant | Hepatocellular carcinoma (HCC) | NC_000017.11:g.7673796C>A | ClinVar |
RCV000441009 | p.Cys275Phe | missense variant | Adrenocortical carcinoma | NC_000017.11:g.7673796C>A | ClinVar |
RCV000440235 | p.Cys275Phe | missense variant | Neoplasm of the large intestine | NC_000017.11:g.7673796C>A | ClinVar |
rs1057519983 | p.Cys275Arg | missense variant | - | NC_000017.11:g.7673797A>G | UniProt,dbSNP |
VAR_045364 | p.Cys275Arg | missense variant | - | NC_000017.11:g.7673797A>G | UniProt |
rs863224451 | p.Cys275Phe | missense variant | - | NC_000017.11:g.7673796C>A | UniProt,dbSNP |
VAR_045362 | p.Cys275Phe | missense variant | - | NC_000017.11:g.7673796C>A | UniProt |
rs1057519983 | p.Cys275Arg | missense variant | - | NC_000017.11:g.7673797A>G | - |
rs863224451 | p.Cys275Ser | missense variant | - | NC_000017.11:g.7673796C>G | UniProt,dbSNP |
VAR_045365 | p.Cys275Ser | missense variant | - | NC_000017.11:g.7673796C>G | UniProt |
rs863224451 | p.Cys275Tyr | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673796C>T | UniProt,dbSNP |
VAR_005998 | p.Cys275Tyr | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673796C>T | UniProt |
rs1555525279 | p.Cys275Trp | missense variant | - | NC_000017.11:g.7673795A>C | - |
rs1555525279 | p.Cys275Trp | missense variant | - | NC_000017.11:g.7673795A>C | UniProt,dbSNP |
VAR_005999 | p.Cys275Trp | missense variant | - | NC_000017.11:g.7673795A>C | UniProt |
rs863224451 | p.Cys275Ser | missense variant | - | NC_000017.11:g.7673796C>G | TOPMed,gnomAD |
rs863224451 | p.Cys275Phe | missense variant | - | NC_000017.11:g.7673796C>A | TOPMed,gnomAD |
rs863224451 | p.Cys275Tyr | missense variant | - | NC_000017.11:g.7673796C>T | TOPMed,gnomAD |
RCV000561423 | p.Cys275Trp | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7673795A>C | ClinVar |
RCV000433579 | p.Cys275Arg | missense variant | Carcinoma of esophagus | NC_000017.11:g.7673797A>G | ClinVar |
RCV000435015 | p.Cys275Arg | missense variant | Glioblastoma | NC_000017.11:g.7673797A>G | ClinVar |
RCV000420225 | p.Cys275Arg | missense variant | Neoplasm of the breast | NC_000017.11:g.7673797A>G | ClinVar |
RCV000435695 | p.Cys275Arg | missense variant | Malignant melanoma of skin (CMM) | NC_000017.11:g.7673797A>G | ClinVar |
RCV000442259 | p.Cys275Arg | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7673797A>G | ClinVar |
RCV000418020 | p.Cys275Arg | missense variant | Neoplasm of brain | NC_000017.11:g.7673797A>G | ClinVar |
RCV000420853 | p.Cys275Arg | missense variant | Hepatocellular carcinoma (HCC) | NC_000017.11:g.7673797A>G | ClinVar |
RCV000440640 | p.Cys275Arg | missense variant | Adrenocortical carcinoma | NC_000017.11:g.7673797A>G | ClinVar |
RCV000425095 | p.Cys275Phe | missense variant | Neoplasm of the breast | NC_000017.11:g.7673796C>A | ClinVar |
RCV000430324 | p.Cys275Phe | missense variant | Malignant melanoma of skin (CMM) | NC_000017.11:g.7673796C>A | ClinVar |
RCV000441652 | p.Cys275Phe | missense variant | Glioblastoma | NC_000017.11:g.7673796C>A | ClinVar |
RCV000432328 | p.Cys275Phe | missense variant | - | NC_000017.11:g.7673796C>A | ClinVar |
RCV000431612 | p.Cys275Phe | missense variant | Multiple myeloma (MM) | NC_000017.11:g.7673796C>A | ClinVar |
RCV000429558 | p.Cys275Phe | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7673796C>A | ClinVar |
RCV000420903 | p.Cys275Phe | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7673796C>A | ClinVar |
RCV000442601 | p.Cys275Phe | missense variant | Chronic lymphocytic leukemia (CLL) | NC_000017.11:g.7673796C>A | ClinVar |
VAR_045363 | p.Cys275Gly | Missense | - | - | UniProt |
RCV000785453 | p.Ala276Pro | missense variant | Ovarian Neoplasms | NC_000017.11:g.7673794C>G | ClinVar |
RCV000164718 | p.Ala276Gly | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7673793G>C | ClinVar |
COSM6019371 | p.Ala276LeuPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7673794_7673795CA>- | NCI-TCGA Cosmic |
NCI-TCGA novel | p.Ala276LeuPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7673794_7673795insACAA | NCI-TCGA |
RCV000223364 | p.Ala276Asp | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7673793G>T | ClinVar |
RCV000236401 | p.Ala276Asp | missense variant | - | NC_000017.11:g.7673793G>T | ClinVar |
rs786202082 | p.Ala276Gly | missense variant | - | NC_000017.11:g.7673793G>C | UniProt,dbSNP |
VAR_045367 | p.Ala276Gly | missense variant | - | NC_000017.11:g.7673793G>C | UniProt |
rs1131691029 | p.Ala276Pro | missense variant | - | NC_000017.11:g.7673794C>G | UniProt,dbSNP |
VAR_045368 | p.Ala276Pro | missense variant | - | NC_000017.11:g.7673794C>G | UniProt |
rs786202082 | p.Ala276Asp | missense variant | - | NC_000017.11:g.7673793G>T | UniProt,dbSNP |
VAR_045366 | p.Ala276Asp | missense variant | - | NC_000017.11:g.7673793G>T | UniProt |
VAR_045369 | p.Ala276Ser | Missense | - | - | UniProt |
VAR_045371 | p.Ala276Val | Missense | - | - | UniProt |
VAR_045370 | p.Ala276Thr | Missense | - | - | UniProt |
rs763098116 | p.Cys277Tyr | missense variant | - | NC_000017.11:g.7673790C>T | ExAC,gnomAD |
rs763098116 | p.Cys277Phe | missense variant | - | NC_000017.11:g.7673790C>A | UniProt,dbSNP |
VAR_045372 | p.Cys277Phe | missense variant | - | NC_000017.11:g.7673790C>A | UniProt |
RCV000819627 | p.Cys277Arg | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673791A>G | ClinVar |
RCV000793572 | p.Cys277Ter | nonsense | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673789A>T | ClinVar |
COSM1324808 | p.Cys277ValPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7673792G>- | NCI-TCGA Cosmic |
COSM45299 | p.Cys277Trp | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7673789A>C | NCI-TCGA Cosmic |
RCV000456858 | p.Cys277Tyr | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673790C>T | ClinVar |
RCV000532028 | p.Cys277Phe | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673790C>A | ClinVar |
rs763098116 | p.Cys277Phe | missense variant | - | NC_000017.11:g.7673790C>A | ExAC,gnomAD |
rs763098116 | p.Cys277Tyr | missense variant | - | NC_000017.11:g.7673790C>T | UniProt,dbSNP |
VAR_045375 | p.Cys277Tyr | missense variant | - | NC_000017.11:g.7673790C>T | UniProt |
rs1064795369 | p.Cys277Gly | missense variant | - | NC_000017.11:g.7673791A>C | UniProt,dbSNP |
VAR_006000 | p.Cys277Gly | missense variant | - | NC_000017.11:g.7673791A>C | UniProt |
rs1064795369 | p.Cys277Gly | missense variant | - | NC_000017.11:g.7673791A>C | TOPMed |
rs1064795369 | p.Cys277Arg | missense variant | - | NC_000017.11:g.7673791A>G | TOPMed |
rs1064795369 | p.Cys277Arg | missense variant | - | NC_000017.11:g.7673791A>G | UniProt,dbSNP |
VAR_045373 | p.Cys277Arg | missense variant | - | NC_000017.11:g.7673791A>G | UniProt |
VAR_047201 | p.Cys277Trp | Missense | - | - | UniProt |
VAR_045374 | p.Cys277Ser | Missense | - | - | UniProt |
rs876659802 | p.Pro278Leu | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673787G>A | UniProt,dbSNP |
VAR_006003 | p.Pro278Leu | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673787G>A | UniProt |
rs17849781 | p.Pro278Thr | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673788G>T | UniProt,dbSNP |
VAR_006005 | p.Pro278Thr | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673788G>T | UniProt |
RCV000417607 | p.Pro278His | missense variant | Neoplasm of brain | NC_000017.11:g.7673787G>T | ClinVar |
RCV000444453 | p.Pro278His | missense variant | Malignant neoplasm of body of uterus | NC_000017.11:g.7673787G>T | ClinVar |
RCV000433712 | p.Pro278His | missense variant | - | NC_000017.11:g.7673787G>T | ClinVar |
COSM1727548 | p.Pro278LeuPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7673787G>- | NCI-TCGA Cosmic |
COSM984875 | p.Pro278LeuPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7673787_7673788insGA | NCI-TCGA Cosmic |
RCV000427714 | p.Pro278Ser | missense variant | Lung adenocarcinoma | NC_000017.11:g.7673788G>A | ClinVar |
RCV000432977 | p.Pro278Ser | missense variant | Carcinoma of esophagus | NC_000017.11:g.7673788G>A | ClinVar |
RCV000426679 | p.Pro278Ser | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7673788G>A | ClinVar |
RCV000433428 | p.Pro278Ser | missense variant | Malignant neoplasm of body of uterus | NC_000017.11:g.7673788G>A | ClinVar |
RCV000626445 | p.Pro278Thr | missense variant | - | NC_000017.11:g.7673788G>T | ClinVar |
RCV000688854 | p.Pro278Ala | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673788G>C | ClinVar |
RCV000421997 | p.Pro278Ser | missense variant | - | NC_000017.11:g.7673788G>A | ClinVar |
RCV000435645 | p.Pro278Ser | missense variant | Neoplasm of the breast | NC_000017.11:g.7673788G>A | ClinVar |
RCV000442821 | p.Pro278Ser | missense variant | Squamous cell lung carcinoma | NC_000017.11:g.7673788G>A | ClinVar |
RCV000444293 | p.Pro278Ser | missense variant | Neoplasm of the large intestine | NC_000017.11:g.7673788G>A | ClinVar |
RCV000797363 | p.Pro278Arg | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673787G>C | ClinVar |
RCV000420265 | p.Pro278His | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7673787G>T | ClinVar |
RCV000443564 | p.Pro278His | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7673787G>T | ClinVar |
RCV000437485 | p.Pro278His | missense variant | Neoplasm of the breast | NC_000017.11:g.7673787G>T | ClinVar |
rs17849781 | p.Pro278Ala | missense variant | - | NC_000017.11:g.7673788G>C | UniProt,dbSNP |
VAR_006001 | p.Pro278Ala | missense variant | - | NC_000017.11:g.7673788G>C | UniProt |
rs876659802 | p.Pro278His | missense variant | - | NC_000017.11:g.7673787G>T | UniProt,dbSNP |
VAR_006002 | p.Pro278His | missense variant | - | NC_000017.11:g.7673787G>T | UniProt |
rs876659802 | p.Pro278Arg | missense variant | - | NC_000017.11:g.7673787G>C | UniProt,dbSNP |
VAR_045376 | p.Pro278Arg | missense variant | - | NC_000017.11:g.7673787G>C | UniProt |
rs17849781 | p.Pro278Ser | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673788G>A | UniProt,dbSNP |
VAR_006004 | p.Pro278Ser | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673788G>A | UniProt |
RCV000567850 | p.Pro278Ala | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7673788G>C | ClinVar |
RCV000785527 | p.Pro278Ser | missense variant | Ovarian Neoplasms | NC_000017.11:g.7673788G>A | ClinVar |
RCV000443572 | p.Pro278Ser | missense variant | Multiple myeloma (MM) | NC_000017.11:g.7673788G>A | ClinVar |
RCV000427094 | p.Pro278Ser | missense variant | Malignant melanoma of skin (CMM) | NC_000017.11:g.7673788G>A | ClinVar |
RCV000437941 | p.Pro278Ser | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7673788G>A | ClinVar |
RCV000424797 | p.Pro278His | missense variant | Squamous cell lung carcinoma | NC_000017.11:g.7673787G>T | ClinVar |
RCV000572417 | p.Pro278Arg | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7673787G>C | ClinVar |
RCV000432228 | p.Pro278Ser | missense variant | Neoplasm of brain | NC_000017.11:g.7673788G>A | ClinVar |
RCV000439725 | p.Pro278Ser | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7673788G>A | ClinVar |
RCV000422133 | p.Pro278His | missense variant | Malignant melanoma of skin (CMM) | NC_000017.11:g.7673787G>T | ClinVar |
RCV000214784 | p.Pro278Leu | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7673787G>A | ClinVar |
RCV000428293 | p.Pro278His | missense variant | Neoplasm of the large intestine | NC_000017.11:g.7673787G>T | ClinVar |
RCV000433513 | p.Pro278His | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7673787G>T | ClinVar |
RCV000426301 | p.Pro278His | missense variant | Carcinoma of esophagus | NC_000017.11:g.7673787G>T | ClinVar |
RCV000427682 | p.Pro278His | missense variant | Multiple myeloma (MM) | NC_000017.11:g.7673787G>T | ClinVar |
RCV000435517 | p.Pro278His | missense variant | Lung adenocarcinoma | NC_000017.11:g.7673787G>T | ClinVar |
VAR_045869 | p.Pro278Phe | Missense | - | - | UniProt |
RCV000584418 | p.Gly279Glu | missense variant | - | NC_000017.11:g.7673784C>T | ClinVar |
COSM417973 | p.Gly279Arg | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7673785C>G | NCI-TCGA Cosmic |
NCI-TCGA novel | p.Gly279ProPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7673786_7673787insGGACAGGC | NCI-TCGA |
rs1555525248 | p.Gly279Arg | missense variant | - | NC_000017.11:g.7673785C>T | UniProt,dbSNP |
VAR_045377 | p.Gly279Arg | missense variant | - | NC_000017.11:g.7673785C>T | UniProt |
rs1555525248 | p.Gly279Arg | missense variant | - | NC_000017.11:g.7673785C>T | - |
rs1064793881 | p.Gly279Glu | missense variant | - | NC_000017.11:g.7673784C>T | UniProt,dbSNP |
VAR_006006 | p.Gly279Glu | missense variant | - | NC_000017.11:g.7673784C>T | UniProt |
RCV000547189 | p.Gly279Arg | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673785C>T | ClinVar |
RCV000566142 | p.Gly279Arg | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7673785C>T | ClinVar |
VAR_045378 | p.Gly279Val | Missense | - | - | UniProt |
VAR_045379 | p.Gly279Trp | Missense | - | - | UniProt |
RCV000421544 | p.Arg280Ile | missense variant | - | NC_000017.11:g.7673781C>A | ClinVar |
RCV000438915 | p.Arg280Ile | missense variant | Neoplasm of the breast | NC_000017.11:g.7673781C>A | ClinVar |
RCV000444610 | p.Arg280Lys | missense variant | Small cell lung cancer | NC_000017.11:g.7673781C>T | ClinVar |
RCV000013167 | p.Arg280Thr | missense variant | Nasopharyngeal carcinoma | NC_000017.11:g.7673781C>G | ClinVar |
RCV000431165 | p.Arg280Lys | missense variant | Neoplasm of the breast | NC_000017.11:g.7673781C>T | ClinVar |
RCV000417523 | p.Arg280Ile | missense variant | Malignant melanoma of skin (CMM) | NC_000017.11:g.7673781C>A | ClinVar |
RCV000434213 | p.Arg280Ile | missense variant | Squamous cell lung carcinoma | NC_000017.11:g.7673781C>A | ClinVar |
RCV000436148 | p.Arg280Lys | missense variant | Uterine Carcinosarcoma | NC_000017.11:g.7673781C>T | ClinVar |
RCV000419067 | p.Arg280Ile | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7673781C>A | ClinVar |
RCV000433708 | p.Arg280Lys | missense variant | Nasopharyngeal Neoplasms | NC_000017.11:g.7673781C>T | ClinVar |
RCV000427666 | p.Arg280Ile | missense variant | Uterine cervical neoplasms | NC_000017.11:g.7673781C>A | ClinVar |
RCV000418023 | p.Arg280Lys | missense variant | Malignant melanoma of skin (CMM) | NC_000017.11:g.7673781C>T | ClinVar |
RCV000492483 | p.Arg280Lys | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7673781C>T | ClinVar |
RCV000437418 | p.Arg280Ile | missense variant | Lung adenocarcinoma | NC_000017.11:g.7673781C>A | ClinVar |
RCV000425366 | p.Arg280Lys | missense variant | Hepatocellular carcinoma (HCC) | NC_000017.11:g.7673781C>T | ClinVar |
RCV000428952 | p.Arg280Lys | missense variant | Uterine cervical neoplasms | NC_000017.11:g.7673781C>T | ClinVar |
RCV000423448 | p.Arg280Lys | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7673781C>T | ClinVar |
RCV000434436 | p.Arg280Ile | missense variant | Carcinoma of esophagus | NC_000017.11:g.7673781C>A | ClinVar |
RCV000442077 | p.Arg280Lys | missense variant | Neoplasm of brain | NC_000017.11:g.7673781C>T | ClinVar |
RCV000425612 | p.Arg280Ile | missense variant | Hepatocellular carcinoma (HCC) | NC_000017.11:g.7673781C>A | ClinVar |
RCV000423739 | p.Arg280Lys | missense variant | Squamous cell lung carcinoma | NC_000017.11:g.7673781C>T | ClinVar |
RCV000445156 | p.Arg280Gly | missense variant | Uterine cervical neoplasms | NC_000017.11:g.7673782T>C | ClinVar |
RCV000426479 | p.Arg280Gly | missense variant | Adenocarcinoma of stomach | NC_000017.11:g.7673782T>C | ClinVar |
RCV000421324 | p.Arg280Gly | missense variant | Nasopharyngeal Neoplasms | NC_000017.11:g.7673782T>C | ClinVar |
RCV000427170 | p.Arg280Gly | missense variant | Carcinoma of esophagus | NC_000017.11:g.7673782T>C | ClinVar |
RCV000438255 | p.Arg280Gly | missense variant | Neoplasm of the breast | NC_000017.11:g.7673782T>C | ClinVar |
RCV000785300 | p.Arg280Gly | missense variant | Ovarian Neoplasms | NC_000017.11:g.7673782T>C | ClinVar |
RCV000439157 | p.Arg280Gly | missense variant | Hepatocellular carcinoma (HCC) | NC_000017.11:g.7673782T>C | ClinVar |
RCV000436708 | p.Arg280Gly | missense variant | Lung adenocarcinoma | NC_000017.11:g.7673782T>C | ClinVar |
RCV000438568 | p.Arg280Lys | missense variant | Carcinoma of esophagus | NC_000017.11:g.7673781C>T | ClinVar |
RCV000428657 | p.Arg280Ile | missense variant | Neoplasm of brain | NC_000017.11:g.7673781C>A | ClinVar |
RCV000440980 | p.Arg280Lys | missense variant | Acute myeloid leukemia (AML) | NC_000017.11:g.7673781C>T | ClinVar |
RCV000433592 | p.Arg280Lys | missense variant | - | NC_000017.11:g.7673781C>T | ClinVar |
RCV000445006 | p.Arg280Ile | missense variant | Uterine Carcinosarcoma | NC_000017.11:g.7673781C>A | ClinVar |
RCV000428734 | p.Arg280Lys | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7673781C>T | ClinVar |
RCV000442289 | p.Arg280Ile | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7673781C>A | ClinVar |
RCV000438665 | p.Arg280Ile | missense variant | - | NC_000017.11:g.7673781C>A | ClinVar |
RCV000444685 | p.Arg280Lys | missense variant | - | NC_000017.11:g.7673781C>T | ClinVar |
RCV000429336 | p.Arg280Ile | missense variant | Adenocarcinoma of stomach | NC_000017.11:g.7673781C>A | ClinVar |
RCV000436528 | p.Arg280Lys | missense variant | Adenocarcinoma of stomach | NC_000017.11:g.7673781C>T | ClinVar |
RCV000435871 | p.Arg280Ile | missense variant | Nasopharyngeal Neoplasms | NC_000017.11:g.7673781C>A | ClinVar |
RCV000423933 | p.Arg280Lys | missense variant | Lung adenocarcinoma | NC_000017.11:g.7673781C>T | ClinVar |
RCV000426315 | p.Arg280Ile | missense variant | Small cell lung cancer | NC_000017.11:g.7673781C>A | ClinVar |
RCV000419744 | p.Arg280Ile | missense variant | Acute myeloid leukemia (AML) | NC_000017.11:g.7673781C>A | ClinVar |
COSM1480058 | p.Arg280Ter | stop gained | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7673782T>A | NCI-TCGA Cosmic |
COSM2744526 | p.Arg280Ser | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7673780T>A | NCI-TCGA Cosmic |
RCV000439812 | p.Arg280Gly | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7673782T>C | ClinVar |
NCI-TCGA novel | p.Arg280LysPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7673763_7673781TCCTCTGTGCGCCGGTCTC>- | NCI-TCGA |
NCI-TCGA novel | p.Arg280GluPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7673783C>- | NCI-TCGA |
RCV000420625 | p.Arg280Gly | missense variant | Squamous cell lung carcinoma | NC_000017.11:g.7673782T>C | ClinVar |
RCV000430194 | p.Arg280Gly | missense variant | - | NC_000017.11:g.7673782T>C | ClinVar |
RCV000418465 | p.Arg280Gly | missense variant | Small cell lung cancer | NC_000017.11:g.7673782T>C | ClinVar |
RCV000429590 | p.Arg280Gly | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7673782T>C | ClinVar |
RCV000419917 | p.Arg280Gly | missense variant | Malignant melanoma of skin (CMM) | NC_000017.11:g.7673782T>C | ClinVar |
RCV000431582 | p.Arg280Gly | missense variant | - | NC_000017.11:g.7673782T>C | ClinVar |
RCV000772426 | p.Arg280Ter | frameshift | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7673781del | ClinVar |
rs753660142 | p.Arg280Gly | missense variant | - | NC_000017.11:g.7673782T>C | ExAC,gnomAD |
rs121912660 | p.Arg280Ile | missense variant | - | NC_000017.11:g.7673781C>A | UniProt,dbSNP |
VAR_006008 | p.Arg280Ile | missense variant | - | NC_000017.11:g.7673781C>A | UniProt |
rs121912660 | p.Arg280Thr | missense variant | - | NC_000017.11:g.7673781C>G | UniProt,dbSNP |
VAR_006009 | p.Arg280Thr | missense variant | - | NC_000017.11:g.7673781C>G | UniProt |
rs121912660 | p.Arg280Lys | missense variant | - | NC_000017.11:g.7673781C>T | UniProt,dbSNP |
VAR_006007 | p.Arg280Lys | missense variant | - | NC_000017.11:g.7673781C>T | UniProt |
RCV000785449 | p.Arg280Ser | missense variant | Ovarian Neoplasms | NC_000017.11:g.7673780T>G | ClinVar |
RCV000424417 | p.Arg280Gly | missense variant | Uterine Carcinosarcoma | NC_000017.11:g.7673782T>C | ClinVar |
RCV000435565 | p.Arg280Gly | missense variant | Neoplasm of brain | NC_000017.11:g.7673782T>C | ClinVar |
RCV000439619 | p.Arg280Gly | missense variant | Acute myeloid leukemia (AML) | NC_000017.11:g.7673782T>C | ClinVar |
RCV000568150 | p.Arg280Gly | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7673782T>C | ClinVar |
VAR_045381 | p.Arg280Pro | Missense | - | - | UniProt |
VAR_045382 | p.Arg280Ser | Missense | - | - | UniProt |
rs764146326 | p.Asp281His | missense variant | - | NC_000017.11:g.7673779C>G | UniProt,dbSNP |
VAR_006013 | p.Asp281His | missense variant | - | NC_000017.11:g.7673779C>G | UniProt |
rs764146326 | p.Asp281His | missense variant | - | NC_000017.11:g.7673779C>G | ExAC,TOPMed,gnomAD |
rs1057519984 | p.Asp281Glu | missense variant | - | NC_000017.11:g.7673777G>T | UniProt,dbSNP |
VAR_006011 | p.Asp281Glu | missense variant | - | NC_000017.11:g.7673777G>T | UniProt |
rs587781525 | p.Asp281Gly | missense variant | - | NC_000017.11:g.7673778T>C | UniProt,dbSNP |
VAR_006012 | p.Asp281Gly | missense variant | - | NC_000017.11:g.7673778T>C | UniProt |
RCV000470818 | p.Asp281Glu | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673777G>T | ClinVar |
RCV000633352 | p.Asp281Glu | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673777G>C | ClinVar |
RCV000499361 | p.Asp281Glu | missense variant | Carcinoma of colon (CRC) | NC_000017.11:g.7673777G>T | ClinVar |
RCV000438210 | p.Asp281Ala | missense variant | Malignant neoplasm of body of uterus | NC_000017.11:g.7673778T>G | ClinVar |
RCV000434194 | p.Asp281Val | missense variant | Renal cell carcinoma, papillary, 1 (RCCP1) | NC_000017.11:g.7673778T>A | ClinVar |
RCV000442104 | p.Asp281Val | missense variant | Squamous cell lung carcinoma | NC_000017.11:g.7673778T>A | ClinVar |
RCV000435611 | p.Asp281Ala | missense variant | Chronic lymphocytic leukemia (CLL) | NC_000017.11:g.7673778T>G | ClinVar |
RCV000427537 | p.Asp281Ala | missense variant | - | NC_000017.11:g.7673778T>G | ClinVar |
RCV000417517 | p.Asp281Ala | missense variant | Uterine Carcinosarcoma | NC_000017.11:g.7673778T>G | ClinVar |
RCV000418100 | p.Asp281Val | missense variant | Uterine Carcinosarcoma | NC_000017.11:g.7673778T>A | ClinVar |
RCV000429671 | p.Asp281His | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7673779C>G | ClinVar |
RCV000436837 | p.Asp281His | missense variant | - | NC_000017.11:g.7673779C>G | ClinVar |
RCV000427507 | p.Asp281His | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7673779C>G | ClinVar |
RCV000420094 | p.Asp281His | missense variant | Malignant melanoma of skin (CMM) | NC_000017.11:g.7673779C>G | ClinVar |
RCV000427301 | p.Asp281His | missense variant | Renal cell carcinoma, papillary, 1 (RCCP1) | NC_000017.11:g.7673779C>G | ClinVar |
RCV000633367 | p.Asp281Gly | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673778T>C | ClinVar |
RCV000440916 | p.Asp281Val | missense variant | Malignant neoplasm of body of uterus | NC_000017.11:g.7673778T>A | ClinVar |
RCV000432892 | p.Asp281Val | missense variant | Multiple myeloma (MM) | NC_000017.11:g.7673778T>A | ClinVar |
RCV000435739 | p.Asp281Val | missense variant | Neoplasm of the breast | NC_000017.11:g.7673778T>A | ClinVar |
RCV000419849 | p.Asp281Ala | missense variant | Adenocarcinoma of stomach | NC_000017.11:g.7673778T>G | ClinVar |
RCV000435784 | p.Asp281Ala | missense variant | Renal cell carcinoma, papillary, 1 (RCCP1) | NC_000017.11:g.7673778T>G | ClinVar |
RCV000443934 | p.Asp281Ala | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7673778T>G | ClinVar |
RCV000442214 | p.Asp281Ala | missense variant | Squamous cell lung carcinoma | NC_000017.11:g.7673778T>G | ClinVar |
RCV000433406 | p.Asp281Ala | missense variant | Neuroblastoma (NBLST1) | NC_000017.11:g.7673778T>G | ClinVar |
RCV000440361 | p.Asp281Ala | missense variant | Malignant melanoma of skin (CMM) | NC_000017.11:g.7673778T>G | ClinVar |
RCV000426125 | p.Asp281Val | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7673778T>A | ClinVar |
RCV000215048 | p.Asp281Val | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7673778T>A | ClinVar |
RCV000431328 | p.Asp281Val | missense variant | Lung adenocarcinoma | NC_000017.11:g.7673778T>A | ClinVar |
RCV000425979 | p.Asp281Ala | missense variant | Lung adenocarcinoma | NC_000017.11:g.7673778T>G | ClinVar |
RCV000423186 | p.Asp281Val | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7673778T>A | ClinVar |
RCV000442965 | p.Asp281Ala | missense variant | - | NC_000017.11:g.7673778T>G | ClinVar |
RCV000430790 | p.Asp281Ala | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7673778T>G | ClinVar |
RCV000440602 | p.Asp281Ala | missense variant | Glioblastoma | NC_000017.11:g.7673778T>G | ClinVar |
RCV000422679 | p.Asp281Ala | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7673778T>G | ClinVar |
RCV000424893 | p.Asp281Ala | missense variant | Hepatocellular carcinoma (HCC) | NC_000017.11:g.7673778T>G | ClinVar |
RCV000438736 | p.Asp281Val | missense variant | Adenocarcinoma of stomach | NC_000017.11:g.7673778T>A | ClinVar |
RCV000423894 | p.Asp281Val | missense variant | Glioblastoma | NC_000017.11:g.7673778T>A | ClinVar |
RCV000433464 | p.Asp281Val | missense variant | Malignant melanoma of skin (CMM) | NC_000017.11:g.7673778T>A | ClinVar |
RCV000439212 | p.Asp281His | missense variant | Hepatocellular carcinoma (HCC) | NC_000017.11:g.7673779C>G | ClinVar |
RCV000438193 | p.Asp281His | missense variant | Neoplasm of the breast | NC_000017.11:g.7673779C>G | ClinVar |
RCV000428355 | p.Asp281His | missense variant | Chronic lymphocytic leukemia (CLL) | NC_000017.11:g.7673779C>G | ClinVar |
RCV000422034 | p.Asp281His | missense variant | Multiple myeloma (MM) | NC_000017.11:g.7673779C>G | ClinVar |
RCV000419869 | p.Asp281His | missense variant | - | NC_000017.11:g.7673779C>G | ClinVar |
RCV000434610 | p.Asp281His | missense variant | Lung adenocarcinoma | NC_000017.11:g.7673779C>G | ClinVar |
NCI-TCGA novel | p.Asp281GluPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7673777_7673778insTCTC | NCI-TCGA |
NCI-TCGA novel | p.Asp281AlaPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7673772_7673778CGCCGGT>- | NCI-TCGA |
NCI-TCGA novel | p.Asp281GlyPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7673775_7673778CGGT>- | NCI-TCGA |
RCV000437082 | p.Asp281His | missense variant | Malignant neoplasm of body of uterus | NC_000017.11:g.7673779C>G | ClinVar |
RCV000423682 | p.Asp281His | missense variant | Uterine Carcinosarcoma | NC_000017.11:g.7673779C>G | ClinVar |
RCV000443566 | p.Asp281His | missense variant | Glioblastoma | NC_000017.11:g.7673779C>G | ClinVar |
RCV000824609 | p.Asp281Asn | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673779C>T | ClinVar |
RCV000691758 | p.Asp281Ter | frameshift | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673778_7673779TC[2] | ClinVar |
rs587781525 | p.Asp281Val | missense variant | - | NC_000017.11:g.7673778T>A | UniProt,dbSNP |
VAR_006014 | p.Asp281Val | missense variant | - | NC_000017.11:g.7673778T>A | UniProt |
rs764146326 | p.Asp281Asn | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673779C>T | UniProt,dbSNP |
VAR_047202 | p.Asp281Asn | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673779C>T | UniProt |
rs764146326 | p.Asp281Asn | missense variant | - | NC_000017.11:g.7673779C>T | ExAC,TOPMed,gnomAD |
rs587781525 | p.Asp281Ala | missense variant | - | NC_000017.11:g.7673778T>G | - |
rs764146326 | p.Asp281Tyr | missense variant | - | NC_000017.11:g.7673779C>A | ExAC,TOPMed,gnomAD |
rs587781525 | p.Asp281Ala | missense variant | - | NC_000017.11:g.7673778T>G | UniProt,dbSNP |
VAR_006010 | p.Asp281Ala | missense variant | - | NC_000017.11:g.7673778T>G | UniProt |
rs764146326 | p.Asp281Tyr | missense variant | - | NC_000017.11:g.7673779C>A | UniProt,dbSNP |
VAR_045383 | p.Asp281Tyr | missense variant | - | NC_000017.11:g.7673779C>A | UniProt |
RCV000429459 | p.Asp281His | missense variant | Adenocarcinoma of stomach | NC_000017.11:g.7673779C>G | ClinVar |
RCV000418744 | p.Asp281His | missense variant | Squamous cell lung carcinoma | NC_000017.11:g.7673779C>G | ClinVar |
RCV000421295 | p.Asp281His | missense variant | Neuroblastoma (NBLST1) | NC_000017.11:g.7673779C>G | ClinVar |
RCV000439019 | p.Asp281His | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7673779C>G | ClinVar |
RCV000792342 | p.Asp281Tyr | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673779C>A | ClinVar |
RCV000443096 | p.Asp281Val | missense variant | Hepatocellular carcinoma (HCC) | NC_000017.11:g.7673778T>A | ClinVar |
RCV000417569 | p.Asp281Val | missense variant | Chronic lymphocytic leukemia (CLL) | NC_000017.11:g.7673778T>A | ClinVar |
RCV000425401 | p.Asp281Val | missense variant | - | NC_000017.11:g.7673778T>A | ClinVar |
RCV000420104 | p.Asp281Ala | missense variant | Neoplasm of the breast | NC_000017.11:g.7673778T>G | ClinVar |
RCV000435682 | p.Asp281Val | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7673778T>A | ClinVar |
RCV000428503 | p.Asp281Val | missense variant | - | NC_000017.11:g.7673778T>A | ClinVar |
RCV000129516 | p.Asp281Gly | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7673778T>C | ClinVar |
RCV000429708 | p.Asp281Ala | missense variant | Multiple myeloma (MM) | NC_000017.11:g.7673778T>G | ClinVar |
RCV000441595 | p.Asp281Val | missense variant | Neuroblastoma (NBLST1) | NC_000017.11:g.7673778T>A | ClinVar |
RCV000658764 | p.Asp281Glu | missense variant | - | NC_000017.11:g.7673777G>T | ClinVar |
RCV000570263 | p.Asp281Ter | frameshift | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7673777_7673778insC | ClinVar |
VAR_047203 | p.Asp281_Arg282delinsGluTrp | deletion_insertion | - | - | UniProt |
VAR_045870 | p.Asp281Arg | Missense | - | - | UniProt |
rs28934574 | p.Arg282Gly | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673776G>C | UniProt,dbSNP |
VAR_045384 | p.Arg282Gly | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673776G>C | UniProt |
rs28934574 | p.Arg282Trp | missense variant | - | NC_000017.11:g.7673776G>A | ESP,ExAC,gnomAD |
RCV000430393 | p.Arg282Gly | missense variant | Malignant neoplasm of body of uterus | NC_000017.11:g.7673776G>C | ClinVar |
RCV000435503 | p.Arg282Gly | missense variant | - | NC_000017.11:g.7673776G>C | ClinVar |
RCV000419993 | p.Arg282Gly | missense variant | Neoplasm of brain | NC_000017.11:g.7673776G>C | ClinVar |
RCV000492443 | p.Arg282Ter | frameshift | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7673777del | ClinVar |
RCV000213059 | p.Arg282Leu | missense variant | - | NC_000017.11:g.7673775C>A | ClinVar |
COSM43813 | p.Arg282GlyPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7673776G>- | NCI-TCGA Cosmic |
RCV000437219 | p.Arg282Gly | missense variant | Neoplasm of the breast | NC_000017.11:g.7673776G>C | ClinVar |
RCV000785299 | p.Arg282Gly | missense variant | Ovarian Neoplasms | NC_000017.11:g.7673776G>C | ClinVar |
RCV000437895 | p.Arg282Gly | missense variant | - | NC_000017.11:g.7673776G>C | ClinVar |
RCV000440653 | p.Arg282Gly | missense variant | Renal cell carcinoma, papillary, 1 (RCCP1) | NC_000017.11:g.7673776G>C | ClinVar |
RCV000442540 | p.Arg282Gly | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7673776G>C | ClinVar |
rs28934574 | p.Arg282Gly | missense variant | - | NC_000017.11:g.7673776G>C | ESP,ExAC,gnomAD |
RCV000161038 | p.Arg282Leu | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7673775C>A | ClinVar |
NCI-TCGA novel | p.Arg282ProPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7673775_7673776insCGGCG | NCI-TCGA |
RCV000226273 | p.Arg282Gln | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673775C>T | ClinVar |
RCV000709402 | p.Arg282Pro | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673775C>G | ClinVar |
rs730882008 | p.Arg282Pro | missense variant | - | NC_000017.11:g.7673775C>G | TOPMed,gnomAD |
rs730882008 | p.Arg282Gln | missense variant | - | NC_000017.11:g.7673775C>T | TOPMed,gnomAD |
rs28934574 | p.Arg282Trp | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673776G>A | UniProt,dbSNP |
VAR_006016 | p.Arg282Trp | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673776G>A | UniProt |
RCV000633381 | p.Arg282Leu | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673775C>A | ClinVar |
RCV000425179 | p.Arg282Gly | missense variant | Glioblastoma | NC_000017.11:g.7673776G>C | ClinVar |
RCV000422134 | p.Arg282Gly | missense variant | Lung adenocarcinoma | NC_000017.11:g.7673776G>C | ClinVar |
RCV000432433 | p.Arg282Gly | missense variant | Squamous cell lung carcinoma | NC_000017.11:g.7673776G>C | ClinVar |
RCV000431764 | p.Arg282Gly | missense variant | Adenocarcinoma of stomach | NC_000017.11:g.7673776G>C | ClinVar |
RCV000419333 | p.Arg282Gly | missense variant | Non-Hodgkin lymphoma (NHL) | NC_000017.11:g.7673776G>C | ClinVar |
RCV000422747 | p.Arg282Gly | missense variant | Carcinoma of esophagus | NC_000017.11:g.7673776G>C | ClinVar |
RCV000210145 | p.Arg282Trp | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7673776G>A | ClinVar |
RCV000430047 | p.Arg282Gly | missense variant | Adenocarcinoma of prostate | NC_000017.11:g.7673776G>C | ClinVar |
RCV000445294 | p.Arg282Gly | missense variant | Neoplasm of the large intestine | NC_000017.11:g.7673776G>C | ClinVar |
RCV000440446 | p.Arg282Gly | missense variant | Malignant melanoma of skin (CMM) | NC_000017.11:g.7673776G>C | ClinVar |
rs730882008 | p.Arg282Leu | missense variant | - | NC_000017.11:g.7673775C>A | TOPMed,gnomAD |
RCV000442627 | p.Arg282Gly | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7673776G>C | ClinVar |
RCV000427647 | p.Arg282Gly | missense variant | Hepatocellular carcinoma (HCC) | NC_000017.11:g.7673776G>C | ClinVar |
RCV000422367 | p.Arg282Gly | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7673776G>C | ClinVar |
VAR_045385 | p.Arg282His | Missense | - | - | UniProt |
RCV000565161 | p.Arg283Pro | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7673772C>G | ClinVar |
RCV000200641 | p.Arg283Cys | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673773G>A | ClinVar |
COSM3718839 | p.Arg283AlaPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7673774C>- | NCI-TCGA Cosmic |
RCV000633386 | p.Arg283Ter | frameshift | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673773_7673776delinsCT | ClinVar |
rs149633775 | p.Arg283Ser | missense variant | - | NC_000017.11:g.7673773G>T | ESP,ExAC,TOPMed,gnomAD |
rs149633775 | p.Arg283Cys | missense variant | - | NC_000017.11:g.7673773G>A | ESP,ExAC,TOPMed,gnomAD |
rs149633775 | p.Arg283Cys | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673773G>A | UniProt,dbSNP |
VAR_006017 | p.Arg283Cys | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673773G>A | UniProt |
rs371409680 | p.Arg283Pro | missense variant | - | NC_000017.11:g.7673772C>G | ESP,ExAC,TOPMed,gnomAD |
rs371409680 | p.Arg283His | missense variant | - | NC_000017.11:g.7673772C>T | ESP,ExAC,TOPMed,gnomAD |
rs149633775 | p.Arg283Ser | missense variant | - | NC_000017.11:g.7673773G>T | UniProt,dbSNP |
VAR_045389 | p.Arg283Ser | missense variant | - | NC_000017.11:g.7673773G>T | UniProt |
RCV000552974 | p.Arg283Ter | frameshift | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673763_7673772del | ClinVar |
RCV000507738 | p.Arg283His | missense variant | - | NC_000017.11:g.7673772C>T | ClinVar |
VAR_006020 | p.Arg283Pro | Missense | - | - | UniProt |
VAR_045388 | p.Arg283Leu | Missense | - | - | UniProt |
VAR_006018 | p.Arg283Gly | Missense | - | - | UniProt |
RCV000563243 | p.Thr284Ser | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7673770T>A | ClinVar |
RCV000546011 | p.Thr284Ser | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673770T>A | ClinVar |
COSM69017 | p.Thr284GlnPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7673770T>- | NCI-TCGA Cosmic |
NCI-TCGA novel | p.Thr284LysPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7673769G>- | NCI-TCGA |
NCI-TCGA novel | p.Thr284HisPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7673771_7673772insA | NCI-TCGA |
RCV000197045 | p.Thr284Ile | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673769G>A | ClinVar |
rs1204379654 | p.Thr284Pro | missense variant | - | NC_000017.11:g.7673770T>G | UniProt,dbSNP |
VAR_006022 | p.Thr284Pro | missense variant | - | NC_000017.11:g.7673770T>G | UniProt |
rs1204379654 | p.Thr284Pro | missense variant | - | NC_000017.11:g.7673770T>G | TOPMed |
rs863224685 | p.Thr284Ile | missense variant | - | NC_000017.11:g.7673769G>A | UniProt,dbSNP |
VAR_045390 | p.Thr284Ile | missense variant | - | NC_000017.11:g.7673769G>A | UniProt |
rs863224685 | p.Thr284Ile | missense variant | - | NC_000017.11:g.7673769G>A | TOPMed |
rs1204379654 | p.Thr284Ser | missense variant | - | NC_000017.11:g.7673770T>A | TOPMed |
RCV000483278 | p.Thr284Ile | missense variant | - | NC_000017.11:g.7673769G>A | ClinVar |
RCV000569733 | p.Thr284Ile | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7673769G>A | ClinVar |
VAR_045391 | p.Thr284Lys | Missense | - | - | UniProt |
VAR_006021 | p.Thr284Ala | Missense | - | - | UniProt |
RCV000479542 | p.Glu285Lys | missense variant | - | NC_000017.11:g.7673767C>T | ClinVar |
RCV000492206 | p.Glu285Lys | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7673767C>T | ClinVar |
RCV000013184 | p.Glu285Val | missense variant | Adrenocortical carcinoma, pediatric | NC_000017.11:g.7673766T>A | ClinVar |
RCV000813961 | p.Glu285Val | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673766T>A | ClinVar |
COSM1649344 | p.Glu285Ter | stop gained | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7673767C>A | NCI-TCGA Cosmic |
NCI-TCGA novel | p.Glu285ArgPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7673749_7673767TGCGGAGATTCTCTTCCTC>- | NCI-TCGA |
rs121912667 | p.Glu285Val | missense variant | - | NC_000017.11:g.7673766T>A | ExAC,gnomAD |
rs121912667 | p.Glu285Val | missense variant | - | NC_000017.11:g.7673766T>A | UniProt,dbSNP |
VAR_006025 | p.Glu285Val | missense variant | - | NC_000017.11:g.7673766T>A | UniProt |
RCV000013185 | p.Glu285Val | missense variant | Choroid plexus carcinoma (CPC) | NC_000017.11:g.7673766T>A | ClinVar |
VAR_006024 | p.Glu285Gln | Missense | Li-Fraumeni syndrome (LFS) [MIM:151623] | - | UniProt |
VAR_045393 | p.Glu285Asp | Missense | - | - | UniProt |
VAR_045394 | p.Glu285Gly | Missense | - | - | UniProt |
VAR_045392 | p.Glu285Ala | Missense | - | - | UniProt |
rs786201059 | p.Glu286Gln | missense variant | - | NC_000017.11:g.7673764C>G | UniProt,dbSNP |
VAR_006030 | p.Glu286Gln | missense variant | - | NC_000017.11:g.7673764C>G | UniProt |
rs786201059 | p.Glu286Lys | missense variant | - | NC_000017.11:g.7673764C>T | UniProt,dbSNP |
VAR_006029 | p.Glu286Lys | missense variant | - | NC_000017.11:g.7673764C>T | UniProt |
RCV000420631 | p.Glu286Val | missense variant | Acute myeloid leukemia (AML) | NC_000017.11:g.7673763T>A | ClinVar |
RCV000556558 | p.Glu286Gly | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673763T>C | ClinVar |
RCV000444095 | p.Glu286Ala | missense variant | - | NC_000017.11:g.7673763T>G | ClinVar |
RCV000439537 | p.Glu286Ala | missense variant | Adenocarcinoma of stomach | NC_000017.11:g.7673763T>G | ClinVar |
RCV000425922 | p.Glu286Val | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7673763T>A | ClinVar |
RCV000440264 | p.Glu286Val | missense variant | Lung adenocarcinoma | NC_000017.11:g.7673763T>A | ClinVar |
RCV000436172 | p.Glu286Val | missense variant | Adenocarcinoma of stomach | NC_000017.11:g.7673763T>A | ClinVar |
RCV000424971 | p.Glu286Ala | missense variant | Hepatocellular carcinoma (HCC) | NC_000017.11:g.7673763T>G | ClinVar |
RCV000419358 | p.Glu286Ala | missense variant | Lung adenocarcinoma | NC_000017.11:g.7673763T>G | ClinVar |
RCV000427672 | p.Glu286Ala | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7673763T>G | ClinVar |
RCV000435554 | p.Glu286Val | missense variant | Hepatocellular carcinoma (HCC) | NC_000017.11:g.7673763T>A | ClinVar |
RCV000443133 | p.Glu286Val | missense variant | Small cell lung cancer | NC_000017.11:g.7673763T>A | ClinVar |
RCV000443104 | p.Glu286Val | missense variant | Malignant melanoma of skin (CMM) | NC_000017.11:g.7673763T>A | ClinVar |
RCV000432539 | p.Glu286Val | missense variant | - | NC_000017.11:g.7673763T>A | ClinVar |
RCV000430190 | p.Glu286Ala | missense variant | - | NC_000017.11:g.7673763T>G | ClinVar |
RCV000443946 | p.Glu286Val | missense variant | - | NC_000017.11:g.7673763T>A | ClinVar |
RCV000438282 | p.Glu286Val | missense variant | Neoplasm of brain | NC_000017.11:g.7673763T>A | ClinVar |
RCV000433092 | p.Glu286Ala | missense variant | Neoplasm of the breast | NC_000017.11:g.7673763T>G | ClinVar |
RCV000437905 | p.Glu286Ala | missense variant | Carcinoma of esophagus | NC_000017.11:g.7673763T>G | ClinVar |
RCV000255724 | p.Glu286Lys | missense variant | - | NC_000017.11:g.7673764C>T | ClinVar |
RCV000435596 | p.Glu286Gln | missense variant | Neoplasm of the large intestine | NC_000017.11:g.7673764C>G | ClinVar |
RCV000433190 | p.Glu286Gln | missense variant | Small cell lung cancer | NC_000017.11:g.7673764C>G | ClinVar |
RCV000436841 | p.Glu286Gln | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7673764C>G | ClinVar |
RCV000435774 | p.Glu286Gln | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7673764C>G | ClinVar |
RCV000418192 | p.Glu286Gln | missense variant | - | NC_000017.11:g.7673764C>G | ClinVar |
RCV000418557 | p.Glu286Gln | missense variant | Lung adenocarcinoma | NC_000017.11:g.7673764C>G | ClinVar |
RCV000423598 | p.Glu286Gln | missense variant | Acute myeloid leukemia (AML) | NC_000017.11:g.7673764C>G | ClinVar |
RCV000441497 | p.Glu286Gln | missense variant | Hepatocellular carcinoma (HCC) | NC_000017.11:g.7673764C>G | ClinVar |
RCV000442043 | p.Glu286Gln | missense variant | Neoplasm of brain | NC_000017.11:g.7673764C>G | ClinVar |
RCV000431245 | p.Glu286Gln | missense variant | - | NC_000017.11:g.7673764C>G | ClinVar |
rs1057519985 | p.Glu286Gly | missense variant | - | NC_000017.11:g.7673763T>C | UniProt,dbSNP |
VAR_006028 | p.Glu286Gly | missense variant | - | NC_000017.11:g.7673763T>C | UniProt |
rs1057519985 | p.Glu286Ala | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673763T>G | UniProt,dbSNP |
VAR_006026 | p.Glu286Ala | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673763T>G | UniProt |
rs1057519985 | p.Glu286Val | missense variant | - | NC_000017.11:g.7673763T>A | UniProt,dbSNP |
VAR_045395 | p.Glu286Val | missense variant | - | NC_000017.11:g.7673763T>A | UniProt |
RCV000430739 | p.Glu286Val | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7673763T>A | ClinVar |
RCV000434375 | p.Glu286Ala | missense variant | Malignant melanoma of skin (CMM) | NC_000017.11:g.7673763T>G | ClinVar |
RCV000423140 | p.Glu286Val | missense variant | Neoplasm of the breast | NC_000017.11:g.7673763T>A | ClinVar |
RCV000443500 | p.Glu286Ala | missense variant | Ovarian Serous Cystadenocarcinoma | NC_000017.11:g.7673763T>G | ClinVar |
RCV000421331 | p.Glu286Ala | missense variant | Neoplasm of the large intestine | NC_000017.11:g.7673763T>G | ClinVar |
RCV000424403 | p.Glu286Val | missense variant | Pancreatic adenocarcinoma | NC_000017.11:g.7673763T>A | ClinVar |
RCV000430027 | p.Glu286Val | missense variant | Neoplasm of the large intestine | NC_000017.11:g.7673763T>A | ClinVar |
RCV000421888 | p.Glu286Ala | missense variant | Neoplasm of brain | NC_000017.11:g.7673763T>G | ClinVar |
RCV000417903 | p.Glu286Val | missense variant | Carcinoma of esophagus | NC_000017.11:g.7673763T>A | ClinVar |
RCV000443287 | p.Glu286Ala | missense variant | Small cell lung cancer | NC_000017.11:g.7673763T>G | ClinVar |
RCV000431576 | p.Glu286Ala | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7673763T>G | ClinVar |
RCV000423414 | p.Glu286Ala | missense variant | Acute myeloid leukemia (AML) | NC_000017.11:g.7673763T>G | ClinVar |
RCV000466372 | p.Glu286Lys | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673764C>T | ClinVar |
RCV000441313 | p.Glu286Gln | missense variant | Neoplasm of the breast | NC_000017.11:g.7673764C>G | ClinVar |
RCV000785476 | p.Glu286Ter | nonsense | Ovarian Neoplasms | NC_000017.11:g.7673764C>A | ClinVar |
RCV000428400 | p.Glu286Gln | missense variant | Adenocarcinoma of stomach | NC_000017.11:g.7673764C>G | ClinVar |
RCV000425968 | p.Glu286Gln | missense variant | Malignant melanoma of skin (CMM) | NC_000017.11:g.7673764C>G | ClinVar |
RCV000428433 | p.Glu286Gln | missense variant | Carcinoma of esophagus | NC_000017.11:g.7673764C>G | ClinVar |
RCV000162466 | p.Glu286Lys | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7673764C>T | ClinVar |
RCV000422952 | p.Glu286Gln | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000017.11:g.7673764C>G | ClinVar |
VAR_045871 | p.Glu286Leu | Missense | - | - | UniProt |
VAR_006027 | p.Glu286Asp | Missense | - | - | UniProt |
RCV000130426 | p.Glu287Lys | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7673761C>T | ClinVar |
RCV000481706 | p.Glu287Asp | missense variant | - | NC_000017.11:g.7673759C>G | ClinVar |
RCV000568299 | p.Glu287Asp | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7673759C>G | ClinVar |
COSM1646819 | p.Glu287Ter | stop gained | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7673761C>A | NCI-TCGA Cosmic |
COSM44077 | p.Glu287Asp | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7673759C>A | NCI-TCGA Cosmic |
NCI-TCGA novel | p.Glu287Gln | missense variant | - | NC_000017.11:g.7673761C>G | NCI-TCGA |
NCI-TCGA novel | p.Glu287ProPheSerTerUnk | frameshift | - | NC_000017.11:g.7673733_7673761TGAGGCTCCCCTTTCTTGCGGAGATTCTC>- | NCI-TCGA |
rs587782006 | p.Glu287Lys | missense variant | - | NC_000017.11:g.7673761C>T | UniProt,dbSNP |
VAR_045398 | p.Glu287Lys | missense variant | - | NC_000017.11:g.7673761C>T | UniProt |
rs587782006 | p.Glu287Lys | missense variant | - | NC_000017.11:g.7673761C>T | ExAC,gnomAD |
rs748891343 | p.Glu287Asp | missense variant | - | NC_000017.11:g.7673759C>G | ExAC,TOPMed,gnomAD |
rs748891343 | p.Glu287Asp | missense variant | - | NC_000017.11:g.7673759C>G | UniProt,dbSNP |
VAR_045396 | p.Glu287Asp | missense variant | - | NC_000017.11:g.7673759C>G | UniProt |
RCV000813960 | p.Glu287Lys | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673761C>T | ClinVar |
VAR_045399 | p.Glu287Val | Missense | - | - | UniProt |
VAR_045397 | p.Glu287Gly | Missense | - | - | UniProt |
VAR_047204 | p.Glu287Ala | Missense | - | - | UniProt |
NCI-TCGA novel | p.Asn288LysPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7673756_7673757insTTCTC | NCI-TCGA |
NCI-TCGA novel | p.Asn288GluPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7673758_7673759insC | NCI-TCGA |
NCI-TCGA novel | p.Asn288LysPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7673756_7673757insT | NCI-TCGA |
RCV000571294 | p.Asn288Ter | frameshift | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7673772_7673773insCTTCTCTTCCTCTGTGC | ClinVar |
RCV000564408 | p.Asn288Ter | frameshift | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7673759_7673760CT[3] | ClinVar |
VAR_045403 | p.Asn288Thr | Missense | - | - | UniProt |
VAR_045402 | p.Asn288Ser | Missense | - | - | UniProt |
VAR_045401 | p.Asn288Lys | Missense | - | - | UniProt |
VAR_045404 | p.Asn288Tyr | Missense | - | - | UniProt |
VAR_045400 | p.Asn288Asp | Missense | - | - | UniProt |
rs1555525154 | p.Leu289Val | missense variant | - | NC_000017.11:g.7673755G>C | - |
rs1555525154 | p.Leu289Val | missense variant | - | NC_000017.11:g.7673755G>C | UniProt,dbSNP |
VAR_045409 | p.Leu289Val | missense variant | - | NC_000017.11:g.7673755G>C | UniProt |
COSM1480056 | p.Leu289Phe | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7673755G>A | NCI-TCGA Cosmic |
RCV000588420 | p.Leu289Val | missense variant | - | NC_000017.11:g.7673755G>C | ClinVar |
NCI-TCGA novel | p.Leu289PhePheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7673755_7673756insATTCTCTTCCTCTGTGCGCCGCGGAA | NCI-TCGA |
VAR_045406 | p.Leu289His | Missense | - | - | UniProt |
VAR_045405 | p.Leu289Phe | Missense | - | - | UniProt |
VAR_045408 | p.Leu289Arg | Missense | - | - | UniProt |
VAR_045407 | p.Leu289Pro | Missense | - | - | UniProt |
rs1060501205 | p.ArgLys290ArgGln | missense variant | - | NC_000017.11:g.7673749_7673750delinsGT | - |
COSM297085 | p.Arg290LysPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7673747_7673753CTTGCGG>- | NCI-TCGA Cosmic |
RCV000781912 | p.Arg290Leu | missense variant | - | NC_000017.11:g.7673751C>A | ClinVar |
RCV000620742 | p.Arg290His | missense variant | Li-Fraumeni syndrome 1 (LFS) | NC_000017.11:g.7673751C>T | ClinVar |
RCV000236248 | p.Arg290Cys | missense variant | - | NC_000017.11:g.7673752G>A | ClinVar |
RCV000492120 | p.Arg290Cys | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7673752G>A | ClinVar |
RCV000198910 | p.Arg290Cys | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673752G>A | ClinVar |
NCI-TCGA novel | p.Arg290AlaPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7673753_7673754insAGATTCTCTTCCTCTGTGCGCC | NCI-TCGA |
NCI-TCGA novel | p.Arg290SerPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7673752_7673753insGA | NCI-TCGA |
RCV000773647 | p.Arg290Gly | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7673752G>C | ClinVar |
rs55819519 | p.Arg290Pro | missense variant | - | NC_000017.11:g.7673751C>G | 1000Genomes,ESP,ExAC,TOPMed,gnomAD |
rs55819519 | p.Arg290His | missense variant | - | NC_000017.11:g.7673751C>T | 1000Genomes,ESP,ExAC,TOPMed,gnomAD |
rs770374782 | p.Arg290Cys | missense variant | - | NC_000017.11:g.7673752G>A | ExAC,TOPMed,gnomAD |
RCV000535005 | p.Arg290Pro | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673751C>G | ClinVar |
RCV000760102 | p.Arg290His | missense variant | - | NC_000017.11:g.7673751C>T | ClinVar |
RCV000213061 | p.Arg290His | missense variant | - | NC_000017.11:g.7673751C>T | ClinVar |
VAR_045412 | p.Arg290Leu | Missense | Li-Fraumeni syndrome (LFS) [MIM:151623] | - | UniProt |
RCV000471030 | p.Lys291Gln | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673749_7673750delinsGT | ClinVar |
RCV000774787 | p.Lys291Asn | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7673747C>G | ClinVar |
NCI-TCGA novel | p.Lys291SerPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7673739_7673748TCCCCTTTCT>- | NCI-TCGA |
RCV000575139 | p.Lys291Glu | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7673749T>C | ClinVar |
rs372613518 | p.Lys291Asn | missense variant | - | NC_000017.11:g.7673747C>G | UniProt,dbSNP |
VAR_045415 | p.Lys291Asn | missense variant | - | NC_000017.11:g.7673747C>G | UniProt |
rs372613518 | p.Lys291Asn | missense variant | - | NC_000017.11:g.7673747C>G | ESP |
rs1555525126 | p.Lys291Glu | missense variant | - | NC_000017.11:g.7673749T>C | UniProt,dbSNP |
VAR_045413 | p.Lys291Glu | missense variant | - | NC_000017.11:g.7673749T>C | UniProt |
rs1555525126 | p.Lys291Glu | missense variant | - | NC_000017.11:g.7673749T>C | - |
rs781490101 | p.Lys291Arg | missense variant | - | NC_000017.11:g.7673748T>C | UniProt,dbSNP |
VAR_045416 | p.Lys291Arg | missense variant | - | NC_000017.11:g.7673748T>C | UniProt |
rs781490101 | p.Lys291Arg | missense variant | - | NC_000017.11:g.7673748T>C | ExAC,gnomAD |
RCV000545094 | p.Lys291Ter | frameshift | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673750dup | ClinVar |
RCV000820689 | p.Lys291Asn | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673747C>G | ClinVar |
RCV000806261 | p.Lys291Glu | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673749T>C | ClinVar |
VAR_045417 | p.Lys291Thr | Missense | - | - | UniProt |
VAR_045414 | p.Lys291Met | Missense | - | - | UniProt |
VAR_047205 | p.Lys291Gln | Missense | - | - | UniProt |
RCV000457955 | p.Lys292Arg | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673745T>C | ClinVar |
RCV000013177 | p.Lys292Ile | missense variant | Li-Fraumeni syndrome 1 (LFS) | NC_000017.11:g.7673745T>A | ClinVar |
RCV000573281 | p.Lys292Arg | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7673745T>C | ClinVar |
COSM1480054 | p.Lys292GlyPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7673743_7673746CTTT>- | NCI-TCGA Cosmic |
COSM1172458 | p.Lys292Ter | stop gained | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7673746T>A | NCI-TCGA Cosmic |
rs121912663 | p.Lys292Ile | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673745T>A | UniProt,dbSNP |
VAR_015819 | p.Lys292Ile | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673745T>A | UniProt |
rs121912663 | p.Lys292Ile | missense variant | Li-fraumeni syndrome 1 (lfs1) | NC_000017.11:g.7673745T>A | gnomAD |
rs121912663 | p.Lys292Arg | missense variant | - | NC_000017.11:g.7673745T>C | UniProt,dbSNP |
VAR_045421 | p.Lys292Arg | missense variant | - | NC_000017.11:g.7673745T>C | UniProt |
rs121912663 | p.Lys292Arg | missense variant | Li-fraumeni syndrome 1 (lfs1) | NC_000017.11:g.7673745T>C | gnomAD |
VAR_045420 | p.Lys292Gln | Missense | - | - | UniProt |
VAR_045872 | p.Lys292Gly | Missense | - | - | UniProt |
VAR_045419 | p.Lys292Asn | Missense | - | - | UniProt |
VAR_045422 | p.Lys292Thr | Missense | - | - | UniProt |
VAR_045418 | p.Lys292Glu | Missense | - | - | UniProt |
rs587780076 | p.Gly293Arg | missense variant | - | NC_000017.11:g.7673743C>T | ExAC,TOPMed,gnomAD |
rs587780076 | p.Gly293Arg | missense variant | - | NC_000017.11:g.7673743C>T | UniProt,dbSNP |
VAR_045424 | p.Gly293Arg | missense variant | - | NC_000017.11:g.7673743C>T | UniProt |
RCV000115741 | p.Gly293Trp | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7673743C>A | ClinVar |
RCV000462367 | p.Gly293Trp | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673743C>A | ClinVar |
RCV000213062 | p.Gly293Trp | missense variant | - | NC_000017.11:g.7673743C>A | ClinVar |
rs587780076 | p.Gly293Trp | missense variant | - | NC_000017.11:g.7673743C>A | ExAC,TOPMed,gnomAD |
rs587780076 | p.Gly293Trp | missense variant | - | NC_000017.11:g.7673743C>A | UniProt,dbSNP |
VAR_045426 | p.Gly293Trp | missense variant | - | NC_000017.11:g.7673743C>A | UniProt |
RCV000219408 | p.Gly293Arg | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7673743C>T | ClinVar |
RCV000410614 | p.Gly293Trp | missense variant | Li-Fraumeni syndrome 1 (LFS) | NC_000017.11:g.7673743C>A | ClinVar |
VAR_045425 | p.Gly293Val | Missense | - | - | UniProt |
VAR_045423 | p.Gly293Ala | Missense | - | - | UniProt |
COSM4596399 | p.Glu294SerPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7673744T>- | NCI-TCGA Cosmic |
COSM45736 | p.Glu294AlaPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7673740_7673741CC>- | NCI-TCGA Cosmic |
COSM44874 | p.Glu294SerPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7673747C>- | NCI-TCGA Cosmic |
COSM2744500 | p.Glu294SerPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7673740C>- | NCI-TCGA Cosmic |
rs1057520607 | p.Glu294Ter | stop gained | - | NC_000017.11:g.7673740C>A | - |
rs1305324490 | p.Glu294Asp | missense variant | - | NC_000017.11:g.7673738C>G | gnomAD |
rs1305324490 | p.Glu294Asp | missense variant | - | NC_000017.11:g.7673738C>G | UniProt,dbSNP |
VAR_045428 | p.Glu294Asp | missense variant | - | NC_000017.11:g.7673738C>G | UniProt |
RCV000433836 | p.Glu294Ter | nonsense | - | NC_000017.11:g.7673740C>A | ClinVar |
VAR_045430 | p.Glu294Gln | Missense | - | - | UniProt |
VAR_047206 | p.Glu294Lys | Missense | - | - | UniProt |
VAR_045431 | p.Glu294Val | Missense | - | - | UniProt |
VAR_045429 | p.Glu294Gly | Missense | - | - | UniProt |
VAR_045427 | p.Glu294Ala | Missense | - | - | UniProt |
rs1131691006 | p.Pro295Ser | missense variant | - | NC_000017.11:g.7673737G>A | UniProt,dbSNP |
VAR_045435 | p.Pro295Ser | missense variant | - | NC_000017.11:g.7673737G>A | UniProt |
rs1131691006 | p.Pro295Ser | missense variant | - | NC_000017.11:g.7673737G>A | gnomAD |
rs751713111 | p.Pro295Leu | missense variant | - | NC_000017.11:g.7673736G>A | ExAC,TOPMed,gnomAD |
RCV000492128 | p.Pro295Ser | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7673737G>A | ClinVar |
RCV000633374 | p.Pro295Leu | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673736G>A | ClinVar |
RCV000486525 | p.Pro295Leu | missense variant | - | NC_000017.11:g.7673736G>A | ClinVar |
rs751713111 | p.Pro295Arg | missense variant | - | NC_000017.11:g.7673736G>C | ExAC,TOPMed,gnomAD |
RCV000774786 | p.Pro295Leu | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7673736G>A | ClinVar |
VAR_045432 | p.Pro295His | Missense | - | - | UniProt |
rs672601296 | p.His296Tyr | missense variant | - | NC_000017.11:g.7673734G>A | UniProt,dbSNP |
VAR_045440 | p.His296Tyr | missense variant | - | NC_000017.11:g.7673734G>A | UniProt |
COSM45069 | p.His296ThrPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7673734G>- | NCI-TCGA Cosmic |
RCV000486480 | p.His296Tyr | missense variant | - | NC_000017.11:g.7673734G>A | ClinVar |
RCV000774785 | p.His296Tyr | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7673734G>A | ClinVar |
rs483352696 | p.His296Arg | missense variant | - | NC_000017.11:g.7673733T>C | - |
rs483352696 | p.His296Arg | missense variant | - | NC_000017.11:g.7673733T>C | UniProt,dbSNP |
VAR_045439 | p.His296Arg | missense variant | - | NC_000017.11:g.7673733T>C | UniProt |
RCV000087174 | p.His296Arg | missense variant | - | NC_000017.11:g.7673733T>C | ClinVar |
RCV000633378 | p.His296Tyr | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673734G>A | ClinVar |
RCV000785495 | p.His296Ter | frameshift | Ovarian Neoplasms | NC_000017.11:g.7673728_7673732del | ClinVar |
VAR_045437 | p.His296Asn | Missense | - | - | UniProt |
VAR_047207 | p.His296Leu | Missense | - | - | UniProt |
VAR_045873 | p.His296Cys | Missense | - | - | UniProt |
VAR_045436 | p.His296Asp | Missense | - | - | UniProt |
VAR_006031 | p.His296Pro | Missense | - | - | UniProt |
VAR_045438 | p.His296Gln | Missense | - | - | UniProt |
COSM4975208 | p.His297ThrPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7673731G>- | NCI-TCGA Cosmic |
COSM45524 | p.His297ProPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7673730T>- | NCI-TCGA Cosmic |
rs876659477 | p.His297Arg | missense variant | - | NC_000017.11:g.7673730T>C | - |
RCV000214757 | p.His297Arg | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7673730T>C | ClinVar |
VAR_045442 | p.His297Asn | Missense | - | - | UniProt |
VAR_045443 | p.His297Pro | Missense | - | - | UniProt |
VAR_045445 | p.His297Tyr | Missense | - | - | UniProt |
VAR_045441 | p.His297Asp | Missense | - | - | UniProt |
rs201744589 | p.Glu298Gln | missense variant | - | NC_000017.11:g.7673728C>G | UniProt,dbSNP |
VAR_045449 | p.Glu298Gln | missense variant | - | NC_000017.11:g.7673728C>G | UniProt |
rs201744589 | p.Glu298Ter | stop gained | - | NC_000017.11:g.7673728C>A | 1000Genomes,ExAC,TOPMed,gnomAD |
RCV000559898 | p.Glu298Ter | nonsense | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673728C>A | ClinVar |
RCV000216964 | p.Glu298Ter | nonsense | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7673728C>A | ClinVar |
RCV000130033 | p.Glu298Lys | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7673728C>T | ClinVar |
rs201744589 | p.Glu298Gln | missense variant | - | NC_000017.11:g.7673728C>G | 1000Genomes,ExAC,TOPMed,gnomAD |
rs201744589 | p.Glu298Lys | missense variant | - | NC_000017.11:g.7673728C>T | UniProt,dbSNP |
VAR_045448 | p.Glu298Lys | missense variant | - | NC_000017.11:g.7673728C>T | UniProt |
rs201744589 | p.Glu298Lys | missense variant | - | NC_000017.11:g.7673728C>T | 1000Genomes,ExAC,TOPMed,gnomAD |
RCV000785528 | p.Glu298Ter | nonsense | Ovarian Neoplasms | NC_000017.11:g.7673728C>A | ClinVar |
RCV000079204 | p.Glu298Ter | nonsense | - | NC_000017.11:g.7673728C>A | ClinVar |
VAR_045450 | p.Glu298Val | Missense | - | - | UniProt |
VAR_045446 | p.Glu298Ala | Missense | - | - | UniProt |
VAR_045447 | p.Glu298Asp | Missense | - | - | UniProt |
NCI-TCGA novel | p.Leu299AlaPheSerTerUnk | frameshift | - | NC_000017.11:g.7673726_7673727insT | NCI-TCGA |
RCV000584285 | p.Leu299Ter | frameshift | - | NC_000017.11:g.7673715_7673728del | ClinVar |
VAR_045454 | p.Leu299Val | Missense | - | - | UniProt |
VAR_045451 | p.Leu299Pro | Missense | - | - | UniProt |
VAR_045452 | p.Leu299Gln | Missense | - | - | UniProt |
VAR_045453 | p.Leu299Arg | Missense | - | - | UniProt |
VAR_045457 | p.Pro300Ser | Missense | - | - | UniProt |
VAR_045455 | p.Pro300Ala | Missense | - | - | UniProt |
VAR_006032 | p.Pro300Arg | Missense | - | - | UniProt |
RCV000219373 | p.Pro301Ter | frameshift | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7673722del | ClinVar |
COSM1386588 | p.Pro301GlnPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7673718G>- | NCI-TCGA Cosmic |
rs1555525067 | p.Pro301Leu | missense variant | - | NC_000017.11:g.7673718G>A | - |
rs1555525067 | p.Pro301Leu | missense variant | - | NC_000017.11:g.7673718G>A | UniProt,dbSNP |
VAR_006033 | p.Pro301Leu | missense variant | - | NC_000017.11:g.7673718G>A | UniProt |
RCV000574619 | p.Pro301Leu | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7673718G>A | ClinVar |
VAR_045458 | p.Pro301Ala | Missense | - | - | UniProt |
VAR_047208 | p.Pro301Thr | Missense | - | - | UniProt |
VAR_045459 | p.Pro301Gln | Missense | - | - | UniProt |
VAR_045460 | p.Pro301Ser | Missense | - | - | UniProt |
COSM5132148 | p.Gly302ArgPheSerTerUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7673717_7673718insG | NCI-TCGA Cosmic |
NCI-TCGA novel | p.Gly302AlaPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7673705_7673715CTTAGTGCTCC>- | NCI-TCGA |
NCI-TCGA novel | p.Gly302GluPheSerTerUnk | frameshift | - | NC_000017.11:g.7673714_7673715CC>- | NCI-TCGA |
rs863224686 | p.Gly302Arg | missense variant | - | NC_000017.11:g.7673716C>G | UniProt,dbSNP |
VAR_045462 | p.Gly302Arg | missense variant | - | NC_000017.11:g.7673716C>G | UniProt |
rs863224686 | p.Gly302Arg | missense variant | - | NC_000017.11:g.7673716C>G | - |
RCV000468864 | p.Gly302Glu | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673715C>T | ClinVar |
rs1060501202 | p.Gly302Glu | missense variant | - | NC_000017.11:g.7673715C>T | - |
RCV000197011 | p.Gly302Arg | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673716C>G | ClinVar |
VAR_006035 | p.Gly302Val | Missense | - | - | UniProt |
VAR_045461 | p.Gly302Ala | Missense | - | - | UniProt |
RCV000164675 | p.Ser303Ter | frameshift | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7673716del | ClinVar |
COSM437474 | p.Ser303AlaPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7673713T>- | NCI-TCGA Cosmic |
RCV000549010 | p.Ser303Gly | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673713T>C | ClinVar |
RCV000131400 | p.Ser303Gly | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7673713T>C | ClinVar |
RCV000760105 | p.Ser303Gly | missense variant | - | NC_000017.11:g.7673713T>C | ClinVar |
RCV000785534 | p.Ser303Ter | frameshift | Ovarian Neoplasms | NC_000017.11:g.7673712_7673713insCCCC | ClinVar |
RCV000218916 | p.Ser303Asn | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7673712C>T | ClinVar |
rs587782391 | p.Ser303Gly | missense variant | - | NC_000017.11:g.7673713T>C | TOPMed |
rs876658714 | p.Ser303Asn | missense variant | - | NC_000017.11:g.7673712C>T | - |
RCV000700080 | p.Ser303Asn | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673712C>T | ClinVar |
VAR_045464 | p.Ser303Ile | Missense | - | - | UniProt |
VAR_045466 | p.Ser303Thr | Missense | - | - | UniProt |
VAR_045463 | p.Ser303Cys | Missense | - | - | UniProt |
rs587782654 | p.Thr304Ala | missense variant | - | NC_000017.11:g.7673710T>C | UniProt,dbSNP |
VAR_045467 | p.Thr304Ala | missense variant | - | NC_000017.11:g.7673710T>C | UniProt |
rs587782654 | p.Thr304Ala | missense variant | - | NC_000017.11:g.7673710T>C | ExAC,gnomAD |
COSM4746583 | p.Thr304IlePheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7673709G>- | NCI-TCGA Cosmic |
RCV000132069 | p.Thr304Ala | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7673710T>C | ClinVar |
VAR_045468 | p.Thr304Ile | Missense | - | - | UniProt |
VAR_047209 | p.Thr304Ser | Missense | - | - | UniProt |
VAR_045469 | p.Thr304Asn | Missense | - | - | UniProt |
COSM1646821 | p.Lys305Ter | stop gained | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7673707T>A | NCI-TCGA Cosmic |
NCI-TCGA novel | p.Lys305Gln | missense variant | - | NC_000017.11:g.7673707T>G | NCI-TCGA |
NCI-TCGA novel | p.Lys305GluPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7673704_7673707GCTT>- | NCI-TCGA |
RCV000776787 | p.Lys305Ter | nonsense | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7673708dup | ClinVar |
VAR_045472 | p.Lys305Asn | Missense | - | - | UniProt |
VAR_045473 | p.Lys305Arg | Missense | - | - | UniProt |
VAR_045471 | p.Lys305Met | Missense | - | - | UniProt |
VAR_045474 | p.Lys305Thr | Missense | - | - | UniProt |
VAR_045470 | p.Lys305Glu | Missense | - | - | UniProt |
rs1048095040 | p.Arg306Gln | missense variant | - | NC_000017.11:g.7673703C>T | gnomAD |
RCV000422102 | p.Arg306Ter | nonsense | Head and Neck Neoplasms | NC_000017.11:g.7673704G>A | ClinVar |
RCV000527123 | p.Arg306Gln | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673703C>T | ClinVar |
RCV000428901 | p.Arg306Ter | nonsense | Neoplasm of the large intestine | NC_000017.11:g.7673704G>A | ClinVar |
NCI-TCGA novel | p.Arg306GlnPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7673703C>- | NCI-TCGA |
NCI-TCGA novel | p.Arg306AlaPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7673704_7673705insC | NCI-TCGA |
VAR_045475 | p.Arg306Pro | Missense | Li-Fraumeni syndrome (LFS) [MIM:151623] | - | UniProt |
RCV000568377 | p.Ala307Gly | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7673608G>C | ClinVar |
COSM111649 | p.Ala307ThrPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7673701_7673702CT>- | NCI-TCGA Cosmic |
rs1457582183 | p.Ala307Val | missense variant | - | NC_000017.11:g.7673608G>A | TOPMed |
rs1457582183 | p.Ala307Gly | missense variant | - | NC_000017.11:g.7673608G>C | TOPMed |
VAR_045476 | p.Ala307Pro | Missense | - | - | UniProt |
VAR_006037 | p.Ala307Thr | Missense | - | - | UniProt |
VAR_045477 | p.Ala307Ser | Missense | - | - | UniProt |
COSM5221252 | p.Leu308AlaPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7673606_7673607GT>- | NCI-TCGA Cosmic |
NCI-TCGA novel | p.Leu308GlnPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7673603_7673607GCAGT>- | NCI-TCGA |
VAR_045478 | p.Leu308Met | Missense | - | - | UniProt |
VAR_045479 | p.Leu308Val | Missense | - | - | UniProt |
RCV000574214 | p.Pro309Ser | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7673603G>A | ClinVar |
RCV000537437 | p.Pro309Ser | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673603G>A | ClinVar |
rs1555525012 | p.Pro309Ser | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673603G>A | UniProt,dbSNP |
VAR_006038 | p.Pro309Ser | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673603G>A | UniProt |
rs1555525012 | p.Pro309Ser | missense variant | - | NC_000017.11:g.7673603G>A | - |
VAR_045480 | p.Pro309Arg | Missense | - | - | UniProt |
rs876660829 | p.Asn310Lys | missense variant | - | NC_000017.11:g.7673598G>T | gnomAD |
COSM249311 | p.Asn310ThrPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7673601G>- | NCI-TCGA Cosmic |
RCV000797410 | p.Asn310Lys | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673598G>T | ClinVar |
RCV000492463 | p.Asn310Lys | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7673598G>C | ClinVar |
rs876660829 | p.Asn310Lys | missense variant | - | NC_000017.11:g.7673598G>C | gnomAD |
RCV000221944 | p.Asn310Lys | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7673598G>T | ClinVar |
VAR_045481 | p.Asn310Ile | Missense | - | - | UniProt |
VAR_045482 | p.Asn310Thr | Missense | - | - | UniProt |
RCV000205077 | p.Asn311Thr | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673596T>G | ClinVar |
RCV000785552 | p.Asn311Ter | frameshift | Ovarian Neoplasms | NC_000017.11:g.7673595del | ClinVar |
RCV000774977 | p.Asn311His | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7673597T>G | ClinVar |
rs56184981 | p.Asn311Ser | missense variant | - | NC_000017.11:g.7673596T>C | UniProt,dbSNP |
VAR_045485 | p.Asn311Ser | missense variant | - | NC_000017.11:g.7673596T>C | UniProt |
rs56184981 | p.Asn311Ser | missense variant | - | NC_000017.11:g.7673596T>C | - |
rs1555525007 | p.Asn311His | missense variant | - | NC_000017.11:g.7673597T>G | UniProt,dbSNP |
VAR_045483 | p.Asn311His | missense variant | - | NC_000017.11:g.7673597T>G | UniProt |
rs56184981 | p.Asn311Thr | missense variant | - | NC_000017.11:g.7673596T>G | - |
rs56184981 | p.Asn311Thr | missense variant | - | NC_000017.11:g.7673596T>G | UniProt,dbSNP |
VAR_045486 | p.Asn311Thr | missense variant | - | NC_000017.11:g.7673596T>G | UniProt |
RCV000473016 | p.Asn311Ser | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673596T>C | ClinVar |
VAR_045484 | p.Asn311Lys | Missense | - | - | UniProt |
RCV000129462 | p.Thr312Ser | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7673593G>C | ClinVar |
NCI-TCGA novel | p.Thr312Asn | missense variant | - | NC_000017.11:g.7673593G>T | NCI-TCGA |
rs145151284 | p.Thr312Ser | missense variant | - | NC_000017.11:g.7673593G>C | UniProt,dbSNP |
VAR_045488 | p.Thr312Ser | missense variant | - | NC_000017.11:g.7673593G>C | UniProt |
rs145151284 | p.Thr312Ser | missense variant | - | NC_000017.11:g.7673593G>C | 1000Genomes,ESP,ExAC,TOPMed,gnomAD |
VAR_045487 | p.Thr312Ile | Missense | - | - | UniProt |
COSM2149481 | p.Ser313AlaPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7673592G>- | NCI-TCGA Cosmic |
NCI-TCGA novel | p.Ser313ThrPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7673590C>- | NCI-TCGA |
RCV000785505 | p.Ser313Ter | frameshift | Ovarian Neoplasms | NC_000017.11:g.7673583_7673592del | ClinVar |
rs1367492395 | p.Ser313Arg | missense variant | - | NC_000017.11:g.7673589G>T | TOPMed |
rs1367492395 | p.Ser313Arg | missense variant | - | NC_000017.11:g.7673589G>T | UniProt,dbSNP |
VAR_045492 | p.Ser313Arg | missense variant | - | NC_000017.11:g.7673589G>T | UniProt |
VAR_045491 | p.Ser313Asn | Missense | - | - | UniProt |
VAR_045489 | p.Ser313Cys | Missense | - | - | UniProt |
VAR_045490 | p.Ser313Ile | Missense | - | - | UniProt |
RCV000570325 | p.Ser314Phe | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7673587G>A | ClinVar |
RCV000456310 | p.Ser314Phe | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673587G>A | ClinVar |
rs751440465 | p.Ser314Phe | missense variant | - | NC_000017.11:g.7673587G>A | ExAC,gnomAD |
rs762620193 | p.Ser315Thr | missense variant | - | NC_000017.11:g.7673585A>T | ExAC,gnomAD |
COSM45098 | p.Ser315Cys | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7673584G>C | NCI-TCGA Cosmic |
RCV000793553 | p.Ser315Thr | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673585A>T | ClinVar |
RCV000164586 | p.Ser315Thr | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7673585A>T | ClinVar |
VAR_045494 | p.Ser315Cys | Missense | - | - | UniProt |
VAR_045495 | p.Ser315Phe | Missense | - | - | UniProt |
VAR_045496 | p.Ser315Pro | Missense | - | - | UniProt |
rs772773208 | p.Pro316Thr | missense variant | - | NC_000017.11:g.7673582G>T | UniProt,dbSNP |
VAR_045498 | p.Pro316Thr | missense variant | - | NC_000017.11:g.7673582G>T | UniProt |
rs772773208 | p.Pro316Thr | missense variant | - | NC_000017.11:g.7673582G>T | ExAC,gnomAD |
RCV000467467 | p.Pro316Thr | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673582G>T | ClinVar |
COSM69194 | p.Pro316SerPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7673582_7673583insA | NCI-TCGA Cosmic |
RCV000235672 | p.Pro316Thr | missense variant | - | NC_000017.11:g.7673582G>T | ClinVar |
rs1555524979 | p.Pro316Leu | missense variant | - | NC_000017.11:g.7673581G>A | UniProt,dbSNP |
VAR_045497 | p.Pro316Leu | missense variant | - | NC_000017.11:g.7673581G>A | UniProt |
rs1555524979 | p.Pro316Leu | missense variant | - | NC_000017.11:g.7673581G>A | - |
RCV000633395 | p.Pro316Leu | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673581G>A | ClinVar |
RCV000215470 | p.Pro316Thr | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7673582G>T | ClinVar |
rs1159579789 | p.Gln317Arg | missense variant | - | NC_000017.11:g.7673578T>C | gnomAD |
rs1060501199 | p.Gln317His | missense variant | - | NC_000017.11:g.7673577C>A | - |
rs764735889 | p.Gln317Lys | missense variant | - | NC_000017.11:g.7673579G>T | ExAC,TOPMed,gnomAD |
rs764735889 | p.Gln317Ter | stop gained | - | NC_000017.11:g.7673579G>A | ExAC,TOPMed,gnomAD |
RCV000477030 | p.Gln317His | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673577C>A | ClinVar |
RCV000704730 | p.Gln317Arg | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673578T>C | ClinVar |
COSM4603956 | p.Gln317ProPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7673578_7673579insG | NCI-TCGA Cosmic |
COSM111396 | p.Gln317AlaPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7673582_7673583GA>- | NCI-TCGA Cosmic |
RCV000561039 | p.Gln317Ter | frameshift | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7673578del | ClinVar |
NCI-TCGA novel | p.Gln317LeuPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7673548_7673578TATTCTCCATCCAGTGGTTTCTTCTTTGGCT>- | NCI-TCGA |
RCV000485421 | p.Gln317Lys | missense variant | - | NC_000017.11:g.7673579G>T | ClinVar |
RCV000223439 | p.Gln317Lys | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7673579G>T | ClinVar |
RCV000541248 | p.Gln317Lys | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673579G>T | ClinVar |
RCV000520579 | p.Gln317Ter | nonsense | - | NC_000017.11:g.7673579G>A | ClinVar |
RCV000699992 | p.Gln317Ter | frameshift | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673582del | ClinVar |
rs764735889 | p.Gln317Lys | missense variant | - | NC_000017.11:g.7673579G>T | UniProt,dbSNP |
VAR_045500 | p.Gln317Lys | missense variant | - | NC_000017.11:g.7673579G>T | UniProt |
RCV000785340 | p.Gln317Ter | frameshift | Ovarian Neoplasms | NC_000017.11:g.7673582del | ClinVar |
VAR_047210 | p.Gln317Leu | Missense | - | - | UniProt |
VAR_045501 | p.Gln317Pro | Missense | - | - | UniProt |
NCI-TCGA novel | p.Pro318ThrPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7673567_7673577TCTTCTTTGGC>- | NCI-TCGA |
rs1555524975 | p.Pro318Leu | missense variant | - | NC_000017.11:g.7673575G>A | - |
rs1555524975 | p.Pro318Leu | missense variant | - | NC_000017.11:g.7673575G>A | UniProt,dbSNP |
VAR_045503 | p.Pro318Leu | missense variant | - | NC_000017.11:g.7673575G>A | UniProt |
RCV000584424 | p.Pro318Leu | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7673575G>A | ClinVar |
COSM4824146 | p.Lys319Asn | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7673571C>G | NCI-TCGA Cosmic |
COSM11658 | p.Lys319Ter | stop gained | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7673573T>A | NCI-TCGA Cosmic |
COSM288986 | p.Lys319AlaPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7673573_7673574insTGGC | NCI-TCGA Cosmic |
NCI-TCGA novel | p.Lys319ArgPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7673572T>- | NCI-TCGA |
VAR_045504 | p.Lys319Glu | Missense | - | - | UniProt |
VAR_045506 | p.Lys319Arg | Missense | - | - | UniProt |
VAR_045505 | p.Lys319Asn | Missense | - | - | UniProt |
COSM5016725 | p.Lys320ArgPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7673571C>- | NCI-TCGA Cosmic |
NCI-TCGA novel | p.Lys320ArgPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7673560_7673569AGTGGTTTCT>- | NCI-TCGA |
NCI-TCGA novel | p.Lys320Glu | missense variant | - | NC_000017.11:g.7673570T>C | NCI-TCGA |
NCI-TCGA novel | p.Lys320AsnPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7673550_7673568TTCTCCATCCAGTGGTTTC>- | NCI-TCGA |
VAR_045507 | p.Lys320Asn | Missense | - | - | UniProt |
COSM3732985 | p.Lys321Ter | stop gained | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7673567T>A | NCI-TCGA Cosmic |
NCI-TCGA novel | p.Lys321GluPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7673568_7673569insT | NCI-TCGA |
VAR_045508 | p.Lys321Glu | Missense | - | - | UniProt |
VAR_045509 | p.Lys321Arg | Missense | - | - | UniProt |
rs863224687 | p.Pro322Ser | missense variant | - | NC_000017.11:g.7673564G>A | TOPMed |
COSM295895 | p.Pro322HisPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7673563G>- | NCI-TCGA Cosmic |
RCV000573146 | p.Pro322Ser | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7673564G>A | ClinVar |
rs863224687 | p.Pro322Thr | missense variant | - | NC_000017.11:g.7673564G>T | TOPMed |
RCV000195973 | p.Pro322Ser | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673564G>A | ClinVar |
RCV000217039 | p.Pro322Thr | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7673564G>T | ClinVar |
VAR_045511 | p.Pro322Arg | Missense | - | - | UniProt |
VAR_045510 | p.Pro322Leu | Missense | - | - | UniProt |
RCV000772929 | p.Leu323Ter | frameshift | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7673545_7673563del | ClinVar |
rs1432281680 | p.Leu323Val | missense variant | - | NC_000017.11:g.7673561G>C | gnomAD |
VAR_045874 | p.Leu323Gly | Missense | - | - | UniProt |
VAR_045514 | p.Leu323Arg | Missense | - | - | UniProt |
VAR_045512 | p.Leu323Met | Missense | - | - | UniProt |
VAR_045513 | p.Leu323Pro | Missense | - | - | UniProt |
rs1064794810 | p.Asp324His | missense variant | - | NC_000017.11:g.7673558C>G | TOPMed,gnomAD |
RCV000776836 | p.Asp324Tyr | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7673558C>A | ClinVar |
RCV000478385 | p.Asp324His | missense variant | - | NC_000017.11:g.7673558C>G | ClinVar |
RCV000555965 | p.Asp324His | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673558C>G | ClinVar |
rs1177881399 | p.Asp324Gly | missense variant | - | NC_000017.11:g.7673557T>C | gnomAD |
rs1064794810 | p.Asp324Asn | missense variant | - | NC_000017.11:g.7673558C>T | TOPMed,gnomAD |
RCV000583103 | p.Asp324Ter | frameshift | - | NC_000017.11:g.7673559del | ClinVar |
RCV000573045 | p.Asp324His | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7673558C>G | ClinVar |
VAR_045516 | p.Asp324Tyr | Missense | - | - | UniProt |
VAR_045875 | p.Asp324Ser | Missense | - | - | UniProt |
VAR_045515 | p.Asp324Glu | Missense | - | - | UniProt |
rs121912659 | p.Gly325Val | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673554C>A | UniProt,dbSNP |
VAR_006039 | p.Gly325Val | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673554C>A | UniProt |
RCV000566077 | p.Gly325Glu | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7673554C>T | ClinVar |
RCV000013165 | p.Gly325Val | missense variant | Non-Hodgkin lymphoma (NHL) | NC_000017.11:g.7673554C>A | ClinVar |
RCV000013166 | p.Gly325Val | missense variant | Familial colorectal cancer (CRC) | NC_000017.11:g.7673554C>A | ClinVar |
RCV000568856 | p.Gly325Arg | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7673555C>T | ClinVar |
rs121912659 | p.Gly325Glu | missense variant | - | NC_000017.11:g.7673554C>T | gnomAD |
rs121912659 | p.Gly325Val | missense variant | - | NC_000017.11:g.7673554C>A | gnomAD |
RCV000195434 | p.Gly325Ter | nonsense | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673555C>A | ClinVar |
VAR_045517 | p.Gly325Ala | Missense | - | - | UniProt |
VAR_045518 | p.Gly325Glu | Missense | - | - | UniProt |
rs876659384 | p.Glu326Ter | stop gained | - | NC_000017.11:g.7673552C>A | - |
rs1000256867 | p.Glu326Asp | missense variant | - | NC_000017.11:g.7673550T>A | gnomAD |
rs1000256867 | p.Glu326Asp | missense variant | - | NC_000017.11:g.7673550T>G | gnomAD |
RCV000218971 | p.Glu326Ter | nonsense | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7673552C>A | ClinVar |
RCV000633385 | p.Glu326Ter | nonsense | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673552C>A | ClinVar |
RCV000785490 | p.Glu326Ter | nonsense | Ovarian Neoplasms | NC_000017.11:g.7673552C>A | ClinVar |
VAR_045519 | p.Glu326Gly | Missense | - | - | UniProt |
COSM4398578 | p.Tyr327Ter | stop gained | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7673547A>T | NCI-TCGA Cosmic |
NCI-TCGA novel | p.Tyr327PhePheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7673548T>- | NCI-TCGA |
NCI-TCGA novel | p.Tyr327AsnPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7673553_7673554insCC | NCI-TCGA |
RCV000235861 | p.Tyr327Ter | nonsense | - | NC_000017.11:g.7673547A>C | ClinVar |
rs879254077 | p.Tyr327Ter | stop gained | - | NC_000017.11:g.7673547A>C | - |
VAR_045521 | p.Tyr327Ser | Missense | - | - | UniProt |
VAR_045520 | p.Tyr327His | Missense | - | - | UniProt |
COSM437470 | p.Phe328SerPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7673545A>- | NCI-TCGA Cosmic |
NCI-TCGA novel | p.Phe328Ile | missense variant | - | NC_000017.11:g.7673546A>T | NCI-TCGA |
VAR_045523 | p.Phe328Ser | Missense | - | - | UniProt |
VAR_045524 | p.Phe328Val | Missense | - | - | UniProt |
VAR_045522 | p.Phe328Leu | Missense | - | - | UniProt |
RCV000286554 | p.Thr329Ter | frameshift | - | NC_000017.11:g.7673547dup | ClinVar |
COSM100040 | p.Thr329HisPheSerTerUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7673544_7673545insA | NCI-TCGA Cosmic |
NCI-TCGA novel | p.Thr329ArgPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7673536_7673542TGAAGGG>- | NCI-TCGA |
rs969930693 | p.Thr329Ile | missense variant | - | NC_000017.11:g.7673542G>A | gnomAD |
VAR_045526 | p.Thr329Ser | Missense | - | - | UniProt |
COSM1162647 | p.Leu330Arg | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7673539A>C | NCI-TCGA Cosmic |
COSM1735380 | p.Leu330PhePheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7673540G>- | NCI-TCGA Cosmic |
VAR_047212 | p.Leu330Pro | Missense | - | - | UniProt |
VAR_045527 | p.Leu330His | Missense | - | - | UniProt |
VAR_045528 | p.Leu330Arg | Missense | - | - | UniProt |
RCV000479182 | p.Gln331Arg | missense variant | - | NC_000017.11:g.7673536T>C | ClinVar |
COSM11354 | p.Gln331Ter | stop gained | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7673537G>A | NCI-TCGA Cosmic |
COSM1646823 | p.Gln331His | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7673535C>G | NCI-TCGA Cosmic |
COSM300447 | p.Gln331SerPheSerTerUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7673537_7673538insA | NCI-TCGA Cosmic |
rs1064795056 | p.Gln331Arg | missense variant | - | NC_000017.11:g.7673536T>C | - |
rs1064795056 | p.Gln331Arg | missense variant | - | NC_000017.11:g.7673536T>C | UniProt,dbSNP |
VAR_045531 | p.Gln331Arg | missense variant | - | NC_000017.11:g.7673536T>C | UniProt |
rs11575996 | p.Gln331His | missense variant | - | NC_000017.11:g.7673535C>A | - |
RCV000540169 | p.Gln331Ter | frameshift | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7673535_7673538del | ClinVar |
VAR_045530 | p.Gln331Pro | Missense | - | - | UniProt |
RCV000554410 | p.Ile332Met | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7670713G>C | ClinVar |
NCI-TCGA novel | p.Ile332Phe | missense variant | - | NC_000017.11:g.7670715T>A | NCI-TCGA |
RCV000785530 | p.Ile332Ter | frameshift | Ovarian Neoplasms | NC_000017.11:g.7670712_7670713del | ClinVar |
rs1555524470 | p.Ile332Met | missense variant | - | NC_000017.11:g.7670713G>C | - |
VAR_045532 | p.Ile332Val | Missense | - | - | UniProt |
RCV000662455 | p.Arg333His | missense variant | Li-Fraumeni syndrome 1 (LFS) | NC_000017.11:g.7670711C>T | ClinVar |
RCV000131296 | p.Arg333His | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7670711C>T | ClinVar |
RCV000227465 | p.Arg333His | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7670711C>T | ClinVar |
COSM437469 | p.Arg333ValPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7670712G>- | NCI-TCGA Cosmic |
RCV000213064 | p.Arg333His | missense variant | - | NC_000017.11:g.7670711C>T | ClinVar |
RCV000485066 | p.Arg333Cys | missense variant | - | NC_000017.11:g.7670712G>A | ClinVar |
RCV000197833 | p.Arg333Cys | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7670712G>A | ClinVar |
RCV000164055 | p.Arg333Cys | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7670712G>A | ClinVar |
rs573154688 | p.Arg333His | missense variant | - | NC_000017.11:g.7670711C>T | 1000Genomes,ExAC,TOPMed,gnomAD |
rs769934890 | p.Arg333Gly | missense variant | - | NC_000017.11:g.7670712G>C | ExAC,gnomAD |
rs769934890 | p.Arg333Cys | missense variant | - | NC_000017.11:g.7670712G>A | ExAC,gnomAD |
RCV000780790 | p.Arg333Cys | missense variant | - | NC_000017.11:g.7670712G>A | ClinVar |
rs730882028 | p.Gly334Arg | missense variant | - | NC_000017.11:g.7670709C>G | ExAC,TOPMed |
RCV000588363 | p.Gly334Arg | missense variant | - | NC_000017.11:g.7670709C>G | ClinVar |
COSM11514 | p.Gly334Val | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7670708C>A | NCI-TCGA Cosmic |
RCV000165615 | p.Gly334Arg | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7670709C>T | ClinVar |
RCV000492343 | p.Gly334Trp | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7670709C>A | ClinVar |
RCV000663214 | p.Gly334Arg | missense variant | Li-Fraumeni syndrome 1 (LFS) | NC_000017.11:g.7670709C>G | ClinVar |
NCI-TCGA novel | p.Gly334AlaPheSerTerUnk | frameshift | - | NC_000017.11:g.7670699_7670708CGCTCACGCC>- | NCI-TCGA |
RCV000468644 | p.Gly334Arg | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7670709C>G | ClinVar |
RCV000161073 | p.Gly334Arg | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7670709C>G | ClinVar |
rs1286563734 | p.Gly334Glu | missense variant | - | NC_000017.11:g.7670708C>T | gnomAD |
rs730882028 | p.Gly334Trp | missense variant | - | NC_000017.11:g.7670709C>A | ExAC,TOPMed |
rs730882028 | p.Gly334Arg | missense variant | - | NC_000017.11:g.7670709C>T | ExAC,TOPMed |
VAR_006040 | p.Gly334Val | Missense | - | - | UniProt |
RCV000538993 | p.Arg335Cys | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7670706G>A | ClinVar |
RCV000563037 | p.Arg335His | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7670705C>T | ClinVar |
COSM295248 | p.Arg335LeuPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7670705C>- | NCI-TCGA Cosmic |
COSM288629 | p.Arg335GlnPheSerTerUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7670705_7670706insT | NCI-TCGA Cosmic |
NCI-TCGA novel | p.Arg335ValPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7670707C>- | NCI-TCGA |
RCV000803182 | p.Arg335His | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7670705C>T | ClinVar |
rs771939956 | p.Arg335His | missense variant | - | NC_000017.11:g.7670705C>T | ExAC,gnomAD |
rs771939956 | p.Arg335His | missense variant | - | NC_000017.11:g.7670705C>T | UniProt,dbSNP |
VAR_045535 | p.Arg335His | missense variant | - | NC_000017.11:g.7670705C>T | UniProt |
rs375444154 | p.Arg335Cys | missense variant | - | NC_000017.11:g.7670706G>A | ESP,TOPMed |
RCV000129547 | p.Arg335Cys | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7670706G>A | ClinVar |
RCV000213066 | p.Arg335Cys | missense variant | - | NC_000017.11:g.7670706G>A | ClinVar |
VAR_045536 | p.Arg335Leu | Missense | - | - | UniProt |
VAR_045534 | p.Arg335Gly | Missense | - | - | UniProt |
COSM11291 | p.Glu336Ter | stop gained | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7670703C>A | NCI-TCGA Cosmic |
NCI-TCGA novel | p.Glu336AlaPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7670701_7670702CT>- | NCI-TCGA |
NCI-TCGA novel | p.Glu336SerPheSerTerUnk | frameshift | - | NC_000017.11:g.7670704A>- | NCI-TCGA |
rs121912664 | p.Arg337His | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7670699C>T | UniProt,dbSNP |
VAR_035016 | p.Arg337His | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7670699C>T | UniProt |
rs121912664 | p.Arg337His | missense variant | - | NC_000017.11:g.7670699C>T | ExAC,TOPMed,gnomAD |
rs121912664 | p.Arg337Leu | missense variant | - | NC_000017.11:g.7670699C>A | ExAC,TOPMed,gnomAD |
rs121912664 | p.Arg337Pro | missense variant | - | NC_000017.11:g.7670699C>G | UniProt,dbSNP |
VAR_045538 | p.Arg337Pro | missense variant | - | NC_000017.11:g.7670699C>G | UniProt |
rs121912664 | p.Arg337Pro | missense variant | - | NC_000017.11:g.7670699C>G | ExAC,TOPMed,gnomAD |
RCV000576817 | p.Arg337His | missense variant | Li-Fraumeni syndrome 1 (LFS) | NC_000017.11:g.7670699C>T | ClinVar |
RCV000413754 | p.Arg337His | missense variant | Neoplasm of the breast | NC_000017.11:g.7670699C>T | ClinVar |
RCV000197240 | p.Arg337His | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7670699C>T | ClinVar |
RCV000226515 | p.Arg337Gly | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7670700G>C | ClinVar |
RCV000785297 | p.Arg337Leu | missense variant | Ovarian Neoplasms | NC_000017.11:g.7670699C>A | ClinVar |
RCV000154527 | p.Arg337Pro | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7670699C>G | ClinVar |
RCV000013178 | p.Arg337His | missense variant | Adrenocortical carcinoma, pediatric | NC_000017.11:g.7670699C>T | ClinVar |
RCV000481814 | p.Arg337His | missense variant | - | NC_000017.11:g.7670699C>T | ClinVar |
RCV000128923 | p.Arg337His | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7670699C>T | ClinVar |
RCV000132259 | p.Arg337Leu | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7670699C>A | ClinVar |
COSM1563605 | p.Arg337Ser | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7670700G>T | NCI-TCGA Cosmic |
RCV000785479 | p.Arg337Cys | missense variant | Ovarian Neoplasms | NC_000017.11:g.7670700G>A | ClinVar |
rs587782529 | p.Arg337Gly | missense variant | - | NC_000017.11:g.7670700G>C | ExAC,gnomAD |
rs587782529 | p.Arg337Cys | missense variant | - | NC_000017.11:g.7670700G>A | ExAC,gnomAD |
rs587782529 | p.Arg337Cys | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7670700G>A | UniProt,dbSNP |
VAR_006041 | p.Arg337Cys | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7670700G>A | UniProt |
rs121912664 | p.Arg337Leu | missense variant | - | NC_000017.11:g.7670699C>A | UniProt,dbSNP |
VAR_045537 | p.Arg337Leu | missense variant | - | NC_000017.11:g.7670699C>A | UniProt |
RCV000492353 | p.Arg337Ter | frameshift | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7670698_7670699GC[1] | ClinVar |
RCV000478445 | p.Phe338Ser | missense variant | - | NC_000017.11:g.7670696A>G | ClinVar |
RCV000576115 | p.Phe338Leu | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7670695G>C | ClinVar |
COSM45767 | p.Phe338Ile | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7670697A>T | NCI-TCGA Cosmic |
COSM235693 | p.Phe338LeuPheSerTerUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7670695G>- | NCI-TCGA Cosmic |
NCI-TCGA novel | p.Phe338SerPheSerTerUnk | frameshift | - | NC_000017.11:g.7670697_7670698insGCGCT | NCI-TCGA |
rs1064796401 | p.Phe338Ser | missense variant | - | NC_000017.11:g.7670696A>G | - |
rs150293825 | p.Phe338Leu | missense variant | - | NC_000017.11:g.7670695G>C | 1000Genomes,ESP,ExAC,TOPMed,gnomAD |
rs150293825 | p.Phe338Leu | missense variant | - | NC_000017.11:g.7670695G>C | UniProt,dbSNP |
VAR_045540 | p.Phe338Leu | missense variant | - | NC_000017.11:g.7670695G>C | UniProt |
RCV000772899 | p.Phe338Cys | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7670696A>C | ClinVar |
VAR_045539 | p.Phe338Ile | Missense | - | - | UniProt |
rs17882252 | p.Glu339Lys | missense variant | - | NC_000017.11:g.7670694C>T | ExAC,TOPMed,gnomAD |
COSM5230441 | p.Glu339ArgPheSerTerUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7670694C>- | NCI-TCGA Cosmic |
RCV000689964 | p.Glu339Ter | nonsense | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7670694C>A | ClinVar |
NCI-TCGA novel | p.Glu339AlaPheSerTerUnk | frameshift | - | NC_000017.11:g.7670693_7670694insCGAAG | NCI-TCGA |
RCV000697643 | p.Glu339Gln | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7670694C>G | ClinVar |
RCV000213068 | p.Glu339Gln | missense variant | - | NC_000017.11:g.7670694C>G | ClinVar |
RCV000505616 | p.Glu339Ter | nonsense | Li-Fraumeni syndrome 1 (LFS) | NC_000017.11:g.7670694C>A | ClinVar |
rs17882252 | p.Glu339Gln | missense variant | - | NC_000017.11:g.7670694C>G | ExAC,TOPMed,gnomAD |
rs1237829645 | p.Glu339Val | missense variant | - | NC_000017.11:g.7670693T>A | gnomAD |
rs17882252 | p.Glu339Ter | stop gained | - | NC_000017.11:g.7670694C>A | ExAC,TOPMed,gnomAD |
RCV000785266 | p.Glu339Ter | nonsense | Ovarian Neoplasms | NC_000017.11:g.7670694_7670695insA | ClinVar |
RCV000130594 | p.Glu339Gln | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7670694C>G | ClinVar |
RCV000254694 | p.Glu339Lys | missense variant | - | NC_000017.11:g.7670694C>T | ClinVar |
NCI-TCGA novel | p.Met340SerPheSerTerUnk | frameshift | - | NC_000017.11:g.7670690_7670691insTCAC | NCI-TCGA |
rs1463722976 | p.Met340Ile | missense variant | - | NC_000017.11:g.7670689C>A | TOPMed |
RCV000492284 | p.Met340Ter | frameshift | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7670691del | ClinVar |
NCI-TCGA novel | p.Phe341LeuPheSerTerUnk | frameshift | - | NC_000017.11:g.7670686_7670687insT | NCI-TCGA |
NCI-TCGA novel | p.Phe341Leu | missense variant | - | NC_000017.11:g.7670686G>C | NCI-TCGA |
NCI-TCGA novel | p.Phe341Val | missense variant | - | NC_000017.11:g.7670688A>C | NCI-TCGA |
NCI-TCGA novel | p.Phe341GluPheSerTerUnk | frameshift | - | NC_000017.11:g.7670688_7670689insCTTC | NCI-TCGA |
VAR_045542 | p.Phe341Cys | Missense | - | - | UniProt |
rs375338359 | p.Arg342Gln | missense variant | - | NC_000017.11:g.7670684C>T | ESP,ExAC,gnomAD |
rs730882029 | p.Arg342Ter | stop gained | - | NC_000017.11:g.7670685G>A | - |
RCV000213668 | p.Arg342Gln | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7670684C>T | ClinVar |
RCV000492610 | p.Arg342Ter | frameshift | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7670686del | ClinVar |
RCV000213069 | p.Arg342Ter | nonsense | - | NC_000017.11:g.7670685G>A | ClinVar |
RCV000161074 | p.Arg342Ter | nonsense | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7670685G>A | ClinVar |
COSM128665 | p.Arg342GluPheSerTerUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7670685G>- | NCI-TCGA Cosmic |
RCV000478259 | p.Arg342Gln | missense variant | - | NC_000017.11:g.7670684C>T | ClinVar |
RCV000688863 | p.Arg342Gln | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7670684C>T | ClinVar |
RCV000785461 | p.Arg342Ter | nonsense | Ovarian Neoplasms | NC_000017.11:g.7670676_7670683del | ClinVar |
RCV000785301 | p.Arg342Ter | nonsense | Ovarian Neoplasms | NC_000017.11:g.7670685G>A | ClinVar |
NCI-TCGA novel | p.Arg342GluPheSerTerUnk | frameshift | - | NC_000017.11:g.7670678_7670685AGCTCTCG>- | NCI-TCGA |
rs375338359 | p.Arg342Pro | missense variant | - | NC_000017.11:g.7670684C>G | ESP,ExAC,gnomAD |
RCV000549233 | p.Arg342Ter | nonsense | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7670685G>A | ClinVar |
RCV000198319 | p.Arg342Pro | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7670684C>G | ClinVar |
RCV000785302 | p.Arg342Ter | frameshift | Ovarian Neoplasms | NC_000017.11:g.7670686del | ClinVar |
VAR_045543 | p.Arg342Leu | Missense | - | - | UniProt |
COSM5752325 | p.Glu343AlaPheSerTerUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7670680_7670681CT>- | NCI-TCGA Cosmic |
COSM11078 | p.Glu343Ter | stop gained | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7670682C>A | NCI-TCGA Cosmic |
rs375573770 | p.Glu343Gln | missense variant | - | NC_000017.11:g.7670682C>G | ESP |
VAR_045545 | p.Glu343Gly | Missense | - | - | UniProt |
RCV000013174 | p.Leu344Pro | missense variant | Li-Fraumeni syndrome 1 (LFS) | NC_000017.11:g.7670678A>G | ClinVar |
rs121912662 | p.Leu344Pro | missense variant | Li-fraumeni syndrome 1 (lfs1) | NC_000017.11:g.7670678A>G | - |
rs121912662 | p.Leu344Pro | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7670678A>G | UniProt,dbSNP |
VAR_045546 | p.Leu344Pro | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7670678A>G | UniProt |
VAR_045547 | p.Leu344Arg | Missense | - | - | UniProt |
COSM4070032 | p.Asn345Asp | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7670676T>C | NCI-TCGA Cosmic |
COSM69016 | p.Asn345MetPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7670677C>- | NCI-TCGA Cosmic |
NCI-TCGA novel | p.Asn345SerPheSerTerUnk | stop gained | - | NC_000017.11:g.7670675_7670676insTCAGC | NCI-TCGA |
RCV000562934 | p.Glu346Asp | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7670671C>G | ClinVar |
NCI-TCGA novel | p.Glu346Ter | frameshift | - | NC_000017.11:g.7670673_7670674insA | NCI-TCGA |
RCV000785295 | p.Glu346Ter | frameshift | Ovarian Neoplasms | NC_000017.11:g.7670673del | ClinVar |
RCV000785313 | p.Glu346Ter | nonsense | Ovarian Neoplasms | NC_000017.11:g.7670673C>A | ClinVar |
VAR_045548 | p.Glu346Ala | Missense | - | - | UniProt |
RCV000484420 | p.Ala347Val | missense variant | - | NC_000017.11:g.7670669G>A | ClinVar |
RCV000567572 | p.Ala347Val | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7670669G>A | ClinVar |
RCV000255021 | p.Ala347Asp | missense variant | - | NC_000017.11:g.7670669G>T | ClinVar |
VAR_045549 | p.Ala347Gly | Missense | - | - | UniProt |
VAR_045550 | p.Ala347Thr | Missense | - | - | UniProt |
rs1060501193 | p.Leu348Val | missense variant | - | NC_000017.11:g.7670667A>C | - |
RCV000473178 | p.Leu348Val | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7670667A>C | ClinVar |
COSM46348 | p.Leu348Phe | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7670665C>A | NCI-TCGA Cosmic |
COSM69193 | p.Leu348Ter | stop gained | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7670666_7670667insAGGCCTT | NCI-TCGA Cosmic |
NCI-TCGA novel | p.Leu348TrpPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7670666A>- | NCI-TCGA |
RCV000699234 | p.Leu348Ter | nonsense | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7670658_7670666delinsC | ClinVar |
VAR_045551 | p.Leu348Phe | Missense | - | - | UniProt |
VAR_045552 | p.Leu348Ser | Missense | - | - | UniProt |
RCV000785303 | p.Glu349Ter | nonsense | Ovarian Neoplasms | NC_000017.11:g.7670664C>A | ClinVar |
RCV000424672 | p.Glu349Ter | frameshift | - | NC_000017.11:g.7670658_7670665del | ClinVar |
VAR_045553 | p.Glu349Asp | Missense | - | - | UniProt |
RCV000492513 | p.Leu350Ter | frameshift | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7670660_7670661del | ClinVar |
RCV000562474 | p.Leu350Phe | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7670661G>A | ClinVar |
NCI-TCGA novel | p.Leu350GlyPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7670657_7670661TTGAG>- | NCI-TCGA |
NCI-TCGA novel | p.Leu350ProPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7670651_7670660GCATCCTTGA>- | NCI-TCGA |
rs768046010 | p.Leu350Phe | missense variant | - | NC_000017.11:g.7670661G>A | ExAC,gnomAD |
rs768046010 | p.Leu350Val | missense variant | - | NC_000017.11:g.7670661G>C | ExAC,gnomAD |
RCV000131779 | p.Lys351Glu | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7670658T>C | ClinVar |
COSM1522202 | p.Lys351Ter | stop gained | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7670658T>A | NCI-TCGA Cosmic |
RCV000552899 | p.Lys351Arg | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7670657T>C | ClinVar |
rs141402957 | p.Lys351Glu | missense variant | - | NC_000017.11:g.7670658T>C | - |
rs1555524396 | p.Lys351Arg | missense variant | - | NC_000017.11:g.7670657T>C | - |
rs1555524394 | p.Asp352Tyr | missense variant | - | NC_000017.11:g.7670655C>A | - |
RCV000574074 | p.Asp352Tyr | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7670655C>A | ClinVar |
VAR_045554 | p.Asp352His | Missense | - | - | UniProt |
VAR_045555 | p.Ala353Thr | Missense | - | - | UniProt |
rs755394212 | p.Gln354Lys | missense variant | - | NC_000017.11:g.7670649G>T | UniProt,dbSNP |
VAR_045557 | p.Gln354Lys | missense variant | - | NC_000017.11:g.7670649G>T | UniProt |
RCV000663226 | p.Gln354Lys | missense variant | Li-Fraumeni syndrome 1 (LFS) | NC_000017.11:g.7670649G>T | ClinVar |
RCV000626710 | p.Gln354Lys | missense variant | Neoplasm of the colon | NC_000017.11:g.7670649G>T | ClinVar |
RCV000222255 | p.Gln354Lys | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7670649G>T | ClinVar |
RCV000469791 | p.Gln354Lys | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7670649G>T | ClinVar |
RCV000531178 | p.Gln354Ter | nonsense | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7670649G>A | ClinVar |
rs755394212 | p.Gln354Lys | missense variant | - | NC_000017.11:g.7670649G>T | ExAC,gnomAD |
rs752142489 | p.Gln354Arg | missense variant | - | NC_000017.11:g.7670648T>C | ExAC,gnomAD |
rs755394212 | p.Gln354Ter | stop gained | - | NC_000017.11:g.7670649G>A | ExAC,gnomAD |
RCV000774782 | p.Gln354Arg | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7670648T>C | ClinVar |
VAR_045556 | p.Gln354Glu | Missense | - | - | UniProt |
rs1157427821 | p.Ala355Thr | missense variant | - | NC_000017.11:g.7670646C>T | gnomAD |
RCV000633335 | p.Ala355Val | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7670645G>A | ClinVar |
rs1555524382 | p.Ala355Val | missense variant | - | NC_000017.11:g.7670645G>A | - |
RCV000781911 | p.Gly356Arg | missense variant | - | NC_000017.11:g.7670643C>G | ClinVar |
RCV000213405 | p.Gly356Arg | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7670643C>G | ClinVar |
RCV000471717 | p.Gly356Arg | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7670643C>G | ClinVar |
rs766786605 | p.Gly356Arg | missense variant | - | NC_000017.11:g.7670643C>T | ExAC,TOPMed,gnomAD |
rs766786605 | p.Gly356Arg | missense variant | - | NC_000017.11:g.7670643C>G | ExAC,TOPMed,gnomAD |
RCV000481680 | p.Gly356Arg | missense variant | - | NC_000017.11:g.7670643C>G | ClinVar |
VAR_045558 | p.Gly356Ala | Missense | - | - | UniProt |
VAR_045559 | p.Gly356Trp | Missense | - | - | UniProt |
RCV000709400 | p.Lys357Glu | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7670640T>C | ClinVar |
rs763426446 | p.Lys357Arg | missense variant | - | NC_000017.11:g.7670639T>C | ExAC,gnomAD |
RCV000249541 | p.Glu358Val | missense variant | - | NC_000017.11:g.7670636T>A | ClinVar |
rs587782237 | p.Glu358Lys | missense variant | - | NC_000017.11:g.7670637C>T | - |
rs587782237 | p.Glu358Lys | missense variant | - | NC_000017.11:g.7670637C>T | UniProt,dbSNP |
VAR_045561 | p.Glu358Lys | missense variant | - | NC_000017.11:g.7670637C>T | UniProt |
rs773553186 | p.Glu358Val | missense variant | - | NC_000017.11:g.7670636T>A | ExAC,gnomAD |
RCV000130938 | p.Glu358Lys | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7670637C>T | ClinVar |
VAR_045560 | p.Glu358Asp | Missense | - | - | UniProt |
rs1483922249 | p.Pro359Leu | missense variant | - | NC_000017.11:g.7670633G>A | gnomAD |
rs35993958 | p.Gly360Val | missense variant | - | NC_000017.11:g.7670630C>A | UniProt,dbSNP |
VAR_045563 | p.Gly360Val | missense variant | - | NC_000017.11:g.7670630C>A | UniProt |
rs35993958 | p.Gly360Val | missense variant | - | NC_000017.11:g.7670630C>A | 1000Genomes,ESP,ExAC,TOPMed,gnomAD |
rs786203298 | p.Gly360Arg | missense variant | - | NC_000017.11:g.7670631C>T | TOPMed,gnomAD |
rs35993958 | p.Gly360Glu | missense variant | - | NC_000017.11:g.7670630C>T | 1000Genomes,ESP,ExAC,TOPMed,gnomAD |
rs35993958 | p.Gly360Ala | missense variant | - | NC_000017.11:g.7670630C>G | UniProt,dbSNP |
VAR_045562 | p.Gly360Ala | missense variant | - | NC_000017.11:g.7670630C>G | UniProt |
RCV000195550 | p.Gly360Val | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7670630C>A | ClinVar |
RCV000130776 | p.Gly360Ala | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7670630C>G | ClinVar |
RCV000541338 | p.Gly360Glu | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7670630C>T | ClinVar |
RCV000254695 | p.Gly360Ala | missense variant | - | NC_000017.11:g.7670630C>G | ClinVar |
rs35993958 | p.Gly360Ala | missense variant | - | NC_000017.11:g.7670630C>G | 1000Genomes,ESP,ExAC,TOPMed,gnomAD |
rs786203298 | p.Gly360Trp | missense variant | - | NC_000017.11:g.7670631C>A | TOPMed,gnomAD |
RCV000213880 | p.Gly360Glu | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7670630C>T | ClinVar |
RCV000166545 | p.Gly360Arg | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7670631C>T | ClinVar |
RCV000569528 | p.Gly360Trp | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7670631C>A | ClinVar |
RCV000633398 | p.Gly361Arg | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7670628C>G | ClinVar |
rs587781663 | p.Gly361Glu | missense variant | - | NC_000017.11:g.7670627C>T | TOPMed |
rs1555524361 | p.Gly361Arg | missense variant | - | NC_000017.11:g.7670628C>G | - |
RCV000129812 | p.Gly361Glu | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7670627C>T | ClinVar |
RCV000581885 | p.Gly361Glu | missense variant | - | NC_000017.11:g.7670627C>T | ClinVar |
RCV000571168 | p.Gly361Arg | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7670628C>G | ClinVar |
rs768803947 | p.Ser362Ile | missense variant | - | NC_000017.11:g.7670624C>A | ExAC,gnomAD |
RCV000552096 | p.Ser362Cys | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7670625T>A | ClinVar |
RCV000572520 | p.Ser362Ile | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7670624C>A | ClinVar |
RCV000530397 | p.Ser362Asn | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7670624C>T | ClinVar |
RCV000677306 | p.Ser362Ter | frameshift | Diamond-Blackfan anemia (DBA) | NC_000017.11:g.7670632del | ClinVar |
NCI-TCGA novel | p.Ser362Thr | missense variant | - | NC_000017.11:g.7670624C>G | NCI-TCGA |
RCV000714961 | p.Ser362Ter | frameshift | BONE MARROW FAILURE SYNDROME 5 (BMFS5) | NC_000017.11:g.7670631del | ClinVar |
rs1287887419 | p.Ser362Cys | missense variant | - | NC_000017.11:g.7670625T>A | gnomAD |
rs768803947 | p.Ser362Asn | missense variant | - | NC_000017.11:g.7670624C>T | ExAC,gnomAD |
RCV000677307 | p.Ser362Ter | frameshift | Diamond-Blackfan anemia (DBA) | NC_000017.11:g.7670631del | ClinVar |
RCV000714962 | p.Ser362Ter | frameshift | BONE MARROW FAILURE SYNDROME 5 (BMFS5) | NC_000017.11:g.7670632del | ClinVar |
rs876660285 | p.Arg363Lys | missense variant | - | NC_000017.11:g.7670621C>T | - |
rs876660285 | p.Arg363Lys | missense variant | - | NC_000017.11:g.7670621C>T | UniProt,dbSNP |
VAR_045564 | p.Arg363Lys | missense variant | - | NC_000017.11:g.7670621C>T | UniProt |
RCV000483595 | p.Arg363Gly | missense variant | - | NC_000017.11:g.7670622T>C | ClinVar |
rs745751553 | p.Arg363Gly | missense variant | - | NC_000017.11:g.7670622T>C | ExAC,gnomAD |
RCV000168038 | p.Arg363Gly | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7670622T>C | ClinVar |
RCV000223158 | p.Arg363Lys | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7670621C>T | ClinVar |
RCV000419155 | p.Arg363Lys | missense variant | - | NC_000017.11:g.7670621C>T | ClinVar |
RCV000689466 | p.Ala364Val | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7670618G>A | ClinVar |
VAR_045566 | p.Ala364Thr | Missense | - | - | UniProt |
VAR_045565 | p.Ala364Pro | Missense | - | - | UniProt |
VAR_045567 | p.Ala364Val | Missense | - | - | UniProt |
RCV000129635 | p.His365Tyr | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7670616G>A | ClinVar |
RCV000701624 | p.His365Tyr | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7670616G>A | ClinVar |
rs267605075 | p.His365Tyr | missense variant | - | NC_000017.11:g.7670616G>A | ExAC,gnomAD |
VAR_047215 | p.His365Arg | Missense | - | - | UniProt |
RCV000122179 | p.Ser366Ala | missense variant | - | NC_000017.11:g.7670613A>C | ClinVar |
rs17881470 | p.Ser366Pro | missense variant | - | NC_000017.11:g.7670613A>G | 1000Genomes,ExAC,TOPMed,gnomAD |
rs17881470 | p.Ser366Ala | missense variant | - | NC_000017.11:g.7670613A>C | 1000Genomes,ExAC,TOPMed,gnomAD |
RCV000197399 | p.Ser366Ala | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7670613A>C | ClinVar |
RCV000588647 | p.Ser366Ala | missense variant | - | NC_000017.11:g.7670613A>C | ClinVar |
RCV000633357 | p.Ser366Pro | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7670613A>G | ClinVar |
RCV000218678 | p.Ser367Gly | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7670610T>C | ClinVar |
rs749150541 | p.Ser367Asn | missense variant | - | NC_000017.11:g.7670609C>T | ExAC,gnomAD |
rs876659459 | p.Ser367Gly | missense variant | - | NC_000017.11:g.7670610T>C | - |
RCV000798387 | p.His368Gln | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7669687G>C | ClinVar |
RCV000575539 | p.His368Gln | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7669687G>C | ClinVar |
rs786204227 | p.His368Tyr | missense variant | - | NC_000017.11:g.7669689G>A | - |
rs1289241865 | p.His368Gln | missense variant | - | NC_000017.11:g.7669687G>T | gnomAD |
rs1289241865 | p.His368Gln | missense variant | - | NC_000017.11:g.7669687G>C | gnomAD |
RCV000222357 | p.His368Tyr | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7669689G>A | ClinVar |
RCV000168367 | p.His368Tyr | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7669689G>A | ClinVar |
VAR_045569 | p.Lys370Gln | Missense | - | - | UniProt |
rs876658876 | p.Lys372Thr | missense variant | - | NC_000017.11:g.7669676T>G | - |
RCV000507724 | p.Lys372Thr | missense variant | - | NC_000017.11:g.7669676T>G | ClinVar |
rs876658876 | p.Lys372Arg | missense variant | - | NC_000017.11:g.7669676T>C | - |
RCV000217059 | p.Lys372Arg | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7669676T>C | ClinVar |
NCI-TCGA novel | p.Lys373ArgPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7669673T>- | NCI-TCGA |
RCV000771476 | p.Lys373Arg | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7669673T>C | ClinVar |
RCV000700219 | p.Lys373Arg | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7669673T>C | ClinVar |
rs587781858 | p.Gly374Ser | missense variant | - | NC_000017.11:g.7669671C>T | ExAC,TOPMed,gnomAD |
RCV000217404 | p.Gly374Arg | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7669671C>G | ClinVar |
rs587781858 | p.Gly374Arg | missense variant | - | NC_000017.11:g.7669671C>G | ExAC,TOPMed,gnomAD |
RCV000233345 | p.Gly374Ter | frameshift | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7669672del | ClinVar |
RCV000130166 | p.Gly374Ser | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7669671C>T | ClinVar |
rs587781858 | p.Gly374Cys | missense variant | - | NC_000017.11:g.7669671C>A | ExAC,TOPMed,gnomAD |
RCV000161058 | p.Gln375Ter | frameshift | - | NC_000017.11:g.7669666del | ClinVar |
COSM3403253 | p.Gln375Lys | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7669668G>T | NCI-TCGA Cosmic |
RCV000563669 | p.Gln375Ter | nonsense | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7669668G>A | ClinVar |
rs1555524156 | p.Gln375Ter | stop gained | - | NC_000017.11:g.7669668G>A | - |
RCV000702325 | p.Gln375Ter | nonsense | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7669668G>A | ClinVar |
COSM4820570 | p.Ser376Cys | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000017.11:g.7669664G>C | NCI-TCGA Cosmic |
RCV000584249 | p.Ser376Phe | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7669664G>A | ClinVar |
rs1555524151 | p.Ser376Phe | missense variant | - | NC_000017.11:g.7669664G>A | - |
VAR_045571 | p.Ser376Thr | Missense | - | - | UniProt |
VAR_045570 | p.Ser376Ala | Missense | - | - | UniProt |
NCI-TCGA novel | p.Thr377ProPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7669659_7669662AGGT>- | NCI-TCGA |
rs774269719 | p.Thr377Pro | missense variant | - | NC_000017.11:g.7669662T>G | ExAC,gnomAD |
rs774269719 | p.Thr377Ser | missense variant | - | NC_000017.11:g.7669662T>A | ExAC,gnomAD |
rs1555524130 | p.Ser378Cys | missense variant | - | NC_000017.11:g.7669658G>C | - |
rs80184930 | p.Ser378Pro | missense variant | - | NC_000017.11:g.7669659A>G | ExAC,gnomAD |
RCV000562179 | p.Ser378Cys | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7669658G>C | ClinVar |
RCV000795303 | p.Arg379Ser | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7669656G>T | ClinVar |
RCV000412389 | p.Arg379Ser | missense variant | Li-Fraumeni syndrome 1 (LFS) | NC_000017.11:g.7669656G>T | ClinVar |
RCV000236607 | p.Arg379Ser | missense variant | - | NC_000017.11:g.7669656G>T | ClinVar |
RCV000166408 | p.Arg379Ser | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7669656G>T | ClinVar |
RCV000581851 | p.Arg379His | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7669655C>T | ClinVar |
rs749061599 | p.Arg379Ser | missense variant | - | NC_000017.11:g.7669656G>T | ExAC,gnomAD |
RCV000166233 | p.Arg379Cys | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7669656G>A | ClinVar |
RCV000696782 | p.Arg379His | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7669655C>T | ClinVar |
RCV000219990 | p.Arg379Leu | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7669655C>A | ClinVar |
RCV000235637 | p.Arg379His | missense variant | - | NC_000017.11:g.7669655C>T | ClinVar |
rs863224682 | p.Arg379Leu | missense variant | - | NC_000017.11:g.7669655C>A | TOPMed,gnomAD |
rs863224682 | p.Arg379His | missense variant | - | NC_000017.11:g.7669655C>T | UniProt,dbSNP |
VAR_045572 | p.Arg379His | missense variant | - | NC_000017.11:g.7669655C>T | UniProt |
rs863224682 | p.Arg379His | missense variant | - | NC_000017.11:g.7669655C>T | TOPMed,gnomAD |
rs749061599 | p.Arg379Cys | missense variant | - | NC_000017.11:g.7669656G>A | ExAC,gnomAD |
RCV000559034 | p.Arg379Cys | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7669656G>A | ClinVar |
RCV000590314 | p.Arg379Leu | missense variant | - | NC_000017.11:g.7669655C>A | ClinVar |
RCV000410457 | p.Arg379His | missense variant | Li-Fraumeni syndrome 1 (LFS) | NC_000017.11:g.7669655C>T | ClinVar |
RCV000199273 | p.Arg379Leu | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7669655C>A | ClinVar |
RCV000492580 | p.His380Ter | frameshift | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7669652del | ClinVar |
RCV000537354 | p.His380Ter | frameshift | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7669651del | ClinVar |
RCV000759367 | p.Lys381Ter | nonsense | - | NC_000017.11:g.7669651dup | ClinVar |
COSM13747 | p.Lys382AsnPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000017.11:g.7669645T>- | NCI-TCGA Cosmic |
RCV000759368 | p.Leu383Phe | missense variant | - | NC_000017.11:g.7669644G>A | ClinVar |
NCI-TCGA novel | p.Leu383CysPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7669641_7669644TGAG>- | NCI-TCGA |
rs150842067 | p.Leu383Phe | missense variant | - | NC_000017.11:g.7669644G>A | - |
rs1060501196 | p.Met384Thr | missense variant | - | NC_000017.11:g.7669640A>G | gnomAD |
rs1060501196 | p.Met384Arg | missense variant | - | NC_000017.11:g.7669640A>C | gnomAD |
RCV000484106 | p.Met384Ter | frameshift | - | NC_000017.11:g.7669638_7669640delinsC | ClinVar |
RCV000662831 | p.Met384Thr | missense variant | Li-Fraumeni syndrome 1 (LFS) | NC_000017.11:g.7669640A>G | ClinVar |
RCV000548129 | p.Met384Arg | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7669640A>C | ClinVar |
RCV000161040 | p.Met384Val | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7669641T>C | ClinVar |
RCV000587685 | p.Met384Val | missense variant | - | NC_000017.11:g.7669641T>C | ClinVar |
rs730882009 | p.Met384Val | missense variant | - | NC_000017.11:g.7669641T>C | TOPMed |
RCV000213071 | p.Met384Val | missense variant | - | NC_000017.11:g.7669641T>C | ClinVar |
RCV000195684 | p.Met384Val | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7669641T>C | ClinVar |
RCV000566404 | p.Met384Thr | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7669640A>G | ClinVar |
RCV000462881 | p.Met384Thr | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7669640A>G | ClinVar |
RCV000561658 | p.Phe385Leu | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7669638A>G | ClinVar |
rs1555524094 | p.Phe385Leu | missense variant | - | NC_000017.11:g.7669638A>G | UniProt,dbSNP |
VAR_045573 | p.Phe385Leu | missense variant | - | NC_000017.11:g.7669638A>G | UniProt |
rs1555524094 | p.Phe385Leu | missense variant | - | NC_000017.11:g.7669638A>G | - |
rs927888647 | p.Thr387Arg | missense variant | - | NC_000017.11:g.7669631G>C | TOPMed,gnomAD |
RCV000569933 | p.Thr387Arg | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7669631G>C | ClinVar |
RCV000226900 | p.Glu388Ala | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7669628T>G | ClinVar |
rs587781736 | p.Glu388Ala | missense variant | - | NC_000017.11:g.7669628T>G | - |
RCV000129934 | p.Glu388Ala | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7669628T>G | ClinVar |
RCV000236435 | p.Glu388Ala | missense variant | - | NC_000017.11:g.7669628T>G | ClinVar |
RCV000144667 | p.Gly389Trp | missense variant | Li-Fraumeni syndrome 1 (LFS) | NC_000017.11:g.7669626C>A | ClinVar |
RCV000558251 | p.Gly389Arg | missense variant | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7669626C>T | ClinVar |
rs587783064 | p.Gly389Arg | missense variant | - | NC_000017.11:g.7669626C>T | gnomAD |
rs587783064 | p.Gly389Trp | missense variant | - | NC_000017.11:g.7669626C>A | gnomAD |
rs587783064 | p.Gly389Trp | missense variant | - | NC_000017.11:g.7669626C>A | UniProt,dbSNP |
VAR_045574 | p.Gly389Trp | missense variant | - | NC_000017.11:g.7669626C>A | UniProt |
NCI-TCGA novel | p.Pro390His | missense variant | - | NC_000017.11:g.7669622G>T | NCI-TCGA |
NCI-TCGA novel | p.Asp391ThrPheSerTerUnkUnk | frameshift | - | NC_000017.11:g.7669621A>- | NCI-TCGA |
RCV000773751 | p.Asp391Glu | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7669618G>C | ClinVar |
rs769664911 | p.Ser392Ter | stop gained | - | NC_000017.11:g.7669616G>T | ExAC,gnomAD |
NCI-TCGA novel | p.Ser392Thr | frameshift | - | NC_000017.11:g.7669610_7669617CAGTCTGA>- | NCI-TCGA |
VAR_045575 | p.Ser392Leu | Missense | - | - | UniProt |
rs1192921623 | p.Asp393Asn | missense variant | - | NC_000017.11:g.7669614C>T | TOPMed,gnomAD |
RCV000584379 | p.Asp393Asn | missense variant | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7669614C>T | ClinVar |
RCV000536567 | p.Asp393Ter | frameshift | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7669614del | ClinVar |
rs1192921623 | p.Asp393Tyr | missense variant | - | NC_000017.11:g.7669614C>A | TOPMed,gnomAD |
rs1555524074 | p.Ter394Cys | stop lost | - | NC_000017.11:g.7669609T>A | - |
RCV000492658 | p.Ter394Leu | stop lost | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7669612dup | ClinVar |
NCI-TCGA novel | p.Ter394Thr | frameshift | - | NC_000017.11:g.7669610_7669611CA>- | NCI-TCGA |
rs1555524079 | p.Ter394Gly | stop lost | - | NC_000017.11:g.7669611A>C | - |
RCV000573419 | p.Ter394Gly | stop lost | Hereditary cancer-predisposing syndrome | NC_000017.11:g.7669611A>C | ClinVar |
RCV000551312 | p.Ter394Cys | stop lost | Li-Fraumeni syndrome (LFS) | NC_000017.11:g.7669609T>A | ClinVar |
rs1057519997 | p.Leu111Gln | missense variant | - | NC_000017.11:g.7676037A>T | - |
rs886039483 | p.Tyr126Asp | missense variant | - | NC_000017.11:g.7675236A>C | - |
rs1057519975 | p.Cys135Gly | missense variant | - | NC_000017.11:g.7675209A>C | - |
rs1555526097 | p.Gln167Ter | stop gained | - | NC_000017.11:g.7675113G>A | - |
rs730882025 | p.Val216Leu | missense variant | - | NC_000017.11:g.7674885C>A | - |
rs587782289 | p.Tyr236His | missense variant | - | NC_000017.11:g.7674257A>G | - |
rs1057519981 | p.Cys238Ser | missense variant | - | NC_000017.11:g.7674251A>T | - |
rs1057519981 | p.Cys238Arg | missense variant | - | NC_000017.11:g.7674251A>G | - |
rs1057519989 | p.Gly244Cys | missense variant | - | NC_000017.11:g.7674233C>A | - |
rs587780074 | p.Met246Lys | missense variant | - | NC_000017.11:g.7674226A>T | - |
rs587781433 | p.Thr256Pro | missense variant | - | NC_000017.11:g.7674197T>G | - |
rs28934577 | p.Leu257Pro | missense variant | - | NC_000017.11:g.7674193A>G | - |
rs876660333 | p.Val272Glu | missense variant | - | NC_000017.11:g.7673805A>T | - |
rs121913344 | p.Arg306Ter | stop gained | - | NC_000017.11:g.7673704G>A | - |
rs1555524406 | p.Glu346Asp | missense variant | - | NC_000017.11:g.7670671C>G | - |
Disease ID | Disease Name | Disease Type | Source |
---|---|---|---|
C0000735 | Abdominal Neoplasms | group | BEFREE |
C0000737 | Abdominal Pain | phenotype | HPO |
C0000768 | Congenital Abnormality | group | BEFREE |
C0001175 | Acquired Immunodeficiency Syndrome | group | BEFREE;LHGDN |
C0001206 | Acromegaly | disease | BEFREE |
C0001418 | Adenocarcinoma | group | BEFREE;CLINVAR;CTD_human;CTD_mouse;LHGDN |
C0001422 | Adenofibroma | disease | BEFREE |
C0001430 | Adenoma | group | BEFREE;CTD_human;LHGDN |
C0001442 | Adenosarcoma | disease | BEFREE |
C0001486 | Adenovirus Infections | group | BEFREE |
C0001618 | Tumors of Adrenal Cortex | group | BEFREE;CGI;HPO;LHGDN |
C0001621 | Adrenal Gland Diseases | group | BEFREE |
C0001624 | Adrenal Gland Neoplasms | group | BEFREE;CTD_human |
C0001627 | Congenital adrenal hyperplasia | disease | BEFREE |
C0001815 | Primary Myelofibrosis | disease | BEFREE |
C0001849 | AIDS Dementia Complex | disease | LHGDN |
C0001857 | AIDS related complex | disease | LHGDN |
C0001969 | Alcoholic Intoxication | disease | BEFREE;PSYGENET |
C0001973 | Alcoholic Intoxication, Chronic | disease | BEFREE;PSYGENET |
C0002152 | Alloxan Diabetes | disease | CTD_human;CTD_mouse |
C0002312 | alpha-Thalassemia | disease | BEFREE |
C0002395 | Alzheimer's Disease | disease | BEFREE;LHGDN |
C0002448 | Ameloblastoma | disease | BEFREE |
C0002726 | Amyloidosis | disease | BEFREE |
C0002736 | Amyotrophic Lateral Sclerosis | disease | BEFREE;CTD_human |
C0002793 | Anaplasia | disease | BEFREE |
C0002871 | Anemia | disease | BEFREE |
C0002874 | Aplastic Anemia | disease | BEFREE;LHGDN |
C0002886 | Anemia, Macrocytic | disease | BEFREE |
C0002893 | Refractory anemias | disease | BEFREE |
C0002940 | Aneurysm | phenotype | BEFREE |
C0002991 | Cutaneous Fibrous Histiocytoma | disease | BEFREE |
C0003123 | Anorexia | disease | HPO |
C0003130 | Anoxia | phenotype | LHGDN |
C0003463 | Anus Neoplasms | group | LHGDN |
C0003467 | Anxiety | disease | BEFREE;HPO |
C0003469 | Anxiety Disorders | group | BEFREE |
C0003504 | Aortic Valve Insufficiency | disease | BEFREE |
C0003850 | Arteriosclerosis | disease | BEFREE |
C0003864 | Arthritis | disease | BEFREE |
C0003872 | Arthritis, Psoriatic | disease | BEFREE |
C0003873 | Rheumatoid Arthritis | disease | BEFREE;LHGDN |
C0004096 | Asthma | disease | BEFREE |
C0004114 | Astrocytoma | disease | BEFREE;CTD_mouse;LHGDN |
C0004134 | Ataxia | phenotype | BEFREE |
C0004135 | Ataxia Telangiectasia | disease | BEFREE |
C0004153 | Atherosclerosis | disease | BEFREE |
C0004238 | Atrial Fibrillation | disease | BEFREE |
C0004277 | Tooth Attrition | phenotype | BEFREE |
C0004352 | Autistic Disorder | group | LHGDN |
C0004364 | Autoimmune Diseases | group | BEFREE |
C0004604 | Back Pain | phenotype | HPO |
C0004698 | Balkan Nephropathy | disease | BEFREE;CTD_human;LHGDN |
C0004763 | Barrett Esophagus | disease | BEFREE;LHGDN |
C0004779 | Basal Cell Nevus Syndrome | disease | BEFREE |
C0004903 | Beckwith-Wiedemann Syndrome | disease | BEFREE |
C0004943 | Behcet Syndrome | disease | BEFREE |
C0004997 | Benign Ovarian Neoplasm | disease | BEFREE |
C0005398 | Cholestasis, Extrahepatic | disease | HPO |
C0005684 | Malignant neoplasm of urinary bladder | disease | BEFREE;CTD_human;CTD_mouse |
C0005695 | Bladder Neoplasm | group | BEFREE;CTD_human;CTD_mouse;LHGDN |
C0005699 | Blast Phase | disease | BEFREE |
C0005859 | Bloom Syndrome | disease | BEFREE |
C0005941 | Bone Diseases, Developmental | group | CTD_mouse |
C0006079 | Bowen's Disease | disease | BEFREE |
C0006118 | Brain Neoplasms | group | BEFREE;CLINVAR;CTD_mouse;LHGDN;UNIPROT |
C0006142 | Malignant neoplasm of breast | disease | BEFREE;CGI;CTD_human;CTD_mouse;GENOMICS_ENGLAND;MGD;UNIPROT |
C0006145 | Breast Diseases | group | BEFREE;LHGDN |
C0006160 | Brenner Tumor | disease | BEFREE |
C0006264 | Bronchial Neoplasms | group | BEFREE |
C0006413 | Burkitt Lymphoma | disease | BEFREE;LHGDN;ORPHANET |
C0006826 | Malignant Neoplasms | group | BEFREE;CGI |
C0007095 | Carcinoid Tumor | group | BEFREE |
C0007097 | Carcinoma | group | CTD_human |
C0007102 | Malignant tumor of colon | disease | BEFREE;CTD_human;HPO |
C0007103 | Malignant neoplasm of endometrium | disease | BEFREE;MGD |
C0007104 | Female Breast Carcinoma | disease | BEFREE |
C0007107 | Malignant neoplasm of larynx | disease | BEFREE |
C0007112 | Adenocarcinoma of prostate | disease | BEFREE;CLINVAR |
C0007113 | Rectal Carcinoma | disease | BEFREE |
C0007114 | Malignant neoplasm of skin | disease | BEFREE;CTD_human;CTD_mouse;HPO |
C0007115 | Malignant neoplasm of thyroid | disease | BEFREE |
C0007117 | Basal cell carcinoma | disease | CTD_human;GWASCAT;GWASDB;LHGDN |
C0007120 | Bronchioloalveolar Adenocarcinoma | disease | BEFREE;RGD |
C0007121 | Bronchogenic Carcinoma | disease | BEFREE |
C0007124 | Noninfiltrating Intraductal Carcinoma | disease | BEFREE;LHGDN |
C0007125 | Carcinoma, Ehrlich Tumor | disease | BEFREE |
C0007129 | Merkel cell carcinoma | disease | BEFREE;LHGDN |
C0007130 | Mucinous Adenocarcinoma | disease | BEFREE;LHGDN |
C0007131 | Non-Small Cell Lung Carcinoma | disease | BEFREE;CTD_human;LHGDN |
C0007133 | Carcinoma, Papillary | disease | BEFREE |
C0007134 | Renal Cell Carcinoma | disease | BEFREE;CLINVAR;CTD_human;HPO;LHGDN |
C0007137 | Squamous cell carcinoma | disease | BEFREE;CTD_human;CTD_mouse;LHGDN;RGD |
C0007138 | Carcinoma, Transitional Cell | disease | BEFREE;CTD_human;LHGDN |
C0007140 | Carcinosarcoma | disease | BEFREE;LHGDN |
C0007193 | Cardiomyopathy, Dilated | group | BEFREE;LHGDN |
C0007194 | Hypertrophic Cardiomyopathy | disease | CTD_human |
C0007222 | Cardiovascular Diseases | group | BEFREE |
C0007273 | Carotid Artery Diseases | group | CTD_human;LHGDN |
C0007528 | Cecal Neoplasms | group | CTD_mouse |
C0007621 | Neoplastic Cell Transformation | phenotype | CTD_human;CTD_mouse |
C0007758 | Cerebellar Ataxia | phenotype | BEFREE |
C0007766 | Intracranial Aneurysm | disease | BEFREE |
C0007785 | Cerebral Infarction | disease | BEFREE |
C0007786 | Brain Ischemia | disease | CTD_human |
C0007787 | Transient Ischemic Attack | disease | BEFREE |
C0007847 | Malignant tumor of cervix | disease | BEFREE;CGI |
C0007867 | Cervix Diseases | group | BEFREE |
C0007868 | Cervical dysplasia | disease | BEFREE |
C0007873 | Uterine Cervical Neoplasm | disease | BEFREE;CGI;LHGDN |
C0007971 | Cheilitis | disease | LHGDN |
C0008031 | Chest Pain | phenotype | HPO |
C0008311 | Cholangitis | disease | BEFREE |
C0008312 | Primary biliary cirrhosis | disease | BEFREE |
C0008325 | Cholecystitis | disease | LHGDN |
C0008441 | Chondroblastoma | disease | BEFREE |
C0008479 | Chondrosarcoma | disease | BEFREE |
C0008487 | Chordoma | disease | LHGDN |
C0008497 | Choriocarcinoma | disease | BEFREE |
C0008626 | Congenital chromosomal disease | group | BEFREE |
C0008677 | Bronchitis, Chronic | disease | BEFREE |
C0008925 | Cleft Palate | disease | BEFREE |
C0009207 | Cockayne Syndrome | disease | BEFREE |
C0009319 | Colitis | disease | BEFREE |
C0009324 | Ulcerative Colitis | disease | BEFREE;LHGDN |
C0009363 | Congenital ocular coloboma (disorder) | disease | BEFREE |
C0009375 | Colonic Neoplasms | group | BEFREE;CTD_human;HPO;LHGDN |
C0009376 | Colonic Polyps | phenotype | BEFREE |
C0009402 | Colorectal Carcinoma | disease | BEFREE;CTD_human |
C0009404 | Colorectal Neoplasms | group | BEFREE;CLINVAR;CTD_human;LHGDN |
C0009405 | Hereditary Nonpolyposis Colorectal Neoplasms | group | LHGDN |
C0009447 | Common Variable Immunodeficiency | disease | BEFREE |
C0009663 | Condylomata Acuminata | disease | BEFREE |
C0010054 | Coronary Arteriosclerosis | disease | BEFREE |
C0010068 | Coronary heart disease | disease | BEFREE |
C0010246 | Coxsackievirus Infections | group | BEFREE |
C0010346 | Crohn Disease | disease | BEFREE;LHGDN |
C0010606 | Adenoid Cystic Carcinoma | disease | BEFREE;CLINVAR;CTD_human |
C0010631 | Cystadenocarcinoma | disease | BEFREE |
C0010633 | Cystadenoma | disease | BEFREE |
C0010635 | Cystadenoma, Mucinous | disease | BEFREE |
C0010692 | Cystitis | disease | BEFREE |
C0010701 | Phyllodes Tumor | disease | BEFREE |
C0010823 | Cytomegalovirus Infections | group | BEFREE |
C0010828 | Cytopenia | phenotype | GENOMICS_ENGLAND |
C0011263 | Multi-infarct dementia | disease | RGD |
C0011265 | Presenile dementia | disease | BEFREE |
C0011269 | Dementia, Vascular | disease | RGD |
C0011303 | Demyelinating Diseases | group | CTD_human |
C0011304 | Demyelination | phenotype | CTD_human |
C0011311 | Dengue Fever | disease | BEFREE |
C0011334 | Dental caries | disease | BEFREE |
C0011570 | Mental Depression | disease | BEFREE |
C0011581 | Depressive disorder | disease | BEFREE |
C0011603 | Dermatitis | disease | BEFREE |
C0011606 | Exfoliative dermatitis | disease | BEFREE |
C0011633 | Dermatomyositis | disease | BEFREE |
C0011644 | Scleroderma | disease | BEFREE |
C0011649 | Dermoid Cyst | disease | BEFREE |
C0011847 | Diabetes | disease | BEFREE |
C0011848 | Diabetes Insipidus | disease | BEFREE |
C0011849 | Diabetes Mellitus | group | BEFREE;HPO |
C0011853 | Diabetes Mellitus, Experimental | disease | CTD_human;CTD_mouse |
C0011854 | Diabetes Mellitus, Insulin-Dependent | disease | BEFREE;LHGDN |
C0011860 | Diabetes Mellitus, Non-Insulin-Dependent | disease | BEFREE |
C0012242 | Digestive System Disorders | group | BEFREE |
C0013080 | Down Syndrome | disease | BEFREE |
C0013146 | Drug abuse | disease | BEFREE |
C0013221 | Drug toxicity | group | CTD_mouse |
C0013274 | Patent ductus arteriosus | disease | BEFREE |
C0013295 | Duodenal Ulcer | disease | BEFREE;LHGDN |
C0013336 | Dwarfism | disease | BEFREE |
C0013426 | Dystrophy of vulva | disease | BEFREE |
C0013990 | Pathological accumulation of air in tissues | phenotype | CTD_human |
C0014038 | Encephalitis | disease | BEFREE |
C0014070 | Encephalomyelitis | disease | BEFREE |
C0014145 | Yolk Sac Tumor | disease | BEFREE |
C0014170 | Endometrial Neoplasms | group | BEFREE;CTD_mouse;LHGDN;MGD |
C0014173 | Endometrial Hyperplasia | disease | BEFREE |
C0014175 | Endometriosis | disease | BEFREE;LHGDN |
C0014474 | Ependymoma | disease | BEFREE |
C0014511 | Epithelial cyst | phenotype | BEFREE |
C0014522 | Epidermodysplasia Verruciformis | disease | BEFREE |
C0014527 | Epidermolysis Bullosa | disease | BEFREE |
C0014544 | Epilepsy | disease | HPO |
C0014556 | Epilepsy, Temporal Lobe | disease | LHGDN |
C0014599 | Epithelial hyperplasia | disease | BEFREE |
C0014818 | Erythroplasia | disease | BEFREE |
C0014859 | Esophageal Neoplasms | group | BEFREE;CTD_human;CTD_mouse;LHGDN |
C0015230 | Exanthema | phenotype | BEFREE |
C0015625 | Fanconi Anemia | disease | BEFREE |
C0016034 | Breast Fibrocystic Disease | disease | BEFREE |
C0016057 | Fibrosarcoma | disease | BEFREE |
C0016059 | Fibrosis | phenotype | LHGDN |
C0016510 | Foot Diseases | group | BEFREE |
C0016781 | Fuchs Endothelial Dystrophy | disease | BEFREE |
C0016977 | Gall Bladder Diseases | group | BEFREE |
C0016978 | gallbladder neoplasm | disease | BEFREE;CTD_human;LHGDN |
C0017150 | Gastrinoma | disease | BEFREE |
C0017152 | Gastritis | disease | BEFREE;LHGDN |
C0017154 | Gastritis, Atrophic | disease | BEFREE |
C0017168 | Gastroesophageal reflux disease | disease | BEFREE |
C0017178 | Gastrointestinal Diseases | group | BEFREE |
C0017185 | Gastrointestinal Neoplasms | group | GENOMICS_ENGLAND |
C0017525 | Giant Cell Tumors | group | BEFREE;LHGDN |
C0017601 | Glaucoma | disease | BEFREE |
C0017612 | Glaucoma, Open-Angle | disease | BEFREE |
C0017636 | Glioblastoma | disease | BEFREE;CLINVAR;LHGDN;MGD |
C0017638 | Glioma | disease | BEFREE;CGI;CTD_human;CTD_mouse;GWASCAT;LHGDN |
C0017661 | IGA Glomerulonephritis | disease | BEFREE;LHGDN |
C0018023 | Nodular Goiter | disease | BEFREE |
C0018133 | Graft-vs-Host Disease | disease | BEFREE |
C0018206 | granulosa cell tumor | disease | BEFREE |
C0018213 | Graves Disease | disease | BEFREE |
C0018552 | Hamartoma | group | BEFREE |
C0018553 | Hamartoma Syndrome, Multiple | disease | BEFREE |
C0018671 | Head and Neck Neoplasms | group | BEFREE;CGI;CLINVAR;LHGDN |
C0018681 | Headache | phenotype | HPO |
C0018790 | Cardiac Arrest | disease | BEFREE |
C0018800 | Cardiomegaly | phenotype | LHGDN |
C0018801 | Heart failure | disease | BEFREE;CTD_mouse;LHGDN |
C0018802 | Congestive heart failure | disease | BEFREE;CTD_mouse |
C0018922 | hemangiopericytoma | disease | BEFREE |
C0018923 | Hemangiosarcoma | disease | BEFREE;CTD_human;CTD_mouse |
C0018939 | Hematological Disease | group | BEFREE |
C0018995 | Hemochromatosis | disease | BEFREE |
C0019112 | Hemorrhoids | disease | BEFREE |
C0019158 | Hepatitis | disease | BEFREE |
C0019159 | Hepatitis A | disease | BEFREE |
C0019163 | Hepatitis B | disease | BEFREE;LHGDN |
C0019187 | Hepatitis, Alcoholic | disease | BEFREE |
C0019189 | Hepatitis, Chronic | disease | BEFREE |
C0019196 | Hepatitis C | disease | BEFREE;LHGDN |
C0019202 | Hepatolenticular Degeneration | disease | BEFREE |
C0019207 | Hepatoma, Morris | disease | CTD_human;CTD_mouse |
C0019208 | Hepatoma, Novikoff | disease | CTD_human;CTD_mouse |
C0019340 | Herpes NOS | disease | BEFREE |
C0019348 | Herpes Simplex Infections | group | BEFREE;LHGDN |
C0019562 | Von Hippel-Lindau Syndrome | disease | BEFREE |
C0019621 | Histiocytosis, Langerhans-Cell | disease | LHGDN |
C0019693 | HIV Infections | group | BEFREE |
C0019829 | Hodgkin Disease | disease | BEFREE;LHGDN |
C0020097 | HTLV-I Infections | group | BEFREE |
C0020179 | Huntington Disease | disease | BEFREE;LHGDN |
C0020217 | Hydatidiform Mole | disease | BEFREE |
C0020255 | Hydrocephalus | disease | HPO |
C0020428 | Hyperaldosteronism | disease | HPO |
C0020437 | Hypercalcemia | disease | BEFREE |
C0020458 | Hyperhidrosis disorder | phenotype | HPO |
C0020503 | Hyperparathyroidism, Secondary | disease | BEFREE |
C0020507 | Hyperplasia | phenotype | LHGDN |
C0020538 | Hypertensive disease | group | BEFREE;CTD_human;HPO |
C0020555 | Hypertrichosis | disease | HPO |
C0020615 | Hypoglycemia | disease | BEFREE |
C0020621 | Hypokalemia | phenotype | HPO |
C0020627 | Hypopharyngeal Neoplasms | group | LHGDN |
C0020981 | Angioimmunoblastic Lymphadenopathy | disease | BEFREE |
C0021051 | Immunologic Deficiency Syndromes | group | BEFREE |
C0021071 | Immunoproliferative Small Intestinal Disease | disease | BEFREE;LHGDN |
C0021361 | Female infertility | phenotype | CTD_human |
C0021364 | Male infertility | disease | BEFREE;CTD_human;LHGDN |
C0021367 | Mammary Ductal Carcinoma | disease | BEFREE |
C0021368 | Inflammation | phenotype | LHGDN |
C0021390 | Inflammatory Bowel Diseases | group | BEFREE;LHGDN |
C0021670 | insulinoma | disease | BEFREE |
C0021841 | Intestinal Neoplasms | group | BEFREE |
C0021847 | Intestinal Pseudo-Obstruction | disease | HPO |
C0022116 | Ischemia | phenotype | CTD_human;RGD |
C0022346 | Icterus | phenotype | HPO |
C0022521 | Kartagener Syndrome | disease | BEFREE |
C0022548 | Keloid | phenotype | BEFREE;LHGDN |
C0022572 | keratoacanthoma | disease | BEFREE;LHGDN |
C0022593 | Keratosis | disease | BEFREE;CTD_human;LHGDN |
C0022594 | Keratosis Blennorrhagica | disease | CTD_human |
C0022602 | Actinic keratosis | disease | BEFREE;LHGDN |
C0022603 | Seborrheic keratosis | disease | BEFREE;LHGDN |
C0022658 | Kidney Diseases | group | BEFREE |
C0022660 | Kidney Failure, Acute | disease | BEFREE;CTD_human |
C0022661 | Kidney Failure, Chronic | disease | BEFREE |
C0022665 | Kidney Neoplasm | disease | BEFREE |
C0022783 | Vulvar Lichen Sclerosus | disease | BEFREE;CTD_human |
C0023051 | Laryngeal Diseases | group | BEFREE |
C0023055 | Laryngeal neoplasm | disease | LHGDN |
C0023212 | Left-Sided Heart Failure | disease | CTD_mouse |
C0023267 | Fibroid Tumor | group | BEFREE;LHGDN |
C0023269 | leiomyosarcoma | disease | BEFREE |
C0023418 | leukemia | disease | BEFREE;LHGDN |
C0023434 | Chronic Lymphocytic Leukemia | disease | BEFREE;CGI;CLINVAR;CTD_human;LHGDN;ORPHANET |
C0023440 | Acute Erythroblastic Leukemia | disease | BEFREE;LHGDN |
C0023443 | Hairy Cell Leukemia | disease | BEFREE |
C0023448 | Lymphoid leukemia | disease | BEFREE |
C0023449 | Acute lymphocytic leukemia | disease | BEFREE |
C0023452 | Childhood Acute Lymphoblastic Leukemia | disease | BEFREE;CTD_human |
C0023453 | Leukemia, Lymphocytic, Acute, L2 | disease | CTD_human |
C0023462 | Acute Megakaryocytic Leukemias | disease | BEFREE;CLINVAR |
C0023465 | Acute monocytic leukemia | disease | BEFREE |
C0023467 | Leukemia, Myelocytic, Acute | disease | BEFREE;CGI;CLINVAR;CTD_mouse;LHGDN |
C0023470 | Myeloid Leukemia | disease | BEFREE;LHGDN |
C0023473 | Myeloid Leukemia, Chronic | disease | BEFREE;LHGDN |
C0023474 | Leukemia, Myeloid, Chronic-Phase | disease | BEFREE |
C0023479 | Acute myelomonocytic leukemia | disease | BEFREE |
C0023480 | Leukemia, Myelomonocytic, Chronic | disease | BEFREE |
C0023484 | Leukemia, Plasma Cell | disease | BEFREE |
C0023485 | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | disease | BEFREE |
C0023486 | Prolymphocytic Leukemia | disease | BEFREE |
C0023487 | Acute Promyelocytic Leukemia | disease | BEFREE |
C0023492 | Leukemia, T-Cell | disease | BEFREE |
C0023493 | Adult T-Cell Lymphoma/Leukemia | disease | BEFREE |
C0023524 | Leukoencephalopathy, Progressive Multifocal | disease | BEFREE |
C0023530 | Leukopenia | disease | BEFREE |
C0023531 | Leukoplakia | disease | BEFREE |
C0023532 | Leukoplakia, Oral | disease | BEFREE |
C0023601 | Leydig Cell Tumor | disease | BEFREE |
C0023646 | Lichen Planus | disease | BEFREE |
C0023652 | Lichen Sclerosus et Atrophicus | disease | BEFREE;LHGDN |
C0023786 | Mucopolysaccharidosis I | disease | BEFREE |
C0023798 | Lipoma | disease | BEFREE |
C0023827 | liposarcoma | disease | BEFREE |
C0023890 | Liver Cirrhosis | disease | BEFREE;LHGDN |
C0023895 | Liver diseases | group | BEFREE;LHGDN |
C0023897 | Liver Diseases, Parasitic | group | CTD_human |
C0023903 | Liver neoplasms | group | BEFREE;CTD_human;LHGDN |
C0023904 | Liver Neoplasms, Experimental | group | CTD_human;CTD_mouse |
C0024115 | Lung diseases | group | BEFREE |
C0024117 | Chronic Obstructive Airway Disease | disease | BEFREE;CTD_human |
C0024121 | Lung Neoplasms | group | BEFREE;CGI;CTD_human;CTD_mouse;LHGDN |
C0024141 | Lupus Erythematosus, Systemic | disease | BEFREE;LHGDN |
C0024299 | Lymphoma | group | BEFREE;CTD_mouse;HPO;LHGDN |
C0024301 | Lymphoma, Follicular | disease | BEFREE;LHGDN |
C0024303 | Small Cell Lymphoma | disease | BEFREE |
C0024305 | Lymphoma, Non-Hodgkin | disease | BEFREE;CLINVAR;LHGDN |
C0024314 | Lymphoproliferative Disorders | group | BEFREE;LHGDN |
C0024408 | Machado-Joseph Disease | disease | BEFREE |
C0024419 | Waldenstrom Macroglobulinemia | disease | BEFREE |
C0024454 | Maffucci Syndrome | disease | BEFREE |
C0024530 | Malaria | disease | BEFREE |
C0024620 | Primary Malignant Liver Neoplasm | disease | BEFREE |
C0024623 | Malignant neoplasm of stomach | disease | BEFREE;CTD_human |
C0024668 | Mammary Neoplasms, Experimental | group | CTD_mouse |
C0024793 | Marek Disease | disease | BEFREE |
C0024809 | Marijuana Abuse | disease | BEFREE;PSYGENET |
C0024814 | Marinesco-Sjogren syndrome | disease | BEFREE |
C0024897 | Mastocytoma | disease | BEFREE |
C0025149 | Medulloblastoma | disease | BEFREE;CLINVAR |
C0025164 | Megaesophagus | disease | BEFREE |
C0025202 | melanoma | disease | BEFREE;CGI;CTD_human;LHGDN |
C0025267 | Multiple Endocrine Neoplasia Type 1 | disease | BEFREE |
C0025268 | Multiple Endocrine Neoplasia Type 2a | disease | BEFREE |
C0025286 | Meningioma | disease | BEFREE;LHGDN |
C0025362 | Mental Retardation | disease | BEFREE |
C0025500 | Mesothelioma | disease | BEFREE;CTD_mouse;LHGDN |
C0025517 | Metabolic Diseases | group | BEFREE |
C0025568 | Metaplasia | phenotype | LHGDN |
C0026010 | Microphthalmos | disease | BEFREE |
C0026277 | Mixed Salivary Gland Tumor | disease | BEFREE;LHGDN |
C0026470 | Monoclonal Gammopathy of Undetermined Significance | disease | BEFREE |
C0026499 | Monosomy | group | BEFREE |
C0026636 | Mouth Diseases | group | BEFREE |
C0026640 | Mouth Neoplasms | group | BEFREE;CTD_human;CTD_mouse;LHGDN |
C0026703 | Mucopolysaccharidoses | group | BEFREE |
C0026764 | Multiple Myeloma | disease | BEFREE;CLINVAR;LHGDN |
C0026769 | Multiple Sclerosis | disease | BEFREE |
C0026847 | Spinal Muscular Atrophy | disease | BEFREE |
C0026936 | Mycoplasma Infections | group | BEFREE |
C0026948 | Mycosis Fungoides | group | BEFREE |
C0026985 | Myelodysplasia | disease | BEFREE |
C0026987 | Myelofibrosis | disease | BEFREE |
C0026998 | Acute Myeloid Leukemia, M1 | disease | CTD_mouse |
C0027019 | Myelomonocytic leukemia | disease | BEFREE |
C0027022 | Myeloproliferative disease | group | BEFREE |
C0027051 | Myocardial Infarction | disease | BEFREE;CTD_mouse;HPO |
C0027149 | Myxoma | disease | BEFREE |
C0027430 | Nasal Polyps | disease | BEFREE |
C0027439 | Nasopharyngeal Neoplasms | group | CGI;CLINVAR;HPO |
C0027497 | Nausea | phenotype | HPO |
C0027533 | Neck Neoplasms | group | BEFREE |
C0027577 | Nelson Syndrome | disease | BEFREE |
C0027627 | Neoplasm Metastasis | phenotype | BEFREE;CTD_human;CTD_mouse;LHGDN |
C0027651 | Neoplasms | group | BEFREE;CLINVAR |
C0027654 | Embryonal Neoplasm | disease | BEFREE |
C0027659 | Neoplasms, Experimental | group | CTD_mouse |
C0027662 | Multiple Endocrine Neoplasia | disease | BEFREE |
C0027666 | Neoplasms, Radiation-Induced | group | BEFREE |
C0027672 | Neoplastic Syndromes, Hereditary | group | BEFREE;CLINVAR |
C0027708 | Nephroblastoma | disease | BEFREE;CTD_human;HPO |
C0027765 | nervous system disorder | group | BEFREE;CTD_mouse |
C0027766 | Nervous System Neoplasms | group | BEFREE;HPO |
C0027794 | Neural Tube Defects | group | BEFREE |
C0027809 | Neurilemmoma | disease | BEFREE |
C0027819 | Neuroblastoma | group | BEFREE;CLINVAR;CTD_mouse;GWASCAT;LHGDN |
C0027830 | neurofibroma | disease | BEFREE |
C0027831 | Neurofibromatosis 1 | disease | BEFREE |
C0027832 | Neurofibromatosis 2 | disease | BEFREE |
C0027859 | Acoustic Neuroma | disease | BEFREE;LHGDN |
C0027947 | Neutropenia | disease | BEFREE |
C0027960 | Nevus | disease | BEFREE |
C0027961 | Nevus of Ota | disease | BEFREE |
C0027962 | Melanocytic nevus | disease | BEFREE |
C0028259 | Nodule | phenotype | BEFREE |
C0028754 | Obesity | disease | BEFREE |
C0028756 | Obesity, Morbid | disease | BEFREE |
C0028945 | oligodendroglioma | disease | BEFREE;LHGDN |
C0029172 | Oral Submucous Fibrosis | disease | BEFREE |
C0029227 | Delirium, Dementia, Amnestic, Cognitive Disorders | group | BEFREE |
C0029401 | Osteitis Deformans | disease | BEFREE |
C0029408 | Degenerative polyarthritis | disease | BEFREE |
C0029445 | Bone necrosis | phenotype | LHGDN |
C0029463 | Osteosarcoma | disease | BEFREE;CLINVAR;CTD_human;CTD_mouse;HPO;LHGDN;MGD;ORPHANET;UNIPROT |
C0029925 | Ovarian Carcinoma | disease | BEFREE;CGI |
C0030186 | Paget Disease Extramammary | disease | BEFREE |
C0030193 | Pain | phenotype | HPO |
C0030246 | Pustulosis of Palms and Soles | disease | CTD_human |
C0030252 | Palpitations | phenotype | HPO |
C0030286 | Pancreatic Diseases | group | BEFREE |
C0030293 | Pancreatic Insufficiency | disease | HPO |
C0030297 | Pancreatic Neoplasm | disease | BEFREE;CGI;CTD_human;CTD_mouse;HPO;LHGDN |
C0030305 | Pancreatitis | disease | BEFREE |
C0030312 | Pancytopenia | disease | BEFREE |
C0030353 | Papilledema | disease | HPO |
C0030354 | Papilloma | disease | BEFREE;LHGDN |
C0030360 | Papillon-Lefevre Disease | disease | BEFREE |
C0030421 | Paraganglioma | disease | BEFREE |
C0030491 | Parapsoriasis | disease | BEFREE |
C0030521 | Parathyroid Neoplasms | group | BEFREE |
C0030554 | Paresthesia | phenotype | HPO |
C0030567 | Parkinson Disease | disease | BEFREE |
C0030581 | Parotid Neoplasms | group | BEFREE |
C0030849 | Penile Neoplasms | group | CTD_human |
C0031036 | Polyarteritis Nodosa | disease | BEFREE |
C0031039 | Pericardial effusion | disease | BEFREE |
C0031099 | Periodontitis | disease | BEFREE |
C0031106 | Periodontitis, Juvenile | disease | BEFREE |
C0031154 | Peritonitis | disease | BEFREE |
C0031269 | Peutz-Jeghers Syndrome | disease | BEFREE |
C0031511 | Pheochromocytoma | disease | BEFREE |
C0031941 | Pineal Gland Neoplasm | disease | BEFREE |
C0032000 | Pituitary Adenoma | disease | BEFREE |
C0032002 | Pituitary Diseases | group | BEFREE |
C0032019 | Pituitary Neoplasms | group | BEFREE;LHGDN |
C0032131 | Plasmacytoma | disease | BEFREE |
C0032227 | Pleural effusion disorder | group | BEFREE;LHGDN |
C0032231 | Pleurisy | disease | LHGDN |
C0032285 | Pneumonia | disease | BEFREE |
C0032339 | Rothmund-Thomson syndrome | disease | BEFREE |
C0032463 | Polycythemia Vera | disease | BEFREE |
C0032578 | Polyploidy | phenotype | CTD_human |
C0032580 | Adenomatous Polyposis Coli | disease | BEFREE |
C0032584 | polyps | phenotype | BEFREE |
C0032927 | Precancerous Conditions | group | BEFREE;CTD_mouse |
C0033036 | Atrial Premature Complexes | disease | BEFREE |
C0033141 | Cardiomyopathies, Primary | group | CTD_mouse |
C0033300 | Progeria | disease | BEFREE |
C0033375 | Prolactinoma | disease | BEFREE |
C0033578 | Prostatic Neoplasms | group | BEFREE;CTD_human;HPO;LHGDN |
C0033626 | Protein Deficiency | disease | BEFREE |
C0033822 | Pseudomyxoma Peritonei | disease | BEFREE |
C0033844 | Pseudotumor | phenotype | BEFREE |
C0033860 | Psoriasis | disease | BEFREE;CTD_human;LHGDN |
C0033999 | Pterygium | disease | BEFREE |
C0034067 | Pulmonary Emphysema | disease | BEFREE |
C0034069 | Pulmonary Fibrosis | disease | BEFREE |
C0034543 | Radicular Cyst | disease | BEFREE |
C0034885 | Rectal Neoplasms | group | BEFREE;LHGDN |
C0035078 | Kidney Failure | disease | BEFREE |
C0035243 | Respiratory Tract Infections | group | BEFREE |
C0035288 | Reticuloendotheliosis, X-linked | disease | BEFREE |
C0035305 | Retinal Detachment | disease | BEFREE |
C0035309 | Retinal Diseases | group | BEFREE |
C0035335 | Retinoblastoma | disease | BEFREE;HPO;LHGDN |
C0035369 | Retroviridae Infections | group | BEFREE |
C0035412 | Rhabdomyosarcoma | disease | BEFREE |
C0035436 | Rheumatic Fever | disease | BEFREE |
C0035869 | Rotavirus Infections | group | BEFREE |
C0036095 | Salivary Gland Neoplasms | group | BEFREE |
C0036220 | Kaposi Sarcoma | disease | BEFREE |
C0036280 | Burn scar | phenotype | BEFREE |
C0036323 | Schistosomiasis | disease | BEFREE;LHGDN |
C0036341 | Schizophrenia | disease | BEFREE;CTD_human;LHGDN |
C0036420 | Localized scleroderma | disease | BEFREE |
C0036421 | Systemic Scleroderma | disease | BEFREE |
C0036529 | Myocardial Diseases, Secondary | group | CTD_mouse |
C0036572 | Seizures | phenotype | BEFREE;HPO |
C0036631 | Seminoma | disease | BEFREE |
C0036646 | Age-related cataract | disease | BEFREE |
C0036920 | Sezary Syndrome | disease | BEFREE;CTD_human |
C0037274 | Dermatologic disorders | group | BEFREE |
C0037286 | Skin Neoplasms | group | BEFREE;CTD_human;CTD_mouse;HPO;LHGDN |
C0037354 | Smallpox | disease | BEFREE |
C0037579 | Soft Tissue Neoplasms | group | BEFREE |
C0037999 | Splenic Neoplasms | group | BEFREE |
C0038002 | Splenomegaly | phenotype | HPO |
C0038220 | Status Epilepticus | disease | BEFREE |
C0038271 | Stereotyped Behavior | phenotype | BEFREE |
C0038273 | Stereotypic Movement Disorder | phenotype | BEFREE |
C0038279 | Sterility, Postpartum | phenotype | CTD_human |
C0038356 | Stomach Neoplasms | group | BEFREE;CTD_human;HPO;LHGDN |
C0038358 | Gastric ulcer | disease | BEFREE |
C0038433 | Streptozotocin Diabetes | disease | CTD_human;CTD_mouse |
C0038454 | Cerebrovascular accident | group | BEFREE;LHGDN |
C0038814 | Sunburn | disease | LHGDN |
C0038990 | Sweating | phenotype | HPO |
C0039101 | synovial sarcoma | disease | BEFREE;LHGDN |
C0039103 | Synovitis | disease | BEFREE |
C0039446 | Telangiectasis | disease | BEFREE |
C0039483 | Giant Cell Arteritis | disease | BEFREE |
C0039503 | Tendinitis | disease | BEFREE |
C0039538 | Teratoma | disease | BEFREE;LHGDN |
C0039590 | Testicular Neoplasms | group | BEFREE |
C0040028 | Thrombocythemia, Essential | disease | BEFREE;ORPHANET |
C0040034 | Thrombocytopenia | phenotype | BEFREE |
C0040100 | Thymoma | disease | BEFREE;CTD_human |
C0040136 | Thyroid Neoplasm | disease | BEFREE;CTD_human;LHGDN |
C0040147 | Thyroiditis | disease | BEFREE |
C0040411 | Tongue Neoplasms | group | CTD_mouse;LHGDN |
C0040517 | Gilles de la Tourette syndrome | disease | BEFREE |
C0040963 | Tricuspid Valve Stenosis | disease | BEFREE |
C0041107 | Trisomy | group | BEFREE |
C0041182 | Trophoblastic Neoplasms | group | BEFREE |
C0041207 | Truncus Arteriosus, Persistent | disease | BEFREE |
C0041296 | Tuberculosis | disease | LHGDN |
C0041326 | Pleural Tuberculosis | disease | BEFREE |
C0041341 | Tuberous Sclerosis | disease | BEFREE |
C0041408 | Turner Syndrome | disease | BEFREE |
C0041582 | Ulcer | disease | BEFREE |
C0041755 | Adverse reaction to drug | group | CTD_mouse |
C0041834 | Erythema | phenotype | BEFREE |
C0041956 | Ureteral obstruction | phenotype | BEFREE |
C0042065 | Genitourinary Neoplasms | group | CTD_human;LHGDN |
C0042076 | Urologic Neoplasms | group | CTD_human |
C0042133 | Uterine Fibroids | group | BEFREE |
C0042344 | Varicose Ulcer | disease | LHGDN |
C0042373 | Vascular Diseases | group | LHGDN |
C0042487 | Venous Thrombosis | phenotype | HPO |
C0042721 | Viral hepatitis | group | BEFREE |
C0042769 | Virus Diseases | group | BEFREE |
C0042900 | Vitiligo | disease | BEFREE |
C0042963 | Vomiting | phenotype | HPO |
C0043037 | Common wart | disease | BEFREE |
C0043094 | Weight Gain | phenotype | HPO |
C0043119 | Werner Syndrome | disease | BEFREE |
C0043346 | Xeroderma Pigmentosum | disease | BEFREE |
C0079218 | Fibromatosis, Aggressive | disease | BEFREE |
C0079474 | Hallopeau-Siemens Disease | disease | BEFREE |
C0079588 | Ichthyosis, X-Linked | disease | BEFREE |
C0079731 | B-Cell Lymphomas | group | BEFREE;CGI;LHGDN |
C0079740 | High Grade Lymphoma (neoplasm) | disease | BEFREE |
C0079744 | Diffuse Large B-Cell Lymphoma | disease | BEFREE;MGD |
C0079745 | Lymphoma, Large-Cell, Follicular | disease | BEFREE |
C0079746 | Immunoblastic Large-Cell Lymphoma | disease | BEFREE |
C0079747 | Low Grade Lymphoma (neoplasm) | disease | BEFREE |
C0079748 | Precursor cell lymphoblastic lymphoma | disease | BEFREE |
C0079770 | Lymphoma, Small Noncleaved-Cell | disease | BEFREE |
C0079772 | T-Cell Lymphoma | disease | BEFREE;CTD_human;LHGDN |
C0079773 | Lymphoma, T-Cell, Cutaneous | disease | BEFREE;CTD_human;LHGDN |
C0079774 | Peripheral T-Cell Lymphoma | disease | BEFREE |
C0085077 | Sweet Syndrome | disease | BEFREE |
C0085078 | Lysosomal Storage Diseases | group | BEFREE |
C0085084 | Motor Neuron Disease | disease | BEFREE |
C0085090 | Lymphoma, AIDS-Related | disease | BEFREE |
C0085110 | Severe Combined Immunodeficiency | disease | BEFREE |
C0085136 | Central Nervous System Neoplasms | group | BEFREE;CTD_human |
C0085138 | Choroid Plexus Neoplasms | group | BEFREE |
C0085183 | Neoplasms, Second Primary | group | BEFREE |
C0085253 | Adult-Onset Still Disease | disease | LHGDN |
C0085390 | Li-Fraumeni Syndrome | disease | BEFREE;CLINGEN;CLINVAR;CTD_human;LHGDN;MGD;ORPHANET |
C0085412 | Encephalitozoonosis | disease | BEFREE |
C0085435 | Arthritis, Reactive | disease | BEFREE |
C0085605 | Liver Failure | disease | BEFREE |
C0085655 | Polymyositis | disease | BEFREE |
C0085668 | Secondary carcinoma | phenotype | BEFREE |
C0085669 | Acute leukemia | disease | BEFREE;HPO |
C0085694 | Chronic cholecystitis | disease | BEFREE |
C0085695 | Chronic gastritis | disease | BEFREE |
C0085702 | Monocytosis | disease | BEFREE |
C0085750 | Adenosis of Breast | disease | BEFREE |
C0085758 | Aganglionosis, Colonic | disease | BEFREE |
C0085786 | Hamman-Rich syndrome | disease | BEFREE |
C0086404 | Experimental Hepatoma | disease | CTD_human;CTD_mouse |
C0086501 | Keratoma | phenotype | CTD_human |
C0086769 | Panic Attacks | disease | HPO |
C0086981 | Sicca Syndrome | disease | BEFREE |
C0149521 | Pancreatitis, Chronic | disease | BEFREE |
C0149614 | Adnexal mass | phenotype | BEFREE |
C0149678 | Epstein-Barr Virus Infections | group | BEFREE;LHGDN |
C0149782 | Squamous cell carcinoma of lung | disease | BEFREE;CLINVAR |
C0149793 | Amaurosis Fugax | phenotype | HPO |
C0149826 | Gastric adenoma | disease | BEFREE |
C0149925 | Small cell carcinoma of lung | disease | BEFREE;CLINVAR;CTD_human;LHGDN;ORPHANET |
C0149978 | Adenocarcinoma of rectum | disease | BEFREE |
C0151449 | Primary Sj?gren's syndrome | disease | BEFREE |
C0151468 | Thyroid Gland Follicular Adenoma | disease | CTD_human |
C0151529 | Prolonged bleeding time | phenotype | HPO |
C0151546 | Oral Cavity Carcinoma | disease | BEFREE |
C0151650 | Renal fibrosis | disease | BEFREE |
C0151779 | Cutaneous Melanoma | disease | BEFREE;CGI;CLINVAR |
C0151786 | Muscle Weakness | phenotype | HPO |
C0151849 | Alkaline phosphatase raised | phenotype | HPO |
C0151942 | Arterial thrombosis | phenotype | HPO |
C0152013 | Adenocarcinoma of lung (disorder) | disease | BEFREE;CLINVAR;CTD_mouse;HPO |
C0152018 | Esophageal carcinoma | disease | BEFREE;CLINVAR |
C0152031 | Joint swelling | phenotype | HPO |
C0152096 | Complete trisomy 18 syndrome | disease | BEFREE |
C0152136 | Low Tension Glaucoma | disease | BEFREE |
C0152459 | Linear atrophy | phenotype | HPO |
C0153340 | Cancer of Lip | disease | BEFREE |
C0153349 | Malignant neoplasm of tongue | disease | BEFREE;CTD_mouse;RGD |
C0153350 | Malignant tumor of base of tongue | disease | RGD |
C0153351 | Malignant neoplasm of dorsal surface of tongue | disease | RGD |
C0153356 | malignant tumor of lingual tonsil | disease | RGD |
C0153381 | Malignant neoplasm of mouth | disease | BEFREE;CTD_human;CTD_mouse |
C0153382 | Malignant neoplasm of oropharynx | disease | BEFREE |
C0153392 | Malignant neoplasm of nasopharynx | disease | BEFREE |
C0153437 | Malignant neoplasm of cecum | disease | CTD_mouse |
C0153446 | Malignant neoplasm of anus | disease | BEFREE |
C0153452 | Malignant neoplasm of gallbladder | disease | BEFREE;CTD_human |
C0153453 | Malignant tumor of extrahepatic bile duct | disease | BEFREE |
C0153519 | Malignant neoplasm of connective and other soft tissue, site unspecified | disease | RGD |
C0153555 | Malignant neoplasm of other specified sites of female breast | disease | MGD |
C0153574 | Malignant Uterine Corpus Neoplasm | disease | BEFREE;CLINVAR |
C0153579 | Malignant neoplasm of fallopian tube | group | BEFREE |
C0153594 | Malignant neoplasm of testis | disease | BEFREE |
C0153601 | Malignant neoplasm of penis | disease | BEFREE;CTD_human |
C0153633 | Malignant neoplasm of brain | disease | BEFREE;CTD_mouse;GENOMICS_ENGLAND |
C0153658 | Malignant neoplasm of endocrine gland | disease | BEFREE |
C0153676 | Secondary malignant neoplasm of lung | disease | BEFREE |
C0153690 | Secondary malignant neoplasm of bone | disease | BEFREE |
C0154084 | Stage 0 Breast Carcinoma | disease | BEFREE |
C0154091 | Carcinoma in situ of bladder | disease | BEFREE |
C0156344 | Endometriosis of ovary | disease | BEFREE |
C0158944 | Infections specific to perinatal period | group | BEFREE |
C0158995 | Congenital anemia | disease | GENOMICS_ENGLAND |
C0162565 | Acute intermittent porphyria | disease | BEFREE |
C0162635 | Angelman Syndrome | disease | BEFREE |
C0162678 | Neurofibromatoses | group | BEFREE |
C0162810 | Cicatrix, Hypertrophic | phenotype | BEFREE;LHGDN |
C0162839 | Porokeratosis | disease | BEFREE |
C0162871 | Aortic Aneurysm, Abdominal | disease | BEFREE |
C0175754 | Agenesis of corpus callosum | disease | BEFREE |
C0178416 | Hypoplastic anemia | disease | BEFREE |
C0178874 | Tumor Progression | phenotype | BEFREE |
C0202218 | Sex hormone binding globulin measurement | phenotype | GWASCAT |
C0205641 | Adenocarcinoma, Basal Cell | disease | CTD_human;CTD_mouse |
C0205642 | Adenocarcinoma, Oxyphilic | disease | CTD_human;CTD_mouse |
C0205643 | Carcinoma, Cribriform | disease | CTD_human;CTD_mouse |
C0205644 | Carcinoma, Granular Cell | disease | CTD_human;CTD_mouse |
C0205645 | Adenocarcinoma, Tubular | disease | BEFREE;CTD_human;CTD_mouse |
C0205646 | Adenoma, Basal Cell | disease | CTD_human |
C0205647 | Follicular adenoma | disease | BEFREE;CTD_human |
C0205648 | Adenoma, Microcystic | disease | CTD_human |
C0205649 | Adenoma, Monomorphic | disease | CTD_human |
C0205650 | Papillary adenoma | disease | CTD_human |
C0205651 | Adenoma, Trabecular | disease | CTD_human |
C0205695 | Carcinoid, Goblet Cell | disease | BEFREE |
C0205696 | Anaplastic carcinoma | disease | BEFREE;CTD_human |
C0205697 | Carcinoma, Spindle-Cell | disease | BEFREE;CTD_human |
C0205698 | Undifferentiated carcinoma | phenotype | BEFREE;CTD_human |
C0205699 | Carcinomatosis | phenotype | CTD_human |
C0205748 | Dysplastic Nevus | disease | BEFREE |
C0205768 | Subependymal Giant Cell Astrocytoma | disease | BEFREE;CTD_mouse |
C0205770 | Choroid Plexus Papilloma | disease | BEFREE;CLINVAR;CTD_human;HPO;LHGDN;ORPHANET |
C0205824 | Liposarcoma, Dedifferentiated | disease | BEFREE |
C0205825 | Liposarcoma, Pleomorphic | disease | BEFREE |
C0205851 | Germ cell tumor | group | BEFREE |
C0205874 | Papilloma, Squamous Cell | disease | BEFREE |
C0205875 | Papillomatosis | disease | BEFREE |
C0205944 | Sarcoma, Epithelioid | disease | BEFREE;CTD_human;CTD_mouse |
C0205945 | Sarcoma, Spindle Cell | disease | CTD_human;CTD_mouse |
C0205969 | Thymic Carcinoma | disease | BEFREE;CGI;CTD_human |
C0206062 | Lung Diseases, Interstitial | group | BEFREE |
C0206093 | Neuroectodermal Tumors | disease | BEFREE |
C0206139 | Lichen Planus, Oral | disease | BEFREE;LHGDN |
C0206180 | Ki-1+ Anaplastic Large Cell Lymphoma | disease | BEFREE |
C0206623 | Adenosquamous carcinoma | disease | BEFREE |
C0206624 | Hepatoblastoma | disease | BEFREE;CLINVAR;LHGDN |
C0206629 | Pulmonary Blastoma | disease | BEFREE |
C0206630 | Endometrial Stromal Sarcoma | disease | BEFREE |
C0206638 | Giant Cell Tumor of Bone | disease | BEFREE |
C0206639 | Neoplasms, Bone Tissue | group | MGD |
C0206644 | Histiocytoma, Benign Fibrous | disease | BEFREE |
C0206647 | Dermatofibrosarcoma | disease | BEFREE;LHGDN |
C0206650 | Fibroadenoma | disease | BEFREE |
C0206654 | Leiomyomatosis | disease | BEFREE |
C0206655 | Alveolar rhabdomyosarcoma | disease | BEFREE |
C0206656 | Embryonal Rhabdomyosarcoma | disease | BEFREE |
C0206659 | Embryonal Carcinoma | disease | BEFREE |
C0206660 | Germinoma | disease | BEFREE |
C0206663 | Neuroectodermal Tumor, Primitive | disease | BEFREE |
C0206664 | Teratocarcinoma | disease | BEFREE |
C0206667 | Adrenal Cortical Adenoma | disease | BEFREE |
C0206669 | Hepatocellular Adenoma | disease | BEFREE |
C0206674 | Adenoma, Villous | disease | BEFREE |
C0206677 | Adenomatous Polyps | disease | BEFREE |
C0206681 | Adenocarcinoma, Clear Cell | disease | BEFREE;CTD_human |
C0206682 | Follicular thyroid carcinoma | disease | BEFREE |
C0206683 | Papillary and follicular adenocarcinoma | disease | BEFREE |
C0206684 | Sebaceous Adenocarcinoma | disease | BEFREE |
C0206685 | Acinar Cell Carcinoma | disease | BEFREE |
C0206686 | Adrenocortical carcinoma | disease | BEFREE;CGI;CLINVAR;CTD_human;HPO;LHGDN;ORPHANET;UNIPROT |
C0206687 | Carcinoma, Endometrioid | disease | BEFREE;LHGDN |
C0206693 | Medullary carcinoma | disease | BEFREE |
C0206694 | Mucoepidermoid Carcinoma | disease | BEFREE |
C0206698 | Cholangiocarcinoma | disease | BEFREE;CTD_human;CTD_mouse;LHGDN |
C0206699 | Cystadenocarcinoma, Mucinous | disease | BEFREE;LHGDN |
C0206700 | Cystadenocarcinoma, Papillary | disease | LHGDN |
C0206701 | Cystadenocarcinoma, Serous | disease | BEFREE |
C0206702 | Klatskin Tumor | disease | BEFREE |
C0206704 | Carcinoma, Large Cell | disease | BEFREE;LHGDN |
C0206706 | Verrucous carcinoma | disease | BEFREE;LHGDN |
C0206708 | Cervical Intraepithelial Neoplasia | disease | BEFREE;LHGDN |
C0206709 | Cystadenoma, Serous | disease | BEFREE |
C0206716 | Ganglioglioma | disease | BEFREE;LHGDN |
C0206717 | Olfactory Neuroblastoma | disease | BEFREE |
C0206718 | Ganglioneuroblastoma | disease | BEFREE |
C0206719 | Central Neurocytoma | disease | BEFREE |
C0206720 | Squamous Cell Neoplasms | group | BEFREE;LHGDN |
C0206721 | Inverted Papilloma | disease | BEFREE;LHGDN |
C0206724 | Sex Cord-Stromal Tumor | disease | BEFREE |
C0206726 | gliosarcoma | disease | BEFREE;ORPHANET |
C0206727 | Nerve Sheath Tumors | group | BEFREE;CTD_mouse;LHGDN |
C0206728 | Plexiform Neurofibroma | disease | BEFREE |
C0206729 | Neurofibrosarcoma | disease | BEFREE |
C0206733 | Strawberry nevus of skin | disease | BEFREE |
C0206737 | Nevus, Intradermal | disease | BEFREE |
C0206743 | Rhabdoid Tumor | disease | BEFREE |
C0206754 | Neuroendocrine Tumors | group | BEFREE;LHGDN |
C0206769 | Nevi and Melanomas | group | BEFREE |
C0220603 | Childhood Brain Neoplasm | disease | BEFREE |
C0220605 | Adult Non-Hodgkin Lymphoma | disease | BEFREE |
C0220611 | Childhood Rhabdomyosarcoma | disease | BEFREE |
C0220613 | Adult Soft Tissue Sarcoma | disease | BEFREE |
C0220615 | Adult Acute Myeloblastic Leukemia | disease | BEFREE |
C0220620 | Gastrointestinal Carcinoid Tumor | disease | BEFREE |
C0220621 | Childhood Acute Myeloid Leukemia | disease | BEFREE |
C0220633 | Uveal melanoma | disease | BEFREE |
C0220641 | Lip and Oral Cavity Carcinoma | disease | BEFREE |
C0220645 | Childhood Soft Tissue Sarcoma | disease | BEFREE |
C0220650 | Metastatic malignant neoplasm to brain | disease | BEFREE |
C0220668 | Congenital contractural arachnodactyly | disease | BEFREE |
C0220810 | Congenital defects | group | BEFREE |
C0221056 | Adult type dermatomyositis | disease | BEFREE |
C0221204 | Lytic lesion | phenotype | HPO |
C0221228 | Comedone | disease | BEFREE |
C0221273 | Juvenile polyp | disease | BEFREE |
C0221373 | Claw hand | disease | BEFREE |
C0221505 | Lesion of brain | group | BEFREE |
C0231254 | Increased body mass index | phenotype | HPO |
C0231341 | Premature aging syndrome | disease | BEFREE |
C0232462 | Decrease in appetite | phenotype | HPO |
C0232487 | Abdominal discomfort | phenotype | HPO |
C0233514 | Abnormal behavior | phenotype | BEFREE |
C0235527 | Heart Failure, Right-Sided | disease | CTD_mouse |
C0235590 | Fibrosing adenosis | disease | BEFREE |
C0235653 | Malignant neoplasm of female breast | disease | BEFREE |
C0235782 | Gallbladder Carcinoma | disease | BEFREE;CLINVAR |
C0235974 | Pancreatic carcinoma | disease | BEFREE;CGI;CLINVAR |
C0237053 | adnexal lesion | phenotype | BEFREE |
C0238019 | Carcinoma of extrahepatic bile duct | disease | BEFREE |
C0238031 | Breast Phyllodes Tumor | disease | BEFREE |
C0238033 | Carcinoma of Male Breast | disease | BEFREE |
C0238034 | Intraductal papilloma of breast | disease | BEFREE |
C0238052 | Xanthomatosis, Cerebrotendinous | disease | BEFREE |
C0238122 | Fallopian Tube Carcinoma | disease | BEFREE |
C0238137 | Gallbladder adenoma | disease | BEFREE |
C0238141 | Gingival Carcinoma | disease | BEFREE |
C0238198 | Gastrointestinal Stromal Tumors | group | BEFREE;LHGDN |
C0238232 | Polyp of larynx | disease | BEFREE |
C0238288 | Muscular Dystrophy, Facioscapulohumeral | disease | BEFREE |
C0238301 | Cancer of Nasopharynx | disease | BEFREE |
C0238339 | Hereditary pancreatitis | disease | BEFREE |
C0238348 | Squamous cell carcinoma of penis | disease | BEFREE |
C0238410 | Renal Pelvis Urothelial Carcinoma | disease | BEFREE |
C0238448 | Testicular embryonal carcinoma | disease | BEFREE |
C0238461 | Anaplastic thyroid carcinoma | disease | BEFREE;CLINVAR |
C0238462 | Medullary carcinoma of thyroid | disease | BEFREE |
C0238463 | Papillary thyroid carcinoma | disease | BEFREE |
C0238517 | Vaginal clear cell adenocarcinoma | disease | BEFREE |
C0239946 | Fibrosis, Liver | disease | BEFREE |
C0240164 | Squamous Papilloma of the Larynx | disease | BEFREE |
C0240995 | Increased serum androstenedione | phenotype | HPO |
C0241961 | Angiomyolipoma of kidney | disease | BEFREE |
C0242363 | Islet Cell Tumor | disease | BEFREE |
C0242379 | Malignant neoplasm of lung | disease | BEFREE;CGI;CTD_human;CTD_mouse |
C0242387 | Mandibulofacial Dysostosis | disease | BEFREE |
C0242422 | Parkinsonian Disorders | group | BEFREE |
C0242510 | Drug usage | phenotype | BEFREE |
C0242594 | Residual Cancer | phenotype | BEFREE |
C0242596 | Neoplasm, Residual | phenotype | BEFREE |
C0242621 | Isochromosomes | phenotype | BEFREE |
C0242647 | Mucosa-Associated Lymphoid Tissue Lymphoma | disease | BEFREE |
C0242670 | Persistent Vegetative State | disease | BEFREE |
C0242787 | Malignant neoplasm of male breast | disease | BEFREE |
C0242852 | Proliferative vitreoretinopathy | disease | BEFREE |
C0259783 | mixed gliomas | disease | BEFREE;CTD_human;CTD_mouse |
C0259785 | Malignant Meningioma | disease | BEFREE |
C0260037 | Multiple tumors | phenotype | BEFREE |
C0262401 | Carcinoma of ampulla of Vater | disease | BEFREE |
C0262584 | Carcinoma, Small Cell | disease | BEFREE;CTD_human;LHGDN |
C0262587 | Parathyroid Adenoma | disease | BEFREE |
C0262659 | Vagina Carcinoma | disease | BEFREE |
C0264490 | Acute respiratory failure | disease | BEFREE |
C0264511 | Lymphoid interstitial pneumonia | disease | BEFREE |
C0264716 | Chronic heart failure | disease | BEFREE |
C0264732 | Cardiac dilatation | disease | BEFREE |
C0265219 | Miller Dieker syndrome | disease | BEFREE |
C0265325 | Turcot syndrome (disorder) | disease | BEFREE |
C0265354 | CHARGE Syndrome | disease | BEFREE;MGD |
C0265479 | Chromosome 20, trisomy | disease | BEFREE |
C0265783 | Congenital hypoplasia of lung | disease | BEFREE |
C0265965 | Dyskeratosis Congenita | disease | BEFREE;MGD |
C0265970 | Porokeratosis, Disseminated Superficial Actinic | disease | BEFREE |
C0266258 | Congenital absence of liver | disease | BEFREE |
C0266453 | Exencephaly | disease | BEFREE |
C0266526 | Norrie disease | disease | BEFREE |
C0266589 | Congenital ear anomaly NOS (disorder) | group | BEFREE |
C0267008 | Erythroplakia of mouth | disease | BEFREE |
C0267026 | Actinic cheilitis | disease | BEFREE |
C0267111 | Gastric dysplasia | disease | BEFREE |
C0267187 | Intestinal metaplasia of gastric mucosa | disease | BEFREE |
C0267375 | Chronic colitis | disease | BEFREE |
C0267792 | Hepatobiliary disease | disease | BEFREE |
C0267812 | Micronodular cirrhosis | disease | HPO |
C0267963 | Exocrine pancreatic insufficiency | disease | HPO |
C0268135 | Xeroderma pigmentosum, group A | disease | BEFREE |
C0268138 | Xeroderma Pigmentosum, Complementation Group D | disease | BEFREE |
C0268186 | Congenital glucose-galactose malabsorption | disease | BEFREE |
C0268398 | Familial lichen amyloidosis | disease | BEFREE |
C0268548 | Hyperargininemia | phenotype | BEFREE |
C0268621 | Hepatic methionine adenosyltransferase deficiency | disease | BEFREE |
C0269102 | Endometrioma | disease | BEFREE |
C0269155 | Germinal inclusion cyst of ovary | phenotype | BEFREE |
C0271650 | Impaired glucose tolerance | phenotype | BEFREE |
C0271907 | Acquired aplastic anemia | disease | BEFREE |
C0272170 | Shwachman syndrome | disease | BEFREE |
C0272285 | Heparin-induced thrombocytopenia | disease | BEFREE |
C0272293 | Chronic idiopathic thrombocytopenic purpura | disease | BEFREE |
C0272394 | Disorder of lymph node | group | BEFREE |
C0274861 | Arsenic Poisoning, Inorganic | disease | CTD_human |
C0274862 | Nervous System, Organic Arsenic Poisoning | disease | CTD_human |
C0275524 | Coinfection | phenotype | BEFREE |
C0276262 | Verruca plana | phenotype | BEFREE |
C0276275 | Disease due to Parvoviridae | disease | BEFREE |
C0276496 | Familial Alzheimer Disease (FAD) | disease | BEFREE |
C0276623 | Chronic viral hepatitis | disease | BEFREE |
C0278480 | Stage III Colon Cancer | disease | BEFREE |
C0278484 | Malignant neoplasm of colon stage IV | disease | BEFREE |
C0278486 | Breast cancer stage II | disease | BEFREE |
C0278487 | Stage III Breast Cancer AJCC v6 | disease | BEFREE |
C0278488 | Carcinoma breast stage IV | disease | BEFREE |
C0278493 | Breast cancer recurrent | disease | BEFREE |
C0278504 | Non-small cell lung cancer stage I | disease | BEFREE |
C0278505 | Non-small cell lung cancer stage II | disease | BEFREE |
C0278506 | Non-small cell lung cancer stage III | disease | BEFREE |
C0278510 | Childhood Medulloblastoma | disease | BEFREE |
C0278511 | Osteosarcoma localised | disease | BEFREE |
C0278512 | Metastatic osteosarcoma | disease | BEFREE |
C0278513 | Stage IIIB Breast Carcinoma | disease | BEFREE |
C0278517 | Non-small cell lung cancer recurrent | disease | BEFREE |
C0278519 | Recurrent Childhood Acute Lymphoblastic Leukemia | disease | BEFREE |
C0278582 | Cervical carcinoma stage IB | disease | BEFREE |
C0278601 | Inflammatory Breast Carcinoma | disease | BEFREE |
C0278619 | Extramedullary Plasmacytoma | disease | BEFREE |
C0278660 | Adult Synovial Sarcoma | disease | BEFREE |
C0278678 | Metastatic Renal Cell Cancer | disease | BEFREE |
C0278687 | Ovarian cancer stage III | disease | BEFREE |
C0278689 | Ovarian epithelial cancer recurrent | disease | BEFREE |
C0278695 | Neuroblastoma recurrent | disease | BEFREE |
C0278701 | Gastric Adenocarcinoma | disease | BEFREE;CLINVAR |
C0278704 | Malignant Childhood Neoplasm | group | BEFREE |
C0278726 | Small cell lung cancer extensive stage | disease | BEFREE |
C0278791 | Chronic lymphocytic leukaemia refractory | disease | BEFREE |
C0278798 | Endometrial neoplasm malignant stage I | disease | BEFREE |
C0278802 | Recurrent Endometrial Cancer | disease | BEFREE |
C0278838 | Prostate cancer recurrent | disease | BEFREE |
C0278876 | Adult Medulloblastoma | disease | BEFREE |
C0278878 | Adult Glioblastoma | disease | BEFREE;MGD |
C0278879 | Childhood Burkitt Lymphoma | disease | BEFREE |
C0278883 | Metastatic melanoma | disease | BEFREE |
C0278987 | Non-small cell lung cancer metastatic | disease | BEFREE |
C0278996 | Malignant Head and Neck Neoplasm | disease | BEFREE;CGI |
C0279000 | Liver and Intrahepatic Biliary Tract Carcinoma | disease | BEFREE |
C0279530 | Malignant Bone Neoplasm | disease | BEFREE |
C0279543 | Philadelphia chromosome positive chronic myelogenous leukemia | disease | BEFREE |
C0279563 | Lobular carcinoma in situ of breast | disease | BEFREE |
C0279565 | Invasive Lobular Breast Carcinoma | disease | BEFREE |
C0279583 | Childhood T Acute Lymphoblastic Leukemia | disease | BEFREE |
C0279602 | Fibroblastic osteosarcoma | disease | BEFREE |
C0279607 | Adult Hepatocellular Carcinoma | disease | ORPHANET |
C0279622 | Small cell osteosarcoma | disease | BEFREE |
C0279626 | Squamous cell carcinoma of esophagus | disease | BEFREE;CTD_human;CTD_mouse |
C0279628 | Adenocarcinoma Of Esophagus | disease | BEFREE;CTD_human |
C0279637 | Anal carcinoma | disease | BEFREE |
C0279651 | Gallbladder adenocarcinoma | disease | BEFREE |
C0279661 | Acinar cell carcinoma of pancreas | disease | BEFREE |
C0279663 | Serous cystadenocarcinoma ovary | disease | CLINVAR |
C0279671 | Cervical Squamous Cell Carcinoma | disease | BEFREE |
C0279672 | Cervical Adenocarcinoma | disease | BEFREE |
C0279674 | Small cell carcinoma of the cervix | disease | BEFREE |
C0279680 | Transitional cell carcinoma of bladder | disease | BEFREE;CLINVAR;HPO |
C0279682 | Bladder Adenocarcinoma | disease | BEFREE |
C0279702 | Conventional (Clear Cell) Renal Cell Carcinoma | disease | BEFREE;CTD_human |
C0279765 | Endometrial Clear Cell Adenocarcinoma | disease | BEFREE |
C0279982 | Childhood Synovial Sarcoma | disease | BEFREE |
C0280089 | Carcinoid tumor of lung | disease | BEFREE |
C0280100 | Solid Neoplasm | phenotype | BEFREE |
C0280141 | Acute Undifferentiated Leukemia | disease | BEFREE |
C0280216 | stage, neuroblastoma | disease | BEFREE |
C0280217 | stage, non-small cell lung cancer | disease | BEFREE |
C0280220 | stage, ovarian epithelial cancer | disease | BEFREE |
C0280255 | stage, endometrial cancer | phenotype | BEFREE |
C0280280 | stage, prostate cancer | disease | BEFREE |
C0280302 | Squamous cell carcinoma of lip | disease | BEFREE |
C0280306 | Verrucous carcinoma of oral cavity | disease | BEFREE |
C0280313 | Squamous cell carcinoma of oropharynx | disease | BEFREE |
C0280321 | Squamous cell carcinoma of the hypopharynx | disease | BEFREE |
C0280324 | Laryngeal Squamous Cell Carcinoma | disease | BEFREE |
C0280391 | Squamous cell carcinoma of the hypopharynx stage IV | disease | BEFREE |
C0280449 | secondary acute myeloid leukemia | disease | BEFREE |
C0280451 | de novo myelodysplastic syndromes | disease | BEFREE |
C0280474 | Childhood Glioblastoma | disease | BEFREE |
C0280630 | Uterine Carcinosarcoma | disease | BEFREE;CLINVAR |
C0280631 | Leiomyosarcoma of uterus | disease | BEFREE;HPO |
C0280746 | Sarcoma of ovary | disease | BEFREE |
C0280783 | Juvenile Pilocytic Astrocytoma | disease | BEFREE;CTD_mouse |
C0280785 | Diffuse Astrocytoma | disease | BEFREE;CTD_mouse |
C0280788 | Anaplastic Ependymoma | disease | BEFREE |
C0280793 | Mixed Oligodendroglioma-Astrocytoma | disease | BEFREE |
C0280856 | Squamous cell carcinoma of vulva | disease | BEFREE |
C0281267 | bilateral breast cancer | disease | BEFREE |
C0281361 | Adenocarcinoma of pancreas | disease | BEFREE;CLINVAR;HPO |
C0281784 | Benign Meningioma | disease | BEFREE |
C0281842 | Abnormality of the fallopian tube | phenotype | HPO |
C0282160 | Aplasia Cutis Congenita | disease | BEFREE |
C0282313 | Condition, Preneoplastic | phenotype | BEFREE;CTD_mouse |
C0282488 | Interstitial Cystitis | disease | BEFREE;LHGDN |
C0282606 | Myomatous neoplasm | disease | BEFREE |
C0282612 | Prostatic Intraepithelial Neoplasias | disease | BEFREE |
C0302180 | Condyloma | disease | BEFREE |
C0302592 | Cervix carcinoma | disease | BEFREE;CGI |
C0311375 | Arsenic Poisoning | disease | CTD_human |
C0333186 | Restenosis | phenotype | BEFREE |
C0333693 | Triploidy syndrome | disease | BEFREE |
C0333873 | Squamous intraepithelial lesion | phenotype | BEFREE |
C0333875 | High-Grade Squamous Intraepithelial Lesions | phenotype | BEFREE |
C0333983 | Hyperplastic Polyp | disease | BEFREE |
C0333997 | Lymphoid hyperplasia | disease | BEFREE |
C0334050 | Adenosis | disease | BEFREE |
C0334092 | Hamartomatous polyp | disease | BEFREE |
C0334106 | Bowenoid papulosis | disease | BEFREE |
C0334108 | Multiple polyps | disease | BEFREE |
C0334121 | Inflammatory Myofibroblastic Tumor | disease | BEFREE |
C0334233 | Pleomorphic carcinoma | disease | BEFREE |
C0334244 | Papillary squamous cell carcinoma | disease | BEFREE |
C0334245 | Intraepithelial Squamous Cell Carcinoma | disease | BEFREE |
C0334246 | Squamous cell carcinoma, metastatic | disease | BEFREE |
C0334247 | Squamous cell carcinoma, keratinizing | disease | BEFREE |
C0334252 | Squamous cell carcinoma, microinvasive | disease | BEFREE |
C0334254 | Lymphoepithelial carcinoma | disease | BEFREE |
C0334267 | Transitional cell carcinoma in situ | disease | BEFREE |
C0334274 | Papillary transitional cell carcinoma | disease | BEFREE |
C0334276 | Adenocarcinoma in Situ | phenotype | BEFREE |
C0334279 | Adenocarcinoma, intestinal type | disease | BEFREE |
C0334287 | Fibrolamellar Hepatocellular Carcinoma | disease | BEFREE |
C0334292 | Tubular adenoma | disease | BEFREE |
C0334294 | Multiple adenomatous polyps | disease | BEFREE |
C0334299 | Carcinoid tumor no ICD-O subtype | phenotype | BEFREE |
C0334307 | Tubulovillous adenoma | disease | BEFREE |
C0334342 | Skin appendage adenoma | disease | BEFREE |
C0334359 | Papillary serous cystadenocarcinoma | disease | BEFREE |
C0334365 | Mucinous cystic tumor of borderline malignancy | disease | BEFREE |
C0334381 | Non-infiltrating lobular carcinoma | disease | BEFREE |
C0334409 | Leydig cell tumor, benign | disease | BEFREE |
C0334438 | Superficial spreading malignant melanoma of skin | disease | BEFREE |
C0334463 | Malignant Fibrous Histiocytoma | disease | BEFREE |
C0334471 | Round cell liposarcoma | disease | BEFREE |
C0334488 | Clear cell sarcoma of kidney | disease | BEFREE |
C0334520 | Teratoma, Malignant | disease | BEFREE |
C0334529 | Hydatidiform Mole, Partial | disease | BEFREE |
C0334552 | Malignant Giant Cell Tumor of Bone | disease | BEFREE |
C0334576 | Gliomatosis cerebri | disease | BEFREE |
C0334579 | Anaplastic astrocytoma | disease | BEFREE;CLINVAR;CTD_mouse |
C0334580 | Protoplasmic astrocytoma | disease | CTD_mouse |
C0334581 | Gemistocytic astrocytoma | disease | BEFREE;CTD_mouse |
C0334582 | Fibrillary Astrocytoma | disease | BEFREE;CTD_mouse |
C0334583 | Pilocytic Astrocytoma | disease | BEFREE;CTD_mouse |
C0334586 | Pleomorphic Xanthoastrocytoma | disease | BEFREE |
C0334588 | Giant Cell Glioblastoma | disease | BEFREE;ORPHANET |
C0334590 | Anaplastic Oligodendroglioma | disease | BEFREE |
C0334616 | Malignant peripheral nerve sheath tumor with rhabdomyoblastic differentiation | disease | BEFREE |
C0334619 | HODGKIN'S AND NON-HODGKIN'S LYMPHOMA | disease | BEFREE |
C0334634 | Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse | disease | BEFREE;LHGDN |
C0334664 | Mast Cell Neoplasm | disease | BEFREE |
C0338070 | Childhood Cerebral Astrocytoma | disease | CTD_mouse |
C0338106 | Adenocarcinoma of colon | disease | BEFREE |
C0339115 | Sebaceous adenocarcinoma of eyelid | disease | BEFREE |
C0339573 | Glaucoma, Primary Open Angle | disease | BEFREE |
C0341038 | Jaw Keratocyst | disease | BEFREE |
C0341189 | Reactive gastritis | disease | BEFREE |
C0341225 | Gastric Hamartoma | disease | BEFREE |
C0341281 | Ulcerative jejunitis | disease | BEFREE |
C0341439 | Chronic liver disease | group | BEFREE |
C0341823 | Epithelial tumor of ovary | disease | BEFREE |
C0341869 | Subfertility, Female | disease | CTD_human |
C0342190 | C-cell hyperplasia of thyroid | disease | BEFREE |
C0342388 | Adrenocorticotropic hormone (ACTH) deficiency (disorder) | disease | HPO |
C0342494 | Adrenocortical hyperplasia | disease | BEFREE |
C0343640 | African Burkitt's lymphoma | disease | BEFREE |
C0343641 | Human papilloma virus infection | disease | BEFREE |
C0343731 | Penile warts | phenotype | BEFREE |
C0344453 | Macroprolactinoma | disease | BEFREE |
C0344460 | Carcinoma ex pleomorphic adenoma | disease | BEFREE |
C0345602 | Parotid Gland Carcinoma | disease | BEFREE |
C0345904 | Malignant neoplasm of liver | disease | BEFREE;CTD_human |
C0345905 | Intrahepatic Cholangiocarcinoma | disease | BEFREE;CTD_human;CTD_mouse |
C0345907 | Angiosarcoma of liver | disease | BEFREE |
C0345967 | Malignant mesothelioma | disease | BEFREE;CTD_human |
C0345984 | Solitary keratoacanthoma | disease | BEFREE |
C0345992 | Pilar tumor | disease | BEFREE |
C0346027 | Eccrine epithelioma | disease | BEFREE |
C0346053 | Atypical fibroxanthoma of skin | disease | BEFREE |
C0346109 | Malignant Mesothelioma of Peritoneum | disease | BEFREE |
C0346153 | Breast Cancer, Familial | disease | BEFREE;CLINVAR |
C0346163 | Endometrioid carcinoma ovary | disease | BEFREE |
C0346210 | Vulval intraepithelial neoplasia | disease | BEFREE |
C0346300 | Pituitary carcinoma | disease | BEFREE |
C0346388 | Malignant melanoma of choroid | disease | BEFREE |
C0346402 | Malignant neoplasm of adrenal cortex | disease | BEFREE;CGI |
C0346429 | Multiple malignancy | phenotype | BEFREE |
C0346627 | Intestinal Cancer | group | BEFREE |
C0346629 | Malignant neoplasm of large intestine | disease | BEFREE;CLINVAR |
C0346647 | Malignant neoplasm of pancreas | disease | BEFREE;CGI;CTD_human;CTD_mouse;HPO |
C0346903 | Malignant neoplasm of cerebrum | disease | BEFREE |
C0346957 | Disseminated Malignant Neoplasm | phenotype | BEFREE |
C0346976 | Secondary malignant neoplasm of pancreas | disease | BEFREE |
C0346990 | Carcinomatosis of peritoneal cavity | disease | BEFREE |
C0346993 | Secondary malignant neoplasm of female breast | disease | BEFREE |
C0347129 | Anal intraepithelial neoplasia | disease | BEFREE |
C0347176 | Carcinoma in situ of fallopian tube | disease | BEFREE |
C0347180 | Penile intraepithelial neoplasia | disease | BEFREE |
C0347266 | Polyp of duodenum | disease | BEFREE |
C0347272 | Benign neoplasm of large intestine | disease | BEFREE |
C0347284 | Benign tumor of pancreas | disease | CGI |
C0348374 | Malignant Central Nervous System Neoplasm | disease | BEFREE;GWASCAT |
C0348801 | Group B streptococcal pneumonia | disease | BEFREE |
C0349458 | Cervical intraepithelial neoplasia grade 1 | disease | BEFREE |
C0349459 | Cervical intraepithelial neoplasia grade 2 | disease | BEFREE |
C0349530 | Early gastric cancer | disease | BEFREE |
C0349532 | Gastric lymphoma | disease | BEFREE |
C0349534 | Carcinoma of anal margin | disease | BEFREE |
C0349560 | Vulval intraepithelial neoplasia grade 3 | disease | BEFREE |
C0349566 | Squamous cell carcinoma of tongue | disease | BEFREE |
C0349579 | Atypical Endometrial Hyperplasia | disease | BEFREE |
C0349631 | Richter's syndrome | disease | BEFREE |
C0349632 | Splenic Marginal Zone B-Cell Lymphoma | disease | BEFREE |
C0349633 | Hairy cell leukemia variant | disease | BEFREE |
C0349639 | Juvenile Myelomonocytic Leukemia | disease | BEFREE |
C0349667 | Sarcoma of breast | disease | BEFREE |
C0362046 | Prediabetes syndrome | disease | BEFREE |
C0369183 | Erythrocyte Mean Corpuscular Hemoglobin Test | phenotype | GWASCAT |
C0375019 | Human T-cell lymphotrophic virus, type I [HTLV-I] | disease | BEFREE |
C0375023 | Respiratory syncytial virus (RSV) infection in conditions classified elsewhere and of unspecified site | disease | BEFREE |
C0375071 | Malignant neoplasm of vulva | disease | BEFREE |
C0376358 | Malignant neoplasm of prostate | disease | BEFREE;CLINVAR;CTD_human;HPO |
C0376407 | Granulomatous Slack Skin | disease | CTD_human |
C0376544 | Hematopoietic Neoplasms | group | BEFREE |
C0376545 | Hematologic Neoplasms | group | BEFREE;GENOMICS_ENGLAND |
C0376634 | Craniofacial Abnormalities | group | BEFREE;CTD_mouse |
C0392475 | Roberts-SC phocomelia syndrome | disease | BEFREE |
C0392514 | Hereditary hemochromatosis | disease | BEFREE |
C0392784 | Dermatofibrosarcoma Protuberans | disease | BEFREE |
C0392885 | High density lipoprotein measurement | phenotype | GWASDB |
C0393554 | Amyotrophic Lateral Sclerosis With Dementia | disease | CTD_human |
C0393706 | Early infantile epileptic encephalopathy with suppression bursts | disease | BEFREE |
C0396072 | Laryngeal papillomatosis | disease | BEFREE |
C0398738 | Leukocyte adhesion deficiency type 1 | disease | BEFREE |
C0398791 | Nijmegen Breakage Syndrome | disease | BEFREE |
C0399440 | Hereditary gingival fibromatosis | disease | BEFREE |
C0400966 | Non-alcoholic Fatty Liver Disease | disease | BEFREE |
C0406704 | Rudiger syndrome 1 | disease | BEFREE |
C0424295 | Hyperactive behavior | phenotype | BEFREE |
C0425591 | Dropped beats - heart | phenotype | HPO |
C0431109 | Choroid Plexus Carcinoma | disease | BEFREE;CLINVAR;ORPHANET |
C0432409 | Trisomy 11 | disease | BEFREE |
C0432411 | Chromosome 9, trisomy | disease | BEFREE |
C0441683 | Hormone measurement | group | GWASCAT |
C0456861 | Low grade B-cell lymphoma | disease | BEFREE |
C0456889 | Enteropathy-Associated T-Cell Lymphoma | disease | BEFREE |
C0457179 | Desmoplastic infantile astrocytoma | disease | BEFREE |
C0457334 | Acute monoblastic leukemia | disease | BEFREE |
C0457521 | Unicystic ameloblastoma | disease | BEFREE |
C0474808 | Follicular neoplasm | disease | BEFREE |
C0474822 | Benign pheochromocytoma | disease | BEFREE |
C0474963 | Malignant tumor of junctional zone of tongue | disease | RGD |
C0475801 | Leukemia, Prolymphocytic, B-Cell | disease | BEFREE |
C0476073 | Papillary neoplasm | disease | BEFREE |
C0476089 | Endometrial Carcinoma | disease | BEFREE;CTD_mouse |
C0494165 | Secondary malignant neoplasm of liver | disease | BEFREE |
C0496755 | Malignant neoplasm of border of tongue | disease | RGD |
C0496836 | Malignant tumor of eye | disease | BEFREE |
C0496899 | Benign neoplasm of brain, unspecified | disease | CTD_mouse |
C0496920 | Neoplasm of uncertain or unknown behavior of ovary | disease | CGI |
C0496956 | Neoplasm of uncertain or unknown behavior of breast | disease | CGI |
C0497156 | Lymphadenopathy | group | HPO |
C0497247 | Increase in blood pressure | phenotype | HPO |
C0497327 | Dementia | disease | BEFREE;LHGDN |
C0497406 | Overweight | phenotype | BEFREE |
C0497550 | Benign neurologic neoplasms | group | BEFREE |
C0518656 | Chronic fatigue | phenotype | HPO |
C0520463 | Chronic active hepatitis | disease | BEFREE |
C0520477 | Prostatic Adenoma | disease | BEFREE |
C0521158 | Recurrent tumor | phenotype | BEFREE |
C0524801 | Retinal Neoplasms | group | HPO |
C0524851 | Neurodegenerative Disorders | group | BEFREE |
C0524909 | Hepatitis B, Chronic | disease | BEFREE |
C0524910 | Hepatitis C, Chronic | disease | BEFREE |
C0542035 | Erythroid hypoplasia | disease | BEFREE |
C0542271 | Environmental Carcinogenesis | phenotype | BEFREE |
C0543822 | Atherosclerotic occlusive disease | disease | BEFREE |
C0543859 | Amyotrophic Lateral Sclerosis, Guam Form | disease | CTD_human |
C0545034 | pituitary giant | phenotype | BEFREE |
C0545074 | Myxoid/Round Cell Liposarcoma | disease | BEFREE |
C0546837 | Malignant neoplasm of esophagus | disease | BEFREE;CLINVAR;CTD_human;CTD_mouse |
C0547065 | Mixed oligoastrocytoma | disease | CTD_mouse |
C0549379 | Recurrent Carcinoma | phenotype | BEFREE |
C0549473 | Thyroid carcinoma | disease | BEFREE;CGI;CTD_human |
C0549523 | Oropharynx (excludes nasopharynx) | disease | BEFREE |
C0549608 | VEINS/LYMPHATICS | phenotype | BEFREE |
C0553580 | Ewings sarcoma | disease | BEFREE |
C0553694 | Oropharyngeal disorders | group | BEFREE |
C0553723 | Squamous cell carcinoma of skin | disease | BEFREE;CLINVAR |
C0555198 | Malignant Glioma | disease | BEFREE;CTD_human;CTD_mouse |
C0558353 | Tongue Carcinoma | disease | BEFREE |
C0558355 | Tonsillar Carcinoma | disease | BEFREE |
C0563211 | Carcinoma of anal canal | disease | BEFREE |
C0566602 | Primary sclerosing cholangitis | disease | BEFREE |
C0577631 | Carotid Atherosclerosis | disease | BEFREE;CTD_human |
C0585362 | Squamous cell carcinoma of mouth | disease | BEFREE |
C0585442 | Osteosarcoma of bone | disease | BEFREE |
C0586354 | Esophageal dysplasia | disease | BEFREE |
C0586364 | Moderate pancreatic duct dysplasia | disease | BEFREE |
C0587248 | Costello syndrome (disorder) | disease | BEFREE |
C0595989 | Carcinoma of larynx | disease | BEFREE |
C0596263 | Carcinogenesis | phenotype | BEFREE |
C0596321 | Chemical Carcinogenesis | phenotype | BEFREE |
C0597645 | Viral Carcinogenesis | phenotype | BEFREE |
C0597984 | Biliary stricture | phenotype | BEFREE |
C0598766 | Leukemogenesis | disease | BEFREE |
C0598894 | Monocytic leukemia | disease | BEFREE |
C0598935 | Tumor Initiation | phenotype | BEFREE |
C0600040 | Chronic interstitial cystitis | disease | BEFREE |
C0600041 | Infective cystitis | disease | BEFREE |
C0600139 | Prostate carcinoma | disease | BEFREE |
C0600178 | External Carotid Artery Diseases | group | CTD_human |
C0677055 | CARCINOMA OF VULVA | disease | BEFREE |
C0677483 | Carcinoma testes | disease | BEFREE |
C0677607 | Hashimoto Disease | disease | BEFREE |
C0677776 | Hereditary Breast and Ovarian Cancer Syndrome | disease | BEFREE;ORPHANET |
C0677865 | Brain Stem Glioma | disease | CLINVAR |
C0677866 | Brain Stem Neoplasms | group | BEFREE |
C0677886 | Epithelial ovarian cancer | disease | BEFREE;CTD_human |
C0677898 | invasive cancer | phenotype | BEFREE |
C0677932 | Progressive Neoplastic Disease | phenotype | BEFREE |
C0677936 | Refractory cancer | phenotype | BEFREE |
C0677944 | Sentinel node (disorder) | disease | BEFREE |
C0677950 | Stage IV Colorectal Cancer | disease | BEFREE |
C0678213 | Complete hydatidiform mole | disease | BEFREE |
C0678222 | Breast Carcinoma | disease | BEFREE;CGI;CTD_human;CTD_mouse;HPO |
C0679427 | myeloblastosis | disease | BEFREE |
C0684249 | Carcinoma of lung | disease | BEFREE;CGI |
C0684333 | Malignant neoplasm of ventral surface of tongue | disease | RGD |
C0684337 | Ewings sarcoma-primitive neuroectodermal tumor (PNET) | disease | BEFREE |
C0684830 | Secondary malignant neoplasm of axilla | disease | BEFREE |
C0685938 | Malignant neoplasm of gastrointestinal tract | disease | BEFREE |
C0686377 | CNS metastases | phenotype | BEFREE |
C0686619 | Secondary malignant neoplasm of lymph node | disease | BEFREE |
C0687150 | Parathyroid Gland Adenocarcinoma | disease | BEFREE |
C0687713 | Gastrointestinal pain | phenotype | HPO |
C0699790 | Colon Carcinoma | disease | BEFREE;CLINVAR |
C0699791 | Stomach Carcinoma | disease | BEFREE |
C0699885 | Carcinoma of bladder | disease | BEFREE |
C0699889 | Malignant Female Reproductive System Neoplasm | group | BEFREE |
C0699893 | Skin carcinoma | disease | BEFREE;HPO |
C0700095 | Central neuroblastoma | disease | BEFREE |
C0700367 | Ependymoblastoma | disease | BEFREE |
C0700590 | Increased sweating | phenotype | HPO |
C0700636 | Focal nodular hyperplasia of liver | disease | BEFREE |
C0740083 | Carcinoma of glottis | disease | BEFREE |
C0740277 | Bile duct carcinoma | disease | BEFREE |
C0740302 | 5q-syndrome | disease | BEFREE |
C0740345 | Germ Cell Cancer | disease | BEFREE |
C0740404 | Limb defects | group | BEFREE |
C0740457 | Malignant neoplasm of kidney | disease | BEFREE;UNIPROT |
C0741682 | Premenopausal breast cancer | disease | BEFREE |
C0741899 | Poorly differentiated carcinoma | disease | BEFREE |
C0742960 | cyst benign | phenotype | BEFREE |
C0746883 | Febrile Neutropenia | disease | BEFREE |
C0747273 | Malignant tumour of parotid gland | disease | BEFREE |
C0747742 | polyp benign | disease | BEFREE |
C0747845 | early pregnancy | phenotype | BEFREE |
C0748505 | Sarcoma, metastatic | disease | BEFREE |
C0750887 | Adrenal Cancer | disease | CTD_human |
C0750935 | Cerebral Astrocytoma | disease | CTD_mouse |
C0750936 | Intracranial Astrocytoma | disease | CTD_mouse |
C0750952 | Biliary Tract Cancer | disease | BEFREE |
C0750974 | Brain Tumor, Primary | disease | BEFREE;CTD_mouse |
C0750977 | Recurrent Brain Neoplasm | disease | CTD_mouse |
C0750979 | Primary malignant neoplasm of brain | disease | CTD_mouse |
C0750986 | Internal Carotid Artery Diseases | disease | CTD_human |
C0750987 | Arterial Diseases, Common Carotid | disease | CTD_human |
C0751038 | Cockayne Syndrome, Type II | disease | BEFREE |
C0751364 | Cancer, Embryonal | phenotype | BEFREE |
C0751366 | Radiation-Induced Cancer | disease | BEFREE |
C0751396 | Well Differentiated Oligodendroglioma | disease | BEFREE |
C0751552 | Malignant neoplasm of thymus | disease | CTD_mouse |
C0751560 | Malignant neoplasm tonsil | disease | BEFREE |
C0751569 | Genitourinary Cancer | disease | BEFREE;CTD_human |
C0751571 | Cancer of Urinary Tract | disease | BEFREE;CTD_human |
C0751606 | Adult Acute Lymphocytic Leukemia | disease | BEFREE |
C0751620 | Central Nervous System Neoplasms, Primary | group | CTD_human |
C0751675 | Cerebral Primitive Neuroectodermal Tumor | disease | BEFREE |
C0751676 | Basal Cell Cancer | disease | BEFREE |
C0751688 | Malignant Squamous Cell Neoplasm | disease | BEFREE |
C0751689 | Peripheral Nerve Sheath Neoplasm | disease | BEFREE;CTD_mouse |
C0751690 | Malignant Peripheral Nerve Sheath Tumor | disease | BEFREE |
C0751691 | Perineurioma | disease | CTD_mouse |
C0751851 | Arsenic Encephalopathy | disease | CTD_human |
C0751852 | Arsenic Induced Polyneuropathy | disease | CTD_human |
C0751955 | Brain Infarction | disease | BEFREE |
C0752125 | Spinocerebellar Ataxia Type 7 | disease | BEFREE |
C0795796 | Chromosome 1, monosomy 1p | disease | BEFREE |
C0795864 | Smith-Magenis syndrome | disease | BEFREE |
C0796070 | MICROPHTHALMIA, SYNDROMIC 7 | disease | BEFREE |
C0796074 | MOHR-TRANEBJAERG SYNDROME | disease | BEFREE |
C0796126 | AICARDI-GOUTIERES SYNDROME 1 | disease | BEFREE |
C0812413 | Malignant Pleural Mesothelioma | disease | BEFREE |
C0812437 | Oculo-dento-digital syndrome | disease | BEFREE |
C0813147 | Stage I Endometrial Carcinoma | disease | BEFREE |
C0848454 | Uterine carcinoma | disease | BEFREE |
C0848676 | Subfertility, Male | phenotype | CTD_human |
C0850572 | Adenomatous polyp of colon | disease | BEFREE |
C0850666 | Infection caused by Helicobacter pylori | disease | BEFREE |
C0850741 | Smoker's lung | disease | BEFREE |
C0851135 | In situ cancer | phenotype | BEFREE |
C0851140 | Carcinoma in situ of uterine cervix | disease | BEFREE;CGI |
C0851887 | Adenoviral infections | group | BEFREE |
C0853105 | Penis carcinoma | disease | BEFREE |
C0853879 | Invasive carcinoma of breast | disease | BEFREE |
C0854196 | Hepatobiliary neoplasm | disease | BEFREE |
C0854778 | Pancreatic carcinoma resectable | disease | BEFREE |
C0854802 | Recurrent Chronic Lymphoid Leukemia | disease | BEFREE |
C0854868 | Non-Hodgkin's lymphoma transformed recurrent | disease | BEFREE |
C0854917 | Rhabdoid Tumor of the Kidney | disease | BEFREE |
C0854988 | Adenocarcinoma of lung, stage IV | disease | BEFREE |
C0855002 | Recurrent Lung Carcinoma Cell Type Unspecified | disease | BEFREE |
C0855073 | Undifferentiated (Embryonal) Sarcoma | disease | BEFREE |
C0855095 | Small Lymphocytic Lymphoma | disease | BEFREE;ORPHANET |
C0855197 | Malignant Testicular Germ Cell Tumor | disease | BEFREE |
C0855742 | Abnormal platelet morphology | phenotype | HPO |
C0858252 | Breast adenocarcinoma | disease | BEFREE;CGI;CLINVAR |
C0858617 | Posterior subcapsular cataract | disease | BEFREE |
C0860580 | Medullary carcinoma of breast | disease | BEFREE |
C0860594 | Malignant melanoma, metastatic | disease | BEFREE |
C0861876 | Recurrent Hepatocellular Carcinoma | disease | BEFREE |
C0862030 | Precursor B-lymphoblastic lymphoma/leukemia | disease | BEFREE |
C0862506 | Borderline ovarian tumour | disease | BEFREE |
C0862636 | Adenocarcinoma of the prostate metastatic | disease | BEFREE |
C0862878 | Dedifferentiated chondrosarcoma | disease | BEFREE |
C0863029 | Ewing's tumour localised | disease | BEFREE |
C0868908 | Pancolitis | disease | BEFREE |
C0870082 | Hyperkeratosis | group | BEFREE |
C0878500 | Intraepithelial Neoplasia | disease | BEFREE |
C0878544 | Cardiomyopathies | group | CTD_mouse |
C0878649 | Gastric hyperplastic polyp | disease | BEFREE |
C0879615 | Stromal Neoplasm | disease | BEFREE |
C0887833 | Carcinoma, Pancreatic Ductal | disease | BEFREE;LHGDN |
C0917730 | Female sterility | phenotype | CTD_human |
C0917731 | Male sterility | phenotype | CTD_human |
C0917796 | Optic Atrophy, Hereditary, Leber | disease | LHGDN |
C0917798 | Cerebral Ischemia | disease | BEFREE;CTD_human |
C0917805 | Transient Cerebral Ischemia | disease | BEFREE;HPO |
C0919267 | ovarian neoplasm | disease | BEFREE;CGI;HPO;LHGDN |
C0920028 | Leukaemia recurrent | disease | BEFREE |
C0920646 | Ischemia of kidney | disease | BEFREE |
C0936223 | Metastatic Prostate Carcinoma | disease | BEFREE |
C0936282 | Blastoma | disease | BEFREE |
C0940937 | precancerous lesions | phenotype | BEFREE |
C0948008 | Ischemic stroke | disease | BEFREE |
C0948216 | Ovarian adenocarcinoma | disease | BEFREE |
C0948380 | Colorectal cancer metastatic | disease | BEFREE |
C0948480 | Coronary Restenosis | disease | BEFREE |
C0948627 | Cancer of lymph node | disease | BEFREE |
C0949506 | Porokeratosis of Mibelli | disease | BEFREE |
C0949541 | Hurthle Cell Tumor | disease | BEFREE |
C0949664 | Tauopathies | group | BEFREE |
C0950124 | Disease due to Papilloma virus | group | BEFREE;LHGDN |
C1096168 | Chromosome 17 trisomy | disease | BEFREE |
C1112530 | Leukoplakia of oral mucosa, incl tongue | disease | RGD |
C1134719 | Invasive Ductal Breast Carcinoma | disease | BEFREE |
C1135868 | Gestational Trophoblastic Neoplasms | group | BEFREE |
C1136033 | Cutaneous Mastocytosis | disease | BEFREE |
C1136084 | Plasma cell dyscrasia | disease | BEFREE |
C1136085 | Monoclonal Gammapathies | group | BEFREE |
C1140680 | Malignant neoplasm of ovary | disease | BEFREE;CGI;CLINGEN;HPO |
C1148551 | X-Linked Dyskeratosis Congenita | disease | BEFREE |
C1153706 | Endometrial adenocarcinoma | disease | BEFREE |
C1167716 | Stage I Gallbladder Carcinoma | disease | BEFREE |
C1167791 | Skin toxicity | disease | BEFREE |
C1168327 | High-Grade Prostatic Intraepithelial Neoplasia | disease | BEFREE |
C1168401 | Squamous cell carcinoma of the head and neck | disease | BEFREE;CLINVAR;CTD_human |
C1176475 | Ductal Carcinoma | disease | BEFREE;LHGDN |
C1257931 | Mammary Neoplasms, Human | group | CTD_human;CTD_mouse |
C1258085 | Barrett Epithelium | disease | BEFREE |
C1260899 | Anemia, Diamond-Blackfan | disease | BEFREE |
C1261473 | Sarcoma | group | BEFREE;CGI;CLINVAR;CTD_human;CTD_mouse;GENOMICS_ENGLAND;HPO;LHGDN |
C1261502 | Finding of Mean Corpuscular Hemoglobin | phenotype | GWASCAT |
C1262091 | Lymphocytic infiltration | disease | BEFREE |
C1262477 | Weight decreased | phenotype | HPO |
C1264606 | Persistent infection | phenotype | BEFREE |
C1265996 | Large cell neuroendocrine carcinoma | disease | BEFREE |
C1266002 | Non-small cell carcinoma | disease | BEFREE |
C1266005 | Basaloid squamous cell carcinoma | disease | BEFREE |
C1266009 | Trichilemmocarcinoma | disease | BEFREE |
C1266010 | Papillary transitional cell neoplasm of low malignant potential | disease | BEFREE |
C1266025 | Traditional Serrated Adenoma | disease | BEFREE |
C1266032 | Atypical carcinoid tumor | disease | BEFREE |
C1266042 | Chromophobe Renal Cell Carcinoma | disease | CTD_human |
C1266043 | Sarcomatoid Renal Cell Carcinoma | disease | CTD_human |
C1266044 | Collecting Duct Carcinoma of the Kidney | disease | CTD_human |
C1266047 | Fetal adenocarcinoma | disease | BEFREE |
C1266082 | Atypical medullary carcinoma | disease | BEFREE |
C1266119 | Solitary fibrous tumor | disease | BEFREE |
C1266129 | Atypical Lipoma | disease | BEFREE |
C1266144 | Pleuropulmonary blastoma | disease | BEFREE |
C1266157 | Intratubular malignant germ cells | disease | BEFREE |
C1266158 | Nongerminomatous Germ Cell Tumor | disease | BEFREE |
C1266166 | Intracortical osteosarcoma | disease | BEFREE |
C1266167 | Clear cell chondrosarcoma | disease | BEFREE |
C1266178 | Gliofibroma | disease | BEFREE |
C1266184 | Atypical Teratoid Rhabdoid Tumor | disease | CLINVAR |
C1270972 | Mild cognitive disorder | disease | BEFREE |
C1275122 | Familial multiple trichoepitheliomata | disease | BEFREE |
C1275278 | Extraskeletal Myxoid Chondrosarcoma | disease | BEFREE |
C1275465 | Tumor stage mycosis fungoides | disease | BEFREE |
C1275685 | Avellino corneal dystrophy | disease | BEFREE |
C1276146 | Cutaneous lymphoma | disease | BEFREE |
C1279945 | Acute interstitial pneumonia | disease | BEFREE |
C1281300 | Vascular degeneration | disease | BEFREE |
C1282496 | Metastasis from malignant tumor of prostate | disease | BEFREE |
C1290398 | Cerebral arterial aneurysm | disease | BEFREE |
C1290884 | Inflammatory disorder | group | BEFREE |
C1290886 | Chronic inflammatory disorder | group | BEFREE |
C1292753 | Primary Effusion Lymphoma | disease | BEFREE;LHGDN |
C1292758 | Precursor T-cell lymphoblastic lymphoma | disease | BEFREE |
C1292769 | Precursor B-cell lymphoblastic leukemia | disease | BEFREE;ORPHANET |
C1292776 | Therapy-related acute myeloid leukemia and myelodysplastic syndrome | disease | BEFREE |
C1292777 | Aggressive natural killer-cell leukemia | disease | BEFREE |
C1292778 | Chronic myeloproliferative disorder | disease | BEFREE |
C1292779 | Myelodysplastic Syndrome with Isolated del(5q) | disease | BEFREE |
C1292780 | Therapy-related myelodysplastic syndrome | disease | BEFREE |
C1295643 | Increased estradiol level | phenotype | HPO |
C1298180 | Single tumor | phenotype | BEFREE |
C1300127 | Perivascular Epithelioid Cell Neoplasms | group | BEFREE |
C1301034 | Pancreatic intraepithelial neoplasia | disease | BEFREE |
C1301194 | Salivary duct carcinoma | disease | BEFREE |
C1301361 | Post-transplant lymphoproliferative disorder, polymorphic | disease | BEFREE |
C1302401 | Adenoma of large intestine | disease | BEFREE |
C1302547 | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | disease | BEFREE |
C1302773 | Low Grade Squamous Intraepithelial Neoplasia | disease | BEFREE |
C1306459 | Primary malignant neoplasm | group | BEFREE |
C1306460 | Primary malignant neoplasm of lung | disease | BEFREE |
C1306726 | Congenital naevus | disease | BEFREE |
C1306837 | Papillary Renal Cell Carcinoma | disease | CTD_human |
C1314694 | Astrocytoma, low grade | disease | BEFREE |
C1318500 | Non-toxic nodular goiter | disease | BEFREE |
C1318544 | M5b Acute differentiated monocytic leukemia | disease | BEFREE |
C1319315 | Adenocarcinoma of large intestine | disease | BEFREE;CGI |
C1319317 | Squamous cell carcinoma of pharynx | disease | BEFREE |
C1321878 | Desmoplastic infantile ganglioglioma | disease | BEFREE |
C1321898 | Blood in stool | phenotype | BEFREE |
C1322286 | Thymoma, type C | disease | BEFREE |
C1328479 | Pancreatic Endocrine Carcinoma | disease | BEFREE |
C1328504 | Hormone refractory prostate cancer | disease | BEFREE |
C1332078 | Anaplastic large cell lymphoma, ALK negative | disease | BEFREE |
C1332153 | Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome | disease | BEFREE |
C1332167 | Adenoid cystic breast carcinoma | disease | BEFREE |
C1332200 | Adult Diffuse Astrocytoma | disease | BEFREE |
C1332201 | Adult Diffuse Large B-Cell Lymphoma | disease | BEFREE;MGD |
C1332225 | Aggressive Non-Hodgkin Lymphoma | disease | BEFREE |
C1332271 | Perianal Squamous Intraepithelial Neoplasia | disease | BEFREE |
C1332347 | Atypical Ductal Breast Hyperplasia | disease | BEFREE |
C1332460 | Barrett's Adenocarcinoma | disease | BEFREE |
C1332629 | Breast Fibrocystic Change, Proliferative Type | disease | BEFREE |
C1332850 | Cardiac Lymphoma | disease | BEFREE |
C1332899 | Cerebellar Glioblastoma | disease | BEFREE |
C1332922 | Cervical Squamous Intraepithelial Neoplasia | disease | BEFREE |
C1332965 | Congenital Mesoblastic Nephroma | disease | BEFREE |
C1332967 | Childhood Diffuse Large B-Cell Lymphoma | disease | BEFREE;MGD |
C1332986 | Childhood Osteosarcoma | disease | BEFREE |
C1333064 | Classical Hodgkin's Lymphoma | disease | BEFREE |
C1333085 | Colon Carcinoma Metastatic in the Liver | disease | BEFREE |
C1333280 | Desmoplastic melanoma | disease | BEFREE |
C1333296 | Activated B-cell type diffuse large B-cell lymphoma | disease | BEFREE |
C1333324 | Barretts esophagus with dysplasia | disease | BEFREE |
C1333394 | Endometrial intraepithelial neoplasia | disease | BEFREE |
C1333396 | Endometrial Squamous Cell Carcinoma | disease | BEFREE |
C1333443 | Esophageal Basaloid Carcinoma | disease | BEFREE |
C1333600 | Hereditary Malignant Neoplasm | group | BEFREE |
C1333762 | Gastric Cardia Adenocarcinoma | disease | BEFREE |
C1333763 | Gastric Cardia Carcinoma | disease | BEFREE |
C1333768 | Gastric Gastrointestinal Stromal Tumor | disease | BEFREE |
C1333782 | Gastric Mucosa-Associated Lymphoid Tissue Lymphoma | disease | BEFREE |
C1333869 | Pancreatic Intraepithelial Neoplasia-1 | disease | BEFREE |
C1333964 | Liver Dysplastic Nodule | disease | BEFREE |
C1333977 | Hepatitis B Virus-Related Hepatocellular Carcinoma | disease | BEFREE |
C1333978 | Hepatitis C Virus-Related Hepatocellular Carcinoma | disease | BEFREE |
C1333990 | Hereditary Nonpolyposis Colorectal Cancer | disease | BEFREE |
C1333992 | Hereditary Ovarian Carcinoma | disease | BEFREE |
C1334015 | High Grade Intraepithelial Neoplasia | disease | BEFREE |
C1334054 | Human Papillomavirus-Related Esophageal Squamous Cell Carcinoma | disease | BEFREE |
C1334170 | Indolent Non-Hodgkin Lymphoma | disease | BEFREE |
C1334177 | Infiltrating Cervical Carcinoma | disease | BEFREE |
C1334260 | Intramuscular Myxoma | disease | BEFREE |
C1334274 | Invasive Carcinoma | phenotype | BEFREE |
C1334281 | Infiltrating Bladder Urothelial Carcinoma | disease | BEFREE |
C1334282 | Inverted urothelial papilloma | disease | BEFREE |
C1334413 | Low Grade Ductal Breast Carcinoma In Situ | disease | BEFREE |
C1334455 | Pulmonary Sclerosing Hemangioma | disease | BEFREE |
C1334603 | Malignant Mixed Mesodermal (Mullerian) Tumor | disease | BEFREE |
C1334647 | Maxillary Sinus Squamous Cell Carcinoma | disease | BEFREE |
C1334708 | Metaplastic breast carcinoma | disease | BEFREE |
C1334820 | Multifocal osteosarcoma | disease | BEFREE |
C1334920 | Adenocarcinoma of the nasal cavity | disease | BEFREE |
C1334953 | Neuroblastic tumors | disease | BEFREE |
C1334971 | Nodular Neoplasm | disease | BEFREE |
C1335101 | Occupational Malignant Neoplasm | phenotype | BEFREE |
C1335113 | Opisthorchis Viverrini-Related Cholangiocarcinoma | disease | BEFREE |
C1335167 | Ovarian Mucinous Adenocarcinoma | disease | BEFREE |
C1335168 | Ovarian mucinous tumor | disease | BEFREE |
C1335177 | Ovarian Serous Adenocarcinoma | disease | BEFREE |
C1335302 | Pancreatic Ductal Adenocarcinoma | disease | BEFREE |
C1335356 | Carcinoma ex pleomorphic adenoma of parotid gland | disease | BEFREE |
C1335473 | Primary chondrosarcoma of bone | disease | BEFREE |
C1335475 | Primary Carcinoma | phenotype | BEFREE |
C1335703 | Recurrent Head and Neck Carcinoma | disease | BEFREE |
C1335710 | Recurrent Malignant Peripheral Nerve Sheath Tumor | disease | BEFREE |
C1335931 | Breast Sclerosing Adenosis | disease | BEFREE |
C1335968 | Vulvar Intraepithelial Neoplasia, Differentiated Type | disease | BEFREE |
C1336076 | Sporadic Breast Carcinoma | disease | BEFREE |
C1336077 | Sporadic Burkitt's lymphoma | disease | BEFREE |
C1336078 | Papillary renal cell carcinoma, sporadic | disease | CLINVAR |
C1336219 | Stage IIIB Cervical Carcinoma | disease | BEFREE |
C1336527 | Carcinoma of urinary bladder, superficial | disease | BEFREE |
C1336538 | Supratentorial Embryonal Tumor, Not Otherwise Specified | disease | BEFREE |
C1336708 | Testicular Germ Cell Tumor | disease | BEFREE |
C1336735 | Treatment related acute myeloid leukaemia | disease | BEFREE |
C1336745 | Thymic Lymphoma | disease | BEFREE |
C1336753 | Thyroid Lymphoma | disease | BEFREE |
C1336899 | Uterine Angiosarcoma | disease | BEFREE |
C1336905 | Endometrial Endometrioid Adenocarcinoma | disease | BEFREE |
C1336921 | Endometrial Serous Adenocarcinoma | disease | BEFREE |
C1337013 | Differentiated Thyroid Gland Carcinoma | disease | BEFREE |
C1367536 | Nasopharyngeal Angiofibroma | disease | BEFREE |
C1367654 | Marginal Zone B-Cell Lymphoma | disease | BEFREE |
C1368019 | Paget Disease | disease | BEFREE |
C1368275 | Pigmented Basal Cell Carcinoma | disease | CTD_human |
C1368404 | Hypopharyngeal Carcinoma | disease | BEFREE |
C1368683 | Epithelioma | disease | BEFREE |
C1368771 | Burkitt-like lymphoma | disease | BEFREE |
C1368910 | Mature Teratoma | disease | BEFREE |
C1370419 | Ovarian Granulosa Cell Tumor | disease | BEFREE |
C1370723 | Stromal sarcoma | disease | BEFREE |
C1370889 | Liposarcoma, well differentiated | disease | BEFREE |
C1370932 | carcinoma of the renal pelvis and ureter | disease | BEFREE |
C1370962 | Prostate cancer stage C | disease | BEFREE |
C1378050 | Oncocytic Neoplasm | disease | BEFREE |
C1378511 | Undifferentiated leukemia | disease | BEFREE |
C1378703 | Renal carcinoma | disease | BEFREE |
C1384494 | Metastatic Carcinoma | group | BEFREE |
C1384514 | Conn Syndrome | disease | BEFREE |
C1402294 | Primary Lesion | phenotype | BEFREE |
C1402315 | Vascular lesions | disease | BEFREE |
C1412004 | Tumor of the Pineal Region | disease | BEFREE |
C1412014 | Infiltrating duct carcinoma | disease | BEFREE |
C1412036 | Anal squamous cell carcinoma | disease | BEFREE |
C1439275 | Disseminated carcinoma | disease | BEFREE |
C1449563 | Cardiomyopathy, Familial Idiopathic | disease | BEFREE |
C1456781 | Benign melanocytic nevus | disease | BEFREE |
C1456873 | alpha^+^ Thalassemia | disease | BEFREE |
C1458155 | Mammary Neoplasms | group | BEFREE;CLINVAR;CTD_human;CTD_mouse;LHGDN;MGD |
C1509147 | Histiocytoma | disease | BEFREE |
C1510420 | Cavitation | phenotype | BEFREE |
C1510426 | choroid plexus carcinoma, childhood | disease | BEFREE |
C1510502 | Oxyphilic Adenoma | disease | BEFREE |
C1510885 | Angiogenic Switch | disease | BEFREE |
C1511789 | Desmoplastic | disease | BEFREE |
C1511934 | Differentiating Neuroblastoma | disease | BEFREE |
C1512127 | HER2 gene amplification | phenotype | BEFREE |
C1512260 | Grade I Meningioma | disease | BEFREE |
C1512409 | Hepatocarcinogenesis | disease | BEFREE |
C1512431 | High Grade B-Cell Non-Hodgkin's Lymphoma | disease | BEFREE |
C1512433 | Cervical high grade squamous intraepithelial lesion | disease | BEFREE |
C1512981 | Mammary Tumorigenesis | phenotype | BEFREE |
C1514225 | Poorly Differentiated Neuroblastoma | disease | BEFREE |
C1514422 | Glioblastoma, IDH-Wildtype | disease | BEFREE;MGD |
C1514428 | Primary peritoneal carcinoma | disease | BEFREE;HPO |
C1516857 | Serous Endometrial Intraepithelial Carcinoma | disease | BEFREE |
C1517445 | Ganglioneuroblastoma, Nodular | disease | BEFREE |
C1518005 | Low Grade Cervical Squamous Intraepithelial Neoplasia | disease | BEFREE |
C1518171 | Malignant Conversion | phenotype | BEFREE |
C1518693 | Ovarian Clear Cell Adenocarcinoma | disease | BEFREE |
C1519214 | Glioblastoma, IDH-Mutant | disease | BEFREE |
C1519346 | Skin Carcinogenesis | disease | BEFREE |
C1519653 | Trisomy 4 | disease | BEFREE |
C1519670 | Tumor Angiogenesis | phenotype | BEFREE |
C1519680 | Tumor Immunity | phenotype | BEFREE |
C1519689 | Tumor Promotion | phenotype | BEFREE |
C1519714 | Type II Endometrial Adenocarcinoma | disease | BEFREE |
C1519787 | Undifferentiated Neuroblastoma | disease | BEFREE |
C1522378 | Leukemia, Large Granular Lymphocytic | disease | BEFREE |
C1527249 | Colorectal Cancer | disease | BEFREE;CTD_human |
C1527303 | Chronic Airflow Obstruction | disease | CTD_human |
C1527336 | Sjogren's Syndrome | disease | BEFREE |
C1527349 | Ductal Breast Carcinoma | disease | BEFREE |
C1527383 | Morphea | disease | BEFREE |
C1527390 | Neoplasms, Intracranial | group | CTD_mouse |
C1531608 | Smoldering myeloma | disease | BEFREE |
C1535510 | ADENOMAS AND ADENOCARCINOMAS | group | BEFREE |
C1536526 | Bowenoid papulosis of penis | disease | BEFREE |
C1541317 | Adult Gliosarcoma | disease | BEFREE |
C1559154 | Rash and Dermatitis Adverse Event Associated with Chemoradiation | disease | BEFREE |
C1561643 | Chronic Kidney Diseases | group | BEFREE |
C1563697 | Chromosome Instability Syndromes | disease | BEFREE |
C1565662 | Acute Kidney Insufficiency | disease | CTD_human |
C1568272 | Tendinopathy | disease | BEFREE |
C1569637 | Adenocarcinoma, Endometrioid | disease | BEFREE |
C1608408 | Malignant transformation | phenotype | BEFREE |
C1611743 | Familial (FPAH) | disease | BEFREE |
C1621958 | Glioblastoma Multiforme | disease | BEFREE;GWASCAT |
C1623038 | Cirrhosis | disease | BEFREE |
C1654637 | androgen independent prostate cancer | disease | BEFREE |
C1704230 | Grade I Astrocytoma | disease | BEFREE;CTD_mouse |
C1704272 | Benign Prostatic Hyperplasia | disease | BEFREE |
C1704356 | Enchondroma | disease | BEFREE |
C1704374 | Carcinoma of Endocrine Gland | disease | BEFREE |
C1704376 | Uterine Corpus Carcinosarcoma | disease | BEFREE |
C1704421 | Skin Pigmentation Disorder | group | BEFREE |
C1704423 | Milroy Disease | disease | BEFREE |
C1707439 | Colorectal Mucinous Adenocarcinoma | disease | BEFREE |
C1707440 | Colorectal Signet Ring Cell Carcinoma | disease | BEFREE |
C1707441 | Colorectal Small Cell Neuroendocrine Carcinoma | disease | BEFREE |
C1707444 | Columnar Cell Change of the Breast | phenotype | BEFREE |
C1708045 | Fetal Lung Adenocarcinoma | disease | BEFREE |
C1708349 | Hereditary Diffuse Gastric Cancer | disease | CTD_human |
C1708350 | Hereditary Leiomyomatosis and Renal Cell Cancer | disease | BEFREE |
C1708604 | Keratocystic Odontogenic Tumor | disease | BEFREE |
C1709781 | Pyothorax-Associated Lymphoma | disease | BEFREE |
C1710095 | paranasal sinus and nasal cavity cancer | disease | BEFREE |
C1710547 | Unilateral Breast Carcinoma | disease | BEFREE |
C1739363 | Prostatic Hypertrophy | disease | BEFREE |
C1762616 | Meningioma, benign, no ICD-O subtype | disease | BEFREE |
C1800706 | Idiopathic Pulmonary Fibrosis | disease | BEFREE |
C1802398 | Chromosome 5, trisomy 5q | disease | BEFREE |
C1827820 | Fast acetylator due to N-acetyltransferase enzyme variant | disease | BEFREE |
C1832648 | Hypoparathyroidism familial isolated | disease | BEFREE |
C1832661 | ANOPHTHALMIA AND PULMONARY HYPOPLASIA | disease | BEFREE |
C1832916 | Timothy syndrome | disease | BEFREE |
C1833561 | UV-Sensitive Syndrome | disease | BEFREE |
C1835398 | LI-FRAUMENI SYNDROME 1 | disease | BEFREE;CLINVAR;UNIPROT |
C1836482 | Li-Fraumeni Syndrome 2 | disease | CLINVAR |
C1837218 | Cleft palate, isolated | disease | BEFREE |
C1838578 | Progressive encephalopathy | phenotype | HPO |
C1840264 | IMMUNE SUPPRESSION | phenotype | BEFREE |
C1842408 | increased risk of pancreatic cancer | phenotype | HPO |
C1845055 | ALPHA-THALASSEMIA/MENTAL RETARDATION SYNDROME, NONDELETION TYPE, X-LINKED | disease | BEFREE |
C1847835 | VITILIGO-ASSOCIATED MULTIPLE AUTOIMMUNE DISEASE SUSCEPTIBILITY 1 (finding) | disease | BEFREE |
C1848411 | XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP E | disease | BEFREE |
C1850900 | Familial primary gastric lymphoma | disease | BEFREE |
C1851584 | Childhood Ependymoma | disease | BEFREE |
C1851585 | MYELOPROLIFERATIVE DISORDER, CHRONIC, WITH EOSINOPHILIA | disease | BEFREE |
C1851710 | LATERAL MENINGOCELE SYNDROME | disease | BEFREE |
C1851841 | ECTRODACTYLY, ECTODERMAL DYSPLASIA, AND CLEFT LIP/PALATE SYNDROME 1 | disease | BEFREE |
C1853195 | Prostate Cancer, Hereditary, 7 | disease | BEFREE |
C1854365 | BREAST CANCER 3 | disease | BEFREE |
C1854465 | TUBEROUS SCLEROSIS 1 (disorder) | disease | BEFREE |
C1856689 | FRIEDREICH ATAXIA 1 | disease | BEFREE |
C1857276 | Trichohepatoenteric Syndrome | disease | BEFREE |
C1858160 | CRANIOSYNOSTOSIS, TYPE 2 | disease | BEFREE |
C1858723 | Poikiloderma with Neutropenia | disease | BEFREE |
C1859972 | ADRENOCORTICAL CARCINOMA, HEREDITARY | disease | BEFREE;CLINVAR;CTD_human |
C1859973 | Adrenocortical Carcinoma, Pediatric | disease | BEFREE;CLINVAR |
C1860707 | TUBEROUS SCLEROSIS 2 (disorder) | disease | BEFREE |
C1860789 | Leukemia, Megakaryoblastic, of Down Syndrome | disease | CTD_human |
C1861305 | TARSAL-CARPAL COALITION SYNDROME | disease | BEFREE |
C1861453 | Pseudohyperkalemia Cardiff | disease | BEFREE |
C1861901 | Subacute progressive viral hepatitis | phenotype | HPO |
C1862761 | Increased hepatocellular carcinoma risk | phenotype | HPO |
C1862941 | Amyotrophic Lateral Sclerosis, Sporadic | disease | BEFREE |
C1863340 | PITUITARY ADENOMA PREDISPOSITION (disorder) | phenotype | BEFREE |
C1863753 | LIMB-MAMMARY SYNDROME | disease | BEFREE |
C1867955 | Increased incidence of hepatocellular carcinoma | phenotype | HPO |
C1868675 | PARKINSON DISEASE 2, AUTOSOMAL RECESSIVE JUVENILE | disease | BEFREE |
C1868683 | B-CELL MALIGNANCY, LOW-GRADE | disease | BEFREE;ORPHANET |
C1869117 | Paroxysmal nonkinesigenic dyskinesia | disease | BEFREE |
C1879321 | Acute Myeloid Leukemia (AML-M2) | disease | CTD_mouse |
C1881254 | Inverted Squamous Cell Papilloma | disease | BEFREE |
C1883486 | Uterine Corpus Cancer | disease | BEFREE |
C1955869 | Malformations of Cortical Development | group | LHGDN |
C1955934 | Trichothiodystrophy Syndromes | disease | BEFREE |
C1956346 | Coronary Artery Disease | disease | BEFREE |
C1959583 | Myocardial Failure | disease | CTD_mouse |
C1959632 | Plasma Cell Neoplasm | group | BEFREE |
C1960397 | Philadelphia chromosome-positive acute lymphoblastic leukemia | disease | BEFREE |
C1961099 | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | disease | BEFREE |
C1961102 | Precursor Cell Lymphoblastic Leukemia Lymphoma | disease | BEFREE;CTD_human;LHGDN |
C1961112 | Heart Decompensation | phenotype | CTD_mouse |
C1968855 | Paradoxical increased cortisol secretion on dexamethasone suppression test | phenotype | HPO |
C1971624 | Loss of appetite (finding) | phenotype | HPO |
C1997217 | Low grade glioma | disease | BEFREE |
C2004493 | Leukemia, B-Cell | disease | BEFREE |
C2145472 | Urothelial Carcinoma | disease | BEFREE |
C2216702 | malignant neoplasm of breast staging | disease | BEFREE |
C2239176 | Liver carcinoma | disease | BEFREE;CGI;CLINVAR;CTD_human;CTD_mouse;HPO;LHGDN |
C2242987 | Benign Mastocytoma | disease | BEFREE |
C2347761 | Childhood Myelodysplastic Syndrome | disease | BEFREE |
C2349952 | Oropharyngeal Carcinoma | disease | BEFREE |
C2350037 | Clinically Isolated Syndrome, CNS Demyelinating | disease | CTD_human |
C2363142 | T-Cell Prolymphocytic Leukemia | disease | BEFREE |
C2585570 | Benign multiple sclerosis | disease | BEFREE |
C2609414 | Acute kidney injury | disease | CTD_human |
C2674218 | SPHEROCYTOSIS, TYPE 1 (disorder) | disease | BEFREE |
C2675080 | Li-Fraumeni-Like Syndrome | disease | BEFREE;CLINVAR;UNIPROT |
C2697638 | Hypodiploid B Acute Lymphoblastic Leukemia | disease | BEFREE |
C2698045 | Merkel Cell Polyomavirus Infection | disease | BEFREE |
C2699572 | Dedifferentiated Solitary Fibrous Tumor | disease | BEFREE |
C2700617 | Irritation - emotion | phenotype | HPO |
C2711227 | Steatohepatitis | disease | BEFREE |
C2713368 | Hematopoetic Myelodysplasia | disease | CTD_human |
C2717836 | Steroid Sulfatase Deficiency Disease | disease | BEFREE |
C2718067 | Alcoholic Steatohepatitis | disease | BEFREE |
C2732473 | Ductal Carcinoma In Situ with Microinvasion | disease | BEFREE |
C2732618 | Sessile Serrated Adenoma/Polyp | disease | BEFREE |
C2739810 | Lentigo maligna melanoma | disease | BEFREE |
C2745900 | Promyelocytic leukemia | disease | BEFREE |
C2750850 | GLIOMA SUSCEPTIBILITY 1 | phenotype | CLINVAR |
C2752147 | XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C | disease | BEFREE |
C2825139 | Acute Myeloid Leukemia with Myelodysplasia-Related Changes | disease | BEFREE |
C2825306 | Treatment related leukaemia | disease | BEFREE |
C2826321 | Refractory Thrombocytopenia | disease | BEFREE |
C2828150 | Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma | disease | BEFREE |
C2830012 | Chemical Gastritis | disease | BEFREE |
C2919828 | Chronic ulcerative colitis | disease | BEFREE |
C2919945 | Cavernous Hemangioma of Brain | phenotype | BEFREE |
C2930471 | Bilateral Wilms Tumor | disease | CTD_human |
C2931038 | Pancreatic carcinoma, familial | disease | ORPHANET |
C2931068 | Desmoplastic cerebral astrocytoma of infancy | disease | BEFREE |
C2931618 | Gestational trophoblastic disease | disease | BEFREE |
C2931713 | Chromosome 17 deletion | disease | CTD_human |
C2931822 | Nasopharyngeal carcinoma | disease | BEFREE;CLINVAR;CTD_human |
C2936502 | Familial CHARGE Syndrome | disease | MGD |
C2936664 | Acquired Hypogammaglobulinemia | disease | BEFREE |
C2936904 | Opitz GBBB Syndrome, X-Linked | disease | BEFREE |
C2937421 | Prostatic Hyperplasia | disease | BEFREE |
C2939419 | Secondary Neoplasm | group | BEFREE |
C2939420 | Metastatic Neoplasm | phenotype | BEFREE |
C2945759 | aggressive cancer | phenotype | BEFREE |
C2945767 | Childhood Malignant Liver Neoplasm | disease | BEFREE |
C2981142 | Refractory anemia, without ringed sideroblasts, without excess blasts | disease | BEFREE |
C2981150 | Uranostaphyloschisis | disease | BEFREE |
C2982481 | Stage IV Hypopharyngeal Carcinoma AJCC v7 | disease | BEFREE |
C2985171 | Glioneuronal Tumor with Neuropil-Like Islands | disease | BEFREE |
C2986664 | Multicentric Breast Carcinoma | disease | BEFREE |
C2986665 | Early-Stage Breast Carcinoma | disease | BEFREE |
C2987252 | Esophageal Spindle Cell Carcinoma | disease | BEFREE |
C2987397 | Gastric Carcinoma with Lymphoid Stroma | disease | BEFREE |
C3146251 | Stage IV Colorectal Cancer AJCC v7 | disease | BEFREE |
C3146254 | Stage III Colon Cancer AJCC v7 | disease | BEFREE |
C3146271 | Stage III Breast Cancer AJCC v7 | disease | BEFREE |
C3150911 | GASTRIC CANCER, INTESTINAL | disease | BEFREE |
C3160718 | PARKINSON DISEASE, LATE-ONSET | disease | BEFREE |
C3163843 | Chondrosarcoma of bone | disease | BEFREE |
C3203102 | Idiopathic pulmonary arterial hypertension | disease | BEFREE |
C3241937 | Nonalcoholic Steatohepatitis | disease | BEFREE |
C3251817 | Condylomatous carcinoma | disease | BEFREE |
C3272820 | Ulcerative Colitis-Associated Colorectal Adenocarcinoma | disease | BEFREE |
C3275124 | Biliary System Disorder | disease | BEFREE |
C3277418 | Gastrointestinal hamartomatous polyps | disease | BEFREE |
C3463824 | MYELODYSPLASTIC SYNDROME | group | BEFREE;CLINVAR;CTD_human;LHGDN |
C3469186 | HEMOCHROMATOSIS, TYPE 1 | disease | BEFREE |
C3469521 | FANCONI ANEMIA, COMPLEMENTATION GROUP A (disorder) | disease | BEFREE |
C3472608 | Micropapillary carcinoma | disease | BEFREE |
C3489398 | Neuroepithelioma, Peripheral | disease | BEFREE |
C3489413 | Lipomatosis, Multiple | disease | BEFREE |
C3495559 | Juvenile arthritis | disease | BEFREE |
C3496549 | Male Germ Cell Tumor | disease | BEFREE |
C3536893 | Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | disease | BEFREE |
C3539781 | Progressive cGVHD | disease | BEFREE |
C3539878 | Triple Negative Breast Neoplasms | disease | BEFREE |
C3549742 | Breast cancer, lobular | disease | BEFREE |
C3553606 | BASAL CELL CARCINOMA, SUSCEPTIBILITY TO, 7 | phenotype | CLINVAR |
C3639956 | Functional intestinal obstruction | phenotype | HPO |
C3642254 | High Grade Ovarian Serous Adenocarcinoma | disease | BEFREE |
C3642345 | Luminal A Breast Carcinoma | disease | BEFREE |
C3642346 | Luminal B Breast Carcinoma | disease | BEFREE |
C3647143 | Secondary malignant neoplasm of ovary | disease | BEFREE |
C3665419 | intracranial glioma | disease | BEFREE |
C3665444 | Neutrophilia (disorder) | disease | BEFREE |
C3665593 | Melanocytic nevus of skin | disease | BEFREE |
C3669246 | Mammary adenocarcinoma | disease | BEFREE |
C3683846 | Chromosome 17p Deletion Syndrome | disease | CTD_human |
C3693482 | Giant Cell Fibroblastoma | disease | BEFREE |
C3698226 | Noninvasive carcinoma ex pleomorphic adenoma | disease | BEFREE |
C3714514 | Infection | group | LHGDN |
C3714524 | Fibromyxosarcoma | disease | BEFREE |
C3714534 | dowling-degos disease | disease | BEFREE |
C3714542 | Lymphoma, Diffuse | disease | BEFREE |
C3714636 | Pneumonitis | disease | BEFREE |
C3714644 | Thymus Neoplasms | group | BEFREE;CGI;CTD_mouse |
C3714756 | Intellectual Disability | group | BEFREE;LHGDN |
C3714757 | Juvenile rheumatoid arthritis | disease | BEFREE |
C3714948 | PACHYONYCHIA CONGENITA 3 | disease | BEFREE |
C3805278 | Extrahepatic Cholangiocarcinoma | disease | BEFREE;CTD_human;CTD_mouse |
C3811653 | Experimental Organism Basal Cell Carcinoma | phenotype | BEFREE |
C3826424 | Neural tube--Abnormalities | phenotype | BEFREE |
C3828416 | Radiation Damage | disease | BEFREE |
C3829122 | Mesenchymal Glioblastoma | disease | BEFREE |
C3839280 | High grade serous carcinoma | disease | BEFREE |
C3839868 | Cytogenetically normal acute myeloid leukemia | disease | BEFREE |
C3873482 | Chronic ulcerative stomatitis | disease | BEFREE |
C3875321 | Inflammatory dermatosis | group | BEFREE |
C3887461 | Head and Neck Carcinoma | disease | BEFREE;CGI |
C3887486 | Interstitial lung fibrosis | phenotype | BEFREE |
C3887499 | Renal cyst | phenotype | BEFREE |
C3887524 | Skin Erosion | disease | BEFREE |
C3887654 | POLYARTERITIS NODOSA, CHILDHOOD-ONSET | disease | BEFREE |
C3887678 | Central Nervous System Embryonal Tumor, Not Otherwise Specified | disease | BEFREE |
C3888194 | MIXED LINEAGE LEUKEMIA | disease | BEFREE |
C3890429 | Liquid Tumor | disease | BEFREE |
C3898127 | Non-Metastatic Childhood Soft Tissue Sarcoma | disease | BEFREE |
C3898709 | Intestinal-Type Sinonasal Adenocarcinoma | disease | BEFREE |
C3899369 | Direct Extension | disease | BEFREE |
C3899658 | Childhood Gliosarcoma | disease | BEFREE |
C3899716 | Canine Osteosarcoma | disease | BEFREE |
C3900098 | Adult Myelodysplastic Syndrome | disease | BEFREE |
C4013426 | Bronchial carcinoid | disease | BEFREE |
C4018978 | Unilateral Breast Neoplasms | disease | BEFREE |
C4020732 | Mitochondrial abnormalities | phenotype | BEFREE |
C4020813 | Increased gastric cancer | phenotype | HPO |
C4020884 | Anxiety disease | disease | HPO |
C4020896 | Abnormality of genital physiology | phenotype | HPO |
C4021768 | Abnormality of metabolism/homeostasis | group | HPO |
C4021820 | Abnormality of reproductive system physiology | phenotype | HPO |
C4023068 | Increased urinary cortisol level | phenotype | HPO |
C4024988 | Intestinal carcinoid | disease | BEFREE |
C4024989 | Hereditary nonpolyposis colorectal carcinoma | disease | HPO |
C4025038 | Abnormality of the tibial metaphysis | phenotype | HPO |
C4025040 | Abnormality of the femoral metaphysis | phenotype | HPO |
C4025187 | Increased megakaryocyte count | phenotype | HPO |
C4041080 | Neurocognitive Disorders | group | BEFREE |
C4041194 | Lesion of fallopian tube | disease | BEFREE |
C4045991 | Perihilar Cholangiocarcinoma | disease | BEFREE |
C4048328 | cervical cancer | disease | BEFREE |
C4049993 | Aristolochic Acid Nephropathy | disease | BEFREE |
C4054188 | Ph-Like Acute Lymphoblastic Leukemia | disease | BEFREE |
C4060446 | Papilloma of breast | disease | BEFREE |
C4073168 | Abnormal lactate dehydrogenase activity | phenotype | HPO |
C4280444 | Abnormality of the wide portion of the femoral bone | phenotype | HPO |
C4280572 | Acute blood cancer | disease | HPO |
C4280575 | Progressive brain disease | disease | HPO |
C4282132 | Malignancy | phenotype | BEFREE |
C4288013 | Vulvar Adenocarcinoma of Mammary Gland Type | disease | CLINVAR |
C4476775 | Elevated serum 11-deoxycortisol | phenotype | HPO |
C4477081 | Abnormal serum dehydroepiandrosterone level | phenotype | HPO |
C4520898 | Stage IV Breast Cancer AJCC v6 and v7 | disease | BEFREE |
C4521042 | Complete Trisomy 21 Syndrome | disease | BEFREE |
GO ID | GO Term | Evidence |
---|---|---|
GO:0000978 | RNA polymerase II cis-regulatory region sequence-specific DNA binding | ISS |
GO:0000978 | RNA polymerase II cis-regulatory region sequence-specific DNA binding | IDA |
GO:0000981 | DNA-binding transcription factor activity, RNA polymerase II-specific | ISA |
GO:0000981 | DNA-binding transcription factor activity, RNA polymerase II-specific | IDA |
GO:0000981 | DNA-binding transcription factor activity, RNA polymerase II-specific | ISM |
GO:0001046 | core promoter sequence-specific DNA binding | IDA |
GO:0001085 | RNA polymerase II transcription factor binding | IPI |
GO:0001094 | TFIID-class transcription factor complex binding | IPI |
GO:0001228 | DNA-binding transcription activator activity, RNA polymerase II-specific | IDA |
GO:0002020 | protease binding | IPI |
GO:0002039 | p53 binding | IPI |
GO:0003677 | DNA binding | IDA |
GO:0003677 | DNA binding | IMP |
GO:0003682 | chromatin binding | IDA |
GO:0003700 | DNA-binding transcription factor activity | IMP |
GO:0003700 | DNA-binding transcription factor activity | IDA |
GO:0003730 | mRNA 3'-UTR binding | IDA |
GO:0005507 | copper ion binding | IDA |
GO:0005515 | protein binding | IPI |
GO:0005524 | ATP binding | IDA |
GO:0008134 | transcription factor binding | IPI |
GO:0008270 | zinc ion binding | TAS |
GO:0019899 | enzyme binding | IPI |
GO:0019901 | protein kinase binding | IPI |
GO:0019903 | protein phosphatase binding | IPI |
GO:0030971 | receptor tyrosine kinase binding | IPI |
GO:0031625 | ubiquitin protein ligase binding | IPI |
GO:0035033 | histone deacetylase regulator activity | IEA |
GO:0035035 | histone acetyltransferase binding | IPI |
GO:0042802 | identical protein binding | IPI |
GO:0042826 | histone deacetylase binding | IPI |
GO:0043621 | protein self-association | IPI |
GO:0044212 | transcription regulatory region DNA binding | IDA |
GO:0046982 | protein heterodimerization activity | IPI |
GO:0047485 | protein N-terminus binding | IPI |
GO:0051087 | chaperone binding | IPI |
GO:0051721 | protein phosphatase 2A binding | IPI |
GO:0097371 | MDM2/MDM4 family protein binding | IEA |
GO:0097718 | disordered domain specific binding | IPI |
GO:1990841 | promoter-specific chromatin binding | IDA |
GO ID | GO Term | Evidence |
---|---|---|
GO:0000122 | negative regulation of transcription by RNA polymerase II | ISS |
GO:0000733 | DNA strand renaturation | IDA |
GO:0001701 | in utero embryonic development | IEA |
GO:0001756 | somitogenesis | IEA |
GO:0001836 | release of cytochrome c from mitochondria | IEA |
GO:0002244 | hematopoietic progenitor cell differentiation | IMP |
GO:0002309 | T cell proliferation involved in immune response | IEA |
GO:0002326 | B cell lineage commitment | IEA |
GO:0002360 | T cell lineage commitment | IEA |
GO:0002931 | response to ischemia | IEA |
GO:0006289 | nucleotide-excision repair | IMP |
GO:0006302 | double-strand break repair | IEA |
GO:0006355 | regulation of transcription, DNA-templated | IMP |
GO:0006355 | regulation of transcription, DNA-templated | IDA |
GO:0006606 | protein import into nucleus | IEA |
GO:0006914 | autophagy | IMP |
GO:0006974 | cellular response to DNA damage stimulus | IDA |
GO:0006974 | cellular response to DNA damage stimulus | IMP |
GO:0006977 | DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest | IMP |
GO:0006977 | DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest | TAS |
GO:0006978 | DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator | IDA |
GO:0006978 | DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator | IMP |
GO:0006983 | ER overload response | IDA |
GO:0007050 | cell cycle arrest | IMP |
GO:0007050 | cell cycle arrest | IDA |
GO:0007179 | transforming growth factor beta receptor signaling pathway | IEA |
GO:0007265 | Ras protein signal transduction | IEP |
GO:0007369 | gastrulation | IEA |
GO:0007406 | negative regulation of neuroblast proliferation | IEA |
GO:0007569 | cell aging | IMP |
GO:0008104 | protein localization | IDA |
GO:0008156 | negative regulation of DNA replication | IEA |
GO:0008285 | negative regulation of cell population proliferation | ISS |
GO:0008285 | negative regulation of cell population proliferation | IMP |
GO:0008285 | negative regulation of cell population proliferation | IDA |
GO:0008340 | determination of adult lifespan | ISS |
GO:0009299 | mRNA transcription | IMP |
GO:0009303 | rRNA transcription | IEA |
GO:0009651 | response to salt stress | IEA |
GO:0010165 | response to X-ray | IEA |
GO:0010332 | response to gamma radiation | IMP |
GO:0010628 | positive regulation of gene expression | ISS |
GO:0010628 | positive regulation of gene expression | IDA |
GO:0010628 | positive regulation of gene expression | IMP |
GO:0010666 | positive regulation of cardiac muscle cell apoptotic process | IEA |
GO:0016032 | viral process | IMP |
GO:0016579 | protein deubiquitination | TAS |
GO:0019221 | cytokine-mediated signaling pathway | TAS |
GO:0021549 | cerebellum development | IEA |
GO:0030308 | negative regulation of cell growth | IMP |
GO:0030330 | DNA damage response, signal transduction by p53 class mediator | IDA |
GO:0030330 | DNA damage response, signal transduction by p53 class mediator | IMP |
GO:0030512 | negative regulation of transforming growth factor beta receptor signaling pathway | IEA |
GO:0031065 | positive regulation of histone deacetylation | IEA |
GO:0031497 | chromatin assembly | IDA |
GO:0031571 | mitotic G1 DNA damage checkpoint | IMP |
GO:0033077 | T cell differentiation in thymus | IEA |
GO:0034103 | regulation of tissue remodeling | IEA |
GO:0034644 | cellular response to UV | IDA |
GO:0035264 | multicellular organism growth | IEA |
GO:0035690 | cellular response to drug | IEP |
GO:0035794 | positive regulation of mitochondrial membrane permeability | IEA |
GO:0036003 | positive regulation of transcription from RNA polymerase II promoter in response to stress | IDA |
GO:0042149 | cellular response to glucose starvation | IDA |
GO:0042771 | intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator | IDA |
GO:0042771 | intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator | IMP |
GO:0042981 | regulation of apoptotic process | IDA |
GO:0042981 | regulation of apoptotic process | TAS |
GO:0043065 | positive regulation of apoptotic process | IDA |
GO:0043066 | negative regulation of apoptotic process | IMP |
GO:0043153 | entrainment of circadian clock by photoperiod | ISS |
GO:0043504 | mitochondrial DNA repair | IEA |
GO:0043516 | regulation of DNA damage response, signal transduction by p53 class mediator | IEA |
GO:0043525 | positive regulation of neuron apoptotic process | IEA |
GO:0045861 | negative regulation of proteolysis | IEA |
GO:0045892 | negative regulation of transcription, DNA-templated | ISS |
GO:0045892 | negative regulation of transcription, DNA-templated | IMP |
GO:0045892 | negative regulation of transcription, DNA-templated | IDA |
GO:0045893 | positive regulation of transcription, DNA-templated | IDA |
GO:0045893 | positive regulation of transcription, DNA-templated | IMP |
GO:0045899 | positive regulation of RNA polymerase II transcriptional preinitiation complex assembly | IDA |
GO:0045944 | positive regulation of transcription by RNA polymerase II | IDA |
GO:0045944 | positive regulation of transcription by RNA polymerase II | IGI |
GO:0045944 | positive regulation of transcription by RNA polymerase II | IMP |
GO:0046677 | response to antibiotic | IEP |
GO:0046827 | positive regulation of protein export from nucleus | TAS |
GO:0048147 | negative regulation of fibroblast proliferation | IMP |
GO:0048512 | circadian behavior | ISS |
GO:0048539 | bone marrow development | IMP |
GO:0048568 | embryonic organ development | IEA |
GO:0050731 | positive regulation of peptidyl-tyrosine phosphorylation | ISS |
GO:0050821 | protein stabilization | IEA |
GO:0051097 | negative regulation of helicase activity | TAS |
GO:0051123 | RNA polymerase II preinitiation complex assembly | IDA |
GO:0051262 | protein tetramerization | IEA |
GO:0051402 | neuron apoptotic process | IEA |
GO:0051974 | negative regulation of telomerase activity | IDA |
GO:0060218 | hematopoietic stem cell differentiation | IMP |
GO:0060333 | interferon-gamma-mediated signaling pathway | IEA |
GO:0060411 | cardiac septum morphogenesis | IEA |
GO:0061419 | positive regulation of transcription from RNA polymerase II promoter in response to hypoxia | IEA |
GO:0062100 | positive regulation of programmed necrotic cell death | IEA |
GO:0065003 | protein-containing complex assembly | IDA |
GO:0070059 | intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress | IEA |
GO:0070245 | positive regulation of thymocyte apoptotic process | ISS |
GO:0070266 | necroptotic process | IEA |
GO:0071158 | positive regulation of cell cycle arrest | IDA |
GO:0071158 | positive regulation of cell cycle arrest | IMP |
GO:0071456 | cellular response to hypoxia | IEP |
GO:0071479 | cellular response to ionizing radiation | IMP |
GO:0071480 | cellular response to gamma radiation | IDA |
GO:0071494 | cellular response to UV-C | IEA |
GO:0071850 | mitotic cell cycle arrest | IEA |
GO:0072331 | signal transduction by p53 class mediator | IDA |
GO:0072332 | intrinsic apoptotic signaling pathway by p53 class mediator | IMP |
GO:0072717 | cellular response to actinomycin D | IDA |
GO:0090200 | positive regulation of release of cytochrome c from mitochondria | IDA |
GO:0090343 | positive regulation of cell aging | IEA |
GO:0090399 | replicative senescence | IMP |
GO:0090403 | oxidative stress-induced premature senescence | IMP |
GO:0097193 | intrinsic apoptotic signaling pathway | TAS |
GO:0097252 | oligodendrocyte apoptotic process | IDA |
GO:1900119 | positive regulation of execution phase of apoptosis | IMP |
GO:1900740 | positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway | TAS |
GO:1901525 | negative regulation of mitophagy | IEA |
GO:1901796 | regulation of signal transduction by p53 class mediator | TAS |
GO:1902108 | regulation of mitochondrial membrane permeability involved in apoptotic process | IEA |
GO:1902253 | regulation of intrinsic apoptotic signaling pathway by p53 class mediator | IEA |
GO:1902749 | regulation of cell cycle G2/M phase transition | TAS |
GO:1902895 | positive regulation of pri-miRNA transcription by RNA polymerase II | IDA |
GO:1903799 | negative regulation of production of miRNAs involved in gene silencing by miRNA | IEA |
GO:1903800 | positive regulation of production of miRNAs involved in gene silencing by miRNA | IDA |
GO:1904024 | negative regulation of glucose catabolic process to lactate via pyruvate | IEA |
GO:1905856 | negative regulation of pentose-phosphate shunt | IMP |
GO:1990144 | intrinsic apoptotic signaling pathway in response to hypoxia | IEA |
GO:1990248 | regulation of transcription from RNA polymerase II promoter in response to DNA damage | IDA |
GO:1990440 | positive regulation of transcription from RNA polymerase II promoter in response to endoplasmic reticulum stress | ISS |
GO:2000269 | regulation of fibroblast apoptotic process | IEA |
GO:2000378 | negative regulation of reactive oxygen species metabolic process | IEA |
GO:2000379 | positive regulation of reactive oxygen species metabolic process | IMP |
GO:2000772 | regulation of cellular senescence | IEA |
GO:2001244 | positive regulation of intrinsic apoptotic signaling pathway | ISS |
GO:2001244 | positive regulation of intrinsic apoptotic signaling pathway | IMP |
GO ID | GO Term | Evidence |
---|---|---|
GO:0000790 | nuclear chromatin | ISA |
GO:0000790 | nuclear chromatin | IDA |
GO:0000790 | nuclear chromatin | IMP |
GO:0005634 | nucleus | IDA |
GO:0005634 | nucleus | IMP |
GO:0005654 | nucleoplasm | IDA |
GO:0005654 | nucleoplasm | TAS |
GO:0005657 | replication fork | IEA |
GO:0005667 | transcription factor complex | IGI |
GO:0005730 | nucleolus | IDA |
GO:0005737 | cytoplasm | IDA |
GO:0005737 | cytoplasm | IMP |
GO:0005739 | mitochondrion | IDA |
GO:0005759 | mitochondrial matrix | IEA |
GO:0005783 | endoplasmic reticulum | IEA |
GO:0005813 | centrosome | IDA |
GO:0005829 | cytosol | IDA |
GO:0005829 | cytosol | TAS |
GO:0016363 | nuclear matrix | IDA |
GO:0016605 | PML body | IDA |
GO:0031965 | nuclear membrane | IDA |
GO:0032991 | protein-containing complex | IMP |
GO:0032991 | protein-containing complex | IDA |
GO:0035861 | site of double-strand break | IEA |
GO:0005669 | transcription factor TFIID complex | IDA |
GO:0016604 | nuclear body | IDA |
Reactome ID | Reactome Term | Evidence |
---|---|---|
R-HSA-109581 | Apoptosis | TAS |
R-HSA-109582 | Hemostasis | IEA |
R-HSA-109606 | Intrinsic Pathway for Apoptosis | TAS |
R-HSA-111448 | Activation of NOXA and translocation to mitochondria | TAS |
R-HSA-114452 | Activation of BH3-only proteins | TAS |
R-HSA-1257604 | PIP3 activates AKT signaling | TAS |
R-HSA-1257604 | PIP3 activates AKT signaling | IEA |
R-HSA-1280215 | Cytokine Signaling in Immune system | TAS |
R-HSA-139915 | Activation of PUMA and translocation to mitochondria | TAS |
R-HSA-157118 | Signaling by NOTCH | TAS |
R-HSA-162582 | Signal Transduction | TAS |
R-HSA-162582 | Signal Transduction | IEA |
R-HSA-1640170 | Cell Cycle | TAS |
R-HSA-168256 | Immune System | TAS |
R-HSA-1912408 | Pre-NOTCH Transcription and Translation | TAS |
R-HSA-1912422 | Pre-NOTCH Expression and Processing | TAS |
R-HSA-212436 | Generic Transcription Pathway | TAS |
R-HSA-2262752 | Cellular responses to stress | TAS |
R-HSA-2559580 | Oxidative Stress Induced Senescence | TAS |
R-HSA-2559583 | Cellular Senescence | TAS |
R-HSA-2559584 | Formation of Senescence-Associated Heterochromatin Foci (SAHF) | TAS |
R-HSA-2559585 | Oncogene Induced Senescence | TAS |
R-HSA-2559586 | DNA Damage/Telomere Stress Induced Senescence | TAS |
R-HSA-2990846 | SUMOylation | TAS |
R-HSA-3108232 | SUMO E3 ligases SUMOylate target proteins | TAS |
R-HSA-3232118 | SUMOylation of transcription factors | TAS |
R-HSA-349425 | Autodegradation of the E3 ubiquitin ligase COP1 | TAS |
R-HSA-3700989 | Transcriptional Regulation by TP53 | TAS |
R-HSA-390466 | Chaperonin-mediated protein folding | IEA |
R-HSA-390471 | Association of TriC/CCT with target proteins during biosynthesis | IEA |
R-HSA-391251 | Protein folding | IEA |
R-HSA-392499 | Metabolism of proteins | TAS |
R-HSA-392499 | Metabolism of proteins | IEA |
R-HSA-449147 | Signaling by Interleukins | TAS |
R-HSA-453274 | Mitotic G2-G2/M phases | TAS |
R-HSA-5357801 | Programmed Cell Death | TAS |
R-HSA-5628897 | TP53 Regulates Metabolic Genes | TAS |
R-HSA-5633007 | Regulation of TP53 Activity | TAS |
R-HSA-5633008 | TP53 Regulates Transcription of Cell Death Genes | TAS |
R-HSA-5688426 | Deubiquitination | TAS |
R-HSA-5689880 | Ub-specific processing proteases | TAS |
R-HSA-5689896 | Ovarian tumor domain proteases | TAS |
R-HSA-5693532 | DNA Double-Strand Break Repair | TAS |
R-HSA-5693565 | Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | TAS |
R-HSA-5693606 | DNA Double Strand Break Response | TAS |
R-HSA-597592 | Post-translational protein modification | TAS |
R-HSA-6785807 | Interleukin-4 and Interleukin-13 signaling | TAS |
R-HSA-6791312 | TP53 Regulates Transcription of Cell Cycle Genes | TAS |
R-HSA-6796648 | TP53 Regulates Transcription of DNA Repair Genes | TAS |
R-HSA-6803204 | TP53 Regulates Transcription of Genes Involved in Cytochrome C Release | TAS |
R-HSA-6803205 | TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain | TAS |
R-HSA-6803207 | TP53 Regulates Transcription of Caspase Activators and Caspases | TAS |
R-HSA-6803211 | TP53 Regulates Transcription of Death Receptors and Ligands | TAS |
R-HSA-6804114 | TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest | TAS |
R-HSA-6804115 | TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain | TAS |
R-HSA-6804116 | TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest | TAS |
R-HSA-6804754 | Regulation of TP53 Expression | TAS |
R-HSA-6804756 | Regulation of TP53 Activity through Phosphorylation | TAS |
R-HSA-6804757 | Regulation of TP53 Degradation | TAS |
R-HSA-6804758 | Regulation of TP53 Activity through Acetylation | TAS |
R-HSA-6804759 | Regulation of TP53 Activity through Association with Co-factors | TAS |
R-HSA-6804760 | Regulation of TP53 Activity through Methylation | TAS |
R-HSA-6806003 | Regulation of TP53 Expression and Degradation | TAS |
R-HSA-6807070 | PTEN Regulation | TAS |
R-HSA-6807070 | PTEN Regulation | IEA |
R-HSA-6811555 | PI5P Regulates TP53 Acetylation | TAS |
R-HSA-69275 | G2/M Transition | TAS |
R-HSA-69278 | Cell Cycle, Mitotic | TAS |
R-HSA-69473 | G2/M DNA damage checkpoint | TAS |
R-HSA-69481 | G2/M Checkpoints | TAS |
R-HSA-69541 | Stabilization of p53 | TAS |
R-HSA-69560 | Transcriptional activation of p53 responsive genes | TAS |
R-HSA-69563 | p53-Dependent G1 DNA Damage Response | TAS |
R-HSA-69580 | p53-Dependent G1/S DNA damage checkpoint | TAS |
R-HSA-69615 | G1/S DNA Damage Checkpoints | TAS |
R-HSA-69620 | Cell Cycle Checkpoints | TAS |
R-HSA-69895 | Transcriptional activation of cell cycle inhibitor p21 | TAS |
R-HSA-73857 | RNA Polymerase II Transcription | TAS |
R-HSA-73894 | DNA Repair | TAS |
R-HSA-74160 | Gene expression (Transcription) | TAS |
R-HSA-8852276 | The role of GTSE1 in G2/M progression after G2 checkpoint | TAS |
R-HSA-8853884 | Transcriptional Regulation by VENTX | TAS |
R-HSA-8878159 | Transcriptional regulation by RUNX3 | TAS |
R-HSA-8941855 | RUNX3 regulates CDKN1A transcription | TAS |
R-HSA-8943724 | Regulation of PTEN gene transcription | TAS |
R-HSA-8943724 | Regulation of PTEN gene transcription | IEA |
R-HSA-8953897 | Cellular responses to external stimuli | TAS |
R-HSA-9006925 | Intracellular signaling by second messengers | TAS |
R-HSA-9006925 | Intracellular signaling by second messengers | IEA |
R-HSA-983231 | Factors involved in megakaryocyte development and platelet production | IEA |
ID | Drug Name | Action | PubMed |
---|---|---|---|
C067795 | 10-decarbamoylmitomycin C | 10-decarbamoylmitomycin C results in increased stability of TP53 protein | 20536192 |
C067795 | 10-decarbamoylmitomycin C | [10-decarbamoylmitomycin C results in increased stability of TP53 protein] which results in increased expression of CDKN1A mRNA | 20536192 |
C490191 | 11,11'-dideoxyverticilin | 11,11'-dideoxyverticilin results in increased expression of and results in increased phosphorylation of TP53 protein | 15963507 |
C026486 | 1,2,5,6-dibenzanthracene | TP53 protein affects the reaction [1,2,5,6-dibenzanthracene results in increased expression of CYP1A1 protein] | 25398514 |
C026486 | 1,2,5,6-dibenzanthracene | TP53 protein results in increased susceptibility to 1,2,5,6-dibenzanthracene | 25398514 |
C517232 | 1,2-dibromo-4-(1,2-dibromoethyl)cyclohexane | 1,2-dibromo-4-(1,2-dibromoethyl)cyclohexane results in increased expression of TP53 mRNA | 23958786 |
C517232 | 1,2-dibromo-4-(1,2-dibromoethyl)cyclohexane | 1,2-dibromo-4-(1,2-dibromoethyl)cyclohexane affects the expression of TP53 mRNA | 24375616 |
C044985 | 1',2'-dihydrorotenone | 1',2'-dihydrorotenone results in decreased phosphorylation of and results in decreased expression of TP53 protein | 24615755 |
D019813 | 1,2-Dimethylhydrazine | 1,2-Dimethylhydrazine results in decreased methylation of TP53 exon | 8863662 |
D019813 | 1,2-Dimethylhydrazine | 1,2-Dimethylhydrazine results in increased expression of TP53 protein | 18155637 |
D019813 | 1,2-Dimethylhydrazine | Folic Acid inhibits the reaction [1,2-Dimethylhydrazine results in decreased methylation of TP53 exon] | 8863662 |
D019813 | 1,2-Dimethylhydrazine | Vanadium inhibits the reaction [1,2-Dimethylhydrazine results in increased expression of TP53 protein] | 18155637 |
C032041 | 1,2-diphenylhydrazine | [Copper co-treated with 1,2-diphenylhydrazine] results in increased mutagenesis of TP53 gene | 10798712 |
C032041 | 1,2-diphenylhydrazine | piperidine promotes the reaction [[Copper co-treated with 1,2-diphenylhydrazine] results in increased mutagenesis of TP53 gene] | 10798712 |
C519184 | 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000) | [1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000) co-treated with Quercetin] results in increased expression of TP53 protein | 23529952 |
C517214 | 12-hydroxyellipticine | TP53 protein results in decreased chemical synthesis of 12-hydroxyellipticine | 29471073 |
C576882 | 1-(2-trifluoromethoxyphenyl)-2-nitroethanone | 1-(2-trifluoromethoxyphenyl)-2-nitroethanone affects the activity of TP53 protein | 25596134 |
C038983 | 1,3-dimethylthiourea | 1,3-dimethylthiourea inhibits the reaction [Puromycin Aminonucleoside results in increased expression of TP53 protein] | 17035936 |
C517215 | 13-hydroxyellipticine | [TP53 protein affects the susceptibility to Benzo(a)pyrene] which affects the chemical synthesis of 13-hydroxyellipticine | 29471073 |
C517215 | 13-hydroxyellipticine | TP53 protein results in decreased chemical synthesis of 13-hydroxyellipticine | 29471073 |
C429685 | 1,4,5,8-naphthalenetetracarboxylic diimide | 1,4,5,8-naphthalenetetracarboxylic diimide analog results in increased expression of TP53 protein | 19954251 |
C479234 | 1-(4-dimethylaminomethylphenyl)-8,9-dihydro-7H-2,7,9a-benzo(cd)azulen-6-one | 1-(4-dimethylaminomethylphenyl)-8,9-dihydro-7H-2,7,9a-benzo(cd)azulen-6-one inhibits the reaction [Resveratrol results in increased acetylation of TP53 protein] | 25533949 |
C074153 | 1,4-phenylenebis(methylene)selenocyanate | 1,4-phenylenebis(methylene)selenocyanate results in increased expression of TP53 mRNA | 17205524 |
C074153 | 1,4-phenylenebis(methylene)selenocyanate | AR protein promotes the reaction [1,4-phenylenebis(methylene)selenocyanate results in increased expression of TP53 mRNA] | 17205524 |
C560296 | 1,5-bis(2,3-dimethoxyphenyl)penta-1,4-dien-3-one | 1,5-bis(2,3-dimethoxyphenyl)penta-1,4-dien-3-one results in increased phosphorylation of TP53 protein | 21504179 |
C072581 | 16-hydroxycleroda-3,13(14)-dien-15,16-olide | 16-hydroxycleroda-3,13(14)-dien-15,16-olide results in increased expression of TP53 protein | 23628706 |
C002029 | 17alpha-ethynylestr-5(10)-ene-3alpha,17beta-diol | 17alpha-ethynylestr-5(10)-ene-3alpha,17beta-diol results in increased expression of TP53 protein | 16019103 |
C448659 | 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin | TP53 gene affects the susceptibility to 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin | 17085670 |
C406982 | 1,8-diazafluoren-one | [1,8-diazafluoren-one results in decreased activity of HMOX1 protein] inhibits the reaction [cobaltiprotoporphyrin results in increased expression of TP53 protein] | 18042465 |
C495172 | (19Z)-halichondramide | (19Z)-halichondramide results in increased expression of TP53 protein | 23147639 |
C047948 | 1'-acetoxychavicol acetate | [1'-acetoxychavicol acetate co-treated with Butyric Acid] results in increased phosphorylation of TP53 protein | 24480522 |
C036423 | 1-aminomethylphosphonic acid | 1-aminomethylphosphonic acid results in increased expression of TP53 protein | 23983455 |
C095284 | 1H-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one | 1H-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one results in increased stability of and results in increased expression of and results in increased phosphorylation of TP53 protein | 16288207 |
C540044 | 1-hexadecyl-3-methylimidazolium chloride | 1-hexadecyl-3-methylimidazolium chloride results in increased expression of TP53 mRNA | 29842889 |
C506325 | 1-hydroxy-1-norresistomycin | 1-hydroxy-1-norresistomycin results in increased expression of TP53 mRNA | 29596799 |
C506325 | 1-hydroxy-1-norresistomycin | 1-hydroxy-1-norresistomycin results in increased expression of TP53 protein | 29596799 |
C105351 | 1-hydroxy-2-oxo-3,3-bis(2-aminoethyl)-1-triazene | [1-hydroxy-2-oxo-3,3-bis(2-aminoethyl)-1-triazene results in decreased degradation of HIF1A protein] which results in increased phosphorylation of and results in increased activity of TP53 protein | 18424783 |
C108731 | 1'-(hydroxymethyl)eugenol | 1'-(hydroxymethyl)eugenol results in increased phosphorylation of TP53 protein | 28818686 |
D015655 | 1-Methyl-4-phenylpyridinium | 1-Methyl-4-phenylpyridinium results in decreased expression of TP53 mRNA | 24810058 |
D015655 | 1-Methyl-4-phenylpyridinium | 1-Methyl-4-phenylpyridinium results in increased expression of TP53 mRNA | 26357513 |
D015655 | 1-Methyl-4-phenylpyridinium | 1-Methyl-4-phenylpyridinium results in increased expression of TP53 protein | 28481321 |
D015655 | 1-Methyl-4-phenylpyridinium | atractylenolide I inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of TP53 protein] | 28481321 |
D015655 | 1-Methyl-4-phenylpyridinium | mangostin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of TP53 mRNA] | 26357513 |
D015655 | 1-Methyl-4-phenylpyridinium | U 0126 affects the reaction [1-Methyl-4-phenylpyridinium affects the expression of TP53 mRNA] | 12710931 |
D015655 | 1-Methyl-4-phenylpyridinium | 1-Methyl-4-phenylpyridinium results in increased acetylation of TP53 protein | 17583434 |
D015655 | 1-Methyl-4-phenylpyridinium | 1-Methyl-4-phenylpyridinium results in increased expression of TP53 protein | 26677001 |
C051246 | 1-methylanthracene | 1-methylanthracene results in increased phosphorylation of TP53 protein | 17941746 |
C041507 | 1-methylphenanthrene | 1-methylphenanthrene results in increased phosphorylation of TP53 protein | 17941746 |
D015058 | 1-Naphthylisothiocyanate | 1-Naphthylisothiocyanate results in increased expression of TP53 mRNA | 17522070 |
C032668 | 1-nitropyrene | 1-nitropyrene results in increased expression of TP53 protein | 10837373; 22044530; |
C032668 | 1-nitropyrene | 1-nitropyrene results in increased expression of TP53 protein modified form | 22044530 |
C032668 | 1-nitropyrene | 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide results in decreased susceptibility to [Tetrachlorodibenzodioxin results in decreased susceptibility to [1-nitropyrene results in increased expression of TP53 protein]] | 22044530 |
C032668 | 1-nitropyrene | [beta-Naphthoflavone binds to and results in increased activity of AHR protein] results in decreased susceptibility to [1-nitropyrene results in increased expression of TP53 protein] | 22044530 |
C032668 | 1-nitropyrene | CYP1A1 protein affects the susceptibility to [Tetrachlorodibenzodioxin results in decreased susceptibility to [1-nitropyrene results in increased expression of TP53 protein]] | 22044530 |
C032668 | 1-nitropyrene | nutlin 3 results in increased susceptibility to [1-nitropyrene results in increased expression of TP53 protein] | 22044530 |
C032668 | 1-nitropyrene | nutlin 3 results in increased susceptibility to [1-nitropyrene results in increased expression of TP53 protein modified form] | 22044530 |
C032668 | 1-nitropyrene | Tetrachlorodibenzodioxin results in decreased susceptibility to [1-nitropyrene results in increased expression of TP53 protein] | 22044530 |
C032668 | 1-nitropyrene | Tetrachlorodibenzodioxin results in decreased susceptibility to [1-nitropyrene results in increased expression of TP53 protein modified form] | 22044530 |
C032668 | 1-nitropyrene | Tetrachlorodibenzodioxin results in decreased susceptibility to [nutlin 3 results in increased susceptibility to [1-nitropyrene results in increased expression of TP53 protein]] | 22044530 |
C032668 | 1-nitropyrene | Tetrachlorodibenzodioxin results in decreased susceptibility to [nutlin 3 results in increased susceptibility to [1-nitropyrene results in increased expression of TP53 protein modified form]] | 22044530 |
C032668 | 1-nitropyrene | TP53 affects the reaction [1-nitropyrene results in increased expression of BAX mRNA] | 10837373 |
C032668 | 1-nitropyrene | TP53 affects the reaction [1-nitropyrene results in increased expression of MDM2 mRNA] | 10837373 |
C032668 | 1-nitropyrene | TP53 affects the susceptibility to 1-nitropyrene | 10837373 |
C032668 | 1-nitropyrene | 1-nitropyrene affects the expression of TP53 mRNA | 11201684 |
C032668 | 1-nitropyrene | 1-nitropyrene results in increased activity of TP53 protein | 22044530 |
C032668 | 1-nitropyrene | pifithrin results in decreased susceptibility to [1-nitropyrene results in increased activity of TP53 protein] | 22044530 |
C032668 | 1-nitropyrene | Tetrachlorodibenzodioxin results in decreased susceptibility to [1-nitropyrene results in increased activity of TP53 protein] | 22044530 |
C532162 | 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine | 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine results in increased expression of TP53 protein | 22101421 |
C532162 | 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine | [U 0126 co-treated with 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine] results in increased expression of TP53 protein | 22101421 |
C094859 | 2,2',3,3',4,6'-hexachlorobiphenyl | 2,2',3,3',4,6'-hexachlorobiphenyl results in decreased expression of TP53 mRNA | 17445852 |
C094859 | 2,2',3,3',4,6'-hexachlorobiphenyl | 2,2',3,3',4,6'-hexachlorobiphenyl results in increased expression of TP53 mRNA | 17445852 |
C511295 | 2,2',4,4'-tetrabromodiphenyl ether | 2,2',4,4'-tetrabromodiphenyl ether results in increased expression of TP53 mRNA | 27291303 |
C546193 | 2-(2,6-dimethylmorpholin-4-yl)-N-(5-(6-morpholin-4-yl-4-oxo-4H-pyran-2-yl)-9H-thioxanthen-2-yl)acetamide | 2-(2,6-dimethylmorpholin-4-yl)-N-(5-(6-morpholin-4-yl-4-oxo-4H-pyran-2-yl)-9H-thioxanthen-2-yl)acetamide inhibits the reaction [potassium chromate(VI) results in increased expression of TP53 protein modified form] | 25977998 |
C093973 | 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one | 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [bisphenol A results in increased phosphorylation of TP53 protein] | 29383186 |
C093973 | 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one | 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Resveratrol affects the localization of TP53 protein] | 18446786 |
C093973 | 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one | 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Resveratrol promotes the reaction [PTGS2 protein binds to TP53 protein modified form]] | 16928824 |
C093973 | 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one | 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Resveratrol results in increased expression of TP53 mRNA] | 11889192 |
C093973 | 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one | 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Resveratrol results in increased phosphorylation of and results in increased activity of TP53 protein] | 12131363; 18446786; |
C093973 | 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one | 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Resveratrol results in increased phosphorylation of TP53 protein] | 11889192; 16814113; 16928824; 29242151; |
C093973 | 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one | 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one results in increased expression of TP53 protein | 15880691 |
C093973 | 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one | TP53 protein promotes the reaction [2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one results in increased abundance of Reactive Oxygen Species] | 15880691 |
C093973 | 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one | TP53 protein results in increased susceptibility to 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one | 15880691 |
C093973 | 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one | 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Doxorubicin results in increased phosphorylation of TP53 protein] | 18775851 |
C006183 | 2-(2-aminoethyl)pyridine | [Copper binds to Isatin binds to 2-(2-aminoethyl)pyridine] which results in increased expression of TP53 protein | 17327230 |
C046728 | 2,2'-azobis(2-amidinopropane) | 2,2'-azobis(2-amidinopropane) results in increased phosphorylation of TP53 protein | 30555576 |
C046728 | 2,2'-azobis(2-amidinopropane) | 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Caffeine inhibits the reaction [2,2'-azobis(2-amidinopropane) results in increased phosphorylation of TP53 protein]] | 30555576 |
C046728 | 2,2'-azobis(2-amidinopropane) | 3-methyladenine inhibits the reaction [Caffeine inhibits the reaction [2,2'-azobis(2-amidinopropane) results in increased phosphorylation of TP53 protein]] | 30555576 |
C046728 | 2,2'-azobis(2-amidinopropane) | 5-amino-7-(2-phenylethyl)-2-(2-furyl)pyrazolo(4,3-e)-1,2,4-triazolo(1,5-c)pyrimidine inhibits the reaction [2,2'-azobis(2-amidinopropane) results in increased phosphorylation of TP53 protein] | 30555576 |
C046728 | 2,2'-azobis(2-amidinopropane) | Acetylcysteine inhibits the reaction [2,2'-azobis(2-amidinopropane) results in increased phosphorylation of TP53 protein] | 30555576 |
C046728 | 2,2'-azobis(2-amidinopropane) | ADORA2A protein promotes the reaction [2,2'-azobis(2-amidinopropane) results in increased phosphorylation of TP53 protein] | 30555576 |
C046728 | 2,2'-azobis(2-amidinopropane) | Caffeine inhibits the reaction [2,2'-azobis(2-amidinopropane) results in increased phosphorylation of TP53 protein] | 30555576 |
C046728 | 2,2'-azobis(2-amidinopropane) | Sirolimus inhibits the reaction [2,2'-azobis(2-amidinopropane) results in increased phosphorylation of TP53 protein] | 30555576 |
C046728 | 2,2'-azobis(2-amidinopropane) | Sirolimus promotes the reaction [Caffeine inhibits the reaction [2,2'-azobis(2-amidinopropane) results in increased phosphorylation of TP53 protein]] | 30555576 |
C046728 | 2,2'-azobis(2-amidinopropane) | SIRT3 protein promotes the reaction [Caffeine inhibits the reaction [2,2'-azobis(2-amidinopropane) results in increased phosphorylation of TP53 protein]] | 30555576 |
C451219 | 2,2-bis(hydroxymethyl)-1-azabicyclo(2,2,2,)octan-3-one | 2,2-bis(hydroxymethyl)-1-azabicyclo(2,2,2,)octan-3-one inhibits the reaction [TP53 protein mutant form binds to TP73 protein] | 21647879 |
C451219 | 2,2-bis(hydroxymethyl)-1-azabicyclo(2,2,2,)octan-3-one | 2,2-bis(hydroxymethyl)-1-azabicyclo(2,2,2,)octan-3-one promotes the reaction [Cisplatin results in increased localization of TP53 protein mutant form] | 21109480 |
C451219 | 2,2-bis(hydroxymethyl)-1-azabicyclo(2,2,2,)octan-3-one | 2,2-bis(hydroxymethyl)-1-azabicyclo(2,2,2,)octan-3-one promotes the reaction [TP53 protein results in increased susceptibility to Resveratrol] | 23152798 |
C451219 | 2,2-bis(hydroxymethyl)-1-azabicyclo(2,2,2,)octan-3-one | 2,2-bis(hydroxymethyl)-1-azabicyclo(2,2,2,)octan-3-one results in increased activity of TP53 protein | 15860260 |
C451219 | 2,2-bis(hydroxymethyl)-1-azabicyclo(2,2,2,)octan-3-one | 2,2-bis(hydroxymethyl)-1-azabicyclo(2,2,2,)octan-3-one results in increased expression of and results in increased localization of and results in increased activity of TP53 protein mutant form | 21109480 |
C451219 | 2,2-bis(hydroxymethyl)-1-azabicyclo(2,2,2,)octan-3-one | TP53 protein affects the reaction [2,2-bis(hydroxymethyl)-1-azabicyclo(2,2,2,)octan-3-one results in increased expression of BAX mRNA] | 21109480 |
C451219 | 2,2-bis(hydroxymethyl)-1-azabicyclo(2,2,2,)octan-3-one | TP53 protein affects the reaction [2,2-bis(hydroxymethyl)-1-azabicyclo(2,2,2,)octan-3-one results in increased expression of CDKN1A mRNA] | 21109480 |
C451219 | 2,2-bis(hydroxymethyl)-1-azabicyclo(2,2,2,)octan-3-one | TP53 protein mutant form results in increased activity of 2,2-bis(hydroxymethyl)-1-azabicyclo(2,2,2,)octan-3-one | 21647879 |
C451219 | 2,2-bis(hydroxymethyl)-1-azabicyclo(2,2,2,)octan-3-one | 2,2-bis(hydroxymethyl)-1-azabicyclo(2,2,2,)octan-3-one results in increased activity of TP53 protein | 23152798 |
C044565 | 2-((((2-chloroethyl)nitrosoamino)carbonyl)amino)propanamide | 2-((((2-chloroethyl)nitrosoamino)carbonyl)amino)propanamide results in increased expression of TP53 | 16142332 |
C044565 | 2-((((2-chloroethyl)nitrosoamino)carbonyl)amino)propanamide | 2-((((2-chloroethyl)nitrosoamino)carbonyl)amino)propanamide results in increased expression of TP53 protein | 15529313; 15754328; 16857806; |
C044565 | 2-((((2-chloroethyl)nitrosoamino)carbonyl)amino)propanamide | 2-((((2-chloroethyl)nitrosoamino)carbonyl)amino)propanamide results in increased expression of TP53 protein modified form | 16857806 |
C044565 | 2-((((2-chloroethyl)nitrosoamino)carbonyl)amino)propanamide | 2-((((2-chloroethyl)nitrosoamino)carbonyl)amino)propanamide results in increased phosphorylation of TP53 protein | 15529313; 15754328; 16142332; |
C044565 | 2-((((2-chloroethyl)nitrosoamino)carbonyl)amino)propanamide | TP53 protein results in increased susceptibility to 2-((((2-chloroethyl)nitrosoamino)carbonyl)amino)propanamide analog | 16142332 |
C587734 | 2,3,5-trichloro-6-phenyl-(1,4)benzoquinone | 2,3,5-trichloro-6-phenyl-(1,4)benzoquinone promotes the reaction [TP53 protein binds to HMGB1 protein] | 30742880 |
C587734 | 2,3,5-trichloro-6-phenyl-(1,4)benzoquinone | 2,3,5-trichloro-6-phenyl-(1,4)benzoquinone results in increased expression of and affects the localization of TP53 protein | 30742880 |
C587734 | 2,3,5-trichloro-6-phenyl-(1,4)benzoquinone | 2,3,5-trichloro-6-phenyl-(1,4)benzoquinone results in increased expression of TP53 protein | 26451628 |
C587734 | 2,3,5-trichloro-6-phenyl-(1,4)benzoquinone | 2,3,5-trichloro-6-phenyl-(1,4)benzoquinone results in increased expression of TP53 protein modified form | 26451628 |
C587734 | 2,3,5-trichloro-6-phenyl-(1,4)benzoquinone | Acetylcysteine inhibits the reaction [2,3,5-trichloro-6-phenyl-(1,4)benzoquinone results in increased expression of TP53 protein] | 26451628 |
C587734 | 2,3,5-trichloro-6-phenyl-(1,4)benzoquinone | Acetylcysteine inhibits the reaction [2,3,5-trichloro-6-phenyl-(1,4)benzoquinone results in increased expression of TP53 protein modified form] | 26451628 |
C587734 | 2,3,5-trichloro-6-phenyl-(1,4)benzoquinone | TP53 protein affects the reaction [2,3,5-trichloro-6-phenyl-(1,4)benzoquinone affects the expression of DRAM1 protein] | 30742880 |
C587734 | 2,3,5-trichloro-6-phenyl-(1,4)benzoquinone | TP53 protein affects the reaction [2,3,5-trichloro-6-phenyl-(1,4)benzoquinone results in increased expression of BAX protein] | 30742880 |
C587734 | 2,3,5-trichloro-6-phenyl-(1,4)benzoquinone | TP53 protein affects the reaction [2,3,5-trichloro-6-phenyl-(1,4)benzoquinone results in increased expression of ULK1 protein] | 30742880 |
C587734 | 2,3,5-trichloro-6-phenyl-(1,4)benzoquinone | TP53 protein promotes the reaction [2,3,5-trichloro-6-phenyl-(1,4)benzoquinone results in decreased expression of CDK2 protein] | 26451628 |
C587734 | 2,3,5-trichloro-6-phenyl-(1,4)benzoquinone | TP53 protein promotes the reaction [2,3,5-trichloro-6-phenyl-(1,4)benzoquinone results in increased cleavage of CASP3 protein] | 26451628 |
C587734 | 2,3,5-trichloro-6-phenyl-(1,4)benzoquinone | TP53 protein promotes the reaction [2,3,5-trichloro-6-phenyl-(1,4)benzoquinone results in increased expression of CDKN1A protein] | 26451628 |
C587734 | 2,3,5-trichloro-6-phenyl-(1,4)benzoquinone | TP53 protein promotes the reaction [2,3,5-trichloro-6-phenyl-(1,4)benzoquinone results in increased expression of FAS protein] | 26451628 |
C416653 | 2-(3'-methoxyphenyl)-6-pyrrolidinyl-4-quinazolinone | 2-(3'-methoxyphenyl)-6-pyrrolidinyl-4-quinazolinone results in increased expression of and results in increased phosphorylation of TP53 protein | 23523585 |
C416653 | 2-(3'-methoxyphenyl)-6-pyrrolidinyl-4-quinazolinone | 2-(3'-methoxyphenyl)-6-pyrrolidinyl-4-quinazolinone results in increased expression of TP53 mRNA | 23523585 |
C416653 | 2-(3'-methoxyphenyl)-6-pyrrolidinyl-4-quinazolinone | Caffeine inhibits the reaction [2-(3'-methoxyphenyl)-6-pyrrolidinyl-4-quinazolinone results in increased phosphorylation of TP53 protein] | 23523585 |
C416653 | 2-(3'-methoxyphenyl)-6-pyrrolidinyl-4-quinazolinone | TP53 protein results in increased susceptibility to 2-(3'-methoxyphenyl)-6-pyrrolidinyl-4-quinazolinone | 23523585 |
C061282 | 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine | 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Caffeine inhibits the reaction [2,2'-azobis(2-amidinopropane) results in increased phosphorylation of TP53 protein]] | 30555576 |
C081766 | 2,4,4'-trichlorobiphenyl | 2,4,4'-trichlorobiphenyl inhibits the reaction [Etoposide results in increased expression of TP53 protein] | 19751709 |
C081766 | 2,4,4'-trichlorobiphenyl | 2,4,4'-trichlorobiphenyl promotes the reaction [Benzo(a)pyrene results in increased phosphorylation of and results in increased expression of TP53 protein] | 20840854 |
C014024 | 2,4,5,2',4',5'-hexachlorobiphenyl | 2,4,5,2',4',5'-hexachlorobiphenyl promotes the reaction [Benzo(a)pyrene affects the localization of and results in increased expression of TP53 protein] | 24954032 |
C014024 | 2,4,5,2',4',5'-hexachlorobiphenyl | 2,4,5,2',4',5'-hexachlorobiphenyl promotes the reaction [Benzo(a)pyrene results in increased phosphorylation of and results in increased expression of TP53 protein] | 20840854 |
C014024 | 2,4,5,2',4',5'-hexachlorobiphenyl | 2,4,5,2',4',5'-hexachlorobiphenyl promotes the reaction [dibenzo(a,l)pyrene affects the localization of and results in increased expression of TP53 protein] | 24954032 |
C014024 | 2,4,5,2',4',5'-hexachlorobiphenyl | 2,4,5,2',4',5'-hexachlorobiphenyl results in increased activity of TP53 protein | 27589886 |
C014024 | 2,4,5,2',4',5'-hexachlorobiphenyl | Okadaic Acid inhibits the reaction [2,4,5,2',4',5'-hexachlorobiphenyl promotes the reaction [Benzo(a)pyrene affects the localization of TP53 protein]] | 24954032 |
C014024 | 2,4,5,2',4',5'-hexachlorobiphenyl | Okadaic Acid promotes the reaction [2,4,5,2',4',5'-hexachlorobiphenyl promotes the reaction [Benzo(a)pyrene results in increased expression of TP53 protein]] | 24954032 |
C009828 | 2,4,5,2',5'-pentachlorobiphenyl | 2,4,5,2',5'-pentachlorobiphenyl inhibits the reaction [Etoposide results in increased expression of TP53 protein] | 19751709 |
C009828 | 2,4,5,2',5'-pentachlorobiphenyl | 2,4,5,2',5'-pentachlorobiphenyl promotes the reaction [Benzo(a)pyrene affects the localization of TP53 protein] | 20840854 |
C009828 | 2,4,5,2',5'-pentachlorobiphenyl | 2,4,5,2',5'-pentachlorobiphenyl promotes the reaction [Benzo(a)pyrene results in increased phosphorylation of and results in increased expression of TP53 protein] | 20840854 |
C009828 | 2,4,5,2',5'-pentachlorobiphenyl | 2,4,5,2',5'-pentachlorobiphenyl results in decreased expression of TP53 protein | 19751709 |
C529061 | 2-(4,5-dihydro-1,3-thiazol-2-ylthio)-1-(3,4-dihydroxyphenyl)ethanone | 2-(4,5-dihydro-1,3-thiazol-2-ylthio)-1-(3,4-dihydroxyphenyl)ethanone inhibits the reaction [TP53 protein mutant form binds to TP73 protein] | 18424558 |
C529061 | 2-(4,5-dihydro-1,3-thiazol-2-ylthio)-1-(3,4-dihydroxyphenyl)ethanone | TP53 protein mutant form affects the reaction [2-(4,5-dihydro-1,3-thiazol-2-ylthio)-1-(3,4-dihydroxyphenyl)ethanone results in increased expression of BBC3 mRNA] | 18424558 |
C529061 | 2-(4,5-dihydro-1,3-thiazol-2-ylthio)-1-(3,4-dihydroxyphenyl)ethanone | TP53 protein mutant form affects the reaction [2-(4,5-dihydro-1,3-thiazol-2-ylthio)-1-(3,4-dihydroxyphenyl)ethanone results in increased expression of CDKN1A mRNA] | 18424558 |
C529061 | 2-(4,5-dihydro-1,3-thiazol-2-ylthio)-1-(3,4-dihydroxyphenyl)ethanone | TP53 protein mutant form affects the reaction [2-(4,5-dihydro-1,3-thiazol-2-ylthio)-1-(3,4-dihydroxyphenyl)ethanone results in increased expression of TP73 mRNA] | 18424558 |
C024564 | 2,4,6-trichlorophenol | 2,4,6-trichlorophenol results in increased mutagenesis of TP53 gene | 18939895 |
C057349 | 2,4-decadienal | 2,4-decadienal results in decreased expression of TP53 mRNA | 12921975 |
C543150 | 2-(4-((dimethylamino)methyl)benzylidene)-5,6-dimethoxy-2,3-dihydroinden-1-one | 2-(4-((dimethylamino)methyl)benzylidene)-5,6-dimethoxy-2,3-dihydroinden-1-one inhibits the reaction [Hydrogen Peroxide results in increased expression of TP53 protein] | 19345205 |
C016403 | 2,4-dinitrotoluene | 2,4-dinitrotoluene affects the expression of TP53 mRNA | 21346803 |
C085911 | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one | [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one co-treated with cyadox] results in increased expression of TP53 mRNA | 30265530 |
C085911 | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one | [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one co-treated with Hydrogen Peroxide] results in increased expression of TP53 mRNA | 30265530 |
C085911 | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ANGPT1 protein inhibits the reaction [Doxorubicin results in increased expression of TP53 protein]] | 15763944 |
C085911 | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Doxorubicin results in increased expression of TP53 protein] | 20856197 |
C085911 | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Nitric Oxide results in increased phosphorylation of TP53 protein] | 16024610 |
C085911 | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Particulate Matter results in decreased expression of TP53 protein] | 26942697 |
C085911 | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Resveratrol results in increased phosphorylation of TP53 protein] | 17534123 |
C085911 | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [spermine nitric oxide complex results in increased phosphorylation of TP53 protein] | 16024610 |
C085911 | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in increased expression of TP53 protein | 15001399 |
C085911 | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in increased phosphorylation of TP53 protein | 25305377 |
C085911 | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one | TP53 protein promotes the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Doxorubicin results in increased cleavage of CASP3 protein]] | 20856197 |
C085911 | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one | TP53 protein promotes the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Doxorubicin results in increased cleavage of CASP8 protein]] | 20856197 |
C085911 | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one | TP53 protein promotes the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Doxorubicin results in increased cleavage of CASP9 protein]] | 20856197 |
C085911 | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one | TP53 protein promotes the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Doxorubicin results in increased expression of and results in increased activity of BAX protein]] | 20856197 |
C085911 | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one | TP53 protein promotes the reaction [[Doxorubicin co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] results in increased expression of BBC3 protein] | 20856197 |
C085911 | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one | TP53 protein results in increased susceptibility to [Doxorubicin co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] | 20856197 |
C588087 | 2-(5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-(1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid | TP53 protein results in increased susceptibility to 2-(5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-(1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid | 30022047 |
C588087 | 2-(5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-(1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid | [TP53 protein results in increased susceptibility to 2-(5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-(1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid] promotes the reaction [2-(5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-(1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid results in increased expression of CDKN1A protein] | 30022047 |
C117776 | 2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone | 2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone analog results in increased expression of and results in increased cleavage of TP53 protein | 26630137 |
C117776 | 2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone | 2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone analog results in increased expression of TP53 protein modified form | 26630137 |
C117776 | 2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone | 2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one inhibits the reaction [2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone analog results in increased expression of TP53 protein] | 26630137 |
C117776 | 2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone | 2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one inhibits the reaction [2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone analog results in increased expression of TP53 protein modified form] | 26630137 |
C117776 | 2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone | Dicumarol inhibits the reaction [2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone analog results in increased expression of TP53 protein] | 26630137 |
C117776 | 2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone | Dicumarol inhibits the reaction [2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone analog results in increased expression of TP53 protein modified form] | 26630137 |
C117776 | 2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone | pyrazolanthrone inhibits the reaction [2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone analog results in increased expression of TP53 protein] | 26630137 |
C117776 | 2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone | pyrazolanthrone inhibits the reaction [2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone analog results in increased expression of TP53 protein modified form] | 26630137 |
D015086 | 2,6-Dichloroindophenol | [2,6-Dichloroindophenol co-treated with NQO1 protein polymorphism] results in increased phosphorylation of TP53 protein | 21034357 |
C023514 | 2,6-dinitrotoluene | 2,6-dinitrotoluene affects the expression of TP53 mRNA | 21346803 |
D015073 | 2-Acetylaminofluorene | 2-Acetylaminofluorene results in increased expression of TP53 protein | 12888115 |
D015073 | 2-Acetylaminofluorene | 2-Acetylaminofluorene results in decreased expression of TP53 protein | 19167416 |
D015073 | 2-Acetylaminofluorene | 2-Acetylaminofluorene results in increased expression of TP53 protein | 10708481; 15565650; 7728945; |
D015073 | 2-Acetylaminofluorene | [Diethylnitrosamine co-treated with 2-Acetylaminofluorene] affects the expression of and affects the localization of TP53 protein | 11003613 |
D015073 | 2-Acetylaminofluorene | [Diethylnitrosamine co-treated with 2-Acetylaminofluorene] affects the expression of TP53 protein | 11915028 |
D015073 | 2-Acetylaminofluorene | [Diethylnitrosamine co-treated with 2-Acetylaminofluorene] results in decreased expression of TP53 mRNA | 14633663 |
D015073 | 2-Acetylaminofluorene | [Diethylnitrosamine co-treated with 2-Acetylaminofluorene] results in increased expression of TP53 protein | 23665045 |
D015073 | 2-Acetylaminofluorene | Diosmin inhibits the reaction [[Diethylnitrosamine co-treated with 2-Acetylaminofluorene] results in increased expression of TP53 protein] | 23665045 |
D015073 | 2-Acetylaminofluorene | IFNA2 protein affects the reaction [[Diethylnitrosamine co-treated with 2-Acetylaminofluorene] affects the expression of TP53 protein] | 11915028 |
D015073 | 2-Acetylaminofluorene | Vanadium promotes the reaction [2-Acetylaminofluorene results in increased expression of TP53 protein] | 15565650 |
C049584 | 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine | 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of TP53 protein | 11425520; 15635149; 17156947; 23810796; |
C036990 | 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline | 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased expression of TP53 protein | 23810796 |
C036990 | 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline | 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased mutagenesis of TP53 gene | 8844820 |
C546460 | 2-amino-3-methyl-3H-imidazo(4,5-f)quinoline | 2-amino-3-methyl-3H-imidazo(4,5-f)quinoline results in increased expression of TP53 mRNA | 23810796 |
C546460 | 2-amino-3-methyl-3H-imidazo(4,5-f)quinoline | 2-amino-3-methyl-3H-imidazo(4,5-f)quinoline results in increased expression of TP53 protein | 23810796 |
C035208 | 2-amino-4,6-dinitrotoluene | 2-amino-4,6-dinitrotoluene results in increased activity of TP53 protein | 14577614 |
C035208 | 2-amino-4,6-dinitrotoluene | 2-amino-4,6-dinitrotoluene results in increased expression of TP53 protein | 14577614 |
C012177 | 2-aminofluorene | 2-aminofluorene results in increased expression of TP53 protein | 9163691 |
C012796 | 2-butenal | 2-butenal results in increased expression of TP53 protein | 23535401 |
C437043 | 2-butylamino-2-demethoxy-hypocrellin B | 2-butylamino-2-demethoxy-hypocrellin B results in increased expression of TP53 mRNA | 17045927 |
C437043 | 2-butylamino-2-demethoxy-hypocrellin B | 2-phenyl-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide inhibits the reaction [2-butylamino-2-demethoxy-hypocrellin B results in increased expression of TP53 mRNA] | 17045927 |
C437043 | 2-butylamino-2-demethoxy-hypocrellin B | Sodium Azide inhibits the reaction [2-butylamino-2-demethoxy-hypocrellin B results in increased expression of TP53 mRNA] | 17045927 |
C031278 | 2-chloroethyl ethyl sulfide | 2-chloroethyl ethyl sulfide results in increased expression of TP53 protein | 19111594 |
C031278 | 2-chloroethyl ethyl sulfide | 2-chloroethyl ethyl sulfide results in increased phosphorylation of TP53 protein | 19111594 |
C031278 | 2-chloroethyl ethyl sulfide | 2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one inhibits the reaction [2-chloroethyl ethyl sulfide results in increased phosphorylation of TP53 protein] | 19111594 |
C031278 | 2-chloroethyl ethyl sulfide | ATM protein affects the reaction [2-chloroethyl ethyl sulfide results in increased phosphorylation of TP53 protein] | 19111594 |
C031278 | 2-chloroethyl ethyl sulfide | ATR protein affects the reaction [2-chloroethyl ethyl sulfide results in increased phosphorylation of TP53 protein] | 19111594 |
C031278 | 2-chloroethyl ethyl sulfide | Wortmannin inhibits the reaction [2-chloroethyl ethyl sulfide results in increased phosphorylation of TP53 protein] | 19111594 |
C070279 | 2'-cyano-2'-deoxyarabinofuranosylcytosine | 2'-cyano-2'-deoxyarabinofuranosylcytosine results in increased phosphorylation of TP53 protein | 16061671 |
C018535 | 2-ethylhexyldiphenylphosphate | 2-ethylhexyldiphenylphosphate results in increased expression of TP53 mRNA | 30981936 |
C120275 | 2-hydroxy-1-naphthylaldehyde isonicotinoyl hydrazone | 2-hydroxy-1-naphthylaldehyde isonicotinoyl hydrazone results in increased expression of and affects the localization of and results in increased activity of TP53 protein | 12869419 |
C120275 | 2-hydroxy-1-naphthylaldehyde isonicotinoyl hydrazone | 2-hydroxy-1-naphthylaldehyde isonicotinoyl hydrazone results in increased expression of and affects the localization of TP53 protein | 12807743 |
C576975 | 2-hydroxy-3',5,5'-trimethoxychalcone | 2-hydroxy-3',5,5'-trimethoxychalcone results in increased expression of TP53 protein | 30408460 |
C576975 | 2-hydroxy-3',5,5'-trimethoxychalcone | Acetylcysteine inhibits the reaction [2-hydroxy-3',5,5'-trimethoxychalcone results in increased expression of TP53 protein] | 30408460 |
C031319 | 2-hydroxyethyl disulfide | TP53 protein affects the susceptibility to 2-hydroxyethyl disulfide | 22926048 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of ADAMTS10 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of ALKBH5 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of ANAPC7 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of ANLN mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of AP1B1 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of AP3S2 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of ARVCF mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of ASF1A mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of ATG9A mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of BICC1 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of C16ORF72 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of C3ORF80 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of C5ORF51 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of CDH24 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of CEP57 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of CHD2 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of CKAP4 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of CNN2 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of COLGALT1 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of CPTP mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of CYP4X1 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of DCAF7 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of DDX54 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of DENND1B mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of DFFA mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of DLG4 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of DNAJC21 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of DOHH mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of DR1 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of EIF1B mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of EIF1 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of EVA1B mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of FAM161A mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of FBXL4 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of FBXO45 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of FCHO1 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of FKSG49 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of FOXC1 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of FTL mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of GABPB1-AS1 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of GOLGA2 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of GPBP1L1 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of GPX8 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of GRIN2A mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of HECTD4 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of HMCN2 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of IL34 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of JMJD6 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of KDELR2 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of KMT2E-AS1 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of LACC1 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of LINC00869 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of LRCH4 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of MAFG mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of MDN1 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of MFHAS1 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of MRPS10 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of NISCH mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of NOL10 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of OTUD5 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of OXER1 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of PER3 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of PIAS2 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of PLA2G4F mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of PLEKHA4 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of PMEPA1 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of PRPF4 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of PRRC2A mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of PSMA3-AS1 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of RAD23A mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of RAD23B mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of RARRES2 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of RBM41 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of RETREG2 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of RFLNB mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of RNF26 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of SCOC mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of SHISA4 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of SLC1A4 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of SLC66A3 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of SLC7A1 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of SPAG16 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of SPCS3 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of SPIN3 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of SPINDOC mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of SPRED3 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of SSBP4 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of SSU72 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of TDRKH mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of TLE4 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of TLNRD1 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of TMCC1 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of TMEM119 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of TMEM67 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of TMEM97 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of TPBG mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of TRIM5 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of TTTY14 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of UBE2QL1 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of UBQLN2 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of VOPP1 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of WAPL mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of WDYHV1 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of WIPF2 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of WSB1 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of XPOT mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of ZBTB21 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of ZKSCAN7 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of ZNF444 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of ZNF473 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one affects the expression of ZNF503 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one results in decreased expression of AKAP9 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one results in decreased expression of PTCH1 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one results in increased expression of AATF mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one results in increased expression of and results in increased cleavage of XBP1 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one results in increased expression of BAX mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one results in increased expression of CARD10 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one results in increased expression of CD81 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one results in increased expression of EIF5 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one results in increased expression of FZD7 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one results in increased expression of GADD45B mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one results in increased expression of GP1BB mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one results in increased expression of IGFBP7 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one results in increased expression of LIMK2 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one results in increased expression of MAP4 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one results in increased expression of MAPK1 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one results in increased expression of MCL1 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one results in increased expression of PDS5A mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one results in increased expression of PEA15 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one results in increased expression of PMAIP1 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one results in increased expression of PMAIP1 protein] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one results in increased expression of RANGAP1 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one results in increased expression of SCNN1A mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one results in increased expression of SHISA5 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one results in increased expression of SLC7A5 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one results in increased expression of STK11 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one results in increased expression of VCL mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one results in increased expression of VEGFA mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one results in increased expression of YWHAG mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one results in increased expression of YWHAG protein] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the reaction [2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one results in increased expression of YY1 mRNA] | 19946333 |
C533410 | 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | TP53 protein affects the susceptibility to 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | 19946333 |
C511621 | 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide | 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide results in decreased susceptibility to [Tetrachlorodibenzodioxin results in decreased susceptibility to [1-nitropyrene results in increased expression of TP53 protein]] | 22044530 |
C011506 | 2-methyl-4-isothiazolin-3-one | 2-methyl-4-isothiazolin-3-one results in increased expression of TP53 protein modified form | 29110394 |
C109834 | 2-methylphenanthrene | 2-methylphenanthrene results in increased phosphorylation of TP53 protein | 17941746 |
C495818 | 2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one | 2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one inhibits the reaction [2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone analog results in increased expression of TP53 protein] | 26630137 |
C495818 | 2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one | 2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one inhibits the reaction [2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone analog results in increased expression of TP53 protein modified form] | 26630137 |
C495818 | 2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one | 2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one inhibits the reaction [2-chloroethyl ethyl sulfide results in increased phosphorylation of TP53 protein] | 19111594 |
C495818 | 2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one | 2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one inhibits the reaction [Bleomycin promotes the reaction [Resveratrol results in increased phosphorylation of TP53 protein]] | 24933654 |
C495818 | 2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one | 2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one inhibits the reaction [Bleomycin results in increased phosphorylation of TP53 protein] | 24933654 |
C495818 | 2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one | 2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one inhibits the reaction [Capsaicin results in increased phosphorylation of and results in increased activity of TP53 protein] | 22226932 |
C495818 | 2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one | 2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one inhibits the reaction [Capsaicin results in increased phosphorylation of and results in increased expression of TP53 protein] | 19502594 |
C495818 | 2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one | 2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one inhibits the reaction [Clioquinol results in increased phosphorylation of TP53 protein] | 22627294 |
C495818 | 2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one | 2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one inhibits the reaction [Doxorubicin results in increased expression of TP53 protein] | 22927544 |
C495818 | 2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one | 2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one inhibits the reaction [Hydrogen Peroxide promotes the reaction [Resveratrol results in increased phosphorylation of TP53 protein]] | 24933654 |
C495818 | 2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one | 2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one inhibits the reaction [Mustard Gas results in increased expression of TP53 protein] | 22119920 |
C495818 | 2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one | 2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one inhibits the reaction [Mustard Gas results in increased phosphorylation of TP53 protein] | 22119920 |
C495818 | 2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one | 2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one inhibits the reaction [potassium chromate(VI) results in increased expression of TP53 protein modified form] | 25977998 |
C495818 | 2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one | 2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one inhibits the reaction [Resveratrol promotes the reaction [Bleomycin results in increased phosphorylation of TP53 protein]] | 24933654 |
C495818 | 2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one | 2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one inhibits the reaction [Resveratrol promotes the reaction [Hydrogen Peroxide results in increased phosphorylation of TP53 protein]] | 24933654 |
C495818 | 2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one | 2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one results in decreased phosphorylation of TP53 protein | 22119920 |
C495818 | 2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one | 2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one inhibits the reaction [Arsenic Trioxide results in increased phosphorylation of TP53 protein] | 23337567 |
D015081 | 2-Naphthylamine | 2-Naphthylamine results in decreased expression of TP53 mRNA | 18247414 |
C079391 | 2-phenyl-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide | 2-phenyl-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide inhibits the reaction [2-butylamino-2-demethoxy-hypocrellin B results in increased expression of TP53 mRNA] | 17045927 |
C004369 | 2-phenylphenol | [2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of TP53 gene | 10334203 |
C004369 | 2-phenylphenol | bathocuproine inhibits the reaction [[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of TP53 gene] | 10334203 |
C004369 | 2-phenylphenol | CAT protein inhibits the reaction [[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of TP53 gene] | 10334203 |
C041525 | 3,3',4,5'-tetrahydroxystilbene | 3,3',4,5'-tetrahydroxystilbene results in increased expression of TP53 protein | 26341291 |
C041525 | 3,3',4,5'-tetrahydroxystilbene | 3,3',4,5'-tetrahydroxystilbene results in increased expression of TP53 protein modified form | 26341291 |
C016392 | 3,3'-diindolylmethane | 3,3'-diindolylmethane results in increased expression of and results in increased phosphorylation of and results in increased activity of TP53 protein | 22290291 |
C016392 | 3,3'-diindolylmethane | [3,3'-diindolylmethane results in increased phosphorylation of and results in increased activity of TP53 protein] which results in increased expression of BBC3 | 22290291 |
C016392 | 3,3'-diindolylmethane | [3,3'-diindolylmethane results in increased phosphorylation of and results in increased activity of TP53 protein] which results in increased expression of PMAIP1 | 22290291 |
C016392 | 3,3'-diindolylmethane | Wortmannin inhibits the reaction [3,3'-diindolylmethane results in increased phosphorylation of TP53 protein] | 22290291 |
C023035 | 3,4,5,3',4'-pentachlorobiphenyl | 3,4,5,3',4'-pentachlorobiphenyl inhibits the reaction [Benzo(a)pyrene affects the localization of TP53 protein] | 20840854 |
C023035 | 3,4,5,3',4'-pentachlorobiphenyl | 3,4,5,3',4'-pentachlorobiphenyl inhibits the reaction [Benzo(a)pyrene results in increased phosphorylation of and results in increased expression of TP53 protein] | 20840854 |
C023035 | 3,4,5,3',4'-pentachlorobiphenyl | 3,4,5,3',4'-pentachlorobiphenyl inhibits the reaction [Etoposide results in increased expression of TP53 protein] | 19751709 |
C023035 | 3,4,5,3',4'-pentachlorobiphenyl | 3,4,5,3',4'-pentachlorobiphenyl inhibits the reaction [leptomycin B results in increased expression of TP53 protein] | 19751709 |
C023035 | 3,4,5,3',4'-pentachlorobiphenyl | 3,4,5,3',4'-pentachlorobiphenyl results in decreased expression of TP53 mRNA | 21703328 |
C023035 | 3,4,5,3',4'-pentachlorobiphenyl | 3,4,5,3',4'-pentachlorobiphenyl results in decreased expression of TP53 protein | 19751709 |
C422863 | 3,4,5,4'-tetrahydroxystilbene | 3,4,5,4'-tetrahydroxystilbene results in increased activity of TP53 protein | 11181455 |
C422863 | 3,4,5,4'-tetrahydroxystilbene | [3,4,5,4'-tetrahydroxystilbene results in increased activity of TP53 protein] which results in increased expression of BAX mRNA | 11181455 |
C422863 | 3,4,5,4'-tetrahydroxystilbene | 3,4,5,4'-tetrahydroxystilbene results in increased expression of TP53 mRNA | 11181455 |
C422863 | 3,4,5,4'-tetrahydroxystilbene | 3,4,5,4'-tetrahydroxystilbene results in increased expression of TP53 protein | 11181455 |
C482492 | 3,4,5,4'-tetramethoxystilbene | 3,4,5,4'-tetramethoxystilbene affects the expression of TP53 protein | 15668717 |
C482492 | 3,4,5,4'-tetramethoxystilbene | 3,4,5,4'-tetramethoxystilbene results in increased expression of TP53 mRNA | 22687606; 24055891; |
C061213 | 3',4',7-trihydroxyisoflavone | 3',4',7-trihydroxyisoflavone promotes the reaction [Epirubicin results in increased expression of TP53 mRNA] | 22914566 |
C061213 | 3',4',7-trihydroxyisoflavone | 3',4',7-trihydroxyisoflavone results in increased expression of TP53 mRNA | 22914566 |
C061213 | 3',4',7-trihydroxyisoflavone | Epirubicin promotes the reaction [3',4',7-trihydroxyisoflavone results in increased expression of TP53 mRNA] | 22914566 |
C045421 | 3,4,8-trimethylimidazo(4,5-f)quinoxalin-2-amine | 3,4,8-trimethylimidazo(4,5-f)quinoxalin-2-amine results in decreased expression of TP53 mRNA | 23810796 |
C045421 | 3,4,8-trimethylimidazo(4,5-f)quinoxalin-2-amine | 3,4,8-trimethylimidazo(4,5-f)quinoxalin-2-amine results in increased expression of TP53 protein | 23810796 |
C501634 | 3-(4-chlorophenyl)-3-(4-hydroxy-3,5-dimethoxybenzyloxy)-2-propyl-2,3-dihydroisoindol-1-one | 3-(4-chlorophenyl)-3-(4-hydroxy-3,5-dimethoxybenzyloxy)-2-propyl-2,3-dihydroisoindol-1-one results in decreased activity of [MDM2 protein binds to TP53 protein] | 21314128 |
C478100 | 3,4-di-O-caffeoylquinic acid | 3,4-di-O-caffeoylquinic acid results in decreased expression of TP53 protein | 21872580 |
C472791 | 3-(4'-hydroxy-3'-adamantylbiphenyl-4-yl)acrylic acid | 3-(4'-hydroxy-3'-adamantylbiphenyl-4-yl)acrylic acid analog results in increased phosphorylation of TP53 protein | 17512204 |
C434003 | 3-(4-methylphenylsulfonyl)-2-propenenitrile | 3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [sodium arsenite results in decreased phosphorylation of TP53 protein] | 22706169 |
C434003 | 3-(4-methylphenylsulfonyl)-2-propenenitrile | 3-(4-methylphenylsulfonyl)-2-propenenitrile promotes the reaction [arsenite promotes the reaction [TP53 protein binds to CREBBP protein]] | 20199942 |
C434003 | 3-(4-methylphenylsulfonyl)-2-propenenitrile | 3-(4-methylphenylsulfonyl)-2-propenenitrile promotes the reaction [sodium arsenite affects the localization of TP53 protein] | 20375080 |
C434003 | 3-(4-methylphenylsulfonyl)-2-propenenitrile | 3-(4-methylphenylsulfonyl)-2-propenenitrile promotes the reaction [sodium arsenite results in increased phosphorylation of TP53 protein] | 20375080 |
C434003 | 3-(4-methylphenylsulfonyl)-2-propenenitrile | HSPA9 protein promotes the reaction [3-(4-methylphenylsulfonyl)-2-propenenitrile promotes the reaction [arsenite promotes the reaction [TP53 protein binds to CREBBP protein]]] | 20199942 |
C553472 | 3-(4-methylpiperazin)-8-oxo-8H-acenaphtho(1,2-b)pyrrole-9-carbonitrile | 3-(4-methylpiperazin)-8-oxo-8H-acenaphtho(1,2-b)pyrrole-9-carbonitrile results in increased phosphorylation of and results in increased expression of and results in increased activity of TP53 protein | 19182866 |
C494914 | 3,5,3',4',5'-pentamethoxystilbene | 3,5,3',4',5'-pentamethoxystilbene results in increased expression of TP53 protein | 19916542 |
C090937 | 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole | 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole promotes the reaction [Camptothecin results in increased expression of TP53 protein] | 19481069 |
C090937 | 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole | 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole results in increased expression of TP53 protein | 19481069 |
C034534 | 3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid | 3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid promotes the reaction [(5-fluoro-2-methyl-1-(4-pyridyl)methylene-3-(N-benzyl)-indene)-acetamide hydrochloride results in increased expression of TP53 protein] | 15475462 |
C025160 | 3-aminobenzamide | 3-aminobenzamide inhibits the reaction [Capsaicin results in increased expression of TP53 protein] | 22226932 |
C025160 | 3-aminobenzamide | 3-aminobenzamide inhibits the reaction [Capsaicin results in increased phosphorylation of and results in increased activity of TP53 protein] | 22226932 |
C479067 | 3-aminothioacridone | 3-aminothioacridone results in increased phosphorylation of and results in increased expression of TP53 protein | 15724842 |
C054121 | 3-chloro-4-(dichloromethyl)-5-hydroxy-2(5H)-furanone | 3-chloro-4-(dichloromethyl)-5-hydroxy-2(5H)-furanone results in increased mutagenesis of TP53 gene | 11152562 |
D020155 | 3-Hydroxybutyric Acid | 3-Hydroxybutyric Acid inhibits the reaction [ERCC6 gene mutant form results in increased acetylation of TP53 protein] | 25440059 |
C091768 | 3'-methoxy-4'-nitroflavone | 3'-methoxy-4'-nitroflavone inhibits the reaction [Dioxins results in decreased expression of TP53 mRNA] | 15111621 |
C091768 | 3'-methoxy-4'-nitroflavone | 3'-methoxy-4'-nitroflavone inhibits the reaction [Dioxins results in decreased expression of TP53 protein] | 15111621 |
C091768 | 3'-methoxy-4'-nitroflavone | 3'-methoxy-4'-nitroflavone inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of TP53 mRNA] | 17070097 |
C091768 | 3'-methoxy-4'-nitroflavone | 3'-methoxy-4'-nitroflavone inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of TP53 protein] | 17070097 |
C091768 | 3'-methoxy-4'-nitroflavone | 3'-methoxy-4'-nitroflavone inhibits the reaction [Tobacco Smoke Pollution results in decreased expression of TP53 mRNA] | 17070097 |
C091768 | 3'-methoxy-4'-nitroflavone | 3'-methoxy-4'-nitroflavone inhibits the reaction [Tobacco Smoke Pollution results in decreased expression of TP53 protein] | 17070097 |
C025946 | 3-methyladenine | [3-methyladenine co-treated with cobaltous chloride co-treated with TP53 gene mutant form] results in increased activity of CASP3 protein | 23380477 |
C025946 | 3-methyladenine | 3-methyladenine inhibits the reaction [Caffeine inhibits the reaction [2,2'-azobis(2-amidinopropane) results in increased phosphorylation of TP53 protein]] | 30555576 |
C025946 | 3-methyladenine | 3-methyladenine inhibits the reaction [[cobaltous chloride co-treated with TP53 gene mutant form] results in increased activity of CTSB protein] | 23380477 |
C025946 | 3-methyladenine | 3-methyladenine inhibits the reaction [Doxorubicin results in increased expression of TP53 protein] | 22927544 |
C117220 | 3-nitrobenzanthrone | 3-nitrobenzanthrone results in increased mutagenesis of TP53 gene | 18765419 |
C000614725 | 3'-oxomethylisoeugenol | 3'-oxomethylisoeugenol results in increased phosphorylation of TP53 protein | 28818686 |
D017878 | 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid | 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid inhibits the reaction [Oxygen deficiency results in increased expression of TP53 protein] | 10951577 |
C090942 | 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole | 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in increased expression of TP53 protein] | 18085531 |
C090942 | 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole | 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [potassium bromate results in increased phosphorylation of TP53 protein] | 20067818 |
C090942 | 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole | 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole results in decreased phosphorylation of TP53 protein | 25305377 |
C580935 | 4-((4-hydroxyphenylimino)methyl)benzene-1,2-diol | 4-((4-hydroxyphenylimino)methyl)benzene-1,2-diol results in increased expression of TP53 protein | 25242450 |
C119130 | 4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide | 4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide inhibits the reaction [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in decreased expression of TP53 protein] | 18805435 |
C119130 | 4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide | 4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide inhibits the reaction [Nicotine results in decreased expression of TP53 protein] | 18805435 |
C035207 | 4-amino-2,6-dinitrotoluene | 4-amino-2,6-dinitrotoluene affects the expression of TP53 mRNA | 21346803 |
C494356 | 4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione | 4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione results in increased phosphorylation of TP53 protein | 24824809 |
C006757 | 4-biphenylamine | 4-biphenylamine binds to TP53 gene | 12376482 |
C006757 | 4-biphenylamine | TP53 protein affects the susceptibility to 4-biphenylamine | 11804609 |
C004658 | 4-chloroaniline | 4-chloroaniline affects the expression of TP53 mRNA | 27825931 |
C027576 | 4-hydroxy-2-nonenal | 4-hydroxy-2-nonenal results in increased expression of TP53 mRNA | 15607904 |
C027576 | 4-hydroxy-2-nonenal | 4-hydroxy-2-nonenal results in increased expression of TP53 protein | 15607904 |
C027576 | 4-hydroxy-2-nonenal | 4-hydroxy-2-nonenal results in increased mutagenesis of TP53 gene | 11050162 |
C065250 | 4-hydroxy-equilenin | 4-hydroxy-equilenin results in decreased expression of TP53 mRNA | 15135645 |
C498826 | 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide | 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased secretion of TP53 protein | 29370077 |
C024836 | 4-nitrophenol | TP53 protein affects the glucuronidation of 4-nitrophenol | 11695553 |
D015112 | 4-Nitroquinoline-1-oxide | 4-Nitroquinoline-1-oxide results in decreased expression of TP53 protein | 20599846 |
C016583 | 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone | 4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide inhibits the reaction [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in decreased expression of TP53 protein] | 18805435 |
C016583 | 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone | 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone affects the localization of TP53 protein | 19931552; 20421341; |
C016583 | 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone | 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone inhibits the reaction [sodium arsenite affects the localization of TP53 protein] | 19931552 |
C016583 | 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone | 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone inhibits the reaction [sodium arsenite results in increased activity of TP53 protein] | 19931552 |
C016583 | 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone | 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in decreased expression of TP53 protein | 18805435 |
C016583 | 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone | 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased ADP-ribosylation of TP53 protein | 20421341 |
C016583 | 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone | 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased expression of TP53 protein | 19931552; 21776270; 26231820; |
C016583 | 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone | 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased phosphorylation of TP53 protein | 20421341 |
C016583 | 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone | [beta Carotene co-treated with alpha-Tocopherol co-treated with Ascorbic Acid] inhibits the reaction [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased expression of TP53 protein] | 16401635 |
C016583 | 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone | [beta Carotene co-treated with alpha-Tocopherol co-treated with Ascorbic Acid] inhibits the reaction [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased phosphorylation of TP53 protein] | 16401635 |
C041594 | 4-nonylphenol | 4-nonylphenol results in increased expression of TP53 mRNA | 27087316; 27109770; |
C041594 | 4-nonylphenol | 4-nonylphenol results in increased expression of TP53 protein | 27087316; 27109770; |
C041594 | 4-nonylphenol | 4-nonylphenol results in increased expression of TP53 mRNA | 20060579 |
C080417 | 4-octylphenol | 4-octylphenol results in increased expression of TP53 mRNA | 20060579 |
C494898 | 4-oxofenretinide | 4-oxofenretinide results in increased expression of TP53 protein | 16540676 |
C075773 | 4-phenylbutyric acid | 4-phenylbutyric acid inhibits the reaction [Streptozocin results in increased expression of TP53 protein] | 30980806 |
C105260 | 4-tert-octylphenol | 4-tert-octylphenol affects the expression of TP53 mRNA | 17950039 |
C105260 | 4-tert-octylphenol | 4-tert-octylphenol results in increased expression of TP53 mRNA | 17011747 |
C573233 | 5,7-dihydroxy-2-methyl-8-(4-(3-hydroxy-1-methyl)-piperidinyl)-4H-1-benzopyran-4-one | 5,7-dihydroxy-2-methyl-8-(4-(3-hydroxy-1-methyl)-piperidinyl)-4H-1-benzopyran-4-one results in increased expression of TP53 protein | 26405812 |
C080669 | 5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one | 5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one results in increased expression of TP53 protein modified form | 23470866 |
C080669 | 5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one | diacetyldiphenylurea bisguanylhydrazone inhibits the reaction [5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one results in increased expression of TP53 protein modified form] | 23470866 |
C060298 | 5,7-dimethoxyflavone | [5,7-dimethoxyflavone co-treated with Diethylnitrosamine] results in increased expression of TP53 mRNA | 21554863 |
C060298 | 5,7-dimethoxyflavone | [5,7-dimethoxyflavone co-treated with Diethylnitrosamine] results in increased expression of TP53 protein | 21554863 |
C098657 | 5-amino-7-(2-phenylethyl)-2-(2-furyl)pyrazolo(4,3-e)-1,2,4-triazolo(1,5-c)pyrimidine | 5-amino-7-(2-phenylethyl)-2-(2-furyl)pyrazolo(4,3-e)-1,2,4-triazolo(1,5-c)pyrimidine inhibits the reaction [2,2'-azobis(2-amidinopropane) results in increased phosphorylation of TP53 protein] | 30555576 |
C439285 | (5-fluoro-2-methyl-1-(4-pyridyl)methylene-3-(N-benzyl)-indene)-acetamide hydrochloride | 3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid promotes the reaction [(5-fluoro-2-methyl-1-(4-pyridyl)methylene-3-(N-benzyl)-indene)-acetamide hydrochloride results in increased expression of TP53 protein] | 15475462 |
C439285 | (5-fluoro-2-methyl-1-(4-pyridyl)methylene-3-(N-benzyl)-indene)-acetamide hydrochloride | (5-fluoro-2-methyl-1-(4-pyridyl)methylene-3-(N-benzyl)-indene)-acetamide hydrochloride results in increased expression of TP53 protein | 15475462 |
C058722 | 5-hydroxy-6,8,11,14,17-eicosapentaenoic acid | 5-hydroxy-6,8,11,14,17-eicosapentaenoic acid affects the expression of TP53 mRNA | 26984781 |
D000078223 | 5-Methoxypsoralen | 5-Methoxypsoralen results in increased expression of and results in increased phosphorylation of TP53 protein | 30576070 |
C471843 | 6-((3-chloro)anilino)-2-(isopropyl-2-hydroxyethylamino)-9-isopropylpurine | 6-((3-chloro)anilino)-2-(isopropyl-2-hydroxyethylamino)-9-isopropylpurine results in increased expression of TP53 protein | 15958644 |
C573097 | 64Cu-CB-TE2A-Y3-TATE | TP53 protein affects the localization of 64Cu-CB-TE2A-Y3-TATE | 22056254 |
C573096 | 64Cu-DOTA-Y3-TATE | TP53 protein affects the localization of 64Cu-DOTA-Y3-TATE | 22056254 |
C485383 | 6,7-dihydroxyflavone | 6,7-dihydroxyflavone results in increased degradation of TP53 protein | 14634213 |
C000595015 | 6,7-dimethoxy-2-(pyrrolidin-1-yl)-N-(5-(pyrrolidin-1-yl)pentyl)quinazolin-4-amine | 6,7-dimethoxy-2-(pyrrolidin-1-yl)-N-(5-(pyrrolidin-1-yl)pentyl)quinazolin-4-amine results in decreased methylation of TP53 protein | 28073004 |
C000595015 | 6,7-dimethoxy-2-(pyrrolidin-1-yl)-N-(5-(pyrrolidin-1-yl)pentyl)quinazolin-4-amine | 6,7-dimethoxy-2-(pyrrolidin-1-yl)-N-(5-(pyrrolidin-1-yl)pentyl)quinazolin-4-amine results in increased expression of and results in decreased methylation of TP53 protein | 28073004 |
C000595015 | 6,7-dimethoxy-2-(pyrrolidin-1-yl)-N-(5-(pyrrolidin-1-yl)pentyl)quinazolin-4-amine | TP53 protein results in increased susceptibility to 6,7-dimethoxy-2-(pyrrolidin-1-yl)-N-(5-(pyrrolidin-1-yl)pentyl)quinazolin-4-amine | 28073004 |
C560597 | 6,7-epoxy-5,17-dihydroxy-1-oxowitha-2,24-dienolide | 6,7-epoxy-5,17-dihydroxy-1-oxowitha-2,24-dienolide inhibits the reaction [HSPA9 protein binds to TP53 protein] | 22155302 |
C560597 | 6,7-epoxy-5,17-dihydroxy-1-oxowitha-2,24-dienolide | [6,7-epoxy-5,17-dihydroxy-1-oxowitha-2,24-dienolide inhibits the reaction [HSPA9 protein binds to TP53 protein]] which affects the localization of and results in increased activity of TP53 protein | 22155302 |
C560597 | 6,7-epoxy-5,17-dihydroxy-1-oxowitha-2,24-dienolide | 6,7-epoxy-5,17-dihydroxy-1-oxowitha-2,24-dienolide inhibits the reaction [methoxyacetic acid results in increased expression of TP53 protein] | 21573189 |
C560597 | 6,7-epoxy-5,17-dihydroxy-1-oxowitha-2,24-dienolide | 6,7-epoxy-5,17-dihydroxy-1-oxowitha-2,24-dienolide results in increased expression of TP53 mRNA | 22973447 |
C550547 | 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide | 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide results in increased acetylation of TP53 protein | 24726431; 29545174; |
C550547 | 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide | Camptothecin inhibits the reaction [6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide results in increased acetylation of TP53 protein] | 24726431 |
C580599 | 6-OH-BDE-47 | 6-OH-BDE-47 results in decreased expression of TP53 mRNA | 29601929 |
C114369 | 7,8-diacetoxy-4-methylcoumarin | 7,8-diacetoxy-4-methylcoumarin results in increased expression of TP53 protein | 19061872 |
C540361 | 7,8-diacetoxy-4-methylthiocoumarin | 7,8-diacetoxy-4-methylthiocoumarin results in increased expression of TP53 protein | 19061872 |
D015123 | 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide | 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in increased expression of TP53 protein] | 18085531 |
D015123 | 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide | 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide binds to TP53 gene | 12727806 |
D015123 | 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide | 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in increased expression of and results in increased phosphorylation of and results in increased localization of and results in increased activity of TP53 protein | 18085531 |
D015123 | 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide | 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in increased expression of and results in increased phosphorylation of TP53 protein | 21983885 |
D015123 | 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide | 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in increased expression of TP53 mRNA | 19150397 |
D015123 | 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide | 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in increased expression of TP53 protein | 11782367; 20382639; |
D015123 | 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide | 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in increased phosphorylation of TP53 protein | 20382639 |
D015123 | 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide | monomethylarsonous acid inhibits the reaction [7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in increased expression of and results in increased phosphorylation of and results in increased localization of and results in increased activity of TP53 protein] | 18085531 |
D015123 | 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide | potassium chromate(VI) promotes the reaction [7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide binds to TP53 gene] | 12727806 |
D015123 | 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide | TP53 protein affects the reaction [7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in increased cleavage of CASP7 protein] | 21983885 |
D015123 | 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide | TP53 protein affects the reaction [7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in increased cleavage of CASP9 protein] | 21983885 |
D015123 | 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide | TP53 protein affects the reaction [7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in increased expression of TP53 protein] | 21983885 |
D015123 | 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide | TP53 protein affects the susceptibility to 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide | 21983885 |
D015123 | 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide | TP53 protein promotes the reaction [7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in decreased expression of BRCA1 mRNA] | 11782367 |
D015123 | 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide | TP53 protein promotes the reaction [7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in decreased expression of BRCA1 protein] | 11782367 |
D015123 | 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide | 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in increased mutagenesis of TP53 gene | 21428456 |
C553817 | 7-(benzylamino)-1,3,4,8-tetrahydropyrrolo(4,3,2-de)quinolin-8(1H)-one | 7-(benzylamino)-1,3,4,8-tetrahydropyrrolo(4,3,2-de)quinolin-8(1H)-one results in increased expression of TP53 mRNA | 19936915 |
C553817 | 7-(benzylamino)-1,3,4,8-tetrahydropyrrolo(4,3,2-de)quinolin-8(1H)-one | 7-(benzylamino)-1,3,4,8-tetrahydropyrrolo(4,3,2-de)quinolin-8(1H)-one results in increased expression of TP53 protein | 19936915 |
C559145 | 7-benzylamino-5-(2-(hydroxymethyl)propyl)amino-3-isopropyl-1(2)H-pyrazolo(4,3-d)pyrimidine | 7-benzylamino-5-(2-(hydroxymethyl)propyl)amino-3-isopropyl-1(2)H-pyrazolo(4,3-d)pyrimidine results in increased expression of TP53 protein | 21417417 |
C411868 | 7-diethylamino-4-methyl coumarin | 7-diethylamino-4-methyl coumarin results in increased expression of TP53 mRNA | 21538407 |
C054852 | 7-hydroxystaurosporine | 7-hydroxystaurosporine results in decreased expression of TP53 protein | 11378265 |
C003001 | 7-ketocholesterol | 7-ketocholesterol results in increased expression of TP53 protein | 25845326 |
C003001 | 7-ketocholesterol | Acetylcysteine inhibits the reaction [7-ketocholesterol results in increased expression of TP53 protein] | 25845326 |
C003001 | 7-ketocholesterol | BAY 11-7085 inhibits the reaction [7-ketocholesterol results in increased expression of TP53 protein] | 25845326 |
C003001 | 7-ketocholesterol | quercetin 3-O-beta-(2''-galloyl)-rhamnopyranoside inhibits the reaction [7-ketocholesterol results in increased expression of TP53 protein] | 25845326 |
C522803 | 7-monohydroxyethylrutoside | 7-monohydroxyethylrutoside inhibits the reaction [Doxorubicin results in increased expression of TP53 protein] | 17285121 |
C080122 | 7-nitroindazole | [7-nitroindazole results in decreased chemical synthesis of Nitric Oxide] inhibits the reaction [Paraquat results in increased phosphorylation of TP53 protein] | 20478973 |
D015124 | 8-Bromo Cyclic Adenosine Monophosphate | 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of TP53 | 11802967 |
D015124 | 8-Bromo Cyclic Adenosine Monophosphate | 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of TP53 protein | 10642304 |
C016276 | 8-bromocyclic GMP | 8-bromocyclic GMP results in increased expression of TP53 protein | 9888876 |
D015127 | 9,10-Dimethyl-1,2-benzanthracene | 9,10-Dimethyl-1,2-benzanthracene results in increased activity of TP53 protein | 20655369 |
D015127 | 9,10-Dimethyl-1,2-benzanthracene | 9,10-Dimethyl-1,2-benzanthracene results in decreased expression of TP53 protein | 21294050 |
D015127 | 9,10-Dimethyl-1,2-benzanthracene | Quercetin inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of TP53 protein] | 21294050 |
D015127 | 9,10-Dimethyl-1,2-benzanthracene | 9,10-Dimethyl-1,2-benzanthracene results in decreased expression of TP53 mRNA | 24269759 |
D015127 | 9,10-Dimethyl-1,2-benzanthracene | 9,10-Dimethyl-1,2-benzanthracene results in increased expression of TP53 mRNA | 24269759 |
C005399 | 9,10-phenanthrenequinone | 9,10-phenanthrenequinone affects the localization of TP53 protein | 29108775 |
C046938 | 9,11-linoleic acid | 9,11-linoleic acid results in increased phosphorylation of and affects the localization of TP53 protein | 15992797 |
C025724 | 9-methoxycamptothecin | 9-methoxycamptothecin results in increased expression of TP53 mRNA | 23369935 |
C025724 | 9-methoxycamptothecin | 9-methoxycamptothecin results in increased expression of TP53 protein | 23369935 |
C072876 | A 771726 | A 771726 results in increased expression of TP53 mRNA | 10076546 |
C072876 | A 771726 | A 771726 results in increased expression of TP53 protein | 10076546 |
C542662 | AC 93253 | AC 93253 affects the expression of TP53 mRNA | 25912555 |
D000082 | Acetaminophen | Acetaminophen results in increased expression of TP53 mRNA | 26946349 |
D000082 | Acetaminophen | Acetaminophen results in decreased expression of TP53 mRNA | 21420995; 25704631; |
D000082 | Acetaminophen | Acetaminophen affects the expression of TP53 mRNA | 16701773 |
D000082 | Acetaminophen | Acetaminophen promotes the reaction [MDM2 protein binds to TP53 protein] | 16330492 |
D000082 | Acetaminophen | Acetaminophen results in decreased expression of TP53 protein | 16330492 |
D000082 | Acetaminophen | Acetaminophen results in increased activity of TP53 protein | 25858767 |
D000082 | Acetaminophen | Acetaminophen results in increased expression of TP53 mRNA | 21807079 |
D000082 | Acetaminophen | Acetaminophen results in increased phosphorylation of TP53 protein | 16330492 |
D000082 | Acetaminophen | benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Acetaminophen results in increased degradation of TP53 protein] | 16330492 |
D000082 | Acetaminophen | Chlormethiazole inhibits the reaction [Acetaminophen results in increased degradation of TP53 protein] | 16330492 |
D000082 | Acetaminophen | Etoposide promotes the reaction [Acetaminophen results in increased phosphorylation of TP53 protein] | 16330492 |
D000082 | Acetaminophen | Fluorouracil promotes the reaction [Acetaminophen results in increased phosphorylation of TP53 protein] | 16330492 |
D000082 | Acetaminophen | lactacystin inhibits the reaction [Acetaminophen results in increased degradation of TP53 protein] | 16330492 |
C464485 | acetamiprid | acetamiprid results in increased expression of TP53 mRNA | 29091792 |
C464485 | acetamiprid | [iprodione co-treated with acetamiprid] results in decreased expression of TP53 mRNA | 29091792 |
C464485 | acetamiprid | [iprodione co-treated with pyrimethanil co-treated with acetamiprid] results in increased expression of TP53 mRNA | 29091792 |
C464485 | acetamiprid | [iprodione co-treated with pyrimethanil co-treated with pyrachlostrobin co-treated with acetamiprid] results in increased expression of TP53 mRNA | 29091792 |
C464485 | acetamiprid | [pyrimethanil co-treated with acetamiprid] results in increased expression of TP53 mRNA | 29091792 |
C464485 | acetamiprid | [pyrimethanil co-treated with pyrachlostrobin co-treated with acetamiprid] results in increased expression of TP53 mRNA | 29091792 |
C056165 | acetovanillone | acetovanillone inhibits the reaction [[Desoxycorticosterone co-treated with Sodium Chloride] results in increased expression of TP53 protein] | 22431579 |
D000099 | Acetoxyacetylaminofluorene | [Acetoxyacetylaminofluorene co-treated with Diethylnitrosamine] results in increased expression of TP53 protein | 10741303 |
C487680 | acetylbritannilatone | acetylbritannilatone analog results in increased expression of TP53 protein | 27262408 |
C487680 | acetylbritannilatone | TP53 protein affects the reaction [acetylbritannilatone analog results in increased activity of CASP3 protein] | 27262408 |
C487680 | acetylbritannilatone | TP53 protein affects the reaction [acetylbritannilatone analog results in increased activity of CASP8 protein] | 27262408 |
C487680 | acetylbritannilatone | TP53 protein affects the reaction [acetylbritannilatone analog results in increased activity of CASP9 protein] | 27262408 |
C487680 | acetylbritannilatone | TP53 protein affects the reaction [acetylbritannilatone analog results in increased cleavage of PARP1 protein] | 27262408 |
C487680 | acetylbritannilatone | TP53 protein affects the reaction [acetylbritannilatone analog results in increased expression of BAX mRNA] | 27262408 |
C487680 | acetylbritannilatone | TP53 protein affects the reaction [acetylbritannilatone analog results in increased expression of BBC3 mRNA] | 27262408 |
C487680 | acetylbritannilatone | TP53 protein affects the reaction [acetylbritannilatone analog results in increased expression of CDKN1A mRNA] | 27262408 |
C487680 | acetylbritannilatone | TP53 protein affects the reaction [acetylbritannilatone analog results in increased expression of FAS mRNA] | 27262408 |
C487680 | acetylbritannilatone | TP53 protein affects the reaction [acetylbritannilatone analog results in increased expression of PMAIP1 mRNA] | 27262408 |
D000111 | Acetylcysteine | Acetylcysteine inhibits the reaction [Arsenic Trioxide results in increased expression of TP53 protein] | 31442540 |
D000111 | Acetylcysteine | [Acetylcysteine co-treated with N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine] inhibits the reaction [[Zinc Sulfate co-treated with prolinedithiocarbamate] results in decreased expression of TP53 protein] | 18951928 |
D000111 | Acetylcysteine | Acetylcysteine inhibits the reaction [2,2'-azobis(2-amidinopropane) results in increased phosphorylation of TP53 protein] | 30555576 |
D000111 | Acetylcysteine | Acetylcysteine inhibits the reaction [2,3,5-trichloro-6-phenyl-(1,4)benzoquinone results in increased expression of TP53 protein] | 26451628 |
D000111 | Acetylcysteine | Acetylcysteine inhibits the reaction [2,3,5-trichloro-6-phenyl-(1,4)benzoquinone results in increased expression of TP53 protein modified form] | 26451628 |
D000111 | Acetylcysteine | Acetylcysteine inhibits the reaction [2-hydroxy-3',5,5'-trimethoxychalcone results in increased expression of TP53 protein] | 30408460 |
D000111 | Acetylcysteine | Acetylcysteine inhibits the reaction [Aristolochic Acids results in increased phosphorylation of TP53 protein] | 24792323 |
D000111 | Acetylcysteine | Acetylcysteine inhibits the reaction [Arsenic Trioxide results in increased expression of TP53 protein] | 15904916 |
D000111 | Acetylcysteine | Acetylcysteine inhibits the reaction [arsenite results in increased expression of TP53 protein] | 22260869 |
D000111 | Acetylcysteine | Acetylcysteine inhibits the reaction [[Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of TP53 protein] | 20530418 |
D000111 | Acetylcysteine | Acetylcysteine inhibits the reaction [ATM protein promotes the reaction [Doxorubicin results in increased activity of TP53 protein]] | 15489221 |
D000111 | Acetylcysteine | Acetylcysteine inhibits the reaction [Camptothecin results in increased expression of TP53 protein modified form] | 17555331 |
D000111 | Acetylcysteine | Acetylcysteine inhibits the reaction [Capsaicin results in increased phosphorylation of TP53 protein] | 14871840 |
D000111 | Acetylcysteine | Acetylcysteine inhibits the reaction [[CD40LG protein co-treated with IL4 protein] results in increased expression of TP53 protein] | 27634759 |
D000111 | Acetylcysteine | Acetylcysteine inhibits the reaction [[Cisplatin co-treated with Arsenic Trioxide] results in increased phosphorylation of TP53 protein] | 29944906 |
D000111 | Acetylcysteine | Acetylcysteine inhibits the reaction [Cisplatin results in increased expression of TP53] | 15496615 |
D000111 | Acetylcysteine | Acetylcysteine inhibits the reaction [Cisplatin results in increased glutathionylation of TP53 protein] | 17555331 |
D000111 | Acetylcysteine | Acetylcysteine inhibits the reaction [cobaltous chloride results in increased expression of and results in increased activity of TP53 protein] | 10951577 |
D000111 | Acetylcysteine | Acetylcysteine inhibits the reaction [cyadox results in increased expression of TP53 mRNA] | 30265530 |
D000111 | Acetylcysteine | Acetylcysteine inhibits the reaction [diallyl disulfide results in increased expression of TP53 protein] | 19202565 |
D000111 | Acetylcysteine | Acetylcysteine inhibits the reaction [dorsomorphin results in increased expression of and results in increased phosphorylation of TP53 protein] | 23274516 |
D000111 | Acetylcysteine | Acetylcysteine inhibits the reaction [Doxorubicin promotes the reaction [ATM protein results in increased phosphorylation of TP53 protein]] | 15489221 |
D000111 | Acetylcysteine | Acetylcysteine inhibits the reaction [Doxorubicin results in increased expression of TP53 protein] | 22927544 |
D000111 | Acetylcysteine | Acetylcysteine inhibits the reaction [Fingolimod Hydrochloride results in increased phosphorylation of TP53 protein] | 25939952 |
D000111 | Acetylcysteine | Acetylcysteine inhibits the reaction [Hydrogen Peroxide results in increased expression of TP53 mRNA] | 9535218 |
D000111 | Acetylcysteine | Acetylcysteine inhibits the reaction [Hydrogen Peroxide results in increased expression of TP53 protein] | 9535218 |
D000111 | Acetylcysteine | Acetylcysteine inhibits the reaction [Methotrexate results in increased expression of TP53 mRNA] | 22183962 |
D000111 | Acetylcysteine | Acetylcysteine inhibits the reaction [Methotrexate results in increased expression of TP53 protein] | 24967384 |
D000111 | Acetylcysteine | Acetylcysteine inhibits the reaction [N-acetylsphingosine results in increased expression of TP53 mRNA] | 9535218 |
D000111 | Acetylcysteine | Acetylcysteine inhibits the reaction [N-acetylsphingosine results in increased expression of TP53 protein] | 9535218 |
D000111 | Acetylcysteine | Acetylcysteine inhibits the reaction [Oxaliplatin results in increased expression of TP53 protein] | 19728331 |
D000111 | Acetylcysteine | Acetylcysteine inhibits the reaction [Oxygen deficiency results in increased expression of TP53 protein] | 10951577 |
D000111 | Acetylcysteine | Acetylcysteine inhibits the reaction [Particulate Matter results in decreased expression of TP53 protein] | 26942697 |
D000111 | Acetylcysteine | Acetylcysteine inhibits the reaction [perfosfamide results in increased expression of TP53] | 18034189 |
D000111 | Acetylcysteine | Acetylcysteine inhibits the reaction [Phytochemicals results in increased phosphorylation of TP53 protein] | 25305377 |
D000111 | Acetylcysteine | Acetylcysteine inhibits the reaction [Reactive Oxygen Species affects the localization of TP53 protein] | 26884717 |
D000111 | Acetylcysteine | Acetylcysteine inhibits the reaction [thymoquinone results in increased expression of TP53 protein] | 31433961 |
D000111 | Acetylcysteine | Acetylcysteine inhibits the reaction [TNF protein results in increased expression of TP53 mRNA] | 9535218 |
D000111 | Acetylcysteine | Acetylcysteine inhibits the reaction [TNF protein results in increased expression of TP53 protein] | 9535218 |
D000111 | Acetylcysteine | Acetylcysteine inhibits the reaction [TNFSF10 protein results in increased expression of TP53 protein] | 23711929 |
D000111 | Acetylcysteine | Acetylcysteine inhibits the reaction [TP53 protein results in increased abundance of Reactive Oxygen Species] | 15059885 |
D000111 | Acetylcysteine | Acetylcysteine inhibits the reaction [[Zinc Sulfate co-treated with prolinedithiocarbamate] results in decreased expression of TP53 protein] | 18951928 |
D000111 | Acetylcysteine | Acetylcysteine results in decreased activity of TP53 protein | 15059885 |
D000111 | Acetylcysteine | Acetylcysteine results in increased expression of TP53 protein | 31433961 |
D000111 | Acetylcysteine | Acetylcysteine inhibits the reaction [Nitroprusside results in increased expression of TP53] | 19725096 |
D000111 | Acetylcysteine | Acetylcysteine inhibits the reaction [7-ketocholesterol results in increased expression of TP53 protein] | 25845326 |
D000111 | Acetylcysteine | Acetylcysteine inhibits the reaction [Aflatoxin B1 promotes the reaction [fumonisin B1 results in increased expression of TP53 protein]] | 28181396 |
D000111 | Acetylcysteine | Acetylcysteine inhibits the reaction [Aflatoxin B1 results in increased expression of TP53 protein] | 28181396 |
D000111 | Acetylcysteine | Acetylcysteine inhibits the reaction [Cadmium results in increased phosphorylation of TP53 protein] | 27658547 |
D000111 | Acetylcysteine | Acetylcysteine inhibits the reaction [fumonisin B1 promotes the reaction [Aflatoxin B1 results in increased expression of TP53 protein]] | 28181396 |
D000111 | Acetylcysteine | Acetylcysteine inhibits the reaction [Potassium Dichromate results in increased expression of TP53 protein] | 18563748 |
D000111 | Acetylcysteine | Acetylcysteine inhibits the reaction [Quercetin analog results in decreased phosphorylation of TP53 protein] | 23907460 |
D000111 | Acetylcysteine | Acetylcysteine results in decreased expression of TP53 protein | 23183129 |
D000111 | Acetylcysteine | Acetylcysteine results in increased phosphorylation of TP53 protein | 23907460 |
D000111 | Acetylcysteine | Acetylcysteine inhibits the reaction [fumonisin B1 promotes the reaction [Zearalenone results in increased expression of TP53 mRNA]] | 29109043 |
D000111 | Acetylcysteine | Acetylcysteine inhibits the reaction [Zearalenone promotes the reaction [fumonisin B1 results in increased expression of TP53 mRNA]] | 29109043 |
D000111 | Acetylcysteine | Acetylcysteine promotes the reaction [deoxynivalenol inhibits the reaction [Zearalenone results in increased expression of TP53 mRNA]] | 29109043 |
D000157 | Aconitine | Aconitine results in increased expression of TP53 protein | 24840785 |
D000165 | Acridine Orange | Acridine Orange results in increased stability of and results in increased activity of TP53 protein | 16177561 |
D000171 | Acrolein | Acrolein results in increased phosphorylation of TP53 protein | 17196791 |
D000171 | Acrolein | Acrolein affects the metabolism of TP53 protein | 12807757 |
D000171 | Acrolein | Acrolein binds to TP53 gene | 17030796 |
D000171 | Acrolein | Acrolein inhibits the reaction [Benzo(a)pyrene results in increased activity of TP53 protein] | 12807757 |
D000171 | Acrolein | Acrolein results in decreased activity of TP53 protein | 12807757; 16753831; |
D000171 | Acrolein | Acrolein results in increased mutagenesis of TP53 gene | 17030796 |
D000171 | Acrolein | TP53 protein affects the reaction [Acrolein results in increased cleavage of CASP3 protein] | 29964147 |
D000171 | Acrolein | TP53 protein affects the reaction [Acrolein results in increased cleavage of CASP9 protein] | 29964147 |
D000171 | Acrolein | TP53 protein affects the reaction [Acrolein results in increased cleavage of PARP1 protein] | 29964147 |
D000171 | Acrolein | TP53 protein affects the susceptibility to Acrolein | 29964147 |
D000171 | Acrolein | [TP53 protein affects the susceptibility to Acrolein] which affects the localization of CCNB1 protein | 29964147 |
D000171 | Acrolein | [ferric oxide analog co-treated with Acrolein] results in increased expression of TP53 protein | 24847785 |
D020106 | Acrylamide | Acrylamide results in increased expression of TP53 protein modified form | 20734998 |
D020106 | Acrylamide | Acrylamide results in increased mutagenesis of TP53 gene | 15240786 |
D020106 | Acrylamide | Acrylamide results in increased phosphorylation of and results in increased expression of TP53 protein | 19426797 |
C549567 | adavosertib | TP53 gene mutant form results in increased susceptibility to adavosertib | 25125259 |
C106812 | adefovir dipivoxil | adefovir dipivoxil affects the activity of TP53 protein | 25596134 |
D000255 | Adenosine Triphosphate | TP53 protein inhibits the reaction [Deoxyglucose results in decreased abundance of Adenosine Triphosphate] | 21042727 |
C011395 | adrenic acid | [TP53 protein mutant form results in increased susceptibility to Niclosamide] which results in increased abundance of adrenic acid | 30258081 |
D016604 | Aflatoxin B1 | Aflatoxin B1 affects the expression of TP53 protein | 20106945 |
D016604 | Aflatoxin B1 | Aflatoxin B1 promotes the reaction [deoxynivalenol results in increased expression of TP53 mRNA] | 30668976 |
D016604 | Aflatoxin B1 | Aflatoxin B1 results in decreased expression of TP53 mRNA | 28943387 |
D016604 | Aflatoxin B1 | Aflatoxin B1 results in increased activity of TP53 protein | 20655369 |
D016604 | Aflatoxin B1 | Aflatoxin B1 results in increased expression of TP53 mRNA | 30668976; 31542801; |
D016604 | Aflatoxin B1 | Aflatoxin B1 results in increased expression of TP53 protein | 22100608; 31542801; |
D016604 | Aflatoxin B1 | Aflatoxin B1 results in increased methylation of TP53 gene | 28458013 |
D016604 | Aflatoxin B1 | Aflatoxin B1 results in increased mutagenesis of TP53 gene | 12619106; 15946497; |
D016604 | Aflatoxin B1 | CYP3A4 protein promotes the reaction [Aflatoxin B1 results in increased activity of TP53 protein] | 20655369 |
D016604 | Aflatoxin B1 | TP53 protein affects the reaction [Aflatoxin B1 results in increased expression of BTG2 mRNA] | 22100608 |
D016604 | Aflatoxin B1 | TP53 protein affects the reaction [Aflatoxin B1 results in increased expression of FDXR mRNA] | 22100608 |
D016604 | Aflatoxin B1 | TP53 protein affects the reaction [Aflatoxin B1 results in increased expression of PPM1D mRNA] | 22100608 |
D016604 | Aflatoxin B1 | TP53 protein affects the reaction [Aflatoxin B1 results in increased expression of TP53I3 mRNA] | 22100608 |
D016604 | Aflatoxin B1 | TP53 protein affects the reaction [Aflatoxin B1 results in increased phosphorylation of H2AX protein] | 28882572 |
D016604 | Aflatoxin B1 | TP53 protein affects the susceptibility to Aflatoxin B1 | 28882572 |
D016604 | Aflatoxin B1 | [Zearalenone co-treated with Aflatoxin B1] promotes the reaction [deoxynivalenol results in increased expression of TP53 mRNA] | 30668976 |
D016604 | Aflatoxin B1 | Acetylcysteine inhibits the reaction [Aflatoxin B1 promotes the reaction [fumonisin B1 results in increased expression of TP53 protein]] | 28181396 |
D016604 | Aflatoxin B1 | Acetylcysteine inhibits the reaction [Aflatoxin B1 results in increased expression of TP53 protein] | 28181396 |
D016604 | Aflatoxin B1 | Acetylcysteine inhibits the reaction [fumonisin B1 promotes the reaction [Aflatoxin B1 results in increased expression of TP53 protein]] | 28181396 |
D016604 | Aflatoxin B1 | Aflatoxin B1 promotes the reaction [fumonisin B1 results in increased expression of TP53 protein] | 28181396 |
D016604 | Aflatoxin B1 | Aflatoxin B1 results in increased expression of TP53 mRNA | 28442411 |
D016604 | Aflatoxin B1 | Aflatoxin B1 results in increased expression of TP53 protein | 28181396; 9163691; |
D016604 | Aflatoxin B1 | fumonisin B1 promotes the reaction [Aflatoxin B1 results in increased expression of TP53 protein] | 28181396 |
C027955 | aflatoxin G1 | aflatoxin G1 results in increased activity of TP53 protein | 23907605 |
C027955 | aflatoxin G1 | aflatoxin G1 results in increased expression of TP53 protein modified form | 23907605 |
C027955 | aflatoxin G1 | Methoxsalen inhibits the reaction [aflatoxin G1 results in increased expression of TP53 protein modified form] | 23907605 |
C027955 | aflatoxin G1 | Nicotine inhibits the reaction [aflatoxin G1 results in increased expression of TP53 protein modified form] | 23907605 |
D000348 | Aflatoxins | Aflatoxins results in increased mutagenesis of TP53 gene | 16007211 |
C031143 | AICA ribonucleotide | [Resveratrol co-treated with AICA ribonucleotide] inhibits the reaction [Glucose results in increased expression of TP53 protein] | 26188290 |
D000393 | Air Pollutants | Air Pollutants analog results in decreased expression of TP53 mRNA | 21757418 |
D000393 | Air Pollutants | Air Pollutants results in decreased methylation of TP53 exon | 21756780 |
D000393 | Air Pollutants | Air Pollutants results in increased methylation of TP53 promoter | 21756780 |
D000393 | Air Pollutants | Air Pollutants results in increased mutagenesis of TP53 exon | 21756780 |
D000393 | Air Pollutants | Air Pollutants results in increased expression of TP53 protein | 28389379 |
D000395 | Air Pollutants, Occupational | Air Pollutants, Occupational affects the expression of TP53 mRNA | 20886531 |
D000395 | Air Pollutants, Occupational | Air Pollutants, Occupational results in decreased expression of TP53 mRNA | 23195993 |
C004363 | alantolactone | alantolactone results in increased expression of TP53 protein | 22721982 |
D000420 | Albuterol | Albuterol results in increased expression of TP53 | 11802967 |
D000447 | Aldehydes | Aldehydes results in decreased expression of TP53 mRNA | 25014914 |
D000487 | Allethrins | Allethrins affects the expression of TP53 protein | 22356257 |
D000487 | Allethrins | Allethrins results in decreased expression of TP53 mRNA | 23595975 |
D000487 | Allethrins | Allethrins results in increased expression of TP53 mRNA | 25072698 |
C006453 | alliin | alliin promotes the reaction [FGF2 protein results in increased expression of TP53 protein] | 16351512 |
C002055 | allose | allose results in increased expression of TP53 mRNA | 18930000 |
C002055 | allose | allose results in increased expression of TP53 protein | 18930000 |
C002055 | allose | Fluorouracil promotes the reaction [allose results in increased expression of TP53 protein] | 18930000 |
C038491 | allyl sulfide | allyl sulfide results in increased expression of TP53 mRNA | 24650757 |
C038491 | allyl sulfide | [allyl sulfide co-treated with Diethylstilbestrol] results in increased expression of TP53 mRNA | 17125941 |
C038491 | allyl sulfide | allyl sulfide results in increased expression of TP53 mRNA | 17125941 |
C518327 | aloe emodin | aloe emodin results in increased expression of TP53 mRNA | 30771440 |
C518327 | aloe emodin | aloe emodin results in increased expression of TP53 protein | 30771440 |
C518327 | aloe emodin | aloe emodin results in increased expression of TP53 protein | 19928967 |
D000517 | alpha-Chlorohydrin | alpha-Chlorohydrin results in increased expression of TP53 protein | 28070108 |
C095512 | alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide | alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [Quercetin analog results in decreased phosphorylation of TP53 protein] | 23907460 |
C040534 | alpha-hexachlorocyclohexane | alpha-hexachlorocyclohexane results in decreased expression of TP53 mRNA | 16940010 |
C040534 | alpha-hexachlorocyclohexane | alpha-hexachlorocyclohexane results in increased expression of TP53 mRNA | 16940010 |
C011512 | alpha-naphthoflavone | alpha-naphthoflavone results in increased expression of TP53 protein | 29274324 |
C011512 | alpha-naphthoflavone | alpha-naphthoflavone inhibits the reaction [Tetrachlorodibenzodioxin inhibits the reaction [leptomycin B results in increased expression of TP53 protein]] | 15459018 |
D024502 | alpha-Tocopherol | alpha-Tocopherol inhibits the reaction [arsenite results in increased expression of TP53 mRNA] | 12126965 |
D024502 | alpha-Tocopherol | alpha-Tocopherol inhibits the reaction [arsenite results in increased expression of TP53 protein] | 12126965 |
D024502 | alpha-Tocopherol | [beta Carotene co-treated with alpha-Tocopherol co-treated with Ascorbic Acid] inhibits the reaction [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased expression of TP53 protein] | 16401635 |
D024502 | alpha-Tocopherol | [beta Carotene co-treated with alpha-Tocopherol co-treated with Ascorbic Acid] inhibits the reaction [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased phosphorylation of TP53 protein] | 16401635 |
C120793 | alsterpaullone | alsterpaullone affects the localization of TP53 protein | 16055726 |
C120793 | alsterpaullone | alsterpaullone results in decreased degradation of and results in increased expression of TP53 protein | 16055726 |
C005197 | alternariol | alternariol results in increased expression of TP53 protein | 22542754 |
C104223 | aluminum lactate | aluminum lactate results in increased expression of TP53 mRNA | 19464335 |
C104223 | aluminum lactate | aluminum lactate results in increased expression of TP53 protein | 19464335; 26944603; |
C104223 | aluminum lactate | Quercetin inhibits the reaction [aluminum lactate results in increased expression of TP53 protein] | 26944603 |
C067527 | aluminum maltolate | aluminum maltolate results in decreased expression of TP53 mRNA | 24878590 |
C067527 | aluminum maltolate | aluminum maltolate results in decreased expression of TP53 protein | 24878590 |
D000537 | Aluminum Oxide | Aluminum Oxide analog results in increased expression of TP53 mRNA | 23132795 |
C077990 | alvocidib | alvocidib results in decreased expression of TP53 protein | 9808574 |
C077990 | alvocidib | alvocidib results in increased expression of TP53 protein | 10537362; 12589031; 15180955; |
C077990 | alvocidib | [alvocidib results in increased expression of TP53 protein] which results in increased expression of CDKN1B protein | 12589031 |
C077990 | alvocidib | [Docetaxel co-treated with alvocidib] results in increased expression of TP53 protein | 15297405 |
C077990 | alvocidib | alvocidib results in increased expression of TP53 protein | 15180955 |
D000577 | Amides | Amides results in increased expression of TP53 mRNA | 23063670 |
D000577 | Amides | Amides results in increased expression of TP53 protein | 23063670 |
D004999 | Amifostine | [Amifostine co-treated with TP53] results in increased expression of MYC mRNA | 14555708 |
D004999 | Amifostine | Amifostine results in increased activity of TP53 protein | 16628227 |
D004999 | Amifostine | Amifostine results in increased expression of TP53 protein | 12618886 |
D004999 | Amifostine | olomoucine inhibits the reaction [TP53 protein promotes the reaction [Amifostine results in decreased phosphorylation of CDK1 protein]] | 16628227 |
D004999 | Amifostine | TP53 affects the susceptibility to Amifostine | 12618886 |
D004999 | Amifostine | TP53 protein promotes the reaction [Amifostine results in decreased phosphorylation of CDK1 protein] | 16628227 |
D000585 | Aminacrine | Aminacrine results in increased stability of and results in increased activity of TP53 protein | 16177561 |
D000602 | Amino Acids, Peptides, and Proteins | Amino Acids, Peptides, and Proteins results in increased expression of TP53 mRNA | 23747718 |
D000622 | Aminolevulinic Acid | Aminolevulinic Acid analog results in increased expression of TP53 | 17311614 |
D000643 | Ammonium Chloride | Ammonium Chloride affects the expression of and affects the phosphorylation of TP53 protein | 29908302 |
D000643 | Ammonium Chloride | NR1I2 protein affects the reaction [Ammonium Chloride affects the expression of and affects the phosphorylation of TP53 protein] | 29908302 |
D000643 | Ammonium Chloride | Ammonium Chloride affects the expression of TP53 mRNA | 16483693 |
D000643 | Ammonium Chloride | Ammonium Chloride results in increased expression of TP53 protein | 16483693 |
D000655 | Amodiaquine | Amodiaquine affects the expression of TP53 protein | 24113242 |
D000655 | Amodiaquine | Amodiaquine results in increased activity of TP53 protein | 12082016 |
D000661 | Amphetamine | Amphetamine results in decreased expression of TP53 mRNA | 30779732 |
D000677 | Amsacrine | Amsacrine analog results in increased activity of TP53 protein | 12082016 |
D000677 | Amsacrine | Amsacrine results in increased expression of TP53 protein | 11774253 |
D000677 | Amsacrine | Amsacrine results in increased glutathionylation of TP53 protein | 17555331 |
D000677 | Amsacrine | Amsacrine results in increased stability of and results in increased activity of TP53 protein | 16177561 |
C088115 | anacardic acid | anacardic acid inhibits the reaction [[Fluorouracil results in increased acetylation of TP53 protein mutant form] which results in increased expression of UBE2C protein] | 27129209 |
C088115 | anacardic acid | anacardic acid inhibits the reaction [Genistein promotes the reaction [trichostatin A results in increased acetylation of TP53 protein]] | 26768552 |
D000728 | Androgens | TP53 protein inhibits the reaction [Androgens results in increased expression of NKX3-1 mRNA] | 17202838 |
C030419 | andrographolide | andrographolide results in increased expression of and results in increased phosphorylation of TP53 protein | 18619950 |
C030419 | andrographolide | andrographolide results in increased expression of TP53 | 19097688 |
C030419 | andrographolide | Fluorouracil promotes the reaction [andrographolide results in increased expression of TP53] | 19097688 |
D000841 | Anisomycin | Anisomycin promotes the reaction [Colistin results in increased expression of TP53 protein] | 28842171 |
C540917 | anthraceno(1,2-c)(1,2,5)selenadiazolo-6,11-dione | anthraceno(1,2-c)(1,2,5)selenadiazolo-6,11-dione results in increased expression of TP53 protein | 19146838 |
C540917 | anthraceno(1,2-c)(1,2,5)selenadiazolo-6,11-dione | TP53 protein promotes the reaction [anthraceno(1,2-c)(1,2,5)selenadiazolo-6,11-dione results in increased cleavage of CASP7 protein] | 19146838 |
D000970 | Antineoplastic Agents | Antineoplastic Agents results in increased activity of TP53 protein | 22010212 |
D000970 | Antineoplastic Agents | TP53 protein promotes the reaction [Methotrexate results in increased susceptibility to Antineoplastic Agents] | 22010212 |
C034321 | aphantoxin | aphantoxin results in increased expression of TP53 mRNA | 21710505 |
C102351 | apicidin | apicidin results in decreased expression of TP53 mRNA | 19070610 |
C102351 | apicidin | apicidin results in decreased expression of TP53 protein | 19070610 |
D047310 | Apigenin | Apigenin results in increased expression of TP53 protein | 16023288 |
D047310 | Apigenin | TP53 protein affects the reaction [Apigenin results in increased expression of CDKN1A protein] | 11790449 |
D016718 | Arachidonic Acid | [TP53 protein results in increased expression of ALOX12B mRNA] which results in increased metabolism of Arachidonic Acid | 30258081 |
D016718 | Arachidonic Acid | [TP53 protein results in increased expression of ALOX5 mRNA] which results in increased metabolism of Arachidonic Acid | 30258081 |
D016718 | Arachidonic Acid | [TP53 protein mutant form results in increased susceptibility to Niclosamide] which results in increased abundance of Arachidonic Acid | 30258081 |
D001115 | Arecoline | [[Arecoline results in decreased expression of CDC25C] co-treated with [Arecoline results in increased expression of TP53]] results in decreased activity of CDK1 protein | 22108589 |
D001115 | Arecoline | Arecoline results in increased expression of TP53 protein | 22108589 |
C047981 | arginyl-glycyl-aspartic acid | arginyl-glycyl-aspartic acid inhibits the reaction [Resveratrol results in increased phosphorylation of TP53 protein] | 16790523 |
D034341 | Aristolochic Acids | Acetylcysteine inhibits the reaction [Aristolochic Acids results in increased phosphorylation of TP53 protein] | 24792323 |
D034341 | Aristolochic Acids | Aristolochic Acids results in increased phosphorylation of TP53 protein | 24792323 |
D001151 | Arsenic | Arsenic affects the expression of TP53 mRNA | 18414638 |
D001151 | Arsenic | Arsenic affects the expression of TP53 protein | 17450239 |
D001151 | Arsenic | Arsenic results in decreased expression of TP53 mRNA | 19945496 |
D001151 | Arsenic | Arsenic results in decreased expression of TP53 protein | 28785074 |
D001151 | Arsenic | Arsenic results in decreased methylation of TP53 exon | 21756780 |
D001151 | Arsenic | Arsenic results in decreased phosphorylation of TP53 protein | 24473091 |
D001151 | Arsenic | Arsenic results in increased expression of TP53 mRNA | 27122327 |
D001151 | Arsenic | Arsenic results in increased expression of TP53 protein | 23174854 |
D001151 | Arsenic | Arsenic results in increased expression of TP53 protein mutant form | 12899209 |
D001151 | Arsenic | Arsenic results in increased methylation of TP53 promoter | 16251483; 21756780; |
D001151 | Arsenic | Arsenic results in increased mutagenesis of TP53 exon | 21756780; 26772154; |
D001151 | Arsenic | Arsenic results in increased mutagenesis of TP53 gene | 15967209; 17450239; |
D001151 | Arsenic | TP53 gene mutant form results in increased susceptibility to Arsenic | 23643801 |
D001151 | Arsenic | TP53 gene polymorphism results in increased susceptibility to Arsenic | 16930632 |
D001151 | Arsenic | TP53 polymorphism affects the susceptibility to Arsenic | 21982800 |
D001151 | Arsenic | Arsenic results in increased mutagenesis of TP53 gene | 19203779 |
C058317 | arsenic disulfide | [arsenic disulfide results in decreased expression of SIRT1 protein] which results in increased expression of TP53 protein | 18298901 |
C058317 | arsenic disulfide | arsenic disulfide results in increased expression of and results in increased phosphorylation of TP53 protein | 18298901 |
C058317 | arsenic disulfide | arsenic disulfide results in increased expression of TP53 protein | 29620191 |
C058317 | arsenic disulfide | sirtinol promotes the reaction [arsenic disulfide results in increased expression of and results in increased phosphorylation of TP53 protein] | 18298901 |
C058317 | arsenic disulfide | Wortmannin promotes the reaction [arsenic disulfide results in increased expression of and results in increased phosphorylation of TP53 protein] | 18298901 |
D000077237 | Arsenic Trioxide | Acetylcysteine inhibits the reaction [Arsenic Trioxide results in increased expression of TP53 protein] | 31442540 |
D000077237 | Arsenic Trioxide | [Arsenic Trioxide co-treated with Copper Sulfate] results in increased expression of TP53 mRNA | 29569195; 30543957; |
D000077237 | Arsenic Trioxide | [Arsenic Trioxide co-treated with Copper Sulfate] results in increased expression of TP53 protein | 29569195; 30543957; |
D000077237 | Arsenic Trioxide | Arsenic Trioxide results in decreased expression of TP53 mRNA | 31442540 |
D000077237 | Arsenic Trioxide | Arsenic Trioxide results in increased expression of TP53 mRNA | 28454103; 29569195; 29705899; 29762750; 30543957; |
D000077237 | Arsenic Trioxide | Arsenic Trioxide results in increased expression of TP53 protein | 28454103; 29569195; 29705899; 29762750; 30516227; 30543957; 31442540; |
D000077237 | Arsenic Trioxide | Acetylcysteine inhibits the reaction [Arsenic Trioxide results in increased expression of TP53 protein] | 15904916 |
D000077237 | Arsenic Trioxide | Acetylcysteine inhibits the reaction [[Cisplatin co-treated with Arsenic Trioxide] results in increased phosphorylation of TP53 protein] | 29944906 |
D000077237 | Arsenic Trioxide | Arsenic Trioxide affects the expression of TP53 | 11775218 |
D000077237 | Arsenic Trioxide | [Arsenic Trioxide co-treated with Curcumin] results in increased expression of TP53 protein | 27430728 |
D000077237 | Arsenic Trioxide | [Arsenic Trioxide co-treated with Doxorubicin co-treated with Magnetite Nanoparticles analog] affects the expression of TP53 mRNA | 24738333 |
D000077237 | Arsenic Trioxide | [Arsenic Trioxide co-treated with Doxorubicin co-treated with Magnetite Nanoparticles analog] affects the expression of TP53 protein | 24738333 |
D000077237 | Arsenic Trioxide | [Arsenic Trioxide co-treated with PML protein] results in increased expression of TP53 | 20377131 |
D000077237 | Arsenic Trioxide | Arsenic Trioxide inhibits the reaction [Dasatinib results in decreased expression of TP53 protein] | 29266867 |
D000077237 | Arsenic Trioxide | Arsenic Trioxide promotes the reaction [tetraarsenic tetrasulfide results in increased expression of TP53 protein] | 26110921 |
D000077237 | Arsenic Trioxide | Arsenic Trioxide results in decreased expression of TP53 mRNA | 27825931 |
D000077237 | Arsenic Trioxide | Arsenic Trioxide results in decreased expression of TP53 protein | 29164574 |
D000077237 | Arsenic Trioxide | Arsenic Trioxide results in decreased expression of TP53 protein mutant form | 21454520 |
D000077237 | Arsenic Trioxide | Arsenic Trioxide results in increased degradation of TP53 protein | 19457607 |
D000077237 | Arsenic Trioxide | Arsenic Trioxide results in increased expression of and results in increased activity of TP53 protein | 17064470; 18167198; |
D000077237 | Arsenic Trioxide | Arsenic Trioxide results in increased expression of TP53 mRNA | 10850458; 17530438; 19769630; 23851143; 29274334; |
D000077237 | Arsenic Trioxide | Arsenic Trioxide results in increased expression of TP53 protein | 10841286; 10850458; 11146441; 11834893; 12490120; 15352174; 15904916; 15979894; 16467208; 19444595; 21454520; 21792014; 23440206; 26110921; 27430728; |
D000077237 | Arsenic Trioxide | Arsenic Trioxide results in increased phosphorylation of and results in increased stability of TP53 protein | 25574600 |
D000077237 | Arsenic Trioxide | Arsenic Trioxide results in increased phosphorylation of TP53 protein | 29944906; 30472098; |
D000077237 | Arsenic Trioxide | [Cisplatin co-treated with Arsenic Trioxide] results in increased phosphorylation of TP53 protein | 29944906 |
D000077237 | Arsenic Trioxide | Erlotinib Hydrochloride promotes the reaction [Arsenic Trioxide results in increased expression of TP53 mRNA] | 29274334 |
D000077237 | Arsenic Trioxide | GH1 protein promotes the reaction [Arsenic Trioxide results in increased expression of TP53 mRNA] | 23851143 |
D000077237 | Arsenic Trioxide | [INCB018424 co-treated with Arsenic Trioxide] results in increased expression of TP53 mRNA | 30012499 |
D000077237 | Arsenic Trioxide | [INCB018424 co-treated with Arsenic Trioxide] results in increased expression of TP53 protein | 30012499 |
D000077237 | Arsenic Trioxide | tetraarsenic tetrasulfide promotes the reaction [Arsenic Trioxide results in increased expression of TP53 protein] | 26110921 |
D000077237 | Arsenic Trioxide | TP53 affects the susceptibility to Arsenic Trioxide | 12851490 |
D000077237 | Arsenic Trioxide | TP53 protein affects the reaction [Arsenic Trioxide results in increased expression of TNFRSF10B protein] | 12851490 |
D000077237 | Arsenic Trioxide | TP53 protein affects the reaction [Arsenic Trioxide results in increased expression of TNFSF10 protein] | 12851490 |
D000077237 | Arsenic Trioxide | TP53 protein affects the susceptibility to Arsenic Trioxide | 29535630 |
D000077237 | Arsenic Trioxide | TP53 protein inhibits the reaction [Arsenic Trioxide results in increased cleavage of and results in increased activity of BID protein] | 12851490 |
D000077237 | Arsenic Trioxide | TP53 protein inhibits the reaction [Arsenic Trioxide results in increased cleavage of and results in increased activity of CASP3 protein] | 12851490 |
D000077237 | Arsenic Trioxide | TP53 protein mutant form results in decreased susceptibility to Arsenic Trioxide | 21454520; 24884809; |
D000077237 | Arsenic Trioxide | Arsenic Trioxide results in increased phosphorylation of TP53 protein | 27638049 |
D000077237 | Arsenic Trioxide | ATF4 protein promotes the reaction [Arsenic Trioxide results in increased phosphorylation of TP53 protein] | 27638049 |
D000077237 | Arsenic Trioxide | 2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one inhibits the reaction [Arsenic Trioxide results in increased phosphorylation of TP53 protein] | 23337567 |
D000077237 | Arsenic Trioxide | Arsenic Trioxide results in increased activity of TP53 protein | 17487067 |
D000077237 | Arsenic Trioxide | Arsenic Trioxide results in increased expression of TP53 mRNA | 21145380; 22801079; 29130132; |
D000077237 | Arsenic Trioxide | Arsenic Trioxide results in increased phosphorylation of TP53 protein | 23337567 |
D000077237 | Arsenic Trioxide | pifithrin inhibits the reaction [Arsenic Trioxide results in increased activity of TP53 protein] | 17487067 |
D000077237 | Arsenic Trioxide | polydatin inhibits the reaction [Arsenic Trioxide results in increased expression of TP53 mRNA] | 29130132 |
D000077237 | Arsenic Trioxide | Arsenic Trioxide results in increased expression of TP53 | 13129816 |
C015001 | arsenite | 3-(4-methylphenylsulfonyl)-2-propenenitrile promotes the reaction [arsenite promotes the reaction [TP53 protein binds to CREBBP protein]] | 20199942 |
C015001 | arsenite | Acetylcysteine inhibits the reaction [arsenite results in increased expression of TP53 protein] | 22260869 |
C015001 | arsenite | alpha-Tocopherol inhibits the reaction [arsenite results in increased expression of TP53 mRNA] | 12126965 |
C015001 | arsenite | alpha-Tocopherol inhibits the reaction [arsenite results in increased expression of TP53 protein] | 12126965 |
C015001 | arsenite | arsenite affects the methylation of TP53 promoter | 11489357 |
C015001 | arsenite | arsenite promotes the reaction [TP53 protein binds to CREBBP protein] | 20199942 |
C015001 | arsenite | arsenite promotes the reaction [TP53 protein binds to MIR34A promoter] | 25281835 |
C015001 | arsenite | arsenite promotes the reaction [TP53 protein binds to SIRT1 promoter] | 25281835 |
C015001 | arsenite | [[arsenite results in increased activity of PRKDC protein] which results in increased phosphorylation of and results in increased activity of MAPK9 protein] promotes the reaction [MAPK9 protein binds to TP53 protein] | 22366412 |
C015001 | arsenite | [[[arsenite results in increased activity of PRKDC protein] which results in increased phosphorylation of and results in increased activity of MAPK9 protein] promotes the reaction [MAPK9 protein binds to TP53 protein]] inhibits the reaction [MDM2 results in increased degradation of and results in decreased stability of TP53 protein] | 22366412 |
C015001 | arsenite | arsenite results in increased expression of and results in increased acetylation of TP53 protein | 25281835 |
C015001 | arsenite | arsenite results in increased expression of TP53 mRNA | 12126965; 22260869; 25281835; |
C015001 | arsenite | arsenite results in increased expression of TP53 protein | 12126965; 22260869; |
C015001 | arsenite | arsenite results in increased phosphorylation of and results in increased localization of and results in increased activity of TP53 protein | 20199942 |
C015001 | arsenite | HSPA9 protein inhibits the reaction [arsenite promotes the reaction [TP53 protein binds to CREBBP protein]] | 20199942 |
C015001 | arsenite | HSPA9 protein inhibits the reaction [arsenite results in increased phosphorylation of and results in increased localization of and results in increased activity of TP53 protein] | 20199942 |
C015001 | arsenite | HSPA9 protein promotes the reaction [3-(4-methylphenylsulfonyl)-2-propenenitrile promotes the reaction [arsenite promotes the reaction [TP53 protein binds to CREBBP protein]]] | 20199942 |
C015001 | arsenite | RELA protein inhibits the reaction [arsenite promotes the reaction [TP53 protein binds to CREBBP protein]] | 20199942 |
C015001 | arsenite | RELA protein inhibits the reaction [arsenite results in increased phosphorylation of and results in increased localization of and results in increased activity of TP53 protein] | 20199942 |
C015001 | arsenite | TP53 mutant form inhibits the reaction [arsenite results in increased activity of CASP3 protein] | 22260869 |
C015001 | arsenite | TP53 mutant form inhibits the reaction [arsenite results in increased activity of CASP7 protein] | 22260869 |
C015001 | arsenite | TP53 mutant form inhibits the reaction [arsenite results in increased cleavage of PARP1 protein] | 22260869 |
C031327 | artemisinine | artemisinine results in increased activity of TP53 protein | 30818834 |
C078098 | ar-turmerone | ar-turmerone results in increased expression of TP53 mRNA | 19250610 |
C078098 | ar-turmerone | ar-turmerone results in increased expression of TP53 protein | 19250610 |
D001194 | Asbestos | Asbestos affects the localization of TP53 protein | 25466987 |
D001194 | Asbestos | TP53 gene SNP affects the susceptibility to Asbestos | 23435014 |
D017639 | Asbestos, Amosite | Asbestos, Amosite affects the localization of TP53 protein | 16357363 |
D017639 | Asbestos, Amosite | Asbestos, Amosite results in increased expression of TP53 mRNA | 16357363 |
D017639 | Asbestos, Amosite | Asbestos, Amosite results in increased expression of TP53 protein | 16357363 |
D017639 | Asbestos, Amosite | Deferoxamine inhibits the reaction [Asbestos, Amosite results in increased expression of TP53 mRNA] | 16357363 |
D017639 | Asbestos, Amosite | Phytic Acid inhibits the reaction [Asbestos, Amosite results in increased expression of TP53 mRNA] | 16357363 |
D017639 | Asbestos, Amosite | Phytic Acid inhibits the reaction [Asbestos, Amosite results in increased expression of TP53 protein] | 16357363 |
D017639 | Asbestos, Amosite | pifithrin inhibits the reaction [Asbestos, Amosite affects the localization of TP53 protein] | 16357363 |
D017639 | Asbestos, Amosite | pifithrin inhibits the reaction [Asbestos, Amosite results in increased expression of TP53 protein] | 16357363 |
D017639 | Asbestos, Amosite | Sodium Benzoate inhibits the reaction [Asbestos, Amosite results in increased expression of TP53 mRNA] | 16357363 |
D017639 | Asbestos, Amosite | TP53 protein results in increased susceptibility to Asbestos, Amosite | 16357363 |
D017636 | Asbestos, Amphibole | Asbestos, Amphibole affects the expression of TP53 protein | 20855422 |
D017636 | Asbestos, Amphibole | Asbestos, Amphibole results in increased phosphorylation of and results in increased stability of TP53 protein | 20705543 |
D017638 | Asbestos, Crocidolite | Asbestos, Crocidolite affects the expression of TP53 mRNA | 17331233 |
D017638 | Asbestos, Crocidolite | Asbestos, Crocidolite affects the expression of TP53 protein | 21570478 |
D017638 | Asbestos, Crocidolite | Asbestos, Crocidolite results in decreased expression of and results in increased phosphorylation of TP53 protein | 23634900 |
D017638 | Asbestos, Crocidolite | Asbestos, Crocidolite results in decreased expression of TP53 protein | 23634900 |
D017638 | Asbestos, Crocidolite | Asbestos, Crocidolite results in decreased expression of TP53 protein modified form | 21570478 |
D017638 | Asbestos, Crocidolite | Asbestos, Crocidolite results in increased expression of TP53 protein | 12676607 |
D017638 | Asbestos, Crocidolite | Asbestos, Crocidolite results in increased phosphorylation of and results in increased stability of TP53 protein | 20705543 |
D017638 | Asbestos, Crocidolite | Asbestos, Crocidolite results in increased phosphorylation of TP53 protein | 12676607 |
D017632 | Asbestos, Serpentine | Asbestos, Serpentine results in increased expression of TP53 protein | 12676607 |
D017632 | Asbestos, Serpentine | Asbestos, Serpentine results in increased phosphorylation of TP53 protein | 12676607 |
D017632 | Asbestos, Serpentine | Wortmannin inhibits the reaction [Asbestos, Serpentine results in increased expression of TP53 protein] | 12676607 |
D017632 | Asbestos, Serpentine | Wortmannin inhibits the reaction [Asbestos, Serpentine results in increased phosphorylation of TP53 protein] | 12676607 |
D001205 | Ascorbic Acid | Acetylcysteine inhibits the reaction [[Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of TP53 protein] | 20530418 |
D001205 | Ascorbic Acid | [Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of TP53 protein | 20530418 |
D001205 | Ascorbic Acid | Ascorbic Acid inhibits the reaction [chromium hexavalent ion results in increased phosphorylation of TP53 protein] | 31388677 |
D001205 | Ascorbic Acid | Ascorbic Acid inhibits the reaction [potassium bromate results in increased phosphorylation of TP53 protein] | 20067818 |
D001205 | Ascorbic Acid | Ascorbic Acid inhibits the reaction [potassium chromate(VI) results in increased expression of TP53 protein] | 25977998 |
D001205 | Ascorbic Acid | Ascorbic Acid inhibits the reaction [potassium chromate(VI) results in increased expression of TP53 protein modified form] | 25977998 |
D001205 | Ascorbic Acid | Ascorbic Acid inhibits the reaction [Silicon Dioxide results in increased expression of TP53 mRNA] | 22245848 |
D001205 | Ascorbic Acid | Ascorbic Acid inhibits the reaction [Silicon Dioxide results in increased expression of TP53 protein] | 22245848 |
D001205 | Ascorbic Acid | Ascorbic Acid promotes the reaction [Cisplatin results in increased expression of TP53 protein] | 21429301 |
D001205 | Ascorbic Acid | benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of TP53 protein] | 20530418 |
D001205 | Ascorbic Acid | [juglone co-treated with Ascorbic Acid] results in increased phosphorylation of TP53 protein | 29992683 |
D001205 | Ascorbic Acid | nutlin 3 inhibits the reaction [[Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of TP53 protein] | 20530418 |
D001205 | Ascorbic Acid | [beta Carotene co-treated with alpha-Tocopherol co-treated with Ascorbic Acid] inhibits the reaction [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased expression of TP53 protein] | 16401635 |
D001205 | Ascorbic Acid | [beta Carotene co-treated with alpha-Tocopherol co-treated with Ascorbic Acid] inhibits the reaction [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased phosphorylation of TP53 protein] | 16401635 |
D001205 | Ascorbic Acid | Ascorbic Acid inhibits the reaction [Potassium Dichromate results in increased expression of and results in increased phosphorylation of TP53 protein] | 21262251 |
D001205 | Ascorbic Acid | Ascorbic Acid inhibits the reaction [Potassium Dichromate results in increased expression of TP53 mRNA] | 21262251 |
D001205 | Ascorbic Acid | Ascorbic Acid inhibits the reaction [Potassium Dichromate results in increased localization of TP53 protein modified form] | 21262251 |
D001241 | Aspirin | Aspirin inhibits the reaction [sodium bichromate results in increased expression of TP53 protein] | 10942736 |
D001241 | Aspirin | Aspirin results in increased acetylation of TP53 protein | 19212664 |
D001241 | Aspirin | Aspirin results in increased expression of TP53 protein | 12535653 |
C005948 | astaxanthine | astaxanthine inhibits the reaction [Cyclophosphamide results in increased expression of TP53 protein] | 20038455 |
C099069 | astilbin | astilbin inhibits the reaction [Cisplatin results in increased expression of TP53 protein] | 29471006 |
C050701 | atipamezole | atipamezole inhibits the reaction [Dexmedetomidine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of TP53 protein]] | 30597158 |
D000069059 | Atorvastatin | Atorvastatin results in increased expression of TP53 protein | 29630879 |
C424804 | atractylenolide I | atractylenolide I inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of TP53 protein] | 28481321 |
C026304 | atranorin | atranorin results in decreased expression of TP53 protein | 22285236 |
D000077868 | Atrasentan | Atrasentan inhibits the reaction [[Desoxycorticosterone co-treated with Sodium Chloride] results in increased expression of TP53 protein] | 22431579 |
D001280 | Atrazine | Atrazine results in decreased expression of TP53 mRNA | 21333729; 22378314; |
D001280 | Atrazine | Atrazine results in decreased expression of TP53 protein | 21333729 |
D001280 | Atrazine | kolaviron inhibits the reaction [Atrazine results in decreased expression of TP53 mRNA] | 21333729 |
D001280 | Atrazine | kolaviron inhibits the reaction [Atrazine results in decreased expression of TP53 protein] | 21333729 |
D001280 | Atrazine | Atrazine affects the expression of TP53 | 21726175 |
D001280 | Atrazine | Atrazine affects the localization of TP53 protein | 9486943 |
D001280 | Atrazine | Atrazine results in increased expression of TP53 protein | 9486943 |
D001280 | Atrazine | kolaviron inhibits the reaction [Atrazine affects the expression of TP53] | 21726175 |
D001285 | Atropine | Atropine inhibits the reaction [Malathion results in increased expression of TP53 protein] | 12762645 |
D001285 | Atropine | Atropine inhibits the reaction [Parathion results in increased expression of TP53 protein] | 12762645 |
C516713 | auriculasin | TNFRSF10B protein affects the reaction [[TNFSF10 protein co-treated with auriculasin] results in increased expression of TP53 protein] | 30817944 |
C516713 | auriculasin | [TNFSF10 protein co-treated with auriculasin] results in increased expression of TP53 protein | 30817944 |
C083578 | aurofusarin | aurofusarin results in increased expression of TP53 protein | 29248571 |
C010329 | azadirachtin | azadirachtin results in increased expression of TP53 mRNA | 20429769 |
C010329 | azadirachtin | azadirachtin results in increased expression of TP53 protein | 20429769 |
D001379 | Azathioprine | Azathioprine results in increased expression of TP53 protein | 14961032 |
D001379 | Azathioprine | Azathioprine results in increased mutagenesis of TP53 gene | 17979968 |
D001397 | Azoxymethane | Azoxymethane results in increased phosphorylation of TP53 protein | 18239060 |
C040929 | bafilomycin A1 | [bafilomycin A1 co-treated with cobaltous chloride co-treated with TP53 gene mutant form] results in increased activity of CASP3 protein | 23380477 |
C040929 | bafilomycin A1 | bafilomycin A1 inhibits the reaction [[cobaltous chloride co-treated with TP53 gene mutant form] results in increased activity of CTSB protein] | 23380477 |
C006680 | baicalein | baicalein results in increased expression of TP53 protein | 21457722 |
C038044 | baicalin | baicalin results in increased expression of TP53 protein | 21457722 |
C002478 | bathocuproine | bathocuproine inhibits the reaction [[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of TP53 gene] | 10334203 |
C002478 | bathocuproine | bathocuproine inhibits the reaction [[phenylhydroquinone co-treated with Copper] results in increased mutagenesis of TP53 gene] | 10334203 |
C028559 | bathocuproine sulfonate | bathocuproine sulfonate inhibits the reaction [[pyrrolidine dithiocarbamic acid results in increased abundance of Copper] which results in increased oxidation of and results in increased expression of TP53 protein] | 11964141 |
C416282 | BAY 11-7085 | BAY 11-7085 inhibits the reaction [7-ketocholesterol results in increased expression of TP53 protein] | 25845326 |
C580697 | BDMC-A | BDMC-A results in increased expression of TP53 protein | 24365254 |
C487081 | belinostat | belinostat results in decreased expression of TP53 mRNA | 19606018 |
D000069461 | Bendamustine Hydrochloride | Bendamustine Hydrochloride results in increased expression of TP53 protein | 12948851 |
D001546 | Bentonite | Bentonite inhibits the reaction [[HT-2 toxin co-treated with T-2 Toxin] results in increased expression of TP53 mRNA] | 25296281 |
D001551 | Benz(a)Anthracenes | Benz(a)Anthracenes analog results in increased phosphorylation of TP53 protein | 18205319 |
D001554 | Benzene | Benzene results in decreased expression of TP53 mRNA | 19505915 |
D001554 | Benzene | Benzene results in increased expression of TP53 mRNA | 21382456 |
D001554 | Benzene | Benzene results in increased mutagenesis of TP53 gene | 19862502 |
D001554 | Benzene | Benzene results in increased phosphorylation of TP53 protein | 8076368 |
D001554 | Benzene | TP53 gene SNP results in increased susceptibility to Benzene | 16728435 |
D001554 | Benzene | TP53 SNP affects the susceptibility to Benzene | 18978339 |
D001554 | Benzene | Benzene results in increased expression of TP53 protein | 18093815 |
D001554 | Benzene | Benzene results in increased phosphorylation of and results in increased activity of TP53 protein | 9118908 |
C029876 | benzidine | benzidine results in increased expression of TP53 protein mutant form | 15748509; 17690521; |
D001564 | Benzo(a)pyrene | 2,4,4'-trichlorobiphenyl promotes the reaction [Benzo(a)pyrene results in increased phosphorylation of and results in increased expression of TP53 protein] | 20840854 |
D001564 | Benzo(a)pyrene | 2,4,5,2',4',5'-hexachlorobiphenyl promotes the reaction [Benzo(a)pyrene affects the localization of and results in increased expression of TP53 protein] | 24954032 |
D001564 | Benzo(a)pyrene | 2,4,5,2',4',5'-hexachlorobiphenyl promotes the reaction [Benzo(a)pyrene results in increased phosphorylation of and results in increased expression of TP53 protein] | 20840854 |
D001564 | Benzo(a)pyrene | 2,4,5,2',5'-pentachlorobiphenyl promotes the reaction [Benzo(a)pyrene affects the localization of TP53 protein] | 20840854 |
D001564 | Benzo(a)pyrene | 2,4,5,2',5'-pentachlorobiphenyl promotes the reaction [Benzo(a)pyrene results in increased phosphorylation of and results in increased expression of TP53 protein] | 20840854 |
D001564 | Benzo(a)pyrene | 3,4,5,3',4'-pentachlorobiphenyl inhibits the reaction [Benzo(a)pyrene affects the localization of TP53 protein] | 20840854 |
D001564 | Benzo(a)pyrene | 3,4,5,3',4'-pentachlorobiphenyl inhibits the reaction [Benzo(a)pyrene results in increased phosphorylation of and results in increased expression of TP53 protein] | 20840854 |
D001564 | Benzo(a)pyrene | Acrolein inhibits the reaction [Benzo(a)pyrene results in increased activity of TP53 protein] | 12807757 |
D001564 | Benzo(a)pyrene | Benzo(a)pyrene affects the activity of TP53 protein | 20624995 |
D001564 | Benzo(a)pyrene | Benzo(a)pyrene affects the expression of TP53 | 24362009 |
D001564 | Benzo(a)pyrene | Benzo(a)pyrene affects the expression of TP53 mRNA | 21393351; 27825931; |
D001564 | Benzo(a)pyrene | Benzo(a)pyrene affects the expression of TP53 mutant form | 24362009 |
D001564 | Benzo(a)pyrene | Benzo(a)pyrene affects the localization of and results in increased expression of TP53 protein | 24954032 |
D001564 | Benzo(a)pyrene | Benzo(a)pyrene affects the localization of TP53 protein | 20840854 |
D001564 | Benzo(a)pyrene | Benzo(a)pyrene affects the phosphorylation of TP53 protein | 24362009 |
D001564 | Benzo(a)pyrene | Benzo(a)pyrene promotes the reaction [TP53 protein binds to MDM2 protein] | 15625077 |
D001564 | Benzo(a)pyrene | Benzo(a)pyrene promotes the reaction [TP53 protein results in increased expression of CYP2A6 mRNA] | 26343999 |
D001564 | Benzo(a)pyrene | Benzo(a)pyrene results in decreased expression of TP53 mRNA | 18247414 |
D001564 | Benzo(a)pyrene | Benzo(a)pyrene results in decreased expression of TP53 protein | 29126329 |
D001564 | Benzo(a)pyrene | Benzo(a)pyrene results in increased activity of TP53 protein | 12807757 |
D001564 | Benzo(a)pyrene | Benzo(a)pyrene results in increased expression of and results in increased phosphorylation of TP53 protein | 15698582 |
D001564 | Benzo(a)pyrene | Benzo(a)pyrene results in increased expression of TP53 mRNA | 19027820; 22889811; 31542801; |
D001564 | Benzo(a)pyrene | Benzo(a)pyrene results in increased expression of TP53 protein | 10837373; 11782367; 12807757; 15548639; 15808406; 16041517; 16258175; 18174961; 20064835; 20862736; 21714911; 22044530; 22053912; 22120587; 22227536; 22266578; 26343999; 29218508; 31542801; |
D001564 | Benzo(a)pyrene | Benzo(a)pyrene results in increased expression of TP53 protein modified form | 22044530 |
D001564 | Benzo(a)pyrene | Benzo(a)pyrene results in increased mutagenesis of TP53 gene | 22319594 |
D001564 | Benzo(a)pyrene | Benzo(a)pyrene results in increased phosphorylation of and results in increased activity of TP53 protein | 24664296 |
D001564 | Benzo(a)pyrene | Benzo(a)pyrene results in increased phosphorylation of and results in increased expression of TP53 protein | 20840854; 21457773; |
D001564 | Benzo(a)pyrene | Benzo(a)pyrene results in increased phosphorylation of TP53 protein | 15837074; 24361490; 25744307; 27694624; |
D001564 | Benzo(a)pyrene | [Buthionine Sulfoximine results in decreased abundance of Glutathione] inhibits the reaction [Benzo(a)pyrene results in increased activity of TP53 protein] | 12807757 |
D001564 | Benzo(a)pyrene | Cadmium Chloride affects the reaction [Benzo(a)pyrene results in increased phosphorylation of TP53 protein] | 25744307 |
D001564 | Benzo(a)pyrene | Curcumin inhibits the reaction [Benzo(a)pyrene results in increased phosphorylation of and results in increased activity of TP53 protein] | 24664296 |
D001564 | Benzo(a)pyrene | Estradiol promotes the reaction [Benzo(a)pyrene affects the localization of and results in increased expression of TP53 protein] | 24954032 |
D001564 | Benzo(a)pyrene | fluoranthene promotes the reaction [Benzo(a)pyrene results in increased expression of TP53 protein] | 22120587 |
D001564 | Benzo(a)pyrene | fostriecin promotes the reaction [Tetrachlorodibenzodioxin promotes the reaction [Benzo(a)pyrene results in increased expression of TP53 protein]] | 24954032 |
D001564 | Benzo(a)pyrene | FOXO3 mutant form promotes the reaction [Benzo(a)pyrene affects the localization of TP53 protein] | 24954032 |
D001564 | Benzo(a)pyrene | MDM2 mutant form promotes the reaction [Benzo(a)pyrene results in increased expression of TP53 protein] | 20840854 |
D001564 | Benzo(a)pyrene | Nitrogen Oxides inhibits the reaction [Benzo(a)pyrene results in increased expression of TP53 protein] | 16041517 |
D001564 | Benzo(a)pyrene | Okadaic Acid affects the reaction [Estradiol promotes the reaction [Benzo(a)pyrene affects the localization of TP53 protein]] | 24954032 |
D001564 | Benzo(a)pyrene | Okadaic Acid affects the reaction [Tetrachlorodibenzodioxin promotes the reaction [Benzo(a)pyrene results in increased expression of TP53 protein]] | 24954032 |
D001564 | Benzo(a)pyrene | Okadaic Acid inhibits the reaction [2,4,5,2',4',5'-hexachlorobiphenyl promotes the reaction [Benzo(a)pyrene affects the localization of TP53 protein]] | 24954032 |
D001564 | Benzo(a)pyrene | Okadaic Acid inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [Benzo(a)pyrene affects the localization of TP53 protein]] | 24954032 |
D001564 | Benzo(a)pyrene | Okadaic Acid promotes the reaction [2,4,5,2',4',5'-hexachlorobiphenyl promotes the reaction [Benzo(a)pyrene results in increased expression of TP53 protein]] | 24954032 |
D001564 | Benzo(a)pyrene | PARG affects the reaction [Benzo(a)pyrene results in increased expression of TP53 mRNA] | 22266578 |
D001564 | Benzo(a)pyrene | PARG affects the reaction [Benzo(a)pyrene results in increased expression of TP53 protein] | 22266578 |
D001564 | Benzo(a)pyrene | pifithrin inhibits the reaction [Benzo(a)pyrene results in increased expression of TP53 protein] | 16258175 |
D001564 | Benzo(a)pyrene | promotes the reaction [Benzo(a)pyrene affects the localization of TP53 protein] | 24954032 |
D001564 | Benzo(a)pyrene | Simvastatin promotes the reaction [Benzo(a)pyrene promotes the reaction [TP53 protein binds to MDM2 protein]] | 15625077 |
D001564 | Benzo(a)pyrene | Tetrachlorodibenzodioxin promotes the reaction [Benzo(a)pyrene affects the localization of and results in increased expression of TP53 protein] | 24954032 |
D001564 | Benzo(a)pyrene | TP53 affects the reaction [Benzo(a)pyrene results in increased expression of BAX mRNA] | 10837373 |
D001564 | Benzo(a)pyrene | TP53 affects the reaction [Benzo(a)pyrene results in increased expression of MDM2 mRNA] | 10837373 |
D001564 | Benzo(a)pyrene | TP53 affects the susceptibility to Benzo(a)pyrene | 10837373 |
D001564 | Benzo(a)pyrene | TP53 mutant form inhibits the reaction [Benzo(a)pyrene results in increased expression of CDKN1A mRNA] | 24361490 |
D001564 | Benzo(a)pyrene | TP53 mutant form inhibits the reaction [Benzo(a)pyrene results in increased expression of CGB3 mRNA] | 24361490 |
D001564 | Benzo(a)pyrene | TP53 mutant form inhibits the reaction [Benzo(a)pyrene results in increased expression of ERVFRD-1 mRNA] | 24361490 |
D001564 | Benzo(a)pyrene | TP53 protein affects the reaction [Benzo(a)pyrene results in increased expression of CDKN1A mRNA] | 28882572 |
D001564 | Benzo(a)pyrene | TP53 protein affects the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 protein] | 25398514 |
D001564 | Benzo(a)pyrene | TP53 protein affects the reaction [Benzo(a)pyrene results in increased phosphorylation of H2AX protein] | 28882572 |
D001564 | Benzo(a)pyrene | TP53 protein affects the susceptibility to Benzo(a)pyrene | 28882572; 29471073; |
D001564 | Benzo(a)pyrene | [TP53 protein affects the susceptibility to Benzo(a)pyrene] which affects the chemical synthesis of 13-hydroxyellipticine | 29471073 |
D001564 | Benzo(a)pyrene | [TP53 protein affects the susceptibility to Benzo(a)pyrene] which results in increased expression of CDKN1A protein | 29471073 |
D001564 | Benzo(a)pyrene | [TP53 protein affects the susceptibility to Benzo(a)pyrene] which results in increased expression of CYP1A1 protein | 29471073 |
D001564 | Benzo(a)pyrene | [TP53 protein binds to CYP1A1 promoter] affects the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 protein] | 25398514 |
D001564 | Benzo(a)pyrene | TP53 protein promotes the reaction [Benzo(a)pyrene results in decreased expression of BRCA1 mRNA] | 11782367 |
D001564 | Benzo(a)pyrene | TP53 protein promotes the reaction [ellipticine inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 protein]] | 29471073 |
D001564 | Benzo(a)pyrene | TP53 protein promotes the reaction [[ellipticine results in increased susceptibility to Benzo(a)pyrene] which results in increased expression of CDKN1A protein] | 29471073 |
D001564 | Benzo(a)pyrene | TP53 protein promotes the reaction [Etoposide promotes the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 protein]] | 29471073 |
D001564 | Benzo(a)pyrene | TP53 protein promotes the reaction [[Etoposide results in increased susceptibility to Benzo(a)pyrene] which results in increased expression of CDKN1A protein] | 29471073 |
D001564 | Benzo(a)pyrene | TP53 protein results in increased susceptibility to Benzo(a)pyrene | 25398514 |
D001564 | Benzo(a)pyrene | Vitamin E inhibits the reaction [Benzo(a)pyrene results in increased phosphorylation of and results in increased activity of TP53 protein] | 24664296 |
D001564 | Benzo(a)pyrene | Vitamin E inhibits the reaction [Benzo(a)pyrene results in increased phosphorylation of TP53 protein] | 15837074 |
D001564 | Benzo(a)pyrene | Wortmannin inhibits the reaction [Benzo(a)pyrene results in increased phosphorylation of TP53 protein] | 15837074 |
D001564 | Benzo(a)pyrene | Benzo(a)pyrene results in increased mutagenesis of TP53 gene | 22410783 |
D001564 | Benzo(a)pyrene | Benzo(a)pyrene results in increased expression of TP53 mRNA | 18656336 |
D001564 | Benzo(a)pyrene | Benzo(a)pyrene results in increased expression of TP53 mRNA | 21899289 |
D001564 | Benzo(a)pyrene | Benzo(a)pyrene results in decreased expression of TP53 mRNA | 28651000 |
D001564 | Benzo(a)pyrene | Benzo(a)pyrene results in increased expression of and results in increased phosphorylation of TP53 protein | 15459018 |
D001564 | Benzo(a)pyrene | Benzo(a)pyrene results in increased expression of TP53 mRNA | 19408242; 20064080; |
D001564 | Benzo(a)pyrene | Benzo(a)pyrene results in increased expression of TP53 protein | 19408242; 20064080; 9789950; |
D001564 | Benzo(a)pyrene | Benzo(a)pyrene results in increased expression of TP53 protein modified form | 21604763 |
D001564 | Benzo(a)pyrene | Benzo(a)pyrene results in increased phosphorylation of TP53 protein | 17961608; 18634860; |
D001564 | Benzo(a)pyrene | [Sulfur Dioxide co-treated with Benzo(a)pyrene] results in increased expression of TP53 mRNA | 19408242 |
D001564 | Benzo(a)pyrene | [Sulfur Dioxide co-treated with Benzo(a)pyrene] results in increased expression of TP53 protein | 19408242 |
D001564 | Benzo(a)pyrene | Sulfur Dioxide promotes the reaction [Benzo(a)pyrene results in increased expression of TP53 mRNA] | 20064080 |
D001564 | Benzo(a)pyrene | Sulfur Dioxide promotes the reaction [Benzo(a)pyrene results in increased expression of TP53 protein] | 20064080 |
D001564 | Benzo(a)pyrene | Tetrachlorodibenzodioxin inhibits the reaction [Benzo(a)pyrene results in increased expression of and results in increased phosphorylation of TP53 protein] | 15459018 |
D001564 | Benzo(a)pyrene | [TNF protein co-treated with Benzo(a)pyrene] results in increased phosphorylation of TP53 protein | 21745554 |
D001564 | Benzo(a)pyrene | Benzo(a)pyrene results in increased activity of TP53 protein | 22044530 |
D001564 | Benzo(a)pyrene | pifithrin results in decreased susceptibility to [Benzo(a)pyrene results in increased activity of TP53 protein] | 22044530 |
C017228 | benzo(a)pyrene 7,8-dihydrodiol | benzo(a)pyrene 7,8-dihydrodiol results in increased expression of and results in increased phosphorylation of TP53 protein | 15698582 |
C017228 | benzo(a)pyrene 7,8-dihydrodiol | Etoposide promotes the reaction [TP53 protein results in increased chemical synthesis of benzo(a)pyrene 7,8-dihydrodiol] | 29471073 |
C017228 | benzo(a)pyrene 7,8-dihydrodiol | TP53 protein results in increased chemical synthesis of benzo(a)pyrene 7,8-dihydrodiol | 29471073 |
C017228 | benzo(a)pyrene 7,8-dihydrodiol | [TP53 protein results in increased susceptibility to Etoposide] which results in decreased chemical synthesis of benzo(a)pyrene 7,8-dihydrodiol | 29471073 |
C072019 | benzo(a)pyrene diolepoxide I | benzo(a)pyrene diolepoxide I promotes the reaction [TP53 protein binds to POLH promoter] | 27694624 |
C072019 | benzo(a)pyrene diolepoxide I | benzo(a)pyrene diolepoxide I results in increased expression of and results in increased phosphorylation of and results in increased activity of TP53 protein | 27694624 |
C072019 | benzo(a)pyrene diolepoxide I | benzo(a)pyrene diolepoxide I results in increased expression of and results in increased phosphorylation of TP53 protein | 15698582 |
C006703 | benzo(b)fluoranthene | benzo(b)fluoranthene results in increased expression of TP53 protein | 21776270 |
C100422 | benzo(g)chrysene | benzo(g)chrysene results in increased phosphorylation of TP53 protein | 17961608 |
C110772 | benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone | benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone inhibits the reaction [TP53 protein affects the reaction [chromium hexavalent ion results in increased activity of CASP3 protein]] | 16166740 |
C403753 | benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone | benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [Bortezomib results in increased phosphorylation of TP53 protein] | 12393500 |
C072553 | benzyloxycarbonylleucyl-leucyl-leucine aldehyde | benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of TP53 protein] | 20530418 |
C072553 | benzyloxycarbonylleucyl-leucyl-leucine aldehyde | benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Capsaicin results in increased degradation of TP53 protein] | 19699254 |
C072553 | benzyloxycarbonylleucyl-leucyl-leucine aldehyde | benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Chlorpyrifos results in decreased expression of TP53 protein] | 27993609 |
C072553 | benzyloxycarbonylleucyl-leucyl-leucine aldehyde | benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [sodium arsenite results in increased degradation of TP53 protein mutant form] | 21454520 |
C072553 | benzyloxycarbonylleucyl-leucyl-leucine aldehyde | benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Zinc Sulfate co-treated with prolinedithiocarbamate] results in decreased expression of TP53 protein] | 18951928 |
C072553 | benzyloxycarbonylleucyl-leucyl-leucine aldehyde | benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of and results in increased expression of TP53 protein | 27129209 |
C072553 | benzyloxycarbonylleucyl-leucyl-leucine aldehyde | benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of TP53 protein | 10837373 |
C072553 | benzyloxycarbonylleucyl-leucyl-leucine aldehyde | benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Acetaminophen results in increased degradation of TP53 protein] | 16330492 |
C072553 | benzyloxycarbonylleucyl-leucyl-leucine aldehyde | benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Curcumin binds to carboxymethyl-chitosan analog] inhibits the reaction [AGT protein modified form results in decreased degradation of TP53 protein]] | 26612707 |
C072553 | benzyloxycarbonylleucyl-leucyl-leucine aldehyde | benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of TP53 protein modified form | 26612707 |
C072553 | benzyloxycarbonylleucyl-leucyl-leucine aldehyde | benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased phosphorylation of and results in increased expression of TP53 protein | 18463101 |
C072553 | benzyloxycarbonylleucyl-leucyl-leucine aldehyde | benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased ubiquitination of TP53 protein | 18463101 |
C517629 | benzyloxycarbonyl-valyl-alanyl-aspartic acid | TP53 gene mutant form affects the reaction [benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[Fluorouracil co-treated with olaparib] results in increased phosphorylation of H2AX protein]] | 26544897 |
D001599 | Berberine | [Berberine co-treated with Niacinamide] results in increased expression of and results in increased acetylation of TP53 protein | 26712469 |
D001599 | Berberine | Berberine results in increased expression of TP53 mRNA | 20656010 |
D001599 | Berberine | Berberine results in increased expression of TP53 protein | 20656010 |
D001599 | Berberine | Berberine results in increased phosphorylation of and results in increased acetylation of TP53 protein | 26712469 |
C020711 | beryllium sulfate | beryllium sulfate promotes the reaction [TP53 protein binds to CDKN1A promoter] | 17395767 |
C020711 | beryllium sulfate | beryllium sulfate results in increased expression of TP53 protein | 17395767; 20974702; |
C000617228 | beta-2-himachalen-6-ol | beta-2-himachalen-6-ol results in increased expression of TP53 protein | 28782499 |
D019207 | beta Carotene | [beta Carotene co-treated with alpha-Tocopherol co-treated with Ascorbic Acid] inhibits the reaction [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased expression of TP53 protein] | 16401635 |
D019207 | beta Carotene | [beta Carotene co-treated with alpha-Tocopherol co-treated with Ascorbic Acid] inhibits the reaction [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased phosphorylation of TP53 protein] | 16401635 |
C014638 | beta-lapachone | beta-lapachone results in increased expression of TP53 mRNA | 22560901 |
D019324 | beta-Naphthoflavone | [beta-Naphthoflavone binds to and results in increased activity of AHR protein] results in decreased susceptibility to [1-nitropyrene results in increased expression of TP53 protein] | 22044530 |
D000077610 | Bexarotene | Bexarotene results in increased phosphorylation of and results in increased activity of TP53 protein | 19067706 |
C053541 | bicalutamide | bicalutamide inhibits the reaction [bisphenol A results in increased phosphorylation of TP53 protein] | 29383186 |
C053541 | bicalutamide | bicalutamide results in increased expression of TP53 protein | 15638997 |
D001647 | Bile Acids and Salts | Bile Acids and Salts results in decreased expression of TP53 protein | 21127259 |
C542674 | bis((2-oxindol-3-ylimino)-2-(2-aminoethyl)pyridine-N,N')copper(II) | bis((2-oxindol-3-ylimino)-2-(2-aminoethyl)pyridine-N,N')copper(II) affects the localization of TP53 protein | 21548882 |
C542674 | bis((2-oxindol-3-ylimino)-2-(2-aminoethyl)pyridine-N,N')copper(II) | bis((2-oxindol-3-ylimino)-2-(2-aminoethyl)pyridine-N,N')copper(II) results in increased expression of TP53 protein | 21548882 |
C542674 | bis((2-oxindol-3-ylimino)-2-(2-aminoethyl)pyridine-N,N')copper(II) | bromopyruvate promotes the reaction [bis((2-oxindol-3-ylimino)-2-(2-aminoethyl)pyridine-N,N')copper(II) results in increased expression of TP53 protein] | 21548882 |
C542674 | bis((2-oxindol-3-ylimino)-2-(2-aminoethyl)pyridine-N,N')copper(II) | Glucose inhibits the reaction [bis((2-oxindol-3-ylimino)-2-(2-aminoethyl)pyridine-N,N')copper(II) results in increased expression of TP53 protein] | 21548882 |
C542674 | bis((2-oxindol-3-ylimino)-2-(2-aminoethyl)pyridine-N,N')copper(II) | MAPK14 protein promotes the reaction [bis((2-oxindol-3-ylimino)-2-(2-aminoethyl)pyridine-N,N')copper(II) results in increased expression of TP53 protein] | 21548882 |
C542674 | bis((2-oxindol-3-ylimino)-2-(2-aminoethyl)pyridine-N,N')copper(II) | monomethyl succinate inhibits the reaction [bis((2-oxindol-3-ylimino)-2-(2-aminoethyl)pyridine-N,N')copper(II) results in increased expression of TP53 protein] | 21548882 |
C542674 | bis((2-oxindol-3-ylimino)-2-(2-aminoethyl)pyridine-N,N')copper(II) | PRKAA2 protein promotes the reaction [bis((2-oxindol-3-ylimino)-2-(2-aminoethyl)pyridine-N,N')copper(II) affects the localization of TP53 protein] | 21548882 |
C542674 | bis((2-oxindol-3-ylimino)-2-(2-aminoethyl)pyridine-N,N')copper(II) | PRKAA2 protein promotes the reaction [bis((2-oxindol-3-ylimino)-2-(2-aminoethyl)pyridine-N,N')copper(II) results in increased expression of TP53 protein] | 21548882 |
C542674 | bis((2-oxindol-3-ylimino)-2-(2-aminoethyl)pyridine-N,N')copper(II) | SOD1 protein inhibits the reaction [bromopyruvate promotes the reaction [bis((2-oxindol-3-ylimino)-2-(2-aminoethyl)pyridine-N,N')copper(II) results in increased expression of TP53 protein]] | 21548882 |
C542674 | bis((2-oxindol-3-ylimino)-2-(2-aminoethyl)pyridine-N,N')copper(II) | [Tretinoin results in increased uptake of Glucose] inhibits the reaction [bis((2-oxindol-3-ylimino)-2-(2-aminoethyl)pyridine-N,N')copper(II) results in increased expression of TP53 protein] | 21548882 |
C070515 | bisindolylmaleimide I | bisindolylmaleimide I results in decreased degradation of and results in increased expression of TP53 protein | 16055726 |
C467001 | bisindolylmaleimide IX | bisindolylmaleimide IX results in decreased degradation of and results in increased expression of TP53 protein | 16055726 |
C006780 | bisphenol A | bisphenol A results in increased expression of TP53 mRNA | 28159858 |
C006780 | bisphenol A | bisphenol A affects the expression of TP53 mRNA | 21786754 |
C006780 | bisphenol A | bisphenol A results in increased expression of TP53 mRNA | 26911650; 28083739; 31272786; |
C006780 | bisphenol A | 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [bisphenol A results in increased phosphorylation of TP53 protein] | 29383186 |
C006780 | bisphenol A | bicalutamide inhibits the reaction [bisphenol A results in increased phosphorylation of TP53 protein] | 29383186 |
C006780 | bisphenol A | bisphenol A results in decreased expression of TP53 mRNA | 27998958; 28238728; |
C006780 | bisphenol A | bisphenol A results in decreased expression of TP53 protein | 23222814 |
C006780 | bisphenol A | bisphenol A results in increased expression of TP53 mRNA | 29275510 |
C006780 | bisphenol A | bisphenol A results in increased expression of TP53 protein | 21277958; 24831732; 29128613; |
C006780 | bisphenol A | bisphenol A results in increased phosphorylation of TP53 protein | 29275510; 29383186; |
C006780 | bisphenol A | Curcumin inhibits the reaction [bisphenol A results in decreased expression of TP53 protein] | 23222814 |
C006780 | bisphenol A | Curcumin inhibits the reaction [bisphenol A results in increased expression of TP53 protein] | 24831732 |
C006780 | bisphenol A | Fulvestrant inhibits the reaction [bisphenol A results in increased phosphorylation of TP53 protein] | 29383186 |
C006780 | bisphenol A | Gefitinib inhibits the reaction [bisphenol A results in increased phosphorylation of TP53 protein] | 29383186 |
C006780 | bisphenol A | MIR149 mRNA inhibits the reaction [bisphenol A results in decreased expression of TP53 mRNA] | 28238728 |
C006780 | bisphenol A | bisphenol A affects the expression of TP53 mRNA | 17950039 |
C006780 | bisphenol A | bisphenol A results in increased expression of TP53 mRNA | 14595849 |
C006780 | bisphenol A | bisphenol A affects the expression of TP53 mRNA | 25181051 |
C006780 | bisphenol A | bisphenol A results in decreased expression of TP53 mRNA | 26982218 |
C006780 | bisphenol A | bisphenol A results in increased expression of TP53 mRNA | 23146694; 27539358; |
C006780 | bisphenol A | bisphenol A results in increased expression of TP53 protein | 25344109; 25454643; 27208089; |
C006780 | bisphenol A | bisphenol A results in increased methylation of TP53 gene | 28505145 |
C006780 | bisphenol A | Melatonin inhibits the reaction [bisphenol A results in increased expression of TP53 protein] | 25454643 |
C006780 | bisphenol A | bisphenol A results in increased expression of TP53 protein | 28819136 |
C006780 | bisphenol A | bisphenol A results in increased expression of TP53 mRNA | 20060579 |
D057886 | Bleaching Agents | Bleaching Agents results in increased expression of TP53 mRNA | 21538407 |
D001761 | Bleomycin | 2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one inhibits the reaction [Bleomycin promotes the reaction [Resveratrol results in increased phosphorylation of TP53 protein]] | 24933654 |
D001761 | Bleomycin | 2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one inhibits the reaction [Bleomycin results in increased phosphorylation of TP53 protein] | 24933654 |
D001761 | Bleomycin | 2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one inhibits the reaction [Resveratrol promotes the reaction [Bleomycin results in increased phosphorylation of TP53 protein]] | 24933654 |
D001761 | Bleomycin | Bleomycin promotes the reaction [Polyphenols results in increased expression of TP53 mRNA] | 26800624 |
D001761 | Bleomycin | Bleomycin promotes the reaction [Resveratrol results in increased phosphorylation of TP53 protein] | 24933654 |
D001761 | Bleomycin | Bleomycin promotes the reaction [Tea results in increased expression of TP53 mRNA] | 26800624 |
D001761 | Bleomycin | Bleomycin results in increased expression of TP53 mRNA | 26800624 |
D001761 | Bleomycin | Bleomycin results in increased phosphorylation of TP53 protein | 24933654 |
D001761 | Bleomycin | Polyphenols promotes the reaction [Bleomycin results in increased expression of TP53 mRNA] | 26800624 |
D001761 | Bleomycin | Resveratrol promotes the reaction [Bleomycin results in increased phosphorylation of TP53 protein] | 24933654 |
D001761 | Bleomycin | Tea promotes the reaction [Bleomycin results in increased expression of TP53 mRNA] | 26800624 |
D001761 | Bleomycin | TP53 protein results in increased susceptibility to Bleomycin | 20135637 |
D000069286 | Bortezomib | benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [Bortezomib results in increased phosphorylation of TP53 protein] | 12393500 |
D000069286 | Bortezomib | Bortezomib promotes the reaction [TP53 protein binds to MDM2 protein] | 12393500 |
D000069286 | Bortezomib | Bortezomib results in increased activity of TP53 protein | 30818834 |
D000069286 | Bortezomib | Bortezomib results in increased expression of TP53 protein | 12393500; 15173093; 16617327; 17898295; 18534018; 18790767; 21532991; |
D000069286 | Bortezomib | Bortezomib results in increased phosphorylation of and results in increased localization of TP53 protein | 12393500 |
D000069286 | Bortezomib | Bortezomib results in increased stability of TP53 protein | 15543232 |
D000069286 | Bortezomib | Caffeine inhibits the reaction [Bortezomib results in increased phosphorylation of TP53 protein] | 12393500 |
D000069286 | Bortezomib | [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased phosphorylation of TP53 protein] | 12393500 |
D000069286 | Bortezomib | [Irinotecan co-treated with Bortezomib] results in increased ubiquitination of TP53 protein | 16373703 |
D000069286 | Bortezomib | SCIO-469 promotes the reaction [Bortezomib results in increased expression of TP53 protein] | 16617327 |
D000069286 | Bortezomib | TP53 protein affects the susceptibility to [Irinotecan co-treated with Bortezomib] | 16373703 |
D000069286 | Bortezomib | [Vorinostat co-treated with Bortezomib] results in increased expression of TP53 protein | 17351739 |
C555919 | BPC96 peptide | BPC96 peptide results in increased expression of TP53 protein | 20708052 |
C023623 | brassinolide | brassinolide results in increased expression of TP53 protein | 20833159 |
D001959 | Bromates | Bromates results in increased phosphorylation of TP53 protein | 21864635 |
D001959 | Bromates | bromochloroacetic acid promotes the reaction [Bromates results in increased phosphorylation of TP53 protein] | 21864635 |
C099813 | bromochloroacetic acid | bromochloroacetic acid promotes the reaction [Bromates results in increased phosphorylation of TP53 protein] | 21864635 |
C017092 | bromopyruvate | bromopyruvate promotes the reaction [bis((2-oxindol-3-ylimino)-2-(2-aminoethyl)pyridine-N,N')copper(II) results in increased expression of TP53 protein] | 21548882 |
C017092 | bromopyruvate | SOD1 protein inhibits the reaction [bromopyruvate promotes the reaction [bis((2-oxindol-3-ylimino)-2-(2-aminoethyl)pyridine-N,N')copper(II) results in increased expression of TP53 protein]] | 21548882 |
D003994 | Bucladesine | [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine co-treated with Decitabine] results in increased expression of TP53 protein | 22534328 |
D003994 | Bucladesine | [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased expression of TP53 protein | 22534328 |
D019819 | Budesonide | Budesonide results in decreased expression of TP53 protein | 15475437 |
D002065 | Buspirone | Buspirone results in decreased expression of TP53 mRNA | 24136188 |
D002066 | Busulfan | Busulfan affects the phosphorylation of and affects the activity of TP53 protein | 16882877 |
D019328 | Buthionine Sulfoximine | [Buthionine Sulfoximine results in decreased abundance of Glutathione] inhibits the reaction [Benzo(a)pyrene results in increased activity of TP53 protein] | 12807757 |
D019328 | Buthionine Sulfoximine | [cyanoginosin LR co-treated with Buthionine Sulfoximine] results in increased expression of TP53 protein | 25410294 |
D002083 | Butylated Hydroxyanisole | Butylated Hydroxyanisole results in increased expression of TP53 protein | 25086368 |
D002083 | Butylated Hydroxyanisole | [propylparaben co-treated with Butylated Hydroxyanisole] results in increased expression of TP53 protein | 25086368 |
D002083 | Butylated Hydroxyanisole | Butylated Hydroxyanisole inhibits the reaction [Methylnitrosourea results in increased phosphorylation of TP53 protein] | 18593901 |
D002084 | Butylated Hydroxytoluene | Butylated Hydroxytoluene results in increased expression of TP53 mRNA | 9780227 |
C026105 | butylidenephthalide | butylidenephthalide results in increased expression of TP53 protein | 16987298 |
C026105 | butylidenephthalide | butylidenephthalide results in increased phosphorylation of TP53 protein | 16987298 |
C018475 | butyraldehyde | butyraldehyde results in decreased expression of TP53 mRNA | 26079696 |
D002087 | Butyrates | Butyrates results in increased expression of TP53 protein | 15978324 |
D020148 | Butyric Acid | Butyric Acid results in decreased expression of and affects the localization of TP53 protein mutant form | 16598767 |
D020148 | Butyric Acid | [1'-acetoxychavicol acetate co-treated with Butyric Acid] results in increased phosphorylation of TP53 protein | 24480522 |
C584509 | C646 compound | C646 compound results in decreased expression of TP53 mRNA | 26191083 |
C584509 | C646 compound | C646 compound results in increased expression of TP53 mRNA | 23698071 |
C584509 | C646 compound | C646 compound inhibits the reaction [AGT protein modified form promotes the reaction [TP53 protein binds to EP300 protein]] | 26612707 |
C584509 | C646 compound | C646 compound inhibits the reaction [AGT protein modified form results in increased acetylation of TP53 protein] | 26612707 |
D002101 | Cacodylic Acid | [sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of TP53 mRNA | 23192986 |
D002101 | Cacodylic Acid | Cacodylic Acid results in increased expression of TP53 mRNA | 17720352 |
D002104 | Cadmium | Cadmium results in decreased expression of TP53 mRNA | 22768170 |
D002104 | Cadmium | Cadmium results in increased expression of TP53 mRNA | 25490952 |
D002104 | Cadmium | Nitric Oxide inhibits the reaction [Cadmium results in increased expression of TP53 mRNA] | 25490952 |
D002104 | Cadmium | spermine nitric oxide complex inhibits the reaction [Cadmium results in increased expression of TP53 mRNA] | 25490952 |
D002104 | Cadmium | Cadmium affects the localization of TP53 protein | 25101185 |
D002104 | Cadmium | Cadmium inhibits the reaction [Dactinomycin results in increased expression of and results in increased activity of TP53 protein] | 10531375 |
D002104 | Cadmium | Cadmium inhibits the reaction [Hydrogen Peroxide results in increased expression of and results in increased activity of TP53 protein] | 10531375 |
D002104 | Cadmium | Cadmium inhibits the reaction [Methyl Methanesulfonate results in increased expression of and results in increased activity of TP53 protein] | 10531375 |
D002104 | Cadmium | Cadmium results in decreased folding of and results in decreased activity of TP53 protein | 10531375 |
D002104 | Cadmium | Cadmium results in increased expression of and results in increased phosphorylation of TP53 protein | 17174997 |
D002104 | Cadmium | Cadmium results in increased expression of TP53 protein | 12189181 |
D002104 | Cadmium | TP53 protein affects the reaction [Cadmium affects the activity of APEX1 protein] | 21605570 |
D002104 | Cadmium | TP53 protein affects the reaction [Cadmium affects the expression of APEX1 mRNA] | 21605570 |
D002104 | Cadmium | TP53 protein affects the susceptibility to Cadmium | 17174997 |
D002104 | Cadmium | Cadmium results in increased expression of TP53 protein | 21467746; 23095357; |
D002104 | Cadmium | Cadmium results in increased expression of TP53 | 24120750 |
D002104 | Cadmium | Acetylcysteine inhibits the reaction [Cadmium results in increased phosphorylation of TP53 protein] | 27658547 |
D002104 | Cadmium | Cadmium results in increased activity of TP53 protein | 16730872 |
D002104 | Cadmium | Cadmium results in increased expression of and results in increased phosphorylation of TP53 protein | 21467746 |
D002104 | Cadmium | Cadmium results in increased expression of and results in increased ubiquitination of TP53 protein | 18463101 |
D002104 | Cadmium | Cadmium results in increased expression of TP53 protein | 24212999 |
D002104 | Cadmium | Cadmium results in increased phosphorylation of TP53 protein | 18463101; 27658547; |
D002104 | Cadmium | Cadmium results in increased expression of and results in increased phosphorylation of TP53 protein | 23095357 |
C028031 | cadmium acetate | cadmium acetate results in decreased expression of TP53 mRNA | 18155341 |
C028031 | cadmium acetate | cadmium acetate results in increased degradation of and affects the localization of TP53 protein | 15450950 |
C028031 | cadmium acetate | cadmium acetate results in increased phosphorylation of TP53 protein | 20839231 |
D019256 | Cadmium Chloride | Cadmium Chloride results in decreased expression of TP53 mRNA | 25456234 |
D019256 | Cadmium Chloride | Cadmium Chloride results in increased expression of TP53 mRNA | 24839000; 25035189; |
D019256 | Cadmium Chloride | Selenium inhibits the reaction [Cadmium Chloride results in increased expression of TP53 mRNA] | 25035189 |
D019256 | Cadmium Chloride | Cadmium Chloride affects the activity of TP53 protein | 25596134 |
D019256 | Cadmium Chloride | Cadmium Chloride affects the localization of TP53 protein | 25118938 |
D019256 | Cadmium Chloride | Cadmium Chloride affects the phosphorylation of TP53 protein | 23941782 |
D019256 | Cadmium Chloride | Cadmium Chloride affects the reaction [Benzo(a)pyrene results in increased phosphorylation of TP53 protein] | 25744307 |
D019256 | Cadmium Chloride | Cadmium Chloride affects the reaction [Etoposide results in increased phosphorylation of TP53 protein] | 25744307 |
D019256 | Cadmium Chloride | Cadmium Chloride affects the reaction [Fluorouracil affects the phosphorylation of TP53 protein] | 23941782 |
D019256 | Cadmium Chloride | Cadmium Chloride affects the reaction [Fluorouracil results in increased expression of TP53 mRNA] | 23941782 |
D019256 | Cadmium Chloride | Cadmium Chloride affects the reaction [Fluorouracil results in increased phosphorylation of TP53 protein] | 25744307 |
D019256 | Cadmium Chloride | Cadmium Chloride inhibits the reaction [Dactinomycin results in increased expression of and results in increased activity of TP53 protein] | 10531375 |
D019256 | Cadmium Chloride | Cadmium Chloride inhibits the reaction [Hydrogen Peroxide results in increased expression of and results in increased activity of TP53 protein] | 10531375 |
D019256 | Cadmium Chloride | Cadmium Chloride inhibits the reaction [Methyl Methanesulfonate results in increased expression of and results in increased activity of TP53 protein] | 10531375 |
D019256 | Cadmium Chloride | Cadmium Chloride results in decreased activity of TP53 protein | 25446071 |
D019256 | Cadmium Chloride | [Cadmium Chloride results in decreased activity of TP53 protein] inhibits the reaction [TP53 protein binds to TP53 gene] | 25446071; 25446071; |
D019256 | Cadmium Chloride | [Cadmium Chloride results in decreased activity of TP63 protein] inhibits the reaction [TP63 protein binds to TP53 gene] | 25446071 |
D019256 | Cadmium Chloride | [Cadmium Chloride results in decreased activity of TP73 protein] inhibits the reaction [TP73 protein binds to TP53 gene] | 25446071 |
D019256 | Cadmium Chloride | Cadmium Chloride results in decreased folding of and results in decreased activity of TP53 protein | 10531375 |
D019256 | Cadmium Chloride | Cadmium Chloride results in increased expression of and results in increased phosphorylation of TP53 protein | 17174997; 25118938; |
D019256 | Cadmium Chloride | Cadmium Chloride results in increased expression of TP53 mRNA | 23941782; 26472689; |
D019256 | Cadmium Chloride | Cadmium Chloride results in increased expression of TP53 protein | 12676607; 25111876; |
D019256 | Cadmium Chloride | Cadmium Chloride results in increased phosphorylation of TP53 protein | 12676607 |
D019256 | Cadmium Chloride | Dithiothreitol inhibits the reaction [[Cadmium Chloride results in decreased activity of TP53 protein] inhibits the reaction [TP53 protein binds to TP53 gene]] | 25446071; 25446071; |
D019256 | Cadmium Chloride | Edetic Acid inhibits the reaction [[Cadmium Chloride results in decreased activity of TP53 protein] inhibits the reaction [TP53 protein binds to TP53 gene]] | 25446071; 25446071; |
D019256 | Cadmium Chloride | Edetic Acid inhibits the reaction [[Cadmium Chloride results in decreased activity of TP63 protein] inhibits the reaction [TP63 protein binds to TP53 gene]] | 25446071 |
D019256 | Cadmium Chloride | Edetic Acid inhibits the reaction [[Cadmium Chloride results in decreased activity of TP73 protein] inhibits the reaction [TP73 protein binds to TP53 gene]] | 25446071 |
D019256 | Cadmium Chloride | Fluorouracil affects the reaction [Cadmium Chloride affects the phosphorylation of TP53 protein] | 23941782 |
D019256 | Cadmium Chloride | Fluorouracil affects the reaction [Cadmium Chloride results in increased expression of TP53 mRNA] | 23941782 |
D019256 | Cadmium Chloride | TP53 protein affects the susceptibility to Cadmium Chloride | 17174997 |
D019256 | Cadmium Chloride | Cadmium Chloride results in increased expression of TP53 protein | 25111876 |
D019256 | Cadmium Chloride | Cadmium Chloride affects the expression of TP53 mRNA | 10647914 |
D019256 | Cadmium Chloride | [Cadmium Chloride co-treated with diallyl disulfide] results in decreased expression of TP53 mRNA | 31077537 |
D019256 | Cadmium Chloride | Cadmium Chloride results in decreased expression of TP53 mRNA | 30606898; 31077537; |
D019256 | Cadmium Chloride | Cadmium Chloride results in increased activity of TP53 protein | 16730872 |
D019256 | Cadmium Chloride | Cadmium Chloride results in increased expression of TP53 mRNA | 21181359; 23405080; 24492640; |
D019256 | Cadmium Chloride | Cadmium Chloride results in increased expression of TP53 protein | 16600092; 19615436; 21181359; |
D019256 | Cadmium Chloride | Resveratrol inhibits the reaction [Cadmium Chloride results in increased expression of TP53 mRNA] | 24492640 |
D019256 | Cadmium Chloride | Selenium inhibits the reaction [Cadmium Chloride results in increased expression of TP53 protein] | 16600092 |
D019256 | Cadmium Chloride | Cadmium Chloride results in increased expression of TP53 | 19475715 |
C037123 | cadmium sulfate | cadmium sulfate results in decreased expression of TP53 mRNA | 23770381 |
C028337 | cadmium telluride | cadmium telluride analog results in decreased expression of TP53 mRNA | 23770381 |
C040048 | caffeic acid | caffeic acid affects the expression of TP53 protein | 11522280 |
C040048 | caffeic acid | caffeic acid promotes the reaction [Thapsigargin results in decreased expression of TP53 mRNA] | 19442820 |
C055494 | caffeic acid phenethyl ester | caffeic acid phenethyl ester inhibits the reaction [Mustard Compounds results in increased phosphorylation of TP53 protein] | 17204746 |
C055494 | caffeic acid phenethyl ester | caffeic acid phenethyl ester inhibits the reaction [Nitrogen Mustard Compounds results in increased phosphorylation of TP53 protein] | 17204746 |
C055494 | caffeic acid phenethyl ester | caffeic acid phenethyl ester inhibits the reaction [sodium arsenite results in decreased expression of TP53 protein] | 22692362 |
C055494 | caffeic acid phenethyl ester | caffeic acid phenethyl ester inhibits the reaction [Diethylnitrosamine results in decreased expression of TP53 mRNA] | 20360939 |
D002110 | Caffeine | 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Caffeine inhibits the reaction [2,2'-azobis(2-amidinopropane) results in increased phosphorylation of TP53 protein]] | 30555576 |
D002110 | Caffeine | 3-methyladenine inhibits the reaction [Caffeine inhibits the reaction [2,2'-azobis(2-amidinopropane) results in increased phosphorylation of TP53 protein]] | 30555576 |
D002110 | Caffeine | Caffeine inhibits the reaction [2,2'-azobis(2-amidinopropane) results in increased phosphorylation of TP53 protein] | 30555576 |
D002110 | Caffeine | Caffeine inhibits the reaction [2-(3'-methoxyphenyl)-6-pyrrolidinyl-4-quinazolinone results in increased phosphorylation of TP53 protein] | 23523585 |
D002110 | Caffeine | Caffeine inhibits the reaction [Bortezomib results in increased phosphorylation of TP53 protein] | 12393500 |
D002110 | Caffeine | Caffeine inhibits the reaction [Capsaicin results in increased phosphorylation of and results in increased activity of TP53 protein] | 22226932 |
D002110 | Caffeine | Caffeine inhibits the reaction [Cytarabine results in increased expression of TP53 protein] | 17977830 |
D002110 | Caffeine | Caffeine inhibits the reaction [Cytarabine results in increased phosphorylation of TP53 protein] | 17977830 |
D002110 | Caffeine | Caffeine inhibits the reaction [Decitabine results in increased expression of TP53 protein] | 17977830 |
D002110 | Caffeine | Caffeine inhibits the reaction [dorsomorphin results in increased expression of and results in increased phosphorylation of TP53 protein] | 23274516 |
D002110 | Caffeine | Caffeine inhibits the reaction [Doxorubicin results in increased expression of TP53 protein] | 22927544 |
D002110 | Caffeine | Caffeine inhibits the reaction [kaempferol results in increased phosphorylation of TP53 protein] | 19028473 |
D002110 | Caffeine | Caffeine inhibits the reaction [Nitric Oxide results in increased phosphorylation of TP53 protein] | 16024610 |
D002110 | Caffeine | Caffeine inhibits the reaction [Oxaliplatin results in increased expression of TP53 protein modified form] | 19735649 |
D002110 | Caffeine | Caffeine inhibits the reaction [Silybin results in increased phosphorylation of TP53 protein] | 16777994 |
D002110 | Caffeine | Caffeine inhibits the reaction [spermine nitric oxide complex results in increased phosphorylation of TP53 protein] | 16024610 |
D002110 | Caffeine | Caffeine results in increased phosphorylation of TP53 protein | 12811820 |
D002110 | Caffeine | Sirolimus promotes the reaction [Caffeine inhibits the reaction [2,2'-azobis(2-amidinopropane) results in increased phosphorylation of TP53 protein]] | 30555576 |
D002110 | Caffeine | SIRT3 protein promotes the reaction [Caffeine inhibits the reaction [2,2'-azobis(2-amidinopropane) results in increased phosphorylation of TP53 protein]] | 30555576 |
D002110 | Caffeine | Caffeine inhibits the reaction [Diethylnitrosamine results in increased expression of TP53 protein] | 11751435 |
D002110 | Caffeine | Caffeine inhibits the reaction [Diethylnitrosamine results in increased phosphorylation of TP53 protein] | 11751435 |
D000001 | Calcimycin | Calcimycin promotes the reaction [[TP53 protein binds to BAX promoter] which results in increased expression of BAX mRNA] | 16000378 |
D000001 | Calcimycin | Calcimycin results in increased expression of TP53 protein | 16000378 |
D000001 | Calcimycin | CRYAB protein inhibits the reaction [Calcimycin results in increased expression of TP53 protein] | 16000378 |
D000001 | Calcimycin | U 0126 inhibits the reaction [Calcimycin results in increased expression of TP53 protein] | 16000378 |
D002117 | Calcitriol | Calcitriol results in increased expression of TP53 protein | 12071473 |
D002118 | Calcium | Calcium results in decreased expression of TP53 protein | 16043423 |
D002118 | Calcium | TP53 protein affects the localization of Calcium | 15059885 |
C028042 | calcium magnesium carbonate | calcium magnesium carbonate results in increased expression of TP53 mRNA | 25663373 |
C059041 | calyculin A | calyculin A inhibits the reaction [N-caproylsphingosine affects the splicing of and results in increased expression of TP53 mRNA] | 25195822 |
C059041 | calyculin A | calyculin A inhibits the reaction [N-caproylsphingosine results in increased expression of TP53 protein modified form] | 25195822 |
C510718 | cambinol | cambinol results in increased expression of and results in decreased acetylation of TP53 protein | 29545174 |
C553149 | camphorquinone | camphorquinone results in increased phosphorylation of TP53 protein | 26658076 |
D002166 | Camptothecin | Camptothecin results in increased expression of TP53 mRNA | 22560901 |
D002166 | Camptothecin | 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole promotes the reaction [Camptothecin results in increased expression of TP53 protein] | 19481069 |
D002166 | Camptothecin | Acetylcysteine inhibits the reaction [Camptothecin results in increased expression of TP53 protein modified form] | 17555331 |
D002166 | Camptothecin | Camptothecin inhibits the reaction [6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide results in increased acetylation of TP53 protein] | 24726431 |
D002166 | Camptothecin | Camptothecin results in decreased acetylation of TP53 protein | 24726431 |
D002166 | Camptothecin | Camptothecin results in increased expression of TP53 protein | 12082016; 17555331; 19481069; 20978201; 24726431; 9673414; |
D002166 | Camptothecin | Camptothecin results in increased glutathionylation of TP53 protein | 17555331 |
D002166 | Camptothecin | Camptothecin results in increased phosphorylation of TP53 protein | 17555331; 26657896; |
D002166 | Camptothecin | Camptothecin results in increased stability of and results in increased expression of and results in increased phosphorylation of and results in increased activity of TP53 protein | 11741290 |
D002166 | Camptothecin | nutlin 3 inhibits the reaction [Camptothecin results in increased expression of TP53 protein] | 24726431 |
D002166 | Camptothecin | S-ethyl glutathione inhibits the reaction [Camptothecin results in increased expression of TP53 protein modified form] | 17555331 |
D002166 | Camptothecin | [SIRT1 mutant form co-treated with Camptothecin] results in increased acetylation of TP53 protein | 24726431 |
D002166 | Camptothecin | TP53 mutant form results in decreased susceptibility to Camptothecin | 24726431 |
D002166 | Camptothecin | TP53 protein mutant form results in decreased susceptibility to Camptothecin | 10692111 |
D002166 | Camptothecin | TP53 protein results in decreased susceptibility to Camptothecin | 25269479 |
D002166 | Camptothecin | TP53 protein results in increased susceptibility to Camptothecin | 23285096; 9673414; |
D002166 | Camptothecin | Camptothecin promotes the reaction [TP53 protein binds to CREBBP protein] | 13679428 |
D002166 | Camptothecin | Camptothecin results in increased activity of TP53 protein | 11279278; 13679428; |
D002166 | Camptothecin | Camptothecin results in increased phosphorylation of TP53 protein | 13679428 |
D002166 | Camptothecin | pifithrin inhibits the reaction [Camptothecin promotes the reaction [TP53 protein binds to CREBBP protein]] | 13679428 |
D002166 | Camptothecin | pifithrin inhibits the reaction [Camptothecin results in increased activity of TP53 protein] | 11279278; 13679428; |
D002166 | Camptothecin | Camptothecin results in increased expression of TP53 protein | 17881359 |
C081643 | candesartan | candesartan results in increased expression of TP53 mRNA | 11409658 |
C081643 | candesartan | candesartan results in increased expression of TP53 protein | 11409658 |
C081643 | candesartan | candesartan inhibits the reaction [AGT protein modified form results in increased phosphorylation of TP53 protein] | 18314486 |
D002211 | Capsaicin | 2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one inhibits the reaction [Capsaicin results in increased phosphorylation of and results in increased activity of TP53 protein] | 22226932 |
D002211 | Capsaicin | 2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one inhibits the reaction [Capsaicin results in increased phosphorylation of and results in increased expression of TP53 protein] | 19502594 |
D002211 | Capsaicin | 3-aminobenzamide inhibits the reaction [Capsaicin results in increased expression of TP53 protein] | 22226932 |
D002211 | Capsaicin | 3-aminobenzamide inhibits the reaction [Capsaicin results in increased phosphorylation of and results in increased activity of TP53 protein] | 22226932 |
D002211 | Capsaicin | Acetylcysteine inhibits the reaction [Capsaicin results in increased phosphorylation of TP53 protein] | 14871840 |
D002211 | Capsaicin | benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Capsaicin results in increased degradation of TP53 protein] | 19699254 |
D002211 | Capsaicin | Caffeine inhibits the reaction [Capsaicin results in increased phosphorylation of and results in increased activity of TP53 protein] | 22226932 |
D002211 | Capsaicin | Capsaicin promotes the reaction [Resveratrol results in increased expression of TP53 protein] | 19846903 |
D002211 | Capsaicin | Capsaicin results in decreased degradation of TP53 protein | 17292493 |
D002211 | Capsaicin | Capsaicin results in increased degradation of TP53 protein | 19699254 |
D002211 | Capsaicin | Capsaicin results in increased expression of and results in increased phosphorylation of and results in increased activity of TP53 protein | 17292493 |
D002211 | Capsaicin | Capsaicin results in increased expression of TP53 mRNA | 19502594; 9461043; |
D002211 | Capsaicin | Capsaicin results in increased expression of TP53 protein | 16540674; 18991268; 19331147; 19846903; 20646592; 22226932; |
D002211 | Capsaicin | Capsaicin results in increased phosphorylation of and results in increased activity of TP53 protein | 22226932 |
D002211 | Capsaicin | Capsaicin results in increased phosphorylation of and results in increased expression of TP53 protein | 19139269; 19502594; |
D002211 | Capsaicin | Capsaicin results in increased phosphorylation of TP53 protein | 14871840 |
D002211 | Capsaicin | CAT protein inhibits the reaction [Capsaicin results in increased phosphorylation of TP53 protein] | 14871840 |
D002211 | Capsaicin | MAPK8 protein promotes the reaction [Capsaicin results in decreased degradation of TP53 protein] | 17292493 |
D002211 | Capsaicin | pifithrin inhibits the reaction [Capsaicin results in increased phosphorylation of and results in increased activity of TP53 protein] | 22226932 |
D002211 | Capsaicin | pyrazolanthrone inhibits the reaction [Capsaicin results in increased expression of and results in increased phosphorylation of and results in increased activity of TP53 protein] | 17292493 |
D002211 | Capsaicin | Resveratrol promotes the reaction [Capsaicin results in increased expression of TP53 protein] | 19846903 |
D002211 | Capsaicin | TP53 affects the reaction [Capsaicin promotes the reaction [Resveratrol results in increased expression of NOS2 protein]] | 19846903 |
D002211 | Capsaicin | TP53 affects the reaction [Capsaicin promotes the reaction [Resveratrol results in increased expression of NOS3 protein]] | 19846903 |
D002211 | Capsaicin | TP53 affects the reaction [Capsaicin results in decreased expression of MDM2 protein] | 19846903 |
D002211 | Capsaicin | TP53 affects the reaction [Capsaicin results in increased expression of NOS1 protein] | 19846903 |
D002211 | Capsaicin | TP53 affects the reaction [Capsaicin results in increased expression of NOS3 protein] | 19846903 |
D002211 | Capsaicin | TP53 affects the reaction [Resveratrol promotes the reaction [Capsaicin results in increased expression of NOS2 protein]] | 19846903 |
D002211 | Capsaicin | TP53 affects the reaction [Resveratrol promotes the reaction [Capsaicin results in increased expression of NOS3 protein]] | 19846903 |
D002211 | Capsaicin | TP53 affects the susceptibility to Capsaicin | 19846903 |
D002211 | Capsaicin | TP53 protein promotes the reaction [Capsaicin results in increased expression of BAX protein] | 17292493 |
D002211 | Capsaicin | Tunicamycin promotes the reaction [Capsaicin results in increased degradation of TP53 protein] | 19699254 |
D002219 | Carbamates | Carbamates analog promotes the reaction [ATM protein results in increased phosphorylation of and results in increased activity of TP53 protein] | 19376255 |
D002219 | Carbamates | Carbamates analog results in increased phosphorylation of and results in increased activity of TP53 protein | 19376255 |
D002220 | Carbamazepine | Carbamazepine affects the expression of TP53 mRNA | 24752500 |
C006698 | carbendazim | carbendazim results in increased expression of TP53 mRNA | 25304545; 26055223; |
D002229 | Carbenoxolone | Carbenoxolone affects the expression of TP53 mRNA | 23678415 |
D002235 | Carbofuran | Carbofuran results in decreased stability of and results in increased degradation of and results in increased mutagenesis of TP53 gene | 22445671 |
D002251 | Carbon Tetrachloride | Carbon Tetrachloride results in decreased expression of TP53 mRNA | 17256749 |
D002251 | Carbon Tetrachloride | Carbon Tetrachloride results in increased expression of TP53 mRNA | 17522070; 31150632; |
D002251 | Carbon Tetrachloride | schizandrin B inhibits the reaction [Carbon Tetrachloride results in increased expression of TP53 mRNA] | 31150632 |
D016190 | Carboplatin | Carboplatin results in increased expression of TP53 protein | 15131059; 9664115; |
C514968 | carboxymethyl-chitosan | benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Curcumin binds to carboxymethyl-chitosan analog] inhibits the reaction [AGT protein modified form results in decreased degradation of TP53 protein]] | 26612707 |
C514968 | carboxymethyl-chitosan | carboxymethyl-chitosan analog promotes the reaction [Curcumin inhibits the reaction [AGT protein modified form results in increased acetylation of TP53 protein]] | 26612707 |
C514968 | carboxymethyl-chitosan | [Curcumin binds to carboxymethyl-chitosan analog] inhibits the reaction [AGT protein modified form results in decreased degradation of TP53 protein] | 26612707 |
C524865 | carfilzomib | carfilzomib results in increased activity of TP53 protein | 30818834 |
D002330 | Carmustine | [Carmustine co-treated with O(6)-benzylguanine] results in increased expression of TP53 protein | 15735757 |
D002330 | Carmustine | Carmustine results in increased expression of TP53 protein | 15735757; 16193384; 18632648; |
D002330 | Carmustine | MDM4 protein promotes the reaction [Carmustine results in increased expression of TP53 protein] | 20472715 |
D002330 | Carmustine | TP53 protein modified form affects the susceptibility to Carmustine | 11861384 |
D002330 | Carmustine | TP53 protein results in decreased susceptibility to Carmustine | 16193384 |
D002330 | Carmustine | TP53 results in increased susceptibility to Carmustine | 10455409 |
D000077261 | Carvedilol | Carvedilol affects the expression of TP53 protein | 22000973 |
D000077261 | Carvedilol | Carvedilol inhibits the reaction [Potassium Dichromate results in increased expression of TP53 protein] | 25245570 |
C024714 | caryophyllene | caryophyllene inhibits the reaction [Doxorubicin results in increased expression of TP53 protein] | 30836069 |
C024714 | caryophyllene | iodopravadoline inhibits the reaction [caryophyllene inhibits the reaction [Doxorubicin results in increased expression of TP53 protein]] | 30836069 |
C054133 | casticin | casticin results in decreased expression of TP53 protein | 29098808 |
C054133 | casticin | casticin results in increased expression of TP53 protein modified form | 29098808 |
D002392 | Catechin | Catechin results in increased expression of TP53 mRNA | 23706674 |
D002392 | Catechin | Catechin results in increased expression of TP53 protein | 23706674 |
C000600690 | cationic amphipathic peptide RT2 | cationic amphipathic peptide RT2 results in increased expression of TP53 protein | 30019842 |
C099555 | CD 437 | CD 437 affects the expression of TP53 | 16720286 |
D002439 | Cefotaxime | Cefotaxime results in increased expression of TP53 protein | 15012731 |
D000068579 | Celecoxib | Celecoxib results in increased activity of and results in increased localization of TP53 protein | 19706164 |
D000068579 | Celecoxib | Celecoxib results in increased expression of and results in increased phosphorylation of TP53 protein | 18760266 |
D000068579 | Celecoxib | Celecoxib results in increased expression of TP53 mRNA | 18202791 |
D000068579 | Celecoxib | Celecoxib results in increased expression of TP53 protein | 19706164 |
D000068579 | Celecoxib | [FEC protocol co-treated with Celecoxib] results in decreased expression of TP53 protein | 16507397 |
D000068579 | Celecoxib | pifithrin inhibits the reaction [Celecoxib results in increased expression of TP53 protein] | 19706164 |
D000068579 | Celecoxib | pifithrin inhibits the reaction [TP53 results in increased susceptibility to Celecoxib] | 19706164 |
D000068579 | Celecoxib | TP53 affects the reaction [Celecoxib results in increased expression of CDKN1A mRNA] | 19706164 |
D000068579 | Celecoxib | TP53 protein promotes the reaction [Celecoxib results in increased expression of BBC3 protein] | 18760266 |
D000068579 | Celecoxib | TP53 results in increased susceptibility to Celecoxib | 19706164 |
C532683 | Cellfood | Cellfood results in increased expression of TP53 protein | 24598211 |
D002512 | Cephalothin | Cephalothin results in increased expression of TP53 protein | 15012731 |
C006947 | cepharanthine | cepharanthine results in increased expression of TP53 protein | 31255635 |
D002518 | Ceramides | Ceramides results in increased phosphorylation of TP53 protein | 23495037 |
D002518 | Ceramides | [fumonisin B1 results in decreased chemical synthesis of Ceramides] which affects the splicing of and results in decreased expression of TP53 mRNA | 25195822 |
D002518 | Ceramides | [fumonisin B1 results in decreased chemical synthesis of Ceramides] which results in decreased phosphorylation of TP53 protein modified form | 25195822 |
D002518 | Ceramides | [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of PTGS2 protein] inhibits the reaction [Ceramides results in increased phosphorylation of TP53 protein] | 23495037 |
D002518 | Ceramides | Resveratrol promotes the reaction [Ceramides results in increased phosphorylation of TP53 protein] | 23495037 |
D002518 | Ceramides | TP53 protein results in increased abundance of Ceramides | 12967322 |
D002518 | Ceramides | [UGCG protein results in decreased abundance of Ceramides] which affects the splicing of and results in decreased expression of TP53 mRNA | 25195822 |
D002518 | Ceramides | [UGCG protein results in decreased abundance of Ceramides] which results in decreased phosphorylation of TP53 protein | 25195822 |
C030583 | ceric oxide | ceric oxide results in increased phosphorylation of TP53 protein | 24987704 |
C062876 | cetrorelix | cetrorelix results in increased expression of TP53 protein | 21062912 |
D002699 | Chlorambucil | Chlorambucil results in increased expression of TP53 | 8822937 |
D002699 | Chlorambucil | Chlorambucil results in increased expression of TP53 protein | 18092340 |
D002699 | Chlorambucil | IL4 protein inhibits the reaction [[Theophylline co-treated with Chlorambucil] results in increased expression of TP53] | 8822937 |
D002699 | Chlorambucil | [Theophylline co-treated with Chlorambucil] results in increased expression of TP53 | 8822937 |
D002719 | Chlormethiazole | Chlormethiazole inhibits the reaction [Acetaminophen results in increased degradation of TP53 protein] | 16330492 |
C095932 | chloro(2,2'-6',2''-terpyridine)(2,2'-bipyridine)ruthenium | chloro(2,2'-6',2''-terpyridine)(2,2'-bipyridine)ruthenium results in increased activity of TP53 protein | 19682442 |
C004656 | chloroacetaldehyde | chloroacetaldehyde affects the activity of TP53 protein | 25596134 |
D002725 | Chloroform | Chloroform results in increased phosphorylation of TP53 protein | 8076368 |
D002725 | Chloroform | Chloroform results in increased expression of TP53 mRNA | 17522070 |
D002734 | Chlorophyll | Chlorophyll inhibits the reaction [dibenzo(a,l)pyrene results in increased expression of TP53 mRNA] | 22079312 |
C007020 | chlorophyllin | chlorophyllin inhibits the reaction [Cyclophosphamide results in increased mutagenesis of TP53 exon] | 19227835 |
C100187 | chloropicrin | chloropicrin results in increased expression of TP53 protein | 22516760; 24548678; |
D002738 | Chloroquine | Chloroquine inhibits the reaction [Doxorubicin results in increased expression of TP53 protein] | 22927544 |
D002738 | Chloroquine | Chloroquine results in increased activity of TP53 | 18089834 |
D002738 | Chloroquine | Chloroquine results in increased activity of TP53 protein | 12082016 |
D002746 | Chlorpromazine | Chlorpromazine affects the activity of TP53 protein | 25596134 |
D004390 | Chlorpyrifos | benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Chlorpyrifos results in decreased expression of TP53 protein] | 27993609 |
D004390 | Chlorpyrifos | Chlorpyrifos results in decreased expression of TP53 protein | 27993609 |
D004390 | Chlorpyrifos | Chlorpyrifos results in increased expression of TP53 mRNA | 30981936 |
D004390 | Chlorpyrifos | Cycloheximide promotes the reaction [Chlorpyrifos results in decreased expression of TP53 protein] | 27993609 |
D004390 | Chlorpyrifos | Chlorpyrifos results in increased expression of TP53 mRNA | 12464398; 17452286; |
D002791 | Cholesterol, Dietary | Cholesterol, Dietary results in increased expression of TP53 mRNA | 27239252 |
D002791 | Cholesterol, Dietary | Rutin inhibits the reaction [Cholesterol, Dietary results in increased expression of TP53 mRNA] | 27239252 |
D002794 | Choline | Choline results in decreased expression of TP53 mRNA | 16014740 |
C034944 | chromic acid | chromic acid results in increased expression of TP53 mRNA | 27005777 |
D002857 | Chromium | CDKN1A affects the reaction [Chromium results in increased expression of TP53 protein] | 18024214 |
D002857 | Chromium | Chromium promotes the reaction [TP53 protein binds to BBC3 promoter] | 18602874 |
D002857 | Chromium | Chromium promotes the reaction [TP53 protein binds to CDKN1A promoter] | 18602874 |
D002857 | Chromium | Chromium results in increased activity of TP53 protein | 14971653 |
D002857 | Chromium | Chromium results in increased expression of TP53 protein | 18024214 |
D002857 | Chromium | Chromium results in increased stability of and results in increased activity of TP53 protein | 18602874 |
D002857 | Chromium | PRKDC protein promotes the reaction [Chromium results in increased stability of and results in increased activity of TP53 protein] | 18602874 |
D002857 | Chromium | RAS protein promotes the reaction [Chromium results in increased activity of TP53 protein] | 14971653 |
D002857 | Chromium | TP53 mutant form inhibits the reaction [CDKN1A gene mutant form results in increased susceptibility to Chromium] | 18024214 |
C074702 | chromium hexavalent ion | Ascorbic Acid inhibits the reaction [chromium hexavalent ion results in increased phosphorylation of TP53 protein] | 31388677 |
C074702 | chromium hexavalent ion | benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone inhibits the reaction [TP53 protein affects the reaction [chromium hexavalent ion results in increased activity of CASP3 protein]] | 16166740 |
C074702 | chromium hexavalent ion | chromium hexavalent ion binds to TP53 gene | 22791815 |
C074702 | chromium hexavalent ion | [chromium hexavalent ion binds to TP53 gene] which results in increased mutagenesis of TP53 gene | 22791815 |
C074702 | chromium hexavalent ion | chromium hexavalent ion results in decreased expression of TP53 protein | 22666341 |
C074702 | chromium hexavalent ion | [chromium hexavalent ion results in increased abundance of Reactive Oxygen Species] which results in increased activity of TP53 protein | 22886373 |
C074702 | chromium hexavalent ion | chromium hexavalent ion results in increased activity of TP53 protein | 10574974 |
C074702 | chromium hexavalent ion | chromium hexavalent ion results in increased expression of and results in increased phosphorylation of TP53 protein | 31388677 |
C074702 | chromium hexavalent ion | chromium hexavalent ion results in increased expression of TP53 mRNA | 27793765 |
C074702 | chromium hexavalent ion | chromium hexavalent ion results in increased expression of TP53 protein | 10788560; 16166740; 29069462; |
C074702 | chromium hexavalent ion | chromium hexavalent ion results in increased mutagenesis of TP53 gene | 22791815 |
C074702 | chromium hexavalent ion | chromium hexavalent ion results in increased phosphorylation of and results in increased expression of TP53 protein | 15831465 |
C074702 | chromium hexavalent ion | chromium hexavalent ion results in increased stability of TP53 protein | 31388677 |
C074702 | chromium hexavalent ion | pifithrin inhibits the reaction [TP53 protein promotes the reaction [chromium hexavalent ion results in decreased expression of BUB1B protein]] | 22886373 |
C074702 | chromium hexavalent ion | TP53 protein affects the reaction [chromium hexavalent ion affects the localization of BAX protein] | 16166740 |
C074702 | chromium hexavalent ion | TP53 protein affects the reaction [chromium hexavalent ion affects the localization of DIABLO protein] | 16166740 |
C074702 | chromium hexavalent ion | TP53 protein affects the reaction [chromium hexavalent ion results in decreased expression of BCL2L1 protein] | 16166740 |
C074702 | chromium hexavalent ion | TP53 protein affects the reaction [chromium hexavalent ion results in increased activity of CASP3 protein] | 16166740 |
C074702 | chromium hexavalent ion | TP53 protein affects the reaction [chromium hexavalent ion results in increased expression of BBC3 protein] | 16166740 |
C074702 | chromium hexavalent ion | TP53 protein affects the reaction [chromium hexavalent ion results in increased expression of PMAIP1 protein] | 16166740 |
C074702 | chromium hexavalent ion | TP53 protein promotes the reaction [chromium hexavalent ion results in decreased expression of BUB1B protein] | 22886373 |
C074702 | chromium hexavalent ion | TP53 protein results in increased susceptibility to chromium hexavalent ion | 10574974; 16166740; |
C043561 | chrysin | chrysin results in increased degradation of TP53 protein | 14634213 |
C043561 | chrysin | chrysin results in increased phosphorylation of and affects the localization of TP53 protein | 25770930 |
C043561 | chrysin | [Cisplatin co-treated with chrysin] affects the localization of TP53 protein | 25770930 |
C043561 | chrysin | [Cisplatin co-treated with chrysin] results in increased phosphorylation of and results in increased expression of TP53 protein | 25770930 |
C043561 | chrysin | U 0126 inhibits the reaction [[Cisplatin co-treated with chrysin] affects the localization of TP53 protein] | 25770930 |
C043561 | chrysin | U 0126 inhibits the reaction [[Cisplatin co-treated with chrysin] results in increased phosphorylation of TP53 protein] | 25770930 |
C043561 | chrysin | chrysin inhibits the reaction [Diethylnitrosamine results in decreased expression of TP53 mRNA] | 21167192 |
C043561 | chrysin | chrysin inhibits the reaction [Testosterone results in decreased expression of TP53 mRNA] | 29247772 |
C043561 | chrysin | [Diethylnitrosamine co-treated with chrysin] results in increased expression of TP53 protein | 21167192 |
C472594 | chrysophsin | chrysophsin promotes the reaction [Epirubicin results in increased expression of TP53 mRNA] | 26335193 |
C472594 | chrysophsin | chrysophsin results in increased expression of TP53 mRNA | 26335193 |
C472594 | chrysophsin | [Epirubicin analog co-treated with chrysophsin analog] results in increased expression of TP53 mRNA | 26335193 |
C472594 | chrysophsin | Epirubicin promotes the reaction [chrysophsin results in increased expression of TP53 mRNA] | 26335193 |
C012842 | Cibacron Blue F 3GA | Cibacron Blue F 3GA results in increased degradation of TP53 protein | 14634213 |
D000077404 | Cidofovir | Cidofovir affects the activity of TP53 protein | 25596134 |
D000077404 | Cidofovir | Cidofovir results in increased expression of TP53 protein | 11697818 |
D000077407 | Cilostazol | Cilostazol results in increased expression of TP53 protein | 10642304 |
D000077407 | Cilostazol | Cilostazol inhibits the reaction [Nitroprusside results in increased phosphorylation of TP53 protein] | 18311796 |
C012843 | cinnamic aldehyde | cinnamic aldehyde results in decreased expression of TP53 mRNA | 17178418 |
C488623 | cis-bis(3-aminoflavone)dichloroplatinum(II) | cis-bis(3-aminoflavone)dichloroplatinum(II) results in increased expression of TP53 mRNA | 16012788 |
D002945 | Cisplatin | 2,2-bis(hydroxymethyl)-1-azabicyclo(2,2,2,)octan-3-one promotes the reaction [Cisplatin results in increased localization of TP53 protein mutant form] | 21109480 |
D002945 | Cisplatin | Acetylcysteine inhibits the reaction [[Cisplatin co-treated with Arsenic Trioxide] results in increased phosphorylation of TP53 protein] | 29944906 |
D002945 | Cisplatin | Acetylcysteine inhibits the reaction [Cisplatin results in increased expression of TP53] | 15496615 |
D002945 | Cisplatin | Acetylcysteine inhibits the reaction [Cisplatin results in increased glutathionylation of TP53 protein] | 17555331 |
D002945 | Cisplatin | Ascorbic Acid promotes the reaction [Cisplatin results in increased expression of TP53 protein] | 21429301 |
D002945 | Cisplatin | astilbin inhibits the reaction [Cisplatin results in increased expression of TP53 protein] | 29471006 |
D002945 | Cisplatin | [ATR co-treated with TP53] results in decreased susceptibility to Cisplatin | 21258400 |
D002945 | Cisplatin | BRCA1 mutant form promotes the reaction [RRM2 mutant form promotes the reaction [TP53 mutant form promotes the reaction [Cisplatin results in increased activity of and results in increased phosphorylation of CHEK1 protein]]] | 21875941 |
D002945 | Cisplatin | BRCA1 mutant form promotes the reaction [RRM2 mutant form promotes the reaction [TP53 mutant form promotes the reaction [Cisplatin results in increased phosphorylation of H2AX protein]]] | 21875941 |
D002945 | Cisplatin | BRCA1 mutant form promotes the reaction [RRM2 mutant form promotes the reaction [TP53 mutant form results in increased susceptibility to Cisplatin]] | 21875941 |
D002945 | Cisplatin | CHEK1 mutant form promotes the reaction [TP53 mutant form results in increased susceptibility to Cisplatin] | 21875941 |
D002945 | Cisplatin | Cisplatin affects the activity of TP53 protein | 25596134 |
D002945 | Cisplatin | Cisplatin affects the localization of TP53 protein | 21858171 |
D002945 | Cisplatin | [Cisplatin co-treated with Arsenic Trioxide] results in increased phosphorylation of TP53 protein | 29944906 |
D002945 | Cisplatin | [Cisplatin co-treated with chrysin] affects the localization of TP53 protein | 25770930 |
D002945 | Cisplatin | [Cisplatin co-treated with chrysin] results in increased phosphorylation of and results in increased expression of TP53 protein | 25770930 |
D002945 | Cisplatin | [Cisplatin co-treated with fisetin] affects the localization of TP53 protein | 21216935 |
D002945 | Cisplatin | [Cisplatin co-treated with fisetin] results in increased expression of TP53 protein | 21216935 |
D002945 | Cisplatin | [Cisplatin co-treated with fisetin] results in increased phosphorylation of TP53 protein | 21216935 |
D002945 | Cisplatin | [Cisplatin co-treated with Quercetin] results in decreased expression of TP53 mRNA | 27514524 |
D002945 | Cisplatin | Cisplatin inhibits the reaction [TP53 protein results in increased expression of CDKN1A protein] | 19548002 |
D002945 | Cisplatin | Cisplatin promotes the reaction [Oxygen deficiency results in increased expression of TP53 protein] | 29690507 |
D002945 | Cisplatin | Cisplatin promotes the reaction [Oxygen deficiency results in increased expression of TP53 protein mutant form] | 29690507 |
D002945 | Cisplatin | Cisplatin promotes the reaction [TP53 protein binds to MDM2 promoter] | 21552291 |
D002945 | Cisplatin | Cisplatin promotes the reaction [TP53 protein binds to STK17A promoter] | 21489989 |
D002945 | Cisplatin | Cisplatin promotes the reaction [TP53 protein results in increased expression of BAX] | 21552291 |
D002945 | Cisplatin | Cisplatin promotes the reaction [TP53 protein results in increased expression of BBC3 mRNA] | 21532991 |
D002945 | Cisplatin | Cisplatin promotes the reaction [TP53 protein results in increased expression of CDKN1A mRNA] | 21489989 |
D002945 | Cisplatin | Cisplatin promotes the reaction [TP53 protein results in increased expression of FAS mRNA] | 21532991 |
D002945 | Cisplatin | Cisplatin promotes the reaction [TP53 protein results in increased expression of MDM2] | 21552291 |
D002945 | Cisplatin | Cisplatin promotes the reaction [TP53 protein results in increased expression of PMAIP1 mRNA] | 21532991 |
D002945 | Cisplatin | Cisplatin promotes the reaction [TP53 protein results in increased expression of STK17A mRNA] | 21489989 |
D002945 | Cisplatin | Cisplatin results in decreased phosphorylation of TP53 protein | 15854392 |
D002945 | Cisplatin | Cisplatin results in increased acetylation of TP53 protein | 21532991 |
D002945 | Cisplatin | Cisplatin results in increased expression of and affects the localization of TP53 protein | 12807743 |
D002945 | Cisplatin | Cisplatin results in increased expression of and results in increased acetylation of TP53 protein | 21660965 |
D002945 | Cisplatin | Cisplatin results in increased expression of and results in increased phosphorylation of TP53 protein | 28371273 |
D002945 | Cisplatin | Cisplatin results in increased expression of TP53 | 15496615; 21552291; 21880462; |
D002945 | Cisplatin | Cisplatin results in increased expression of TP53 mRNA | 15454482; 20878077; |
D002945 | Cisplatin | Cisplatin results in increased expression of TP53 protein | 12082016; 15990222; 16193384; 16601104; 16797627; 17555331; 19144690; 20100536; 20477830; 20623183; 20674069; 21109480; 21216935; 21274007; 21356574; 21429301; 21532991; 21624110; 21696631; 21742020; 21858171; 23300844; 25776512; 26961604; 27358234; 29471006; 29471073; 29690507; 9664115; |
D002945 | Cisplatin | Cisplatin results in increased expression of TP53 protein modified form | 21274007 |
D002945 | Cisplatin | Cisplatin results in increased glutathionylation of TP53 protein | 17555331 |
D002945 | Cisplatin | Cisplatin results in increased localization of TP53 protein | 21109480 |
D002945 | Cisplatin | Cisplatin results in increased localization of TP53 protein mutant form | 21109480 |
D002945 | Cisplatin | Cisplatin results in increased phosphorylation of and results in increased expression of TP53 protein | 24799992 |
D002945 | Cisplatin | Cisplatin results in increased phosphorylation of TP53 protein | 20145152; 21285353; 21532991; 21552291; 21660965; 21801448; 29944906; |
D002945 | Cisplatin | Cisplatin results in increased stability of and results in increased activity of TP53 protein | 14562046 |
D002945 | Cisplatin | CITED2 mutant form promotes the reaction [Cisplatin results in increased expression of and results in increased acetylation of TP53 protein] | 21660965 |
D002945 | Cisplatin | CITED2 mutant form promotes the reaction [Cisplatin results in increased phosphorylation of TP53 protein] | 21660965 |
D002945 | Cisplatin | [CITED2 results in decreased susceptibility to Cisplatin] which results in decreased expression of and results in decreased acetylation of TP53 protein | 21660965 |
D002945 | Cisplatin | [CITED2 results in decreased susceptibility to Cisplatin] which results in decreased phosphorylation of TP53 protein | 21660965 |
D002945 | Cisplatin | ERCC1 mutant form inhibits the reaction [RRM2 mutant form promotes the reaction [TP53 mutant form promotes the reaction [Cisplatin results in increased phosphorylation of H2AX protein]]] | 21875941 |
D002945 | Cisplatin | ERCC1 mutant form inhibits the reaction [TP53 mutant form promotes the reaction [Cisplatin results in increased phosphorylation of H2AX protein]] | 21875941 |
D002945 | Cisplatin | ERCC1 mutant form promotes the reaction [RRM2 mutant form promotes the reaction [TP53 mutant form results in increased susceptibility to Cisplatin]] | 21875941 |
D002945 | Cisplatin | ERCC5 mutant form inhibits the reaction [RRM2 mutant form promotes the reaction [TP53 mutant form promotes the reaction [Cisplatin results in increased phosphorylation of H2AX protein]]] | 21875941 |
D002945 | Cisplatin | Melatonin inhibits the reaction [Cisplatin results in increased phosphorylation of and results in increased expression of TP53 protein] | 24799992 |
D002945 | Cisplatin | MIR630 mRNA inhibits the reaction [Cisplatin results in increased phosphorylation of TP53 protein] | 20145152 |
D002945 | Cisplatin | MSH2 protein promotes the reaction [Cisplatin results in increased phosphorylation of TP53 protein] | 21285353 |
D002945 | Cisplatin | Nicotine inhibits the reaction [Cisplatin results in increased expression of TP53 protein] | 16601104 |
D002945 | Cisplatin | Noscapine promotes the reaction [Cisplatin results in increased expression of TP53 protein] | 20674069 |
D002945 | Cisplatin | nutlin 3 promotes the reaction [Cisplatin results in increased expression of TP53 mRNA] | 21109480 |
D002945 | Cisplatin | nutlin 3 promotes the reaction [Cisplatin results in increased expression of TP53 protein] | 21624110 |
D002945 | Cisplatin | nutlin 3 promotes the reaction [Cisplatin results in increased localization of TP53 protein] | 21109480 |
D002945 | Cisplatin | [nutlin 3 results in increased stability of TP53 protein] which results in increased susceptibility to Cisplatin | 21205074 |
D002945 | Cisplatin | pifithrin inhibits the reaction [Cisplatin results in increased expression of TP53 protein] | 21660965 |
D002945 | Cisplatin | pifithrin inhibits the reaction [CITED2 mutant form promotes the reaction [Cisplatin results in increased expression of TP53 protein]] | 21660965 |
D002945 | Cisplatin | Piroxicam promotes the reaction [Cisplatin results in increased expression of TP53 protein] | 21858171 |
D002945 | Cisplatin | RAD23B mutant form inhibits the reaction [Cisplatin results in increased expression of TP53 protein] | 21742020 |
D002945 | Cisplatin | RRM2 mutant form promotes the reaction [TP53 mutant form promotes the reaction [Cisplatin results in increased phosphorylation of and results in increased activity of CHEK1 protein]] | 21875941 |
D002945 | Cisplatin | RRM2 mutant form promotes the reaction [TP53 mutant form promotes the reaction [Cisplatin results in increased phosphorylation of H2AX protein]] | 21875941 |
D002945 | Cisplatin | RRM2 mutant form promotes the reaction [TP53 mutant form results in increased susceptibility to Cisplatin] | 21875941 |
D002945 | Cisplatin | SB 203580 inhibits the reaction [[Cisplatin co-treated with fisetin] results in increased phosphorylation of TP53 protein] | 21216935 |
D002945 | Cisplatin | sodium arsenite inhibits the reaction [Cisplatin results in increased expression of TP53 protein] | 21696631 |
D002945 | Cisplatin | [TFAP2A protein co-treated with TP53 gene mutant form] results in decreased susceptibility to Cisplatin | 21489314 |
D002945 | Cisplatin | TP53 affects the reaction [Cisplatin results in increased activity of and results in increased expression of CDKN1A protein] | 21624110 |
D002945 | Cisplatin | TP53 affects the reaction [Cisplatin results in increased activity of and results in increased expression of MDM2 protein] | 21624110 |
D002945 | Cisplatin | TP53 affects the reaction [Cisplatin results in increased expression of RRM2B protein] | 21875941 |
D002945 | Cisplatin | TP53 affects the reaction [CITED2 results in decreased susceptibility to Cisplatin] | 21660965 |
D002945 | Cisplatin | TP53 affects the reaction [nutlin 3 promotes the reaction [Cisplatin results in increased activity of and results in increased expression of CDKN1A protein]] | 21624110 |
D002945 | Cisplatin | TP53 affects the reaction [nutlin 3 promotes the reaction [Cisplatin results in increased activity of and results in increased expression of MDM2 protein]] | 21624110 |
D002945 | Cisplatin | TP53 gene mutant form results in decreased susceptibility to Cisplatin | 15578696 |
D002945 | Cisplatin | TP53 mutant form promotes the reaction [Cisplatin results in increased phosphorylation of and results in increased activity of CHEK1 protein] | 21875941 |
D002945 | Cisplatin | TP53 mutant form promotes the reaction [Cisplatin results in increased phosphorylation of H2AX protein] | 21875941 |
D002945 | Cisplatin | TP53 mutant form results in increased susceptibility to Cisplatin | 21875941 |
D002945 | Cisplatin | TP53 protein affects the reaction [Cisplatin inhibits the reaction [Oxygen deficiency results in increased expression of HIF1A protein]] | 29690507 |
D002945 | Cisplatin | TP53 protein affects the reaction [Cisplatin results in increased degradation of HIF1A protein] | 17498666 |
D002945 | Cisplatin | TP53 protein affects the reaction [Cisplatin results in increased expression of BBC3 mRNA] | 29690507 |
D002945 | Cisplatin | TP53 protein affects the reaction [Cisplatin results in increased expression of CDKN1A mRNA] | 29690507 |
D002945 | Cisplatin | TP53 protein affects the reaction [Cisplatin results in increased expression of PMAIP1 mRNA] | 29690507 |
D002945 | Cisplatin | TP53 protein affects the reaction [Cisplatin results in increased expression of XPC protein] | 22331493 |
D002945 | Cisplatin | TP53 protein affects the reaction [Cisplatin results in increased susceptibility to TNFSF10 protein] | 21152876 |
D002945 | Cisplatin | TP53 protein affects the reaction [[Oxygen deficiency co-treated with Cisplatin] results in increased expression of CDKN1A mRNA] | 29690507 |
D002945 | Cisplatin | TP53 protein affects the reaction [sodium arsenite results in increased susceptibility to Cisplatin] | 22331493 |
D002945 | Cisplatin | TP53 protein affects the susceptibility to Cisplatin | 22331493 |
D002945 | Cisplatin | TP53 protein affects the susceptibility to [Fluorouracil co-treated with Cisplatin] | 15999354 |
D002945 | Cisplatin | [TP53 protein binds to MDM2 protein] which results in decreased susceptibility to Cisplatin | 21509038 |
D002945 | Cisplatin | TP53 protein inhibits the reaction [Cisplatin results in increased expression of CCNB1 protein] | 19548002 |
D002945 | Cisplatin | TP53 protein inhibits the reaction [ESR2 protein results in increased susceptibility to Cisplatin] | 20623183 |
D002945 | Cisplatin | TP53 protein modified form affects the susceptibility to Cisplatin | 11861384 |
D002945 | Cisplatin | TP53 protein promotes the reaction [Cisplatin results in increased expression of CDKN1A protein] | 29471073 |
D002945 | Cisplatin | TP53 protein promotes the reaction [Cisplatin results in increased expression of PMAIP1 mRNA] | 17216584 |
D002945 | Cisplatin | TP53 protein promotes the reaction [Y 27632 results in decreased susceptibility to Cisplatin] | 20878077 |
D002945 | Cisplatin | TP53 protein results in decreased susceptibility to Cisplatin | 15990222; 16020667; |
D002945 | Cisplatin | TP53 protein results in increased susceptibility to Cisplatin | 16193384; 16211088; 19548002; 21447800; 21532991; 21552291; 29471073; |
D002945 | Cisplatin | TP53 protein results in increased susceptibility to [Cisplatin co-treated with Fluorouracil] | 16077963 |
D002945 | Cisplatin | TP53 protein results in increased susceptibility to [Fluorouracil co-treated with Cisplatin] | 15254702 |
D002945 | Cisplatin | TP53 results in increased susceptibility to Cisplatin | 21258400 |
D002945 | Cisplatin | Tretinoin inhibits the reaction [Cisplatin results in increased acetylation of TP53 protein] | 21532991 |
D002945 | Cisplatin | U 0126 inhibits the reaction [[Cisplatin co-treated with chrysin] affects the localization of TP53 protein] | 25770930 |
D002945 | Cisplatin | U 0126 inhibits the reaction [[Cisplatin co-treated with chrysin] results in increased phosphorylation of TP53 protein] | 25770930 |
D002945 | Cisplatin | Vorinostat inhibits the reaction [Tretinoin inhibits the reaction [Cisplatin results in increased acetylation of TP53 protein]] | 21532991 |
D002945 | Cisplatin | XPA mutant form inhibits the reaction [RRM2 mutant form promotes the reaction [TP53 mutant form promotes the reaction [Cisplatin results in increased phosphorylation of H2AX protein]]] | 21875941 |
D002945 | Cisplatin | Y 27632 inhibits the reaction [Cisplatin results in increased expression of TP53 mRNA] | 20878077 |
D002945 | Cisplatin | Cisplatin results in increased phosphorylation of TP53 protein | 21151649 |
D002945 | Cisplatin | Cisplatin results in increased acetylation of TP53 protein | 21416250 |
D002945 | Cisplatin | Cisplatin results in increased expression of and results in increased phosphorylation of and results in increased activity of TP53 protein | 15315938 |
D002945 | Cisplatin | Cisplatin results in increased expression of TP53 mRNA | 25640527; 26120027; 26612654; |
D002945 | Cisplatin | Cisplatin results in increased expression of TP53 protein | 20650967; 25184746; 28119452; 28414026; 29852128; |
D002945 | Cisplatin | Cisplatin results in increased expression of TP53 protein modified form | 26739623 |
D002945 | Cisplatin | Cisplatin results in increased phosphorylation of and results in increased stability of TP53 protein | 18310471 |
D002945 | Cisplatin | fisetin inhibits the reaction [Cisplatin results in increased expression of TP53 protein] | 25184746 |
D002945 | Cisplatin | formononetin inhibits the reaction [Cisplatin results in increased expression of TP53 protein] | 28414026 |
D002945 | Cisplatin | Lovastatin inhibits the reaction [Cisplatin results in increased expression of TP53 protein modified form] | 26739623 |
D002945 | Cisplatin | naringin inhibits the reaction [Cisplatin results in increased expression of TP53 mRNA] | 26120027; 26612654; |
D002945 | Cisplatin | pifithrin inhibits the reaction [Cisplatin results in increased activity of TP53 protein] | 15315938 |
D002945 | Cisplatin | pifithrin inhibits the reaction [TP53 protein results in increased susceptibility to Cisplatin] | 15315938 |
D002945 | Cisplatin | Plant Extracts inhibits the reaction [Cisplatin results in increased expression of TP53 mRNA] | 25640527 |
D002945 | Cisplatin | Pravastatin inhibits the reaction [Cisplatin results in increased expression of TP53 protein] | 20650967 |
D002945 | Cisplatin | TP53 protein mutant form inhibits the reaction [Cisplatin results in increased expression of MIR375 mRNA] | 28119452 |
D002945 | Cisplatin | TP53 protein results in increased susceptibility to Cisplatin | 15315938 |
D002945 | Cisplatin | Venlafaxine Hydrochloride inhibits the reaction [Cisplatin results in increased expression of TP53 protein] | 29852128 |
D002945 | Cisplatin | Cisplatin results in increased expression of TP53 | 12712633; 20603111; |
D002945 | Cisplatin | mangostin inhibits the reaction [Cisplatin results in increased expression of TP53] | 20603111 |
D002945 | Cisplatin | Cisplatin results in increased expression of TP53 protein | 21837762 |
D002953 | Citrinin | Citrinin results in increased expression of TP53 protein | 20929984 |
D002953 | Citrinin | Citrinin results in increased expression of TP53 protein modified form | 22564900 |
C402823 | CLIK 148 | CLIK 148 results in increased expression of TP53 protein | 21484410 |
D007464 | Clioquinol | 2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one inhibits the reaction [Clioquinol results in increased phosphorylation of TP53 protein] | 22627294 |
D007464 | Clioquinol | Clioquinol results in increased phosphorylation of TP53 protein | 22627294 |
D004002 | Clodronic Acid | Clodronic Acid affects the activity of TP53 protein | 25596134 |
D000077866 | Clofarabine | [Resveratrol co-treated with Clofarabine] affects the localization of TP53 protein modified form | 24239893 |
D000077866 | Clofarabine | [Resveratrol co-treated with Clofarabine] results in increased expression of and results in increased activity of TP53 protein modified form | 24239893 |
D000077866 | Clofarabine | TP53 protein affects the susceptibility to [Resveratrol co-treated with Clofarabine] | 24239893 |
D002995 | Clofibric Acid | Clofibric Acid affects the expression of TP53 mRNA | 17602206 |
D002995 | Clofibric Acid | [Diethylnitrosamine co-treated with Clofibric Acid] affects the expression of TP53 mRNA | 17602206 |
D000077144 | Clopidogrel | Clopidogrel results in increased expression of TP53 mRNA | 9447704 |
D000077144 | Clopidogrel | Clopidogrel results in increased expression of TP53 protein | 9447704 |
D003022 | Clotrimazole | Clotrimazole results in increased expression of TP53 protein | 10223459 |
D003024 | Clozapine | Clozapine results in increased expression of TP53 mRNA | 16160616 |
D003024 | Clozapine | CSF3 protein inhibits the reaction [Clozapine results in increased expression of TP53 mRNA] | 16160616 |
D003035 | Cobalt | Cobalt results in increased expression of TP53 mRNA | 22983774 |
D003035 | Cobalt | Cobalt results in increased expression of and results in increased phosphorylation of TP53 protein | 24068677 |
D003035 | Cobalt | Cobalt results in increased expression of and results in increased stability of TP53 protein | 23052192 |
D003035 | Cobalt | Cobalt results in increased expression of TP53 protein | 21598295 |
D003035 | Cobalt | TP53 protein affects the reaction [Cobalt results in increased expression of BBC3 mRNA] | 24068677 |
D003035 | Cobalt | TP53 protein affects the reaction [Cobalt results in increased expression of CDKN1A mRNA] | 24068677 |
D003035 | Cobalt | TP53 protein affects the reaction [Cobalt results in increased expression of MDM2 mRNA] | 24068677 |
D003035 | Cobalt | TP53 protein affects the reaction [Cobalt results in increased expression of PMAIP1 mRNA] | 24068677 |
D003035 | Cobalt | [tungsten carbide co-treated with Cobalt] results in increased expression of and results in increased stability of TP53 protein | 23052192 |
C007095 | cobaltiprotoporphyrin | [1,8-diazafluoren-one results in decreased activity of HMOX1 protein] inhibits the reaction [cobaltiprotoporphyrin results in increased expression of TP53 protein] | 18042465 |
C007095 | cobaltiprotoporphyrin | cobaltiprotoporphyrin affects the expression of TP53 protein | 24211270 |
C007095 | cobaltiprotoporphyrin | cobaltiprotoporphyrin results in increased expression of TP53 protein | 18042465 |
C007095 | cobaltiprotoporphyrin | [zinc protoporphyrin results in decreased activity of HMOX1 protein] inhibits the reaction [cobaltiprotoporphyrin results in increased expression of TP53 protein] | 18042465 |
C007095 | cobaltiprotoporphyrin | cobaltiprotoporphyrin results in decreased expression of TP53 protein | 20357190 |
C007095 | cobaltiprotoporphyrin | zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin results in decreased expression of TP53 protein] | 20357190 |
C018021 | cobaltous chloride | [3-methyladenine co-treated with cobaltous chloride co-treated with TP53 gene mutant form] results in increased activity of CASP3 protein | 23380477 |
C018021 | cobaltous chloride | 3-methyladenine inhibits the reaction [[cobaltous chloride co-treated with TP53 gene mutant form] results in increased activity of CTSB protein] | 23380477 |
C018021 | cobaltous chloride | Acetylcysteine inhibits the reaction [cobaltous chloride results in increased expression of and results in increased activity of TP53 protein] | 10951577 |
C018021 | cobaltous chloride | [bafilomycin A1 co-treated with cobaltous chloride co-treated with TP53 gene mutant form] results in increased activity of CASP3 protein | 23380477 |
C018021 | cobaltous chloride | bafilomycin A1 inhibits the reaction [[cobaltous chloride co-treated with TP53 gene mutant form] results in increased activity of CTSB protein] | 23380477 |
C018021 | cobaltous chloride | [cobaltous chloride co-treated with TP53 gene mutant form] results in decreased expression of and results in decreased phosphorylation of TP53 protein | 21687937; 21687937; |
C018021 | cobaltous chloride | [cobaltous chloride co-treated with TP53 gene mutant form] results in decreased expression of BBC3 protein | 21687937 |
C018021 | cobaltous chloride | [cobaltous chloride co-treated with TP53 gene mutant form] results in decreased expression of TP53 protein | 23380477; 23380477; |
C018021 | cobaltous chloride | [cobaltous chloride co-treated with TP53 gene mutant form] results in decreased expression of TP53 protein modified form | 23380477; 23380477; |
C018021 | cobaltous chloride | [cobaltous chloride co-treated with TP53 gene mutant form] results in increased activity of CASP3 protein | 21687937 |
C018021 | cobaltous chloride | [cobaltous chloride co-treated with TP53 gene mutant form] results in increased activity of CTSB protein | 21687937; 23380477; |
C018021 | cobaltous chloride | [cobaltous chloride co-treated with TP53 gene mutant form] results in increased expression of ATG12 protein | 23380477 |
C018021 | cobaltous chloride | [cobaltous chloride co-treated with TP53 gene mutant form] results in increased expression of BECN1 protein | 23380477 |
C018021 | cobaltous chloride | [cobaltous chloride co-treated with TP53 gene mutant form] results in increased expression of CDKN1A protein | 21687937 |
C018021 | cobaltous chloride | cobaltous chloride inhibits the reaction [Doxorubicin results in increased phosphorylation of and results in increased activity of TP53 protein] | 19714248 |
C018021 | cobaltous chloride | cobaltous chloride inhibits the reaction [[Doxorubicin results in increased phosphorylation of and results in increased activity of TP53 protein] which results in increased expression of BAX mRNA] | 19714248 |
C018021 | cobaltous chloride | cobaltous chloride inhibits the reaction [[Doxorubicin results in increased phosphorylation of and results in increased activity of TP53 protein] which results in increased expression of BBC3 mRNA] | 19714248 |
C018021 | cobaltous chloride | cobaltous chloride inhibits the reaction [HIPK2 protein promotes the reaction [Doxorubicin results in increased phosphorylation of and results in increased activity of TP53 protein]] | 19714248 |
C018021 | cobaltous chloride | cobaltous chloride promotes the reaction [TP53 protein mutant form binds to COL13A1 gene] | 30381462 |
C018021 | cobaltous chloride | cobaltous chloride promotes the reaction [TP53 protein mutant form binds to COL7A1 gene] | 30381462 |
C018021 | cobaltous chloride | cobaltous chloride promotes the reaction [TP53 protein mutant form binds to HIF1A protein] | 30381462 |
C018021 | cobaltous chloride | cobaltous chloride promotes the reaction [TP53 protein mutant form binds to [HIF1A protein binds to ARNT protein]] | 30381462 |
C018021 | cobaltous chloride | cobaltous chloride promotes the reaction [TP53 protein mutant form binds to SMARCA4 protein] | 30381462 |
C018021 | cobaltous chloride | cobaltous chloride promotes the reaction [TP53 protein mutant form binds to SMARCC1 protein] | 30381462 |
C018021 | cobaltous chloride | cobaltous chloride results in decreased activity of TP53 protein | 25446071 |
C018021 | cobaltous chloride | [cobaltous chloride results in decreased activity of TP53 protein] inhibits the reaction [TP53 protein binds to TP53 gene] | 25446071; 25446071; |
C018021 | cobaltous chloride | [cobaltous chloride results in decreased activity of TP63 protein] inhibits the reaction [TP63 protein binds to TP53 gene] | 25446071 |
C018021 | cobaltous chloride | [cobaltous chloride results in decreased activity of TP73 protein] inhibits the reaction [TP73 protein binds to TP53 gene] | 25446071 |
C018021 | cobaltous chloride | cobaltous chloride results in increased expression of and results in increased activity of TP53 protein | 10951577 |
C018021 | cobaltous chloride | cobaltous chloride results in increased expression of and results in increased phosphorylation of TP53 protein | 21687937 |
C018021 | cobaltous chloride | cobaltous chloride results in increased expression of TP53 mRNA | 22269387 |
C018021 | cobaltous chloride | cobaltous chloride results in increased expression of TP53 protein | 20974702; 23380477; |
C018021 | cobaltous chloride | cobaltous chloride results in increased stability of TP53 protein | 30381462 |
C018021 | cobaltous chloride | Ditiocarb inhibits the reaction [cobaltous chloride results in increased expression of and results in increased activity of TP53 protein] | 10951577 |
C018021 | cobaltous chloride | HIF1A protein promotes the reaction [cobaltous chloride promotes the reaction [TP53 protein mutant form binds to COL7A1 gene]] | 30381462 |
C018021 | cobaltous chloride | MDM2 protein promotes the reaction [cobaltous chloride inhibits the reaction [HIPK2 protein promotes the reaction [Doxorubicin results in increased phosphorylation of and results in increased activity of TP53 protein]]] | 19714248 |
C018021 | cobaltous chloride | peoniflorin inhibits the reaction [cobaltous chloride results in increased expression of TP53 mRNA] | 22269387 |
C018021 | cobaltous chloride | [pifithrin co-treated with cobaltous chloride] results in increased expression of and affects the localization of TP53 protein | 23380477 |
C018021 | cobaltous chloride | TP53 gene mutant form promotes the reaction [cobaltous chloride results in increased expression of HIF1A protein] | 16527254 |
C018021 | cobaltous chloride | [TP53 protein co-treated with cobaltous chloride] affects the localization of AIFM1 protein | 21687937 |
C018021 | cobaltous chloride | TP53 protein promotes the reaction [cobaltous chloride results in increased activity of CASP3 protein] | 21687937 |
C018021 | cobaltous chloride | TP53 protein promotes the reaction [cobaltous chloride results in increased activity of CASP9 protein] | 23380477 |
C018021 | cobaltous chloride | zinc chloride inhibits the reaction [cobaltous chloride inhibits the reaction [Doxorubicin results in increased phosphorylation of and results in increased activity of TP53 protein]] | 19714248 |
C018021 | cobaltous chloride | cobaltous chloride promotes the reaction [Diethylnitrosamine results in increased expression of TP53 protein] | 11751435 |
D003078 | Colchicine | TP53 protein affects the reaction [Colchicine results in increased phosphorylation of JUN protein] | 12221076 |
D003078 | Colchicine | TP53 protein affects the reaction [Colchicine results in increased phosphorylation of MAPK8 protein] | 12221076 |
D003078 | Colchicine | TP53 protein affects the reaction [Colchicine results in increased phosphorylation of MAPK9 protein] | 12221076 |
D005576 | Colforsin | Colforsin results in increased expression of TP53 protein | 10642304 |
D003091 | Colistin | Anisomycin promotes the reaction [Colistin results in increased expression of TP53 protein] | 28842171 |
D003091 | Colistin | Colistin results in increased expression of TP53 protein | 28842171 |
D003091 | Colistin | pyrazolanthrone inhibits the reaction [Colistin results in increased expression of TP53 protein] | 28842171 |
D003300 | Copper | [2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of TP53 gene | 10334203 |
D003300 | Copper | bathocuproine inhibits the reaction [[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of TP53 gene] | 10334203 |
D003300 | Copper | bathocuproine inhibits the reaction [[phenylhydroquinone co-treated with Copper] results in increased mutagenesis of TP53 gene] | 10334203 |
D003300 | Copper | bathocuproine sulfonate inhibits the reaction [[pyrrolidine dithiocarbamic acid results in increased abundance of Copper] which results in increased oxidation of and results in increased expression of TP53 protein] | 11964141 |
D003300 | Copper | CAT protein inhibits the reaction [[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of TP53 gene] | 10334203 |
D003300 | Copper | CAT protein inhibits the reaction [[phenylhydroquinone co-treated with Copper] results in increased mutagenesis of TP53 gene] | 10334203 |
D003300 | Copper | [Copper binds to Isatin binds to 2-(2-aminoethyl)pyridine] which results in increased expression of TP53 protein | 17327230 |
D003300 | Copper | [Copper binds to Isatin binds to trimethylenediamine] which results in increased expression of TP53 protein | 17327230 |
D003300 | Copper | Copper results in decreased activity of TP53 protein | 16246896 |
D003300 | Copper | [Copper results in increased activity of TP53 protein] which results in increased expression of CDKN1A mRNA | 16391388 |
D003300 | Copper | [Copper results in increased activity of TP53 protein] which results in increased expression of CDKN2A mRNA | 16391388 |
D003300 | Copper | [Copper results in increased activity of TP53 protein] which results in increased expression of EI24 mRNA | 16391388 |
D003300 | Copper | [Copper results in increased activity of TP53 protein] which results in increased expression of ENC1 mRNA | 16391388 |
D003300 | Copper | [Copper results in increased activity of TP53 protein] which results in increased expression of IGFBP6 mRNA | 16391388 |
D003300 | Copper | [Copper results in increased activity of TP53 protein] which results in increased expression of PTGES mRNA | 16391388 |
D003300 | Copper | [Copper results in increased activity of TP53 protein] which results in increased expression of RPRM mRNA | 16391388 |
D003300 | Copper | Copper results in increased expression of and affects the localization of TP53 protein | 16391388 |
D003300 | Copper | Copper results in increased expression of TP53 protein | 15880691; 20875833; |
D003300 | Copper | Copper results in increased oxidation of TP53 protein | 11964141 |
D003300 | Copper | [N-hydroxy-4-aminobiphenyl co-treated with Copper] results in increased mutagenesis of TP53 gene | 11275476 |
D003300 | Copper | [phenylhydroquinone co-treated with Copper] results in increased mutagenesis of TP53 gene | 10334203 |
D003300 | Copper | [pyrrolidine dithiocarbamic acid results in increased abundance of Copper] which results in increased oxidation of and results in increased expression of TP53 protein | 11964141 |
D003300 | Copper | [Thiosemicarbazones binds to Copper] which results in decreased activity of TP53 protein | 20931265 |
D003300 | Copper | TP53 protein inhibits the reaction [Copper results in increased phosphorylation of MAPK1 protein] | 15880691 |
D003300 | Copper | TP53 protein inhibits the reaction [Copper results in increased phosphorylation of MAPK3 protein] | 15880691 |
D003300 | Copper | TP53 protein promotes the reaction [Copper results in increased abundance of Reactive Oxygen Species] | 15880691 |
D003300 | Copper | TP53 protein results in increased susceptibility to Copper | 15880691 |
D003300 | Copper | Tretinoin inhibits the reaction [[Copper binds to Isatin binds to trimethylenediamine] which results in increased expression of TP53 protein] | 17327230 |
D003300 | Copper | [Copper deficiency co-treated with tetrathiomolybdate] results in increased expression of TP53 protein | 22276220 |
D003300 | Copper | [Copper co-treated with 1,2-diphenylhydrazine] results in increased mutagenesis of TP53 gene | 10798712 |
D003300 | Copper | piperidine promotes the reaction [[Copper co-treated with 1,2-diphenylhydrazine] results in increased mutagenesis of TP53 gene] | 10798712 |
C464760 | copper-1,10-phenanthroline | copper-1,10-phenanthroline results in increased expression of TP53 protein | 24638265 |
D019327 | Copper Sulfate | [Arsenic Trioxide co-treated with Copper Sulfate] results in increased expression of TP53 mRNA | 29569195; 30543957; |
D019327 | Copper Sulfate | [Arsenic Trioxide co-treated with Copper Sulfate] results in increased expression of TP53 protein | 29569195; 30543957; |
D019327 | Copper Sulfate | Copper Sulfate results in increased expression of TP53 mRNA | 29569195; 30543957; |
D019327 | Copper Sulfate | Copper Sulfate results in increased expression of TP53 protein | 29569195; 30543957; |
D019327 | Copper Sulfate | Copper Sulfate results in decreased expression of TP53 mRNA | 27825931 |
D019327 | Copper Sulfate | Copper Sulfate results in increased phosphorylation of and results in increased expression of TP53 protein | 15001399 |
C058120 | cordycepin | cordycepin results in increased expression of TP53 mRNA | 28987792 |
C058120 | cordycepin | ADORA2A mutant form inhibits the reaction [cordycepin results in increased phosphorylation of and results in increased expression of TP53 protein] | 24704558 |
C058120 | cordycepin | cordycepin promotes the reaction [Etoposide results in increased expression of TP53 protein] | 23690541 |
C058120 | cordycepin | cordycepin results in increased phosphorylation of and results in increased expression of TP53 protein | 24704558 |
C058120 | cordycepin | TP53 mutant form inhibits the reaction [cordycepin results in increased cleavage of CASP7 protein] | 24704558 |
C058120 | cordycepin | TP53 mutant form inhibits the reaction [cordycepin results in increased cleavage of PARP1 protein] | 24704558 |
C058120 | cordycepin | ZM 241385 inhibits the reaction [cordycepin results in increased phosphorylation of and results in increased expression of TP53 protein] | 24704558 |
C030123 | coumarin | coumarin results in increased expression of TP53 mRNA | 26946349 |
C402665 | CP 31398 | CP 31398 results in increased activity of TP53 protein | 15155752; 16177561; |
C402665 | CP 31398 | CP 31398 results in increased expression of and results in increased activity of TP53 protein mutant form | 21109480 |
C539572 | CpG-ODN DSP30 | [CpG-ODN DSP30 co-treated with IL2 protein] results in increased expression of TP53 protein | 27634759 |
C408982 | CPG-oligonucleotide | CPG-oligonucleotide results in decreased expression of TP53 mRNA | 21878529 |
C024015 | cryptolepine | cryptolepine results in increased activity of TP53 protein | 16120219 |
C024015 | cryptolepine | cryptolepine results in increased expression of TP53 protein | 16120219 |
C542041 | cudraflavone B | cudraflavone B results in increased expression of TP53 protein | 23881456 |
C542041 | cudraflavone B | Resveratrol inhibits the reaction [cudraflavone B results in increased expression of TP53 protein] | 23881456 |
C542041 | cudraflavone B | sirtinol promotes the reaction [cudraflavone B results in increased expression of TP53 protein] | 23881456 |
C029892 | cupric chloride | CAT protein inhibits the reaction [[cupric chloride co-treated with di(2-picolyl)amine-3(bromoacetyl)coumarin] results in increased expression of TP53 protein] | 29803612 |
C029892 | cupric chloride | [cupric chloride co-treated with di(2-picolyl)amine-3(bromoacetyl)coumarin] results in increased expression of TP53 protein | 29803612 |
C029892 | cupric chloride | Ethanol inhibits the reaction [[cupric chloride co-treated with di(2-picolyl)amine-3(bromoacetyl)coumarin] results in increased expression of TP53 protein] | 29803612 |
C029892 | cupric chloride | Mannitol inhibits the reaction [[cupric chloride co-treated with di(2-picolyl)amine-3(bromoacetyl)coumarin] results in increased expression of TP53 protein] | 29803612 |
C029892 | cupric chloride | neocuproine inhibits the reaction [[cupric chloride co-treated with di(2-picolyl)amine-3(bromoacetyl)coumarin] results in increased expression of TP53 protein] | 29803612 |
C029892 | cupric chloride | Thiourea inhibits the reaction [[cupric chloride co-treated with di(2-picolyl)amine-3(bromoacetyl)coumarin] results in increased expression of TP53 protein] | 29803612 |
C030973 | cupric oxide | cupric oxide analog results in decreased phosphorylation of and results in decreased expression of TP53 protein | 25336953 |
C030973 | cupric oxide | cupric oxide results in decreased expression of TP53 mRNA | 22077320 |
D003471 | Cuprizone | Cuprizone results in increased expression of TP53 mRNA | 26577399; 27523638; |
D003474 | Curcumin | [Arsenic Trioxide co-treated with Curcumin] results in increased expression of TP53 protein | 27430728 |
D003474 | Curcumin | Curcumin affects the expression of TP53 protein | 24211270 |
D003474 | Curcumin | Curcumin affects the localization of TP53 protein | 17332930 |
D003474 | Curcumin | Curcumin analog affects the expression of TP53 mRNA | 17041101 |
D003474 | Curcumin | Curcumin analog affects the expression of TP53 protein | 17041101 |
D003474 | Curcumin | Curcumin analog results in decreased expression of TP53 mRNA | 26409325 |
D003474 | Curcumin | [Curcumin co-treated with Metribolone] results in increased phosphorylation of TP53 protein | 21134073 |
D003474 | Curcumin | Curcumin inhibits the reaction [Benzo(a)pyrene results in increased phosphorylation of and results in increased activity of TP53 protein] | 24664296 |
D003474 | Curcumin | Curcumin inhibits the reaction [bisphenol A results in decreased expression of TP53 protein] | 23222814 |
D003474 | Curcumin | Curcumin inhibits the reaction [bisphenol A results in increased expression of TP53 protein] | 24831732 |
D003474 | Curcumin | Curcumin results in decreased expression of TP53 protein | 30935902 |
D003474 | Curcumin | Curcumin results in increased acetylation of TP53 protein | 17332930 |
D003474 | Curcumin | [Curcumin results in increased expression of SERPINB5] which results in increased expression of TP53 protein | 19944674 |
D003474 | Curcumin | Curcumin results in increased expression of TP53 | 25644192 |
D003474 | Curcumin | Curcumin results in increased expression of TP53 protein | 23222814; 25256401; |
D003474 | Curcumin | Curcumin results in increased phosphorylation of TP53 protein | 17332930; 19020741; 21134073; |
D003474 | Curcumin | dorsomorphin inhibits the reaction [Curcumin results in increased phosphorylation of TP53 protein] | 19020741 |
D003474 | Curcumin | [piperine co-treated with Curcumin] results in decreased expression of TP53 protein | 30935902 |
D003474 | Curcumin | SB 203580 inhibits the reaction [Curcumin results in increased phosphorylation of TP53 protein] | 19020741 |
D003474 | Curcumin | [Vitamin E co-treated with Curcumin] results in decreased expression of TP53 protein | 30935902 |
D003474 | Curcumin | Curcumin results in decreased expression of TP53 protein | 22714040 |
D003474 | Curcumin | benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Curcumin binds to carboxymethyl-chitosan analog] inhibits the reaction [AGT protein modified form results in decreased degradation of TP53 protein]] | 26612707 |
D003474 | Curcumin | carboxymethyl-chitosan analog promotes the reaction [Curcumin inhibits the reaction [AGT protein modified form results in increased acetylation of TP53 protein]] | 26612707 |
D003474 | Curcumin | [Curcumin binds to carboxymethyl-chitosan analog] inhibits the reaction [AGT protein modified form results in decreased degradation of TP53 protein] | 26612707 |
D003474 | Curcumin | Curcumin inhibits the reaction [AGT protein modified form promotes the reaction [TP53 protein binds to EP300 protein]] | 26612707 |
D003474 | Curcumin | Curcumin inhibits the reaction [AGT protein modified form results in increased expression of and results in increased phosphorylation of and results in increased acetylation of TP53 protein] | 26612707 |
D003474 | Curcumin | Curcumin inhibits the reaction [Cyclophosphamide results in increased mutagenesis of TP53 exon] | 19227835 |
D003474 | Curcumin | Curcumin inhibits the reaction [TP53 protein binds to EP300 protein] | 26612707 |
D003474 | Curcumin | Curcumin results in decreased expression of and results in decreased acetylation of TP53 protein | 26612707 |
D003474 | Curcumin | Curcumin results in increased expression of TP53 | 18462866 |
C020728 | cyadox | [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one co-treated with cyadox] results in increased expression of TP53 mRNA | 30265530 |
C020728 | cyadox | Acetylcysteine inhibits the reaction [cyadox results in increased expression of TP53 mRNA] | 30265530 |
C020728 | cyadox | cyadox results in increased expression of TP53 mRNA | 30265530 |
C020728 | cyadox | cyadox results in increased expression of TP53 protein | 30265530 |
C020728 | cyadox | perifosine inhibits the reaction [cyadox results in increased expression of TP53 mRNA] | 30265530 |
C020728 | cyadox | perifosine inhibits the reaction [cyadox results in increased expression of TP53 protein] | 30265530 |
D003484 | Cyanamide | [Ethanol co-treated with Cyanamide] results in increased expression of TP53 mRNA | 12003908 |
C057862 | cyanoginosin LR | cyanoginosin LR results in increased expression of TP53 mRNA | 22407967 |
C057862 | cyanoginosin LR | cyanoginosin LR results in increased expression of TP53 | 16624733 |
C057862 | cyanoginosin LR | cyanoginosin LR results in increased expression of TP53 mRNA | 22539157 |
C057862 | cyanoginosin LR | cyanoginosin LR results in increased expression of TP53 protein | 18214937; 20421190; |
C057862 | cyanoginosin LR | cyanoginosin LR results in increased phosphorylation of TP53 protein | 20421190 |
C057862 | cyanoginosin LR | [cyanoginosin LR co-treated with Buthionine Sulfoximine] results in increased expression of TP53 protein | 25410294 |
C057862 | cyanoginosin LR | cyanoginosin LR results in increased expression of TP53 protein | 31157505 |
C057862 | cyanoginosin LR | pifithrin inhibits the reaction [cyanoginosin LR results in increased expression of TP53 protein] | 31157505 |
D003513 | Cycloheximide | Cycloheximide inhibits the reaction [Fluorouracil results in increased expression of TP53 protein] | 15016801 |
D003513 | Cycloheximide | Cycloheximide promotes the reaction [Chlorpyrifos results in decreased expression of TP53 protein] | 27993609 |
D003513 | Cycloheximide | Cycloheximide results in decreased expression of TP53 protein | 20943951 |
D003513 | Cycloheximide | TP53 mutant form results in increased susceptibility to Cycloheximide | 21875941 |
D003513 | Cycloheximide | Cycloheximide inhibits the reaction [TGFB1 protein results in increased expression of TP53 protein] | 9790906 |
D003520 | Cyclophosphamide | Cyclophosphamide metabolite results in increased activity of TP53 protein | 20655369; 22010212; |
D003520 | Cyclophosphamide | Cyclophosphamide results in increased mutagenesis of TP53 exon | 9610789 |
D003520 | Cyclophosphamide | TP53 protein affects the susceptibility to Cyclophosphamide | 15182437 |
D003520 | Cyclophosphamide | TP53 protein promotes the reaction [Methotrexate results in increased susceptibility to Cyclophosphamide metabolite] | 22010212 |
D003520 | Cyclophosphamide | astaxanthine inhibits the reaction [Cyclophosphamide results in increased expression of TP53 protein] | 20038455 |
D003520 | Cyclophosphamide | chlorophyllin inhibits the reaction [Cyclophosphamide results in increased mutagenesis of TP53 exon] | 19227835 |
D003520 | Cyclophosphamide | Curcumin inhibits the reaction [Cyclophosphamide results in increased mutagenesis of TP53 exon] | 19227835 |
D003520 | Cyclophosphamide | Cyclophosphamide results in increased expression of TP53 protein | 20038455 |
D003520 | Cyclophosphamide | Cyclophosphamide results in increased mutagenesis of TP53 exon | 19227835 |
D016572 | Cyclosporine | Cyclosporine affects the activity of TP53 protein | 25596134 |
D016572 | Cyclosporine | [Cyclosporine co-treated with NGF protein] results in increased expression of TP53 mRNA | 24244623 |
D016572 | Cyclosporine | Cyclosporine inhibits the reaction [Reactive Oxygen Species affects the localization of TP53 protein] | 26884717 |
D016572 | Cyclosporine | Cyclosporine results in increased expression of TP53 mRNA | 20106945 |
D016572 | Cyclosporine | Cyclosporine affects the expression of TP53 protein | 24971338 |
D016572 | Cyclosporine | Cyclosporine results in increased expression of TP53 | 25299210 |
D016572 | Cyclosporine | Cyclosporine results in increased expression of TP53 mRNA | 24971338 |
C017160 | cypermethrin | cypermethrin results in increased expression of TP53 mRNA | 20965546; 21316461; 21840035; |
C017160 | cypermethrin | cypermethrin results in decreased expression of TP53 mRNA | 27704156 |
C017160 | cypermethrin | cypermethrin results in increased mutagenesis of TP53 exon | 28584332 |
C017160 | cypermethrin | cypermethrin results in increased expression of TP53 mRNA | 22528246; 24759048; |
C017160 | cypermethrin | cypermethrin results in increased expression of TP53 protein | 22528246 |
C017160 | cypermethrin | Vitamin E inhibits the reaction [cypermethrin results in increased expression of TP53 mRNA] | 24759048 |
D003561 | Cytarabine | Caffeine inhibits the reaction [Cytarabine results in increased expression of TP53 protein] | 17977830 |
D003561 | Cytarabine | Caffeine inhibits the reaction [Cytarabine results in increased phosphorylation of TP53 protein] | 17977830 |
D003561 | Cytarabine | Cytarabine results in increased activity of TP53 protein | 22010212 |
D003561 | Cytarabine | Cytarabine results in increased expression of TP53 protein | 10200513; 12082016; 12781215; 17977830; 24675086; |
D003561 | Cytarabine | [Cytarabine results in increased expression of TP53 protein] which results in increased expression of BAX protein | 10200513 |
D003561 | Cytarabine | Cytarabine results in increased phosphorylation of TP53 protein | 10200513; 17977830; 19628630; |
D003561 | Cytarabine | [fludarabine co-treated with Cytarabine co-treated with Docetaxel] results in increased expression of TP53 protein | 9703875 |
D003561 | Cytarabine | TP53 gene mutant form results in increased susceptibility to Cytarabine | 24675086 |
D003561 | Cytarabine | Cytarabine results in increased expression of TP53 protein | 14766721; 15203180; 22212197; 9880587; |
D003561 | Cytarabine | Cytarabine results in increased expression of TP53 protein | 12781215 |
D003571 | Cytochalasin B | Cytochalasin B results in increased expression of TP53 protein | 27640744 |
C015773 | dabequin | dabequin results in increased activity of TP53 protein | 12082016 |
D003609 | Dactinomycin | Cadmium Chloride inhibits the reaction [Dactinomycin results in increased expression of and results in increased activity of TP53 protein] | 10531375 |
D003609 | Dactinomycin | Cadmium inhibits the reaction [Dactinomycin results in increased expression of and results in increased activity of TP53 protein] | 10531375 |
D003609 | Dactinomycin | Dactinomycin promotes the reaction [MRPL41 protein results in increased stability of and affects the localization of TP53 protein] | 16024796 |
D003609 | Dactinomycin | Dactinomycin results in increased activity of TP53 protein | 12869419; 20655369; |
D003609 | Dactinomycin | Dactinomycin results in increased expression of and affects the localization of TP53 protein | 12807743 |
D003609 | Dactinomycin | Dactinomycin results in increased expression of and results in increased activity of TP53 protein | 10531375 |
D003609 | Dactinomycin | Dactinomycin results in increased expression of TP53 protein | 17581298 |
D003609 | Dactinomycin | Dactinomycin results in increased expression of TP53 protein modified form | 12927789 |
D003609 | Dactinomycin | Morphine inhibits the reaction [Dactinomycin results in increased expression of TP53 protein modified form] | 12927789 |
D003609 | Dactinomycin | Naloxone inhibits the reaction [Morphine inhibits the reaction [Dactinomycin results in increased expression of TP53 protein modified form]] | 12927789 |
C004742 | daidzein | daidzein results in increased expression of TP53 protein | 19800779 |
D000069439 | Dasatinib | Arsenic Trioxide inhibits the reaction [Dasatinib results in decreased expression of TP53 protein] | 29266867 |
D000069439 | Dasatinib | Dasatinib results in decreased expression of TP53 protein | 29266867 |
D003630 | Daunorubicin | [Daunorubicin co-treated with Magnetite Nanoparticles] results in increased activity of TP53 protein | 21518493 |
D003630 | Daunorubicin | Daunorubicin results in increased activity of TP53 protein | 12112851 |
D003630 | Daunorubicin | Daunorubicin results in increased expression of TP53 mRNA | 12656675 |
D003630 | Daunorubicin | Daunorubicin results in increased phosphorylation of and results in increased expression of TP53 protein | 23872705 |
D003634 | DDT | DDT results in decreased expression of TP53 mRNA | 25410620 |
D003634 | DDT | DDT results in decreased expression of TP53 protein | 25410620 |
D003634 | DDT | DDT results in increased methylation of TP53 promoter | 25410620 |
C017180 | decamethrin | decamethrin results in increased expression of TP53 mRNA | 25439240; 26013673; |
C017180 | decamethrin | decamethrin results in increased expression of TP53 protein | 10771154; 26013673; 28595958; |
C017180 | decamethrin | oleuropein inhibits the reaction [decamethrin results in increased expression of TP53 protein] | 28595958 |
C017180 | decamethrin | Plant Extracts inhibits the reaction [decamethrin results in increased expression of TP53 protein] | 28595958 |
C017180 | decamethrin | Tea inhibits the reaction [decamethrin results in increased expression of TP53 mRNA] | 26013673 |
C017180 | decamethrin | Tea inhibits the reaction [decamethrin results in increased expression of TP53 protein] | 26013673 |
C017180 | decamethrin | Vitamin E inhibits the reaction [decamethrin results in increased expression of TP53 mRNA] | 25439240 |
D000077209 | Decitabine | ATR protein affects the reaction [Decitabine results in increased expression of TP53 protein] | 17977830 |
D000077209 | Decitabine | Caffeine inhibits the reaction [Decitabine results in increased expression of TP53 protein] | 17977830 |
D000077209 | Decitabine | Decitabine affects the localization of TP53 protein | 19037090 |
D000077209 | Decitabine | Decitabine affects the localization of TP53 protein modified form | 17991895 |
D000077209 | Decitabine | [Decitabine affects the methylation of BAX gene] affects the reaction [TP53 protein results in increased expression of BAX mRNA] | 18608210 |
D000077209 | Decitabine | [Decitabine affects the methylation of PMAIP1 gene] affects the reaction [TP53 protein results in increased expression of PMAIP1 mRNA] | 18608210 |
D000077209 | Decitabine | [Decitabine affects the methylation of TP53AIP1 gene] affects the reaction [TP53 protein results in increased expression of TP53AIP1 mRNA] | 18608210 |
D000077209 | Decitabine | [Decitabine affects the methylation of TP53I3 gene] affects the reaction [TP53 protein results in increased expression of TP53I3 mRNA] | 18608210 |
D000077209 | Decitabine | [Decitabine co-treated with TP53 protein] results in increased expression of RAB6C mRNA | 18992151 |
D000077209 | Decitabine | Decitabine promotes the reaction [ATR protein results in increased phosphorylation of TP53 protein] | 17977830 |
D000077209 | Decitabine | Decitabine promotes the reaction [EP300 protein binds to TP53 protein] | 17977830 |
D000077209 | Decitabine | Decitabine promotes the reaction [KAT2B protein binds to TP53 protein] | 17977830 |
D000077209 | Decitabine | [Decitabine promotes the reaction [TP53 protein binds to CDKN1A promoter]] which results in increased expression of CDKN1A protein | 14722112 |
D000077209 | Decitabine | Decitabine promotes the reaction [TP53 protein binds to FPR1 promoter] | 19037090 |
D000077209 | Decitabine | Decitabine promotes the reaction [TP53 protein binds to RAB6C protein] | 18992151 |
D000077209 | Decitabine | Decitabine promotes the reaction [TP53 protein modified form binds to CDKN1A promoter] | 17977830 |
D000077209 | Decitabine | Decitabine results in decreased methylation of TP53 promoter | 19037090 |
D000077209 | Decitabine | Decitabine results in decreased ubiquitination of TP53 protein | 17977830 |
D000077209 | Decitabine | Decitabine results in increased acetylation of TP53 protein | 17977830 |
D000077209 | Decitabine | Decitabine results in increased activity of TP53 protein | 30818834 |
D000077209 | Decitabine | [Decitabine results in increased expression of and affects the localization of CDKN1A protein] which results in increased activity of TP53 protein | 17389721 |
D000077209 | Decitabine | Decitabine results in increased expression of and results in increased localization of and results in increased activity of TP53 protein | 17389721 |
D000077209 | Decitabine | Decitabine results in increased expression of and results in increased stability of TP53 protein | 23300844 |
D000077209 | Decitabine | Decitabine results in increased expression of TP53 mRNA | 16025287; 17785578; 19037090; 19037991; 19950695; 20480522; |
D000077209 | Decitabine | Decitabine results in increased expression of TP53 protein | 15753979; 16025287; 17977830; 19037090; 22534328; |
D000077209 | Decitabine | Decitabine results in increased phosphorylation of TP53 protein | 18636160; 19732952; |
D000077209 | Decitabine | [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine co-treated with Decitabine] results in increased expression of TP53 protein | 22534328 |
D000077209 | Decitabine | TP53 affects the reaction [Decitabine results in increased expression of CDKN1A protein] | 14722112 |
D000077209 | Decitabine | TP53 gene mutant form inhibits the reaction [Decitabine results in increased expression of CDKN1A protein] | 14722112 |
D000077209 | Decitabine | TP53 protein affects the reaction [Decitabine affects the expression of APAF1 mRNA] | 17133271 |
D000077209 | Decitabine | TP53 protein affects the reaction [Decitabine results in decreased expression of ABHD18 mRNA] | 19363521 |
D000077209 | Decitabine | TP53 protein affects the reaction [Decitabine results in decreased expression of ALDH6A1 mRNA] | 19363521 |
D000077209 | Decitabine | TP53 protein affects the reaction [Decitabine results in decreased expression of AMH mRNA] | 19363521 |
D000077209 | Decitabine | TP53 protein affects the reaction [Decitabine results in decreased expression of BAG2 mRNA] | 19363521 |
D000077209 | Decitabine | TP53 protein affects the reaction [Decitabine results in decreased expression of BIRC5 mRNA] | 19363521 |
D000077209 | Decitabine | TP53 protein affects the reaction [Decitabine results in decreased expression of BIRC5 protein] | 19363521 |
D000077209 | Decitabine | TP53 protein affects the reaction [Decitabine results in decreased expression of BSN mRNA] | 19363521 |
D000077209 | Decitabine | TP53 protein affects the reaction [Decitabine results in decreased expression of C3ORF62 mRNA] | 19363521 |
D000077209 | Decitabine | TP53 protein affects the reaction [Decitabine results in decreased expression of CAPN5 mRNA] | 19363521 |
D000077209 | Decitabine | TP53 protein affects the reaction [Decitabine results in decreased expression of CCDC18 mRNA] | 19363521 |
D000077209 | Decitabine | TP53 protein affects the reaction [Decitabine results in decreased expression of CCNF mRNA] | 19363521 |
D000077209 | Decitabine | TP53 protein affects the reaction [Decitabine results in decreased expression of CDC25C mRNA] | 19363521 |
D000077209 | Decitabine | TP53 protein affects the reaction [Decitabine results in decreased expression of CENPF mRNA] | 19363521 |
D000077209 | Decitabine | TP53 protein affects the reaction [Decitabine results in decreased expression of CEP57 mRNA] | 19363521 |
D000077209 | Decitabine | TP53 protein affects the reaction [Decitabine results in decreased expression of CNTRL mRNA] | 19363521 |
D000077209 | Decitabine | TP53 protein affects the reaction [Decitabine results in decreased expression of ENOX1 mRNA] | 19363521 |
D000077209 | Decitabine | TP53 protein affects the reaction [Decitabine results in decreased expression of FAM29A mRNA] | 19363521 |
D000077209 | Decitabine | TP53 protein affects the reaction [Decitabine results in decreased expression of FZD7 mRNA] | 19363521 |
D000077209 | Decitabine | TP53 protein affects the reaction [Decitabine results in decreased expression of GLI2 mRNA] | 19363521 |
D000077209 | Decitabine | TP53 protein affects the reaction [Decitabine results in decreased expression of GPR162 mRNA] | 19363521 |
D000077209 | Decitabine | TP53 protein affects the reaction [Decitabine results in decreased expression of HMGB1 mRNA] | 19363521 |
D000077209 | Decitabine | TP53 protein affects the reaction [Decitabine results in decreased expression of LMNB1 mRNA] | 19363521 |
D000077209 | Decitabine | TP53 protein affects the reaction [Decitabine results in decreased expression of LZTFL1 mRNA] | 19363521 |
D000077209 | Decitabine | TP53 protein affects the reaction [Decitabine results in decreased expression of MET mRNA] | 19363521 |
D000077209 | Decitabine | TP53 protein affects the reaction [Decitabine results in decreased expression of MSI1 mRNA] | 19363521 |
D000077209 | Decitabine | TP53 protein affects the reaction [Decitabine results in decreased expression of MYO18A mRNA] | 19363521 |
D000077209 | Decitabine | TP53 protein affects the reaction [Decitabine results in decreased expression of NEDD4L mRNA] | 19363521 |
D000077209 | Decitabine | TP53 protein affects the reaction [Decitabine results in decreased expression of NEK2 mRNA] | 19363521 |
D000077209 | Decitabine | TP53 protein affects the reaction [Decitabine results in decreased expression of NFIX mRNA] | 19363521 |
D000077209 | Decitabine | TP53 protein affects the reaction [Decitabine results in decreased expression of NR2F1 mRNA] | 19363521 |
D000077209 | Decitabine | TP53 protein affects the reaction [Decitabine results in decreased expression of NRTN mRNA] | 19363521 |
D000077209 | Decitabine | TP53 protein affects the reaction [Decitabine results in decreased expression of NUMA1 mRNA] | 19363521 |
D000077209 | Decitabine | TP53 protein affects the reaction [Decitabine results in decreased expression of NXPH4 mRNA] | 19363521 |
D000077209 | Decitabine | TP53 protein affects the reaction [Decitabine results in decreased expression of OLA1 mRNA] | 19363521 |
D000077209 | Decitabine | TP53 protein affects the reaction [Decitabine results in decreased expression of PABPC3 mRNA] | 19363521 |
D000077209 | Decitabine | TP53 protein affects the reaction [Decitabine results in decreased expression of PTPN9 mRNA] | 19363521 |
D000077209 | Decitabine | TP53 protein affects the reaction [Decitabine results in decreased expression of RAPGEFL1 mRNA] | 19363521 |
D000077209 | Decitabine | TP53 protein affects the reaction [Decitabine results in decreased expression of REEP3 mRNA] | 19363521 |
D000077209 | Decitabine | TP53 protein affects the reaction [Decitabine results in decreased expression of RPSA mRNA] | 19363521 |
D000077209 | Decitabine | TP53 protein affects the reaction [Decitabine results in decreased expression of RTN3 mRNA] | 19363521 |
D000077209 | Decitabine | TP53 protein affects the reaction [Decitabine results in decreased expression of SAMD5 mRNA] | 19363521 |
D000077209 | Decitabine | TP53 protein affects the reaction [Decitabine results in decreased expression of SH3RF2 mRNA] | 19363521 |
D000077209 | Decitabine | TP53 protein affects the reaction [Decitabine results in decreased expression of SUN2 mRNA] | 19363521 |
D000077209 | Decitabine | TP53 protein affects the reaction [Decitabine results in decreased expression of TBC1D17 mRNA] | 19363521 |
D000077209 | Decitabine | TP53 protein affects the reaction [Decitabine results in decreased expression of TMEM18 mRNA] | 19363521 |
D000077209 | Decitabine | TP53 protein affects the reaction [Decitabine results in decreased expression of TNKS1BP1 mRNA] | 19363521 |
D000077209 | Decitabine | TP53 protein affects the reaction [Decitabine results in decreased expression of ZC3H3 mRNA] | 19363521 |
D000077209 | Decitabine | TP53 protein affects the reaction [Decitabine results in increased expression of CDKN1A protein] | 18223691 |
D000077209 | Decitabine | TP53 protein affects the reaction [Decitabine results in increased expression of RRM2B mRNA] | 19010910 |
D000077209 | Decitabine | TP53 protein modified form affects the reaction [Decitabine results in increased expression of CDKN1A protein] | 17977830 |
D000077209 | Decitabine | TP53 protein promotes the reaction [Decitabine results in increased expression of CDKN1A protein] | 15753979 |
D000077209 | Decitabine | Decitabine results in decreased methylation of TP53 promoter | 21449042 |
D000077209 | Decitabine | Decitabine results in increased expression of TP53 mRNA | 21449042 |
D003671 | DEET | [Pyridostigmine Bromide co-treated with DEET co-treated with Permethrin] results in increased expression of TP53 protein | 12587291 |
D003676 | Deferoxamine | Deferoxamine inhibits the reaction [Asbestos, Amosite results in increased expression of TP53 mRNA] | 16357363 |
D003676 | Deferoxamine | Deferoxamine inhibits the reaction [sodium bichromate results in increased expression of TP53 protein] | 10942736 |
D003676 | Deferoxamine | Deferoxamine results in increased expression of TP53 protein | 23483119 |
D003676 | Deferoxamine | TP53 gene mutant form promotes the reaction [Deferoxamine results in increased expression of HIF1A protein] | 16527254 |
D003676 | Deferoxamine | TP53 gene mutant form promotes the reaction [Deferoxamine results in increased expression of PTGS2 protein] | 16527254 |
D003676 | Deferoxamine | TP53 protein results in decreased susceptibility to Deferoxamine | 16527254 |
C107676 | deguelin | [deguelin results in decreased expression of NPM1 protein mutant form] which results in decreased expression of TP53 protein | 25242579 |
C107676 | deguelin | deguelin results in decreased expression of TP53 mRNA | 22227970 |
D003687 | Dehydroepiandrosterone | Dehydroepiandrosterone results in increased expression of TP53 mRNA | 15752352 |
C576677 | demycarosyl-3D-digitoxosylmithramycin SK | demycarosyl-3D-digitoxosylmithramycin SK results in increased expression of TP53 mRNA | 26079942 |
C576677 | demycarosyl-3D-digitoxosylmithramycin SK | [Deoxyglucose co-treated with demycarosyl-3D-digitoxosylmithramycin SK] results in increased expression of TP53 mRNA | 26079942 |
C576677 | demycarosyl-3D-digitoxosylmithramycin SK | Deoxyglucose promotes the reaction [demycarosyl-3D-digitoxosylmithramycin SK results in increased expression of TP53 mRNA] | 26079942 |
D003840 | Deoxycholic Acid | Deoxycholic Acid results in increased expression of TP53 mRNA | 20137712 |
D003840 | Deoxycholic Acid | TP53 protein affects the reaction [[Deoxycholic Acid results in increased expression of CCND1 protein] which affects the localization of BAX protein] | 17431217 |
D003840 | Deoxycholic Acid | Ursodeoxycholic Acid inhibits the reaction [Deoxycholic Acid results in increased expression of TP53 mRNA] | 20137712 |
D003847 | Deoxyglucose | [Deoxyglucose co-treated with demycarosyl-3D-digitoxosylmithramycin SK] results in increased expression of TP53 mRNA | 26079942 |
D003847 | Deoxyglucose | Deoxyglucose promotes the reaction [demycarosyl-3D-digitoxosylmithramycin SK results in increased expression of TP53 mRNA] | 26079942 |
D003847 | Deoxyglucose | TP53 protein inhibits the reaction [Deoxyglucose results in decreased abundance of Adenosine Triphosphate] | 21042727 |
C007262 | deoxynivalenol | Aflatoxin B1 promotes the reaction [deoxynivalenol results in increased expression of TP53 mRNA] | 30668976 |
C007262 | deoxynivalenol | deoxynivalenol results in increased activity of TP53 protein | 19664677 |
C007262 | deoxynivalenol | deoxynivalenol results in increased expression of TP53 mRNA | 30668976 |
C007262 | deoxynivalenol | [Zearalenone co-treated with Aflatoxin B1] promotes the reaction [deoxynivalenol results in increased expression of TP53 mRNA] | 30668976 |
C007262 | deoxynivalenol | [pifithrin results in decreased activity of TP53 protein] which results in decreased susceptibility to deoxynivalenol | 22491426 |
C007262 | deoxynivalenol | Acetylcysteine promotes the reaction [deoxynivalenol inhibits the reaction [Zearalenone results in increased expression of TP53 mRNA]] | 29109043 |
C007262 | deoxynivalenol | [deoxynivalenol co-treated with fumonisin B1] results in increased expression of TP53 mRNA | 29109043 |
C007262 | deoxynivalenol | deoxynivalenol inhibits the reaction [Zearalenone results in increased expression of TP53 mRNA] | 29109043 |
C007262 | deoxynivalenol | fumonisin B1 inhibits the reaction [deoxynivalenol inhibits the reaction [Zearalenone results in increased expression of TP53 mRNA]] | 29109043 |
C007262 | deoxynivalenol | Zearalenone promotes the reaction [[deoxynivalenol co-treated with fumonisin B1] results in increased expression of TP53 mRNA] | 29109043 |
D003868 | Dequalinium | Dequalinium results in increased expression of TP53 protein | 21548882 |
D003900 | Desoxycorticosterone | acetovanillone inhibits the reaction [[Desoxycorticosterone co-treated with Sodium Chloride] results in increased expression of TP53 protein] | 22431579 |
D003900 | Desoxycorticosterone | Atrasentan inhibits the reaction [[Desoxycorticosterone co-treated with Sodium Chloride] results in increased expression of TP53 protein] | 22431579 |
D003900 | Desoxycorticosterone | [Desoxycorticosterone co-treated with Sodium Chloride] results in increased expression of TP53 protein | 22431579 |
D064791 | Desoxycorticosterone Acetate | [Desoxycorticosterone Acetate co-treated with Sodium Chloride, Dietary co-treated with Potassium Chloride] results in increased expression of TP53 mRNA | 22228705 |
D003907 | Dexamethasone | Dexamethasone inhibits the reaction [TP53 protein binds to FPR1 promoter] | 19037090 |
D003907 | Dexamethasone | Dexamethasone results in decreased expression of TP53 protein | 19037090 |
D003907 | Dexamethasone | Dexamethasone results in increased activity of TP53 protein | 22010212 |
D003907 | Dexamethasone | Dexamethasone results in decreased expression of TP53 mRNA | 17522070 |
D020927 | Dexmedetomidine | atipamezole inhibits the reaction [Dexmedetomidine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of TP53 protein]] | 30597158 |
D020927 | Dexmedetomidine | Dexmedetomidine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of TP53 protein] | 30597158 |
C000627634 | di(2-picolyl)amine-3(bromoacetyl)coumarin | CAT protein inhibits the reaction [[cupric chloride co-treated with di(2-picolyl)amine-3(bromoacetyl)coumarin] results in increased expression of TP53 protein] | 29803612 |
C000627634 | di(2-picolyl)amine-3(bromoacetyl)coumarin | [cupric chloride co-treated with di(2-picolyl)amine-3(bromoacetyl)coumarin] results in increased expression of TP53 protein | 29803612 |
C000627634 | di(2-picolyl)amine-3(bromoacetyl)coumarin | Ethanol inhibits the reaction [[cupric chloride co-treated with di(2-picolyl)amine-3(bromoacetyl)coumarin] results in increased expression of TP53 protein] | 29803612 |
C000627634 | di(2-picolyl)amine-3(bromoacetyl)coumarin | Mannitol inhibits the reaction [[cupric chloride co-treated with di(2-picolyl)amine-3(bromoacetyl)coumarin] results in increased expression of TP53 protein] | 29803612 |
C000627634 | di(2-picolyl)amine-3(bromoacetyl)coumarin | neocuproine inhibits the reaction [[cupric chloride co-treated with di(2-picolyl)amine-3(bromoacetyl)coumarin] results in increased expression of TP53 protein] | 29803612 |
C000627634 | di(2-picolyl)amine-3(bromoacetyl)coumarin | Thiourea inhibits the reaction [[cupric chloride co-treated with di(2-picolyl)amine-3(bromoacetyl)coumarin] results in increased expression of TP53 protein] | 29803612 |
C100261 | diacetyldiphenylurea bisguanylhydrazone | diacetyldiphenylurea bisguanylhydrazone inhibits the reaction [5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one results in increased expression of TP53 protein modified form] | 23470866 |
C028009 | diallyl disulfide | Acetylcysteine inhibits the reaction [diallyl disulfide results in increased expression of TP53 protein] | 19202565 |
C028009 | diallyl disulfide | diallyl disulfide results in increased expression of TP53 protein | 11925476; 19202565; |
C028009 | diallyl disulfide | Glutathione inhibits the reaction [diallyl disulfide results in increased expression of TP53 protein] | 19202565 |
C028009 | diallyl disulfide | TP53 protein affects the reaction [diallyl disulfide results in increased expression of GDF15 protein] | 11925476 |
C028009 | diallyl disulfide | [Cadmium Chloride co-treated with diallyl disulfide] results in decreased expression of TP53 mRNA | 31077537 |
C042577 | diallyl trisulfide | diallyl trisulfide affects the localization of TP53 protein | 24415872 |
C042577 | diallyl trisulfide | diallyl trisulfide results in increased expression of and affects the localization of TP53 protein | 19823037 |
C042577 | diallyl trisulfide | diallyl trisulfide results in increased expression of TP53 mRNA | 19823037; 24415872; |
C042577 | diallyl trisulfide | diallyl trisulfide results in increased expression of TP53 protein | 23754639; 28571773; |
D003958 | Diamide | Diamide results in increased glutathionylation of TP53 protein | 17555331 |
D003974 | Diatrizoate Meglumine | Diatrizoate Meglumine results in increased expression of TP53 mRNA | 28412091 |
D003974 | Diatrizoate Meglumine | Lansoprazole inhibits the reaction [Diatrizoate Meglumine results in increased expression of TP53 mRNA] | 28412091 |
D003976 | Diazinon | Diazinon results in increased expression of TP53 mRNA | 27920530 |
D003976 | Diazinon | Magnesium Oxide analog inhibits the reaction [Diazinon results in increased expression of TP53 mRNA] | 27920530 |
D003976 | Diazinon | [Selenium analog co-treated with Magnesium Oxide analog] inhibits the reaction [Diazinon results in increased expression of TP53 mRNA] | 27920530 |
D003976 | Diazinon | Diazinon affects the expression of TP53 mRNA | 22546817 |
D003976 | Diazinon | Diazinon results in increased expression of TP53 mRNA | 17452286 |
D003981 | Diazoxide | Diazoxide results in decreased expression of TP53 mRNA | 16426753 |
C041516 | dibenzo(a,e)pyrene | dibenzo(a,e)pyrene results in increased phosphorylation of TP53 protein | 17961608 |
C041517 | dibenzo(a,l)pyrene | 2,4,5,2',4',5'-hexachlorobiphenyl promotes the reaction [dibenzo(a,l)pyrene affects the localization of and results in increased expression of TP53 protein] | 24954032 |
C041517 | dibenzo(a,l)pyrene | dibenzo(a,l)pyrene affects the localization of and results in increased expression of TP53 protein | 24954032 |
C041517 | dibenzo(a,l)pyrene | dibenzo(a,l)pyrene results in increased expression of TP53 protein | 15548639 |
C041517 | dibenzo(a,l)pyrene | Estradiol promotes the reaction [dibenzo(a,l)pyrene affects the localization of and results in increased expression of TP53 protein] | 24954032 |
C041517 | dibenzo(a,l)pyrene | Tetrachlorodibenzodioxin promotes the reaction [dibenzo(a,l)pyrene affects the localization of and results in increased expression of TP53 protein] | 24954032 |
C041517 | dibenzo(a,l)pyrene | TP53 protein affects the reaction [dibenzo(a,l)pyrene results in increased expression of CYP1A1 protein] | 25398514 |
C041517 | dibenzo(a,l)pyrene | TP53 protein results in increased susceptibility to dibenzo(a,l)pyrene | 25398514 |
C041517 | dibenzo(a,l)pyrene | Chlorophyll inhibits the reaction [dibenzo(a,l)pyrene results in increased expression of TP53 mRNA] | 22079312 |
C041517 | dibenzo(a,l)pyrene | dibenzo(a,l)pyrene results in increased expression of TP53 mRNA | 22079312 |
C041517 | dibenzo(a,l)pyrene | dibenzo(a,l)pyrene results in increased phosphorylation of TP53 protein | 16005925; 17961608; |
C041517 | dibenzo(a,l)pyrene | pifithrin inhibits the reaction [dibenzo(a,l)pyrene results in increased phosphorylation of TP53 protein] | 16005925 |
C041517 | dibenzo(a,l)pyrene | SB 203580 inhibits the reaction [dibenzo(a,l)pyrene results in increased phosphorylation of TP53 protein] | 16005925 |
C041517 | dibenzo(a,l)pyrene | U 0126 inhibits the reaction [dibenzo(a,l)pyrene results in increased phosphorylation of TP53 protein] | 16005925 |
D000072338 | Dibenzofurans, Polychlorinated | [Polychlorinated Dibenzodioxins co-treated with Dibenzofurans, Polychlorinated] results in increased expression of TP53 mRNA | 17850846 |
D003633 | Dichlorodiphenyl Dichloroethylene | Dichlorodiphenyl Dichloroethylene results in increased activity of TP53 protein | 27589886 |
D003633 | Dichlorodiphenyl Dichloroethylene | Dichlorodiphenyl Dichloroethylene results in increased expression of TP53 mRNA | 19545618 |
D004006 | Dichlorvos | Dichlorvos results in decreased expression of TP53 mRNA | 23053939 |
D004006 | Dichlorvos | Dichlorvos results in increased expression of TP53 mRNA | 24369695 |
D004006 | Dichlorvos | Dichlorvos results in increased expression of TP53 protein | 24369695 |
D004006 | Dichlorvos | TEMPOL-H inhibits the reaction [Dichlorvos results in increased expression of TP53 mRNA] | 24369695 |
D004006 | Dichlorvos | TEMPOL-H inhibits the reaction [Dichlorvos results in increased expression of TP53 protein] | 24369695 |
D004008 | Diclofenac | Diclofenac affects the expression of TP53 mRNA | 24752500 |
C000944 | dicrotophos | dicrotophos results in increased expression of TP53 mRNA | 28302478 |
D001728 | Dicumarol | Dicumarol inhibits the reaction [2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone analog results in increased expression of TP53 protein] | 26630137 |
D001728 | Dicumarol | Dicumarol inhibits the reaction [2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone analog results in increased expression of TP53 protein modified form] | 26630137 |
D001728 | Dicumarol | Dicumarol inhibits the reaction [IL1B protein results in increased expression of TP53 protein] | 17959154 |
D001728 | Dicumarol | Dicumarol inhibits the reaction [RB1CC1 protein results in increased expression of TP53 protein] | 16061648 |
D001728 | Dicumarol | Dicumarol inhibits the reaction [RB1CC1 protein results in increased stability of TP53 protein] | 16061648 |
D001728 | Dicumarol | Dicumarol inhibits the reaction [TP53 protein binds to NQO1 protein] | 14634213 |
D001728 | Dicumarol | Dicumarol results in decreased expression of TP53 protein | 22692362 |
D001728 | Dicumarol | Dicumarol results in increased degradation of TP53 protein | 14634213 |
D004026 | Dieldrin | Dieldrin affects the expression of TP53 mRNA | 22546817 |
C007366 | diepoxybutane | ATM protein affects the reaction [diepoxybutane results in increased phosphorylation of TP53 protein] | 20024960 |
C007366 | diepoxybutane | diepoxybutane inhibits the reaction [TP53 protein binds to MDM2 protein] | 20024960 |
C007366 | diepoxybutane | diepoxybutane results in increased acetylation of and results in increased phosphorylation of TP53 protein | 20024960 |
C007366 | diepoxybutane | diepoxybutane results in increased expression of and results in increased stability of TP53 protein | 20024960 |
C007366 | diepoxybutane | diepoxybutane results in increased expression of TP53 protein | 14998682 |
C020283 | diethanolamine | diethanolamine results in decreased expression of TP53 mRNA | 16014740 |
C502471 | diethoxyphosphoryloxymethyl butanoate | diethoxyphosphoryloxymethyl butanoate promotes the reaction [Doxorubicin results in increased acetylation of TP53 protein] | 16826403 |
C502471 | diethoxyphosphoryloxymethyl butanoate | diethoxyphosphoryloxymethyl butanoate results in increased acetylation of TP53 protein | 16826403 |
C502471 | diethoxyphosphoryloxymethyl butanoate | Doxorubicin promotes the reaction [diethoxyphosphoryloxymethyl butanoate results in increased acetylation of TP53 protein] | 16826403 |
D004051 | Diethylhexyl Phthalate | Diethylhexyl Phthalate results in increased expression of TP53 protein | 31163220 |
D004051 | Diethylhexyl Phthalate | Diethylhexyl Phthalate results in decreased expression of TP53 mRNA | 27614199 |
D004051 | Diethylhexyl Phthalate | Diethylhexyl Phthalate results in increased expression of TP53 mRNA | 28115068 |
D004051 | Diethylhexyl Phthalate | Ethanol promotes the reaction [Diethylhexyl Phthalate results in increased expression of TP53 mRNA] | 28115068 |
C014476 | diethyl maleate | TP53 protein affects the reaction [diethyl maleate results in increased expression of CDKN1A protein] | 27982581 |
C014476 | diethyl maleate | TP53 protein affects the reaction [diethyl maleate results in increased expression of SRXN1 protein] | 27982581 |
D004052 | Diethylnitrosamine | Diethylnitrosamine results in increased expression of TP53 protein | 21776270 |
D004052 | Diethylnitrosamine | [5,7-dimethoxyflavone co-treated with Diethylnitrosamine] results in increased expression of TP53 mRNA | 21554863 |
D004052 | Diethylnitrosamine | [5,7-dimethoxyflavone co-treated with Diethylnitrosamine] results in increased expression of TP53 protein | 21554863 |
D004052 | Diethylnitrosamine | [Acetoxyacetylaminofluorene co-treated with Diethylnitrosamine] results in increased expression of TP53 protein | 10741303 |
D004052 | Diethylnitrosamine | AHR protein promotes the reaction [Tetrachlorodibenzodioxin inhibits the reaction [Diethylnitrosamine results in increased phosphorylation of TP53 protein]] | 15459018 |
D004052 | Diethylnitrosamine | ATM protein affects the reaction [Diethylnitrosamine results in increased expression of TP53 protein] | 11751435 |
D004052 | Diethylnitrosamine | caffeic acid phenethyl ester inhibits the reaction [Diethylnitrosamine results in decreased expression of TP53 mRNA] | 20360939 |
D004052 | Diethylnitrosamine | Caffeine inhibits the reaction [Diethylnitrosamine results in increased expression of TP53 protein] | 11751435 |
D004052 | Diethylnitrosamine | Caffeine inhibits the reaction [Diethylnitrosamine results in increased phosphorylation of TP53 protein] | 11751435 |
D004052 | Diethylnitrosamine | chrysin inhibits the reaction [Diethylnitrosamine results in decreased expression of TP53 mRNA] | 21167192 |
D004052 | Diethylnitrosamine | cobaltous chloride promotes the reaction [Diethylnitrosamine results in increased expression of TP53 protein] | 11751435 |
D004052 | Diethylnitrosamine | [Diethylnitrosamine co-treated with 2-Acetylaminofluorene] affects the expression of and affects the localization of TP53 protein | 11003613 |
D004052 | Diethylnitrosamine | [Diethylnitrosamine co-treated with 2-Acetylaminofluorene] affects the expression of TP53 protein | 11915028 |
D004052 | Diethylnitrosamine | [Diethylnitrosamine co-treated with 2-Acetylaminofluorene] results in decreased expression of TP53 mRNA | 14633663 |
D004052 | Diethylnitrosamine | [Diethylnitrosamine co-treated with 2-Acetylaminofluorene] results in increased expression of TP53 protein | 23665045 |
D004052 | Diethylnitrosamine | [Diethylnitrosamine co-treated with chrysin] results in increased expression of TP53 protein | 21167192 |
D004052 | Diethylnitrosamine | [Diethylnitrosamine co-treated with Clofibric Acid] affects the expression of TP53 mRNA | 17602206 |
D004052 | Diethylnitrosamine | [Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of TP53 mRNA | 18544905 |
D004052 | Diethylnitrosamine | Diethylnitrosamine results in decreased expression of TP53 mRNA | 21167192; 21554863; 24954034; 30423403; |
D004052 | Diethylnitrosamine | Diethylnitrosamine results in decreased expression of TP53 protein | 24954034 |
D004052 | Diethylnitrosamine | Diethylnitrosamine results in increased expression of and results in increased phosphorylation of TP53 protein | 15459018 |
D004052 | Diethylnitrosamine | Diethylnitrosamine results in increased expression of TP53 mRNA | 14555611; 19874807; 20360939; |
D004052 | Diethylnitrosamine | Diethylnitrosamine results in increased expression of TP53 protein | 11751435; 14555611; 18367157; 19254457; 9163691; |
D004052 | Diethylnitrosamine | Diethylnitrosamine results in increased phosphorylation of TP53 protein | 11751435 |
D004052 | Diethylnitrosamine | Diosmin inhibits the reaction [[Diethylnitrosamine co-treated with 2-Acetylaminofluorene] results in increased expression of TP53 protein] | 23665045 |
D004052 | Diethylnitrosamine | [ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in increased expression of TP53 mRNA | 21907755 |
D004052 | Diethylnitrosamine | [ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in increased expression of TP53 protein | 21907755 |
D004052 | Diethylnitrosamine | geraniol inhibits the reaction [[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in increased expression of TP53 mRNA] | 21907755 |
D004052 | Diethylnitrosamine | geraniol inhibits the reaction [[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in increased expression of TP53 protein] | 21907755 |
D004052 | Diethylnitrosamine | IFNA2 protein affects the reaction [[Diethylnitrosamine co-treated with 2-Acetylaminofluorene] affects the expression of TP53 protein] | 11915028 |
D004052 | Diethylnitrosamine | lanreotide inhibits the reaction [Diethylnitrosamine results in increased expression of TP53 mRNA] | 19874807 |
D004052 | Diethylnitrosamine | myrtenal inhibits the reaction [[Phenobarbital co-treated with Diethylnitrosamine] results in decreased expression of TP53 mRNA] | 22436021 |
D004052 | Diethylnitrosamine | myrtenal inhibits the reaction [[Phenobarbital co-treated with Diethylnitrosamine] results in decreased expression of TP53 protein] | 22436021 |
D004052 | Diethylnitrosamine | neferine inhibits the reaction [Diethylnitrosamine results in decreased expression of TP53 mRNA] | 30423403 |
D004052 | Diethylnitrosamine | [Phenobarbital co-treated with Diethylnitrosamine] results in decreased expression of TP53 mRNA | 22436021 |
D004052 | Diethylnitrosamine | [Phenobarbital co-treated with Diethylnitrosamine] results in decreased expression of TP53 protein | 22436021 |
D004052 | Diethylnitrosamine | Phenobarbital promotes the reaction [Diethylnitrosamine results in increased expression of TP53 protein] | 11751435 |
D004052 | Diethylnitrosamine | Plant Extracts inhibits the reaction [Diethylnitrosamine results in increased expression of TP53 protein] | 18367157 |
D004052 | Diethylnitrosamine | Tetrachlorodibenzodioxin inhibits the reaction [Diethylnitrosamine results in increased expression of and results in increased phosphorylation of TP53 protein] | 15459018 |
D004052 | Diethylnitrosamine | Wortmannin inhibits the reaction [Diethylnitrosamine results in increased expression of TP53 protein] | 11751435 |
D004052 | Diethylnitrosamine | Wortmannin inhibits the reaction [Diethylnitrosamine results in increased phosphorylation of TP53 protein] | 11751435 |
D004054 | Diethylstilbestrol | Diethylstilbestrol results in decreased expression of TP53 mRNA | 27825931 |
D004054 | Diethylstilbestrol | [allyl sulfide co-treated with Diethylstilbestrol] results in increased expression of TP53 mRNA | 17125941 |
D004054 | Diethylstilbestrol | Diethylstilbestrol results in decreased expression of TP53 mRNA | 17125941 |
D004054 | Diethylstilbestrol | Diethylstilbestrol results in increased expression of TP53 mRNA | 17011747 |
C011612 | diethyl sulfate | diethyl sulfate results in decreased expression of TP53 protein | 23830811 |
C011612 | diethyl sulfate | diethyl sulfate results in increased expression of TP53 protein | 23830811 |
D004074 | Digitoxin | Digitoxin analog results in decreased expression of TP53 protein | 22037315 |
D004074 | Digitoxin | Digitoxin results in decreased expression of TP53 protein | 22037315 |
C039060 | dihydroartemisinin | dihydroartemisinin results in increased phosphorylation of TP53 protein | 21547369 |
C012906 | dihydrocapsaicin | dihydrocapsaicin results in increased phosphorylation of TP53 protein | 19139269 |
C539241 | dihydroptychantol A | dihydroptychantol A results in decreased expression of TP53 protein | 21185854 |
C539241 | dihydroptychantol A | dihydroptychantol A results in increased expression of TP53 mRNA | 21185854 |
C539241 | dihydroptychantol A | dihydroptychantol A results in increased phosphorylation of and results in increased localization of TP53 protein | 21185854 |
D013196 | Dihydrotestosterone | Dihydrotestosterone results in decreased expression of TP53 mRNA | 29458080 |
C025605 | diisobutyl phthalate | diisobutyl phthalate results in increased expression of TP53 mRNA | 29458080 |
C012125 | diisononyl phthalate | diisononyl phthalate results in increased expression of TP53 mRNA | 31230093 |
C012920 | dimefox | dimefox results in increased expression of TP53 mRNA | 18418871 |
C002302 | dimethoxon | dimethoxon results in decreased expression of TP53 mRNA | 28718371 |
C521105 | dimethoxycurcumin | dimethoxycurcumin results in decreased phosphorylation of TP53 protein | 31513842 |
D004126 | Dimethylformamide | CAT protein inhibits the reaction [Dimethylformamide results in increased expression of TP53 protein] | 29984871 |
D004126 | Dimethylformamide | Dimethylformamide results in increased expression of TP53 protein modified form | 29984871 |
D004126 | Dimethylformamide | Thiocarbamates analog inhibits the reaction [Dimethylformamide results in increased expression of TP53 protein] | 29984871 |
C065087 | di-n-butylphosphoric acid | di-n-butylphosphoric acid binds to TP53 protein | 24411723 |
C065087 | di-n-butylphosphoric acid | di-n-butylphosphoric acid binds to TP53 gene | 25510514 |
C076221 | dinophysistoxin 2 | dinophysistoxin 2 affects the localization of TP53 protein | 21512803 |
C019357 | dioscin | dioscin results in increased expression of TP53 mRNA | 22334414; 29990575; |
C019357 | dioscin | dioscin results in increased expression of TP53 protein | 29990575 |
D004145 | Diosmin | Diosmin inhibits the reaction [[Diethylnitrosamine co-treated with 2-Acetylaminofluorene] results in increased expression of TP53 protein] | 23665045 |
D004147 | Dioxins | Dioxins affects the expression of TP53 mRNA | 20463971 |
D004147 | Dioxins | 3'-methoxy-4'-nitroflavone inhibits the reaction [Dioxins results in decreased expression of TP53 mRNA] | 15111621 |
D004147 | Dioxins | 3'-methoxy-4'-nitroflavone inhibits the reaction [Dioxins results in decreased expression of TP53 protein] | 15111621 |
D004147 | Dioxins | AHR protein affects the reaction [Dioxins results in decreased expression of TP53 mRNA] | 15111621 |
D004147 | Dioxins | Dioxins results in decreased expression of TP53 mRNA | 15111621 |
D004147 | Dioxins | Dioxins results in decreased expression of TP53 protein | 15111621 |
C001082 | diphenylcresyl phosphate | diphenylcresyl phosphate results in increased expression of TP53 mRNA | 30981936 |
C001087 | diphenyl methyl phosphate | diphenyl methyl phosphate results in increased expression of TP53 mRNA | 30981936 |
D004178 | Diquat | Diquat results in increased expression of and affects the localization of TP53 protein | 29484840 |
D004178 | Diquat | pifithrin inhibits the reaction [Diquat results in increased expression of and affects the localization of TP53 protein] | 29484840 |
D004178 | Diquat | SN50 peptide inhibits the reaction [Diquat results in increased expression of and affects the localization of TP53 protein] | 29484840 |
D004229 | Dithiothreitol | Dithiothreitol inhibits the reaction [[Cadmium Chloride results in decreased activity of TP53 protein] inhibits the reaction [TP53 protein binds to TP53 gene]] | 25446071; 25446071; |
D004229 | Dithiothreitol | Dithiothreitol inhibits the reaction [Glutathione Disulfide results in increased glutathionylation of TP53 protein] | 17555331 |
D004229 | Dithiothreitol | Dithiothreitol inhibits the reaction [Glutathione results in increased glutathionylation of TP53 protein] | 17555331 |
D004050 | Ditiocarb | Ditiocarb inhibits the reaction [cobaltous chloride results in increased expression of and results in increased activity of TP53 protein] | 10951577 |
D004050 | Ditiocarb | Ditiocarb inhibits the reaction [Oxygen deficiency results in increased expression of TP53 protein] | 10951577 |
D004050 | Ditiocarb | Ditiocarb results in increased expression of TP53 protein | 11964141 |
D000077143 | Docetaxel | [Docetaxel co-treated with alvocidib] results in increased expression of TP53 protein | 15297405 |
D000077143 | Docetaxel | Docetaxel promotes the reaction [[TP53 protein mutant form results in increased susceptibility to fatostatin] which results in decreased expression of MKI67 protein] | 26512780 |
D000077143 | Docetaxel | Docetaxel promotes the reaction [[TP53 protein mutant form results in increased susceptibility to fatostatin] which results in increased cleavage of CASP3 protein] | 26512780 |
D000077143 | Docetaxel | Docetaxel promotes the reaction [[TP53 protein mutant form results in increased susceptibility to fatostatin] which results in increased cleavage of PARP1 protein] | 26512780 |
D000077143 | Docetaxel | Docetaxel results in decreased expression of TP53 protein mutant form | 15970518 |
D000077143 | Docetaxel | Docetaxel results in decreased ubiquitination of TP53 protein | 15970518 |
D000077143 | Docetaxel | Docetaxel results in increased expression of TP53 mRNA | 16080190; 22445862; |
D000077143 | Docetaxel | [Docetaxel results in increased expression of TP53 mRNA] which results in decreased expression of ABCB1 mRNA | 22445862 |
D000077143 | Docetaxel | Docetaxel results in increased expression of TP53 protein | 15970518; 16080190; 16797627; |
D000077143 | Docetaxel | Docetaxel results in increased ubiquitination of TP53 protein mutant form | 15970518 |
D000077143 | Docetaxel | [fludarabine co-treated with Cytarabine co-treated with Docetaxel] results in increased expression of TP53 protein | 9703875 |
D000077143 | Docetaxel | TP53 promoter mutant form results in decreased susceptibility to Docetaxel | 22445862 |
D000077143 | Docetaxel | TP53 protein affects the reaction [Docetaxel results in decreased expression of ABCB1 mRNA] | 22445862 |
D000077143 | Docetaxel | TP53 protein inhibits the reaction [Docetaxel results in increased expression of TUBB mRNA] | 16080190 |
D000077143 | Docetaxel | TP53 protein mutant form results in decreased susceptibility to Docetaxel | 26512780 |
D000077143 | Docetaxel | [TP53 protein mutant form results in decreased susceptibility to Docetaxel] which results in increased cleavage of SREBF1 protein | 26512780 |
D000077143 | Docetaxel | [TP53 protein mutant form results in decreased susceptibility to Docetaxel] which results in increased cleavage of SREBF2 protein | 26512780 |
D004281 | Docosahexaenoic Acids | Docosahexaenoic Acids affects the localization of TP53 protein | 28807874 |
D004281 | Docosahexaenoic Acids | OSGIN1 protein promotes the reaction [Docosahexaenoic Acids affects the localization of TP53 protein] | 28807874 |
D004281 | Docosahexaenoic Acids | [TP53 protein mutant form results in increased susceptibility to Niclosamide] which results in increased abundance of Docosahexaenoic Acids | 30258081 |
D000077265 | Donepezil | Donepezil inhibits the reaction [Hydrogen Peroxide results in increased expression of TP53 protein] | 19345205 |
D004298 | Dopamine | [Dopamine results in increased expression of HIF1A protein] which results in increased expression of and results in increased phosphorylation of TP53 protein | 19410601 |
D004298 | Dopamine | [Dopamine results in increased expression of HIF1A protein] which results in increased expression of TP53 protein | 19410601 |
C516138 | dorsomorphin | Acetylcysteine inhibits the reaction [dorsomorphin results in increased expression of and results in increased phosphorylation of TP53 protein] | 23274516 |
C516138 | dorsomorphin | Caffeine inhibits the reaction [dorsomorphin results in increased expression of and results in increased phosphorylation of TP53 protein] | 23274516 |
C516138 | dorsomorphin | dorsomorphin affects the localization of TP53 protein | 23274516 |
C516138 | dorsomorphin | dorsomorphin inhibits the reaction [Curcumin results in increased phosphorylation of TP53 protein] | 19020741 |
C516138 | dorsomorphin | dorsomorphin results in increased phosphorylation of and results in increased expression of TP53 protein | 23274516 |
C516138 | dorsomorphin | TP53 mutant form inhibits the reaction [dorsomorphin results in decreased expression of CCNB1 protein] | 23274516 |
C516138 | dorsomorphin | TP53 mutant form inhibits the reaction [dorsomorphin results in decreased phosphorylation of and results in decreased expression of CDK1 protein] | 23274516 |
C516138 | dorsomorphin | TP53 mutant form inhibits the reaction [dorsomorphin results in increased cleavage of CASP3 protein] | 23274516 |
C516138 | dorsomorphin | TP53 mutant form inhibits the reaction [dorsomorphin results in increased cleavage of PARP1 protein] | 23274516 |
C516138 | dorsomorphin | TP53 mutant form inhibits the reaction [dorsomorphin results in increased expression of CDKN1A protein] | 23274516 |
C516138 | dorsomorphin | TP53 protein results in increased susceptibility to dorsomorphin | 23274516 |
D004317 | Doxorubicin | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ANGPT1 protein inhibits the reaction [Doxorubicin results in increased expression of TP53 protein]] | 15763944 |
D004317 | Doxorubicin | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Doxorubicin results in increased expression of TP53 protein] | 20856197 |
D004317 | Doxorubicin | 2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one inhibits the reaction [Doxorubicin results in increased expression of TP53 protein] | 22927544 |
D004317 | Doxorubicin | 3-methyladenine inhibits the reaction [Doxorubicin results in increased expression of TP53 protein] | 22927544 |
D004317 | Doxorubicin | 7-monohydroxyethylrutoside inhibits the reaction [Doxorubicin results in increased expression of TP53 protein] | 17285121 |
D004317 | Doxorubicin | Acetylcysteine inhibits the reaction [ATM protein promotes the reaction [Doxorubicin results in increased activity of TP53 protein]] | 15489221 |
D004317 | Doxorubicin | Acetylcysteine inhibits the reaction [Doxorubicin promotes the reaction [ATM protein results in increased phosphorylation of TP53 protein]] | 15489221 |
D004317 | Doxorubicin | Acetylcysteine inhibits the reaction [Doxorubicin results in increased expression of TP53 protein] | 22927544 |
D004317 | Doxorubicin | ANGPT1 protein inhibits the reaction [Doxorubicin results in increased expression of TP53 protein] | 15763944 |
D004317 | Doxorubicin | [Arsenic Trioxide co-treated with Doxorubicin co-treated with Magnetite Nanoparticles analog] affects the expression of TP53 mRNA | 24738333 |
D004317 | Doxorubicin | [Arsenic Trioxide co-treated with Doxorubicin co-treated with Magnetite Nanoparticles analog] affects the expression of TP53 protein | 24738333 |
D004317 | Doxorubicin | ATM protein promotes the reaction [Doxorubicin results in increased activity of TP53 protein] | 15489221 |
D004317 | Doxorubicin | Caffeine inhibits the reaction [Doxorubicin results in increased expression of TP53 protein] | 22927544 |
D004317 | Doxorubicin | CDC25C protein inhibits the reaction [Doxorubicin results in increased expression of TP53 protein] | 19074854 |
D004317 | Doxorubicin | Chloroquine inhibits the reaction [Doxorubicin results in increased expression of TP53 protein] | 22927544 |
D004317 | Doxorubicin | cobaltous chloride inhibits the reaction [Doxorubicin results in increased phosphorylation of and results in increased activity of TP53 protein] | 19714248 |
D004317 | Doxorubicin | cobaltous chloride inhibits the reaction [[Doxorubicin results in increased phosphorylation of and results in increased activity of TP53 protein] which results in increased expression of BAX mRNA] | 19714248 |
D004317 | Doxorubicin | cobaltous chloride inhibits the reaction [[Doxorubicin results in increased phosphorylation of and results in increased activity of TP53 protein] which results in increased expression of BBC3 mRNA] | 19714248 |
D004317 | Doxorubicin | cobaltous chloride inhibits the reaction [HIPK2 protein promotes the reaction [Doxorubicin results in increased phosphorylation of and results in increased activity of TP53 protein]] | 19714248 |
D004317 | Doxorubicin | CSE1L protein promotes the reaction [Doxorubicin results in increased expression of TP53 protein] | 18377724 |
D004317 | Doxorubicin | diethoxyphosphoryloxymethyl butanoate promotes the reaction [Doxorubicin results in increased acetylation of TP53 protein] | 16826403 |
D004317 | Doxorubicin | Doxorubicin affects the expression of TP53 mRNA | 27825931 |
D004317 | Doxorubicin | Doxorubicin affects the expression of TP53 protein | 12006519; 17893511; |
D004317 | Doxorubicin | Doxorubicin affects the localization of TP53 protein | 19363521 |
D004317 | Doxorubicin | [Doxorubicin co-treated with Paclitaxel] results in increased expression of TP53 protein | 16168113 |
D004317 | Doxorubicin | [Doxorubicin co-treated with Resveratrol] results in increased expression of TP53 mRNA | 26969377 |
D004317 | Doxorubicin | [Doxorubicin co-treated with Resveratrol] results in increased expression of TP53 protein | 26969377 |
D004317 | Doxorubicin | [Doxorubicin co-treated with Vincristine co-treated with Etoposide co-treated with Mitotane] results in decreased expression of TP53 protein | 9815696 |
D004317 | Doxorubicin | Doxorubicin inhibits the reaction [TP53 protein binds to MDM2 protein] | 19351845 |
D004317 | Doxorubicin | Doxorubicin promotes the reaction [ATM protein results in increased phosphorylation of TP53 protein] | 15489221 |
D004317 | Doxorubicin | Doxorubicin promotes the reaction [[CD40LG protein co-treated with IL4 protein] results in increased expression of TP53 protein] | 27634759 |
D004317 | Doxorubicin | Doxorubicin promotes the reaction [diethoxyphosphoryloxymethyl butanoate results in increased acetylation of TP53 protein] | 16826403 |
D004317 | Doxorubicin | Doxorubicin promotes the reaction [[TP53 protein binds to BBC3 promoter] which results in increased expression of BBC3 mRNA] | 19714248 |
D004317 | Doxorubicin | Doxorubicin promotes the reaction [TP53 protein binds to BIRC5 promoter] | 17124180 |
D004317 | Doxorubicin | Doxorubicin promotes the reaction [TP53 protein binds to CARM1 protein] | 19351845 |
D004317 | Doxorubicin | Doxorubicin promotes the reaction [TP53 protein binds to CDKN1A promoter] | 19351845 |
D004317 | Doxorubicin | Doxorubicin promotes the reaction [TP53 protein binds to CREBBP protein] | 19351845 |
D004317 | Doxorubicin | Doxorubicin promotes the reaction [TP53 protein binds to ESR1 promoter] | 19351845 |
D004317 | Doxorubicin | Doxorubicin promotes the reaction [TP53 protein binds to JUN protein] | 19351845 |
D004317 | Doxorubicin | Doxorubicin promotes the reaction [TP53 protein binds to SP1 protein] | 19351845 |
D004317 | Doxorubicin | Doxorubicin results in decreased expression of TP53 mRNA | 18510171 |
D004317 | Doxorubicin | Doxorubicin results in increased acetylation of TP53 protein | 16826403 |
D004317 | Doxorubicin | Doxorubicin results in increased acetylation of TP53 protein mutant form | 27129209 |
D004317 | Doxorubicin | [Doxorubicin results in increased acetylation of TP53 protein mutant form] which results in increased expression of UBE2C protein | 27129209 |
D004317 | Doxorubicin | Doxorubicin results in increased activity of TP53 protein | 15141020; 17124180; 22010212; |
D004317 | Doxorubicin | Doxorubicin results in increased expression of and affects the phosphorylation of and results in increased localization of TP53 protein | 17653088 |
D004317 | Doxorubicin | Doxorubicin results in increased expression of and results in increased phosphorylation of and results in increased acetylation of TP53 protein | 17634554 |
D004317 | Doxorubicin | Doxorubicin results in increased expression of and results in increased phosphorylation of TP53 protein | 16432175; 27163855; |
D004317 | Doxorubicin | Doxorubicin results in increased expression of TP53 | 16013437 |
D004317 | Doxorubicin | Doxorubicin results in increased expression of TP53 mRNA | 15939500; 16001973; 16404146; 17959036; 19351845; 26969377; |
D004317 | Doxorubicin | Doxorubicin results in increased expression of TP53 protein | 10969820; 11779855; 12082016; 14665630; 15555623; 15601469; 15671536; 15763944; 15781256; 16108013; 16537896; 16857806; 17088865; 17285121; 17339365; 17912235; 17959036; 18377724; 19074854; 19351845; 19560264; 20856197; 20978201; 21356574; 21624110; 22927544; 26969377; 27129209; |
D004317 | Doxorubicin | Doxorubicin results in increased expression of TP53 protein modified form | 16857806 |
D004317 | Doxorubicin | Doxorubicin results in increased glutathionylation of TP53 protein | 17555331 |
D004317 | Doxorubicin | Doxorubicin results in increased phosphorylation of and results in increased activity of TP53 protein | 19714248 |
D004317 | Doxorubicin | [Doxorubicin results in increased phosphorylation of and results in increased activity of TP53 protein] which results in increased expression of BAX mRNA | 19714248 |
D004317 | Doxorubicin | [Doxorubicin results in increased phosphorylation of and results in increased activity of TP53 protein] which results in increased expression of BBC3 mRNA | 19714248 |
D004317 | Doxorubicin | Doxorubicin results in increased phosphorylation of TP53 protein | 15177039; 15671536; 19106633; 20346999; |
D004317 | Doxorubicin | Doxorubicin results in increased stability of TP53 protein | 25124555 |
D004317 | Doxorubicin | Fluorouracil promotes the reaction [[Doxorubicin co-treated with Paclitaxel] results in increased expression of TP53 protein] | 16168113 |
D004317 | Doxorubicin | Glutathione inhibits the reaction [Doxorubicin results in increased expression of TP53 protein] | 22927544 |
D004317 | Doxorubicin | HIPK2 protein promotes the reaction [Doxorubicin results in increased phosphorylation of and results in increased activity of TP53 protein] | 19714248 |
D004317 | Doxorubicin | IFNA1 protein promotes the reaction [Doxorubicin results in increased expression of TP53 protein] | 17959036 |
D004317 | Doxorubicin | Lovastatin inhibits the reaction [Doxorubicin results in increased expression of TP53 protein] | 17088865 |
D004317 | Doxorubicin | MDM2 protein inhibits the reaction [HIPK2 protein promotes the reaction [Doxorubicin results in increased phosphorylation of and results in increased activity of TP53 protein]] | 19714248 |
D004317 | Doxorubicin | MDM2 protein promotes the reaction [cobaltous chloride inhibits the reaction [HIPK2 protein promotes the reaction [Doxorubicin results in increased phosphorylation of and results in increased activity of TP53 protein]]] | 19714248 |
D004317 | Doxorubicin | NFKB1 protein affects the reaction [Doxorubicin results in increased expression of TP53 protein] | 17912235 |
D004317 | Doxorubicin | nutlin 3 promotes the reaction [Doxorubicin results in increased expression of TP53 protein] | 21624110 |
D004317 | Doxorubicin | PI103 inhibits the reaction [Doxorubicin results in increased expression of TP53 protein] | 20856197 |
D004317 | Doxorubicin | pluronic block copolymer p85 promotes the reaction [Doxorubicin results in increased expression of TP53 mRNA] | 15939500 |
D004317 | Doxorubicin | SETD7 protein promotes the reaction [Doxorubicin results in increased stability of TP53 protein] | 25124555 |
D004317 | Doxorubicin | TNF protein inhibits the reaction [TP53 gene mutant form results in decreased susceptibility to Doxorubicin] | 15823547 |
D004317 | Doxorubicin | TP53 affects the reaction [Doxorubicin results in increased activity of and results in increased expression of CDKN1A protein] | 21624110 |
D004317 | Doxorubicin | TP53 affects the reaction [Doxorubicin results in increased activity of and results in increased expression of MDM2 protein] | 21624110 |
D004317 | Doxorubicin | TP53 affects the reaction [nutlin 3 promotes the reaction [Doxorubicin results in increased activity of and results in increased expression of CDKN1A protein]] | 21624110 |
D004317 | Doxorubicin | TP53 affects the reaction [nutlin 3 promotes the reaction [Doxorubicin results in increased activity of and results in increased expression of MDM2 protein]] | 21624110 |
D004317 | Doxorubicin | TP53 gene affects the susceptibility to Doxorubicin | 17085670 |
D004317 | Doxorubicin | TP53 gene mutant form inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein] | 15578696 |
D004317 | Doxorubicin | TP53 gene mutant form inhibits the reaction [Doxorubicin results in increased expression of ALOX12B mRNA] | 30258081 |
D004317 | Doxorubicin | TP53 gene mutant form inhibits the reaction [Doxorubicin results in increased expression of ALOX5 mRNA] | 30258081 |
D004317 | Doxorubicin | TP53 gene mutant form inhibits the reaction [Doxorubicin results in increased expression of CDKN1A mRNA] | 30258081 |
D004317 | Doxorubicin | TP53 gene mutant form results in decreased susceptibility to Doxorubicin | 15578696; 17369602; |
D004317 | Doxorubicin | TP53 protein affects the reaction [APP protein affects the susceptibility to Doxorubicin] | 17608641 |
D004317 | Doxorubicin | TP53 protein affects the reaction [CHEK1 protein affects the susceptibility to Doxorubicin] | 18698031 |
D004317 | Doxorubicin | TP53 protein affects the reaction [Doxorubicin affects the reaction [RELA protein results in increased expression of CDKN1A mRNA]] | 18269916 |
D004317 | Doxorubicin | TP53 protein affects the reaction [Doxorubicin results in decreased expression of BIRC5 protein] | 19363521 |
D004317 | Doxorubicin | TP53 protein affects the reaction [Doxorubicin results in increased expression of CDKN1A mRNA] | 17079232 |
D004317 | Doxorubicin | TP53 protein affects the reaction [Doxorubicin results in increased expression of ESR1 mRNA] | 19351845 |
D004317 | Doxorubicin | TP53 protein affects the reaction [Doxorubicin results in increased expression of ESR1 protein] | 19351845 |
D004317 | Doxorubicin | TP53 protein affects the reaction [Doxorubicin results in increased expression of GPX1 mRNA] | 15059885 |
D004317 | Doxorubicin | TP53 protein affects the reaction [Doxorubicin results in increased expression of NFKB1 protein] | 17912235 |
D004317 | Doxorubicin | TP53 protein affects the reaction [Doxorubicin results in increased expression of SOD2 mRNA] | 15059885 |
D004317 | Doxorubicin | TP53 protein affects the reaction [FHL2 protein affects the reaction [Doxorubicin results in increased expression of CDKN1A protein]] | 17682292 |
D004317 | Doxorubicin | TP53 protein affects the reaction [IFNA1 protein results in increased susceptibility to Doxorubicin] | 17959036 |
D004317 | Doxorubicin | TP53 protein affects the susceptibility to Doxorubicin | 15182437; 17912235; 25124555; |
D004317 | Doxorubicin | TP53 protein inhibits the reaction [Doxorubicin results in decreased activity of CDK2 protein] | 25124555 |
D004317 | Doxorubicin | TP53 protein inhibits the reaction [Doxorubicin results in decreased expression of UBE2C protein] | 27129209 |
D004317 | Doxorubicin | TP53 protein inhibits the reaction [Sildenafil Citrate results in increased susceptibility to Doxorubicin] | 20155316 |
D004317 | Doxorubicin | TP53 protein mutant form affects the reaction [Doxorubicin results in decreased expression of BAX mRNA] | 24816189 |
D004317 | Doxorubicin | TP53 protein mutant form affects the reaction [Doxorubicin results in decreased expression of SFN mRNA] | 24816189 |
D004317 | Doxorubicin | TP53 protein mutant form affects the reaction [Doxorubicin results in increased expression of BAX protein] | 24816189 |
D004317 | Doxorubicin | TP53 protein mutant form affects the reaction [Doxorubicin results in increased expression of BBC3 protein] | 24816189 |
D004317 | Doxorubicin | TP53 protein mutant form affects the reaction [Doxorubicin results in increased expression of BCL2L1 protein] | 24816189 |
D004317 | Doxorubicin | TP53 protein mutant form affects the reaction [Doxorubicin results in increased expression of CDKN1A mRNA] | 24816189 |
D004317 | Doxorubicin | TP53 protein mutant form affects the reaction [Doxorubicin results in increased expression of SFN protein] | 24816189 |
D004317 | Doxorubicin | TP53 protein promotes the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Doxorubicin results in increased cleavage of CASP3 protein]] | 20856197 |
D004317 | Doxorubicin | TP53 protein promotes the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Doxorubicin results in increased cleavage of CASP8 protein]] | 20856197 |
D004317 | Doxorubicin | TP53 protein promotes the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Doxorubicin results in increased cleavage of CASP9 protein]] | 20856197 |
D004317 | Doxorubicin | TP53 protein promotes the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Doxorubicin results in increased expression of and results in increased activity of BAX protein]] | 20856197 |
D004317 | Doxorubicin | TP53 protein promotes the reaction [[Doxorubicin co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] results in increased expression of BBC3 protein] | 20856197 |
D004317 | Doxorubicin | TP53 protein promotes the reaction [[Doxorubicin co-treated with PI103] results in increased expression of BBC3 protein] | 20856197 |
D004317 | Doxorubicin | TP53 protein promotes the reaction [Doxorubicin results in increased expression of ALOX12B mRNA] | 30258081 |
D004317 | Doxorubicin | TP53 protein promotes the reaction [Doxorubicin results in increased expression of ALOX5 mRNA] | 30258081 |
D004317 | Doxorubicin | TP53 protein promotes the reaction [Doxorubicin results in increased expression of FAS mRNA] | 11779855 |
D004317 | Doxorubicin | TP53 protein promotes the reaction [Doxorubicin results in increased expression of TNFSF10 mRNA] | 19106633 |
D004317 | Doxorubicin | TP53 protein promotes the reaction [Doxorubicin results in increased expression of TNFSF10 protein] | 19106633 |
D004317 | Doxorubicin | TP53 protein promotes the reaction [PI103 promotes the reaction [Doxorubicin results in increased activity of BAX protein]] | 20856197 |
D004317 | Doxorubicin | TP53 protein promotes the reaction [PI103 promotes the reaction [Doxorubicin results in increased cleavage of CASP3 protein]] | 20856197 |
D004317 | Doxorubicin | TP53 protein promotes the reaction [PI103 promotes the reaction [Doxorubicin results in increased cleavage of CASP8 protein]] | 20856197 |
D004317 | Doxorubicin | TP53 protein promotes the reaction [PI103 promotes the reaction [Doxorubicin results in increased cleavage of CASP9 protein]] | 20856197 |
D004317 | Doxorubicin | TP53 protein results in increased susceptibility to Doxorubicin | 14704126; 15601469; 15823547; 16211088; 20856197; 9395239; |
D004317 | Doxorubicin | TP53 protein results in increased susceptibility to [Doxorubicin co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] | 20856197 |
D004317 | Doxorubicin | TP53 protein results in increased susceptibility to [Doxorubicin co-treated with PI103] | 20856197 |
D004317 | Doxorubicin | Wortmannin inhibits the reaction [Doxorubicin promotes the reaction [ATM protein results in increased phosphorylation of TP53 protein]] | 15489221 |
D004317 | Doxorubicin | zinc chloride inhibits the reaction [cobaltous chloride inhibits the reaction [Doxorubicin results in increased phosphorylation of and results in increased activity of TP53 protein]] | 19714248 |
D004317 | Doxorubicin | Doxorubicin results in increased expression of TP53 protein | 25896364 |
D004317 | Doxorubicin | PSMB10 protein inhibits the reaction [Doxorubicin results in increased expression of TP53 protein] | 25896364 |
D004317 | Doxorubicin | PSMB8 protein inhibits the reaction [Doxorubicin results in increased expression of TP53 protein] | 25896364 |
D004317 | Doxorubicin | PSMB9 protein inhibits the reaction [Doxorubicin results in increased expression of TP53 protein] | 25896364 |
D004317 | Doxorubicin | 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Doxorubicin results in increased phosphorylation of TP53 protein] | 18775851 |
D004317 | Doxorubicin | caryophyllene inhibits the reaction [Doxorubicin results in increased expression of TP53 protein] | 30836069 |
D004317 | Doxorubicin | Doxorubicin affects the reaction [TP53 protein binds to HSPB1 protein] | 18263706 |
D004317 | Doxorubicin | [Doxorubicin affects the reaction [TP53 protein binds to HSPB1 protein]] which results in increased expression of CDKN1A protein | 18263706 |
D004317 | Doxorubicin | Doxorubicin promotes the reaction [TP53 protein binds to BAX promoter] | 22155320 |
D004317 | Doxorubicin | Doxorubicin promotes the reaction [TP53 protein binds to BCL2 promoter] | 22155320 |
D004317 | Doxorubicin | Doxorubicin results in decreased expression of TP53 mRNA | 27255381 |
D004317 | Doxorubicin | Doxorubicin results in increased expression of and results in increased localization of TP53 protein modified form | 18775851 |
D004317 | Doxorubicin | Doxorubicin results in increased expression of and results in increased phosphorylation of and results in increased stability of and results in increased activity of TP53 protein | 16687611 |
D004317 | Doxorubicin | Doxorubicin results in increased expression of TP53 mRNA | 15667795; 18632596; 22155320; |
D004317 | Doxorubicin | Doxorubicin results in increased expression of TP53 protein | 15983034; 17285121; 18775851; 20470772; 21194538; 22015447; 22155320; 24902966; 25997894; 26318906; 30009776; 30836069; 30885636; |
D004317 | Doxorubicin | Doxorubicin results in increased phosphorylation of and results in increased localization of TP53 protein | 18775851 |
D004317 | Doxorubicin | Exenatide inhibits the reaction [Doxorubicin results in increased expression of TP53 protein] | 30885636 |
D004317 | Doxorubicin | Ginkgo biloba extract inhibits the reaction [Doxorubicin results in increased expression of TP53 mRNA] | 18632596 |
D004317 | Doxorubicin | [Glucose deficiency co-treated with Galactose co-treated with Pyruvic Acid] inhibits the reaction [Doxorubicin results in increased expression of TP53 protein] | 25997894 |
D004317 | Doxorubicin | iodopravadoline inhibits the reaction [caryophyllene inhibits the reaction [Doxorubicin results in increased expression of TP53 protein]] | 30836069 |
D004317 | Doxorubicin | kaempferol inhibits the reaction [Doxorubicin promotes the reaction [TP53 protein binds to BAX promoter]] | 22155320 |
D004317 | Doxorubicin | kaempferol inhibits the reaction [Doxorubicin results in increased expression of TP53 mRNA] | 22155320 |
D004317 | Doxorubicin | pifithrin inhibits the reaction [Doxorubicin results in increased expression of and results in increased localization of TP53 protein modified form] | 18775851 |
D004317 | Doxorubicin | pifithrin inhibits the reaction [Doxorubicin results in increased expression of and results in increased phosphorylation of and results in increased activity of TP53 protein] | 16687611 |
D004317 | Doxorubicin | pifithrin inhibits the reaction [Doxorubicin results in increased phosphorylation of and results in increased localization of TP53 protein] | 18775851 |
D004317 | Doxorubicin | Propofol inhibits the reaction [Doxorubicin results in increased expression of TP53 protein] | 22015447 |
D004317 | Doxorubicin | Quercetin inhibits the reaction [Doxorubicin results in increased expression of TP53 protein] | 24902966 |
D004317 | Doxorubicin | SHC1 protein promotes the reaction [Doxorubicin results in increased expression of TP53 protein] | 26318906 |
D004317 | Doxorubicin | U 0126 inhibits the reaction [Doxorubicin results in increased expression of and results in increased localization of TP53 protein modified form] | 18775851 |
D004317 | Doxorubicin | U 0126 inhibits the reaction [Doxorubicin results in increased phosphorylation of and results in increased localization of TP53 protein] | 18775851 |
D004317 | Doxorubicin | Doxorubicin results in increased activity of TP53 protein | 18775851 |
D004317 | Doxorubicin | TP53 protein affects the susceptibility to Doxorubicin | 15059885 |
C060327 | dracorhodin | dracorhodin analog results in increased expression of TP53 protein | 15684474 |
C060327 | dracorhodin | dracorhodin analog results in increased phosphorylation of TP53 protein | 15684474 |
D013759 | Dronabinol | CNR1 affects the reaction [Dronabinol results in decreased sumoylation of TP53 protein] | 19819240 |
D013759 | Dronabinol | Dronabinol results in decreased sumoylation of TP53 protein | 19819240 |
D004365 | Drugs, Chinese Herbal | Drugs, Chinese Herbal results in increased expression of TP53 protein | 21457722; 29667321; |
D004391 | Dust | Dust results in decreased expression of TP53 mRNA | 17805423 |
D004441 | Ecdysterone | Ecdysterone results in increased expression of TP53 mRNA | 15776001 |
D004492 | Edetic Acid | Edetic Acid inhibits the reaction [[Cadmium Chloride results in decreased activity of TP53 protein] inhibits the reaction [TP53 protein binds to TP53 gene]] | 25446071; 25446071; |
D004492 | Edetic Acid | Edetic Acid inhibits the reaction [[Cadmium Chloride results in decreased activity of TP63 protein] inhibits the reaction [TP63 protein binds to TP53 gene]] | 25446071 |
D004492 | Edetic Acid | Edetic Acid inhibits the reaction [[Cadmium Chloride results in decreased activity of TP73 protein] inhibits the reaction [TP73 protein binds to TP53 gene]] | 25446071 |
D015118 | Eicosapentaenoic Acid | [TP53 protein mutant form results in increased susceptibility to Niclosamide] which results in increased abundance of Eicosapentaenoic Acid | 30258081 |
C004934 | eleostearic acid | eleostearic acid results in increased expression of TP53 protein | 15961301 |
D004610 | Ellagic Acid | Ellagic Acid promotes the reaction [Quercetin results in increased phosphorylation of TP53 protein] | 15735102 |
D004610 | Ellagic Acid | Ellagic Acid results in increased expression of TP53 protein | 23554011 |
D004610 | Ellagic Acid | pifithrin inhibits the reaction [Ellagic Acid promotes the reaction [Quercetin results in increased phosphorylation of TP53 protein]] | 15735102 |
D004610 | Ellagic Acid | Ellagic Acid inhibits the reaction [phosalone results in increased expression of TP53 mRNA] | 27965107 |
D004610 | Ellagic Acid | Ellagic Acid inhibits the reaction [phosalone results in increased expression of TP53 protein] | 27965107 |
C034192 | ellipticine | ellipticine results in increased expression of TP53 protein | 29471073 |
C034192 | ellipticine | TP53 protein promotes the reaction [ellipticine inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 protein]] | 29471073 |
C034192 | ellipticine | TP53 protein promotes the reaction [ellipticine results in increased expression of CDKN1A protein] | 29471073 |
C034192 | ellipticine | TP53 protein promotes the reaction [ellipticine results in increased expression of CYP1A1 protein] | 29471073 |
C034192 | ellipticine | TP53 protein promotes the reaction [[ellipticine results in increased susceptibility to Benzo(a)pyrene] which results in increased expression of CDKN1A protein] | 29471073 |
C034192 | ellipticine | TP53 protein results in increased susceptibility to ellipticine | 29471073 |
C561944 | EMD 534085 | EMD 534085 results in increased expression of TP53 protein modified form | 18451153 |
D004642 | Emodin | Emodin affects the expression of TP53 protein | 19549930 |
D004726 | Endosulfan | Endosulfan results in increased expression of TP53 mRNA | 29705383 |
C118739 | entinostat | entinostat promotes the reaction [Etoposide results in increased expression of and results in increased acetylation of TP53 protein] | 25699604 |
C118739 | entinostat | entinostat results in increased expression of TP53 protein | 25699604 |
C118739 | entinostat | Etoposide promotes the reaction [entinostat results in increased expression of TP53 protein] | 25699604 |
D004791 | Enzyme Inhibitors | [Enzyme Inhibitors results in decreased activity of OGA protein] which results in increased O-linked glycosylation of TP53 protein | 23301498 |
C045651 | epigallocatechin gallate | epigallocatechin gallate inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of and results in increased activity of TP53 protein] | 15795422 |
C045651 | epigallocatechin gallate | epigallocatechin gallate results in increased expression of and results in increased phosphorylation of and results in increased activity of TP53 protein | 15764647 |
C045651 | epigallocatechin gallate | epigallocatechin gallate results in increased expression of and results in increased phosphorylation of TP53 protein | 15657356; 19406223; |
C045651 | epigallocatechin gallate | epigallocatechin gallate results in increased expression of TP53 protein | 26341291 |
C045651 | epigallocatechin gallate | epigallocatechin gallate results in increased expression of TP53 protein modified form | 26341291 |
C045651 | epigallocatechin gallate | TP53 mRNA affects the susceptibility to epigallocatechin gallate | 19406223 |
C045651 | epigallocatechin gallate | TP53 protein results in increased susceptibility to epigallocatechin gallate | 15764647; 23285096; |
C045651 | epigallocatechin gallate | epigallocatechin gallate affects the expression of TP53 protein | 22000973 |
C045651 | epigallocatechin gallate | epigallocatechin gallate results in increased activity of TP53 promoter | 19406223 |
D015251 | Epirubicin | 3',4',7-trihydroxyisoflavone promotes the reaction [Epirubicin results in increased expression of TP53 mRNA] | 22914566 |
D015251 | Epirubicin | chrysophsin promotes the reaction [Epirubicin results in increased expression of TP53 mRNA] | 26335193 |
D015251 | Epirubicin | [Epirubicin analog co-treated with chrysophsin analog] results in increased expression of TP53 mRNA | 26335193 |
D015251 | Epirubicin | Epirubicin promotes the reaction [3',4',7-trihydroxyisoflavone results in increased expression of TP53 mRNA] | 22914566 |
D015251 | Epirubicin | Epirubicin promotes the reaction [chrysophsin results in increased expression of TP53 mRNA] | 26335193 |
D015251 | Epirubicin | Epirubicin results in increased expression of TP53 mRNA | 22914566; 26335193; |
D000069347 | Erlotinib Hydrochloride | Erlotinib Hydrochloride promotes the reaction [Arsenic Trioxide results in increased expression of TP53 mRNA] | 29274334 |
D000069347 | Erlotinib Hydrochloride | Erlotinib Hydrochloride promotes the reaction [Resveratrol results in increased expression of TP53 protein] | 25895606 |
D000069347 | Erlotinib Hydrochloride | Erlotinib Hydrochloride results in increased expression of TP53 protein | 25895606 |
D000069347 | Erlotinib Hydrochloride | Resveratrol promotes the reaction [Erlotinib Hydrochloride results in increased expression of TP53 protein] | 25895606 |
D004918 | Erythromycin Estolate | Erythromycin Estolate results in decreased expression of TP53 mRNA | 17522070 |
D004923 | Erythrosine | Erythrosine results in increased activity of TP53 protein | 9168006 |
C007628 | esculetin | esculetin results in increased degradation of TP53 protein | 14634213 |
D004958 | Estradiol | Estradiol affects the expression of TP53 mRNA | 24349563 |
D004958 | Estradiol | Estradiol affects the expression of TP53 mRNA | 22574217 |
D004958 | Estradiol | Estradiol affects the localization of and results in decreased activity of TP53 protein | 15870704 |
D004958 | Estradiol | [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine co-treated with Decitabine] results in increased expression of TP53 protein | 22534328 |
D004958 | Estradiol | [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased expression of TP53 protein | 22534328 |
D004958 | Estradiol | Estradiol inhibits the reaction [TP53 protein binds to MIR34B promoter] | 22113133 |
D004958 | Estradiol | Estradiol promotes the reaction [Benzo(a)pyrene affects the localization of and results in increased expression of TP53 protein] | 24954032 |
D004958 | Estradiol | Estradiol promotes the reaction [dibenzo(a,l)pyrene affects the localization of and results in increased expression of TP53 protein] | 24954032 |
D004958 | Estradiol | Estradiol results in increased expression of and results in increased activity of and affects the localization of TP53 protein | 16053526 |
D004958 | Estradiol | Estradiol results in increased expression of TP53 mRNA | 23804311; 24481588; |
D004958 | Estradiol | Estradiol results in increased expression of TP53 protein | 18174961; 19647730; 24481588; |
D004958 | Estradiol | Fulvestrant inhibits the reaction [Estradiol affects the localization of TP53 protein] | 15870704 |
D004958 | Estradiol | [Hexachlorocyclohexane co-treated with Estradiol] results in increased expression of TP53 protein | 18174961 |
D004958 | Estradiol | Okadaic Acid affects the reaction [Estradiol promotes the reaction [Benzo(a)pyrene affects the localization of TP53 protein]] | 24954032 |
D004958 | Estradiol | [Parathion co-treated with Estradiol] results in increased expression of TP53 protein mutant form | 17622325 |
D004958 | Estradiol | Estradiol results in increased expression of TP53 mRNA | 14595849 |
D004958 | Estradiol | [Estradiol co-treated with Methylnitrosourea co-treated with Progesterone] results in decreased expression of TP53 mRNA | 20732338 |
D004958 | Estradiol | Estradiol results in decreased expression of TP53 protein | 24894866 |
D004958 | Estradiol | Estradiol results in increased expression of TP53 mRNA | 17522070 |
D004958 | Estradiol | Estradiol results in increased expression of TP53 protein | 14685795 |
D004958 | Estradiol | Resveratrol inhibits the reaction [Estradiol results in decreased expression of TP53 protein] | 24894866 |
C074283 | estradiol 3-benzoate | estradiol 3-benzoate results in increased expression of TP53 mRNA | 24316378 |
C074283 | estradiol 3-benzoate | estradiol 3-benzoate results in increased expression of TP53 protein | 24316378 |
C074283 | estradiol 3-benzoate | Quercetin inhibits the reaction [estradiol 3-benzoate results in increased expression of TP53 mRNA] | 24316378 |
C074283 | estradiol 3-benzoate | Quercetin inhibits the reaction [estradiol 3-benzoate results in increased expression of TP53 protein] | 24316378 |
C007633 | estragole | estragole results in increased phosphorylation of TP53 protein | 29054680 |
D004967 | Estrogens | Estrogens results in increased expression of TP53 mRNA | 18204794 |
D004966 | Estrogens, Conjugated (USP) | [Estrogens, Conjugated (USP) co-treated with Medroxyprogesterone Acetate] results in decreased expression of TP53 protein | 16021059 |
C088768 | estrone-3-O-sulfamate | estrone-3-O-sulfamate analog results in increased expression of TP53 protein | 14991574 |
D004976 | Ethacrynic Acid | Ethacrynic Acid affects the localization of TP53 protein | 25817893 |
D000431 | Ethanol | Ethanol inhibits the reaction [[cupric chloride co-treated with di(2-picolyl)amine-3(bromoacetyl)coumarin] results in increased expression of TP53 protein] | 29803612 |
D000431 | Ethanol | Ethanol results in increased expression of and results in increased phosphorylation of TP53 protein | 27270636 |
D000431 | Ethanol | MAPK14 protein promotes the reaction [Ethanol results in increased expression of and results in increased phosphorylation of TP53 protein] | 27270636 |
D000431 | Ethanol | SB 203580 inhibits the reaction [Ethanol results in increased expression of and results in increased phosphorylation of TP53 protein] | 27270636 |
D000431 | Ethanol | SIAH1 protein promotes the reaction [Ethanol results in increased expression of and results in increased phosphorylation of TP53 protein] | 27270636 |
D000431 | Ethanol | [Ethanol co-treated with Cyanamide] results in increased expression of TP53 mRNA | 12003908 |
D000431 | Ethanol | Ethanol promotes the reaction [Diethylhexyl Phthalate results in increased expression of TP53 mRNA] | 28115068 |
D000431 | Ethanol | Ethanol promotes the reaction [[manganese chloride results in increased abundance of Manganese] which results in increased expression of TP53 protein] | 30844427 |
D000431 | Ethanol | Ethanol results in increased acetylation of TP53 protein | 24769256 |
D000431 | Ethanol | Ethanol results in increased expression of TP53 mRNA | 23273579 |
D000431 | Ethanol | Ethanol results in increased expression of TP53 protein | 29769550; 30844427; |
D000431 | Ethanol | salvianolic acid B inhibits the reaction [Ethanol results in increased acetylation of TP53 protein] | 24769256 |
D004997 | Ethinyl Estradiol | Ethinyl Estradiol results in decreased expression of TP53 mRNA | 20227414 |
D004997 | Ethinyl Estradiol | Ethinyl Estradiol results in increased expression of TP53 mRNA | 29458080 |
D004997 | Ethinyl Estradiol | Ethinyl Estradiol results in increased expression of TP53 mRNA | 16940010 |
D004997 | Ethinyl Estradiol | Ethinyl Estradiol results in decreased expression of TP53 mRNA | 23129252 |
D005028 | Ethylenebis(dithiocarbamates) | Ethylenebis(dithiocarbamates) results in increased expression of TP53 protein | 11964141 |
D015946 | Ethylene Dibromide | Ethylene Dibromide results in increased mutagenesis of TP53 gene | 14715658 |
D005038 | Ethylnitrosourea | Ethylnitrosourea results in increased mutagenesis of TP53 gene | 14715658 |
D005038 | Ethylnitrosourea | [Ethylnitrosourea results in increased mutagenesis of TP53 gene] which results in decreased activity of TP53 protein | 14715658; 14715658; |
D005038 | Ethylnitrosourea | Ethylnitrosourea results in increased mutagenesis of TP53 exon | 17156454 |
D005038 | Ethylnitrosourea | Ethylnitrosourea results in increased mutagenesis of TP53 gene | 16495775 |
C054207 | etomoxir | etomoxir results in increased expression of TP53 mRNA | 19234235 |
D005047 | Etoposide | 2,4,4'-trichlorobiphenyl inhibits the reaction [Etoposide results in increased expression of TP53 protein] | 19751709 |
D005047 | Etoposide | 2,4,5,2',5'-pentachlorobiphenyl inhibits the reaction [Etoposide results in increased expression of TP53 protein] | 19751709 |
D005047 | Etoposide | 3,4,5,3',4'-pentachlorobiphenyl inhibits the reaction [Etoposide results in increased expression of TP53 protein] | 19751709 |
D005047 | Etoposide | Cadmium Chloride affects the reaction [Etoposide results in increased phosphorylation of TP53 protein] | 25744307 |
D005047 | Etoposide | [CASP8 co-treated with TP53] affects the reaction [Etoposide results in increased cleavage of and results in increased activity of CASP9 protein] | 21801448 |
D005047 | Etoposide | [CASP8 co-treated with TP53] affects the reaction [Etoposide results in increased cleavage of CASP3 protein] | 21801448 |
D005047 | Etoposide | [CASP8 co-treated with TP53] affects the reaction [Etoposide results in increased cleavage of PARP1 protein] | 21801448 |
D005047 | Etoposide | [CASP8 co-treated with TP53] inhibits the reaction [CASP8 protein mutant form results in decreased susceptibility to Etoposide] | 21801448 |
D005047 | Etoposide | [Doxorubicin co-treated with Vincristine co-treated with Etoposide co-treated with Mitotane] results in decreased expression of TP53 protein | 9815696 |
D005047 | Etoposide | entinostat promotes the reaction [Etoposide results in increased expression of and results in increased acetylation of TP53 protein] | 25699604 |
D005047 | Etoposide | Etoposide promotes the reaction [entinostat results in increased expression of TP53 protein] | 25699604 |
D005047 | Etoposide | Etoposide promotes the reaction [[TP53 protein binds to GDF15 promoter] which results in increased expression of GDF15 mRNA] | 11895857 |
D005047 | Etoposide | Etoposide promotes the reaction [TP53 protein binds to TNFRSF10B promoter] | 15964798 |
D005047 | Etoposide | Etoposide promotes the reaction [TP53 protein results in increased chemical synthesis of benzo(a)pyrene 7,8-dihydrodiol] | 29471073 |
D005047 | Etoposide | Etoposide promotes the reaction [trichostatin A results in increased expression of TP53 protein] | 25699604 |
D005047 | Etoposide | Etoposide promotes the reaction [UF010 compound results in increased expression of TP53 protein] | 25699604 |
D005047 | Etoposide | Etoposide results in increased acetylation of TP53 protein | 20299546 |
D005047 | Etoposide | Etoposide results in increased acetylation of TP53 protein mutant form | 27129209 |
D005047 | Etoposide | [Etoposide results in increased acetylation of TP53 protein mutant form] which results in increased expression of UBE2C protein | 27129209 |
D005047 | Etoposide | Etoposide results in increased activity of TP53 protein | 16120219; 20655369; 22010212; 30818834; |
D005047 | Etoposide | Etoposide results in increased expression of and results in increased acetylation of TP53 protein | 25699604 |
D005047 | Etoposide | Etoposide results in increased expression of TP53 protein | 11895857; 12082016; 15131059; 16120219; 19751709; 21212465; 27129209; 27358234; 27982581; 29471073; 31542801; |
D005047 | Etoposide | [Etoposide results in increased expression of TP53 protein] which results in increased expression of GDF15 protein | 11895857 |
D005047 | Etoposide | Etoposide results in increased phosphorylation of and affects the localization of TP53 protein | 26259609 |
D005047 | Etoposide | Etoposide results in increased phosphorylation of and results in increased activity of TP53 protein | 16882877; 20299546; 25078064; |
D005047 | Etoposide | Etoposide results in increased phosphorylation of TP53 protein | 21801448; 23144690; 25744307; |
D005047 | Etoposide | NFE2L2 protein affects the reaction [Etoposide results in increased expression of TP53 protein] | 27982581 |
D005047 | Etoposide | Oxygen deficiency inhibits the reaction [Etoposide results in increased phosphorylation of TP53 protein] | 23144690 |
D005047 | Etoposide | pifithrin inhibits the reaction [Etoposide results in increased activity of TP53 protein] | 16882877 |
D005047 | Etoposide | Tetrachlorodibenzodioxin inhibits the reaction [Etoposide results in increased acetylation of TP53 protein] | 20299546 |
D005047 | Etoposide | Tetrachlorodibenzodioxin inhibits the reaction [Etoposide results in increased phosphorylation of and results in increased activity of TP53 protein] | 20299546 |
D005047 | Etoposide | TP53 affects the reaction [Etoposide results in increased expression of CDKN1A mRNA] | 24067374 |
D005047 | Etoposide | TP53 affects the reaction [Etoposide results in increased expression of TPT1 mRNA] | 24067374 |
D005047 | Etoposide | TP53 promotes the reaction [Etoposide results in increased expression of BTG2 protein] | 27358234 |
D005047 | Etoposide | TP53 promotes the reaction [Etoposide results in increased expression of CDKN1A protein] | 27358234 |
D005047 | Etoposide | TP53 protein affects the reaction [CHEK1 protein affects the susceptibility to Etoposide] | 18698031 |
D005047 | Etoposide | TP53 protein affects the reaction [Etoposide results in decreased expression of UBE2C mRNA] | 27129209 |
D005047 | Etoposide | TP53 protein affects the reaction [Etoposide results in increased expression of SRXN1 protein] | 27982581 |
D005047 | Etoposide | TP53 protein inhibits the reaction [ESR2 protein results in increased susceptibility to Etoposide] | 20623183 |
D005047 | Etoposide | TP53 protein inhibits the reaction [Etoposide results in decreased expression of UBE2C protein] | 27129209 |
D005047 | Etoposide | TP53 protein promotes the reaction [Etoposide promotes the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 protein]] | 29471073 |
D005047 | Etoposide | TP53 protein promotes the reaction [Etoposide results in increased expression of CDKN1A protein] | 29471073 |
D005047 | Etoposide | TP53 protein promotes the reaction [Etoposide results in increased expression of CYP1A1 protein] | 29471073 |
D005047 | Etoposide | TP53 protein promotes the reaction [[Etoposide results in increased susceptibility to Benzo(a)pyrene] which results in increased expression of CDKN1A protein] | 29471073 |
D005047 | Etoposide | TP53 protein results in increased susceptibility to Etoposide | 21552291; 29471073; |
D005047 | Etoposide | [TP53 protein results in increased susceptibility to Etoposide] which results in decreased chemical synthesis of benzo(a)pyrene 7,8-dihydrodiol | 29471073 |
D005047 | Etoposide | TP53 results in increased susceptibility to Etoposide | 16882877 |
D005047 | Etoposide | trichostatin A promotes the reaction [Etoposide results in increased expression of and results in increased acetylation of TP53 protein] | 25699604 |
D005047 | Etoposide | UF010 compound promotes the reaction [Etoposide results in increased expression of and results in increased acetylation of TP53 protein] | 25699604 |
D005047 | Etoposide | cordycepin promotes the reaction [Etoposide results in increased expression of TP53 protein] | 23690541 |
D005047 | Etoposide | Etoposide promotes the reaction [Acetaminophen results in increased phosphorylation of TP53 protein] | 16330492 |
D005047 | Etoposide | Etoposide results in increased expression of and results in increased phosphorylation of TP53 protein | 15459018 |
D005047 | Etoposide | Etoposide results in increased expression of TP53 protein | 17516866; 23690541; |
D005047 | Etoposide | Niacin deficiency inhibits the reaction [Etoposide results in increased expression of TP53 protein] | 17516866 |
D005047 | Etoposide | Tetrachlorodibenzodioxin inhibits the reaction [Etoposide results in increased expression of and results in increased phosphorylation of TP53 protein] | 15459018 |
D005047 | Etoposide | Etoposide results in increased activity of TP53 protein | 18557930 |
D005054 | Eugenol | Eugenol results in increased mutagenesis of TP53 gene | 15576237 |
D005054 | Eugenol | Eugenol inhibits the reaction [Methylnitronitrosoguanidine results in decreased expression of TP53 protein] | 19851710 |
C433928 | EUK-134 | EUK-134 inhibits the reaction [Hydrogen Peroxide results in increased expression of TP53 protein] | 25005833 |
C433928 | EUK-134 | EUK-134 inhibits the reaction [Vitamin K 3 results in increased expression of TP53 protein] | 25005833 |
C506425 | eurycomanone | eurycomanone results in decreased expression of TP53 protein | 21903368 |
D000077270 | Exenatide | Exenatide inhibits the reaction [Doxorubicin results in increased expression of TP53 protein] | 30885636 |
C545733 | fatostatin | Docetaxel promotes the reaction [[TP53 protein mutant form results in increased susceptibility to fatostatin] which results in decreased expression of MKI67 protein] | 26512780 |
C545733 | fatostatin | Docetaxel promotes the reaction [[TP53 protein mutant form results in increased susceptibility to fatostatin] which results in increased cleavage of CASP3 protein] | 26512780 |
C545733 | fatostatin | Docetaxel promotes the reaction [[TP53 protein mutant form results in increased susceptibility to fatostatin] which results in increased cleavage of PARP1 protein] | 26512780 |
C545733 | fatostatin | fatostatin results in decreased expression of TP53 protein | 28483521 |
C545733 | fatostatin | TP53 protein mutant form results in increased susceptibility to fatostatin | 26512780 |
C545733 | fatostatin | [TP53 protein mutant form results in increased susceptibility to fatostatin] promotes the reaction [fatostatin results in decreased expression of ACLY mRNA] | 26512780 |
C545733 | fatostatin | [TP53 protein mutant form results in increased susceptibility to fatostatin] promotes the reaction [fatostatin results in decreased expression of FASN mRNA] | 26512780 |
C545733 | fatostatin | [TP53 protein mutant form results in increased susceptibility to fatostatin] promotes the reaction [fatostatin results in decreased expression of HMGCR mRNA] | 26512780 |
C545733 | fatostatin | [TP53 protein mutant form results in increased susceptibility to fatostatin] promotes the reaction [fatostatin results in decreased expression of HMGCS1 mRNA] | 26512780 |
C545733 | fatostatin | [TP53 protein mutant form results in increased susceptibility to fatostatin] promotes the reaction [fatostatin results in decreased expression of INSIG1 mRNA] | 26512780 |
C545733 | fatostatin | [TP53 protein mutant form results in increased susceptibility to fatostatin] promotes the reaction [fatostatin results in decreased expression of LDLR mRNA] | 26512780 |
C545733 | fatostatin | [TP53 protein mutant form results in increased susceptibility to fatostatin] promotes the reaction [fatostatin results in decreased expression of MVD mRNA] | 26512780 |
C545733 | fatostatin | [TP53 protein mutant form results in increased susceptibility to fatostatin] promotes the reaction [fatostatin results in decreased expression of MVK mRNA] | 26512780 |
C545733 | fatostatin | [TP53 protein mutant form results in increased susceptibility to fatostatin] promotes the reaction [fatostatin results in decreased expression of SCAP mRNA] | 26512780 |
C545733 | fatostatin | [TP53 protein mutant form results in increased susceptibility to fatostatin] promotes the reaction [fatostatin results in decreased expression of SCD mRNA] | 26512780 |
C545733 | fatostatin | [TP53 protein mutant form results in increased susceptibility to fatostatin] promotes the reaction [fatostatin results in decreased expression of SREBF1 mRNA] | 26512780 |
C545733 | fatostatin | [TP53 protein mutant form results in increased susceptibility to fatostatin] promotes the reaction [fatostatin results in decreased expression of SREBF2 mRNA] | 26512780 |
C545733 | fatostatin | [TP53 protein mutant form results in increased susceptibility to fatostatin] which results in decreased cleavage of SREBF1 protein | 26512780 |
C545733 | fatostatin | [TP53 protein mutant form results in increased susceptibility to fatostatin] which results in decreased cleavage of SREBF2 protein | 26512780 |
C545733 | fatostatin | [TP53 protein mutant form results in increased susceptibility to fatostatin] which results in decreased expression of CCNB1 protein | 26512780 |
C545733 | fatostatin | [TP53 protein mutant form results in increased susceptibility to fatostatin] which results in decreased expression of FASN protein | 26512780 |
C545733 | fatostatin | [TP53 protein mutant form results in increased susceptibility to fatostatin] which results in decreased expression of MKI67 protein | 26512780 |
C545733 | fatostatin | [TP53 protein mutant form results in increased susceptibility to fatostatin] which results in decreased phosphorylation of CDK1 protein | 26512780 |
C545733 | fatostatin | [TP53 protein mutant form results in increased susceptibility to fatostatin] which results in increased cleavage of CASP3 protein | 26512780 |
C545733 | fatostatin | [TP53 protein mutant form results in increased susceptibility to fatostatin] which results in increased cleavage of CASP9 protein | 26512780 |
C545733 | fatostatin | [TP53 protein mutant form results in increased susceptibility to fatostatin] which results in increased cleavage of PARP1 protein | 26512780 |
D015525 | Fatty Acids, Omega-3 | TP53 protein affects the susceptibility to Fatty Acids, Omega-3 | 16043214 |
C052498 | FEC protocol | [FEC protocol co-treated with Celecoxib] results in decreased expression of TP53 protein | 16507397 |
D005273 | Fenbendazole | Fenbendazole results in increased expression of TP53 protein | 23411599 |
D011345 | Fenofibrate | Fenofibrate affects the activity of TP53 protein | 25596134 |
D011345 | Fenofibrate | Fenofibrate results in increased expression of TP53 mRNA | 17264098 |
D017313 | Fenretinide | Fenretinide affects the expression of TP53 | 16720286 |
D017313 | Fenretinide | Fenretinide results in decreased expression of TP53 mRNA | 7811993 |
D017313 | Fenretinide | Fenretinide results in increased expression of TP53 mRNA | 17216584 |
D017313 | Fenretinide | Fenretinide results in increased expression of TP53 protein | 16540676; 16570282; 17159502; |
D005290 | Ferric Compounds | Ferric Compounds results in increased expression of TP53 mRNA | 24035972 |
D005290 | Ferric Compounds | Ferric Compounds results in increased expression of TP53 protein | 24035972 |
C020326 | ferric nitrilotriacetate | [ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in increased expression of TP53 mRNA | 21907755 |
C020326 | ferric nitrilotriacetate | [ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in increased expression of TP53 protein | 21907755 |
C020326 | ferric nitrilotriacetate | geraniol inhibits the reaction [[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in increased expression of TP53 mRNA] | 21907755 |
C020326 | ferric nitrilotriacetate | geraniol inhibits the reaction [[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in increased expression of TP53 protein] | 21907755 |
C000499 | ferric oxide | [ferric oxide analog co-treated with Acrolein] results in increased expression of TP53 protein | 24847785 |
C000499 | ferric oxide | ferric oxide analog results in increased phosphorylation of TP53 protein | 22995439 |
D000077605 | Ferric Oxide, Saccharated | Ferric Oxide, Saccharated results in increased expression of TP53 protein | 16957011 |
C421458 | ferric-sorbitol-citrate | ferric-sorbitol-citrate results in increased expression of TP53 | 17257079 |
D052203 | Ferrosoferric Oxide | [Ferrosoferric Oxide binds to titanium dioxide] which results in increased expression of TP53 protein | 30098274 |
D000068876 | Fingolimod Hydrochloride | Acetylcysteine inhibits the reaction [Fingolimod Hydrochloride results in increased phosphorylation of TP53 protein] | 25939952 |
D000068876 | Fingolimod Hydrochloride | Fingolimod Hydrochloride results in increased phosphorylation of TP53 protein | 25939952 |
D000068876 | Fingolimod Hydrochloride | necrostatin-1 inhibits the reaction [Fingolimod Hydrochloride results in increased phosphorylation of TP53 protein] | 25939952 |
D000068876 | Fingolimod Hydrochloride | pyrazolanthrone inhibits the reaction [Fingolimod Hydrochloride results in increased phosphorylation of TP53 protein] | 25939952 |
D000068876 | Fingolimod Hydrochloride | RIPK3 mutant form inhibits the reaction [Fingolimod Hydrochloride results in increased phosphorylation of TP53 protein] | 25939952 |
C082360 | fipronil | fipronil affects the localization of TP53 protein | 21296133 |
C017875 | fisetin | [Cisplatin co-treated with fisetin] affects the localization of TP53 protein | 21216935 |
C017875 | fisetin | [Cisplatin co-treated with fisetin] results in increased expression of TP53 protein | 21216935 |
C017875 | fisetin | [Cisplatin co-treated with fisetin] results in increased phosphorylation of TP53 protein | 21216935 |
C017875 | fisetin | fisetin affects the localization of TP53 protein | 21216935 |
C017875 | fisetin | fisetin inhibits the reaction [Silicon Dioxide results in increased expression of TP53 mRNA] | 22931364 |
C017875 | fisetin | fisetin results in increased expression of TP53 protein | 21216935 |
C017875 | fisetin | SB 203580 inhibits the reaction [[Cisplatin co-treated with fisetin] results in increased phosphorylation of TP53 protein] | 21216935 |
C017875 | fisetin | fisetin inhibits the reaction [Cisplatin results in increased expression of TP53 protein] | 25184746 |
C061872 | FK 409 | FK 409 results in increased expression of TP53 protein | 9888876 |
D005411 | Flame Retardants | Flame Retardants results in increased expression of TP53 mRNA | 19356805 |
D005411 | Flame Retardants | Flame Retardants results in decreased expression of TP53 mRNA | 26808241 |
D005411 | Flame Retardants | Flame Retardants results in increased expression of TP53 mRNA | 19858236 |
C028610 | flavanone | flavanone results in increased expression of and results in increased phosphorylation of TP53 protein | 22056764 |
D044950 | Flavanones | Flavanones results in increased expression of TP53 protein | 21616090 |
D044950 | Flavanones | TP53 gene mutant form promotes the reaction [Flavanones results in increased cleavage of CASP7 protein] | 21616090 |
D044950 | Flavanones | TP53 gene mutant form promotes the reaction [Flavanones results in increased phosphorylation of H2AX protein] | 21616090 |
D044950 | Flavanones | TP53 protein results in decreased susceptibility to Flavanones | 21616090 |
D005419 | Flavonoids | Flavonoids results in increased activity of TP53 protein | 12082016 |
D005467 | Floxuridine | Floxuridine results in increased expression of TP53 protein | 19015155 |
C075780 | fluazinam | fluazinam results in increased expression of TP53 protein | 21907236 |
D005437 | Flucytosine | Flucytosine results in increased expression of TP53 protein | 15592511 |
C024352 | fludarabine | [fludarabine co-treated with Cytarabine co-treated with Docetaxel] results in increased expression of TP53 protein | 9703875 |
C024352 | fludarabine | fludarabine results in increased expression of and results in increased phosphorylation of TP53 protein | 16439677 |
C024352 | fludarabine | fludarabine results in increased expression of TP53 protein | 18092340 |
C024352 | fludarabine | TP53 protein affects the susceptibility to fludarabine | 17226861 |
C007738 | fluoranthene | fluoranthene promotes the reaction [Benzo(a)pyrene results in increased expression of TP53 protein] | 22120587 |
D005472 | Fluorouracil | anacardic acid inhibits the reaction [[Fluorouracil results in increased acetylation of TP53 protein mutant form] which results in increased expression of UBE2C protein] | 27129209 |
D005472 | Fluorouracil | Cadmium Chloride affects the reaction [Fluorouracil affects the phosphorylation of TP53 protein] | 23941782 |
D005472 | Fluorouracil | Cadmium Chloride affects the reaction [Fluorouracil results in increased expression of TP53 mRNA] | 23941782 |
D005472 | Fluorouracil | Cadmium Chloride affects the reaction [Fluorouracil results in increased phosphorylation of TP53 protein] | 25744307 |
D005472 | Fluorouracil | [CHEK1 protein co-treated with TP53 protein] affects the susceptibility to Fluorouracil | 18698031 |
D005472 | Fluorouracil | Cycloheximide inhibits the reaction [Fluorouracil results in increased expression of TP53 protein] | 15016801 |
D005472 | Fluorouracil | Fluorouracil affects the phosphorylation of TP53 protein | 23941782 |
D005472 | Fluorouracil | Fluorouracil affects the reaction [Cadmium Chloride affects the phosphorylation of TP53 protein] | 23941782 |
D005472 | Fluorouracil | Fluorouracil affects the reaction [Cadmium Chloride results in increased expression of TP53 mRNA] | 23941782 |
D005472 | Fluorouracil | [Fluorouracil co-treated with Genistein] results in increased expression of TP53 mRNA | 15896711 |
D005472 | Fluorouracil | [Fluorouracil co-treated with olaparib] results in increased expression of TP53 protein | 26544897 |
D005472 | Fluorouracil | Fluorouracil promotes the reaction [allose results in increased expression of TP53 protein] | 18930000 |
D005472 | Fluorouracil | Fluorouracil promotes the reaction [andrographolide results in increased expression of TP53] | 19097688 |
D005472 | Fluorouracil | Fluorouracil promotes the reaction [[Doxorubicin co-treated with Paclitaxel] results in increased expression of TP53 protein] | 16168113 |
D005472 | Fluorouracil | Fluorouracil promotes the reaction [TP53 protein binds to CES2 intron] | 16963839 |
D005472 | Fluorouracil | Fluorouracil promotes the reaction [[TP53 protein binds to SP1 protein] which binds to CDKN1A promoter] | 15489892 |
D005472 | Fluorouracil | Fluorouracil promotes the reaction [TP53 protein mutant form binds to UBE2C promoter] | 27129209 |
D005472 | Fluorouracil | Fluorouracil results in decreased degradation of TP53 protein | 15625077 |
D005472 | Fluorouracil | Fluorouracil results in decreased expression of TP53 mRNA | 16709241; 18930000; |
D005472 | Fluorouracil | Fluorouracil results in increased acetylation of TP53 protein mutant form | 27129209 |
D005472 | Fluorouracil | [Fluorouracil results in increased acetylation of TP53 protein mutant form] which results in increased expression of UBE2C protein | 27129209 |
D005472 | Fluorouracil | Fluorouracil results in increased activity of TP53 protein | 18779317; 19010883; |
D005472 | Fluorouracil | Fluorouracil results in increased expression of and results in increased phosphorylation of TP53 protein | 17634554; 17982676; |
D005472 | Fluorouracil | Fluorouracil results in increased expression of TP53 | 11750847; 14646558; |
D005472 | Fluorouracil | Fluorouracil results in increased expression of TP53 mRNA | 12792779; 22445862; 23056627; 23941782; |
D005472 | Fluorouracil | Fluorouracil results in increased expression of TP53 protein | 12082016; 12792779; 14665630; 15016801; 15546879; 15865071; 15896711; 16584549; 16709241; 16963839; 17056233; 17699798; 19015155; 19098008; 26544897; 27129209; 29879413; 9192825; |
D005472 | Fluorouracil | Fluorouracil results in increased phosphorylation of and results in increased activity of TP53 protein | 16963839 |
D005472 | Fluorouracil | Fluorouracil results in increased phosphorylation of TP53 protein | 15489892; 17971768; 19010883; 25744307; |
D005472 | Fluorouracil | Genistein promotes the reaction [Fluorouracil results in increased expression of TP53 protein] | 15896711 |
D005472 | Fluorouracil | IFNA1 protein promotes the reaction [Fluorouracil results in increased phosphorylation of TP53 protein] | 17971768 |
D005472 | Fluorouracil | N(1),N(11)-diethylnorspermine promotes the reaction [Fluorouracil results in increased expression of TP53 protein] | 15546879 |
D005472 | Fluorouracil | [nutlin 3 results in increased stability of TP53 protein] which results in increased susceptibility to Fluorouracil | 21205074 |
D005472 | Fluorouracil | Pravastatin inhibits the reaction [Fluorouracil results in decreased degradation of TP53 protein] | 15625077 |
D005472 | Fluorouracil | [TP53 affects the expression of TYMS] which affects the susceptibility to Fluorouracil | 18600534 |
D005472 | Fluorouracil | TP53 affects the reaction [Resveratrol affects the reaction [Fluorouracil results in increased activity of CASP6 protein]] | 18497562 |
D005472 | Fluorouracil | TP53 gene mutant form affects the reaction [benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[Fluorouracil co-treated with olaparib] results in increased phosphorylation of H2AX protein]] | 26544897 |
D005472 | Fluorouracil | TP53 gene polymorphism affects the susceptibility to Fluorouracil | 18498133 |
D005472 | Fluorouracil | TP53 promoter mutant form results in decreased susceptibility to Fluorouracil | 22445862 |
D005472 | Fluorouracil | TP53 protein affects the reaction [CHEK1 protein affects the susceptibility to Fluorouracil] | 18698031 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil promotes the reaction [E2F4 protein binds to UBE2C promoter]] | 27129209 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of AARS1 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of ACKR3 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of ACTL8 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of ACY1 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of ADAM10 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of ADAM3A mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of ADAMTS9 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of AGR2 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of ALG3 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of ANLN mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of ANP32E mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of AP3S1 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of ARMCX1 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of ASAH1 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of ATP5F1D mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of ATXN10 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of BCAT1 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of BNIP3 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of BOP1 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of CA14 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of CAD mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of CANX mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of CBS mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of CCNB1 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of CCNB2 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of CCND2 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of CD52 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of CD8A mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of CDC20 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of CDKN3 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of CHEK1 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of CHRNA4 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of CLTC mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of COL6A3 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of CPD mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of CP mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of CRYGS mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of CRYL1 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of CSE1L mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of CUTC mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of CYC1 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of DCK mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of DCLK1 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of DCXR mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of DIMT1 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of DLC1 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of DLK1 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of DTYMK mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of EGFR protein] | 17982676 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of EHF mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of EIF4E mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of EIPR1 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of EP400 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of ETF1 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of ETS1 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of FAH mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of FAM107B mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of FKBP5 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of GAMT mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of GCSH mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of GDF1 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of GPX2 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of GSPT1 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of GYG2 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of H2AX mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of H4C2 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of HAND1 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of HBA1 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of HDGFL3 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of HERPUD1 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of HMG1 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of HMMR mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of HNRNPA1 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of HNRNPA2B1 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of HNRNPF mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of HNRNPH1 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of HNRNPL mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of HPX mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of IFI16 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of INPP5E mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of IQGAP2 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of ITPR1 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of KCNQ2 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of KIF15 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of KIF23 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of KLF5 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of KPNA2 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of L1TD1 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of LDHA mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of LRBA mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of LYPLA1 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of MACF1 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of MAP4K5 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of MARS1 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of MCM3 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of MCM6 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of MCM7 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of METAP2 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of MMP1 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of MMS19 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of NASP mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of NBN mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of NCAPG mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of NEK2 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of NIPSNAP2 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of NR1D2 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of NUCKS1 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of ODC1 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of OXCT1 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of PAFAH1B1 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of PAIP1 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of PDCD1LG2 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of PFN2 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of PGLYRP1 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of PHIP mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of PI4KB mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of PLK1 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of PMF1 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of PMS2P4 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of PPA2 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of PPP1CC mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of PREPL mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of PRKAG2 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of PRKCI mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of PRKDC mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of PTTG1 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of PTTG3P mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of PURG mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of QSOX1 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of RANBP1 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of RECQL4 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of RFC4 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of RPL10A mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of SAH mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of SAP30 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of SEC31B mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of SELENOP mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of SERPINA7 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of SERPIND1 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of SEZ6L mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of SF3B3 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of SHMT2 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of SIGLEC9 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of SMS mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of SP3 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of SPAG5 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of SRP9 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of SRSF6 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of TBCD mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of TERT mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of TFF1 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of TFRC mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of TOP2A mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of TRAP1 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of TROAP mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of TSPO mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of TUBA4B mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of TXNIP mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of TXNRD3 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of UBE2C mRNA] | 27129209 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of UBE2S mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of UGT8 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of UQCRB mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of USH2A mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of VANGL2 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of WARS1 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of WDR61 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of WEE1 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of WTAP mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of YARS1 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of ZIM2 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of ZMYND8 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of ZNF266 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in increased expression of ANXA2 mRNA] | 15152939 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in increased expression of ATF3 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in increased expression of BBC3 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in increased expression of BBC3 protein] | 14665630 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in increased expression of BDKRB2 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in increased expression of BTG2 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in increased expression of CDKN1A mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in increased expression of CES2 mRNA] | 16963839 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in increased expression of CNK mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in increased expression of CYFIP2 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in increased expression of DUSP14 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in increased expression of DUSP5 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in increased expression of EPHA2 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in increased expression of FAS mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in increased expression of FAS protein] | 15161716 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in increased expression of FDXR mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in increased expression of FMOD mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in increased expression of GADD45A mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in increased expression of GDF15 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in increased expression of GJC1 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in increased expression of ID2B mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in increased expression of IER5 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in increased expression of INKA2 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in increased expression of NINJ1 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in increased expression of PLK2 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in increased expression of PMAIP1 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in increased expression of PPM1D mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in increased expression of PROCR mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in increased expression of RPS27L mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in increased expression of RRM2B mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in increased expression of S100A2 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in increased expression of SAT1 mRNA] | 15152939 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in increased expression of SERPINB5 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in increased expression of SERTAD1 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in increased expression of SESN1 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in increased expression of SESN2 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in increased expression of SFN mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in increased expression of TGFA mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in increased expression of TIGAR mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in increased expression of TLR3 mRNA] | 18779317 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in increased expression of TNFRSF10D mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in increased expression of TOB1 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in increased expression of TP53I3 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in increased expression of TP53INP1 mRNA] | 15016801 |
D005472 | Fluorouracil | TP53 protein affects the susceptibility to Fluorouracil | 14665630; 15041737; 15534911; 15608686; 17339891; 18600534; 22525470; |
D005472 | Fluorouracil | TP53 protein affects the susceptibility to [Fluorouracil co-treated with Cisplatin] | 15999354 |
D005472 | Fluorouracil | TP53 protein inhibits the reaction [Fluorouracil results in decreased expression of ANLN mRNA] | 17982676 |
D005472 | Fluorouracil | TP53 protein inhibits the reaction [Fluorouracil results in decreased expression of BRCA1 mRNA] | 17982676 |
D005472 | Fluorouracil | TP53 protein inhibits the reaction [Fluorouracil results in decreased expression of CCNA2 protein] | 15546879 |
D005472 | Fluorouracil | TP53 protein inhibits the reaction [Fluorouracil results in decreased expression of CCNB1 mRNA] | 17982676 |
D005472 | Fluorouracil | TP53 protein inhibits the reaction [Fluorouracil results in decreased expression of CCNB1 protein] | 15546879 |
D005472 | Fluorouracil | TP53 protein inhibits the reaction [Fluorouracil results in decreased expression of CCND1 protein] | 17982676 |
D005472 | Fluorouracil | TP53 protein inhibits the reaction [Fluorouracil results in decreased expression of CRYZ mRNA] | 17982676 |
D005472 | Fluorouracil | TP53 protein inhibits the reaction [Fluorouracil results in decreased expression of SCD mRNA] | 17982676 |
D005472 | Fluorouracil | TP53 protein inhibits the reaction [Fluorouracil results in decreased expression of UBE2C mRNA] | 27129209 |
D005472 | Fluorouracil | TP53 protein inhibits the reaction [Fluorouracil results in decreased expression of UBE2C protein] | 27129209 |
D005472 | Fluorouracil | TP53 protein inhibits the reaction [Fluorouracil results in decreased expression of VEGFA mRNA] | 17982676 |
D005472 | Fluorouracil | TP53 protein inhibits the reaction [Fluorouracil results in increased cleavage of and results in increased activity of CASP9 protein] | 15546879 |
D005472 | Fluorouracil | TP53 protein inhibits the reaction [Fluorouracil results in increased expression of CHEK1 protein] | 15016801 |
D005472 | Fluorouracil | TP53 protein inhibits the reaction [Fluorouracil results in increased expression of EEF1A1 mRNA] | 17982676 |
D005472 | Fluorouracil | TP53 protein inhibits the reaction [Fluorouracil results in increased expression of PLK1 protein] | 15016801 |
D005472 | Fluorouracil | TP53 protein inhibits the reaction [Fluorouracil results in increased expression of PTTG1 protein] | 15016801 |
D005472 | Fluorouracil | TP53 protein inhibits the reaction [N(1),N(11)-diethylnorspermine promotes the reaction [Fluorouracil results in decreased expression of CCNA2 protein]] | 15546879 |
D005472 | Fluorouracil | TP53 protein inhibits the reaction [N(1),N(11)-diethylnorspermine promotes the reaction [Fluorouracil results in decreased expression of CCNB1 protein]] | 15546879 |
D005472 | Fluorouracil | TP53 protein inhibits the reaction [N(1),N(11)-diethylnorspermine promotes the reaction [Fluorouracil results in increased cleavage of and results in increased activity of CASP9 protein]] | 15546879 |
D005472 | Fluorouracil | TP53 protein mutant form affects the reaction [Fluorouracil promotes the reaction [NFYA protein binds to UBE2C promoter]] | 27129209 |
D005472 | Fluorouracil | TP53 protein mutant form affects the reaction [Fluorouracil promotes the reaction [NFYB protein binds to UBE2C promoter]] | 27129209 |
D005472 | Fluorouracil | TP53 protein promotes the reaction [Fluorouracil promotes the reaction [N(1),N(11)-diethylnorspermine results in increased expression of CDKN1A protein]] | 15546879 |
D005472 | Fluorouracil | TP53 protein promotes the reaction [Fluorouracil promotes the reaction [N(1),N(11)-diethylnorspermine results in increased expression of MDM2 protein]] | 15546879 |
D005472 | Fluorouracil | TP53 protein promotes the reaction [Fluorouracil results in decreased expression of ECT2 mRNA] | 17982676 |
D005472 | Fluorouracil | TP53 protein promotes the reaction [Fluorouracil results in decreased expression of MYC mRNA] | 16557594 |
D005472 | Fluorouracil | TP53 protein promotes the reaction [Fluorouracil results in increased cleavage of PARP1 protein] | 17982676 |
D005472 | Fluorouracil | TP53 protein promotes the reaction [Fluorouracil results in increased expression of BTG2 mRNA] | 17982676 |
D005472 | Fluorouracil | TP53 protein promotes the reaction [Fluorouracil results in increased expression of CASP8 mRNA] | 17637740 |
D005472 | Fluorouracil | TP53 protein promotes the reaction [Fluorouracil results in increased expression of CASP8 protein] | 17637740 |
D005472 | Fluorouracil | TP53 protein promotes the reaction [Fluorouracil results in increased expression of CCNG1 mRNA] | 17982676 |
D005472 | Fluorouracil | TP53 protein promotes the reaction [Fluorouracil results in increased expression of CDKN1A mRNA] | 16557594 |
D005472 | Fluorouracil | TP53 protein promotes the reaction [Fluorouracil results in increased expression of CDKN1A protein] | 15546879; 17699798; 17982676; |
D005472 | Fluorouracil | TP53 protein promotes the reaction [Fluorouracil results in increased expression of CYFIP2 mRNA] | 17982676 |
D005472 | Fluorouracil | TP53 protein promotes the reaction [Fluorouracil results in increased expression of DDB2 mRNA] | 17982676 |
D005472 | Fluorouracil | TP53 protein promotes the reaction [Fluorouracil results in increased expression of DRAM1 mRNA] | 17982676 |
D005472 | Fluorouracil | TP53 protein promotes the reaction [Fluorouracil results in increased expression of FAS protein] | 15546879; 17982676; |
D005472 | Fluorouracil | TP53 protein promotes the reaction [Fluorouracil results in increased expression of FDXR mRNA] | 17982676; 22966307; |
D005472 | Fluorouracil | TP53 protein promotes the reaction [Fluorouracil results in increased expression of FDXR protein] | 22966307 |
D005472 | Fluorouracil | TP53 protein promotes the reaction [Fluorouracil results in increased expression of GADD45A mRNA] | 17982676 |
D005472 | Fluorouracil | TP53 protein promotes the reaction [Fluorouracil results in increased expression of GPX1 mRNA] | 17982676 |
D005472 | Fluorouracil | TP53 protein promotes the reaction [Fluorouracil results in increased expression of ID1 mRNA] | 16557594 |
D005472 | Fluorouracil | TP53 protein promotes the reaction [Fluorouracil results in increased expression of ID2 mRNA] | 16557594 |
D005472 | Fluorouracil | TP53 protein promotes the reaction [Fluorouracil results in increased expression of IKBIP mRNA] | 17982676 |
D005472 | Fluorouracil | TP53 protein promotes the reaction [Fluorouracil results in increased expression of MDM2 mRNA] | 17982676 |
D005472 | Fluorouracil | TP53 protein promotes the reaction [Fluorouracil results in increased expression of MDM2 protein] | 15546879 |
D005472 | Fluorouracil | TP53 protein promotes the reaction [Fluorouracil results in increased expression of PLK2 mRNA] | 17982676 |
D005472 | Fluorouracil | TP53 protein promotes the reaction [Fluorouracil results in increased expression of PPM1D mRNA] | 17982676 |
D005472 | Fluorouracil | TP53 protein promotes the reaction [Fluorouracil results in increased expression of S100A2 mRNA] | 17982676 |
D005472 | Fluorouracil | TP53 protein promotes the reaction [Fluorouracil results in increased expression of SERPINB5 mRNA] | 17982676 |
D005472 | Fluorouracil | TP53 protein promotes the reaction [Fluorouracil results in increased expression of SESN1 mRNA] | 17982676 |
D005472 | Fluorouracil | TP53 protein promotes the reaction [Fluorouracil results in increased expression of SFN mRNA] | 17982676 |
D005472 | Fluorouracil | TP53 protein promotes the reaction [Fluorouracil results in increased expression of TAP1 mRNA] | 17982676 |
D005472 | Fluorouracil | TP53 protein promotes the reaction [Fluorouracil results in increased expression of TNFRSF10B mRNA] | 17982676 |
D005472 | Fluorouracil | TP53 protein promotes the reaction [Fluorouracil results in increased expression of TNFSF10 mRNA] | 19106633 |
D005472 | Fluorouracil | TP53 protein promotes the reaction [Fluorouracil results in increased expression of TNFSF10 protein] | 19106633 |
D005472 | Fluorouracil | TP53 protein promotes the reaction [Fluorouracil results in increased expression of TP53I3 mRNA] | 17982676 |
D005472 | Fluorouracil | TP53 protein promotes the reaction [Fluorouracil results in increased expression of TP53INP1 mRNA] | 16557594; 17982676; |
D005472 | Fluorouracil | TP53 protein promotes the reaction [Fluorouracil results in increased expression of TRIAP1 mRNA] | 17982676 |
D005472 | Fluorouracil | TP53 protein promotes the reaction [Fluorouracil results in increased expression of ZMAT3 mRNA] | 17982676 |
D005472 | Fluorouracil | TP53 protein promotes the reaction [N(1),N(11)-diethylnorspermine promotes the reaction [Fluorouracil results in increased expression of FAS protein]] | 15546879 |
D005472 | Fluorouracil | TP53 protein results in increased susceptibility to [Cisplatin co-treated with Fluorouracil] | 16077963 |
D005472 | Fluorouracil | TP53 protein results in increased susceptibility to Fluorouracil | 14704126; 16686938; |
D005472 | Fluorouracil | TP53 protein results in increased susceptibility to [Fluorouracil co-treated with Cisplatin] | 15254702 |
D005472 | Fluorouracil | TP53 results in increased susceptibility to Fluorouracil | 14646558 |
D005472 | Fluorouracil | TP53 results in increased susceptibility to [Poly I-C co-treated with Fluorouracil] | 20367642 |
D005472 | Fluorouracil | Fluorouracil promotes the reaction [Acetaminophen results in increased phosphorylation of TP53 protein] | 16330492 |
D005472 | Fluorouracil | Fluorouracil results in increased expression of TP53 protein | 15459018 |
D005472 | Fluorouracil | Tetrachlorodibenzodioxin inhibits the reaction [Fluorouracil results in increased expression of TP53 protein] | 15459018 |
D005472 | Fluorouracil | Fluorouracil results in increased activity of TP53 protein | 19098008 |
D005472 | Fluorouracil | Fluorouracil results in increased expression of TP53 | 20633010 |
D005473 | Fluoxetine | Fluoxetine results in increased expression of TP53 mRNA | 18836303 |
D005480 | Flurbiprofen | Flurbiprofen results in increased abundance of and results in increased phosphorylation of TP53 protein | 15710360 |
D005480 | Flurbiprofen | Flurbiprofen results in increased expression of TP53 protein | 11687965 |
D005480 | Flurbiprofen | TP53 protein mutant form results in decreased susceptibility to Flurbiprofen | 15710360 |
D005480 | Flurbiprofen | TP53 protein results in increased susceptibility to Flurbiprofen | 15710360 |
D005485 | Flutamide | Flutamide results in decreased expression of TP53 mRNA | 21126777 |
D005485 | Flutamide | Flutamide results in decreased expression of TP53 mRNA | 24793618 |
D005485 | Flutamide | Flutamide results in increased expression of TP53 mRNA | 24136188 |
C475882 | flutolanil | flutolanil affects the expression of TP53 mRNA | 30942079 |
D005492 | Folic Acid | Folic Acid affects the expression of TP53 mRNA | 16361273; 16611376; |
D005492 | Folic Acid | Folic Acid affects the expression of TP53 protein | 16361273 |
D005492 | Folic Acid | Folic Acid inhibits the reaction [Methotrexate results in increased expression of TP53 mRNA] | 22183962 |
D005492 | Folic Acid | Folic Acid affects the methylation of TP53 protein | 17056795 |
D005492 | Folic Acid | [Folic Acid co-treated with Isoflavones] results in decreased expression of TP53 protein | 20060418 |
D005492 | Folic Acid | Folic Acid inhibits the reaction [1,2-Dimethylhydrazine results in decreased methylation of TP53 exon] | 8863662 |
D005557 | Formaldehyde | Formaldehyde results in increased expression of TP53 mRNA | 22525295 |
D005557 | Formaldehyde | Formaldehyde results in increased expression of TP53 protein | 15715472; 22525295; |
C030544 | formic acid | formic acid inhibits the reaction [sodium bichromate results in increased expression of TP53 protein] | 10942736 |
C007768 | formononetin | formononetin results in decreased expression of TP53 protein | 28414026 |
C007768 | formononetin | XI-006 inhibits the reaction [formononetin results in decreased expression of TP53 protein] | 28414026 |
C007768 | formononetin | formononetin inhibits the reaction [Cisplatin results in increased expression of TP53 protein] | 28414026 |
C040313 | fostriecin | fostriecin promotes the reaction [Tetrachlorodibenzodioxin promotes the reaction [Benzo(a)pyrene results in increased expression of TP53 protein]] | 24954032 |
C054368 | fotemustine | fotemustine promotes the reaction [TP53 protein binds to POLH promoter] | 25125662 |
C054368 | fotemustine | fotemustine results in increased expression of TP53 protein | 25125662 |
C054368 | fotemustine | fotemustine results in increased expression of TP53 protein modified form | 25125662 |
C096856 | FTI 277 | FTI 277 inhibits the reaction [lopinavir-ritonavir drug combination results in increased expression of TP53 protein] | 20884875 |
C096856 | FTI 277 | FTI 277 inhibits the reaction [Ritonavir results in increased expression of TP53 protein] | 20884875 |
C069837 | fullerene C60 | fullerene C60 analog results in increased phosphorylation of and results in increased expression of TP53 protein | 20045429 |
C069837 | fullerene C60 | fullerene C60 results in decreased expression of TP53 mRNA | 19167457 |
D000077267 | Fulvestrant | Fulvestrant inhibits the reaction [bisphenol A results in increased phosphorylation of TP53 protein] | 29383186 |
D000077267 | Fulvestrant | Fulvestrant inhibits the reaction [Estradiol affects the localization of TP53 protein] | 15870704 |
D000077267 | Fulvestrant | Fulvestrant results in decreased expression of TP53 protein | 24169358 |
C056933 | fumonisin B1 | [fumonisin B1 results in decreased chemical synthesis of Ceramides] which affects the splicing of and results in decreased expression of TP53 mRNA | 25195822 |
C056933 | fumonisin B1 | [fumonisin B1 results in decreased chemical synthesis of Ceramides] which results in decreased phosphorylation of TP53 protein modified form | 25195822 |
C056933 | fumonisin B1 | fumonisin B1 results in decreased expression of TP53 mRNA | 27757495 |
C056933 | fumonisin B1 | Acetylcysteine inhibits the reaction [Aflatoxin B1 promotes the reaction [fumonisin B1 results in increased expression of TP53 protein]] | 28181396 |
C056933 | fumonisin B1 | Acetylcysteine inhibits the reaction [fumonisin B1 promotes the reaction [Aflatoxin B1 results in increased expression of TP53 protein]] | 28181396 |
C056933 | fumonisin B1 | Aflatoxin B1 promotes the reaction [fumonisin B1 results in increased expression of TP53 protein] | 28181396 |
C056933 | fumonisin B1 | fumonisin B1 promotes the reaction [Aflatoxin B1 results in increased expression of TP53 protein] | 28181396 |
C056933 | fumonisin B1 | fumonisin B1 results in increased expression of TP53 protein | 28181396 |
C056933 | fumonisin B1 | Acetylcysteine inhibits the reaction [fumonisin B1 promotes the reaction [Zearalenone results in increased expression of TP53 mRNA]] | 29109043 |
C056933 | fumonisin B1 | Acetylcysteine inhibits the reaction [Zearalenone promotes the reaction [fumonisin B1 results in increased expression of TP53 mRNA]] | 29109043 |
C056933 | fumonisin B1 | [deoxynivalenol co-treated with fumonisin B1] results in increased expression of TP53 mRNA | 29109043 |
C056933 | fumonisin B1 | fumonisin B1 inhibits the reaction [deoxynivalenol inhibits the reaction [Zearalenone results in increased expression of TP53 mRNA]] | 29109043 |
C056933 | fumonisin B1 | fumonisin B1 promotes the reaction [Zearalenone results in increased expression of TP53 mRNA] | 29109043 |
C056933 | fumonisin B1 | fumonisin B1 results in increased expression of TP53 mRNA | 29109043 |
C056933 | fumonisin B1 | Zearalenone promotes the reaction [[deoxynivalenol co-treated with fumonisin B1] results in increased expression of TP53 mRNA] | 29109043 |
C056933 | fumonisin B1 | Zearalenone promotes the reaction [fumonisin B1 results in increased expression of TP53 mRNA] | 29109043 |
D062610 | Fungal Polysaccharides | Fungal Polysaccharides results in increased expression of TP53 mRNA | 27181935 |
C039281 | furan | furan results in increased expression of TP53 protein | 20124500 |
C039281 | furan | furan results in increased methylation of TP53 gene | 22079235 |
D005690 | Galactose | Galactose results in increased expression of TP53 protein | 23036742; 29426000; |
D005690 | Galactose | Phycocyanin inhibits the reaction [Galactose results in increased expression of TP53 protein] | 23036742 |
D005690 | Galactose | [Glucose deficiency co-treated with Galactose co-treated with Pyruvic Acid] inhibits the reaction [Doxorubicin results in increased expression of TP53 protein] | 25997894 |
D005707 | Gallic Acid | Gallic Acid results in decreased expression of TP53 mRNA | 21887735 |
D015774 | Ganciclovir | Ganciclovir results in increased expression of TP53 protein | 15592511 |
D000077156 | Gefitinib | Gefitinib inhibits the reaction [bisphenol A results in increased phosphorylation of TP53 protein] | 29383186 |
D000077156 | Gefitinib | TP53 protein affects the susceptibility to Gefitinib | 21216229 |
D000077156 | Gefitinib | [TP53 protein results in decreased expression of AURKA protein] which results in increased susceptibility to Gefitinib | 21216229 |
D000077156 | Gefitinib | Gefitinib results in increased expression of TP53 mRNA | 27084042 |
D000077156 | Gefitinib | Gefitinib results in increased expression of TP53 protein | 27084042 |
C001277 | geldanamycin | geldanamycin affects the expression of TP53 protein | 24211270 |
C001277 | geldanamycin | geldanamycin affects the localization of TP53 protein | 17293044 |
C001277 | geldanamycin | Tretinoin inhibits the reaction [geldanamycin affects the localization of TP53 protein] | 17293044 |
C056507 | gemcitabine | gemcitabine results in increased expression of TP53 protein | 12082016; 16601104; 17671697; |
C056507 | gemcitabine | Nicotine inhibits the reaction [gemcitabine results in increased expression of TP53 protein] | 16601104 |
C056507 | gemcitabine | [TFAP2A protein co-treated with TP53 gene mutant form] results in decreased susceptibility to gemcitabine | 21489314 |
D019833 | Genistein | Genistein results in increased expression of TP53 mRNA | 29458080 |
D019833 | Genistein | anacardic acid inhibits the reaction [Genistein promotes the reaction [trichostatin A results in increased acetylation of TP53 protein]] | 26768552 |
D019833 | Genistein | ATM protein affects the reaction [Genistein results in increased expression of and results in increased phosphorylation of TP53 protein] | 15177039 |
D019833 | Genistein | EP300 promotes the reaction [Genistein promotes the reaction [trichostatin A results in increased expression of TP53 mRNA]] | 26768552 |
D019833 | Genistein | EP300 promotes the reaction [Genistein promotes the reaction [trichostatin A results in increased expression of TP53 protein]] | 26768552 |
D019833 | Genistein | [Fluorouracil co-treated with Genistein] results in increased expression of TP53 mRNA | 15896711 |
D019833 | Genistein | [Genistein co-treated with trichostatin A] results in increased expression of TP53 protein | 22626855 |
D019833 | Genistein | Genistein promotes the reaction [Fluorouracil results in increased expression of TP53 protein] | 15896711 |
D019833 | Genistein | Genistein promotes the reaction [trichostatin A results in increased expression of and results in increased acetylation of TP53 protein] | 26768552 |
D019833 | Genistein | Genistein promotes the reaction [trichostatin A results in increased expression of TP53 mRNA] | 26768552 |
D019833 | Genistein | Genistein results in increased expression of and results in increased phosphorylation of TP53 protein | 15177039 |
D019833 | Genistein | Genistein results in increased expression of TP53 protein | 19800779 |
D019833 | Genistein | TP53 protein results in increased susceptibility to Genistein | 26768552 |
D019833 | Genistein | Genistein results in increased activity of TP53 protein | 15177039 |
D005839 | Gentamicins | Gentamicins results in increased expression of TP53 mRNA | 29992668 |
D005839 | Gentamicins | Gentamicins results in increased expression of TP53 mRNA | 22061828 |
C007836 | geraniol | geraniol results in increased expression of TP53 mRNA | 27683099 |
C007836 | geraniol | geraniol inhibits the reaction [[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in increased expression of TP53 mRNA] | 21907755 |
C007836 | geraniol | geraniol inhibits the reaction [[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in increased expression of TP53 protein] | 21907755 |
C040155 | geranylgeranic acid | geranylgeranic acid affects the localization of TP53 protein mutant form | 24658405 |
C040155 | geranylgeranic acid | Ivermectin inhibits the reaction [geranylgeranic acid affects the localization of TP53 protein mutant form] | 24658405 |
C040155 | geranylgeranic acid | TP53 protein results in decreased susceptibility to geranylgeranic acid | 24658405 |
C007845 | gingerol | gingerol results in increased expression of TP53 protein | 18030663; 25034532; |
C007845 | gingerol | [gingerol results in increased expression of TP53 protein] which results in increased susceptibility to TNFSF10 protein | 25034532 |
C007845 | gingerol | [Testosterone co-treated with gingerol] results in increased expression of TP53 protein | 18030663 |
C007845 | gingerol | TP53 protein affects the reaction [gingerol results in increased expression of TNFRSF10B protein] | 25034532 |
C007845 | gingerol | TP53 protein affects the reaction [gingerol results in increased susceptibility to TNFSF10 protein] | 25034532 |
C063170 | Ginkgo biloba extract | Ginkgo biloba extract inhibits the reaction [Doxorubicin results in increased expression of TP53 mRNA] | 18632596 |
C472077 | ginsenoside Rk1 | ginsenoside Rk1 results in increased expression of TP53 protein | 30797898 |
D005897 | Glafenine | Glafenine results in increased expression of TP53 mRNA | 24136188 |
D005947 | Glucose | Glucose affects the localization of TP53 protein | 24218232 |
D005947 | Glucose | Glucose inhibits the reaction [bis((2-oxindol-3-ylimino)-2-(2-aminoethyl)pyridine-N,N')copper(II) results in increased expression of TP53 protein] | 21548882 |
D005947 | Glucose | Glucose results in increased acetylation of TP53 protein | 20068143 |
D005947 | Glucose | Glucose results in increased expression of TP53 mRNA | 27049278 |
D005947 | Glucose | Glucose results in increased expression of TP53 protein | 26188290 |
D005947 | Glucose | [Palmitic Acid co-treated with Glucose] results in increased acetylation of TP53 protein | 24451382 |
D005947 | Glucose | [Resveratrol co-treated with AICA ribonucleotide] inhibits the reaction [Glucose results in increased expression of TP53 protein] | 26188290 |
D005947 | Glucose | Resveratrol inhibits the reaction [Glucose affects the localization of TP53 protein] | 24218232 |
D005947 | Glucose | Resveratrol inhibits the reaction [Glucose results in increased acetylation of TP53 protein] | 20068143 |
D005947 | Glucose | Resveratrol inhibits the reaction [Glucose results in increased expression of TP53 mRNA] | 27049278 |
D005947 | Glucose | Resveratrol inhibits the reaction [Glucose results in increased expression of TP53 protein] | 26188290 |
D005947 | Glucose | SIRT1 protein inhibits the reaction [[Palmitic Acid co-treated with Glucose] results in increased acetylation of TP53 protein] | 24451382 |
D005947 | Glucose | SIRT1 protein promotes the reaction [Resveratrol inhibits the reaction [Glucose results in increased acetylation of TP53 protein]] | 20068143 |
D005947 | Glucose | [Tretinoin results in increased uptake of Glucose] inhibits the reaction [bis((2-oxindol-3-ylimino)-2-(2-aminoethyl)pyridine-N,N')copper(II) results in increased expression of TP53 protein] | 21548882 |
D005947 | Glucose | [Glucose deficiency co-treated with Galactose co-treated with Pyruvic Acid] inhibits the reaction [Doxorubicin results in increased expression of TP53 protein] | 25997894 |
D005947 | Glucose | [Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of TP53 protein | 23451161 |
D005947 | Glucose | TP53 protein affects the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of NDRG2] | 23451161 |
D005947 | Glucose | TP53 protein affects the susceptibility to [Oxygen deficiency co-treated with Glucose deficiency] | 23451161 |
D005978 | Glutathione | [Buthionine Sulfoximine results in decreased abundance of Glutathione] inhibits the reaction [Benzo(a)pyrene results in increased activity of TP53 protein] | 12807757 |
D005978 | Glutathione | Dithiothreitol inhibits the reaction [Glutathione results in increased glutathionylation of TP53 protein] | 17555331 |
D005978 | Glutathione | Glutathione inhibits the reaction [[CD40LG protein co-treated with IL4 protein] results in increased expression of TP53 protein] | 27634759 |
D005978 | Glutathione | Glutathione inhibits the reaction [diallyl disulfide results in increased expression of TP53 protein] | 19202565 |
D005978 | Glutathione | Glutathione inhibits the reaction [Doxorubicin results in increased expression of TP53 protein] | 22927544 |
D005978 | Glutathione | Glutathione results in increased expression of TP53 protein | 10897038 |
D005978 | Glutathione | Glutathione results in increased glutathionylation of TP53 protein | 17555331 |
D005978 | Glutathione | TP53 protein results in decreased abundance of Glutathione | 12967322 |
D019803 | Glutathione Disulfide | Dithiothreitol inhibits the reaction [Glutathione Disulfide results in increased glutathionylation of TP53 protein] | 17555331 |
D019803 | Glutathione Disulfide | Glutathione Disulfide results in increased expression of and results in increased phosphorylation of and results in increased activity of TP53 protein | 15993333 |
D019803 | Glutathione Disulfide | Glutathione Disulfide results in increased glutathionylation of TP53 protein | 17555331 |
D005905 | Glyburide | Glyburide inhibits the reaction [Streptozocin results in increased expression of TP53 mRNA] | 30817903 |
D005990 | Glycerol | Glycerol results in increased activity of TP53 protein mutant form | 15975526 |
C071834 | glycidamide | glycidamide results in increased mutagenesis of TP53 gene | 15240786 |
C086566 | glycitein | glycitein results in increased expression of TP53 protein | 19800779 |
C024033 | glycoursodeoxycholic acid | glycoursodeoxycholic acid inhibits the reaction [TP53 protein results in increased expression of BAX mRNA] | 17881359 |
C010974 | glyphosate | glyphosate results in increased expression of TP53 mRNA | 25636363 |
D006046 | Gold | Gold analog results in increased expression of TP53 mRNA | 23549158 |
D006046 | Gold | Gold results in increased expression of TP53 mRNA | 22094122 |
C103280 | goniothalamin | goniothalamin results in increased activity of TP53 protein | 21810437 |
C103280 | goniothalamin | goniothalamin results in increased expression of TP53 protein | 20498002 |
C103280 | goniothalamin | goniothalamin results in increased localization of TP53 protein | 21810437 |
C103280 | goniothalamin | goniothalamin results in increased phosphorylation of and results in increased expression of TP53 protein | 21810437 |
C103280 | goniothalamin | pifithrin inhibits the reaction [goniothalamin results in increased phosphorylation of and results in increased expression of TP53 protein] | 21810437 |
C103280 | goniothalamin | TP53 mutant form inhibits the reaction [goniothalamin results in increased cleavage of PARP1 protein] | 21810437 |
C103280 | goniothalamin | TP53 mutant form inhibits the reaction [goniothalamin results in increased expression of PMAIP1 mRNA] | 21810437 |
C103280 | goniothalamin | TP53 mutant form inhibits the reaction [goniothalamin results in increased expression of PMAIP1 protein] | 21810437 |
D017273 | Goserelin | Goserelin results in decreased expression of TP53 protein | 16973256 |
C511402 | Grape Seed Proanthocyanidins | Grape Seed Proanthocyanidins affects the expression of TP53 | 12587719 |
C511402 | Grape Seed Proanthocyanidins | Grape Seed Proanthocyanidins inhibits the reaction [Lead results in increased expression of TP53 protein] | 29630945 |
C412815 | GW 4064 | GW 4064 results in decreased expression of TP53 mRNA | 28496032 |
C412815 | GW 4064 | GW 4064 results in decreased expression of TP53 protein | 28496032 |
C000617853 | GW 506033X | GW 506033X inhibits the reaction [satratoxin G results in increased expression of TP53 mRNA] | 18535002 |
C120727 | gyrophoric acid | gyrophoric acid results in decreased expression of TP53 protein | 22285236 |
D055768 | Halogenated Diphenyl Ethers | Halogenated Diphenyl Ethers results in decreased expression of TP53 mRNA | 26808241 |
D006220 | Haloperidol | Haloperidol results in increased expression of TP53 mRNA | 16462815 |
D006220 | Haloperidol | Haloperidol results in increased expression of TP53 protein | 16462815 |
C007904 | harmalol | harmalol results in increased expression of TP53 mRNA | 27590872 |
C007904 | harmalol | harmalol results in increased expression of TP53 protein | 27590872 |
D015386 | Hazardous Substances | Hazardous Substances results in increased mutagenesis of TP53 exon | 21550362 |
C042349 | heminordihydroguaiaretic acid | heminordihydroguaiaretic acid results in increased stability of and results in increased expression of TP53 protein | 17393435 |
D006493 | Heparin | Heparin analog results in decreased expression of TP53 protein | 20201787 |
D006533 | Heptachlor | Heptachlor results in decreased expression of TP53 protein | 9544696 |
C013015 | hesperetin | hesperetin inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of and results in increased activity of TP53 protein] | 15795422 |
D006575 | Heterocyclic Compounds, 3-Ring | Heterocyclic Compounds, 3-Ring results in increased expression of TP53 protein | 21500194 |
C517828 | hexabrominated diphenyl ether 153 | hexabrominated diphenyl ether 153 results in increased expression of TP53 mRNA | 29621559; 31029751; |
C517828 | hexabrominated diphenyl ether 153 | hexabrominated diphenyl ether 153 results in increased expression of TP53 protein | 29621559; 31029751; |
C089796 | hexabromocyclododecane | hexabromocyclododecane results in increased expression of TP53 mRNA | 19356805 |
C089796 | hexabromocyclododecane | hexabromocyclododecane results in decreased expression of TP53 protein | 24960055 |
C089796 | hexabromocyclododecane | hexabromocyclododecane results in increased expression of TP53 protein | 24960055 |
C089796 | hexabromocyclododecane | hexabromocyclododecane results in increased expression of TP53 mRNA | 24780359 |
C089796 | hexabromocyclododecane | hexabromocyclododecane results in increased expression of TP53 protein | 24780359 |
C089796 | hexabromocyclododecane | hexabromocyclododecane results in increased expression of TP53 mRNA | 27718427 |
D001556 | Hexachlorocyclohexane | [Hexachlorocyclohexane co-treated with Estradiol] results in increased expression of TP53 protein | 18174961 |
C070164 | homocastasterone | homocastasterone results in increased expression of TP53 protein | 20833159 |
D006710 | Homocysteine | Homocysteine results in increased expression of TP53 protein | 31082465 |
D006710 | Homocysteine | Homocysteine results in increased phosphorylation of TP53 protein | 13679428 |
C012351 | HT-2 toxin | Bentonite inhibits the reaction [[HT-2 toxin co-treated with T-2 Toxin] results in increased expression of TP53 mRNA] | 25296281 |
C012351 | HT-2 toxin | [HT-2 toxin co-treated with T-2 Toxin] results in increased expression of TP53 mRNA | 25296281 |
D006812 | Humic Substances | Humic Substances results in increased expression of TP53 protein | 18683188 |
D006812 | Humic Substances | Humic Substances results in increased phosphorylation of TP53 protein | 18683188 |
C050426 | huperzine A | huperzine A affects the expression of TP53 | 15956816 |
D006830 | Hydralazine | [Hydralazine co-treated with Valproic Acid] results in increased expression of TP53 mRNA | 17183730 |
D006830 | Hydralazine | Hydralazine results in increased activity of TP53 protein | 12082016 |
D006835 | Hydrazones | Hydrazones results in increased expression of and results in increased phosphorylation of TP53 protein | 22056764 |
D006861 | Hydrogen Peroxide | [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one co-treated with Hydrogen Peroxide] results in increased expression of TP53 mRNA | 30265530 |
D006861 | Hydrogen Peroxide | 2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one inhibits the reaction [Hydrogen Peroxide promotes the reaction [Resveratrol results in increased phosphorylation of TP53 protein]] | 24933654 |
D006861 | Hydrogen Peroxide | 2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one inhibits the reaction [Resveratrol promotes the reaction [Hydrogen Peroxide results in increased phosphorylation of TP53 protein]] | 24933654 |
D006861 | Hydrogen Peroxide | Acetylcysteine inhibits the reaction [Hydrogen Peroxide results in increased expression of TP53 mRNA] | 9535218 |
D006861 | Hydrogen Peroxide | Acetylcysteine inhibits the reaction [Hydrogen Peroxide results in increased expression of TP53 protein] | 9535218 |
D006861 | Hydrogen Peroxide | Cadmium Chloride inhibits the reaction [Hydrogen Peroxide results in increased expression of and results in increased activity of TP53 protein] | 10531375 |
D006861 | Hydrogen Peroxide | Cadmium inhibits the reaction [Hydrogen Peroxide results in increased expression of and results in increased activity of TP53 protein] | 10531375 |
D006861 | Hydrogen Peroxide | epigallocatechin gallate inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of and results in increased activity of TP53 protein] | 15795422 |
D006861 | Hydrogen Peroxide | ESRRA protein inhibits the reaction [Hydrogen Peroxide results in increased expression of TP53 protein] | 24967384 |
D006861 | Hydrogen Peroxide | EUK-134 inhibits the reaction [Hydrogen Peroxide results in increased expression of TP53 protein] | 25005833 |
D006861 | Hydrogen Peroxide | hesperetin inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of and results in increased activity of TP53 protein] | 15795422 |
D006861 | Hydrogen Peroxide | HIF1A protein affects the reaction [Hydrogen Peroxide results in increased expression of TP53 protein] | 25108166 |
D006861 | Hydrogen Peroxide | Hydrogen Peroxide inhibits the reaction [N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of TP53 protein] | 25005833 |
D006861 | Hydrogen Peroxide | Hydrogen Peroxide inhibits the reaction [SIRT1 protein results in decreased acetylation of TP53 protein] | 24451382 |
D006861 | Hydrogen Peroxide | Hydrogen Peroxide promotes the reaction [MAPT results in increased expression of TP53 protein] | 28526263 |
D006861 | Hydrogen Peroxide | Hydrogen Peroxide promotes the reaction [Resveratrol results in increased phosphorylation of TP53 protein] | 24933654 |
D006861 | Hydrogen Peroxide | Hydrogen Peroxide promotes the reaction [TP53 protein binds to HMOX1 promoter] | 21552291 |
D006861 | Hydrogen Peroxide | Hydrogen Peroxide promotes the reaction [TP53 protein binds to MDM2 promoter] | 21552291 |
D006861 | Hydrogen Peroxide | Hydrogen Peroxide promotes the reaction [TP53 protein results in increased expression of BAX] | 21552291 |
D006861 | Hydrogen Peroxide | Hydrogen Peroxide promotes the reaction [TP53 protein results in increased expression of HMOX1 mRNA] | 21552291 |
D006861 | Hydrogen Peroxide | Hydrogen Peroxide promotes the reaction [TP53 protein results in increased expression of HMOX1 protein] | 21552291 |
D006861 | Hydrogen Peroxide | Hydrogen Peroxide promotes the reaction [TP53 protein results in increased expression of MDM2] | 21552291 |
D006861 | Hydrogen Peroxide | Hydrogen Peroxide results in decreased expression of TP53 mRNA | 12419474 |
D006861 | Hydrogen Peroxide | Hydrogen Peroxide results in increased acetylation of TP53 protein | 18681908; 30139380; |
D006861 | Hydrogen Peroxide | Hydrogen Peroxide results in increased activity of TP53 protein | 15242773 |
D006861 | Hydrogen Peroxide | Hydrogen Peroxide results in increased expression of and results in increased activity of TP53 protein | 10531375 |
D006861 | Hydrogen Peroxide | Hydrogen Peroxide results in increased expression of and results in increased phosphorylation of TP53 protein | 29110037 |
D006861 | Hydrogen Peroxide | Hydrogen Peroxide results in increased expression of TP53 | 21552291 |
D006861 | Hydrogen Peroxide | Hydrogen Peroxide results in increased expression of TP53 mRNA | 27049278; 29486183; 30265530; 9535218; |
D006861 | Hydrogen Peroxide | Hydrogen Peroxide results in increased expression of TP53 protein | 11964141; 15081873; 21454520; 23639522; 23859249; 24967384; 25005833; 25108166; 29486183; 9535218; 9989825; |
D006861 | Hydrogen Peroxide | [Hydrogen Peroxide results in increased expression of TP53 protein] which results in increased expression of BAX protein | 15081873 |
D006861 | Hydrogen Peroxide | [Hydrogen Peroxide results in increased expression of TP53 protein] which results in increased expression of CDKN1A protein | 15081873 |
D006861 | Hydrogen Peroxide | [Hydrogen Peroxide results in increased expression of TP53 protein] which results in increased expression of MSH2 protein | 15081873 |
D006861 | Hydrogen Peroxide | Hydrogen Peroxide results in increased glutathionylation of TP53 protein | 17555331 |
D006861 | Hydrogen Peroxide | Hydrogen Peroxide results in increased phosphorylation of and results in increased activity of TP53 protein | 15795422 |
D006861 | Hydrogen Peroxide | Hydrogen Peroxide results in increased phosphorylation of TP53 | 21552291 |
D006861 | Hydrogen Peroxide | Hydrogen Peroxide results in increased phosphorylation of TP53 protein | 24933654 |
D006861 | Hydrogen Peroxide | myricitrin inhibits the reaction [Hydrogen Peroxide results in increased expression of TP53 protein] | 23639522 |
D006861 | Hydrogen Peroxide | naringenin inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of and results in increased activity of TP53 protein] | 15795422 |
D006861 | Hydrogen Peroxide | [Niacinamide results in decreased activity of SIRT1 protein] promotes the reaction [Hydrogen Peroxide results in increased acetylation of TP53 protein] | 18681908 |
D006861 | Hydrogen Peroxide | N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [Hydrogen Peroxide results in increased acetylation of TP53 protein] | 30139380 |
D006861 | Hydrogen Peroxide | Pergolide inhibits the reaction [Hydrogen Peroxide results in increased expression of TP53 protein] | 15081873 |
D006861 | Hydrogen Peroxide | Pergolide inhibits the reaction [[Hydrogen Peroxide results in increased expression of TP53 protein] which results in increased expression of BAX protein] | 15081873 |
D006861 | Hydrogen Peroxide | Pergolide inhibits the reaction [[Hydrogen Peroxide results in increased expression of TP53 protein] which results in increased expression of CDKN1A protein] | 15081873 |
D006861 | Hydrogen Peroxide | Pergolide inhibits the reaction [[Hydrogen Peroxide results in increased expression of TP53 protein] which results in increased expression of MSH2 protein] | 15081873 |
D006861 | Hydrogen Peroxide | perifosine inhibits the reaction [Hydrogen Peroxide results in increased expression of TP53 mRNA] | 30265530 |
D006861 | Hydrogen Peroxide | Quercetin inhibits the reaction [Hydrogen Peroxide results in increased expression of TP53 protein] | 25108166 |
D006861 | Hydrogen Peroxide | Quercetin inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of and results in increased activity of TP53 protein] | 15795422 |
D006861 | Hydrogen Peroxide | Resveratrol inhibits the reaction [Hydrogen Peroxide results in increased expression of TP53 mRNA] | 27049278 |
D006861 | Hydrogen Peroxide | Resveratrol inhibits the reaction [Hydrogen Peroxide results in increased expression of TP53 protein] | 23859249 |
D006861 | Hydrogen Peroxide | Resveratrol promotes the reaction [Hydrogen Peroxide results in increased phosphorylation of TP53 protein] | 24933654 |
D006861 | Hydrogen Peroxide | [Resveratrol results in increased activity of SIRT1 protein] inhibits the reaction [Hydrogen Peroxide results in increased acetylation of TP53 protein] | 18681908 |
D006861 | Hydrogen Peroxide | SIRT1 protein inhibits the reaction [Hydrogen Peroxide results in increased acetylation of TP53 protein] | 18681908 |
D006861 | Hydrogen Peroxide | SIRT1 protein promotes the reaction [N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [Hydrogen Peroxide results in increased acetylation of TP53 protein]] | 30139380 |
D006861 | Hydrogen Peroxide | [sirtinol results in decreased activity of SIRT1 protein] promotes the reaction [Hydrogen Peroxide results in increased acetylation of TP53 protein] | 18681908 |
D006861 | Hydrogen Peroxide | SN50 peptide inhibits the reaction [Hydrogen Peroxide results in increased expression of TP53 protein] | 15081873 |
D006861 | Hydrogen Peroxide | SN50 peptide inhibits the reaction [[Hydrogen Peroxide results in increased expression of TP53 protein] which results in increased expression of BAX protein] | 15081873 |
D006861 | Hydrogen Peroxide | SN50 peptide inhibits the reaction [[Hydrogen Peroxide results in increased expression of TP53 protein] which results in increased expression of CDKN1A protein] | 15081873 |
D006861 | Hydrogen Peroxide | SN50 peptide inhibits the reaction [[Hydrogen Peroxide results in increased expression of TP53 protein] which results in increased expression of MSH2 protein] | 15081873 |
D006861 | Hydrogen Peroxide | TP53 affects the reaction [Hydrogen Peroxide results in increased expression of CDKN1A mRNA] | 24067374 |
D006861 | Hydrogen Peroxide | TP53 affects the reaction [Hydrogen Peroxide results in increased expression of TPT1 mRNA] | 24067374 |
D006861 | Hydrogen Peroxide | TP53 protein affects the reaction [Hydrogen Peroxide results in increased expression of CDKN1A mRNA] | 8943236 |
D006861 | Hydrogen Peroxide | TP53 protein results in decreased susceptibility to Hydrogen Peroxide | 21552291; 24067374; |
D006861 | Hydrogen Peroxide | TP53 protein results in increased susceptibility to Hydrogen Peroxide | 17301063 |
D006861 | Hydrogen Peroxide | Hydrogen Peroxide results in increased acetylation of TP53 protein | 31276434 |
D006861 | Hydrogen Peroxide | N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [Hydrogen Peroxide results in increased acetylation of TP53 protein] | 31276434 |
D006861 | Hydrogen Peroxide | SIRT1 protein promotes the reaction [N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [Hydrogen Peroxide results in increased acetylation of TP53 protein]] | 31276434 |
D006861 | Hydrogen Peroxide | 2-(4-((dimethylamino)methyl)benzylidene)-5,6-dimethoxy-2,3-dihydroinden-1-one inhibits the reaction [Hydrogen Peroxide results in increased expression of TP53 protein] | 19345205 |
D006861 | Hydrogen Peroxide | Donepezil inhibits the reaction [Hydrogen Peroxide results in increased expression of TP53 protein] | 19345205 |
D006861 | Hydrogen Peroxide | Hydrogen Peroxide results in increased expression of and affects the localization of TP53 protein | 14689451 |
D006861 | Hydrogen Peroxide | Hydrogen Peroxide results in increased expression of TP53 mRNA | 12414117; 14689451; |
D006861 | Hydrogen Peroxide | Hydrogen Peroxide results in increased expression of TP53 protein | 12414117; 12642403; 16647178; 19345205; 20041988; 27525270; |
D006861 | Hydrogen Peroxide | Luteolin inhibits the reaction [Hydrogen Peroxide results in increased expression of TP53 protein] | 27525270 |
D006861 | Hydrogen Peroxide | Melatonin inhibits the reaction [Hydrogen Peroxide results in increased expression of TP53 protein] | 20041988 |
D006861 | Hydrogen Peroxide | Quercetin inhibits the reaction [Hydrogen Peroxide results in increased expression of TP53 protein] | 16647178; 27525270; |
D006861 | Hydrogen Peroxide | Tacrine inhibits the reaction [Hydrogen Peroxide results in increased expression of TP53 mRNA] | 12414117 |
D006861 | Hydrogen Peroxide | Tacrine inhibits the reaction [Hydrogen Peroxide results in increased expression of TP53 protein] | 12414117 |
D006861 | Hydrogen Peroxide | Tacrolimus inhibits the reaction [Hydrogen Peroxide results in increased expression of TP53 protein] | 12642403 |
D006861 | Hydrogen Peroxide | V 10367 inhibits the reaction [Hydrogen Peroxide results in increased expression of TP53 protein] | 12642403 |
D006861 | Hydrogen Peroxide | Hydrogen Peroxide results in increased phosphorylation of and results in increased activity of TP53 protein | 18608517 |
C031927 | hydroquinone | hydroquinone results in decreased expression of TP53 mRNA | 26047893 |
C031927 | hydroquinone | hydroquinone results in increased expression of TP53 protein | 17875398 |
C031927 | hydroquinone | [PARP1 protein affects the susceptibility to hydroquinone] which affects the expression of TP53 protein | 28444915 |
C031927 | hydroquinone | WRN protein affects the reaction [hydroquinone results in increased acetylation of TP53 protein] | 17875398 |
C031927 | hydroquinone | WRN protein affects the reaction [hydroquinone results in increased expression of TP53 protein] | 17875398 |
D006877 | Hydroxamic Acids | Hydroxamic Acids analog results in increased acetylation of TP53 protein | 19084294 |
D006881 | Hydroxyacetylaminofluorene | Hydroxyacetylaminofluorene results in increased expression of TP53 protein | 9163691 |
D006882 | Hydroxyapatites | Hydroxyapatites results in increased expression of TP53 protein | 22162110 |
D006918 | Hydroxyurea | Hydroxyurea results in increased expression of TP53 protein | 10978678; 16005713; 21840268; |
D006918 | Hydroxyurea | Hydroxyurea results in increased expression of TP53 protein modified form | 25125662 |
C559745 | hyperforin dicyclohexylammonium | hyperforin dicyclohexylammonium results in increased expression of TP53 protein | 21376709 |
C000623387 | HZ-6d compound | HZ-6d compound results in increased expression of TP53 protein | 28919514 |
D007052 | Ibuprofen | Ibuprofen affects the activity of TP53 protein | 25596134 |
C411652 | IC 261 | IC 261 affects the expression of TP53 protein | 16027726 |
D007069 | Ifosfamide | Ifosfamide affects the activity of TP53 protein | 25596134 |
C540383 | INCB018424 | [INCB018424 co-treated with Arsenic Trioxide] results in increased expression of TP53 mRNA | 30012499 |
C540383 | INCB018424 | [INCB018424 co-treated with Arsenic Trioxide] results in increased expression of TP53 protein | 30012499 |
D007213 | Indomethacin | Indomethacin results in increased expression of TP53 protein | 10403534; 11260862; |
C094023 | iodopravadoline | iodopravadoline inhibits the reaction [caryophyllene inhibits the reaction [Doxorubicin results in increased expression of TP53 protein]] | 30836069 |
D007472 | Iohexol | Iohexol results in increased expression of TP53 mRNA | 29705293 |
D015759 | Ionomycin | [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TP53 mRNA | 25613284 |
D007479 | Iopamidol | Iopamidol results in increased expression of TP53 mRNA | 29705293 |
C033148 | iprodione | [iprodione co-treated with acetamiprid] results in decreased expression of TP53 mRNA | 29091792 |
C033148 | iprodione | [iprodione co-treated with pyrachlostrobin] results in decreased expression of TP53 mRNA | 29091792 |
C033148 | iprodione | [iprodione co-treated with pyrimethanil co-treated with acetamiprid] results in increased expression of TP53 mRNA | 29091792 |
C033148 | iprodione | [iprodione co-treated with pyrimethanil co-treated with pyrachlostrobin co-treated with acetamiprid] results in increased expression of TP53 mRNA | 29091792 |
C033148 | iprodione | [iprodione co-treated with pyrimethanil co-treated with pyrachlostrobin] results in increased expression of TP53 mRNA | 29091792 |
C033148 | iprodione | [iprodione co-treated with pyrimethanil] results in decreased expression of TP53 mRNA | 29091792 |
C033148 | iprodione | iprodione results in decreased expression of TP53 mRNA | 29091792 |
D000077146 | Irinotecan | [Irinotecan co-treated with Bortezomib] results in increased ubiquitination of TP53 protein | 16373703 |
D000077146 | Irinotecan | Irinotecan results in increased expression of TP53 mRNA | 22898888 |
D000077146 | Irinotecan | Irinotecan results in increased expression of TP53 protein | 16963839; 22510560; |
D000077146 | Irinotecan | Irinotecan results in increased phosphorylation of and results in increased activity of TP53 protein | 16963839 |
D000077146 | Irinotecan | Irinotecan results in increased phosphorylation of and results in increased expression of TP53 protein | 22898888 |
D000077146 | Irinotecan | Irinotecan results in increased phosphorylation of TP53 protein | 22510560 |
D000077146 | Irinotecan | TP53 protein affects the susceptibility to Irinotecan | 16963839 |
D000077146 | Irinotecan | TP53 protein affects the susceptibility to [Irinotecan co-treated with Bortezomib] | 16373703 |
D000077146 | Irinotecan | TP53 protein inhibits the reaction [Irinotecan results in increased phosphorylation of STAT1 protein] | 16204068 |
D000077146 | Irinotecan | TP53 results in increased susceptibility to Irinotecan | 22898888 |
D007501 | Iron | Iron results in increased expression of TP53 protein | 16957011 |
D058085 | Iron Compounds | Iron Compounds results in increased expression of TP53 protein | 28483490 |
D058085 | Iron Compounds | Iron Compounds results in increased expression of TP53 protein modified form | 28483490 |
D007510 | Isatin | [Copper binds to Isatin binds to 2-(2-aminoethyl)pyridine] which results in increased expression of TP53 protein | 17327230 |
D007510 | Isatin | [Copper binds to Isatin binds to trimethylenediamine] which results in increased expression of TP53 protein | 17327230 |
D007510 | Isatin | Tretinoin inhibits the reaction [[Copper binds to Isatin binds to trimethylenediamine] which results in increased expression of TP53 protein] | 17327230 |
D017953 | Isocyanates | Isocyanates results in increased expression of TP53 protein | 19283680 |
D007529 | Isoflavones | [Folic Acid co-treated with Isoflavones] results in decreased expression of TP53 protein | 20060418 |
D007530 | Isoflurane | Isoflurane results in decreased expression of TP53 mRNA | 16978161 |
C550177 | isoliquiritigenin 2'-methyl ether | isoliquiritigenin 2'-methyl ether results in increased expression of TP53 protein | 20040371 |
D007545 | Isoproterenol | Isoproterenol results in decreased expression of TP53 mRNA | 24286936 |
D007545 | Isoproterenol | Isoproterenol results in increased expression of TP53 mRNA | 24286936 |
D007545 | Isoproterenol | Isoproterenol results in increased expression of TP53 protein | 19466570 |
C016527 | isoquercitrin | isoquercitrin inhibits the reaction [Streptozocin results in increased expression of TP53 mRNA] | 30817903 |
D007559 | Ivermectin | Ivermectin inhibits the reaction [geranylgeranic acid affects the localization of TP53 protein mutant form] | 24658405 |
C561695 | (+)-JQ1 compound | (+)-JQ1 compound promotes the reaction [tetraarsenic tetrasulfide results in increased expression of TP53 protein] | 26586936 |
C561695 | (+)-JQ1 compound | (+)-JQ1 compound results in decreased acetylation of TP53 protein | 26212199 |
C561695 | (+)-JQ1 compound | (+)-JQ1 compound results in increased expression of TP53 protein | 26586936 |
C561695 | (+)-JQ1 compound | tetraarsenic tetrasulfide promotes the reaction [(+)-JQ1 compound results in increased expression of TP53 protein] | 26586936 |
C561695 | (+)-JQ1 compound | TP53 gene mutant form results in decreased susceptibility to (+)-JQ1 compound | 24231268 |
C005134 | juglone | [juglone co-treated with Ascorbic Acid] results in increased phosphorylation of TP53 protein | 29992683 |
C006552 | kaempferol | Caffeine inhibits the reaction [kaempferol results in increased phosphorylation of TP53 protein] | 19028473 |
C006552 | kaempferol | kaempferol results in increased expression of TP53 protein | 19028473 |
C006552 | kaempferol | kaempferol results in increased phosphorylation of TP53 protein | 19028473 |
C006552 | kaempferol | TP53 protein affects the reaction [kaempferol promotes the reaction [BBC3 protein binds to BCL2L1 protein]] | 19028473 |
C006552 | kaempferol | TP53 protein affects the susceptibility to kaempferol | 19028473 |
C006552 | kaempferol | kaempferol inhibits the reaction [Doxorubicin promotes the reaction [TP53 protein binds to BAX promoter]] | 22155320 |
C006552 | kaempferol | kaempferol inhibits the reaction [Doxorubicin results in increased expression of TP53 mRNA] | 22155320 |
C524169 | kaempferol 7-O-glucoside | kaempferol 7-O-glucoside affects the expression of TP53 protein | 18343026 |
D007608 | Kainic Acid | Kainic Acid results in increased expression of TP53 protein | 20955365 |
D007649 | Ketamine | Ketamine results in increased expression of TP53 mRNA | 28716577 |
D007649 | Ketamine | Ketamine results in increased expression of TP53 protein | 19919587 |
C011890 | kojic acid | [Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of TP53 mRNA | 18544905 |
C045492 | kolaviron | kolaviron inhibits the reaction [Atrazine results in decreased expression of TP53 mRNA] | 21333729 |
C045492 | kolaviron | kolaviron inhibits the reaction [Atrazine results in decreased expression of TP53 protein] | 21333729 |
C045492 | kolaviron | kolaviron inhibits the reaction [Atrazine affects the expression of TP53] | 21726175 |
C469328 | kresoxim-methyl | kresoxim-methyl results in increased activity of TP53 protein | 30818834 |
C067713 | lactacystin | lactacystin inhibits the reaction [Acetaminophen results in increased degradation of TP53 protein] | 16330492 |
C067713 | lactacystin | lactacystin results in increased phosphorylation of and results in increased expression of TP53 protein | 18463101 |
C067713 | lactacystin | lactacystin results in increased ubiquitination of TP53 protein | 18463101 |
C060347 | lanreotide | lanreotide inhibits the reaction [Diethylnitrosamine results in increased expression of TP53 mRNA] | 19874807 |
D064747 | Lansoprazole | Lansoprazole inhibits the reaction [Diatrizoate Meglumine results in increased expression of TP53 mRNA] | 28412091 |
D007854 | Lead | [Lead co-treated with APP protein modified form] results in increased expression of TP53 protein | 22610977 |
D007854 | Lead | [lead nitrate results in increased abundance of Lead] which results in increased expression of TP53 mRNA | 30738203 |
D007854 | Lead | Lead results in decreased expression of TP53 mRNA | 19921347 |
D007854 | Lead | Lead results in increased expression of TP53 protein | 22610977 |
D007854 | Lead | titanium dioxide inhibits the reaction [[lead nitrate results in increased abundance of Lead] which results in increased expression of TP53 mRNA] | 30738203 |
D007854 | Lead | Grape Seed Proanthocyanidins inhibits the reaction [Lead results in increased expression of TP53 protein] | 29630945 |
D007854 | Lead | Lead results in increased expression of TP53 protein | 29630945 |
C017461 | lead nitrate | [lead nitrate results in increased abundance of Lead] which results in increased expression of TP53 mRNA | 30738203 |
C017461 | lead nitrate | titanium dioxide inhibits the reaction [[lead nitrate results in increased abundance of Lead] which results in increased expression of TP53 mRNA] | 30738203 |
C038753 | leptomycin B | 3,4,5,3',4'-pentachlorobiphenyl inhibits the reaction [leptomycin B results in increased expression of TP53 protein] | 19751709 |
C038753 | leptomycin B | leptomycin B affects the localization of and results in decreased degradation of TP53 protein | 24792400 |
C038753 | leptomycin B | [leptomycin B co-treated with TP53 gene mutant form] results in decreased expression of BRCA1 mRNA | 20803015 |
C038753 | leptomycin B | [leptomycin B co-treated with TP53 gene mutant form] results in decreased expression of CHEK2 mRNA | 20803015 |
C038753 | leptomycin B | [leptomycin B co-treated with TP53 gene mutant form] results in decreased expression of DNMT1 mRNA | 20803015 |
C038753 | leptomycin B | [leptomycin B co-treated with TP53 gene mutant form] results in decreased expression of HK2 mRNA | 20803015 |
C038753 | leptomycin B | [leptomycin B co-treated with TP53 gene mutant form] results in decreased expression of MDM4 mRNA | 20803015 |
C038753 | leptomycin B | [leptomycin B co-treated with TP53 gene mutant form] results in decreased expression of PRKCA mRNA | 20803015 |
C038753 | leptomycin B | [leptomycin B co-treated with TP53 gene mutant form] results in decreased expression of TP63 mRNA | 20803015 |
C038753 | leptomycin B | [leptomycin B co-treated with TP53 gene mutant form] results in increased expression of APAF1 mRNA | 20803015 |
C038753 | leptomycin B | [leptomycin B co-treated with TP53 gene mutant form] results in increased expression of BIRC5 mRNA | 20803015 |
C038753 | leptomycin B | [leptomycin B co-treated with TP53 gene mutant form] results in increased expression of IL6 mRNA | 20803015 |
C038753 | leptomycin B | [leptomycin B co-treated with TP53 gene mutant form] results in increased expression of NFKB1 mRNA | 20803015 |
C038753 | leptomycin B | [leptomycin B co-treated with TP53 gene mutant form] results in increased expression of TNFRSF10D mRNA | 20803015 |
C038753 | leptomycin B | leptomycin B inhibits the reaction [sodium arsenite affects the localization of TP53 protein] | 19010883 |
C038753 | leptomycin B | leptomycin B inhibits the reaction [sodium arsenite results in increased degradation of TP53 protein mutant form] | 21454520 |
C038753 | leptomycin B | leptomycin B inhibits the reaction [TP53 protein results in increased susceptibility to trichostatin A] | 16467109 |
C038753 | leptomycin B | leptomycin B results in decreased degradation of TP53 protein | 15625077 |
C038753 | leptomycin B | leptomycin B results in increased expression of TP53 protein | 16467109; 19751709; |
C038753 | leptomycin B | PCB 180 promotes the reaction [leptomycin B results in increased expression of TP53 protein] | 19751709 |
C038753 | leptomycin B | Pravastatin inhibits the reaction [leptomycin B results in decreased degradation of TP53 protein] | 15625077 |
C038753 | leptomycin B | [sodium arsenite co-treated with leptomycin B] results in increased phosphorylation of TP53 protein | 19010883 |
C038753 | leptomycin B | TP53 gene mutant form inhibits the reaction [leptomycin B results in decreased expression of BIRC5 protein] | 20803015 |
C038753 | leptomycin B | TP53 gene mutant form inhibits the reaction [leptomycin B results in increased expression of CDKN1A protein] | 20803015 |
C038753 | leptomycin B | TP53 gene mutant form results in increased susceptibility to leptomycin B | 20803015 |
C038753 | leptomycin B | alpha-naphthoflavone inhibits the reaction [Tetrachlorodibenzodioxin inhibits the reaction [leptomycin B results in increased expression of TP53 protein]] | 15459018 |
C038753 | leptomycin B | leptomycin B affects the expression of TP53 protein | 11751435 |
C038753 | leptomycin B | leptomycin B results in increased expression of TP53 protein | 15459018 |
C038753 | leptomycin B | Tetrachlorodibenzodioxin inhibits the reaction [leptomycin B results in increased expression of TP53 protein] | 15459018 |
D007978 | Levamisole | Levamisole results in decreased expression of TP53 mRNA | 11139434 |
D007978 | Levamisole | Levamisole results in decreased expression of TP53 protein | 11139434 |
D000077222 | Limonene | Limonene results in increased expression of TP53 protein | 12921557 |
C018584 | linalool | linalool results in increased expression of TP53 mRNA | 26703569 |
C018584 | linalool | linalool results in increased expression of TP53 protein | 19922762 |
C018584 | linalool | TP53 results in increased susceptibility to linalool | 19922762 |
D044243 | Linoleic Acids, Conjugated | Linoleic Acids, Conjugated results in increased expression of TP53 protein | 15961301 |
C440499 | lipopolysaccharide, Escherichia coli O111 B4 | atipamezole inhibits the reaction [Dexmedetomidine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of TP53 protein]] | 30597158 |
C440499 | lipopolysaccharide, Escherichia coli O111 B4 | Dexmedetomidine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of TP53 protein] | 30597158 |
C440499 | lipopolysaccharide, Escherichia coli O111 B4 | lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of TP53 protein | 30597158 |
C440499 | lipopolysaccharide, Escherichia coli O111 B4 | SB 216763 inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of TP53 protein] | 30597158 |
D008070 | Lipopolysaccharides | Lipopolysaccharides results in increased expression of TP53 mRNA | 9409811 |
D008070 | Lipopolysaccharides | Lipopolysaccharides results in increased localization of TP53 protein | 12665479 |
D008070 | Lipopolysaccharides | pifithrin inhibits the reaction [Lipopolysaccharides results in increased localization of TP53 protein] | 12665479 |
C506643 | liposomal doxorubicin | liposomal doxorubicin results in increased phosphorylation of TP53 protein | 27923599 |
D008094 | Lithium | Lithium results in increased expression of TP53 protein | 11337498 |
D008094 | Lithium | Lithium inhibits the reaction [GSK3B protein binds to TP53 protein] | 15475000 |
D008094 | Lithium | Lithium inhibits the reaction [sodium arsenite results in increased expression of and affects the localization of TP53 protein] | 17849503 |
D008094 | Lithium | TP53 affects the reaction [Lithium results in increased expression of CDKN1A protein] | 11337498 |
D018021 | Lithium Chloride | TP53 protein promotes the reaction [Lithium Chloride results in increased expression of MMP1 mRNA] | 19407340 |
D018021 | Lithium Chloride | Lithium Chloride results in increased expression of TP53 protein | 17210701 |
C558899 | lopinavir-ritonavir drug combination | FTI 277 inhibits the reaction [lopinavir-ritonavir drug combination results in increased expression of TP53 protein] | 20884875 |
C558899 | lopinavir-ritonavir drug combination | lopinavir-ritonavir drug combination results in increased expression of TP53 protein | 20884875 |
C558899 | lopinavir-ritonavir drug combination | manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [lopinavir-ritonavir drug combination results in increased expression of TP53 protein] | 20884875 |
C558899 | lopinavir-ritonavir drug combination | Pravastatin inhibits the reaction [lopinavir-ritonavir drug combination results in increased expression of TP53 protein] | 20884875 |
D019808 | Losartan | Losartan affects the expression of TP53 protein | 22000973 |
D008148 | Lovastatin | Lovastatin inhibits the reaction [Doxorubicin results in increased expression of TP53 protein] | 17088865 |
D008148 | Lovastatin | Lovastatin results in increased expression of and results in increased phosphorylation of TP53 protein | 21199873 |
D008148 | Lovastatin | Lovastatin results in increased expression of TP53 mRNA | 21199873 |
D008148 | Lovastatin | Lovastatin inhibits the reaction [Cisplatin results in increased expression of TP53 protein modified form] | 26739623 |
C010480 | lupeol | lupeol inhibits the reaction [mancozeb results in increased expression of TP53 mRNA] | 27235710 |
D047311 | Luteolin | Luteolin inhibits the reaction [Hydrogen Peroxide results in increased expression of TP53 protein] | 27525270 |
D000077276 | Lycopene | Lycopene results in decreased expression of TP53 mRNA | 16886892 |
D008244 | Lysophosphatidylcholines | [TP53 protein mutant form results in increased susceptibility to Niclosamide] which results in increased abundance of Lysophosphatidylcholines | 30258081 |
C008301 | lysophosphatidylethanolamine | [TP53 protein mutant form results in increased susceptibility to Niclosamide] which results in increased abundance of lysophosphatidylethanolamine | 30258081 |
D015636 | Magnesium Chloride | Magnesium Chloride affects the expression of TP53 mRNA | 10506531 |
D008277 | Magnesium Oxide | Magnesium Oxide analog inhibits the reaction [Diazinon results in increased expression of TP53 mRNA] | 27920530 |
D008277 | Magnesium Oxide | [Selenium analog co-treated with Magnesium Oxide analog] inhibits the reaction [Diazinon results in increased expression of TP53 mRNA] | 27920530 |
D058185 | Magnetite Nanoparticles | [Arsenic Trioxide co-treated with Doxorubicin co-treated with Magnetite Nanoparticles analog] affects the expression of TP53 mRNA | 24738333 |
D058185 | Magnetite Nanoparticles | [Arsenic Trioxide co-treated with Doxorubicin co-treated with Magnetite Nanoparticles analog] affects the expression of TP53 protein | 24738333 |
D058185 | Magnetite Nanoparticles | [Daunorubicin co-treated with Magnetite Nanoparticles] results in increased activity of TP53 protein | 21518493 |
C005095 | malachite green | malachite green results in increased expression of TP53 protein | 10840942 |
D008294 | Malathion | Atropine inhibits the reaction [Malathion results in increased expression of TP53 protein] | 12762645 |
D008294 | Malathion | Malathion results in increased expression of TP53 mRNA | 18204794 |
D008294 | Malathion | Malathion results in increased expression of TP53 protein | 12762645; 19787260; |
D008294 | Malathion | Malathion results in increased expression of TP53 mRNA | 21628957 |
D008294 | Malathion | [Vitamin E co-treated with Selenium] inhibits the reaction [Malathion results in increased expression of TP53 mRNA] | 21628957 |
C043592 | maleimide | maleimide analog binds to and results in increased activity of TP53 protein mutant form | 15998635 |
D008315 | Malondialdehyde | Malondialdehyde results in increased mutagenesis of TP53 gene | 30658077 |
C013099 | mancozeb | lupeol inhibits the reaction [mancozeb results in increased expression of TP53 mRNA] | 27235710 |
C013099 | mancozeb | mancozeb results in increased expression of TP53 mRNA | 27235710 |
D008345 | Manganese | Manganese results in increased expression of TP53 protein | 18284614; 20188756; |
D008345 | Manganese | Ethanol promotes the reaction [[manganese chloride results in increased abundance of Manganese] which results in increased expression of TP53 protein] | 30844427 |
D008345 | Manganese | KHSRP protein affects the reaction [Manganese results in increased expression of TP53 protein] | 25027559 |
D008345 | Manganese | [manganese chloride results in increased abundance of Manganese] which results in increased expression of TP53 protein | 30844427 |
D008345 | Manganese | [Manganese co-treated with NGF protein] results in increased expression of and affects the localization of TP53 protein | 25448048 |
D008345 | Manganese | [Manganese co-treated with NGF protein] results in increased phosphorylation of and results in increased expression of TP53 protein | 25791630 |
D008345 | Manganese | Manganese results in increased expression of TP53 mRNA | 23997110 |
D008345 | Manganese | Manganese results in increased expression of TP53 protein | 24845367; 25027559; 25448048; |
D008345 | Manganese | Manganese results in increased phosphorylation of and results in increased expression of TP53 protein | 25791630 |
D008345 | Manganese | PPM1D mutant form promotes the reaction [[Manganese co-treated with NGF protein] results in increased phosphorylation of TP53 protein] | 25791630 |
D008345 | Manganese | PPM1D protein inhibits the reaction [[Manganese co-treated with NGF protein] results in increased phosphorylation of TP53 protein] | 25791630 |
D008345 | Manganese | TP53 protein results in increased susceptibility to Manganese | 25791630 |
C025340 | manganese chloride | Ethanol promotes the reaction [[manganese chloride results in increased abundance of Manganese] which results in increased expression of TP53 protein] | 30844427 |
C025340 | manganese chloride | [manganese chloride results in increased abundance of Manganese] which results in increased expression of TP53 protein | 30844427 |
C025340 | manganese chloride | manganese chloride results in increased expression of TP53 mRNA | 17623882 |
C097284 | manganese(III)-tetrakis(4-benzoic acid)porphyrin | manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [lopinavir-ritonavir drug combination results in increased expression of TP53 protein] | 20884875 |
C097284 | manganese(III)-tetrakis(4-benzoic acid)porphyrin | manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [Ritonavir results in increased expression of TP53 protein] | 20884875 |
C097284 | manganese(III)-tetrakis(4-benzoic acid)porphyrin | manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [IL1B protein results in increased expression of TP53 protein] | 12384474 |
C097284 | manganese(III)-tetrakis(4-benzoic acid)porphyrin | manganese(III)-tetrakis(4-benzoic acid)porphyrin results in increased expression of TP53 protein | 12384474 |
C520506 | manganese tetrakis-(N-ethyl-2 pyridyl) porphyrin | manganese tetrakis-(N-ethyl-2 pyridyl) porphyrin results in decreased activity of TP53 | 20454814 |
C013592 | mangiferin | mangiferin inhibits the reaction [Oxygen deficiency results in increased expression of TP53 protein] | 10657591 |
C021053 | mangostin | mangostin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of TP53 mRNA] | 26357513 |
C021053 | mangostin | mangostin results in increased expression of TP53 protein | 24480042 |
C021053 | mangostin | mangostin inhibits the reaction [Cisplatin results in increased expression of TP53] | 20603111 |
D008353 | Mannitol | Mannitol inhibits the reaction [[cupric chloride co-treated with di(2-picolyl)amine-3(bromoacetyl)coumarin] results in increased expression of TP53 protein] | 29803612 |
D009637 | Masoprocol | Masoprocol results in increased expression of TP53 protein | 15034932 |
D009637 | Masoprocol | MYC affects the reaction [Masoprocol results in increased expression of TP53 protein] | 15034932 |
C034244 | matrine | BCL9 protein inhibits the reaction [matrine results in increased expression of TP53 protein] | 31112718 |
C034244 | matrine | matrine results in increased expression of TP53 mRNA | 11489473 |
C034244 | matrine | matrine results in increased expression of TP53 protein | 31112718 |
D008466 | Mechlorethamine | Mechlorethamine results in increased expression of TP53 protein | 16738803 |
D017258 | Medroxyprogesterone Acetate | [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine co-treated with Decitabine] results in increased expression of TP53 protein | 22534328 |
D017258 | Medroxyprogesterone Acetate | [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased expression of TP53 protein | 22534328 |
D017258 | Medroxyprogesterone Acetate | [Estrogens, Conjugated (USP) co-treated with Medroxyprogesterone Acetate] results in decreased expression of TP53 protein | 16021059 |
D000077485 | Meglumine Antimoniate | Meglumine Antimoniate results in increased expression of TP53 mRNA | 30599190 |
D008550 | Melatonin | Melatonin inhibits the reaction [Cisplatin results in increased phosphorylation of and results in increased expression of TP53 protein] | 24799992 |
D008550 | Melatonin | Melatonin results in increased expression of TP53 protein | 12071473; 19012662; |
D008550 | Melatonin | Melatonin inhibits the reaction [bisphenol A results in increased expression of TP53 protein] | 25454643 |
D008550 | Melatonin | Melatonin inhibits the reaction [Hydrogen Peroxide results in increased expression of TP53 protein] | 20041988 |
D008550 | Melatonin | Melatonin inhibits the reaction [Puromycin Aminonucleoside results in increased expression of TP53 protein] | 14993511 |
D008610 | Menthol | Menthol results in increased expression of TP53 mRNA | 26760959 |
D008687 | Metformin | Metformin affects the activity of TP53 protein | 25596134 |
D008701 | Methapyrilene | Methapyrilene results in increased expression of TP53 mRNA | 26558467 |
C054938 | methoctramine | methoctramine analog results in increased expression of TP53 protein | 19576191 |
D008727 | Methotrexate | [Methotrexate results in decreased susceptibility to Methotrexate] inhibits the reaction [Mitomycin results in increased expression of TP53 protein mutant form] | 16598767 |
D008727 | Methotrexate | [Methotrexate results in decreased susceptibility to Methotrexate] which affects the localization of and results in decreased activity of TP53 protein mutant form | 16598767 |
D008727 | Methotrexate | Acetylcysteine inhibits the reaction [Methotrexate results in increased expression of TP53 mRNA] | 22183962 |
D008727 | Methotrexate | Acetylcysteine inhibits the reaction [Methotrexate results in increased expression of TP53 protein] | 24967384 |
D008727 | Methotrexate | BRCA1 mutant form promotes the reaction [TP53 mutant form results in increased susceptibility to Methotrexate] | 21875941 |
D008727 | Methotrexate | ESRRA protein inhibits the reaction [Methotrexate results in increased expression of TP53 protein] | 24967384 |
D008727 | Methotrexate | Folic Acid inhibits the reaction [Methotrexate results in increased expression of TP53 mRNA] | 22183962 |
D008727 | Methotrexate | MAPK9 gene mutant form inhibits the reaction [Methotrexate results in increased expression of TP53 protein] | 22183962 |
D008727 | Methotrexate | Methotrexate inhibits the reaction [TP53 protein results in increased expression of CDKN1A protein] | 19548002 |
D008727 | Methotrexate | Methotrexate results in decreased expression of TP53 mRNA | 17400583; 24449571; |
D008727 | Methotrexate | Methotrexate results in increased expression of TP53 mRNA | 21678067; 22183962; |
D008727 | Methotrexate | Methotrexate results in increased expression of TP53 protein | 21624110; 22183962; 24967384; |
D008727 | Methotrexate | Methotrexate results in increased phosphorylation of and results in increased acetylation of and results in increased stability of TP53 protein | 21114963 |
D008727 | Methotrexate | nutlin 3 promotes the reaction [Methotrexate results in increased expression of TP53 protein] | 21624110 |
D008727 | Methotrexate | sapropterin inhibits the reaction [Methotrexate results in increased expression of TP53 protein] | 22183962 |
D008727 | Methotrexate | TP53 affects the reaction [Methotrexate results in increased activity of and results in increased expression of CDKN1A protein] | 21624110 |
D008727 | Methotrexate | TP53 affects the reaction [Methotrexate results in increased activity of and results in increased expression of MDM2 protein] | 21624110 |
D008727 | Methotrexate | TP53 affects the reaction [nutlin 3 promotes the reaction [Methotrexate results in increased activity of and results in increased expression of CDKN1A protein]] | 21624110 |
D008727 | Methotrexate | TP53 affects the reaction [nutlin 3 promotes the reaction [Methotrexate results in increased activity of and results in increased expression of MDM2 protein]] | 21624110 |
D008727 | Methotrexate | TP53 mutant form results in increased susceptibility to Methotrexate | 21875941 |
D008727 | Methotrexate | TP53 protein inhibits the reaction [Methotrexate results in increased expression of CCNB1 protein] | 19548002 |
D008727 | Methotrexate | TP53 protein promotes the reaction [Methotrexate results in increased expression of CASP8 mRNA] | 17637740 |
D008727 | Methotrexate | TP53 protein promotes the reaction [Methotrexate results in increased expression of CASP8 protein] | 17637740; 22010212; |
D008727 | Methotrexate | TP53 protein promotes the reaction [Methotrexate results in increased expression of CDKN1A protein] | 21114963 |
D008727 | Methotrexate | TP53 protein promotes the reaction [Methotrexate results in increased susceptibility to Antineoplastic Agents] | 22010212 |
D008727 | Methotrexate | TP53 protein promotes the reaction [Methotrexate results in increased susceptibility to Cyclophosphamide metabolite] | 22010212 |
D008727 | Methotrexate | TP53 protein results in increased susceptibility to Methotrexate | 19548002 |
D008727 | Methotrexate | Methotrexate results in increased expression of TP53 protein | 19900424 |
D008727 | Methotrexate | Thioctic Acid inhibits the reaction [Methotrexate results in increased expression of TP53 protein] | 19900424 |
D008730 | Methoxsalen | Methoxsalen inhibits the reaction [aflatoxin G1 results in increased expression of TP53 protein modified form] | 23907605 |
D008730 | Methoxsalen | Methoxsalen results in increased expression of TP53 protein | 22796345 |
C013598 | methoxyacetic acid | 6,7-epoxy-5,17-dihydroxy-1-oxowitha-2,24-dienolide inhibits the reaction [methoxyacetic acid results in increased expression of TP53 protein] | 21573189 |
C013598 | methoxyacetic acid | methoxyacetic acid results in increased expression of TP53 protein | 21573189 |
C587228 | methyl 3-hydroxyimino-11-oxoolean-12-en-28-oate | methyl 3-hydroxyimino-11-oxoolean-12-en-28-oate affects the localization of TP53 protein | 24291674 |
C042405 | methyl caffeate | methyl caffeate analog results in increased expression of TP53 protein | 25481497 |
C005219 | methyl cellosolve | methyl cellosolve results in increased expression of TP53 mRNA | 19643169 |
D008748 | Methylcholanthrene | Methylcholanthrene results in increased expression of TP53 mRNA | 23273579 |
C005223 | methyleugenol | methyleugenol results in decreased expression of TP53 mRNA | 26011634 |
C005223 | methyleugenol | methyleugenol results in increased expression of TP53 protein | 23411599 |
C000614724 | methyleugenol-2',3'-epoxide | methyleugenol-2',3'-epoxide results in increased phosphorylation of TP53 protein | 28818686 |
C008461 | methyl isocyanate | methyl isocyanate affects the expression of TP53 protein | 19513903 |
C004925 | methylmercuric chloride | methylmercuric chloride results in increased expression of TP53 mRNA | 23458150 |
D008767 | Methylmercury Compounds | Methylmercury Compounds results in increased expression of TP53 protein | 20153410 |
D008741 | Methyl Methanesulfonate | Cadmium Chloride inhibits the reaction [Methyl Methanesulfonate results in increased expression of and results in increased activity of TP53 protein] | 10531375 |
D008741 | Methyl Methanesulfonate | Cadmium inhibits the reaction [Methyl Methanesulfonate results in increased expression of and results in increased activity of TP53 protein] | 10531375 |
D008741 | Methyl Methanesulfonate | Methyl Methanesulfonate results in increased activity of TP53 protein | 20655369 |
D008741 | Methyl Methanesulfonate | Methyl Methanesulfonate results in increased expression of and results in increased activity of TP53 protein | 10531375 |
D008741 | Methyl Methanesulfonate | Methyl Methanesulfonate results in increased phosphorylation of and results in increased activity of TP53 protein | 25078064 |
D008741 | Methyl Methanesulfonate | TP53 gene mutant form results in increased susceptibility to Methyl Methanesulfonate | 25595616 |
D008741 | Methyl Methanesulfonate | TP53 protein affects the reaction [Methyl Methanesulfonate results in increased expression of CDKN1A mRNA] | 17079232 |
D008769 | Methylnitronitrosoguanidine | Methylnitronitrosoguanidine results in increased expression of TP53 mRNA | 12634122 |
D008769 | Methylnitronitrosoguanidine | TP53 protein mutant form results in decreased susceptibility to Methylnitronitrosoguanidine | 15589979 |
D008769 | Methylnitronitrosoguanidine | TP53 protein results in increased susceptibility to Methylnitronitrosoguanidine | 15589979 |
D008769 | Methylnitronitrosoguanidine | Eugenol inhibits the reaction [Methylnitronitrosoguanidine results in decreased expression of TP53 protein] | 19851710 |
D008769 | Methylnitronitrosoguanidine | Methylnitronitrosoguanidine results in decreased expression of TP53 protein | 19851710 |
D008769 | Methylnitronitrosoguanidine | Methylnitronitrosoguanidine results in increased acetylation of TP53 protein | 17147953 |
D008769 | Methylnitronitrosoguanidine | Resveratrol inhibits the reaction [Methylnitronitrosoguanidine results in increased acetylation of TP53 protein] | 17147953 |
D008770 | Methylnitrosourea | Methylnitrosourea results in increased expression of and results in increased phosphorylation of TP53 protein | 29110037 |
D008770 | Methylnitrosourea | Methylnitrosourea results in increased expression of TP53 mRNA | 20965277 |
D008770 | Methylnitrosourea | Butylated Hydroxyanisole inhibits the reaction [Methylnitrosourea results in increased phosphorylation of TP53 protein] | 18593901 |
D008770 | Methylnitrosourea | [Estradiol co-treated with Methylnitrosourea co-treated with Progesterone] results in decreased expression of TP53 mRNA | 20732338 |
D008770 | Methylnitrosourea | [Methylnitrosourea co-treated with Progesterone] results in decreased expression of TP53 mRNA | 20732338 |
D008770 | Methylnitrosourea | Methylnitrosourea results in increased expression of TP53 mRNA | 17412507; 28688903; |
D008770 | Methylnitrosourea | Methylnitrosourea results in increased phosphorylation of TP53 protein | 18593901 |
C008480 | methylparaoxon | methylparaoxon results in increased expression of TP53 mRNA | 18418871 |
D008743 | Methyl Parathion | Methyl Parathion results in increased expression of TP53 mRNA | 18418871 |
C425324 | methyl protodioscin | methyl protodioscin results in increased expression of TP53 mRNA | 31271762 |
C425324 | methyl protodioscin | methyl protodioscin results in increased expression of TP53 protein | 31271762 |
D008777 | Methyltestosterone | Methyltestosterone results in increased expression of TP53 mRNA | 29458080 |
D015741 | Metribolone | [Curcumin co-treated with Metribolone] results in increased phosphorylation of TP53 protein | 21134073 |
D015741 | Metribolone | TP53 protein inhibits the reaction [Metribolone results in increased expression of NKX3-1 mRNA] | 17202838 |
C574930 | MI-219 | MI-219 results in decreased activity of [MDM2 protein binds to TP53 protein] | 21314128 |
C063855 | microcystin RR | microcystin RR results in increased expression of TP53 protein | 19111056 |
D052998 | Microcystins | Microcystins results in increased expression of TP53 mRNA | 19760617 |
D052998 | Microcystins | Microcystins results in increased expression of TP53 protein | 19760617 |
C059539 | midostaurin | midostaurin affects the reaction [Resveratrol results in increased phosphorylation of and results in increased activity of and results in increased localization of TP53 protein] | 15542774 |
C059539 | midostaurin | midostaurin inhibits the reaction [EGF protein inhibits the reaction [Resveratrol results in increased phosphorylation of and results in increased activity of and results in increased localization of TP53 protein]] | 15542774 |
D008911 | Minocycline | Minocycline results in decreased expression of TP53 protein | 15172883 |
C066851 | mithramycin A | mithramycin A inhibits the reaction [[TP53 protein binds to SP1 protein] which results in increased expression of BBC3 mRNA] | 15489892 |
C066851 | mithramycin A | mithramycin A inhibits the reaction [[TP53 protein binds to SP1 protein] which results in increased expression of CDKN1A mRNA] | 15489892 |
C066851 | mithramycin A | mithramycin A results in increased activity of TP53 protein | 17124180 |
C066851 | mithramycin A | mithramycin A results in increased phosphorylation of TP53 protein | 15489892 |
D016685 | Mitomycin | [Methotrexate results in decreased susceptibility to Methotrexate] inhibits the reaction [Mitomycin results in increased expression of TP53 protein mutant form] | 16598767 |
D016685 | Mitomycin | Mitomycin results in increased expression of TP53 protein | 16598767 |
D016685 | Mitomycin | Mitomycin results in increased expression of TP53 protein mutant form | 16598767 |
D016685 | Mitomycin | Mitomycin promotes the reaction [TP53 protein results in increased expression of CCNB1 mRNA] | 18647660 |
D016685 | Mitomycin | Mitomycin promotes the reaction [TP53 protein results in increased expression of CDKN1A mRNA] | 18647660 |
D016685 | Mitomycin | Mitomycin promotes the reaction [TP53 protein results in increased expression of DDB2 mRNA] | 18647660 |
D016685 | Mitomycin | Mitomycin promotes the reaction [TP53 protein results in increased expression of GADD45A mRNA] | 18647660 |
D016685 | Mitomycin | Mitomycin promotes the reaction [TP53 protein results in increased expression of HSPA8 mRNA] | 18647660 |
D016685 | Mitomycin | Mitomycin promotes the reaction [TP53 protein results in increased expression of PCNA mRNA] | 18647660 |
D016685 | Mitomycin | Mitomycin promotes the reaction [TP53 protein results in increased expression of SGK1 mRNA] | 18647660 |
D016685 | Mitomycin | Mitomycin promotes the reaction [TP53 protein results in increased expression of TP53I3 mRNA] | 18647660 |
D016685 | Mitomycin | Mitomycin promotes the reaction [TP53 protein results in increased expression of TRIAP1 mRNA] | 18647660 |
D016685 | Mitomycin | Mitomycin results in increased expression of TP53 | 19834285 |
D016685 | Mitomycin | Mitomycin results in increased expression of TP53 mRNA | 18647660 |
D016685 | Mitomycin | Mitomycin results in increased expression of TP53 protein | 12082016; 24675086; |
D016685 | Mitomycin | Mitomycin results in increased expression of TP53 protein modified form | 16186332 |
D016685 | Mitomycin | Mitomycin results in increased phosphorylation of and results in increased activity of TP53 protein | 24675086 |
D016685 | Mitomycin | Mitomycin results in increased stability of TP53 protein | 20536192 |
D016685 | Mitomycin | [Mitomycin results in increased stability of TP53 protein] which results in increased expression of CDKN1A mRNA | 20536192 |
D016685 | Mitomycin | [Mitomycin results in increased stability of TP53 protein] which results in increased expression of MDM2 mRNA | 20536192 |
D016685 | Mitomycin | Silybin inhibits the reaction [Mitomycin results in increased expression of TP53] | 19834285 |
D016685 | Mitomycin | TP53 protein affects the susceptibility to Mitomycin | 15182437; 20000476; |
C019215 | mitonafide | mitonafide analog results in increased expression of TP53 protein | 19954251 |
D008939 | Mitotane | [Doxorubicin co-treated with Vincristine co-treated with Etoposide co-treated with Mitotane] results in decreased expression of TP53 protein | 9815696 |
D008939 | Mitotane | Mitotane analog affects the expression of TP53 protein | 23485034 |
D008939 | Mitotane | Mitotane analog results in increased expression of TP53 mRNA | 23485034 |
D008939 | Mitotane | Mitotane results in increased expression of TP53 mRNA | 23485034 |
D008939 | Mitotane | Mitotane results in increased expression of TP53 protein | 23485034 |
D008982 | Molybdenum | Molybdenum analog results in increased expression of and results in increased phosphorylation of TP53 protein | 26391003 |
C016599 | mono-(2-ethylhexyl)phthalate | mono-(2-ethylhexyl)phthalate results in increased activity of TP53 protein | 21515331 |
C016599 | mono-(2-ethylhexyl)phthalate | mono-(2-ethylhexyl)phthalate results in increased phosphorylation of and results in increased expression of TP53 protein | 24706461 |
C016599 | mono-(2-ethylhexyl)phthalate | Selenomethionine inhibits the reaction [mono-(2-ethylhexyl)phthalate results in increased activity of TP53 protein] | 21515331 |
C016599 | mono-(2-ethylhexyl)phthalate | Sodium Selenite inhibits the reaction [mono-(2-ethylhexyl)phthalate results in increased activity of TP53 protein] | 21515331 |
C016599 | mono-(2-ethylhexyl)phthalate | TP53 protein results in decreased susceptibility to mono-(2-ethylhexyl)phthalate | 24706461 |
D008999 | Monocrotophos | Monocrotophos results in increased expression of TP53 mRNA | 20957986 |
D008999 | Monocrotophos | Monocrotophos results in increased expression of TP53 protein | 20957986 |
C091888 | monoisoamyl-2,3-dimercaptosuccinate | monoisoamyl-2,3-dimercaptosuccinate results in increased expression of TP53 mRNA | 19615344 |
C020300 | monomethylarsonic acid | [sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of TP53 mRNA | 23192986 |
C406082 | monomethylarsonous acid | monomethylarsonous acid inhibits the reaction [7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in increased expression of and results in increased phosphorylation of and results in increased localization of and results in increased activity of TP53 protein] | 18085531 |
C406082 | monomethylarsonous acid | monomethylarsonous acid results in decreased expression of TP53 mRNA | 22108045 |
C406082 | monomethylarsonous acid | monomethylarsonous acid results in increased expression of TP53 protein | 19382146 |
C406082 | monomethylarsonous acid | TP53 protein results in increased susceptibility to monomethylarsonous acid | 18085531 |
C041105 | monomethyl succinate | monomethyl succinate inhibits the reaction [bis((2-oxindol-3-ylimino)-2-(2-aminoethyl)pyridine-N,N')copper(II) results in increased expression of TP53 protein] | 21548882 |
C093875 | montelukast | montelukast inhibits the reaction [Rotenone results in increased expression of TP53 mRNA] | 30222980 |
C008548 | morin | morin results in increased expression of TP53 mRNA | 28689916 |
D009020 | Morphine | Morphine inhibits the reaction [Dactinomycin results in increased expression of TP53 protein modified form] | 12927789 |
D009020 | Morphine | Morphine results in increased expression of TP53 mRNA | 19397953 |
D009020 | Morphine | Morphine results in increased phosphorylation of and results in increased activity of TP53 protein | 19397953 |
D009020 | Morphine | Morphine results in increased phosphorylation of and results in increased stability of TP53 protein | 12702572 |
D009020 | Morphine | [Morphine results in increased phosphorylation of and results in increased stability of TP53 protein] which results in increased expression of BAX protein | 12702572 |
D009020 | Morphine | [Morphine results in increased phosphorylation of and results in increased stability of TP53 protein] which results in increased expression of CDKN1A protein | 12702572 |
D009020 | Morphine | [Morphine results in increased phosphorylation of and results in increased stability of TP53 protein] which results in increased expression of FAS protein | 12702572 |
D009020 | Morphine | Naloxone inhibits the reaction [Morphine inhibits the reaction [Dactinomycin results in increased expression of TP53 protein modified form]] | 12927789 |
D009020 | Morphine | Naloxone inhibits the reaction [Morphine results in increased expression of TP53] | 19397953 |
D009020 | Morphine | Naloxone inhibits the reaction [Morphine results in increased phosphorylation of TP53 protein] | 19397953 |
D009020 | Morphine | Morphine results in increased expression of TP53 protein | 9469450 |
C437683 | motexafin gadolinium | Acetylcysteine inhibits the reaction [[Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of TP53 protein] | 20530418 |
C437683 | motexafin gadolinium | [Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of TP53 protein | 20530418 |
C437683 | motexafin gadolinium | benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of TP53 protein] | 20530418 |
C437683 | motexafin gadolinium | nutlin 3 inhibits the reaction [[Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of TP53 protein] | 20530418 |
C523799 | MRK 003 | MRK 003 inhibits the reaction [Resveratrol results in increased expression of TP53] | 21743969 |
D009150 | Mustard Compounds | caffeic acid phenethyl ester inhibits the reaction [Mustard Compounds results in increased phosphorylation of TP53 protein] | 17204746 |
D009150 | Mustard Compounds | Mustard Compounds results in increased phosphorylation of TP53 protein | 17204746 |
D009151 | Mustard Gas | 2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one inhibits the reaction [Mustard Gas results in increased expression of TP53 protein] | 22119920 |
D009151 | Mustard Gas | 2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one inhibits the reaction [Mustard Gas results in increased phosphorylation of TP53 protein] | 22119920 |
D009151 | Mustard Gas | Mustard Gas results in increased expression of TP53 protein | 11428642; 19748996; 22119920; 25102026; 9665388; |
D009151 | Mustard Gas | Mustard Gas results in increased expression of TP53 protein modified form | 25102026 |
D009151 | Mustard Gas | Mustard Gas results in increased phosphorylation of TP53 protein | 19845377; 20143454; 22119920; |
D009151 | Mustard Gas | Wortmannin inhibits the reaction [Mustard Gas results in increased expression of TP53 protein] | 22119920 |
D009151 | Mustard Gas | Wortmannin inhibits the reaction [Mustard Gas results in increased phosphorylation of TP53 protein] | 22119920 |
D009151 | Mustard Gas | Mustard Gas results in increased expression of TP53 protein | 9302645 |
C008577 | myricitrin | myricitrin inhibits the reaction [Hydrogen Peroxide results in increased expression of TP53 protein] | 23639522 |
C061545 | myrtenal | myrtenal inhibits the reaction [[Phenobarbital co-treated with Diethylnitrosamine] results in decreased expression of TP53 mRNA] | 22436021 |
C061545 | myrtenal | myrtenal inhibits the reaction [[Phenobarbital co-treated with Diethylnitrosamine] results in decreased expression of TP53 protein] | 22436021 |
C514580 | N1-(2-aminophenyl)-N8-phenyloctanediamide | N1-(2-aminophenyl)-N8-phenyloctanediamide affects the expression of TP53 protein | 17341627 |
C059685 | N(1),N(11)-diethylnorspermine | N(1),N(11)-diethylnorspermine promotes the reaction [Fluorouracil results in increased expression of TP53 protein] | 15546879 |
C059685 | N(1),N(11)-diethylnorspermine | TP53 protein inhibits the reaction [N(1),N(11)-diethylnorspermine promotes the reaction [Fluorouracil results in decreased expression of CCNA2 protein]] | 15546879 |
C059685 | N(1),N(11)-diethylnorspermine | TP53 protein inhibits the reaction [N(1),N(11)-diethylnorspermine promotes the reaction [Fluorouracil results in decreased expression of CCNB1 protein]] | 15546879 |
C059685 | N(1),N(11)-diethylnorspermine | TP53 protein inhibits the reaction [N(1),N(11)-diethylnorspermine promotes the reaction [Fluorouracil results in increased cleavage of and results in increased activity of CASP9 protein]] | 15546879 |
C059685 | N(1),N(11)-diethylnorspermine | TP53 protein promotes the reaction [Fluorouracil promotes the reaction [N(1),N(11)-diethylnorspermine results in increased expression of CDKN1A protein]] | 15546879 |
C059685 | N(1),N(11)-diethylnorspermine | TP53 protein promotes the reaction [Fluorouracil promotes the reaction [N(1),N(11)-diethylnorspermine results in increased expression of MDM2 protein]] | 15546879 |
C059685 | N(1),N(11)-diethylnorspermine | TP53 protein promotes the reaction [N(1),N(11)-diethylnorspermine promotes the reaction [Fluorouracil results in increased expression of FAS protein]] | 15546879 |
C059685 | N(1),N(11)-diethylnorspermine | TP53 protein promotes the reaction [N(1),N(11)-diethylnorspermine results in increased expression of CDKN1A protein] | 15546879 |
C059685 | N(1),N(11)-diethylnorspermine | TP53 protein promotes the reaction [N(1),N(11)-diethylnorspermine results in increased expression of MDM2 protein] | 15546879 |
C469937 | N(2)-(2-aminocyclohexyl)-N(6)-(3-chlorophenyl)-9-ethyl-9H-purine-2,6-diamine | MYC mutant form inhibits the reaction [N(2)-(2-aminocyclohexyl)-N(6)-(3-chlorophenyl)-9-ethyl-9H-purine-2,6-diamine results in increased expression of TP53 protein] | 24444383 |
C469937 | N(2)-(2-aminocyclohexyl)-N(6)-(3-chlorophenyl)-9-ethyl-9H-purine-2,6-diamine | [N(2)-(2-aminocyclohexyl)-N(6)-(3-chlorophenyl)-9-ethyl-9H-purine-2,6-diamine co-treated with MYC protein] results in increased expression of TP53 protein | 24444383 |
C469937 | N(2)-(2-aminocyclohexyl)-N(6)-(3-chlorophenyl)-9-ethyl-9H-purine-2,6-diamine | N(2)-(2-aminocyclohexyl)-N(6)-(3-chlorophenyl)-9-ethyl-9H-purine-2,6-diamine results in increased expression of TP53 protein | 16140939; 24444383; |
C080955 | N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide | N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Resveratrol results in increased expression of TP53 mRNA] | 29242151 |
C080955 | N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide | N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Resveratrol results in increased phosphorylation of TP53 protein] | 16928824; 29242151; |
C080955 | N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide | [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of PTGS2 protein] inhibits the reaction [Ceramides results in increased phosphorylation of TP53 protein] | 23495037 |
C080955 | N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide | [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of PTGS2 protein] inhibits the reaction [Resveratrol results in increased activity of TP53 protein] | 18446786 |
C080955 | N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide | N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased expression of TP53 mRNA | 29242151 |
C080955 | N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide | N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Resveratrol results in increased phosphorylation of TP53 protein] | 17984113 |
C556398 | N-(2-(dimethylamino)ethyl)-2-aminothiazonaphthalimide | N-(2-(dimethylamino)ethyl)-2-aminothiazonaphthalimide promotes the reaction [TP53 protein binds to BCL2 promoter] | 21821060 |
C556398 | N-(2-(dimethylamino)ethyl)-2-aminothiazonaphthalimide | N-(2-(dimethylamino)ethyl)-2-aminothiazonaphthalimide results in increased expression of TP53 protein | 21821060 |
C556398 | N-(2-(dimethylamino)ethyl)-2-aminothiazonaphthalimide | TP53 mutant form inhibits the reaction [N-(2-(dimethylamino)ethyl)-2-aminothiazonaphthalimide results in decreased expression of BCL2 protein] | 21821060 |
C556398 | N-(2-(dimethylamino)ethyl)-2-aminothiazonaphthalimide | TP53 mutant form inhibits the reaction [N-(2-(dimethylamino)ethyl)-2-aminothiazonaphthalimide results in increased expression of CDKN1A protein] | 21821060 |
C064769 | N-acetylsphingosine | Acetylcysteine inhibits the reaction [N-acetylsphingosine results in increased expression of TP53 mRNA] | 9535218 |
C064769 | N-acetylsphingosine | Acetylcysteine inhibits the reaction [N-acetylsphingosine results in increased expression of TP53 protein] | 9535218 |
C064769 | N-acetylsphingosine | N-acetylsphingosine results in increased expression of TP53 mRNA | 9535218 |
C064769 | N-acetylsphingosine | N-acetylsphingosine results in increased expression of TP53 protein | 9535218 |
D009243 | NAD | [2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of TP53 gene | 10334203 |
D009243 | NAD | bathocuproine inhibits the reaction [[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of TP53 gene] | 10334203 |
D009243 | NAD | CAT protein inhibits the reaction [[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of TP53 gene] | 10334203 |
D009243 | NAD | NAD results in decreased expression of TP53 protein | 12390773 |
D009249 | NADP | NADP promotes the reaction [sodium bichromate results in increased expression of TP53 protein] | 10942736 |
D009270 | Naloxone | Naloxone inhibits the reaction [Morphine inhibits the reaction [Dactinomycin results in increased expression of TP53 protein modified form]] | 12927789 |
D009270 | Naloxone | Naloxone inhibits the reaction [Morphine results in increased expression of TP53] | 19397953 |
D009270 | Naloxone | Naloxone inhibits the reaction [Morphine results in increased phosphorylation of TP53 protein] | 19397953 |
D009270 | Naloxone | Naloxone results in decreased expression of TP53 mRNA | 17522070 |
D037742 | Nanotubes, Carbon | Nanotubes, Carbon results in decreased expression of and results in increased phosphorylation of TP53 protein | 23634900 |
D037742 | Nanotubes, Carbon | Nanotubes, Carbon results in decreased expression of TP53 mRNA | 15585362 |
D037742 | Nanotubes, Carbon | Nanotubes, Carbon results in increased expression of TP53 mRNA | 26146619 |
C031721 | naphthalene | [naphthalene binds to pyrrolo(2,1-c)(1,4)benzodiazepine] which results in increased expression of TP53 protein | 21732540 |
C542131 | naphthalenediimide | naphthalenediimide analog results in increased phosphorylation of TP53 protein | 30840857 |
D009281 | Naphthalenes | Naphthalenes results in increased expression of TP53 protein | 17224139 |
C005273 | naringenin | naringenin inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of and results in increased activity of TP53 protein] | 15795422 |
C005273 | naringenin | naringenin results in increased expression of and results in increased phosphorylation of TP53 protein | 27838343 |
C005273 | naringenin | naringenin results in increased expression of TP53 mRNA | 30153467 |
C005273 | naringenin | [Tamoxifen co-treated with naringenin] results in increased expression of TP53 mRNA | 30153467 |
C005274 | naringin | naringin results in increased expression of TP53 mRNA | 22847135 |
C005274 | naringin | naringin inhibits the reaction [Cisplatin results in increased expression of TP53 mRNA] | 26120027; 26612654; |
C101954 | N-caproylsphingosine | calyculin A inhibits the reaction [N-caproylsphingosine affects the splicing of and results in increased expression of TP53 mRNA] | 25195822 |
C101954 | N-caproylsphingosine | calyculin A inhibits the reaction [N-caproylsphingosine results in increased expression of TP53 protein modified form] | 25195822 |
C101954 | N-caproylsphingosine | N-caproylsphingosine affects the splicing of and results in increased expression of TP53 mRNA | 25195822 |
C101954 | N-caproylsphingosine | N-caproylsphingosine results in increased phosphorylation of TP53 protein | 25195822 |
C101954 | N-caproylsphingosine | SRSF1 protein promotes the reaction [N-caproylsphingosine affects the splicing of and results in increased expression of TP53 mRNA] | 25195822 |
C101954 | N-caproylsphingosine | SRSF1 protein promotes the reaction [N-caproylsphingosine results in increased expression of TP53 protein modified form] | 25195822 |
C066471 | NCS 382 | NCS 382 affects the expression of TP53 mRNA | 28119166 |
C507699 | necrostatin-1 | necrostatin-1 inhibits the reaction [Fingolimod Hydrochloride results in increased phosphorylation of TP53 protein] | 25939952 |
C057222 | neferine | neferine inhibits the reaction [Diethylnitrosamine results in decreased expression of TP53 mRNA] | 30423403 |
C002701 | neocuproine | neocuproine inhibits the reaction [[cupric chloride co-treated with di(2-picolyl)amine-3(bromoacetyl)coumarin] results in increased expression of TP53 protein] | 29803612 |
C010463 | n-hexanal | n-hexanal results in decreased expression of TP53 mRNA | 12921975 |
C014593 | N-hydroxy-4-aminobiphenyl | [N-hydroxy-4-aminobiphenyl co-treated with Copper] results in increased mutagenesis of TP53 gene | 11275476 |
D009525 | Niacin | Niacin deficiency affects the expression of TP53 protein | 17516866 |
D009525 | Niacin | Niacin deficiency inhibits the reaction [Etoposide results in increased expression of TP53 protein] | 17516866 |
D009525 | Niacin | Niacin deficiency results in decreased expression of TP53 mRNA | 17516866 |
D009536 | Niacinamide | [Berberine co-treated with Niacinamide] results in increased expression of and results in increased acetylation of TP53 protein | 26712469 |
D009536 | Niacinamide | Niacinamide inhibits the reaction [tert-Butylhydroperoxide results in increased expression of TP53 protein] | 12782109 |
D009536 | Niacinamide | [Niacinamide results in decreased activity of SIRT1 protein] promotes the reaction [Hydrogen Peroxide results in increased acetylation of TP53 protein] | 18681908 |
D009536 | Niacinamide | Niacinamide results in decreased activity of [SIRT1 protein results in decreased acetylation of TP53 protein] | 18482975 |
D009536 | Niacinamide | Niacinamide results in decreased expression of TP53 protein | 12782109 |
D009536 | Niacinamide | Niacinamide results in increased phosphorylation of and results in increased acetylation of TP53 protein | 26712469 |
D009532 | Nickel | Nickel analog results in increased expression of TP53 protein | 23776134 |
D009532 | Nickel | Nickel results in decreased expression of TP53 mRNA | 23195993 |
D009532 | Nickel | Nickel results in increased expression of and results in increased phosphorylation of TP53 protein | 24068677 |
D009532 | Nickel | [Quercetin analog co-treated with Nickel] results in increased expression of TP53 protein | 20577783 |
D009532 | Nickel | TP53 protein affects the reaction [Nickel results in increased cleavage of and results in increased activity of CASP3 protein] | 24068677 |
D009532 | Nickel | TP53 protein affects the reaction [Nickel results in increased expression of CDKN1A mRNA] | 24068677 |
D009532 | Nickel | TP53 protein affects the reaction [Nickel results in increased expression of MDM2 mRNA] | 24068677 |
C022838 | nickel chloride | nickel chloride results in decreased activity of TP53 protein | 25446071 |
C022838 | nickel chloride | [nickel chloride results in decreased activity of TP53 protein] inhibits the reaction [TP53 protein binds to TP53 gene] | 25446071; 25446071; |
C022838 | nickel chloride | [nickel chloride results in decreased activity of TP63 protein] inhibits the reaction [TP63 protein binds to TP53 gene] | 25446071 |
C022838 | nickel chloride | [nickel chloride results in decreased activity of TP73 protein] inhibits the reaction [TP73 protein binds to TP53 gene] | 25446071 |
C022838 | nickel chloride | nickel chloride results in increased expression of TP53 protein | 23566959; 28552779; 29110037; |
C022838 | nickel chloride | nickel chloride results in increased expression of TP53 protein modified form | 28552779 |
C022838 | nickel chloride | nickel chloride results in increased phosphorylation of and results in increased activity of TP53 protein | 23566959 |
C022838 | nickel chloride | nickel chloride results in increased phosphorylation of TP53 protein | 21466819 |
C022838 | nickel chloride | TP53 mutant form inhibits the reaction [nickel chloride results in increased activity of CASP9 protein] | 23566959 |
C022838 | nickel chloride | [TP53 mutant form inhibits the reaction [nickel chloride results in increased activity of CASP9 protein]] which results in decreased cleavage of CASP3 protein | 23566959 |
C022838 | nickel chloride | TP53 mutant form results in decreased susceptibility to nickel chloride | 23566959 |
C022838 | nickel chloride | [TP53 mutant form results in decreased susceptibility to nickel chloride] which results in decreased cleavage of PARP1 protein | 23566959 |
C022838 | nickel chloride | TP53 protein affects the reaction [nickel chloride results in increased expression of BBC3 mRNA] | 23566959 |
C022838 | nickel chloride | TP53 protein affects the reaction [nickel chloride results in increased expression of BTG2 mRNA] | 23566959 |
C022838 | nickel chloride | TP53 protein affects the reaction [nickel chloride results in increased expression of CDKN1A mRNA] | 23566959 |
C022838 | nickel chloride | TP53 protein affects the reaction [nickel chloride results in increased expression of MCL1 mRNA] | 23566959 |
C022838 | nickel chloride | TP53 protein affects the reaction [nickel chloride results in increased expression of MDM2 mRNA] | 23566959 |
C022838 | nickel chloride | nickel chloride affects the expression of TP53 mRNA | 22546817 |
C550717 | nickel ferrite | nickel ferrite analog results in increased expression of TP53 mRNA | 25966046 |
C550717 | nickel ferrite | nickel ferrite results in increased expression of TP53 mRNA | 21382431 |
C028007 | nickel monoxide | nickel monoxide results in decreased expression of TP53 mRNA | 19167457 |
C017557 | nickel subsulfide | nickel subsulfide results in decreased expression of TP53 mRNA | 24952340 |
C029938 | nickel sulfate | nickel sulfate inhibits the reaction [Potassium Dichromate results in increased phosphorylation of TP53 protein] | 20493934 |
C029938 | nickel sulfate | nickel sulfate results in increased expression of TP53 protein | 21776270; 23568779; |
D009534 | Niclosamide | Niclosamide results in decreased expression of TP53 mRNA | 31398420 |
D009534 | Niclosamide | [Niclosamide binds to Polyethyleneimine] which results in increased expression of TP53 mRNA | 25988281 |
D009534 | Niclosamide | Niclosamide results in increased expression of TP53 mRNA | 22576131 |
D009534 | Niclosamide | Niclosamide results in increased expression of TP53 protein | 29031202; 30258081; |
D009534 | Niclosamide | TP53 gene mutant form inhibits the reaction [Niclosamide results in increased expression of ALOX12B mRNA] | 30258081 |
D009534 | Niclosamide | TP53 gene mutant form inhibits the reaction [Niclosamide results in increased expression of ALOX5 mRNA] | 30258081 |
D009534 | Niclosamide | TP53 gene mutant form inhibits the reaction [Niclosamide results in increased expression of BBC3 mRNA] | 30258081 |
D009534 | Niclosamide | TP53 gene mutant form inhibits the reaction [Niclosamide results in increased expression of CDKN1A mRNA] | 30258081 |
D009534 | Niclosamide | TP53 gene mutant form promotes the reaction [Niclosamide results in increased cleavage of CASP3 protein] | 30258081 |
D009534 | Niclosamide | TP53 gene mutant form promotes the reaction [Niclosamide results in increased cleavage of CASP9 protein] | 30258081 |
D009534 | Niclosamide | TP53 gene mutant form promotes the reaction [Niclosamide results in increased cleavage of PARP1 protein] | 30258081 |
D009534 | Niclosamide | TP53 gene mutant form results in increased susceptibility to Niclosamide | 30258081 |
D009534 | Niclosamide | TP53 protein mutant form inhibits the reaction [Niclosamide results in increased expression of ALOX12B mRNA] | 30258081 |
D009534 | Niclosamide | TP53 protein mutant form inhibits the reaction [Niclosamide results in increased expression of ALOX5 mRNA] | 30258081 |
D009534 | Niclosamide | TP53 protein mutant form inhibits the reaction [Niclosamide results in increased expression of CDKN1A mRNA] | 30258081 |
D009534 | Niclosamide | TP53 protein mutant form results in increased susceptibility to Niclosamide | 30258081 |
D009534 | Niclosamide | TP53 protein results in decreased susceptibility to Niclosamide | 30258081 |
D009534 | Niclosamide | [TP53 protein mutant form results in increased susceptibility to Niclosamide] which results in increased abundance of adrenic acid | 30258081 |
D009534 | Niclosamide | [TP53 protein mutant form results in increased susceptibility to Niclosamide] which results in increased abundance of Arachidonic Acid | 30258081 |
D009534 | Niclosamide | [TP53 protein mutant form results in increased susceptibility to Niclosamide] which results in increased abundance of Docosahexaenoic Acids | 30258081 |
D009534 | Niclosamide | [TP53 protein mutant form results in increased susceptibility to Niclosamide] which results in increased abundance of Eicosapentaenoic Acid | 30258081 |
D009534 | Niclosamide | [TP53 protein mutant form results in increased susceptibility to Niclosamide] which results in increased abundance of Lysophosphatidylcholines | 30258081 |
D009534 | Niclosamide | [TP53 protein mutant form results in increased susceptibility to Niclosamide] which results in increased abundance of lysophosphatidylethanolamine | 30258081 |
D009534 | Niclosamide | [TP53 protein mutant form results in increased susceptibility to Niclosamide] which results in increased cleavage of PARP1 protein | 30258081 |
D009534 | Niclosamide | [TP53 protein mutant form results in increased susceptibility to Niclosamide] which results in increased expression of CASP3 protein modified form | 30258081 |
D009538 | Nicotine | 4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide inhibits the reaction [Nicotine results in decreased expression of TP53 protein] | 18805435 |
D009538 | Nicotine | Nicotine inhibits the reaction [aflatoxin G1 results in increased expression of TP53 protein modified form] | 23907605 |
D009538 | Nicotine | Nicotine inhibits the reaction [Cisplatin results in increased expression of TP53 protein] | 16601104 |
D009538 | Nicotine | Nicotine inhibits the reaction [gemcitabine results in increased expression of TP53 protein] | 16601104 |
D009538 | Nicotine | Nicotine inhibits the reaction [Paclitaxel results in increased expression of TP53 protein] | 16601104 |
D009538 | Nicotine | [[Nicotine results in decreased expression of RPS27A protein] which results in increased phosphorylation of MDM2 protein] which results in increased ubiquitination of TP53 protein | 30272249 |
D009538 | Nicotine | Nicotine results in decreased expression of TP53 mRNA | 18247414 |
D009538 | Nicotine | Nicotine results in decreased expression of TP53 protein | 16011614; 18805435; 19139119; 30272249; |
D009538 | Nicotine | Nicotine results in increased expression of TP53 protein | 20727180 |
D009538 | Nicotine | Rosiglitazone inhibits the reaction [Nicotine results in decreased expression of TP53 protein] | 19139119 |
D009538 | Nicotine | TP53 protein affects the reaction [Nicotine results in increased phosphorylation of MAPK1 protein] | 20727180 |
D009538 | Nicotine | TP53 protein affects the reaction [Nicotine results in increased phosphorylation of MAPK3 protein] | 20727180 |
D009538 | Nicotine | TP53 protein affects the reaction [Nicotine results in increased phosphorylation of MAPK8 protein] | 20727180 |
D009538 | Nicotine | Nicotine affects the expression of TP53 mRNA | 10837795 |
D009538 | Nicotine | Nicotine results in increased expression of TP53 mRNA | 20339300; 20426880; |
D009538 | Nicotine | TP53 protein affects the susceptibility to Nicotine | 15983034 |
D009543 | Nifedipine | Nifedipine results in increased activity of TP53 protein | 12082016 |
C042198 | nimbolide | nimbolide results in increased expression of TP53 mRNA | 20429769 |
C042198 | nimbolide | nimbolide results in increased expression of TP53 protein | 20429769 |
D015376 | Nimustine | TP53 affects the reaction [Nimustine results in increased expression of DDB2 mRNA] | 18089819 |
D015376 | Nimustine | TP53 affects the reaction [Nimustine results in increased expression of XPC mRNA] | 18089819 |
D015376 | Nimustine | TP53 protein affects the susceptibility to Nimustine | 15182437 |
D009569 | Nitric Oxide | Nitric Oxide inhibits the reaction [Cadmium results in increased expression of TP53 mRNA] | 25490952 |
D009569 | Nitric Oxide | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Nitric Oxide results in increased phosphorylation of TP53 protein] | 16024610 |
D009569 | Nitric Oxide | Caffeine inhibits the reaction [Nitric Oxide results in increased phosphorylation of TP53 protein] | 16024610 |
D009569 | Nitric Oxide | [Nitric Oxide Donors results in increased abundance of Nitric Oxide] which results in increased expression of TP53 protein | 10608825 |
D009569 | Nitric Oxide | Nitric Oxide results in increased expression of TP53 protein | 15979383 |
D009569 | Nitric Oxide | Nitric Oxide results in increased glutathionylation of TP53 protein | 17555331 |
D009569 | Nitric Oxide | Nitric Oxide results in increased phosphorylation of TP53 protein | 15177039; 16024610; |
D009569 | Nitric Oxide | TP53 protein affects the susceptibility to Nitric Oxide | 16024610 |
D009569 | Nitric Oxide | Wortmannin inhibits the reaction [Nitric Oxide results in increased phosphorylation of TP53 protein] | 16024610 |
D009569 | Nitric Oxide | [Nitroprusside results in increased abundance of Nitric Oxide] which results in increased expression of TP53 protein | 22293420 |
D009569 | Nitric Oxide | pyrazolanthrone inhibits the reaction [[Nitroprusside results in increased abundance of Nitric Oxide] which results in increased expression of TP53 protein] | 22293420 |
D009569 | Nitric Oxide | [7-nitroindazole results in decreased chemical synthesis of Nitric Oxide] inhibits the reaction [Paraquat results in increased phosphorylation of TP53 protein] | 20478973 |
D009569 | Nitric Oxide | [NOS2 protein results in increased abundance of Nitric Oxide] which results in increased expression of TP53 protein | 9743513 |
D009569 | Nitric Oxide | [S-Nitrosoglutathione results in increased abundance of Nitric Oxide] which results in increased expression of TP53 protein | 8982730 |
D009569 | Nitric Oxide | ATM protein affects the reaction [Nitric Oxide results in increased phosphorylation of TP53 protein] | 15177039 |
D020030 | Nitric Oxide Donors | [Nitric Oxide Donors results in increased abundance of Nitric Oxide] which results in increased expression of TP53 protein | 10608825 |
D009583 | Nitrofurazone | Nitrofurazone results in increased mutagenesis of TP53 gene | 15488632 |
D009585 | Nitrogen Dioxide | Nitrogen Dioxide results in increased expression of TP53 mRNA | 22621880 |
D009585 | Nitrogen Dioxide | Nitrogen Dioxide results in increased expression of TP53 protein | 22621880 |
D009588 | Nitrogen Mustard Compounds | caffeic acid phenethyl ester inhibits the reaction [Nitrogen Mustard Compounds results in increased phosphorylation of TP53 protein] | 17204746 |
D009588 | Nitrogen Mustard Compounds | Nitrogen Mustard Compounds results in increased phosphorylation of TP53 protein | 17204746 |
D009589 | Nitrogen Oxides | Nitrogen Oxides inhibits the reaction [Benzo(a)pyrene results in increased expression of TP53 protein] | 16041517 |
D009599 | Nitroprusside | Nitroprusside results in increased expression of TP53 protein | 15979383 |
D009599 | Nitroprusside | Acetylcysteine inhibits the reaction [Nitroprusside results in increased expression of TP53] | 19725096 |
D009599 | Nitroprusside | [Nitroprusside results in increased abundance of Nitric Oxide] which results in increased expression of TP53 protein | 22293420 |
D009599 | Nitroprusside | Nitroprusside results in increased expression of TP53 | 19725096 |
D009599 | Nitroprusside | pyrazolanthrone inhibits the reaction [[Nitroprusside results in increased abundance of Nitric Oxide] which results in increased expression of TP53 protein] | 22293420 |
D009599 | Nitroprusside | Cilostazol inhibits the reaction [Nitroprusside results in increased phosphorylation of TP53 protein] | 18311796 |
D009599 | Nitroprusside | Nitroprusside results in increased phosphorylation of TP53 protein | 18311796 |
C000623013 | NMS-873 | NMS-873 results in increased expression of TP53 protein | 29693262 |
C419410 | N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester | Hydrogen Peroxide inhibits the reaction [N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of TP53 protein] | 25005833 |
C419410 | N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester | N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of TP53 protein | 25005833 |
C002741 | N-nitrosomorpholine | N-nitrosomorpholine results in increased expression of TP53 protein | 10326863; 14587038; 7728945; |
C044387 | N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine | [Acetylcysteine co-treated with N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine] inhibits the reaction [[Zinc Sulfate co-treated with prolinedithiocarbamate] results in decreased expression of TP53 protein] | 18951928 |
C044387 | N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine | N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine affects the localization of TP53 protein | 18778698 |
C044387 | N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine | N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine inhibits the reaction [[Zinc Sulfate co-treated with prolinedithiocarbamate] results in decreased expression of TP53 protein] | 18951928 |
C044387 | N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine | N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine results in increased expression of TP53 protein | 12888634 |
C044387 | N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine | TP53 mutant form inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine results in decreased expression of LATS2 mRNA] | 18778698 |
C044387 | N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine | TP53 mutant form inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine results in decreased expression of STAT3 mRNA] | 18778698 |
C044387 | N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine | TP53 mutant form inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine results in increased expression of KRT8 mRNA] | 18778698 |
C044387 | N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine | TP53 mutant form inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine results in increased expression of RB1 mRNA] | 18778698 |
C044387 | N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine | TP53 mutant form inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine results in increased expression of RPRM mRNA] | 18778698 |
C044387 | N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine | TP53 mutant form inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine results in increased expression of SFN mRNA] | 18778698 |
C044387 | N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine | TP53 mutant form inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine results in increased expression of TIMP3 mRNA] | 18778698 |
C044387 | N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine | TP53 mutant form inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine results in increased expression of TP73 mRNA] | 18778698 |
C044387 | N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine | TP53 mutant form inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine results in increased expression of YWHAZ mRNA] | 18778698 |
D015739 | Nocodazole | Nocodazole analog results in increased expression of TP53 protein | 28412508 |
D015739 | Nocodazole | Nocodazole results in increased expression of TP53 protein | 21559451 |
D015739 | Nocodazole | TP53 protein affects the reaction [Nocodazole results in increased phosphorylation of JUN protein] | 12221076 |
D015739 | Nocodazole | TP53 protein affects the reaction [Nocodazole results in increased phosphorylation of MAPK8 protein] | 12221076 |
D015739 | Nocodazole | TP53 protein affects the reaction [Nocodazole results in increased phosphorylation of MAPK9 protein] | 12221076 |
C099178 | nolatrexed | TP53 protein affects the susceptibility to nolatrexed | 17339891 |
C010615 | Nonidet P-40 | Nonidet P-40 results in decreased expression of TP53 mRNA | 26552463 |
C025256 | nonylphenol | nonylphenol affects the expression of TP53 mRNA | 17950039 |
C025256 | nonylphenol | nonylphenol results in increased expression of TP53 mRNA | 14595849 |
D009640 | Norethindrone | Norethindrone results in increased expression of and results in increased activity of TP53 protein | 15905198 |
D009665 | Noscapine | Noscapine promotes the reaction [Cisplatin results in increased expression of TP53 protein] | 20674069 |
D009665 | Noscapine | Noscapine results in increased expression of and results in increased phosphorylation of TP53 protein | 22848370 |
D009665 | Noscapine | Noscapine results in increased expression of TP53 protein | 20674069 |
C434926 | N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride | N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [Hydrogen Peroxide results in increased acetylation of TP53 protein] | 30139380 |
C434926 | N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride | N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride results in decreased expression of TP53 protein modified form | 30139380 |
C434926 | N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride | N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride results in increased expression of TP53 protein | 21840268 |
C434926 | N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride | N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride results in increased expression of TP53 protein modified form | 21840268 |
C434926 | N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride | SIRT1 protein promotes the reaction [N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [Hydrogen Peroxide results in increased acetylation of TP53 protein]] | 30139380 |
C434926 | N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride | N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [Hydrogen Peroxide results in increased acetylation of TP53 protein] | 31276434 |
C434926 | N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride | SIRT1 protein promotes the reaction [N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [Hydrogen Peroxide results in increased acetylation of TP53 protein]] | 31276434 |
C118989 | NSC 652287 | NSC 652287 results in increased expression of TP53 protein mutant form | 21109480 |
C118989 | NSC 652287 | NSC 652287 results in increased phosphorylation of TP53 protein mutant form | 21109480 |
C118989 | NSC 652287 | TP53 protein affects the reaction [NSC 652287 results in increased expression of MDM2 mRNA] | 21109480 |
C118989 | NSC 652287 | TP53 protein promotes the reaction [NSC 652287 results in increased expression of MDM2 protein] | 21109480 |
C553898 | NSC 724998 | TP53 protein results in decreased susceptibility to NSC 724998 | 25269479 |
C482205 | nutlin 3 | nutlin 3 inhibits the reaction [[Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of TP53 protein] | 20530418 |
C482205 | nutlin 3 | nutlin 3 inhibits the reaction [Camptothecin results in increased expression of TP53 protein] | 24726431 |
C482205 | nutlin 3 | nutlin 3 inhibits the reaction [TP53 protein binds to MDM2 protein] | 21509038; 22260869; |
C482205 | nutlin 3 | [nutlin 3 inhibits the reaction [TP53 protein binds to MDM2 protein]] which results in increased activity of TP53 protein | 21509038 |
C482205 | nutlin 3 | nutlin 3 promotes the reaction [Cisplatin results in increased expression of TP53 mRNA] | 21109480 |
C482205 | nutlin 3 | nutlin 3 promotes the reaction [Cisplatin results in increased expression of TP53 protein] | 21624110 |
C482205 | nutlin 3 | nutlin 3 promotes the reaction [Cisplatin results in increased localization of TP53 protein] | 21109480 |
C482205 | nutlin 3 | nutlin 3 promotes the reaction [Doxorubicin results in increased expression of TP53 protein] | 21624110 |
C482205 | nutlin 3 | nutlin 3 promotes the reaction [Methotrexate results in increased expression of TP53 protein] | 21624110 |
C482205 | nutlin 3 | nutlin 3 promotes the reaction [TP53 protein binds to BCL2L1 protein] | 16014563 |
C482205 | nutlin 3 | nutlin 3 promotes the reaction [TP53 protein results in increased expression of FAS protein] | 21509038 |
C482205 | nutlin 3 | nutlin 3 results in increased activity of TP53 protein | 16014563 |
C482205 | nutlin 3 | nutlin 3 results in increased expression of and affects the localization of TP53 protein | 16014563 |
C482205 | nutlin 3 | nutlin 3 results in increased expression of and results in increased localization of and results in increased activity of TP53 protein | 21109480 |
C482205 | nutlin 3 | nutlin 3 results in increased expression of and results in increased phosphorylation of TP53 protein | 16439677 |
C482205 | nutlin 3 | nutlin 3 results in increased expression of TP53 mRNA | 22260869 |
C482205 | nutlin 3 | nutlin 3 results in increased expression of TP53 protein | 16439685; 18092340; 19098008; 21212465; 21532991; 21624110; 22044530; 22260869; 24726431; |
C482205 | nutlin 3 | nutlin 3 results in increased expression of TP53 protein modified form | 22044530 |
C482205 | nutlin 3 | nutlin 3 results in increased stability of TP53 protein | 21205074 |
C482205 | nutlin 3 | [nutlin 3 results in increased stability of TP53 protein] which results in increased susceptibility to Cisplatin | 21205074 |
C482205 | nutlin 3 | [nutlin 3 results in increased stability of TP53 protein] which results in increased susceptibility to Fluorouracil | 21205074 |
C482205 | nutlin 3 | nutlin 3 results in increased susceptibility to [1-nitropyrene results in increased expression of TP53 protein] | 22044530 |
C482205 | nutlin 3 | nutlin 3 results in increased susceptibility to [1-nitropyrene results in increased expression of TP53 protein modified form] | 22044530 |
C482205 | nutlin 3 | Tetrachlorodibenzodioxin results in decreased susceptibility to [nutlin 3 results in increased susceptibility to [1-nitropyrene results in increased expression of TP53 protein]] | 22044530 |
C482205 | nutlin 3 | Tetrachlorodibenzodioxin results in decreased susceptibility to [nutlin 3 results in increased susceptibility to [1-nitropyrene results in increased expression of TP53 protein modified form]] | 22044530 |
C482205 | nutlin 3 | TP53 affects the reaction [nutlin 3 promotes the reaction [Cisplatin results in increased activity of and results in increased expression of CDKN1A protein]] | 21624110 |
C482205 | nutlin 3 | TP53 affects the reaction [nutlin 3 promotes the reaction [Cisplatin results in increased activity of and results in increased expression of MDM2 protein]] | 21624110 |
C482205 | nutlin 3 | TP53 affects the reaction [nutlin 3 promotes the reaction [Doxorubicin results in increased activity of and results in increased expression of CDKN1A protein]] | 21624110 |
C482205 | nutlin 3 | TP53 affects the reaction [nutlin 3 promotes the reaction [Doxorubicin results in increased activity of and results in increased expression of MDM2 protein]] | 21624110 |
C482205 | nutlin 3 | TP53 affects the reaction [nutlin 3 promotes the reaction [Methotrexate results in increased activity of and results in increased expression of CDKN1A protein]] | 21624110 |
C482205 | nutlin 3 | TP53 affects the reaction [nutlin 3 promotes the reaction [Methotrexate results in increased activity of and results in increased expression of MDM2 protein]] | 21624110 |
C482205 | nutlin 3 | TP53 affects the reaction [nutlin 3 results in increased activity of and results in increased expression of CDKN1A protein] | 21624110 |
C482205 | nutlin 3 | TP53 affects the reaction [nutlin 3 results in increased activity of and results in increased expression of MDM2 protein] | 21624110 |
C482205 | nutlin 3 | TP53 mutant form inhibits the reaction [nutlin 3 results in increased activity of CASP3 protein] | 22260869 |
C482205 | nutlin 3 | TP53 mutant form inhibits the reaction [nutlin 3 results in increased activity of CASP7 protein] | 22260869 |
C482205 | nutlin 3 | TP53 mutant form inhibits the reaction [nutlin 3 results in increased cleavage of PARP1 protein] | 22260869 |
C482205 | nutlin 3 | TP53 protein affects the reaction [nutlin 3 results in increased expression of BBC3 protein] | 16439685 |
C482205 | nutlin 3 | TP53 protein affects the reaction [nutlin 3 results in increased expression of CDKN1A protein] | 16439685 |
C482205 | nutlin 3 | TP53 protein affects the reaction [nutlin 3 results in increased expression of MDM2 protein] | 16439685 |
C482205 | nutlin 3 | TP53 protein promotes the reaction [nutlin 3 results in increased expression of BAX mRNA] | 21109480 |
C482205 | nutlin 3 | TP53 protein promotes the reaction [nutlin 3 results in increased expression of CDKN1A mRNA] | 21109480 |
C482205 | nutlin 3 | TP53 protein promotes the reaction [nutlin 3 results in increased expression of CDKN1A protein] | 21109480 |
C482205 | nutlin 3 | TP53 protein promotes the reaction [nutlin 3 results in increased expression of MDM2 mRNA] | 21109480 |
C482205 | nutlin 3 | TP53 protein promotes the reaction [nutlin 3 results in increased expression of MDM2 protein] | 21109480 |
C482205 | nutlin 3 | TP53 results in increased susceptibility to nutlin 3 | 21624110 |
C482205 | nutlin 3 | nutlin 3 inhibits the reaction [MDM2 protein binds to TP53 protein] | 16014563 |
C482205 | nutlin 3 | nutlin 3 inhibits the reaction [TP53 protein binds to MDM2 protein] | 22260869 |
C482205 | nutlin 3 | nutlin 3 results in decreased activity of [MDM2 protein binds to TP53 protein] | 21314128 |
C482205 | nutlin 3 | nutlin 3 results in increased activity of TP53 protein | 19098008 |
C064976 | O(6)-benzylguanine | [Carmustine co-treated with O(6)-benzylguanine] results in increased expression of TP53 protein | 15735757 |
C064976 | O(6)-benzylguanine | [O(6)-benzylguanine results in increased susceptibility to O-(6)-methylguanine] which results in increased expression of TP53 mRNA mutant form | 29666243 |
C064976 | O(6)-benzylguanine | [Temozolomide co-treated with O(6)-benzylguanine] results in increased expression of TP53 protein | 20980775 |
C064976 | O(6)-benzylguanine | TP53 protein results in increased susceptibility to [Temozolomide co-treated with O(6)-benzylguanine] | 20980775 |
C008449 | O-(6)-methylguanine | [O(6)-benzylguanine results in increased susceptibility to O-(6)-methylguanine] which results in increased expression of TP53 mRNA mutant form | 29666243 |
C067207 | obacunone | obacunone results in increased expression of TP53 protein | 21333732; 25592883; |
C411188 | obacunone glucoside | obacunone glucoside results in increased expression of TP53 protein | 25592883 |
D000077609 | O-(Chloroacetylcarbamoyl)fumagillol | O-(Chloroacetylcarbamoyl)fumagillol results in increased expression of TP53 protein | 15276080 |
C025589 | ochratoxin A | ochratoxin A results in increased expression of TP53 mRNA | 31154016 |
C025589 | ochratoxin A | ochratoxin A results in increased expression of TP53 protein | 19367635; 28286205; |
C025589 | ochratoxin A | TP53 mutant form inhibits the reaction [ochratoxin A results in decreased expression of RAD51] | 24525463 |
C025589 | ochratoxin A | ochratoxin A results in decreased expression of TP53 | 25218026 |
C025589 | ochratoxin A | ochratoxin A results in increased expression of TP53 mRNA | 19562491; 23208426; |
C025589 | ochratoxin A | NFE2L2 protein affects the reaction [ochratoxin A results in increased expression of TP53 protein] | 28710020 |
C025589 | ochratoxin A | ochratoxin A results in increased expression of TP53 protein | 28710020 |
D015282 | Octreotide | Octreotide results in decreased expression of TP53 protein | 21764706 |
C080077 | oenothein B | oenothein B results in increased expression of TP53 protein | 30452899 |
D019319 | Okadaic Acid | Okadaic Acid affects the localization of TP53 protein | 21512803 |
D019319 | Okadaic Acid | Okadaic Acid affects the reaction [Estradiol promotes the reaction [Benzo(a)pyrene affects the localization of TP53 protein]] | 24954032 |
D019319 | Okadaic Acid | Okadaic Acid affects the reaction [Tetrachlorodibenzodioxin promotes the reaction [Benzo(a)pyrene results in increased expression of TP53 protein]] | 24954032 |
D019319 | Okadaic Acid | Okadaic Acid inhibits the reaction [2,4,5,2',4',5'-hexachlorobiphenyl promotes the reaction [Benzo(a)pyrene affects the localization of TP53 protein]] | 24954032 |
D019319 | Okadaic Acid | Okadaic Acid inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [Benzo(a)pyrene affects the localization of TP53 protein]] | 24954032 |
D019319 | Okadaic Acid | Okadaic Acid promotes the reaction [2,4,5,2',4',5'-hexachlorobiphenyl promotes the reaction [Benzo(a)pyrene results in increased expression of TP53 protein]] | 24954032 |
D019319 | Okadaic Acid | Okadaic Acid results in decreased expression of TP53 protein | 18937299 |
D000077152 | Olanzapine | Olanzapine results in increased expression of TP53 mRNA | 16160616 |
C531550 | olaparib | [Fluorouracil co-treated with olaparib] results in increased expression of TP53 protein | 26544897 |
C531550 | olaparib | TP53 gene mutant form affects the reaction [benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[Fluorouracil co-treated with olaparib] results in increased phosphorylation of H2AX protein]] | 26544897 |
C013168 | olaquindox | olaquindox results in decreased expression of TP53 protein | 28757460 |
C013168 | olaquindox | olaquindox results in increased expression of TP53 mRNA | 21549799 |
C013168 | olaquindox | olaquindox results in increased expression of TP53 protein | 21549799 |
C013168 | olaquindox | pifithrin inhibits the reaction [olaquindox results in decreased expression of TP53 protein] | 28757460 |
C002769 | oleuropein | oleuropein inhibits the reaction [decamethrin results in increased expression of TP53 protein] | 28595958 |
C090046 | olomoucine | olomoucine inhibits the reaction [TP53 protein promotes the reaction [Amifostine results in decreased phosphorylation of CDK1 protein]] | 16628227 |
C090046 | olomoucine | olomoucine inhibits the reaction [TP53 results in decreased phosphorylation of CDK1 protein] | 16628227 |
C475587 | olomoucine II | olomoucine II results in increased expression of TP53 protein | 16003486 |
C507134 | ON 01910 | ON 01910 results in increased expression of and results in increased phosphorylation of TP53 protein | 25472472 |
C507134 | ON 01910 | TP53 protein affects the susceptibility to ON 01910 | 23873848 |
C016340 | o,p'-DDT | o,p'-DDT analog results in increased expression of TP53 mRNA | 22937105 |
C016340 | o,p'-DDT | o,p'-DDT analog results in increased expression of TP53 protein | 22937105 |
C016340 | o,p'-DDT | o,p'-DDT results in increased expression of TP53 mRNA | 22937105 |
C016340 | o,p'-DDT | o,p'-DDT results in increased expression of TP53 protein | 22937105 |
D009942 | Organometallic Compounds | Organometallic Compounds results in increased expression of and results in increased phosphorylation of TP53 protein | 26391003 |
D009942 | Organometallic Compounds | Organometallic Compounds results in increased expression of TP53 protein | 17210701 |
D000077150 | Oxaliplatin | Acetylcysteine inhibits the reaction [Oxaliplatin results in increased expression of TP53 protein] | 19728331 |
D000077150 | Oxaliplatin | Caffeine inhibits the reaction [Oxaliplatin results in increased expression of TP53 protein modified form] | 19735649 |
D000077150 | Oxaliplatin | Oxaliplatin affects the localization of TP53 protein modified form | 19735649 |
D000077150 | Oxaliplatin | Oxaliplatin promotes the reaction [TP53 protein binds to DUT promoter] | 19015155 |
D000077150 | Oxaliplatin | Oxaliplatin results in increased expression of TP53 protein | 19015155; 19728331; 20708607; |
D000077150 | Oxaliplatin | Oxaliplatin results in increased expression of TP53 protein modified form | 19735649; 20708607; |
D000077150 | Oxaliplatin | Oxaliplatin results in increased phosphorylation of and results in increased activity of TP53 protein | 19728331 |
D000077150 | Oxaliplatin | [pifithrin results in decreased activity of TP53 protein] results in decreased susceptibility to [Oxaliplatin results in increased activity of CASP3 protein] | 20708607 |
D000077150 | Oxaliplatin | [pifithrin results in decreased activity of TP53 protein] which results in decreased susceptibility to Oxaliplatin | 20708607 |
D000077150 | Oxaliplatin | [pifithrin results in decreased phosphorylation of TP53 protein] inhibits the reaction [Oxaliplatin results in increased expression of H2AX protein modified form] | 19735649 |
D000077150 | Oxaliplatin | pifithrin results in decreased susceptibility to [Oxaliplatin results in increased expression of TP53 protein] | 20708607 |
D000077150 | Oxaliplatin | pifithrin results in decreased susceptibility to [Oxaliplatin results in increased expression of TP53 protein modified form] | 20708607 |
D000077150 | Oxaliplatin | TP53 mutant form inhibits the reaction [[Oxaliplatin co-treated with Ursodeoxycholic Acid] results in increased activity of CASP3 protein] | 19728331 |
D000077150 | Oxaliplatin | TP53 mutant form inhibits the reaction [[Oxaliplatin co-treated with Ursodeoxycholic Acid] results in increased activity of CASP8 protein] | 19728331 |
D000077150 | Oxaliplatin | TP53 protein affects the reaction [Oxaliplatin results in decreased activity of DUT protein] | 19015155 |
D000077150 | Oxaliplatin | TP53 protein affects the reaction [Oxaliplatin results in decreased expression of DUT mRNA] | 19015155 |
D000077150 | Oxaliplatin | TP53 protein affects the reaction [Oxaliplatin results in decreased expression of DUT protein] | 19015155 |
D000077150 | Oxaliplatin | TP53 protein affects the susceptibility to Oxaliplatin | 15041737 |
D000077150 | Oxaliplatin | TP53 protein promotes the reaction [Oxaliplatin results in increased expression of CDKN1A protein] | 16227409 |
D000077150 | Oxaliplatin | TP53 protein results in increased susceptibility to Oxaliplatin | 16227409 |
C011030 | oxfendazole | oxfendazole results in decreased expression of TP53 mRNA | 26558467 |
D016627 | Oxidopamine | Oxidopamine results in increased expression of TP53 protein | 17368433 |
D016627 | Oxidopamine | SN50 peptide inhibits the reaction [Oxidopamine results in increased expression of TP53 protein] | 17368433 |
C005290 | oxybenzone | oxybenzone results in decreased expression of TP53 mRNA | 30316929 |
D010100 | Oxygen | Oxygen deficiency results in increased expression of TP53 protein | 10951577 |
D010100 | Oxygen | 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid inhibits the reaction [Oxygen deficiency results in increased expression of TP53 protein] | 10951577 |
D010100 | Oxygen | Acetylcysteine inhibits the reaction [Oxygen deficiency results in increased expression of TP53 protein] | 10951577 |
D010100 | Oxygen | Cisplatin promotes the reaction [Oxygen deficiency results in increased expression of TP53 protein] | 29690507 |
D010100 | Oxygen | Cisplatin promotes the reaction [Oxygen deficiency results in increased expression of TP53 protein mutant form] | 29690507 |
D010100 | Oxygen | Ditiocarb inhibits the reaction [Oxygen deficiency results in increased expression of TP53 protein] | 10951577 |
D010100 | Oxygen | Oxygen deficiency affects the activity of TP53 protein | 25596134 |
D010100 | Oxygen | Oxygen deficiency inhibits the reaction [Etoposide results in increased phosphorylation of TP53 protein] | 23144690 |
D010100 | Oxygen | Oxygen deficiency promotes the reaction [HIF1A protein binds to TP53 protein mutant form] | 30381462 |
D010100 | Oxygen | Oxygen deficiency results in increased expression of and results in increased activity of TP53 protein | 10951577 |
D010100 | Oxygen | Oxygen deficiency results in increased expression of TP53 protein | 29690507 |
D010100 | Oxygen | Oxygen deficiency results in increased expression of TP53 protein mutant form | 29690507 |
D010100 | Oxygen | Oxygen deficiency results in increased stability of TP53 protein | 30381462 |
D010100 | Oxygen | [Tetrachlorodibenzodioxin co-treated with Oxygen deficiency] results in decreased expression of TP53 mRNA | 19578757 |
D010100 | Oxygen | [Tetrachlorodibenzodioxin co-treated with Oxygen deficiency] results in decreased expression of TP53 protein | 19578757 |
D010100 | Oxygen | TP53 protein affects the reaction [Cisplatin inhibits the reaction [Oxygen deficiency results in increased expression of HIF1A protein]] | 29690507 |
D010100 | Oxygen | TP53 protein affects the reaction [[Oxygen deficiency co-treated with Cisplatin] results in increased expression of CDKN1A mRNA] | 29690507 |
D010100 | Oxygen | TP53 protein mutant form promotes the reaction [Oxygen deficiency results in increased expression of COL13A1 mRNA] | 30381462 |
D010100 | Oxygen | TP53 protein mutant form promotes the reaction [Oxygen deficiency results in increased expression of COL7A1 mRNA] | 30381462 |
D010100 | Oxygen | TP53 protein mutant form promotes the reaction [Oxygen deficiency results in increased expression of COL7A1 protein] | 30381462 |
D010100 | Oxygen | TP53 protein mutant form promotes the reaction [Oxygen deficiency results in increased expression of LAMC1 mRNA] | 30381462 |
D010100 | Oxygen | TP53 protein mutant form promotes the reaction [Oxygen deficiency results in increased expression of LAMC2 mRNA] | 30381462 |
D010100 | Oxygen | TP53 protein mutant form promotes the reaction [Oxygen deficiency results in increased expression of LAMC2 protein] | 30381462 |
D010100 | Oxygen | TP53 protein mutant form results in increased susceptibility to Oxygen deficiency | 30381462 |
D010100 | Oxygen | mangiferin inhibits the reaction [Oxygen deficiency results in increased expression of TP53 protein] | 10657591 |
D010100 | Oxygen | [Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of TP53 protein | 23451161 |
D010100 | Oxygen | Oxygen deficiency results in increased expression of TP53 protein | 10657591 |
D010100 | Oxygen | TP53 protein affects the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of NDRG2] | 23451161 |
D010100 | Oxygen | TP53 protein affects the susceptibility to [Oxygen deficiency co-treated with Glucose deficiency] | 23451161 |
D017239 | Paclitaxel | [Doxorubicin co-treated with Paclitaxel] results in increased expression of TP53 protein | 16168113 |
D017239 | Paclitaxel | Fluorouracil promotes the reaction [[Doxorubicin co-treated with Paclitaxel] results in increased expression of TP53 protein] | 16168113 |
D017239 | Paclitaxel | Nicotine inhibits the reaction [Paclitaxel results in increased expression of TP53 protein] | 16601104 |
D017239 | Paclitaxel | Paclitaxel inhibits the reaction [TP53 gene mutant form results in decreased susceptibility to Platinum Compounds] | 12440809 |
D017239 | Paclitaxel | Paclitaxel results in decreased expression of TP53 protein | 11774260 |
D017239 | Paclitaxel | Paclitaxel results in increased expression of TP53 protein | 11774260; 12082016; 14991574; 15990222; 16601104; 18516295; 19815708; 9041188; |
D017239 | Paclitaxel | Paclitaxel results in increased expression of TP53 protein modified form | 18451153 |
D017239 | Paclitaxel | [Paclitaxel results in increased expression of TP53 protein] which results in increased expression of BAX mRNA | 9041188 |
D017239 | Paclitaxel | [Paclitaxel results in increased expression of TP53 protein] which results in increased expression of CDKN1A mRNA | 9041188 |
D017239 | Paclitaxel | [Paclitaxel results in increased expression of TP53 protein] which results in increased expression of GADD45A mRNA | 9041188 |
D017239 | Paclitaxel | [PD168393 co-treated with Paclitaxel] results in increased expression of TP53 protein | 16413505 |
D017239 | Paclitaxel | TP53 protein results in decreased susceptibility to Paclitaxel | 15990222; 16734730; |
D017239 | Paclitaxel | Paclitaxel results in increased expression of TP53 protein | 9231689 |
C500026 | palbociclib | TP53 protein mutant form results in decreased susceptibility to palbociclib | 21278246 |
D010168 | Palmitates | Palmitates results in increased acetylation of TP53 protein | 20068143 |
D010168 | Palmitates | Resveratrol inhibits the reaction [Palmitates results in increased acetylation of TP53 protein] | 20068143 |
D010168 | Palmitates | SIRT1 protein promotes the reaction [Resveratrol inhibits the reaction [Palmitates results in increased acetylation of TP53 protein]] | 20068143 |
D019308 | Palmitic Acid | [Palmitic Acid co-treated with Glucose] results in increased acetylation of TP53 protein | 24451382 |
D019308 | Palmitic Acid | SIRT1 protein inhibits the reaction [[Palmitic Acid co-treated with Glucose] results in increased acetylation of TP53 protein] | 24451382 |
D000077767 | Panobinostat | [Panobinostat co-treated with SRT2183] results in increased acetylation of TP53 protein | 23681230 |
D000077767 | Panobinostat | Panobinostat results in increased acetylation of TP53 protein | 23681230 |
D010269 | Paraquat | Paraquat results in increased expression of TP53 mRNA | 27288846 |
D010269 | Paraquat | Paraquat results in increased expression of TP53 mRNA | 15458575 |
D010269 | Paraquat | Paraquat promotes the reaction [Trientine results in increased phosphorylation of TP53 protein] | 11369509 |
D010269 | Paraquat | Paraquat results in increased expression of TP53 mRNA | 18836921; 19526292; 24060684; |
D010269 | Paraquat | Paraquat results in increased expression of TP53 protein | 10969820; 15162845; 18253895; 28428137; |
D010269 | Paraquat | Paraquat results in increased phosphorylation of TP53 protein | 11369509 |
D010269 | Paraquat | Paraquat results in increased expression of TP53 | 28428137 |
D010269 | Paraquat | [7-nitroindazole results in decreased chemical synthesis of Nitric Oxide] inhibits the reaction [Paraquat results in increased phosphorylation of TP53 protein] | 20478973 |
D010269 | Paraquat | NFE2L2 mutant form inhibits the reaction [Paraquat results in increased expression of TP53 mRNA] | 22678742 |
D010269 | Paraquat | Paraquat results in decreased expression of TP53 mRNA | 18198484 |
D010269 | Paraquat | Paraquat results in increased expression of TP53 mRNA | 22678742; 24912633; |
D010269 | Paraquat | Paraquat results in increased expression of TP53 protein | 17561093 |
D010269 | Paraquat | Paraquat results in increased phosphorylation of TP53 protein | 20478973 |
D010269 | Paraquat | Sodium Salicylate inhibits the reaction [Paraquat results in increased expression of TP53 protein] | 17561093 |
D010278 | Parathion | Atropine inhibits the reaction [Parathion results in increased expression of TP53 protein] | 12762645 |
D010278 | Parathion | [Parathion co-treated with Estradiol] results in increased expression of TP53 protein mutant form | 17622325 |
D010278 | Parathion | Parathion results in increased expression of TP53 protein | 12762645; 19787260; |
D010278 | Parathion | Parathion results in increased expression of TP53 protein mutant form | 17390078; 17622325; |
C002669 | parthenolide | parthenolide results in increased expression of TP53 protein | 16024633 |
D052638 | Particulate Matter | Particulate Matter analog results in increased mutagenesis of TP53 gene | 10682588 |
D052638 | Particulate Matter | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Particulate Matter results in decreased expression of TP53 protein] | 26942697 |
D052638 | Particulate Matter | Acetylcysteine inhibits the reaction [Particulate Matter results in decreased expression of TP53 protein] | 26942697 |
D052638 | Particulate Matter | DNMT3B protein affects the reaction [Particulate Matter results in decreased expression of TP53 protein] | 26942697 |
D052638 | Particulate Matter | DNMT3B protein affects the reaction [Particulate Matter results in increased methylation of TP53 promoter] | 26942697 |
D052638 | Particulate Matter | Particulate Matter results in decreased expression of TP53 mRNA | 26942697; 28366736; |
D052638 | Particulate Matter | Particulate Matter results in decreased expression of TP53 protein | 26942697 |
D052638 | Particulate Matter | Particulate Matter results in decreased phosphorylation of and results in decreased expression of TP53 protein | 25336953 |
D052638 | Particulate Matter | Particulate Matter results in increased expression of TP53 mRNA | 23454527 |
D052638 | Particulate Matter | Particulate Matter results in increased expression of TP53 protein | 20850422; 21818627; |
D052638 | Particulate Matter | Particulate Matter results in increased methylation of TP53 promoter | 26942697 |
D052638 | Particulate Matter | Particulate Matter results in increased phosphorylation of TP53 protein | 20850422 |
D052638 | Particulate Matter | TP53 protein polymorphism affects the susceptibility to Particulate Matter | 19750108 |
D052638 | Particulate Matter | [[Vehicle Emissions results in increased abundance of Particulate Matter] which results in decreased expression of MDM2 protein] which results in increased expression of TP53 protein | 28013216 |
D052638 | Particulate Matter | [Vehicle Emissions results in increased abundance of Particulate Matter] which results in increased expression of TP53 protein | 28013216 |
D052638 | Particulate Matter | Particulate Matter results in increased expression of TP53 mRNA | 24216475 |
D010365 | Patulin | Patulin results in increased expression of TP53 protein | 19744505 |
C410127 | PCB 180 | PCB 180 promotes the reaction [leptomycin B results in increased expression of TP53 protein] | 19751709 |
C410127 | PCB 180 | PCB 180 results in increased expression of TP53 protein | 19751709 |
C509204 | PD168393 | [PD168393 co-treated with Paclitaxel] results in increased expression of TP53 protein | 16413505 |
D000068437 | Pemetrexed | TP53 protein affects the reaction [Pemetrexed results in increased expression of FAS protein] | 15161716 |
D000068437 | Pemetrexed | TP53 protein affects the susceptibility to Pemetrexed | 17339891 |
D010396 | Penicillamine | Penicillamine results in decreased expression of TP53 mRNA | 22843330 |
D010396 | Penicillamine | Penicillamine results in increased expression of TP53 protein | 22843330 |
C074968 | pentaacetyl geniposide | pentaacetyl geniposide results in increased activity of TP53 protein | 15975050 |
C086401 | pentabromodiphenyl ether | pentabromodiphenyl ether results in increased expression of TP53 mRNA | 19858236 |
C086401 | pentabromodiphenyl ether | pentabromodiphenyl ether results in decreased expression of TP53 mRNA | 23948077 |
D010416 | Pentachlorophenol | Pentachlorophenol results in increased mutagenesis of TP53 gene | 16904934 |
D010416 | Pentachlorophenol | Pentachlorophenol affects the expression of TP53 protein | 12724925 |
D010416 | Pentachlorophenol | Pentachlorophenol results in increased phosphorylation of TP53 protein | 19442831 |
D010419 | Pentamidine | Pentamidine inhibits the reaction [KAT5 protein results in increased acetylation of TP53 protein] | 20144237 |
C046012 | pentanal | pentanal results in decreased expression of TP53 mRNA | 26079696 |
D004369 | Pentetic Acid | Pentetic Acid inhibits the reaction [pyrithione zinc results in increased expression of TP53 protein] | 21557991 |
D004369 | Pentetic Acid | Pentetic Acid inhibits the reaction [pyrithione zinc results in increased phosphorylation of TP53 protein] | 21557991 |
C015423 | peoniflorin | peoniflorin inhibits the reaction [cobaltous chloride results in increased expression of TP53 mRNA] | 22269387 |
C076994 | perfluorooctane sulfonic acid | perfluorooctane sulfonic acid results in increased expression of TP53 mRNA | 18407306 |
C076994 | perfluorooctane sulfonic acid | perfluorooctane sulfonic acid results in decreased expression of TP53 protein | 29063134 |
C076994 | perfluorooctane sulfonic acid | perfluorooctane sulfonic acid results in increased expression of TP53 mRNA | 19468714 |
C076994 | perfluorooctane sulfonic acid | perfluorooctane sulfonic acid results in increased expression of TP53 protein | 24301089 |
C076994 | perfluorooctane sulfonic acid | perfluorooctane sulfonic acid results in increased expression of TP53 mRNA | 24616003 |
C076994 | perfluorooctane sulfonic acid | perfluorooctane sulfonic acid results in increased expression of TP53 protein | 24616003 |
C023036 | perfluorooctanoic acid | perfluorooctanoic acid results in decreased expression of TP53 mRNA | 23427857 |
C023036 | perfluorooctanoic acid | perfluorooctanoic acid results in increased expression of TP53 mRNA | 25868421 |
C011272 | perfosfamide | Acetylcysteine inhibits the reaction [perfosfamide results in increased expression of TP53] | 18034189 |
C011272 | perfosfamide | perfosfamide results in increased expression of TP53 | 18034189 |
D010479 | Pergolide | Pergolide inhibits the reaction [Hydrogen Peroxide results in increased expression of TP53 protein] | 15081873 |
D010479 | Pergolide | Pergolide inhibits the reaction [[Hydrogen Peroxide results in increased expression of TP53 protein] which results in increased expression of BAX protein] | 15081873 |
D010479 | Pergolide | Pergolide inhibits the reaction [[Hydrogen Peroxide results in increased expression of TP53 protein] which results in increased expression of CDKN1A protein] | 15081873 |
D010479 | Pergolide | Pergolide inhibits the reaction [[Hydrogen Peroxide results in increased expression of TP53 protein] which results in increased expression of MSH2 protein] | 15081873 |
C105905 | perifosine | perifosine inhibits the reaction [cyadox results in increased expression of TP53 mRNA] | 30265530 |
C105905 | perifosine | perifosine inhibits the reaction [cyadox results in increased expression of TP53 protein] | 30265530 |
C105905 | perifosine | perifosine inhibits the reaction [Hydrogen Peroxide results in increased expression of TP53 mRNA] | 30265530 |
D026023 | Permethrin | [Pyridostigmine Bromide co-treated with DEET co-treated with Permethrin] results in increased expression of TP53 protein | 12587291 |
C570314 | PF-429242 | PF-429242 results in decreased expression of TP53 protein | 28483521 |
C062400 | PFL protocol | TP53 protein results in increased susceptibility to PFL protocol | 15611505 |
C058305 | phenethyl isothiocyanate | phenethyl isothiocyanate results in increased expression of TP53 protein | 16054126 |
D010630 | Phenindione | Phenindione results in increased degradation of TP53 protein | 14634213 |
D010634 | Phenobarbital | myrtenal inhibits the reaction [[Phenobarbital co-treated with Diethylnitrosamine] results in decreased expression of TP53 mRNA] | 22436021 |
D010634 | Phenobarbital | myrtenal inhibits the reaction [[Phenobarbital co-treated with Diethylnitrosamine] results in decreased expression of TP53 protein] | 22436021 |
D010634 | Phenobarbital | [Phenobarbital co-treated with Diethylnitrosamine] results in decreased expression of TP53 mRNA | 22436021 |
D010634 | Phenobarbital | [Phenobarbital co-treated with Diethylnitrosamine] results in decreased expression of TP53 protein | 22436021 |
D010634 | Phenobarbital | Phenobarbital promotes the reaction [Diethylnitrosamine results in increased expression of TP53 protein] | 11751435 |
D010634 | Phenobarbital | Phenobarbital results in decreased expression of TP53 mRNA | 25247799 |
D010634 | Phenobarbital | Phenobarbital results in decreased expression of TP53 protein | 25247799 |
D010634 | Phenobarbital | Phenobarbital results in increased expression of TP53 mRNA | 23273579 |
C066330 | phenylhydroquinone | bathocuproine inhibits the reaction [[phenylhydroquinone co-treated with Copper] results in increased mutagenesis of TP53 gene] | 10334203 |
C066330 | phenylhydroquinone | CAT protein inhibits the reaction [[phenylhydroquinone co-treated with Copper] results in increased mutagenesis of TP53 gene] | 10334203 |
C066330 | phenylhydroquinone | [phenylhydroquinone co-treated with Copper] results in increased mutagenesis of TP53 gene | 10334203 |
D010672 | Phenytoin | Phenytoin results in increased expression of TP53 mRNA | 11134551 |
D010702 | Phorate | Phorate results in increased expression of TP53 mRNA | 22197610 |
D010702 | Phorate | Phorate results in increased expression of TP53 protein | 22197610 |
C003117 | phosalone | Ellagic Acid inhibits the reaction [phosalone results in increased expression of TP53 mRNA] | 27965107 |
C003117 | phosalone | Ellagic Acid inhibits the reaction [phosalone results in increased expression of TP53 protein] | 27965107 |
C003117 | phosalone | phosalone results in increased expression of TP53 mRNA | 27965107 |
C003117 | phosalone | phosalone results in increased expression of TP53 protein | 27965107 |
D010713 | Phosphatidylcholines | Phosphatidylcholines inhibits the reaction [rubitecan results in increased expression of TP53 protein] | 21695227 |
D054735 | Phosphorothioate Oligonucleotides | Phosphorothioate Oligonucleotides results in increased expression of TP53 protein | 16498393 |
D010798 | Phycocyanin | Phycocyanin inhibits the reaction [Galactose results in increased expression of TP53 protein] | 23036742 |
D010833 | Phytic Acid | Phytic Acid inhibits the reaction [Asbestos, Amosite results in increased expression of TP53 mRNA] | 16357363 |
D010833 | Phytic Acid | Phytic Acid inhibits the reaction [Asbestos, Amosite results in increased expression of TP53 protein] | 16357363 |
D064209 | Phytochemicals | Acetylcysteine inhibits the reaction [Phytochemicals results in increased phosphorylation of TP53 protein] | 25305377 |
D064209 | Phytochemicals | Phytochemicals results in increased phosphorylation of TP53 protein | 25305377 |
C522973 | PI103 | PI103 inhibits the reaction [Doxorubicin results in increased expression of TP53 protein] | 20856197 |
C522973 | PI103 | TP53 protein promotes the reaction [[Doxorubicin co-treated with PI103] results in increased expression of BBC3 protein] | 20856197 |
C522973 | PI103 | TP53 protein promotes the reaction [PI103 promotes the reaction [Doxorubicin results in increased activity of BAX protein]] | 20856197 |
C522973 | PI103 | TP53 protein promotes the reaction [PI103 promotes the reaction [Doxorubicin results in increased cleavage of CASP3 protein]] | 20856197 |
C522973 | PI103 | TP53 protein promotes the reaction [PI103 promotes the reaction [Doxorubicin results in increased cleavage of CASP8 protein]] | 20856197 |
C522973 | PI103 | TP53 protein promotes the reaction [PI103 promotes the reaction [Doxorubicin results in increased cleavage of CASP9 protein]] | 20856197 |
C522973 | PI103 | TP53 protein results in increased susceptibility to [Doxorubicin co-treated with PI103] | 20856197 |
C556557 | picoxystrobin | picoxystrobin results in increased activity of TP53 protein | 30818834 |
C121565 | pifithrin | [pifithrin co-treated with cobaltous chloride] results in increased expression of and affects the localization of TP53 protein | 23380477 |
C121565 | pifithrin | pifithrin inhibits the reaction [Asbestos, Amosite affects the localization of TP53 protein] | 16357363 |
C121565 | pifithrin | pifithrin inhibits the reaction [Asbestos, Amosite results in increased expression of TP53 protein] | 16357363 |
C121565 | pifithrin | pifithrin inhibits the reaction [Benzo(a)pyrene results in increased expression of TP53 protein] | 16258175 |
C121565 | pifithrin | pifithrin inhibits the reaction [Capsaicin results in increased phosphorylation of and results in increased activity of TP53 protein] | 22226932 |
C121565 | pifithrin | pifithrin inhibits the reaction [Celecoxib results in increased expression of TP53 protein] | 19706164 |
C121565 | pifithrin | pifithrin inhibits the reaction [Cisplatin results in increased expression of TP53 protein] | 21660965 |
C121565 | pifithrin | pifithrin inhibits the reaction [CITED2 mutant form promotes the reaction [Cisplatin results in increased expression of TP53 protein]] | 21660965 |
C121565 | pifithrin | pifithrin inhibits the reaction [Ellagic Acid promotes the reaction [Quercetin results in increased phosphorylation of TP53 protein]] | 15735102 |
C121565 | pifithrin | pifithrin inhibits the reaction [Etoposide results in increased activity of TP53 protein] | 16882877 |
C121565 | pifithrin | pifithrin inhibits the reaction [goniothalamin results in increased phosphorylation of and results in increased expression of TP53 protein] | 21810437 |
C121565 | pifithrin | pifithrin inhibits the reaction [[KITLG protein co-treated with EDN1 protein] results in increased phosphorylation of TP53 protein] | 19098008 |
C121565 | pifithrin | pifithrin inhibits the reaction [KITLG protein results in increased phosphorylation of TP53 protein] | 19098008 |
C121565 | pifithrin | pifithrin inhibits the reaction [olaquindox results in decreased expression of TP53 protein] | 28757460 |
C121565 | pifithrin | pifithrin inhibits the reaction [Pyrroles analog results in increased phosphorylation of TP53 protein] | 30543781 |
C121565 | pifithrin | pifithrin inhibits the reaction [Quercetin results in increased phosphorylation of TP53 protein] | 15735102; 22983795; |
C121565 | pifithrin | pifithrin inhibits the reaction [Reactive Oxygen Species affects the localization of TP53 protein] | 26884717 |
C121565 | pifithrin | pifithrin inhibits the reaction [Resveratrol results in increased expression of and results in increased phosphorylation of TP53 protein] | 11889192 |
C121565 | pifithrin | pifithrin inhibits the reaction [Resveratrol results in increased phosphorylation of TP53 protein] | 16814113 |
C121565 | pifithrin | pifithrin inhibits the reaction [Silybin results in increased phosphorylation of TP53 protein] | 16777994 |
C121565 | pifithrin | pifithrin inhibits the reaction [Simvastatin results in increased expression of TP53 protein] | 20045437 |
C121565 | pifithrin | pifithrin inhibits the reaction [Smoke analog results in increased expression of TP53 mRNA] | 23665932 |
C121565 | pifithrin | pifithrin inhibits the reaction [SOX30 protein results in increased expression of TP53 mRNA] | 25435374 |
C121565 | pifithrin | pifithrin inhibits the reaction [SOX30 protein results in increased expression of TP53 protein] | 25435374 |
C121565 | pifithrin | pifithrin inhibits the reaction [TP53 protein promotes the reaction [chromium hexavalent ion results in decreased expression of BUB1B protein]] | 22886373 |
C121565 | pifithrin | pifithrin inhibits the reaction [TP53 protein results in increased susceptibility to Resveratrol] | 23152798 |
C121565 | pifithrin | pifithrin inhibits the reaction [TP53 protein results in increased susceptibility to trichostatin A] | 16467109 |
C121565 | pifithrin | pifithrin inhibits the reaction [TP53 results in increased susceptibility to Celecoxib] | 19706164 |
C121565 | pifithrin | pifithrin results in decreased activity of TP53 protein | 20878077; 22886373; 25956474; 26259609; |
C121565 | pifithrin | [pifithrin results in decreased activity of TP53 protein] results in decreased susceptibility to [Oxaliplatin results in increased activity of CASP3 protein] | 20708607 |
C121565 | pifithrin | [pifithrin results in decreased activity of TP53 protein] which results in decreased susceptibility to Oxaliplatin | 20708607 |
C121565 | pifithrin | pifithrin results in decreased expression of TP53 protein | 12893085; 16467109; 16777994; |
C121565 | pifithrin | pifithrin results in decreased phosphorylation of TP53 protein | 19735649; 21810437; |
C121565 | pifithrin | [pifithrin results in decreased phosphorylation of TP53 protein] inhibits the reaction [Oxaliplatin results in increased expression of H2AX protein modified form] | 19735649 |
C121565 | pifithrin | pifithrin results in decreased susceptibility to [Oxaliplatin results in increased expression of TP53 protein] | 20708607 |
C121565 | pifithrin | pifithrin results in decreased susceptibility to [Oxaliplatin results in increased expression of TP53 protein modified form] | 20708607 |
C121565 | pifithrin | [pifithrin results in decreased activity of TP53 protein] which results in decreased susceptibility to deoxynivalenol | 22491426 |
C121565 | pifithrin | pifithrin inhibits the reaction [APP protein alternative form results in increased phosphorylation of TP53 protein] | 24567336 |
C121565 | pifithrin | pifithrin inhibits the reaction [Arsenic Trioxide results in increased activity of TP53 protein] | 17487067 |
C121565 | pifithrin | pifithrin inhibits the reaction [Camptothecin promotes the reaction [TP53 protein binds to CREBBP protein]] | 13679428 |
C121565 | pifithrin | pifithrin inhibits the reaction [Camptothecin results in increased activity of TP53 protein] | 11279278; 13679428; |
C121565 | pifithrin | pifithrin inhibits the reaction [Cisplatin results in increased activity of TP53 protein] | 15315938 |
C121565 | pifithrin | pifithrin inhibits the reaction [cyanoginosin LR results in increased expression of TP53 protein] | 31157505 |
C121565 | pifithrin | pifithrin inhibits the reaction [dibenzo(a,l)pyrene results in increased phosphorylation of TP53 protein] | 16005925 |
C121565 | pifithrin | pifithrin inhibits the reaction [Diquat results in increased expression of and affects the localization of TP53 protein] | 29484840 |
C121565 | pifithrin | pifithrin inhibits the reaction [Doxorubicin results in increased expression of and results in increased localization of TP53 protein modified form] | 18775851 |
C121565 | pifithrin | pifithrin inhibits the reaction [Doxorubicin results in increased expression of and results in increased phosphorylation of and results in increased activity of TP53 protein] | 16687611 |
C121565 | pifithrin | pifithrin inhibits the reaction [Doxorubicin results in increased phosphorylation of and results in increased localization of TP53 protein] | 18775851 |
C121565 | pifithrin | pifithrin inhibits the reaction [Lipopolysaccharides results in increased localization of TP53 protein] | 12665479 |
C121565 | pifithrin | pifithrin inhibits the reaction [TP53 protein results in increased expression of CDKN1A protein] | 15144874 |
C121565 | pifithrin | pifithrin inhibits the reaction [TP53 protein results in increased susceptibility to Cisplatin] | 15315938 |
C121565 | pifithrin | pifithrin inhibits the reaction [triptolide results in increased expression of TP53 protein] | 30009776 |
C121565 | pifithrin | pifithrin inhibits the reaction [triptolide results in increased expression of TP53 protein modified form] | 30009776 |
C121565 | pifithrin | pifithrin results in decreased activity of TP53 protein | 11279278; 12143041; 13679428; |
C121565 | pifithrin | pifithrin results in decreased expression of TP53 protein | 18364113 |
C121565 | pifithrin | TP53 protein affects the reaction [pifithrin results in decreased expression of TGFA protein] | 12143041 |
C121565 | pifithrin | pifithrin results in decreased activity of TP53 | 19728331 |
C121565 | pifithrin | pifithrin results in decreased activity of TP53 protein | 12967348; 15753979; 15996546; 16005638; 16061640; 18557930; 18660518; 19098008; 19475672; 19541794; 20708607; 22044530; 22491426; 23152798; |
C121565 | pifithrin | pifithrin results in decreased expression of TP53 mRNA | 21810437 |
C121565 | pifithrin | pifithrin results in decreased susceptibility to [1-nitropyrene results in increased activity of TP53 protein] | 22044530 |
C121565 | pifithrin | pifithrin results in decreased susceptibility to [Benzo(a)pyrene results in increased activity of TP53 protein] | 22044530 |
C049032 | pinosylvin | pinosylvin results in increased expression of TP53 protein | 23333577 |
C032727 | piperidine | piperidine promotes the reaction [[Copper co-treated with 1,2-diphenylhydrazine] results in increased mutagenesis of TP53 gene] | 10798712 |
C008922 | piperine | [piperine co-treated with Curcumin] results in decreased expression of TP53 protein | 30935902 |
C498077 | piperlonguminine | piperlonguminine affects the localization of TP53 protein | 26026911 |
C006253 | pirinixic acid | pirinixic acid results in increased expression of TP53 mRNA | 22484513 |
D010894 | Piroxicam | Piroxicam promotes the reaction [Cisplatin results in increased expression of TP53 protein] | 21858171 |
D010936 | Plant Extracts | Plant Extracts inhibits the reaction [TNFSF10 protein results in increased expression of TP53 protein] | 20971099 |
D010936 | Plant Extracts | Plant Extracts results in decreased expression of TP53 mRNA | 22143989 |
D010936 | Plant Extracts | Plant Extracts results in increased expression of TP53 | 21300767 |
D010936 | Plant Extracts | Plant Extracts results in increased expression of TP53 mRNA | 22143989; 23911803; 30905866; |
D010936 | Plant Extracts | Plant Extracts results in increased expression of TP53 protein | 18834353; 22143989; 24677778; 26122529; 30905866; |
D010936 | Plant Extracts | Plant Extracts inhibits the reaction [Cisplatin results in increased expression of TP53 mRNA] | 25640527 |
D010936 | Plant Extracts | Plant Extracts inhibits the reaction [decamethrin results in increased expression of TP53 protein] | 28595958 |
D010936 | Plant Extracts | Plant Extracts inhibits the reaction [Diethylnitrosamine results in increased expression of TP53 protein] | 18367157 |
D010936 | Plant Extracts | Plant Extracts results in decreased expression of TP53 | 25616030 |
D010936 | Plant Extracts | Plant Extracts results in increased expression of TP53 mRNA | 20521779 |
D010938 | Plant Oils | Plant Oils results in increased expression of TP53 protein | 15961301 |
D028321 | Plant Preparations | LRP1 protein promotes the reaction [Plant Preparations results in increased phosphorylation of TP53 protein] | 27262837 |
D028321 | Plant Preparations | Plant Preparations results in increased phosphorylation of TP53 protein | 27262837 |
D028321 | Plant Preparations | Plant Preparations results in increased expression of TP53 mRNA | 24973489 |
D017671 | Platinum Compounds | Paclitaxel inhibits the reaction [TP53 gene mutant form results in decreased susceptibility to Platinum Compounds] | 12440809 |
D017671 | Platinum Compounds | TP53 affects the susceptibility to Platinum Compounds | 12440809 |
D017671 | Platinum Compounds | TP53 gene mutant form results in decreased susceptibility to Platinum Compounds | 12440809 |
C108953 | platycodin D | platycodin D results in decreased expression of TP53 protein mutant form | 27432230 |
C422648 | pluronic block copolymer p85 | pluronic block copolymer p85 promotes the reaction [Doxorubicin results in increased expression of TP53 mRNA] | 15939500 |
D011078 | Polychlorinated Biphenyls | Polychlorinated Biphenyls results in decreased expression of TP53 protein | 24960055 |
D011078 | Polychlorinated Biphenyls | Polychlorinated Biphenyls results in increased expression of TP53 protein | 24960055 |
D000072317 | Polychlorinated Dibenzodioxins | [Polychlorinated Dibenzodioxins co-treated with Dibenzofurans, Polychlorinated] results in increased expression of TP53 mRNA | 17850846 |
D011084 | Polycyclic Aromatic Hydrocarbons | Polycyclic Aromatic Hydrocarbons results in decreased methylation of TP53 promoter | 19892797 |
C058229 | polydatin | polydatin inhibits the reaction [Arsenic Trioxide results in increased expression of TP53 mRNA] | 29130132 |
D011094 | Polyethyleneimine | [Niclosamide binds to Polyethyleneimine] which results in increased expression of TP53 mRNA | 25988281 |
C060540 | polyhexamethyleneguanidine | polyhexamethyleneguanidine results in increased expression of TP53 protein | 24583197 |
C060540 | polyhexamethyleneguanidine | polyhexamethyleneguanidine results in increased expression of TP53 protein modified form | 29309811 |
D011070 | Poly I-C | TP53 protein affects the reaction [Poly I-C affects the localization of RELA protein] | 18779317 |
D011070 | Poly I-C | TP53 protein affects the reaction [Poly I-C results in increased expression of CXCL8 mRNA] | 18779317 |
D011070 | Poly I-C | TP53 protein affects the reaction [Poly I-C results in increased expression of IFNB1 mRNA] | 18779317 |
D011070 | Poly I-C | TP53 protein affects the reaction [Poly I-C results in increased phosphorylation of IRF3 protein] | 18779317 |
D011070 | Poly I-C | TP53 protein affects the reaction [Poly I-C results in increased phosphorylation of NFKBIA protein] | 18779317 |
D011070 | Poly I-C | TP53 results in increased susceptibility to [Poly I-C co-treated with Fluorouracil] | 20367642 |
D059808 | Polyphenols | Bleomycin promotes the reaction [Polyphenols results in increased expression of TP53 mRNA] | 26800624 |
D059808 | Polyphenols | Polyphenols promotes the reaction [Bleomycin results in increased expression of TP53 mRNA] | 26800624 |
D059808 | Polyphenols | Polyphenols results in increased expression of TP53 mRNA | 26800624; 30529121; |
C472086 | polyphenon E | polyphenon E results in increased expression of TP53 protein | 23285096 |
C472086 | polyphenon E | TP53 mutant form promotes the reaction [polyphenon E results in decreased expression of HDAC1 protein] | 23285096 |
C472086 | polyphenon E | TP53 mutant form promotes the reaction [polyphenon E results in decreased expression of HDAC2 protein] | 23285096 |
C472086 | polyphenon E | TP53 mutant form promotes the reaction [polyphenon E results in decreased expression of HDAC3 protein] | 23285096 |
D011134 | Polysaccharides | Polysaccharides results in increased expression of TP53 mRNA | 23911803 |
D011134 | Polysaccharides | Polysaccharides inhibits the reaction [sodium arsenite results in increased expression of TP53 mRNA] | 31163222 |
D011134 | Polysaccharides | Polysaccharides inhibits the reaction [sodium arsenite results in increased phosphorylation of TP53 protein] | 31163222 |
C019536 | potassium bromate | 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [potassium bromate results in increased phosphorylation of TP53 protein] | 20067818 |
C019536 | potassium bromate | Ascorbic Acid inhibits the reaction [potassium bromate results in increased phosphorylation of TP53 protein] | 20067818 |
C019536 | potassium bromate | potassium bromate results in increased phosphorylation of TP53 protein | 20067818 |
C019536 | potassium bromate | potassium bromate results in increased phosphorylation of TP53 protein | 20067818; 25015661; |
D011189 | Potassium Chloride | [Desoxycorticosterone Acetate co-treated with Sodium Chloride, Dietary co-treated with Potassium Chloride] results in increased expression of TP53 mRNA | 22228705 |
C027373 | potassium chromate(VI) | 2-(2,6-dimethylmorpholin-4-yl)-N-(5-(6-morpholin-4-yl-4-oxo-4H-pyran-2-yl)-9H-thioxanthen-2-yl)acetamide inhibits the reaction [potassium chromate(VI) results in increased expression of TP53 protein modified form] | 25977998 |
C027373 | potassium chromate(VI) | 2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one inhibits the reaction [potassium chromate(VI) results in increased expression of TP53 protein modified form] | 25977998 |
C027373 | potassium chromate(VI) | Ascorbic Acid inhibits the reaction [potassium chromate(VI) results in increased expression of TP53 protein] | 25977998 |
C027373 | potassium chromate(VI) | Ascorbic Acid inhibits the reaction [potassium chromate(VI) results in increased expression of TP53 protein modified form] | 25977998 |
C027373 | potassium chromate(VI) | potassium chromate(VI) promotes the reaction [7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide binds to TP53 gene] | 12727806 |
C027373 | potassium chromate(VI) | potassium chromate(VI) results in increased expression of TP53 protein | 25977998 |
C027373 | potassium chromate(VI) | potassium chromate(VI) results in increased expression of TP53 protein modified form | 25977998 |
C120482 | potassium diazoacetate | potassium diazoacetate results in increased mutagenesis of TP53 gene | 16926174 |
D011192 | Potassium Dichromate | nickel sulfate inhibits the reaction [Potassium Dichromate results in increased phosphorylation of TP53 protein] | 20493934 |
D011192 | Potassium Dichromate | Potassium Dichromate results in increased phosphorylation of TP53 protein | 20493934 |
D011192 | Potassium Dichromate | Acetylcysteine inhibits the reaction [Potassium Dichromate results in increased expression of TP53 protein] | 18563748 |
D011192 | Potassium Dichromate | Ascorbic Acid inhibits the reaction [Potassium Dichromate results in increased expression of and results in increased phosphorylation of TP53 protein] | 21262251 |
D011192 | Potassium Dichromate | Ascorbic Acid inhibits the reaction [Potassium Dichromate results in increased expression of TP53 mRNA] | 21262251 |
D011192 | Potassium Dichromate | Ascorbic Acid inhibits the reaction [Potassium Dichromate results in increased localization of TP53 protein modified form] | 21262251 |
D011192 | Potassium Dichromate | Carvedilol inhibits the reaction [Potassium Dichromate results in increased expression of TP53 protein] | 25245570 |
D011192 | Potassium Dichromate | Potassium Dichromate results in increased expression of and results in increased phosphorylation of TP53 protein | 21262251 |
D011192 | Potassium Dichromate | Potassium Dichromate results in increased expression of TP53 mRNA | 18547707; 21262251; |
D011192 | Potassium Dichromate | Potassium Dichromate results in increased expression of TP53 protein | 18563748; 25245570; 26348139; |
D011192 | Potassium Dichromate | Potassium Dichromate results in increased localization of TP53 protein modified form | 21262251 |
D011205 | Povidone | [Silver co-treated with Povidone] affects the phosphorylation of TP53 protein | 27387714 |
D011205 | Povidone | [Silver co-treated with Povidone] results in decreased expression of TP53 mRNA | 27387714 |
D011205 | Povidone | [Silver co-treated with Povidone] results in decreased expression of TP53 protein | 27387714 |
D017035 | Pravastatin | Pravastatin inhibits the reaction [Fluorouracil results in decreased degradation of TP53 protein] | 15625077 |
D017035 | Pravastatin | Pravastatin inhibits the reaction [leptomycin B results in decreased degradation of TP53 protein] | 15625077 |
D017035 | Pravastatin | Pravastatin inhibits the reaction [lopinavir-ritonavir drug combination results in increased expression of TP53 protein] | 20884875 |
D017035 | Pravastatin | Pravastatin inhibits the reaction [Ritonavir results in increased expression of TP53 protein] | 20884875 |
D017035 | Pravastatin | [Pravastatin results in increased phosphorylation of MDM2 protein] which results in increased degradation of TP53 protein | 15625077 |
D017035 | Pravastatin | Pravastatin inhibits the reaction [Cisplatin results in increased expression of TP53 protein] | 20650967 |
D044945 | Proanthocyanidins | Proanthocyanidins results in increased expression of TP53 mRNA | 29654773 |
D044945 | Proanthocyanidins | Proanthocyanidins results in increased expression of TP53 protein | 29654773 |
C017674 | procyanidin | procyanidin results in decreased phosphorylation of TP53 protein | 15827326 |
D011370 | Proflavine | Proflavine results in increased activity of TP53 protein | 30818834 |
D011374 | Progesterone | Progesterone results in decreased expression of TP53 mRNA | 23012394 |
D011374 | Progesterone | Progesterone results in decreased expression of TP53 protein | 14529565 |
D011374 | Progesterone | Progesterone results in increased expression of TP53 mRNA | 18850315 |
D011374 | Progesterone | Progesterone results in increased expression of TP53 protein | 18850315 |
D011374 | Progesterone | TP53 mutant form inhibits the reaction [Progesterone results in increased expression of CDKN1A mRNA] | 18850315 |
D011374 | Progesterone | TP53 mutant form inhibits the reaction [Progesterone results in increased expression of CDKN1A protein] | 18850315 |
D011374 | Progesterone | TP53 mutant form inhibits the reaction [Progesterone results in increased expression of CDKN1B mRNA] | 18850315 |
D011374 | Progesterone | TP53 mutant form inhibits the reaction [Progesterone results in increased expression of CDKN1B protein] | 18850315 |
D011374 | Progesterone | TP53 protein results in increased susceptibility to Progesterone | 14529565 |
D011374 | Progesterone | [Estradiol co-treated with Methylnitrosourea co-treated with Progesterone] results in decreased expression of TP53 mRNA | 20732338 |
D011374 | Progesterone | [Methylnitrosourea co-treated with Progesterone] results in decreased expression of TP53 mRNA | 20732338 |
D011374 | Progesterone | [TP53 protein co-treated with LEP protein] results in increased secretion of Progesterone | 22151798 |
D011374 | Progesterone | TP53 protein results in decreased secretion of Progesterone | 22151798 |
D011374 | Progesterone | TP53 protein results in decreased abundance of Progesterone | 18703674 |
D011372 | Progestins | TP53 protein inhibits the reaction [Progestins results in increased expression of VEGFA mRNA] | 15860260 |
C066229 | prolinedithiocarbamate | [Acetylcysteine co-treated with N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine] inhibits the reaction [[Zinc Sulfate co-treated with prolinedithiocarbamate] results in decreased expression of TP53 protein] | 18951928 |
C066229 | prolinedithiocarbamate | Acetylcysteine inhibits the reaction [[Zinc Sulfate co-treated with prolinedithiocarbamate] results in decreased expression of TP53 protein] | 18951928 |
C066229 | prolinedithiocarbamate | benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Zinc Sulfate co-treated with prolinedithiocarbamate] results in decreased expression of TP53 protein] | 18951928 |
C066229 | prolinedithiocarbamate | N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine inhibits the reaction [[Zinc Sulfate co-treated with prolinedithiocarbamate] results in decreased expression of TP53 protein] | 18951928 |
C066229 | prolinedithiocarbamate | prolinedithiocarbamate results in increased phosphorylation of TP53 protein | 18951928 |
C066229 | prolinedithiocarbamate | [Zinc Sulfate co-treated with prolinedithiocarbamate] results in decreased expression of TP53 protein | 18951928 |
C066229 | prolinedithiocarbamate | Zinc Sulfate inhibits the reaction [prolinedithiocarbamate results in increased phosphorylation of TP53 protein] | 18951928 |
D011398 | Promethazine | Promethazine results in decreased expression of TP53 mRNA | 26011634 |
C045950 | propiconazole | propiconazole results in increased expression of TP53 mRNA | 29458080 |
C045950 | propiconazole | propiconazole results in decreased expression of TP53 mRNA | 26619215 |
C045950 | propiconazole | TP53 protein mutant form results in increased susceptibility to propiconazole | 26619215 |
C005556 | propionaldehyde | propionaldehyde results in decreased expression of TP53 mRNA | 26079696 |
D015742 | Propofol | Propofol results in increased expression of TP53 protein | 28804952 |
D015742 | Propofol | Propofol inhibits the reaction [Doxorubicin results in increased expression of TP53 protein] | 22015447 |
C006068 | propylparaben | [propylparaben co-treated with Butylated Hydroxyanisole] results in increased expression of TP53 protein | 25086368 |
C006068 | propylparaben | propylparaben results in increased expression of TP53 protein | 25086368 |
C006068 | propylparaben | propylparaben results in increased expression of TP53 mRNA | 24481588 |
C006068 | propylparaben | propylparaben results in increased expression of TP53 protein | 24481588 |
D011441 | Propylthiouracil | Propylthiouracil results in increased expression of TP53 mRNA | 24780913 |
D011458 | Prostaglandins E | TP53 protein results in increased secretion of Prostaglandins E | 18703674 |
D011460 | Prostaglandins F | TP53 protein results in decreased secretion of Prostaglandins F | 18703674 |
C043680 | ptaquiloside | ptaquiloside results in decreased expression of TP53 mRNA | 22143989 |
C043680 | ptaquiloside | ptaquiloside results in increased expression of TP53 mRNA | 22143989 |
C043680 | ptaquiloside | ptaquiloside results in increased expression of TP53 protein | 22143989 |
C107773 | pterostilbene | pterostilbene results in increased expression of TP53 mRNA | 20152895 |
D011692 | Puromycin Aminonucleoside | 1,3-dimethylthiourea inhibits the reaction [Puromycin Aminonucleoside results in increased expression of TP53 protein] | 17035936 |
D011692 | Puromycin Aminonucleoside | Melatonin inhibits the reaction [Puromycin Aminonucleoside results in increased expression of TP53 protein] | 14993511 |
D011692 | Puromycin Aminonucleoside | Puromycin Aminonucleoside results in increased expression of TP53 protein | 14993511; 15113391; 16152783; 17035936; |
C513428 | pyrachlostrobin | [iprodione co-treated with pyrachlostrobin] results in decreased expression of TP53 mRNA | 29091792 |
C513428 | pyrachlostrobin | [iprodione co-treated with pyrimethanil co-treated with pyrachlostrobin co-treated with acetamiprid] results in increased expression of TP53 mRNA | 29091792 |
C513428 | pyrachlostrobin | [iprodione co-treated with pyrimethanil co-treated with pyrachlostrobin] results in increased expression of TP53 mRNA | 29091792 |
C513428 | pyrachlostrobin | pyrachlostrobin results in increased expression of TP53 mRNA | 29091792 |
C513428 | pyrachlostrobin | [pyrimethanil co-treated with pyrachlostrobin co-treated with acetamiprid] results in increased expression of TP53 mRNA | 29091792 |
C513428 | pyrachlostrobin | [pyrimethanil co-treated with pyrachlostrobin] results in decreased expression of TP53 mRNA | 29091792 |
C513428 | pyrachlostrobin | pyrachlostrobin results in increased activity of TP53 protein | 30818834 |
C432165 | pyrazolanthrone | MYC affects the reaction [pyrazolanthrone results in increased expression of TP53 protein] | 15034932 |
C432165 | pyrazolanthrone | pyrazolanthrone inhibits the reaction [2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone analog results in increased expression of TP53 protein] | 26630137 |
C432165 | pyrazolanthrone | pyrazolanthrone inhibits the reaction [2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone analog results in increased expression of TP53 protein modified form] | 26630137 |
C432165 | pyrazolanthrone | pyrazolanthrone inhibits the reaction [Capsaicin results in increased expression of and results in increased phosphorylation of and results in increased activity of TP53 protein] | 17292493 |
C432165 | pyrazolanthrone | pyrazolanthrone inhibits the reaction [Fingolimod Hydrochloride results in increased phosphorylation of TP53 protein] | 25939952 |
C432165 | pyrazolanthrone | pyrazolanthrone inhibits the reaction [Pyrogallol results in increased expression of TP53 protein] | 20191265 |
C432165 | pyrazolanthrone | pyrazolanthrone inhibits the reaction [sodium arsenite results in increased phosphorylation of TP53 protein] | 22706169 |
C432165 | pyrazolanthrone | pyrazolanthrone results in decreased expression of TP53 protein | 16450001 |
C432165 | pyrazolanthrone | pyrazolanthrone results in increased expression of TP53 protein | 15034932; 16061660; |
C432165 | pyrazolanthrone | pyrazolanthrone results in increased expression of TP53 protein modified form | 26630137 |
C432165 | pyrazolanthrone | pyrazolanthrone results in increased phosphorylation of TP53 protein | 25305377 |
C432165 | pyrazolanthrone | [sodium arsenite co-treated with pyrazolanthrone] promotes the reaction [HSPA9 protein binds to TP53 protein modified form] | 22706169 |
C432165 | pyrazolanthrone | pyrazolanthrone inhibits the reaction [[Nitroprusside results in increased abundance of Nitric Oxide] which results in increased expression of TP53 protein] | 22293420 |
C432165 | pyrazolanthrone | pyrazolanthrone inhibits the reaction [Colistin results in increased expression of TP53 protein] | 28842171 |
C432165 | pyrazolanthrone | pyrazolanthrone results in increased phosphorylation of TP53 protein | 16046226 |
C014175 | pyrazolo(3,4-d)pyrimidine | pyrazolo(3,4-d)pyrimidine analog affects the expression of TP53 mRNA | 21152443 |
D011729 | Pyridostigmine Bromide | [Pyridostigmine Bromide co-treated with DEET co-treated with Permethrin] results in increased expression of TP53 protein | 12587291 |
C108337 | pyrimethanil | [iprodione co-treated with pyrimethanil co-treated with acetamiprid] results in increased expression of TP53 mRNA | 29091792 |
C108337 | pyrimethanil | [iprodione co-treated with pyrimethanil co-treated with pyrachlostrobin co-treated with acetamiprid] results in increased expression of TP53 mRNA | 29091792 |
C108337 | pyrimethanil | [iprodione co-treated with pyrimethanil co-treated with pyrachlostrobin] results in increased expression of TP53 mRNA | 29091792 |
C108337 | pyrimethanil | [iprodione co-treated with pyrimethanil] results in decreased expression of TP53 mRNA | 29091792 |
C108337 | pyrimethanil | [pyrimethanil co-treated with acetamiprid] results in increased expression of TP53 mRNA | 29091792 |
C108337 | pyrimethanil | [pyrimethanil co-treated with pyrachlostrobin co-treated with acetamiprid] results in increased expression of TP53 mRNA | 29091792 |
C108337 | pyrimethanil | [pyrimethanil co-treated with pyrachlostrobin] results in decreased expression of TP53 mRNA | 29091792 |
C108337 | pyrimethanil | pyrimethanil results in decreased expression of TP53 mRNA | 29091792 |
C009131 | pyrimidin-2-one beta-ribofuranoside | pyrimidin-2-one beta-ribofuranoside results in increased expression of TP53 protein | 23320119 |
C010423 | pyrithione zinc | Pentetic Acid inhibits the reaction [pyrithione zinc results in increased expression of TP53 protein] | 21557991 |
C010423 | pyrithione zinc | Pentetic Acid inhibits the reaction [pyrithione zinc results in increased phosphorylation of TP53 protein] | 21557991 |
C010423 | pyrithione zinc | pyrithione zinc results in increased expression of and results in increased phosphorylation of TP53 protein | 20151177 |
C010423 | pyrithione zinc | pyrithione zinc results in increased expression of TP53 mRNA | 21424779 |
C010423 | pyrithione zinc | pyrithione zinc results in increased expression of TP53 protein | 21557991 |
C010423 | pyrithione zinc | pyrithione zinc results in increased phosphorylation of and results in increased activity of TP53 protein | 21557991 |
D011748 | Pyrogallol | pyrazolanthrone inhibits the reaction [Pyrogallol results in increased expression of TP53 protein] | 20191265 |
D011748 | Pyrogallol | Pyrogallol results in increased expression of TP53 protein | 20191265 |
D011748 | Pyrogallol | SB 203580 inhibits the reaction [Pyrogallol results in increased expression of TP53 protein] | 20191265 |
D011758 | Pyrroles | pifithrin inhibits the reaction [Pyrroles analog results in increased phosphorylation of TP53 protein] | 30543781 |
D011758 | Pyrroles | Pyrroles analog results in increased phosphorylation of TP53 protein | 30543781 |
C020972 | pyrrolidine dithiocarbamic acid | bathocuproine sulfonate inhibits the reaction [[pyrrolidine dithiocarbamic acid results in increased abundance of Copper] which results in increased oxidation of and results in increased expression of TP53 protein] | 11964141 |
C020972 | pyrrolidine dithiocarbamic acid | [pyrrolidine dithiocarbamic acid results in increased abundance of Copper] which results in increased oxidation of and results in increased expression of TP53 protein | 11964141 |
C020972 | pyrrolidine dithiocarbamic acid | pyrrolidine dithiocarbamic acid results in increased oxidation of and results in increased expression of TP53 protein | 11964141 |
C020972 | pyrrolidine dithiocarbamic acid | pyrrolidine dithiocarbamic acid results in decreased expression of TP53 protein | 16049548 |
C438462 | pyrrolo(2,1-c)(1,4)benzodiazepine | [naphthalene binds to pyrrolo(2,1-c)(1,4)benzodiazepine] which results in increased expression of TP53 protein | 21732540 |
D019289 | Pyruvic Acid | [Glucose deficiency co-treated with Galactose co-treated with Pyruvic Acid] inhibits the reaction [Doxorubicin results in increased expression of TP53 protein] | 25997894 |
D011791 | Quartz | Quartz results in decreased expression of TP53 mRNA | 27917503 |
D011794 | Quercetin | [Cisplatin co-treated with Quercetin] results in decreased expression of TP53 mRNA | 27514524 |
D011794 | Quercetin | Ellagic Acid promotes the reaction [Quercetin results in increased phosphorylation of TP53 protein] | 15735102 |
D011794 | Quercetin | MIR34A mRNA affects the reaction [Quercetin results in increased acetylation of TP53 protein] | 25896587 |
D011794 | Quercetin | pifithrin inhibits the reaction [Ellagic Acid promotes the reaction [Quercetin results in increased phosphorylation of TP53 protein]] | 15735102 |
D011794 | Quercetin | pifithrin inhibits the reaction [Quercetin results in increased phosphorylation of TP53 protein] | 15735102; 22983795; |
D011794 | Quercetin | [Quercetin analog co-treated with Nickel] results in increased expression of TP53 protein | 20577783 |
D011794 | Quercetin | Quercetin analog results in increased expression of TP53 mRNA | 25289772 |
D011794 | Quercetin | Quercetin analog results in increased expression of TP53 protein | 25289772 |
D011794 | Quercetin | Quercetin inhibits the reaction [Hydrogen Peroxide results in increased expression of TP53 protein] | 25108166 |
D011794 | Quercetin | Quercetin inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of and results in increased activity of TP53 protein] | 15795422 |
D011794 | Quercetin | Quercetin inhibits the reaction [KRAS protein affects the activity of TP53 protein] | 19424582 |
D011794 | Quercetin | Quercetin results in decreased degradation of and results in increased stability of TP53 mRNA | 18323654 |
D011794 | Quercetin | Quercetin results in decreased expression of TP53 mRNA | 23727915 |
D011794 | Quercetin | Quercetin results in decreased expression of TP53 protein | 16948901; 24849437; |
D011794 | Quercetin | Quercetin results in decreased expression of TP53 protein mutant form | 16720314 |
D011794 | Quercetin | Quercetin results in decreased ubiquitination of and results in increased stability of TP53 protein | 18323654 |
D011794 | Quercetin | Quercetin results in increased acetylation of TP53 protein | 25896587 |
D011794 | Quercetin | Quercetin results in increased expression of and affects the localization of TP53 protein | 23918355 |
D011794 | Quercetin | Quercetin results in increased expression of and results in increased phosphorylation of TP53 protein | 15177039; 15735102; 18323654; |
D011794 | Quercetin | Quercetin results in increased expression of TP53 mRNA | 14715546; 19293639; 21632981; |
D011794 | Quercetin | Quercetin results in increased expression of TP53 protein | 17973296; 19623560; 20803121; 21933852; 25896587; 26311153; 26341291; |
D011794 | Quercetin | Quercetin results in increased expression of TP53 protein modified form | 26341291 |
D011794 | Quercetin | Quercetin results in increased phosphorylation of and results in increased activity of TP53 protein | 25078064 |
D011794 | Quercetin | Quercetin results in increased phosphorylation of TP53 protein | 22983795 |
D011794 | Quercetin | TP53 protein affects the reaction [Quercetin results in increased expression of MIR34A mRNA] | 25896587 |
D011794 | Quercetin | Quercetin inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of TP53 protein] | 21294050 |
D011794 | Quercetin | [1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000) co-treated with Quercetin] results in increased expression of TP53 protein | 23529952 |
D011794 | Quercetin | Acetylcysteine inhibits the reaction [Quercetin analog results in decreased phosphorylation of TP53 protein] | 23907460 |
D011794 | Quercetin | alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [Quercetin analog results in decreased phosphorylation of TP53 protein] | 23907460 |
D011794 | Quercetin | Quercetin affects the expression of TP53 protein | 22000973 |
D011794 | Quercetin | Quercetin analog results in increased expression of and results in decreased phosphorylation of TP53 protein | 23907460 |
D011794 | Quercetin | Quercetin inhibits the reaction [aluminum lactate results in increased expression of TP53 protein] | 26944603 |
D011794 | Quercetin | Quercetin inhibits the reaction [Doxorubicin results in increased expression of TP53 protein] | 24902966 |
D011794 | Quercetin | Quercetin inhibits the reaction [estradiol 3-benzoate results in increased expression of TP53 mRNA] | 24316378 |
D011794 | Quercetin | Quercetin inhibits the reaction [estradiol 3-benzoate results in increased expression of TP53 protein] | 24316378 |
D011794 | Quercetin | Quercetin inhibits the reaction [Hydrogen Peroxide results in increased expression of TP53 protein] | 16647178; 27525270; |
D011794 | Quercetin | Quercetin results in increased expression of TP53 mRNA | 18095365 |
C523166 | quercetin 3-O-beta-(2''-galloyl)-rhamnopyranoside | quercetin 3-O-beta-(2''-galloyl)-rhamnopyranoside inhibits the reaction [TNFSF10 protein results in increased expression of TP53 protein] | 23711929 |
C523166 | quercetin 3-O-beta-(2''-galloyl)-rhamnopyranoside | quercetin 3-O-beta-(2''-galloyl)-rhamnopyranoside inhibits the reaction [7-ketocholesterol results in increased expression of TP53 protein] | 25845326 |
D011796 | Quinacrine | Quinacrine results in increased activity of TP53 protein | 12082016 |
D011796 | Quinacrine | Quinacrine results in increased stability of and results in increased activity of TP53 protein | 16177561 |
D011802 | Quinidine | Quinidine results in decreased expression of TP53 mRNA | 17522070 |
C037219 | quinoline | quinoline analog results in increased activity of TP53 protein | 12082016 |
C037219 | quinoline | quinoline analog results in increased expression of TP53 protein | 18645022 |
C037219 | quinoline | quinoline analog results in increased expression of TP53 protein mutant form | 18645022 |
C037219 | quinoline | [quinoline analog results in increased expression of TP53 protein] which results in increased expression of CDKN1A protein | 18645022 |
C004532 | quinone | quinone results in increased expression of TP53 protein | 20499891 |
D020849 | Raloxifene Hydrochloride | Raloxifene Hydrochloride results in decreased expression of TP53 mRNA | 29458080 |
C068874 | raltitrexed | TP53 protein affects the reaction [raltitrexed results in increased expression of FAS protein] | 15161716 |
C068874 | raltitrexed | TP53 protein affects the susceptibility to raltitrexed | 17339891 |
C068874 | raltitrexed | TP53 protein inhibits the reaction [raltitrexed results in increased phosphorylation of STAT1 protein] | 16204068 |
D017382 | Reactive Oxygen Species | Reactive Oxygen Species results in increased expression of TP53 protein | 11517458 |
D017382 | Reactive Oxygen Species | Acetylcysteine inhibits the reaction [Reactive Oxygen Species affects the localization of TP53 protein] | 26884717 |
D017382 | Reactive Oxygen Species | Acetylcysteine inhibits the reaction [TP53 protein results in increased abundance of Reactive Oxygen Species] | 15059885 |
D017382 | Reactive Oxygen Species | [[CD40LG protein co-treated with IL4 protein] results in increased abundance of Reactive Oxygen Species] which results in increased expression of and results in increased phosphorylation of and results in increased stability of TP53 protein | 27634759 |
D017382 | Reactive Oxygen Species | [[[CD40LG protein co-treated with IL4 protein] results in increased abundance of Reactive Oxygen Species] which results in increased expression of and results in increased phosphorylation of and results in increased stability of TP53 protein] which results in decreased expression of BCL2L11 protein | 27634759 |
D017382 | Reactive Oxygen Species | [[[CD40LG protein co-treated with IL4 protein] results in increased abundance of Reactive Oxygen Species] which results in increased expression of and results in increased phosphorylation of and results in increased stability of TP53 protein] which results in decreased expression of BCL2 protein | 27634759 |
D017382 | Reactive Oxygen Species | [[[CD40LG protein co-treated with IL4 protein] results in increased abundance of Reactive Oxygen Species] which results in increased expression of and results in increased phosphorylation of and results in increased stability of TP53 protein] which results in increased expression of BCL2A1 protein | 27634759 |
D017382 | Reactive Oxygen Species | [[[CD40LG protein co-treated with IL4 protein] results in increased abundance of Reactive Oxygen Species] which results in increased expression of and results in increased phosphorylation of and results in increased stability of TP53 protein] which results in increased expression of BCL2L1 protein | 27634759 |
D017382 | Reactive Oxygen Species | [[[CD40LG protein co-treated with IL4 protein] results in increased abundance of Reactive Oxygen Species] which results in increased expression of and results in increased phosphorylation of and results in increased stability of TP53 protein] which results in increased expression of BID protein | 27634759 |
D017382 | Reactive Oxygen Species | [[[CD40LG protein co-treated with IL4 protein] results in increased abundance of Reactive Oxygen Species] which results in increased expression of and results in increased phosphorylation of and results in increased stability of TP53 protein] which results in increased expression of DDR1 mRNA | 27634759 |
D017382 | Reactive Oxygen Species | [[[CD40LG protein co-treated with IL4 protein] results in increased abundance of Reactive Oxygen Species] which results in increased expression of and results in increased phosphorylation of and results in increased stability of TP53 protein] which results in increased expression of ICAM1 mRNA | 27634759 |
D017382 | Reactive Oxygen Species | [[[CD40LG protein co-treated with IL4 protein] results in increased abundance of Reactive Oxygen Species] which results in increased expression of and results in increased phosphorylation of and results in increased stability of TP53 protein] which results in increased expression of MCL1 protein | 27634759 |
D017382 | Reactive Oxygen Species | [[[CD40LG protein co-treated with IL4 protein] results in increased abundance of Reactive Oxygen Species] which results in increased expression of and results in increased phosphorylation of and results in increased stability of TP53 protein] which results in increased expression of MDM2 protein | 27634759 |
D017382 | Reactive Oxygen Species | [[[CD40LG protein co-treated with IL4 protein] results in increased abundance of Reactive Oxygen Species] which results in increased expression of and results in increased phosphorylation of and results in increased stability of TP53 protein] which results in increased expression of NR4A2 mRNA | 27634759 |
D017382 | Reactive Oxygen Species | [[[CD40LG protein co-treated with IL4 protein] results in increased abundance of Reactive Oxygen Species] which results in increased expression of and results in increased phosphorylation of and results in increased stability of TP53 protein] which results in increased expression of PTGS2 mRNA | 27634759 |
D017382 | Reactive Oxygen Species | [[[CD40LG protein co-treated with IL4 protein] results in increased abundance of Reactive Oxygen Species] which results in increased expression of and results in increased phosphorylation of and results in increased stability of TP53 protein] which results in increased expression of SCO2 protein | 27634759 |
D017382 | Reactive Oxygen Species | [[[CD40LG protein co-treated with IL4 protein] results in increased abundance of Reactive Oxygen Species] which results in increased expression of and results in increased phosphorylation of and results in increased stability of TP53 protein] which results in increased expression of SOCS1 mRNA | 27634759 |
D017382 | Reactive Oxygen Species | [chromium hexavalent ion results in increased abundance of Reactive Oxygen Species] which results in increased activity of TP53 protein | 22886373 |
D017382 | Reactive Oxygen Species | Cyclosporine inhibits the reaction [Reactive Oxygen Species affects the localization of TP53 protein] | 26884717 |
D017382 | Reactive Oxygen Species | pifithrin inhibits the reaction [Reactive Oxygen Species affects the localization of TP53 protein] | 26884717 |
D017382 | Reactive Oxygen Species | Reactive Oxygen Species affects the localization of TP53 protein | 26884717 |
D017382 | Reactive Oxygen Species | Reactive Oxygen Species results in increased expression of TP53 protein | 10951577; 27634759; |
D017382 | Reactive Oxygen Species | sanglifehrin A inhibits the reaction [Reactive Oxygen Species affects the localization of TP53 protein] | 26884717 |
D017382 | Reactive Oxygen Species | [Sulindac results in increased abundance of Reactive Oxygen Species] which results in increased activity of TP53 protein | 17136320 |
D017382 | Reactive Oxygen Species | TP53 protein promotes the reaction [2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one results in increased abundance of Reactive Oxygen Species] | 15880691 |
D017382 | Reactive Oxygen Species | TP53 protein promotes the reaction [Copper results in increased abundance of Reactive Oxygen Species] | 15880691 |
D017382 | Reactive Oxygen Species | TP53 protein promotes the reaction [Reactive Oxygen Species results in increased expression of GPX1 protein] | 21042727 |
D017382 | Reactive Oxygen Species | TP53 protein promotes the reaction [Reactive Oxygen Species results in increased expression of SCO2 mRNA] | 21042727 |
D017382 | Reactive Oxygen Species | TP53 protein promotes the reaction [Reactive Oxygen Species results in increased expression of SOD2 protein] | 21042727 |
D017382 | Reactive Oxygen Species | TP53 protein promotes the reaction [Reactive Oxygen Species results in increased expression of TIGAR mRNA] | 21042727 |
D017382 | Reactive Oxygen Species | TP53 protein promotes the reaction [Zinc results in increased abundance of Reactive Oxygen Species] | 15880691 |
D017382 | Reactive Oxygen Species | TP53 protein results in increased abundance of Reactive Oxygen Species | 15059885 |
D017382 | Reactive Oxygen Species | TP53 protein affects the chemical synthesis of Reactive Oxygen Species | 15059885 |
D000077185 | Resveratrol | Resveratrol inhibits the reaction [IL1B protein results in increased activity of TP53 protein] | 19011540 |
D000077185 | Resveratrol | 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Resveratrol affects the localization of TP53 protein] | 18446786 |
D000077185 | Resveratrol | 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Resveratrol promotes the reaction [PTGS2 protein binds to TP53 protein modified form]] | 16928824 |
D000077185 | Resveratrol | 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Resveratrol results in increased expression of TP53 mRNA] | 11889192 |
D000077185 | Resveratrol | 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Resveratrol results in increased phosphorylation of and results in increased activity of TP53 protein] | 12131363; 18446786; |
D000077185 | Resveratrol | 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Resveratrol results in increased phosphorylation of TP53 protein] | 11889192; 16814113; 16928824; 29242151; |
D000077185 | Resveratrol | 2,2-bis(hydroxymethyl)-1-azabicyclo(2,2,2,)octan-3-one promotes the reaction [TP53 protein results in increased susceptibility to Resveratrol] | 23152798 |
D000077185 | Resveratrol | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Resveratrol results in increased phosphorylation of TP53 protein] | 17534123 |
D000077185 | Resveratrol | 2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one inhibits the reaction [Bleomycin promotes the reaction [Resveratrol results in increased phosphorylation of TP53 protein]] | 24933654 |
D000077185 | Resveratrol | 2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one inhibits the reaction [Hydrogen Peroxide promotes the reaction [Resveratrol results in increased phosphorylation of TP53 protein]] | 24933654 |
D000077185 | Resveratrol | 2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one inhibits the reaction [Resveratrol promotes the reaction [Bleomycin results in increased phosphorylation of TP53 protein]] | 24933654 |
D000077185 | Resveratrol | 2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one inhibits the reaction [Resveratrol promotes the reaction [Hydrogen Peroxide results in increased phosphorylation of TP53 protein]] | 24933654 |
D000077185 | Resveratrol | arginyl-glycyl-aspartic acid inhibits the reaction [Resveratrol results in increased phosphorylation of TP53 protein] | 16790523 |
D000077185 | Resveratrol | BCL2 protein inhibits the reaction [Resveratrol promotes the reaction [PML protein binds to TP53 protein]] | 19631782 |
D000077185 | Resveratrol | Bleomycin promotes the reaction [Resveratrol results in increased phosphorylation of TP53 protein] | 24933654 |
D000077185 | Resveratrol | Capsaicin promotes the reaction [Resveratrol results in increased expression of TP53 protein] | 19846903 |
D000077185 | Resveratrol | [Doxorubicin co-treated with Resveratrol] results in increased expression of TP53 mRNA | 26969377 |
D000077185 | Resveratrol | [Doxorubicin co-treated with Resveratrol] results in increased expression of TP53 protein | 26969377 |
D000077185 | Resveratrol | EGF protein inhibits the reaction [Resveratrol inhibits the reaction [TP53 protein binds to MDM2 protein]] | 15542774 |
D000077185 | Resveratrol | EGF protein inhibits the reaction [Resveratrol results in increased phosphorylation of and results in increased activity of and results in increased localization of TP53 protein] | 15542774 |
D000077185 | Resveratrol | Erlotinib Hydrochloride promotes the reaction [Resveratrol results in increased expression of TP53 protein] | 25895606 |
D000077185 | Resveratrol | HRAS protein promotes the reaction [Resveratrol results in increased expression of and results in increased phosphorylation of TP53 protein] | 11889192 |
D000077185 | Resveratrol | HRAS protein promotes the reaction [Resveratrol results in increased expression of TP53 mRNA] | 11889192 |
D000077185 | Resveratrol | HRAS protein promotes the reaction [TP53 protein results in increased susceptibility to Resveratrol] | 11889192 |
D000077185 | Resveratrol | Hydrogen Peroxide promotes the reaction [Resveratrol results in increased phosphorylation of TP53 protein] | 24933654 |
D000077185 | Resveratrol | [ITGA5 protein binds to ITGB3 protein] promotes the reaction [Resveratrol results in increased phosphorylation of TP53 protein] | 16790523 |
D000077185 | Resveratrol | midostaurin affects the reaction [Resveratrol results in increased phosphorylation of and results in increased activity of and results in increased localization of TP53 protein] | 15542774 |
D000077185 | Resveratrol | midostaurin inhibits the reaction [EGF protein inhibits the reaction [Resveratrol results in increased phosphorylation of and results in increased activity of and results in increased localization of TP53 protein]] | 15542774 |
D000077185 | Resveratrol | MRK 003 inhibits the reaction [Resveratrol results in increased expression of TP53] | 21743969 |
D000077185 | Resveratrol | MTA1 protein inhibits the reaction [Resveratrol results in increased acetylation of TP53 protein] | 19810103 |
D000077185 | Resveratrol | N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Resveratrol results in increased expression of TP53 mRNA] | 29242151 |
D000077185 | Resveratrol | N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Resveratrol results in increased phosphorylation of TP53 protein] | 16928824; 29242151; |
D000077185 | Resveratrol | [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of PTGS2 protein] inhibits the reaction [Resveratrol results in increased activity of TP53 protein] | 18446786 |
D000077185 | Resveratrol | PARP1 protein affects the reaction [Resveratrol results in increased acetylation of and results in increased phosphorylation of TP53 protein] | 25533949 |
D000077185 | Resveratrol | pifithrin inhibits the reaction [Resveratrol results in increased expression of and results in increased phosphorylation of TP53 protein] | 11889192 |
D000077185 | Resveratrol | pifithrin inhibits the reaction [Resveratrol results in increased phosphorylation of TP53 protein] | 16814113 |
D000077185 | Resveratrol | pifithrin inhibits the reaction [TP53 protein results in increased susceptibility to Resveratrol] | 23152798 |
D000077185 | Resveratrol | PRKCA protein affects the reaction [EGF protein inhibits the reaction [Resveratrol results in increased phosphorylation of and results in increased activity of and results in increased localization of TP53 protein]] | 15542774 |
D000077185 | Resveratrol | Resveratrol affects the expression of TP53 protein | 11522280 |
D000077185 | Resveratrol | [Resveratrol affects the localization of PTGS2 protein] which results in increased activity of TP53 protein | 18446786 |
D000077185 | Resveratrol | Resveratrol affects the localization of TP53 protein | 18446786; 24587049; |
D000077185 | Resveratrol | Resveratrol analog results in increased expression of TP53 protein | 25776512; 26970359; |
D000077185 | Resveratrol | [Resveratrol co-treated with AICA ribonucleotide] inhibits the reaction [Glucose results in increased expression of TP53 protein] | 26188290 |
D000077185 | Resveratrol | [Resveratrol co-treated with Clofarabine] affects the localization of TP53 protein modified form | 24239893 |
D000077185 | Resveratrol | [Resveratrol co-treated with Clofarabine] results in increased expression of and results in increased activity of TP53 protein modified form | 24239893 |
D000077185 | Resveratrol | Resveratrol inhibits the reaction [cudraflavone B results in increased expression of TP53 protein] | 23881456 |
D000077185 | Resveratrol | Resveratrol inhibits the reaction [Glucose affects the localization of TP53 protein] | 24218232 |
D000077185 | Resveratrol | Resveratrol inhibits the reaction [Glucose results in increased acetylation of TP53 protein] | 20068143 |
D000077185 | Resveratrol | Resveratrol inhibits the reaction [Glucose results in increased expression of TP53 mRNA] | 27049278 |
D000077185 | Resveratrol | Resveratrol inhibits the reaction [Glucose results in increased expression of TP53 protein] | 26188290 |
D000077185 | Resveratrol | Resveratrol inhibits the reaction [Hydrogen Peroxide results in increased expression of TP53 mRNA] | 27049278 |
D000077185 | Resveratrol | Resveratrol inhibits the reaction [Hydrogen Peroxide results in increased expression of TP53 protein] | 23859249 |
D000077185 | Resveratrol | Resveratrol inhibits the reaction [IL1B protein results in increased expression of TP53 protein] | 17959154 |
D000077185 | Resveratrol | Resveratrol inhibits the reaction [Palmitates results in increased acetylation of TP53 protein] | 20068143 |
D000077185 | Resveratrol | Resveratrol inhibits the reaction [Rotenone promotes the reaction [TP53 protein modified form binds to SIRT1 protein]] | 25991017 |
D000077185 | Resveratrol | Resveratrol inhibits the reaction [Rotenone results in increased expression of TP53 mRNA] | 25991017 |
D000077185 | Resveratrol | Resveratrol inhibits the reaction [Rotenone results in increased expression of TP53 protein] | 25991017 |
D000077185 | Resveratrol | Resveratrol inhibits the reaction [Rotenone results in increased expression of TP53 protein modified form] | 25991017 |
D000077185 | Resveratrol | Resveratrol inhibits the reaction [TNF protein results in increased acetylation of TP53 protein] | 23257246 |
D000077185 | Resveratrol | Resveratrol inhibits the reaction [TP53 protein binds to MDM2 protein] | 15542774 |
D000077185 | Resveratrol | Resveratrol metabolite results in increased expression of TP53 protein | 11895857 |
D000077185 | Resveratrol | Resveratrol promotes the reaction [Bleomycin results in increased phosphorylation of TP53 protein] | 24933654 |
D000077185 | Resveratrol | Resveratrol promotes the reaction [Capsaicin results in increased expression of TP53 protein] | 19846903 |
D000077185 | Resveratrol | Resveratrol promotes the reaction [Ceramides results in increased phosphorylation of TP53 protein] | 23495037 |
D000077185 | Resveratrol | Resveratrol promotes the reaction [Erlotinib Hydrochloride results in increased expression of TP53 protein] | 25895606 |
D000077185 | Resveratrol | Resveratrol promotes the reaction [Hydrogen Peroxide results in increased phosphorylation of TP53 protein] | 24933654 |
D000077185 | Resveratrol | Resveratrol promotes the reaction [[LMNA protein binds to and results in increased activity of SIRT1 protein] which results in decreased acetylation of TP53 protein] | 23217256 |
D000077185 | Resveratrol | Resveratrol promotes the reaction [PML protein binds to TP53 protein] | 19631782 |
D000077185 | Resveratrol | Resveratrol promotes the reaction [PTGS2 protein binds to TP53 protein modified form] | 16928824 |
D000077185 | Resveratrol | Resveratrol promotes the reaction [TP53 protein binds to BECN1 protein] | 23088850 |
D000077185 | Resveratrol | Resveratrol promotes the reaction [TP53 protein binds to CDKN1A promoter] | 18446786 |
D000077185 | Resveratrol | Resveratrol promotes the reaction [[TP53 protein binds to GDF15 promoter] which results in increased expression of GDF15 mRNA] | 11895857 |
D000077185 | Resveratrol | Resveratrol promotes the reaction [TP53 protein binds to PML protein binds to CREBBP protein] | 19631782 |
D000077185 | Resveratrol | Resveratrol results in decreased activity of TP53 protein | 22252971; 25956474; |
D000077185 | Resveratrol | [[Resveratrol results in decreased expression of MTA1 protein] inhibits the reaction [MTA1 protein binds to HDAC1 protein]] which results in increased acetylation of and results in increased activity of TP53 protein | 19810103 |
D000077185 | Resveratrol | Resveratrol results in increased acetylation of and results in increased activity of TP53 protein | 19810103 |
D000077185 | Resveratrol | [Resveratrol results in increased acetylation of and results in increased activity of TP53 protein] promotes the reaction [TP53 protein binds to BAX promoter] | 19810103 |
D000077185 | Resveratrol | [Resveratrol results in increased acetylation of and results in increased activity of TP53 protein] promotes the reaction [TP53 protein binds to CDKN1A promoter] | 19810103 |
D000077185 | Resveratrol | Resveratrol results in increased acetylation of and results in increased phosphorylation of TP53 protein | 25533949 |
D000077185 | Resveratrol | Resveratrol results in increased activity of and results in increased acetylation of TP53 protein | 24603648 |
D000077185 | Resveratrol | [Resveratrol results in increased activity of SIRT1 protein] inhibits the reaction [Hydrogen Peroxide results in increased acetylation of TP53 protein] | 18681908 |
D000077185 | Resveratrol | Resveratrol results in increased activity of TP53 protein | 17174366; 20504360; 21740780; |
D000077185 | Resveratrol | Resveratrol results in increased expression of and results in increased phosphorylation of and results in increased activity of TP53 protein | 12131363 |
D000077185 | Resveratrol | Resveratrol results in increased expression of and results in increased phosphorylation of TP53 protein | 11889192; 19559722; |
D000077185 | Resveratrol | [Resveratrol results in increased expression of and results in increased phosphorylation of TP53 protein] which results in increased expression of CDKN1A mRNA | 11889192 |
D000077185 | Resveratrol | Resveratrol results in increased expression of TP53 | 16209266; 21743969; |
D000077185 | Resveratrol | Resveratrol results in increased expression of TP53 mRNA | 11889192; 15149879; 17261084; 18089832; 25436977; 26969377; 29242151; |
D000077185 | Resveratrol | [Resveratrol results in increased expression of TP53] promotes the reaction [[TP53 protein binds to GDF15 promoter] which results in increased expression of GDF15] | 11895857 |
D000077185 | Resveratrol | Resveratrol results in increased expression of TP53 protein | 11895857; 15993843; 16091005; 16759640; 17007014; 17050787; 17088997; 18089832; 18347188; 19800779; 19846903; 22029423; 23152798; 25242450; 25776512; 25895606; 26341291; 26911335; 26969377; 26970359; 29274324; |
D000077185 | Resveratrol | Resveratrol results in increased expression of TP53 protein modified form | 26341291 |
D000077185 | Resveratrol | [Resveratrol results in increased expression of TP53 protein] which results in increased expression of GDF15 protein | 11895857 |
D000077185 | Resveratrol | Resveratrol results in increased phosphorylation of and results in increased activity of and results in increased localization of TP53 protein | 15542774 |
D000077185 | Resveratrol | Resveratrol results in increased phosphorylation of and results in increased activity of TP53 protein | 17534123; 17868649; 18446786; |
D000077185 | Resveratrol | Resveratrol results in increased phosphorylation of TP53 protein | 16790523; 16814113; 16928824; 18222423; 23495037; 23651583; 24933654; 25311616; 29242151; |
D000077185 | Resveratrol | [Resveratrol results in increased phosphorylation of TP53 protein] which results in increased expression of BAX protein | 18222423 |
D000077185 | Resveratrol | [Resveratrol results in increased phosphorylation of TP53 protein] which results in increased expression of CDKN1A protein | 18222423 |
D000077185 | Resveratrol | SIRT1 mutant form inhibits the reaction [Resveratrol inhibits the reaction [TNF protein results in increased acetylation of TP53 protein]] | 23257246 |
D000077185 | Resveratrol | SIRT1 protein inhibits the reaction [Resveratrol results in increased acetylation of TP53 protein] | 24603648 |
D000077185 | Resveratrol | SIRT1 protein promotes the reaction [Resveratrol inhibits the reaction [Glucose results in increased acetylation of TP53 protein]] | 20068143 |
D000077185 | Resveratrol | SIRT1 protein promotes the reaction [Resveratrol inhibits the reaction [Palmitates results in increased acetylation of TP53 protein]] | 20068143 |
D000077185 | Resveratrol | Staurosporine inhibits the reaction [EGF protein inhibits the reaction [Resveratrol inhibits the reaction [TP53 protein binds to MDM2 protein]]] | 15542774 |
D000077185 | Resveratrol | Staurosporine inhibits the reaction [EGF protein inhibits the reaction [Resveratrol results in increased phosphorylation of and results in increased activity of and results in increased localization of TP53 protein]] | 15542774 |
D000077185 | Resveratrol | Staurosporine promotes the reaction [Resveratrol results in increased phosphorylation of and results in increased activity of and results in increased localization of TP53 protein] | 15542774 |
D000077185 | Resveratrol | SUMO1 protein affects the reaction [Resveratrol results in increased expression of TP53 mRNA] | 29242151 |
D000077185 | Resveratrol | Tetradecanoylphorbol Acetate inhibits the reaction [Resveratrol results in increased phosphorylation of and results in increased activity of and affects the localization of TP53 protein] | 15542774 |
D000077185 | Resveratrol | Thyroxine inhibits the reaction [Resveratrol results in increased activity of TP53 protein] | 17174366 |
D000077185 | Resveratrol | TP53 affects the reaction [Capsaicin promotes the reaction [Resveratrol results in increased expression of NOS2 protein]] | 19846903 |
D000077185 | Resveratrol | TP53 affects the reaction [Capsaicin promotes the reaction [Resveratrol results in increased expression of NOS3 protein]] | 19846903 |
D000077185 | Resveratrol | TP53 affects the reaction [Resveratrol affects the reaction [Fluorouracil results in increased activity of CASP6 protein]] | 18497562 |
D000077185 | Resveratrol | TP53 affects the reaction [Resveratrol promotes the reaction [Capsaicin results in increased expression of NOS2 protein]] | 19846903 |
D000077185 | Resveratrol | TP53 affects the reaction [Resveratrol promotes the reaction [Capsaicin results in increased expression of NOS3 protein]] | 19846903 |
D000077185 | Resveratrol | TP53 affects the reaction [Resveratrol results in decreased expression of MDM2 protein] | 19846903 |
D000077185 | Resveratrol | TP53 affects the reaction [Resveratrol results in increased activity of CASP6 protein] | 18497562 |
D000077185 | Resveratrol | TP53 affects the reaction [Resveratrol results in increased expression of BAX protein] | 19846903 |
D000077185 | Resveratrol | TP53 affects the reaction [Resveratrol results in increased expression of NOS1 protein] | 19846903 |
D000077185 | Resveratrol | TP53 affects the reaction [Resveratrol results in increased expression of NOS3 protein] | 19846903 |
D000077185 | Resveratrol | TP53 affects the susceptibility to Resveratrol | 18497562; 19846903; |
D000077185 | Resveratrol | TP53 mutant form inhibits the reaction [Resveratrol results in decreased expression of NANOG protein] | 23651583 |
D000077185 | Resveratrol | TP53 protein affects the susceptibility to [Resveratrol co-treated with Clofarabine] | 24239893 |
D000077185 | Resveratrol | TP53 protein promotes the reaction [Resveratrol promotes the reaction [CASP6 protein results in increased cleavage of LMNA protein]] | 16518869 |
D000077185 | Resveratrol | TP53 protein promotes the reaction [Resveratrol results in increased expression of CDKN1A mRNA] | 12131363 |
D000077185 | Resveratrol | TP53 protein results in increased susceptibility to Resveratrol | 11889192; 16518869; 23152798; |
D000077185 | Resveratrol | Vorinostat promotes the reaction [Resveratrol results in increased acetylation of TP53 protein] | 19810103 |
D000077185 | Resveratrol | Wortmannin inhibits the reaction [Resveratrol results in increased phosphorylation of TP53 protein] | 17534123 |
D000077185 | Resveratrol | YARS1 protein affects the reaction [Resveratrol results in increased acetylation of TP53 protein] | 25533949 |
D000077185 | Resveratrol | 1-(4-dimethylaminomethylphenyl)-8,9-dihydro-7H-2,7,9a-benzo(cd)azulen-6-one inhibits the reaction [Resveratrol results in increased acetylation of TP53 protein] | 25533949 |
D000077185 | Resveratrol | Resveratrol results in increased acetylation of TP53 protein | 25533949 |
D000077185 | Resveratrol | N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Resveratrol results in increased phosphorylation of TP53 protein] | 17984113 |
D000077185 | Resveratrol | Resveratrol inhibits the reaction [Cadmium Chloride results in increased expression of TP53 mRNA] | 24492640 |
D000077185 | Resveratrol | Resveratrol inhibits the reaction [Estradiol results in decreased expression of TP53 protein] | 24894866 |
D000077185 | Resveratrol | Resveratrol inhibits the reaction [Methylnitronitrosoguanidine results in increased acetylation of TP53 protein] | 17147953 |
D000077185 | Resveratrol | Resveratrol inhibits the reaction [Streptozocin results in increased expression of TP53 protein] | 23792339 |
D000077185 | Resveratrol | Resveratrol results in decreased expression of TP53 protein | 23792339 |
D000077185 | Resveratrol | Resveratrol results in increased expression of TP53 protein | 20797428 |
D000077185 | Resveratrol | Resveratrol results in increased expression of TP53 protein modified form | 20972827 |
D000077185 | Resveratrol | Resveratrol results in increased phosphorylation of TP53 protein | 17984113 |
D000077185 | Resveratrol | TP53 protein promotes the reaction [Resveratrol results in increased expression of CDKN1A mRNA] | 20797428 |
D000077185 | Resveratrol | Resveratrol results in increased expression of and results in increased acetylation of TP53 protein | 23065251 |
D000077185 | Resveratrol | G3BP1 protein affects the reaction [Resveratrol results in increased expression of TP53] | 24998844 |
D000077185 | Resveratrol | Resveratrol results in decreased ubiquitination of TP53 protein | 24998844 |
D000077185 | Resveratrol | [Resveratrol results in decreased ubiquitination of TP53 protein] which results in increased expression of TP53 protein | 24998844 |
D000077185 | Resveratrol | Resveratrol results in increased expression of TP53 | 24998844 |
D012176 | Retinoids | Retinoids analog results in increased phosphorylation of TP53 protein | 17512204 |
D012176 | Retinoids | Retinoids results in increased phosphorylation of and results in increased activity of TP53 protein | 19067706 |
C579783 | RG7112 | RG7112 results in increased expression of TP53 protein | 30022047 |
C579783 | RG7112 | TP53 protein affects the reaction [RG7112 results in increased expression of CDKN1A protein] | 30022047 |
C579783 | RG7112 | TP53 protein affects the reaction [RG7112 results in increased expression of MDM2 protein] | 30022047 |
C579783 | RG7112 | TP53 protein results in increased susceptibility to RG7112 | 30022047 |
C579783 | RG7112 | [TP53 protein results in increased susceptibility to RG7112] promotes the reaction [RG7112 results in increased expression of CDKN1A protein] | 30022047 |
D012256 | Riboflavin | Riboflavin results in increased expression of TP53 protein | 12654180 |
C013672 | riddelliine | riddelliine results in increased expression of TP53 protein | 12460743; 20737008; |
D019438 | Ritonavir | FTI 277 inhibits the reaction [Ritonavir results in increased expression of TP53 protein] | 20884875 |
D019438 | Ritonavir | manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [Ritonavir results in increased expression of TP53 protein] | 20884875 |
D019438 | Ritonavir | Pravastatin inhibits the reaction [Ritonavir results in increased expression of TP53 protein] | 20884875 |
D019438 | Ritonavir | Ritonavir results in increased expression of TP53 protein | 19386116; 20884875; |
C512984 | RO 3306 | MYC mutant form inhibits the reaction [RO 3306 results in increased expression of TP53 protein] | 24444383 |
C512984 | RO 3306 | [RO 3306 co-treated with MYC protein] results in increased expression of TP53 protein | 24444383 |
C512984 | RO 3306 | RO 3306 results in increased expression of TP53 protein | 24444383 |
C071721 | Ro 41-0960 | Ro 41-0960 results in increased expression of TP53 mRNA | 21896544 |
D000077546 | Roscovitine | Roscovitine results in increased expression of TP53 protein | 16003486; 16140939; 21217777; 21417417; |
D000077154 | Rosiglitazone | Rosiglitazone affects the activity of TP53 protein | 25596134 |
D000077154 | Rosiglitazone | Rosiglitazone inhibits the reaction [Nicotine results in decreased expression of TP53 protein] | 19139119 |
D000077154 | Rosiglitazone | Rosiglitazone results in decreased expression of TP53 protein | 17018897 |
D000077154 | Rosiglitazone | Rosiglitazone results in increased expression of TP53 mRNA | 17639046 |
D000077154 | Rosiglitazone | Rosiglitazone results in increased expression of TP53 protein | 17639046; 19139119; |
D000077154 | Rosiglitazone | [Rosiglitazone results in increased expression of TP53 protein] promotes the reaction [Rosiglitazone results in decreased expression of CHRNA4 protein] | 19139119 |
D012402 | Rotenone | Rotenone results in increased expression of TP53 mRNA | 22560901 |
D012402 | Rotenone | Resveratrol inhibits the reaction [Rotenone promotes the reaction [TP53 protein modified form binds to SIRT1 protein]] | 25991017 |
D012402 | Rotenone | Resveratrol inhibits the reaction [Rotenone results in increased expression of TP53 mRNA] | 25991017 |
D012402 | Rotenone | Resveratrol inhibits the reaction [Rotenone results in increased expression of TP53 protein] | 25991017 |
D012402 | Rotenone | Resveratrol inhibits the reaction [Rotenone results in increased expression of TP53 protein modified form] | 25991017 |
D012402 | Rotenone | Rotenone affects the localization of TP53 protein | 21223980 |
D012402 | Rotenone | Rotenone promotes the reaction [TP53 protein modified form binds to SIRT1 protein] | 25991017 |
D012402 | Rotenone | Rotenone results in increased expression of and results in increased phosphorylation of TP53 protein | 21223980 |
D012402 | Rotenone | Rotenone results in increased expression of TP53 mRNA | 18191903; 23963993; 25991017; |
D012402 | Rotenone | Rotenone results in increased expression of TP53 protein | 23963993; 25991017; |
D012402 | Rotenone | Rotenone results in increased expression of TP53 protein modified form | 25991017 |
D012402 | Rotenone | GAPDH mutant form inhibits the reaction [Rotenone results in increased expression of TP53 protein] | 25725130 |
D012402 | Rotenone | montelukast inhibits the reaction [Rotenone results in increased expression of TP53 mRNA] | 30222980 |
D012402 | Rotenone | Rotenone results in increased expression of TP53 mRNA | 28374803; 30222980; |
D012402 | Rotenone | Rotenone results in increased expression of TP53 protein | 25725130 |
C101044 | RTKI cpd | RTKI cpd inhibits the reaction [sodium arsenite results in increased expression of TP53 protein] | 15734884 |
C079905 | rubitecan | Phosphatidylcholines inhibits the reaction [rubitecan results in increased expression of TP53 protein] | 21695227 |
C079905 | rubitecan | rubitecan results in increased expression of TP53 protein | 21695227 |
D012428 | Ruthenium | Ruthenium results in increased expression of TP53 protein | 17210701 |
D017975 | Ruthenium Compounds | Ruthenium Compounds results in increased expression of TP53 protein | 17210701 |
D012431 | Rutin | Rutin inhibits the reaction [Cholesterol, Dietary results in increased expression of TP53 mRNA] | 27239252 |
C033110 | RV 538 | RV 538 affects the splicing of and results in increased expression of TP53 mRNA | 25195822 |
C033110 | RV 538 | RV 538 results in increased phosphorylation of TP53 protein | 25195822 |
C039961 | S-(1,2-dichlorovinyl)cysteine | S-(1,2-dichlorovinyl)cysteine results in increased expression of TP53 protein | 15967204 |
C046570 | S-(2-chloroethyl)glutathione | S-(2-chloroethyl)glutathione results in increased mutagenesis of TP53 gene | 14715658 |
C046570 | S-(2-chloroethyl)glutathione | [S-(2-chloroethyl)glutathione results in increased mutagenesis of TP53 gene] which results in decreased activity of TP53 protein | 14715658; 14715658; |
C076944 | salvianolic acid B | salvianolic acid B results in decreased acetylation of TP53 protein | 24769256 |
C076944 | salvianolic acid B | salvianolic acid B inhibits the reaction [Ethanol results in increased acetylation of TP53 protein] | 24769256 |
C121329 | sanglifehrin A | sanglifehrin A inhibits the reaction [Reactive Oxygen Species affects the localization of TP53 protein] | 26884717 |
C044363 | sappanchalcone | sappanchalcone results in increased expression of TP53 protein | 21963806 |
C003402 | sapropterin | sapropterin inhibits the reaction [Methotrexate results in increased expression of TP53 protein] | 22183962 |
C028268 | satratoxin G | GW 506033X inhibits the reaction [satratoxin G results in increased expression of TP53 mRNA] | 18535002 |
C028268 | satratoxin G | satratoxin G results in increased expression of TP53 mRNA | 18535002 |
C093642 | SB 203580 | SB 203580 inhibits the reaction [[Cisplatin co-treated with fisetin] results in increased phosphorylation of TP53 protein] | 21216935 |
C093642 | SB 203580 | SB 203580 inhibits the reaction [Curcumin results in increased phosphorylation of TP53 protein] | 19020741 |
C093642 | SB 203580 | SB 203580 inhibits the reaction [Pyrogallol results in increased expression of TP53 protein] | 20191265 |
C093642 | SB 203580 | SB 203580 inhibits the reaction [[sodium arsenite co-treated with Vitamin K 3] results in increased phosphorylation of TP53 protein] | 19082730 |
C093642 | SB 203580 | SB 203580 inhibits the reaction [sodium arsenite results in increased expression of TP53 protein] | 15734884 |
C093642 | SB 203580 | SB 203580 inhibits the reaction [Sulindac affects the localization of TP53 protein] | 17136320 |
C093642 | SB 203580 | SB 203580 inhibits the reaction [Ethanol results in increased expression of and results in increased phosphorylation of TP53 protein] | 27270636 |
C093642 | SB 203580 | SB 203580 inhibits the reaction [dibenzo(a,l)pyrene results in increased phosphorylation of TP53 protein] | 16005925 |
C417521 | SB 216763 | SB 216763 inhibits the reaction [sodium arsenite results in increased expression of and affects the localization of TP53 protein] | 17849503 |
C417521 | SB 216763 | SB 216763 results in increased expression of TP53 protein | 15958644; 17210701; |
C417521 | SB 216763 | SB 216763 inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of TP53 protein] | 30597158 |
C015499 | schizandrin B | schizandrin B inhibits the reaction [Carbon Tetrachloride results in increased expression of TP53 mRNA] | 31150632 |
C499748 | SCIO-469 | SCIO-469 promotes the reaction [Bortezomib results in increased expression of TP53 protein] | 16617327 |
C066198 | SDZ 51641 | SDZ 51641 results in increased expression of TP53 mRNA | 19234235 |
C110822 | SDZ CPI 975 | SDZ CPI 975 results in increased expression of TP53 mRNA | 19234235 |
C094089 | SDZ FOX 988 | SDZ FOX 988 results in increased expression of TP53 mRNA | 19234235 |
D012643 | Selenium | Selenium inhibits the reaction [Cadmium Chloride results in increased expression of TP53 mRNA] | 25035189 |
D012643 | Selenium | [Selenium analog co-treated with Magnesium Oxide analog] inhibits the reaction [Diazinon results in increased expression of TP53 mRNA] | 27920530 |
D012643 | Selenium | [Selenium co-treated with Vitamin E] results in increased expression of TP53 mRNA | 19244175 |
D012643 | Selenium | Selenium results in decreased expression of TP53 protein | 17523932 |
D012643 | Selenium | Selenium results in increased expression of TP53 mRNA | 19244175 |
D012643 | Selenium | Selenium inhibits the reaction [Cadmium Chloride results in increased expression of TP53 protein] | 16600092 |
D012643 | Selenium | [Vitamin E co-treated with Selenium] inhibits the reaction [Malathion results in increased expression of TP53 mRNA] | 21628957 |
D064588 | Selenium Oxides | Selenium Oxides results in increased expression of TP53 | 15485790 |
D064588 | Selenium Oxides | Selenium Oxides results in increased expression of TP53 protein | 11342237 |
D012645 | Selenomethionine | AR protein promotes the reaction [Selenomethionine results in increased expression of TP53 mRNA] | 17205524 |
D012645 | Selenomethionine | Selenomethionine inhibits the reaction [mono-(2-ethylhexyl)phthalate results in increased activity of TP53 protein] | 21515331 |
D012645 | Selenomethionine | Selenomethionine results in decreased activity of TP53 protein | 17100737 |
D012645 | Selenomethionine | Selenomethionine results in increased expression of TP53 mRNA | 17205524 |
C042431 | S-ethyl glutathione | S-ethyl glutathione inhibits the reaction [Camptothecin results in increased expression of TP53 protein modified form] | 17555331 |
C042431 | S-ethyl glutathione | S-ethyl glutathione inhibits the reaction [tert-Butylhydroperoxide results in increased expression of TP53 protein modified form] | 17555331 |
D000077149 | Sevoflurane | Sevoflurane results in increased expression of TP53 mRNA | 19572936 |
C016101 | shikonin | shikonin results in increased expression of TP53 protein | 28684144 |
D000068677 | Sildenafil Citrate | TP53 protein inhibits the reaction [Sildenafil Citrate results in increased susceptibility to Doxorubicin] | 20155316 |
D012822 | Silicon Dioxide | Ascorbic Acid inhibits the reaction [Silicon Dioxide results in increased expression of TP53 mRNA] | 22245848 |
D012822 | Silicon Dioxide | Ascorbic Acid inhibits the reaction [Silicon Dioxide results in increased expression of TP53 protein] | 22245848 |
D012822 | Silicon Dioxide | fisetin inhibits the reaction [Silicon Dioxide results in increased expression of TP53 mRNA] | 22931364 |
D012822 | Silicon Dioxide | Silicon Dioxide promotes the reaction [SIRT1 protein binds to TP53 protein] | 31082419 |
D012822 | Silicon Dioxide | Silicon Dioxide results in decreased expression of TP53 mRNA | 25351596 |
D012822 | Silicon Dioxide | Silicon Dioxide results in increased acetylation of and results in increased phosphorylation of and affects the localization of TP53 protein | 31082419 |
D012822 | Silicon Dioxide | Silicon Dioxide results in increased expression of TP53 mRNA | 22245848; 22931364; |
D012822 | Silicon Dioxide | Silicon Dioxide results in increased expression of TP53 protein | 20060462; 21766316; 22245848; |
D012822 | Silicon Dioxide | SIRT1 protein inhibits the reaction [Silicon Dioxide results in increased acetylation of and results in increased phosphorylation of and affects the localization of TP53 protein] | 31082419 |
D012822 | Silicon Dioxide | Silicon Dioxide results in increased expression of TP53 protein | 26865670 |
D012822 | Silicon Dioxide | ZC3H12A affects the reaction [Silicon Dioxide results in increased expression of TP53 protein] | 26865670 |
D012834 | Silver | Silver analog results in decreased expression of TP53 mRNA | 23800688 |
D012834 | Silver | NFE2L2 protein affects the reaction [Silver results in increased expression of TP53 protein] | 22546375 |
D012834 | Silver | [Silver co-treated with Povidone] affects the phosphorylation of TP53 protein | 27387714 |
D012834 | Silver | [Silver co-treated with Povidone] results in decreased expression of TP53 mRNA | 27387714 |
D012834 | Silver | [Silver co-treated with Povidone] results in decreased expression of TP53 protein | 27387714 |
D012834 | Silver | Silver results in increased expression of TP53 protein | 22546375 |
D012834 | Silver | Silver analog results in increased expression of TP53 mRNA | 22727896 |
D018030 | Silver Compounds | [ERCC4 gene mutant form results in increased susceptibility to Silver Compounds] which results in increased expression of TP53 protein | 29462690 |
D018030 | Silver Compounds | [ERCC4 gene mutant form results in increased susceptibility to Silver Compounds] which results in increased expression of TP53 protein modified form | 29462690 |
D012835 | Silver Nitrate | Silver Nitrate analog results in decreased expression of TP53 mRNA | 22831968 |
D012835 | Silver Nitrate | Silver Nitrate results in increased expression of TP53 mRNA | 22727896 |
D000077385 | Silybin | Caffeine inhibits the reaction [Silybin results in increased phosphorylation of TP53 protein] | 16777994 |
D000077385 | Silybin | pifithrin inhibits the reaction [Silybin results in increased phosphorylation of TP53 protein] | 16777994 |
D000077385 | Silybin | Silybin affects the localization of TP53 protein | 16777994 |
D000077385 | Silybin | Silybin inhibits the reaction [Mitomycin results in increased expression of TP53] | 19834285 |
D000077385 | Silybin | Silybin results in increased expression of TP53 protein | 16777994 |
D000077385 | Silybin | Silybin results in increased phosphorylation of TP53 protein | 16777994 |
D019821 | Simvastatin | pifithrin inhibits the reaction [Simvastatin results in increased expression of TP53 protein] | 20045437 |
D019821 | Simvastatin | Simvastatin promotes the reaction [Benzo(a)pyrene promotes the reaction [TP53 protein binds to MDM2 protein]] | 15625077 |
D019821 | Simvastatin | Simvastatin promotes the reaction [TP53 protein binds to CD44 promoter] | 21199873 |
D019821 | Simvastatin | Simvastatin results in increased expression of and results in increased phosphorylation of TP53 protein | 21199873 |
D019821 | Simvastatin | Simvastatin results in increased expression of TP53 mRNA | 21199873 |
D019821 | Simvastatin | Simvastatin results in increased expression of TP53 mutant form | 21199873 |
D019821 | Simvastatin | Simvastatin results in increased expression of TP53 protein | 20045437; 21199873; |
D019821 | Simvastatin | Simvastatin results in increased phosphorylation of TP53 protein | 20045437 |
D019821 | Simvastatin | Simvastatin results in increased expression of TP53 protein | 18804536 |
D020123 | Sirolimus | Sirolimus inhibits the reaction [2,2'-azobis(2-amidinopropane) results in increased phosphorylation of TP53 protein] | 30555576 |
D020123 | Sirolimus | Sirolimus promotes the reaction [Caffeine inhibits the reaction [2,2'-azobis(2-amidinopropane) results in increased phosphorylation of TP53 protein]] | 30555576 |
D020123 | Sirolimus | Sirolimus promotes the reaction [TP53 protein results in increased expression of BBC3 protein] | 19560264 |
D020123 | Sirolimus | [Sirolimus results in decreased activity of MTOR protein] which results in decreased phosphorylation of TP53 protein | 11602639 |
D020123 | Sirolimus | Sirolimus results in decreased phosphorylation of TP53 protein | 11602639 |
D020123 | Sirolimus | Sirolimus results in increased expression of TP53 mRNA | 24971338 |
C439060 | sirtinol | sirtinol promotes the reaction [arsenic disulfide results in increased expression of and results in increased phosphorylation of TP53 protein] | 18298901 |
C439060 | sirtinol | sirtinol promotes the reaction [cudraflavone B results in increased expression of TP53 protein] | 23881456 |
C439060 | sirtinol | [sirtinol results in decreased activity of SIRT1 protein] promotes the reaction [Hydrogen Peroxide results in increased acetylation of TP53 protein] | 18681908 |
D012862 | Skatole | Skatole results in increased phosphorylation of and affects the localization of TP53 protein | 19700606 |
C027744 | S-methylisothiopseudouronium | S-methylisothiopseudouronium inhibits the reaction [IL1B protein results in increased expression of TP53 protein] | 12384474 |
D012906 | Smoke | pifithrin inhibits the reaction [Smoke analog results in increased expression of TP53 mRNA] | 23665932 |
D012906 | Smoke | Smoke analog results in increased expression of TP53 mRNA | 23665932 |
D012906 | Smoke | Smoke analog results in increased phosphorylation of TP53 protein | 23665932 |
D012906 | Smoke | Smoke results in increased activity of TP53 protein | 22516759 |
C118258 | SN50 peptide | SN50 peptide inhibits the reaction [Hydrogen Peroxide results in increased expression of TP53 protein] | 15081873 |
C118258 | SN50 peptide | SN50 peptide inhibits the reaction [[Hydrogen Peroxide results in increased expression of TP53 protein] which results in increased expression of BAX protein] | 15081873 |
C118258 | SN50 peptide | SN50 peptide inhibits the reaction [[Hydrogen Peroxide results in increased expression of TP53 protein] which results in increased expression of CDKN1A protein] | 15081873 |
C118258 | SN50 peptide | SN50 peptide inhibits the reaction [[Hydrogen Peroxide results in increased expression of TP53 protein] which results in increased expression of MSH2 protein] | 15081873 |
C118258 | SN50 peptide | SN50 peptide inhibits the reaction [Diquat results in increased expression of and affects the localization of TP53 protein] | 29484840 |
C118258 | SN50 peptide | SN50 peptide inhibits the reaction [Oxidopamine results in increased expression of TP53 protein] | 17368433 |
C021315 | S-nitrosocysteine | S-nitrosocysteine inhibits the reaction [SIRT1 protein results in decreased acetylation of TP53 protein] | 24451382 |
D026422 | S-Nitrosoglutathione | S-Nitrosoglutathione inhibits the reaction [PRKN protein binds to TP53 promoter] | 23985028 |
D026422 | S-Nitrosoglutathione | S-Nitrosoglutathione inhibits the reaction [PRKN protein results in decreased expression of TP53 mRNA] | 23985028 |
D026422 | S-Nitrosoglutathione | S-Nitrosoglutathione inhibits the reaction [PRKN protein results in decreased expression of TP53 protein] | 23985028 |
D026422 | S-Nitrosoglutathione | [S-Nitrosoglutathione results in increased nitrosation of PRKN protein] inhibits the reaction [PRKN protein binds to TP53 promoter] | 23985028 |
D026422 | S-Nitrosoglutathione | [S-Nitrosoglutathione results in increased nitrosation of PRKN protein] inhibits the reaction [PRKN protein results in decreased expression of TP53 mRNA] | 23985028 |
D026422 | S-Nitrosoglutathione | [S-Nitrosoglutathione results in increased nitrosation of PRKN protein] inhibits the reaction [PRKN protein results in decreased expression of TP53 protein] | 23985028 |
D026422 | S-Nitrosoglutathione | [S-Nitrosoglutathione results in increased abundance of Nitric Oxide] which results in increased expression of TP53 protein | 8982730 |
D026423 | S-Nitroso-N-Acetylpenicillamine | S-Nitroso-N-Acetylpenicillamine promotes the reaction [FGF2 protein results in increased expression of TP53 protein] | 16351512 |
C009277 | sodium arsenate | sodium arsenate results in increased expression of TP53 mRNA | 24349563 |
C017947 | sodium arsenite | sodium arsenite results in decreased expression of TP53 mRNA | 30098560 |
C017947 | sodium arsenite | sodium arsenite results in increased expression of TP53 mRNA | 29361514 |
C017947 | sodium arsenite | 3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [sodium arsenite results in decreased phosphorylation of TP53 protein] | 22706169 |
C017947 | sodium arsenite | 3-(4-methylphenylsulfonyl)-2-propenenitrile promotes the reaction [sodium arsenite affects the localization of TP53 protein] | 20375080 |
C017947 | sodium arsenite | 3-(4-methylphenylsulfonyl)-2-propenenitrile promotes the reaction [sodium arsenite results in increased phosphorylation of TP53 protein] | 20375080 |
C017947 | sodium arsenite | 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone inhibits the reaction [sodium arsenite affects the localization of TP53 protein] | 19931552 |
C017947 | sodium arsenite | 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone inhibits the reaction [sodium arsenite results in increased activity of TP53 protein] | 19931552 |
C017947 | sodium arsenite | ATM gene mutant form inhibits the reaction [sodium arsenite results in increased expression of TP53 protein] | 11507245 |
C017947 | sodium arsenite | benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [sodium arsenite results in increased degradation of TP53 protein mutant form] | 21454520 |
C017947 | sodium arsenite | caffeic acid phenethyl ester inhibits the reaction [sodium arsenite results in decreased expression of TP53 protein] | 22692362 |
C017947 | sodium arsenite | HIF1A protein affects the reaction [sodium arsenite results in decreased phosphorylation of TP53 protein] | 27287256 |
C017947 | sodium arsenite | HSPA9 protein inhibits the reaction [sodium arsenite affects the localization of TP53 protein] | 20375080 |
C017947 | sodium arsenite | HSPA9 protein inhibits the reaction [sodium arsenite results in increased phosphorylation of TP53 protein] | 20375080 |
C017947 | sodium arsenite | leptomycin B inhibits the reaction [sodium arsenite affects the localization of TP53 protein] | 19010883 |
C017947 | sodium arsenite | leptomycin B inhibits the reaction [sodium arsenite results in increased degradation of TP53 protein mutant form] | 21454520 |
C017947 | sodium arsenite | Lithium inhibits the reaction [sodium arsenite results in increased expression of and affects the localization of TP53 protein] | 17849503 |
C017947 | sodium arsenite | MAP2K4 mutant form affects the reaction [sodium arsenite results in increased expression of TP53 protein] | 15734884 |
C017947 | sodium arsenite | MAPK1 protein promotes the reaction [sodium arsenite results in decreased expression of TP53 protein] | 28785074 |
C017947 | sodium arsenite | pyrazolanthrone inhibits the reaction [sodium arsenite results in increased phosphorylation of TP53 protein] | 22706169 |
C017947 | sodium arsenite | RTKI cpd inhibits the reaction [sodium arsenite results in increased expression of TP53 protein] | 15734884 |
C017947 | sodium arsenite | SB 203580 inhibits the reaction [[sodium arsenite co-treated with Vitamin K 3] results in increased phosphorylation of TP53 protein] | 19082730 |
C017947 | sodium arsenite | SB 203580 inhibits the reaction [sodium arsenite results in increased expression of TP53 protein] | 15734884 |
C017947 | sodium arsenite | SB 216763 inhibits the reaction [sodium arsenite results in increased expression of and affects the localization of TP53 protein] | 17849503 |
C017947 | sodium arsenite | sodium arsenite affects the expression of TP53 mRNA | 23804311 |
C017947 | sodium arsenite | sodium arsenite affects the localization of TP53 protein | 19010883; 19931552; 20375080; |
C017947 | sodium arsenite | [sodium arsenite co-treated with leptomycin B] results in increased phosphorylation of TP53 protein | 19010883 |
C017947 | sodium arsenite | [sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of TP53 mRNA | 23192986 |
C017947 | sodium arsenite | [sodium arsenite co-treated with pyrazolanthrone] promotes the reaction [HSPA9 protein binds to TP53 protein modified form] | 22706169 |
C017947 | sodium arsenite | [sodium arsenite co-treated with Vitamin K 3] results in increased phosphorylation of TP53 protein | 19082730 |
C017947 | sodium arsenite | sodium arsenite inhibits the reaction [Cisplatin results in increased expression of TP53 protein] | 21696631 |
C017947 | sodium arsenite | sodium arsenite promotes the reaction [MAPK8 protein binds to MAPK9 protein binds to TP53 protein modified form] | 22706169 |
C017947 | sodium arsenite | sodium arsenite promotes the reaction [TP53 protein binds to ATF3 promoter] | 26148435 |
C017947 | sodium arsenite | sodium arsenite promotes the reaction [TP53 protein binds to SESN1 promoter] | 26148435 |
C017947 | sodium arsenite | sodium arsenite results in decreased expression of and affects the localization of TP53 protein | 28785074 |
C017947 | sodium arsenite | sodium arsenite results in decreased expression of and results in increased degradation of TP53 protein mutant form | 21454520 |
C017947 | sodium arsenite | sodium arsenite results in decreased expression of TP53 mRNA | 12377979; 19615344; 22199297; 22692362; 24068038; |
C017947 | sodium arsenite | sodium arsenite results in decreased expression of TP53 protein | 17567589; 22692362; 27908234; |
C017947 | sodium arsenite | sodium arsenite results in decreased expression of TP53 protein modified form | 22706169 |
C017947 | sodium arsenite | sodium arsenite results in decreased expression of TP53 protein mutant form | 21454520 |
C017947 | sodium arsenite | sodium arsenite results in decreased methylation of TP53 gene | 25199682 |
C017947 | sodium arsenite | sodium arsenite results in decreased phosphorylation of TP53 protein | 22706169; 27287256; |
C017947 | sodium arsenite | sodium arsenite results in increased activity of TP53 protein | 17567589; 19931552; 23219847; |
C017947 | sodium arsenite | sodium arsenite results in increased expression of and affects the localization of TP53 protein | 17849503 |
C017947 | sodium arsenite | sodium arsenite results in increased expression of and results in increased phosphorylation of and results in decreased acetylation of TP53 protein | 29319823 |
C017947 | sodium arsenite | sodium arsenite results in increased expression of TP53 mRNA | 15734884; 26091798; |
C017947 | sodium arsenite | sodium arsenite results in increased expression of TP53 protein | 11507245; 11813266; 15734884; 16338954; 17567589; 19382146; 19931552; 20390378; 22102309; 23549458; 31120745; |
C017947 | sodium arsenite | sodium arsenite results in increased expression of TP53 protein modified form | 16338954; 22706169; 23219847; |
C017947 | sodium arsenite | sodium arsenite results in increased methylation of TP53 promoter | 22551203 |
C017947 | sodium arsenite | sodium arsenite results in increased phosphorylation of TP53 protein | 16614167; 20375080; 22706169; 26091798; |
C017947 | sodium arsenite | sodium arsenite results in increased ribosylation of TP53 protein | 20036271 |
C017947 | sodium arsenite | Sodium Selenite inhibits the reaction [sodium arsenite results in increased expression of TP53 protein] | 20390378 |
C017947 | sodium arsenite | TP53 mutant form inhibits the reaction [sodium arsenite results in decreased expression of BIRC5 protein] | 22706169 |
C017947 | sodium arsenite | TP53 protein affects the reaction [sodium arsenite results in decreased expression of MIR200B mRNA] | 21292642 |
C017947 | sodium arsenite | TP53 protein affects the reaction [sodium arsenite results in decreased expression of MIR200C mRNA] | 21292642 |
C017947 | sodium arsenite | TP53 protein affects the reaction [sodium arsenite results in decreased expression of MIR205 mRNA] | 21292642 |
C017947 | sodium arsenite | TP53 protein affects the reaction [sodium arsenite results in increased expression of and results in decreased degradation of CCNB1 protein] | 16614167 |
C017947 | sodium arsenite | TP53 protein affects the reaction [sodium arsenite results in increased expression of FZD2 mRNA] | 16966095 |
C017947 | sodium arsenite | TP53 protein affects the reaction [sodium arsenite results in increased expression of MIR605 mRNA] | 21292642 |
C017947 | sodium arsenite | TP53 protein affects the reaction [sodium arsenite results in increased expression of UBE2C mRNA] | 16966095 |
C017947 | sodium arsenite | TP53 protein affects the reaction [sodium arsenite results in increased expression of UBE2K mRNA] | 16966095 |
C017947 | sodium arsenite | TP53 protein affects the reaction [sodium arsenite results in increased expression of UBE2N mRNA] | 16966095 |
C017947 | sodium arsenite | TP53 protein affects the reaction [sodium arsenite results in increased susceptibility to Cisplatin] | 22331493 |
C017947 | sodium arsenite | TP53 protein affects the susceptibility to sodium arsenite | 16338954; 20000476; 22331493; |
C017947 | sodium arsenite | TP53 protein inhibits the reaction [sodium arsenite results in increased cleavage of CASP3 protein] | 16614167 |
C017947 | sodium arsenite | TP53 protein inhibits the reaction [sodium arsenite results in increased cleavage of PARP1 protein] | 16614167 |
C017947 | sodium arsenite | TP53 protein inhibits the reaction [sodium arsenite results in increased expression of and results in increased phosphorylation of CDK1 protein] | 16614167 |
C017947 | sodium arsenite | TP53 protein mutant form affects the susceptibility to sodium arsenite | 17567589 |
C017947 | sodium arsenite | TP53 protein mutant form inhibits the reaction [sodium arsenite results in increased expression of MDM2 mRNA] | 28785074 |
C017947 | sodium arsenite | TP53 protein mutant form results in decreased susceptibility to sodium arsenite | 21454520 |
C017947 | sodium arsenite | TP53 protein promotes the reaction [sodium arsenite results in increased expression of DLX2 mRNA] | 16966095 |
C017947 | sodium arsenite | TP53 protein promotes the reaction [sodium arsenite results in increased expression of DUSP1 mRNA] | 16966095 |
C017947 | sodium arsenite | TP53 protein promotes the reaction [sodium arsenite results in increased expression of HSPA1A mRNA] | 16966095 |
C017947 | sodium arsenite | TP53 protein promotes the reaction [sodium arsenite results in increased expression of ID1 mRNA] | 16966095 |
C017947 | sodium arsenite | TP53 protein promotes the reaction [sodium arsenite results in increased expression of ID1 protein] | 16966095 |
C017947 | sodium arsenite | TP53 protein promotes the reaction [sodium arsenite results in increased expression of MDM2 protein] | 20375080 |
C017947 | sodium arsenite | TP53 protein results in decreased susceptibility to sodium arsenite | 16614167 |
C017947 | sodium arsenite | tyrphostin AG825 inhibits the reaction [sodium arsenite results in increased expression of TP53 protein] | 15734884 |
C017947 | sodium arsenite | U 0126 inhibits the reaction [sodium arsenite results in decreased phosphorylation of TP53 protein] | 22706169 |
C017947 | sodium arsenite | sodium arsenite results in increased expression of TP53 protein | 16338954 |
C017947 | sodium arsenite | Polysaccharides inhibits the reaction [sodium arsenite results in increased expression of TP53 mRNA] | 31163222 |
C017947 | sodium arsenite | Polysaccharides inhibits the reaction [sodium arsenite results in increased phosphorylation of TP53 protein] | 31163222 |
C017947 | sodium arsenite | sodium arsenite results in decreased expression of TP53 protein | 28785074 |
C017947 | sodium arsenite | sodium arsenite results in increased expression of TP53 mRNA | 31163222 |
C017947 | sodium arsenite | sodium arsenite results in increased expression of TP53 protein | 16797887 |
C017947 | sodium arsenite | sodium arsenite results in increased phosphorylation of TP53 protein | 31163222 |
C017947 | sodium arsenite | Succimer inhibits the reaction [sodium arsenite results in increased expression of TP53 mRNA] | 31163222 |
C017947 | sodium arsenite | Succimer inhibits the reaction [sodium arsenite results in increased phosphorylation of TP53 protein] | 31163222 |
C017947 | sodium arsenite | sodium arsenite results in increased expression of TP53 | 13129816 |
D019810 | Sodium Azide | Sodium Azide inhibits the reaction [2-butylamino-2-demethoxy-hypocrellin B results in increased expression of TP53 mRNA] | 17045927 |
D020160 | Sodium Benzoate | Sodium Benzoate inhibits the reaction [Asbestos, Amosite results in increased expression of TP53 mRNA] | 16357363 |
C016104 | sodium bichromate | Aspirin inhibits the reaction [sodium bichromate results in increased expression of TP53 protein] | 10942736 |
C016104 | sodium bichromate | CAT protein inhibits the reaction [sodium bichromate results in increased expression of TP53 protein] | 10942736 |
C016104 | sodium bichromate | Deferoxamine inhibits the reaction [sodium bichromate results in increased expression of TP53 protein] | 10942736 |
C016104 | sodium bichromate | formic acid inhibits the reaction [sodium bichromate results in increased expression of TP53 protein] | 10942736 |
C016104 | sodium bichromate | NADP promotes the reaction [sodium bichromate results in increased expression of TP53 protein] | 10942736 |
C016104 | sodium bichromate | sodium bichromate results in decreased expression of TP53 mRNA | 27825931 |
C016104 | sodium bichromate | sodium bichromate results in increased expression of TP53 mRNA | 26091798 |
C016104 | sodium bichromate | sodium bichromate results in increased expression of TP53 protein | 10942736 |
C016104 | sodium bichromate | sodium bichromate results in increased phosphorylation of TP53 protein | 26091798 |
C016104 | sodium bichromate | sodium bichromate affects the expression of TP53 mRNA | 11960910 |
C016104 | sodium bichromate | sodium bichromate results in decreased expression of TP53 mRNA | 21437922 |
C016104 | sodium bichromate | sodium bichromate results in decreased expression of TP53 protein | 21437922 |
C016104 | sodium bichromate | sodium bichromate results in increased expression of TP53 mRNA | 22561333 |
D012965 | Sodium Chloride | Sodium Chloride results in increased expression of TP53 mRNA | 23634900 |
D012965 | Sodium Chloride | acetovanillone inhibits the reaction [[Desoxycorticosterone co-treated with Sodium Chloride] results in increased expression of TP53 protein] | 22431579 |
D012965 | Sodium Chloride | Atrasentan inhibits the reaction [[Desoxycorticosterone co-treated with Sodium Chloride] results in increased expression of TP53 protein] | 22431579 |
D012965 | Sodium Chloride | [Desoxycorticosterone co-treated with Sodium Chloride] results in increased expression of TP53 protein | 22431579 |
D017673 | Sodium Chloride, Dietary | [Desoxycorticosterone Acetate co-treated with Sodium Chloride, Dietary co-treated with Potassium Chloride] results in increased expression of TP53 mRNA | 22228705 |
C028982 | sodium chromate(VI) | sodium chromate(VI) results in increased expression of TP53 protein | 16283527 |
D012969 | Sodium Fluoride | Sodium Fluoride results in increased expression of TP53 mRNA | 22525295 |
D012969 | Sodium Fluoride | Sodium Fluoride results in increased expression of TP53 protein | 22525295 |
D012980 | Sodium Salicylate | Sodium Salicylate inhibits the reaction [Paraquat results in increased expression of TP53 protein] | 17561093 |
D018038 | Sodium Selenite | Sodium Selenite inhibits the reaction [mono-(2-ethylhexyl)phthalate results in increased activity of TP53 protein] | 21515331 |
D018038 | Sodium Selenite | Sodium Selenite inhibits the reaction [sodium arsenite results in increased expression of TP53 protein] | 20390378 |
D018038 | Sodium Selenite | Sodium Selenite results in increased phosphorylation of TP53 protein | 15845651 |
D018038 | Sodium Selenite | TP53 protein affects the susceptibility to Sodium Selenite | 22200533 |
D053260 | Soot | Soot results in decreased expression of TP53 mRNA | 23634900 |
D053260 | Soot | Soot results in decreased expression of TP53 mRNA | 21914721 |
D000077157 | Sorafenib | Sorafenib promotes the reaction [GSK3B protein results in increased phosphorylation of TP53 protein] | 17991738 |
C013195 | sparfosic acid | sparfosic acid results in increased expression of and affects the localization of TP53 protein | 8548770 |
C091861 | spermine nitric oxide complex | spermine nitric oxide complex inhibits the reaction [Cadmium results in increased expression of TP53 mRNA] | 25490952 |
C091861 | spermine nitric oxide complex | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [spermine nitric oxide complex results in increased phosphorylation of TP53 protein] | 16024610 |
C091861 | spermine nitric oxide complex | Caffeine inhibits the reaction [spermine nitric oxide complex results in increased phosphorylation of TP53 protein] | 16024610 |
C091861 | spermine nitric oxide complex | spermine nitric oxide complex results in increased phosphorylation of TP53 protein | 16024610 |
C091861 | spermine nitric oxide complex | TP53 protein affects the susceptibility to spermine nitric oxide complex | 16024610 |
C091861 | spermine nitric oxide complex | Wortmannin inhibits the reaction [spermine nitric oxide complex results in increased phosphorylation of TP53 protein] | 16024610 |
C525423 | SRT2183 | [Panobinostat co-treated with SRT2183] results in increased acetylation of TP53 protein | 23681230 |
C530804 | S,S'-1,4-phenylenebis(1,2-ethanediyl)bisisoselenourea | S,S'-1,4-phenylenebis(1,2-ethanediyl)bisisoselenourea results in increased expression of TP53 protein | 19497413 |
D019311 | Staurosporine | Staurosporine results in increased expression of TP53 protein | 20886113 |
D019311 | Staurosporine | Staurosporine inhibits the reaction [EGF protein inhibits the reaction [Resveratrol inhibits the reaction [TP53 protein binds to MDM2 protein]]] | 15542774 |
D019311 | Staurosporine | Staurosporine inhibits the reaction [EGF protein inhibits the reaction [Resveratrol results in increased phosphorylation of and results in increased activity of and results in increased localization of TP53 protein]] | 15542774 |
D019311 | Staurosporine | Staurosporine promotes the reaction [Resveratrol results in increased phosphorylation of and results in increased activity of and results in increased localization of TP53 protein] | 15542774 |
D019311 | Staurosporine | HR protein inhibits the reaction [Staurosporine results in increased expression of TP53 protein] | 20886113 |
D013267 | Stilbenes | Stilbenes results in increased expression of TP53 protein | 23059970 |
D013267 | Stilbenes | [Stilbenes results in increased expression of TP53 protein] which results in increased expression of BAX protein | 23059970 |
D013311 | Streptozocin | 4-phenylbutyric acid inhibits the reaction [Streptozocin results in increased expression of TP53 protein] | 30980806 |
D013311 | Streptozocin | Glyburide inhibits the reaction [Streptozocin results in increased expression of TP53 mRNA] | 30817903 |
D013311 | Streptozocin | isoquercitrin inhibits the reaction [Streptozocin results in increased expression of TP53 mRNA] | 30817903 |
D013311 | Streptozocin | Resveratrol inhibits the reaction [Streptozocin results in increased expression of TP53 protein] | 23792339 |
D013311 | Streptozocin | Streptozocin results in increased expression of TP53 mRNA | 30817903 |
D013311 | Streptozocin | Streptozocin results in increased expression of TP53 protein | 15976052; 23792339; 30980806; |
C013690 | styrene oxide | styrene oxide affects the expression of TP53 mRNA | 11230554 |
D004113 | Succimer | Succimer inhibits the reaction [sodium arsenite results in increased expression of TP53 mRNA] | 31163222 |
D004113 | Succimer | Succimer inhibits the reaction [sodium arsenite results in increased phosphorylation of TP53 protein] | 31163222 |
D013458 | Sulfur Dioxide | [Sulfur Dioxide co-treated with Benzo(a)pyrene] results in increased expression of TP53 mRNA | 19408242 |
D013458 | Sulfur Dioxide | [Sulfur Dioxide co-treated with Benzo(a)pyrene] results in increased expression of TP53 protein | 19408242 |
D013458 | Sulfur Dioxide | Sulfur Dioxide inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased phosphorylation of and results in increased activity of TP53 protein] | 30503585 |
D013458 | Sulfur Dioxide | Sulfur Dioxide promotes the reaction [Benzo(a)pyrene results in increased expression of TP53 mRNA] | 20064080 |
D013458 | Sulfur Dioxide | Sulfur Dioxide promotes the reaction [Benzo(a)pyrene results in increased expression of TP53 protein] | 20064080 |
D013458 | Sulfur Dioxide | Sulfur Dioxide results in increased expression of TP53 mRNA | 19408242; 19434695; 20064080; |
D013458 | Sulfur Dioxide | Sulfur Dioxide results in increased expression of TP53 protein | 19408242; 19434695; 20064080; |
D013467 | Sulindac | SB 203580 inhibits the reaction [Sulindac affects the localization of TP53 protein] | 17136320 |
D013467 | Sulindac | Sulindac affects the localization of TP53 protein | 17136320 |
D013467 | Sulindac | [Sulindac results in increased abundance of Reactive Oxygen Species] which results in increased activity of TP53 protein | 17136320 |
D013467 | Sulindac | Sulindac results in increased expression of TP53 protein | 15713900 |
C025462 | sulindac sulfide | sulindac sulfide results in decreased expression of TP53 protein | 9192825 |
C473643 | sulphoraphene | sulphoraphene results in increased expression of and affects the localization of TP53 protein | 29247643 |
D013498 | Suramin | Suramin results in decreased activity of [SIRT1 protein results in decreased acetylation of TP53 protein] | 18482975 |
D013605 | T-2 Toxin | Bentonite inhibits the reaction [[HT-2 toxin co-treated with T-2 Toxin] results in increased expression of TP53 mRNA] | 25296281 |
D013605 | T-2 Toxin | [HT-2 toxin co-treated with T-2 Toxin] results in increased expression of TP53 mRNA | 25296281 |
D013605 | T-2 Toxin | T-2 Toxin results in increased expression of TP53 protein | 19524637 |
D013605 | T-2 Toxin | T-2 Toxin results in increased expression of TP53 mRNA | 21296132; 29567467; 29870751; |
D013605 | T-2 Toxin | T-2 Toxin results in increased expression of TP53 protein | 21296132; 29567467; |
D013619 | Tacrine | Tacrine inhibits the reaction [Hydrogen Peroxide results in increased expression of TP53 mRNA] | 12414117 |
D013619 | Tacrine | Tacrine inhibits the reaction [Hydrogen Peroxide results in increased expression of TP53 protein] | 12414117 |
D016559 | Tacrolimus | Tacrolimus inhibits the reaction [Hydrogen Peroxide results in increased expression of TP53 protein] | 12642403 |
D013629 | Tamoxifen | Tamoxifen results in increased expression of TP53 mRNA | 26908177 |
D013629 | Tamoxifen | [Tamoxifen co-treated with naringenin] results in increased expression of TP53 mRNA | 30153467 |
D013629 | Tamoxifen | Tamoxifen results in increased expression of TP53 mRNA | 30153467 |
D013629 | Tamoxifen | Tamoxifen results in increased expression of TP53 protein | 16450001; 20549698; |
D013629 | Tamoxifen | TP53 gene mutant form results in decreased susceptibility to Tamoxifen | 10786679 |
D013629 | Tamoxifen | TP53 protein affects the susceptibility to Tamoxifen | 15832264 |
D013629 | Tamoxifen | TP53 protein inhibits the reaction [Tamoxifen results in decreased phosphorylation of AKT1 protein] | 20549698 |
D013629 | Tamoxifen | TP53 protein inhibits the reaction [Tamoxifen results in decreased phosphorylation of MAPK1 protein] | 20549698 |
D013629 | Tamoxifen | TP53 protein inhibits the reaction [Tamoxifen results in decreased phosphorylation of MAPK3 protein] | 20549698 |
D013629 | Tamoxifen | TP53 protein inhibits the reaction [Tamoxifen results in increased expression of ESR1 protein] | 20549698 |
D013629 | Tamoxifen | TP53 protein promotes the reaction [Tamoxifen results in decreased expression of BCL2 mRNA] | 20549698 |
D013629 | Tamoxifen | TP53 protein promotes the reaction [Tamoxifen results in increased expression of GADD45A mRNA] | 20549698 |
D013629 | Tamoxifen | TP53 protein results in increased susceptibility to Tamoxifen | 20549698 |
D013629 | Tamoxifen | Tamoxifen results in increased mutagenesis of TP53 gene | 8033108 |
C112765 | tanespimycin | tanespimycin results in decreased expression of TP53 protein | 10564678 |
C021751 | tanshinone | tanshinone results in decreased expression of TP53 protein | 19885617; 20369472; |
C021751 | tanshinone | tanshinone results in increased expression of TP53 protein | 16009009 |
C030141 | taurine-ursodeoxycholate conjugate | taurine-ursodeoxycholate conjugate inhibits the reaction [E2F1 protein results in increased expression of TP53 protein] | 14514686 |
C030141 | taurine-ursodeoxycholate conjugate | taurine-ursodeoxycholate conjugate inhibits the reaction [TGFB1 protein results in increased expression of TP53 protein] | 14514686 |
C030141 | taurine-ursodeoxycholate conjugate | taurine-ursodeoxycholate conjugate inhibits the reaction [TP53 protein results in increased expression of BAX protein] | 14514686 |
C031655 | tauroursodeoxycholic acid | tauroursodeoxycholic acid inhibits the reaction [TP53 protein results in increased expression of BAX mRNA] | 17881359 |
C031655 | tauroursodeoxycholic acid | tauroursodeoxycholic acid results in increased expression of and results in increased stability of TP53 protein | 15255934 |
C031655 | tauroursodeoxycholic acid | TP53 protein affects the susceptibility to tauroursodeoxycholic acid | 17431217 |
C508490 | TDP 521252 | TDP 521252 inhibits the reaction [MDM2 protein binds to TP53 protein] | 16432175 |
C508490 | TDP 521252 | TDP 521252 results in increased stability of TP53 protein | 16432175 |
C508491 | TDP 665759 | TDP 665759 inhibits the reaction [MDM2 protein binds to TP53 protein] | 16432175 |
C508491 | TDP 665759 | TDP 665759 results in increased stability of TP53 protein | 16432175 |
D013662 | Tea | Bleomycin promotes the reaction [Tea results in increased expression of TP53 mRNA] | 26800624 |
D013662 | Tea | Tea promotes the reaction [Bleomycin results in increased expression of TP53 mRNA] | 26800624 |
D013662 | Tea | Tea results in increased expression of TP53 mRNA | 26800624 |
D013662 | Tea | Tea inhibits the reaction [decamethrin results in increased expression of TP53 mRNA] | 26013673 |
D013662 | Tea | Tea inhibits the reaction [decamethrin results in increased expression of TP53 protein] | 26013673 |
D005641 | Tegafur | TP53 protein affects the susceptibility to Tegafur | 15182437 |
D005641 | Tegafur | TP53 protein affects the susceptibility to [Uracil co-treated with Tegafur] | 15182437 |
D000077204 | Temozolomide | [Temozolomide co-treated with O(6)-benzylguanine] results in increased expression of TP53 protein | 20980775 |
D000077204 | Temozolomide | Temozolomide promotes the reaction [TP53 protein binds to SP1 protein] | 29164620 |
D000077204 | Temozolomide | Temozolomide results in increased expression of TP53 protein | 16193384 |
D000077204 | Temozolomide | TP53 protein promotes the reaction [Temozolomide results in increased expression of PMAIP1 mRNA] | 17216584 |
D000077204 | Temozolomide | TP53 protein results in decreased susceptibility to Temozolomide | 16193384 |
D000077204 | Temozolomide | TP53 protein results in increased susceptibility to Temozolomide | 16405512 |
D000077204 | Temozolomide | TP53 protein results in increased susceptibility to [Temozolomide co-treated with O(6)-benzylguanine] | 20980775 |
C001803 | tempol | tempol results in increased expression of TP53 protein | 15601469 |
C505333 | TEMPOL-H | TEMPOL-H inhibits the reaction [Dichlorvos results in increased expression of TP53 mRNA] | 24369695 |
C505333 | TEMPOL-H | TEMPOL-H inhibits the reaction [Dichlorvos results in increased expression of TP53 protein] | 24369695 |
C037565 | terbutylazine | terbutylazine results in decreased stability of and results in increased degradation of and results in increased mutagenesis of TP53 gene | 22445671 |
D016593 | Terfenadine | Terfenadine results in increased expression of TP53 protein | 12244568 |
C028786 | teroxirone | teroxirone results in increased expression of TP53 protein | 23954467 |
C028786 | teroxirone | TP53 protein results in increased susceptibility to teroxirone | 23954467 |
C028786 | teroxirone | [TP53 protein results in increased susceptibility to teroxirone] which results in increased cleavage of CASP3 protein | 23954467 |
C028786 | teroxirone | [TP53 protein results in increased susceptibility to teroxirone] which results in increased cleavage of PARP1 protein | 23954467 |
D020122 | tert-Butylhydroperoxide | Niacinamide inhibits the reaction [tert-Butylhydroperoxide results in increased expression of TP53 protein] | 12782109 |
D020122 | tert-Butylhydroperoxide | S-ethyl glutathione inhibits the reaction [tert-Butylhydroperoxide results in increased expression of TP53 protein modified form] | 17555331 |
D020122 | tert-Butylhydroperoxide | tert-Butylhydroperoxide results in decreased expression of TP53 mRNA | 12419474 |
D020122 | tert-Butylhydroperoxide | tert-Butylhydroperoxide results in increased expression of TP53 protein | 12782109 |
D020122 | tert-Butylhydroperoxide | tert-Butylhydroperoxide results in increased glutathionylation of TP53 protein | 17555331 |
D013739 | Testosterone | [Testosterone co-treated with gingerol] results in increased expression of TP53 protein | 18030663 |
D013739 | Testosterone | chrysin inhibits the reaction [Testosterone results in decreased expression of TP53 mRNA] | 29247772 |
D013739 | Testosterone | Testosterone results in decreased expression of TP53 mRNA | 29247772 |
C534735 | tetraarsenic tetrasulfide | Arsenic Trioxide promotes the reaction [tetraarsenic tetrasulfide results in increased expression of TP53 protein] | 26110921 |
C534735 | tetraarsenic tetrasulfide | (+)-JQ1 compound promotes the reaction [tetraarsenic tetrasulfide results in increased expression of TP53 protein] | 26586936 |
C534735 | tetraarsenic tetrasulfide | tetraarsenic tetrasulfide promotes the reaction [Arsenic Trioxide results in increased expression of TP53 protein] | 26110921 |
C534735 | tetraarsenic tetrasulfide | tetraarsenic tetrasulfide promotes the reaction [(+)-JQ1 compound results in increased expression of TP53 protein] | 26586936 |
C534735 | tetraarsenic tetrasulfide | tetraarsenic tetrasulfide results in increased expression of TP53 protein | 26110921; 26586936; |
C020806 | tetrabromobisphenol A | tetrabromobisphenol A results in increased expression of TP53 mRNA | 24596333 |
C020806 | tetrabromobisphenol A | tetrabromobisphenol A results in increased expression of TP53 mRNA | 28970181 |
C020806 | tetrabromobisphenol A | tetrabromobisphenol A results in increased mutagenesis of TP53 gene | 26353976 |
C000591600 | tetrachlorobenzoquinone | tetrachlorobenzoquinone affects the reaction [TP53 protein binds to RAD51 protein] | 27989139 |
C000591600 | tetrachlorobenzoquinone | tetrachlorobenzoquinone results in increased expression of and results in increased phosphorylation of TP53 protein | 27989139 |
C000591600 | tetrachlorobenzoquinone | TP53 protein promotes the reaction [tetrachlorobenzoquinone results in decreased expression of RAD51 protein] | 27989139 |
C000591600 | tetrachlorobenzoquinone | TP53 protein promotes the reaction [tetrachlorobenzoquinone results in increased expression of CASP3 protein modified form] | 27989139 |
C000591600 | tetrachlorobenzoquinone | TP53 protein promotes the reaction [tetrachlorobenzoquinone results in increased expression of H2AX protein modified form] | 27989139 |
C000591600 | tetrachlorobenzoquinone | TP53 protein results in increased susceptibility to tetrachlorobenzoquinone | 27989139 |
D013749 | Tetrachlorodibenzodioxin | Tetrachlorodibenzodioxin affects the expression of TP53 protein | 22015590 |
D013749 | Tetrachlorodibenzodioxin | Tetrachlorodibenzodioxin affects the phosphorylation of TP53 protein | 22015590 |
D013749 | Tetrachlorodibenzodioxin | Tetrachlorodibenzodioxin results in decreased expression of TP53 mRNA | 24349563 |
D013749 | Tetrachlorodibenzodioxin | 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide results in decreased susceptibility to [Tetrachlorodibenzodioxin results in decreased susceptibility to [1-nitropyrene results in increased expression of TP53 protein]] | 22044530 |
D013749 | Tetrachlorodibenzodioxin | 3'-methoxy-4'-nitroflavone inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of TP53 mRNA] | 17070097 |
D013749 | Tetrachlorodibenzodioxin | 3'-methoxy-4'-nitroflavone inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of TP53 protein] | 17070097 |
D013749 | Tetrachlorodibenzodioxin | CYP1A1 protein affects the susceptibility to [Tetrachlorodibenzodioxin results in decreased susceptibility to [1-nitropyrene results in increased expression of TP53 protein]] | 22044530 |
D013749 | Tetrachlorodibenzodioxin | fostriecin promotes the reaction [Tetrachlorodibenzodioxin promotes the reaction [Benzo(a)pyrene results in increased expression of TP53 protein]] | 24954032 |
D013749 | Tetrachlorodibenzodioxin | Okadaic Acid affects the reaction [Tetrachlorodibenzodioxin promotes the reaction [Benzo(a)pyrene results in increased expression of TP53 protein]] | 24954032 |
D013749 | Tetrachlorodibenzodioxin | Okadaic Acid inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [Benzo(a)pyrene affects the localization of TP53 protein]] | 24954032 |
D013749 | Tetrachlorodibenzodioxin | [Tetrachlorodibenzodioxin co-treated with Oxygen deficiency] results in decreased expression of TP53 mRNA | 19578757 |
D013749 | Tetrachlorodibenzodioxin | [Tetrachlorodibenzodioxin co-treated with Oxygen deficiency] results in decreased expression of TP53 protein | 19578757 |
D013749 | Tetrachlorodibenzodioxin | Tetrachlorodibenzodioxin inhibits the reaction [Etoposide results in increased acetylation of TP53 protein] | 20299546 |
D013749 | Tetrachlorodibenzodioxin | Tetrachlorodibenzodioxin inhibits the reaction [Etoposide results in increased phosphorylation of and results in increased activity of TP53 protein] | 20299546 |
D013749 | Tetrachlorodibenzodioxin | Tetrachlorodibenzodioxin promotes the reaction [Benzo(a)pyrene affects the localization of and results in increased expression of TP53 protein] | 24954032 |
D013749 | Tetrachlorodibenzodioxin | Tetrachlorodibenzodioxin promotes the reaction [dibenzo(a,l)pyrene affects the localization of and results in increased expression of TP53 protein] | 24954032 |
D013749 | Tetrachlorodibenzodioxin | Tetrachlorodibenzodioxin results in decreased expression of TP53 mRNA | 17070097 |
D013749 | Tetrachlorodibenzodioxin | Tetrachlorodibenzodioxin results in decreased expression of TP53 protein | 17070097 |
D013749 | Tetrachlorodibenzodioxin | Tetrachlorodibenzodioxin results in decreased susceptibility to [1-nitropyrene results in increased expression of TP53 protein] | 22044530 |
D013749 | Tetrachlorodibenzodioxin | Tetrachlorodibenzodioxin results in decreased susceptibility to [1-nitropyrene results in increased expression of TP53 protein modified form] | 22044530 |
D013749 | Tetrachlorodibenzodioxin | Tetrachlorodibenzodioxin results in decreased susceptibility to [nutlin 3 results in increased susceptibility to [1-nitropyrene results in increased expression of TP53 protein]] | 22044530 |
D013749 | Tetrachlorodibenzodioxin | Tetrachlorodibenzodioxin results in decreased susceptibility to [nutlin 3 results in increased susceptibility to [1-nitropyrene results in increased expression of TP53 protein modified form]] | 22044530 |
D013749 | Tetrachlorodibenzodioxin | Tetrachlorodibenzodioxin results in decreased expression of TP53 protein | 9707505 |
D013749 | Tetrachlorodibenzodioxin | AHR protein promotes the reaction [Tetrachlorodibenzodioxin inhibits the reaction [Diethylnitrosamine results in increased phosphorylation of TP53 protein]] | 15459018 |
D013749 | Tetrachlorodibenzodioxin | AHR protein promotes the reaction [Tetrachlorodibenzodioxin results in increased phosphorylation of TP53 protein] | 15093247 |
D013749 | Tetrachlorodibenzodioxin | alpha-naphthoflavone inhibits the reaction [Tetrachlorodibenzodioxin inhibits the reaction [leptomycin B results in increased expression of TP53 protein]] | 15459018 |
D013749 | Tetrachlorodibenzodioxin | Tetrachlorodibenzodioxin affects the expression of TP53 mRNA | 22298810 |
D013749 | Tetrachlorodibenzodioxin | Tetrachlorodibenzodioxin inhibits the reaction [Benzo(a)pyrene results in increased expression of and results in increased phosphorylation of TP53 protein] | 15459018 |
D013749 | Tetrachlorodibenzodioxin | Tetrachlorodibenzodioxin inhibits the reaction [Diethylnitrosamine results in increased expression of and results in increased phosphorylation of TP53 protein] | 15459018 |
D013749 | Tetrachlorodibenzodioxin | Tetrachlorodibenzodioxin inhibits the reaction [Etoposide results in increased expression of and results in increased phosphorylation of TP53 protein] | 15459018 |
D013749 | Tetrachlorodibenzodioxin | Tetrachlorodibenzodioxin inhibits the reaction [Fluorouracil results in increased expression of TP53 protein] | 15459018 |
D013749 | Tetrachlorodibenzodioxin | Tetrachlorodibenzodioxin inhibits the reaction [leptomycin B results in increased expression of TP53 protein] | 15459018 |
D013749 | Tetrachlorodibenzodioxin | Tetrachlorodibenzodioxin results in decreased expression of and results in increased phosphorylation of TP53 protein | 15093247 |
D013749 | Tetrachlorodibenzodioxin | Tetrachlorodibenzodioxin results in decreased expression of TP53 protein | 8640813 |
D013749 | Tetrachlorodibenzodioxin | Tetrachlorodibenzodioxin results in increased degradation of TP53 protein | 15459018 |
D013749 | Tetrachlorodibenzodioxin | Tetrachlorodibenzodioxin results in increased expression of TP53 mRNA | 19520675 |
D013749 | Tetrachlorodibenzodioxin | Tetrachlorodibenzodioxin results in decreased activity of TP53 protein | 22044530 |
D013749 | Tetrachlorodibenzodioxin | Tetrachlorodibenzodioxin results in decreased susceptibility to [1-nitropyrene results in increased activity of TP53 protein] | 22044530 |
D013750 | Tetrachloroethylene | Tetrachloroethylene results in increased expression of TP53 protein | 12160929 |
D013752 | Tetracycline | Tetracycline results in increased expression of TP53 mRNA | 17522070 |
D013755 | Tetradecanoylphorbol Acetate | Tetradecanoylphorbol Acetate inhibits the reaction [Resveratrol results in increased phosphorylation of and results in increased activity of and affects the localization of TP53 protein] | 15542774 |
D013755 | Tetradecanoylphorbol Acetate | Tetradecanoylphorbol Acetate results in decreased expression of TP53 protein | 10910098 |
D013755 | Tetradecanoylphorbol Acetate | Tetradecanoylphorbol Acetate results in increased phosphorylation of TP53 protein | 8076368; 8927716; |
D013755 | Tetradecanoylphorbol Acetate | [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TP53 mRNA | 25613284 |
D013755 | Tetradecanoylphorbol Acetate | Tetradecanoylphorbol Acetate results in increased phosphorylation of TP53 protein | 8076368 |
D013755 | Tetradecanoylphorbol Acetate | Tetradecanoylphorbol Acetate results in increased activity of TP53 | 20454814 |
C011126 | tetraiodothyroacetic acid | tetraiodothyroacetic acid inhibits the reaction [Thyroxine affects the localization of TP53 protein modified form] | 17984113 |
C050950 | tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex | tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex affects the expression of TP53 protein | 16002045 |
C020809 | tetrathiomolybdate | [Copper deficiency co-treated with tetrathiomolybdate] results in increased expression of TP53 protein | 22276220 |
D013792 | Thalidomide | Thalidomide analog results in increased expression of TP53 mRNA | 20525221 |
C026995 | thallium acetate | thallium acetate results in increased expression of TP53 protein | 15965099 |
C042172 | thallium nitrate | EGF protein inhibits the reaction [thallium nitrate analog results in increased phosphorylation of TP53 protein] | 27412756 |
C042172 | thallium nitrate | EGF protein inhibits the reaction [thallium nitrate results in increased phosphorylation of TP53 protein] | 27412756 |
C042172 | thallium nitrate | thallium nitrate analog results in decreased expression of and results in increased phosphorylation of TP53 protein | 27412756 |
C042172 | thallium nitrate | thallium nitrate results in increased phosphorylation of TP53 protein | 27412756 |
D019284 | Thapsigargin | caffeic acid promotes the reaction [Thapsigargin results in decreased expression of TP53 mRNA] | 19442820 |
D019284 | Thapsigargin | Thapsigargin results in decreased expression of TP53 mRNA | 19442820 |
D013806 | Theophylline | IL4 protein inhibits the reaction [[Theophylline co-treated with Chlorambucil] results in increased expression of TP53] | 8822937 |
D013806 | Theophylline | [Theophylline co-treated with Chlorambucil] results in increased expression of TP53 | 8822937 |
D013806 | Theophylline | Theophylline results in decreased expression of TP53 | 8822937 |
D013806 | Theophylline | Theophylline results in decreased expression of TP53 mRNA | 17522070 |
D013827 | Thiabendazole | Thiabendazole results in increased expression of TP53 mRNA | 18539377 |
D013853 | Thioacetamide | Thioacetamide results in increased expression of TP53 mRNA | 17997003 |
D013853 | Thioacetamide | Thioacetamide results in increased expression of and results in increased phosphorylation of and results in increased activity of TP53 protein | 16937528 |
D013853 | Thioacetamide | Thioacetamide results in increased expression of TP53 mRNA | 23411599; 26011634; |
D013853 | Thioacetamide | Thioacetamide results in increased expression of TP53 protein | 23411599 |
D013859 | Thiocarbamates | Thiocarbamates analog inhibits the reaction [Dimethylformamide results in increased expression of TP53 protein] | 29984871 |
D008063 | Thioctic Acid | Thioctic Acid inhibits the reaction [Methotrexate results in increased expression of TP53 protein] | 19900424 |
C523062 | thio-dimethylarsinate | thio-dimethylarsinate results in increased expression of TP53 mRNA | 27320638 |
D013866 | Thioguanine | Thioguanine results in increased activity of TP53 protein | 22010212 |
D013882 | Thiosemicarbazones | [Thiosemicarbazones binds to Copper] which results in decreased activity of TP53 protein | 20931265 |
D013883 | Thiostrepton | Thiostrepton results in decreased expression of TP53 mRNA | 22321511 |
D013883 | Thiostrepton | Thiostrepton results in decreased expression of TP53 protein | 22321511 |
D013890 | Thiourea | Thiourea inhibits the reaction [[cupric chloride co-treated with di(2-picolyl)amine-3(bromoacetyl)coumarin] results in increased expression of TP53 protein] | 29803612 |
C003466 | thymoquinone | Acetylcysteine inhibits the reaction [thymoquinone results in increased expression of TP53 protein] | 31433961 |
C003466 | thymoquinone | thymoquinone results in increased expression of TP53 protein | 21609759; 31433961; |
D013974 | Thyroxine | Thyroxine inhibits the reaction [Resveratrol results in increased activity of TP53 protein] | 17174366 |
D013974 | Thyroxine | tetraiodothyroacetic acid inhibits the reaction [Thyroxine affects the localization of TP53 protein modified form] | 17984113 |
D013974 | Thyroxine | Thyroxine affects the localization of TP53 protein modified form | 17984113 |
C027385 | tibolone | tibolone results in decreased expression of TP53 protein | 16021059 |
C016151 | tinuvin | tinuvin analog results in increased expression of TP53 mRNA | 30315675 |
C402769 | tipifarnib | tipifarnib results in decreased expression of TP53 mRNA | 16403772 |
D000077704 | Tirapazamine | Tirapazamine results in increased expression of TP53 | 15814660 |
D000077704 | Tirapazamine | TP53 results in increased susceptibility to Tirapazamine | 15814660 |
C009495 | titanium dioxide | [Ferrosoferric Oxide binds to titanium dioxide] which results in increased expression of TP53 protein | 30098274 |
C009495 | titanium dioxide | titanium dioxide inhibits the reaction [[lead nitrate results in increased abundance of Lead] which results in increased expression of TP53 mRNA] | 30738203 |
C009495 | titanium dioxide | titanium dioxide results in increased expression of TP53 | 23111874 |
C009495 | titanium dioxide | titanium dioxide results in increased expression of TP53 mRNA | 19695317; 21067279; 30910687; |
C009495 | titanium dioxide | titanium dioxide results in increased expression of TP53 protein | 20362650; 30098274; |
C009495 | titanium dioxide | titanium dioxide results in increased phosphorylation of TP53 protein | 30126039 |
C009495 | titanium dioxide | titanium dioxide results in increased phosphorylation of TP53 protein | 20863874 |
D014028 | Tobacco Smoke Pollution | 3'-methoxy-4'-nitroflavone inhibits the reaction [Tobacco Smoke Pollution results in decreased expression of TP53 mRNA] | 17070097 |
D014028 | Tobacco Smoke Pollution | 3'-methoxy-4'-nitroflavone inhibits the reaction [Tobacco Smoke Pollution results in decreased expression of TP53 protein] | 17070097 |
D014028 | Tobacco Smoke Pollution | MIR145 mRNA inhibits the reaction [Tobacco Smoke Pollution results in increased expression of TP53 protein] | 30639269 |
D014028 | Tobacco Smoke Pollution | Tobacco Smoke Pollution results in decreased expression of TP53 mRNA | 17070097; 27404394; |
D014028 | Tobacco Smoke Pollution | Tobacco Smoke Pollution results in decreased expression of TP53 protein | 17070097 |
D014028 | Tobacco Smoke Pollution | Tobacco Smoke Pollution results in increased expression of TP53 mRNA | 27865774; 30076938; |
D014028 | Tobacco Smoke Pollution | Tobacco Smoke Pollution results in increased expression of TP53 protein | 30639269 |
D014028 | Tobacco Smoke Pollution | Tobacco Smoke Pollution results in increased mutagenesis of TP53 gene | 10824542 |
D024505 | Tocopherols | Tocopherols results in increased activity of TP53 protein | 15883045 |
D014044 | Tolbutamide | Tolbutamide results in increased expression of TP53 mRNA | 16426753 |
D014050 | Toluene | Toluene results in increased phosphorylation of TP53 protein | 8076368 |
D014050 | Toluene | Toluene results in increased phosphorylation of and results in increased activity of TP53 protein | 9118908 |
D019772 | Topotecan | Topotecan results in increased activity of TP53 protein | 12698201; 30818834; |
D019772 | Topotecan | Topotecan results in increased expression of TP53 protein | 12698201; 20038611; |
D019772 | Topotecan | TP53 inhibits the reaction [Topotecan results in increased activity of CASP3 protein] | 19812371 |
D019772 | Topotecan | TP53 inhibits the reaction [Topotecan results in increased cleavage of CASP2 protein] | 19812371 |
D019772 | Topotecan | TP53 protein results in increased susceptibility to Topotecan | 22101337 |
D014108 | Tosylphenylalanyl Chloromethyl Ketone | Tosylphenylalanyl Chloromethyl Ketone results in decreased phosphorylation of and results in increased activity of TP53 protein | 12821135 |
D014108 | Tosylphenylalanyl Chloromethyl Ketone | TP53 protein promotes the reaction [Tosylphenylalanyl Chloromethyl Ketone results in increased activity of CASP3 protein] | 12821135 |
D014108 | Tosylphenylalanyl Chloromethyl Ketone | TP53 protein promotes the reaction [Tosylphenylalanyl Chloromethyl Ketone results in increased activity of CASP7 protein] | 12821135 |
D014108 | Tosylphenylalanyl Chloromethyl Ketone | TP53 protein results in increased susceptibility to Tosylphenylalanyl Chloromethyl Ketone | 12821135 |
C496197 | trans-10,cis-12-conjugated linoleic acid | trans-10,cis-12-conjugated linoleic acid results in increased phosphorylation of and affects the localization of TP53 protein | 15992797 |
C495469 | trans-3-(4'-hydroxyphenyl)-2-propenoic acid | trans-3-(4'-hydroxyphenyl)-2-propenoic acid results in increased expression of TP53 protein | 29879413 |
D014212 | Tretinoin | Tretinoin affects the expression of TP53 | 16720286 |
D014212 | Tretinoin | [Tretinoin co-treated with Zoledronic Acid] results in decreased expression of TP53 protein | 20349282 |
D014212 | Tretinoin | Tretinoin inhibits the reaction [Cisplatin results in increased acetylation of TP53 protein] | 21532991 |
D014212 | Tretinoin | Tretinoin inhibits the reaction [[Copper binds to Isatin binds to trimethylenediamine] which results in increased expression of TP53 protein] | 17327230 |
D014212 | Tretinoin | Tretinoin inhibits the reaction [geldanamycin affects the localization of TP53 protein] | 17293044 |
D014212 | Tretinoin | Tretinoin results in decreased expression of TP53 protein | 16461808 |
D014212 | Tretinoin | Tretinoin results in increased activity of TP53 protein | 15674351 |
D014212 | Tretinoin | Tretinoin results in increased expression of TP53 mRNA | 16054129 |
D014212 | Tretinoin | Tretinoin results in increased expression of TP53 protein | 15254726; 16473924; 16752155; 16935849; 20507312; |
D014212 | Tretinoin | Tretinoin results in increased ubiquitination of and results in increased degradation of TP53 protein | 16740359 |
D014212 | Tretinoin | [Tretinoin results in increased uptake of Glucose] inhibits the reaction [bis((2-oxindol-3-ylimino)-2-(2-aminoethyl)pyridine-N,N')copper(II) results in increased expression of TP53 protein] | 21548882 |
D014212 | Tretinoin | Vorinostat inhibits the reaction [Tretinoin inhibits the reaction [Cisplatin results in increased acetylation of TP53 protein]] | 21532991 |
D014212 | Tretinoin | Tretinoin results in decreased expression of TP53 protein | 17962954 |
C072782 | tri-(2-chloroisopropyl)phosphate | tri-(2-chloroisopropyl)phosphate binds to TP53 gene | 25510514 |
C072782 | tri-(2-chloroisopropyl)phosphate | tri-(2-chloroisopropyl)phosphate results in increased expression of TP53 mRNA | 25510514 |
C032910 | triadimefon | triadimefon results in increased expression of TP53 mRNA | 24962053 |
C015008 | triazolopyrimidinone | triazolopyrimidinone analog results in increased expression of TP53 protein | 15993080 |
C009524 | tributyl phosphate | tributyl phosphate binds to TP53 protein | 24411723 |
C011559 | tributyltin | tributyltin results in decreased expression of TP53 protein | 26961604 |
C011559 | tributyltin | tributyltin results in increased expression of TP53 protein | 25743928 |
C447082 | tricarbonyldichlororuthenium (II) dimer | tricarbonyldichlororuthenium (II) dimer affects the expression of TP53 protein | 24211270 |
D014236 | Trichlorfon | Trichlorfon results in increased expression of TP53 protein | 19631781 |
D014241 | Trichloroethylene | Trichloroethylene results in increased expression of TP53 protein | 12160929 |
C012589 | trichostatin A | anacardic acid inhibits the reaction [Genistein promotes the reaction [trichostatin A results in increased acetylation of TP53 protein]] | 26768552 |
C012589 | trichostatin A | EP300 promotes the reaction [Genistein promotes the reaction [trichostatin A results in increased expression of TP53 mRNA]] | 26768552 |
C012589 | trichostatin A | EP300 promotes the reaction [Genistein promotes the reaction [trichostatin A results in increased expression of TP53 protein]] | 26768552 |
C012589 | trichostatin A | EP300 promotes the reaction [trichostatin A results in increased expression of TP53 protein] | 26768552 |
C012589 | trichostatin A | Etoposide promotes the reaction [trichostatin A results in increased expression of TP53 protein] | 25699604 |
C012589 | trichostatin A | [Genistein co-treated with trichostatin A] results in increased expression of TP53 protein | 22626855 |
C012589 | trichostatin A | Genistein promotes the reaction [trichostatin A results in increased expression of and results in increased acetylation of TP53 protein] | 26768552 |
C012589 | trichostatin A | Genistein promotes the reaction [trichostatin A results in increased expression of TP53 mRNA] | 26768552 |
C012589 | trichostatin A | leptomycin B inhibits the reaction [TP53 protein results in increased susceptibility to trichostatin A] | 16467109 |
C012589 | trichostatin A | pifithrin inhibits the reaction [TP53 protein results in increased susceptibility to trichostatin A] | 16467109 |
C012589 | trichostatin A | TP53 protein affects the reaction [trichostatin A results in increased expression of TP63 protein alternative form] | 20043870 |
C012589 | trichostatin A | TP53 protein results in increased susceptibility to trichostatin A | 16467109 |
C012589 | trichostatin A | trichostatin A promotes the reaction [Etoposide results in increased expression of and results in increased acetylation of TP53 protein] | 25699604 |
C012589 | trichostatin A | trichostatin A results in decreased expression of TP53 mRNA | 19606018 |
C012589 | trichostatin A | trichostatin A results in decreased expression of TP53 protein | 15179185 |
C012589 | trichostatin A | trichostatin A results in decreased expression of TP53 protein mutant form | 15179185 |
C012589 | trichostatin A | trichostatin A results in increased acetylation of and results in increased activity of TP53 protein | 15964798 |
C012589 | trichostatin A | trichostatin A results in increased expression of and results in increased acetylation of TP53 protein | 26768552 |
C012589 | trichostatin A | trichostatin A results in increased expression of TP53 mRNA | 16865256; 26768552; |
C012589 | trichostatin A | trichostatin A results in increased expression of TP53 protein | 25699604 |
C012589 | trichostatin A | trichostatin A results in decreased activity of TP53 protein | 16426753 |
C012589 | trichostatin A | trichostatin A results in decreased expression of TP53 mRNA | 23558232 |
D014266 | Trientine | Paraquat promotes the reaction [Trientine results in increased phosphorylation of TP53 protein] | 11369509 |
D014266 | Trientine | Trientine results in increased expression of and results in increased activity of TP53 protein | 14513838 |
D014266 | Trientine | Trientine results in increased phosphorylation of TP53 protein | 11369509 |
C009549 | triethyl phosphate | triethyl phosphate binds to TP53 protein | 24411723 |
C009549 | triethyl phosphate | triethyl phosphate binds to TP53 gene | 25510514 |
C011560 | triisopropyl phosphate | triisopropyl phosphate binds to TP53 gene | 25510514 |
C009475 | trimethylenediamine | [Copper binds to Isatin binds to trimethylenediamine] which results in increased expression of TP53 protein | 17327230 |
C009475 | trimethylenediamine | Tretinoin inhibits the reaction [[Copper binds to Isatin binds to trimethylenediamine] which results in increased expression of TP53 protein] | 17327230 |
C003715 | trimethyl phosphate | trimethyl phosphate binds to TP53 gene | 25510514 |
C040533 | trimethyltin chloride | trimethyltin chloride promotes the reaction [TP53 protein results in increased expression of BBC3 mRNA] | 19655806 |
C040533 | trimethyltin chloride | trimethyltin chloride promotes the reaction [TP53 protein results in increased expression of CDKN1A mRNA] | 19655806 |
D014302 | Trinitrobenzenesulfonic Acid | Sulfur Dioxide inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased phosphorylation of and results in increased activity of TP53 protein] | 30503585 |
D014302 | Trinitrobenzenesulfonic Acid | Trinitrobenzenesulfonic Acid results in increased phosphorylation of and results in increased activity of TP53 protein | 30503585 |
C068051 | tripchlorolide | tripchlorolide affects the reaction [TP53 protein affects the expression of BIRC5 mRNA] | 15916722 |
C068051 | tripchlorolide | tripchlorolide results in increased expression of TP53 mRNA | 15916722 |
C005445 | triphenyl phosphate | triphenyl phosphate binds to and results in increased expression of TP53 protein | 25333763 |
C005445 | triphenyl phosphate | triphenyl phosphate results in increased expression of TP53 mRNA | 25333763 |
C005445 | triphenyl phosphate | triphenyl phosphate binds to TP53 gene | 25510514 |
C005445 | triphenyl phosphate | triphenyl phosphate results in increased expression of TP53 mRNA | 25510514 |
C030665 | triphenyltin | triphenyltin results in increased expression of TP53 protein | 25743928 |
C050414 | tripterine | tripterine results in increased expression of TP53 protein | 27374097 |
C050414 | tripterine | Uridine inhibits the reaction [tripterine results in increased expression of TP53 protein] | 27374097 |
C001899 | triptolide | pifithrin inhibits the reaction [triptolide results in increased expression of TP53 protein] | 30009776 |
C001899 | triptolide | pifithrin inhibits the reaction [triptolide results in increased expression of TP53 protein modified form] | 30009776 |
C001899 | triptolide | triptolide results in increased expression of TP53 mRNA | 30009776 |
C001899 | triptolide | triptolide results in increased expression of TP53 protein | 30009776 |
C001899 | triptolide | triptolide results in increased expression of TP53 protein modified form | 30009776 |
C012085 | tris(2,3-dibromopropyl)phosphate | tris(2,3-dibromopropyl)phosphate results in increased expression of TP53 protein | 9163691 |
C049232 | tris(2-ethylhexyl)phosphate | tris(2-ethylhexyl)phosphate binds to TP53 gene | 25510514 |
C031324 | tris(chloroethyl)phosphate | tris(chloroethyl)phosphate binds to TP53 protein | 24411723; 25333763; |
C031324 | tris(chloroethyl)phosphate | tris(chloroethyl)phosphate binds to TP53 gene | 25510514 |
D014317 | Tritolyl Phosphates | Tritolyl Phosphates binds to TP53 gene | 25510514 |
D000077288 | Troglitazone | TP53 protein results in increased susceptibility to Troglitazone | 12824901 |
D000077288 | Troglitazone | Troglitazone promotes the reaction [TP53 protein results in increased expression of PRODH mRNA] | 16303758 |
D000077288 | Troglitazone | Troglitazone results in decreased expression of TP53 mRNA | 19631733 |
D000077288 | Troglitazone | Troglitazone results in increased expression of TP53 mRNA | 17143939; 19631733; |
D000077288 | Troglitazone | Troglitazone results in increased expression of TP53 protein | 12595159; 12824901; 16303758; 16374840; 17143939; |
D000077288 | Troglitazone | Troglitazone results in increased expression of TP53 mRNA | 11068018 |
D000077288 | Troglitazone | Troglitazone results in increased expression of TP53 protein | 11068018; 15767042; |
C046243 | tryptanthrine | tryptanthrine results in decreased expression of and results in increased degradation of TP53 protein | 17482571 |
C002802 | tungsten carbide | [tungsten carbide co-treated with Cobalt] results in increased expression of and results in increased stability of TP53 protein | 23052192 |
D014415 | Tunicamycin | Tunicamycin results in increased expression of TP53 protein | 20886113 |
D014415 | Tunicamycin | Tunicamycin promotes the reaction [Capsaicin results in increased degradation of TP53 protein] | 19699254 |
D014415 | Tunicamycin | HR protein inhibits the reaction [Tunicamycin results in increased expression of TP53 protein] | 20886113 |
C098214 | tyrphostin AG825 | tyrphostin AG825 inhibits the reaction [sodium arsenite results in increased expression of TP53 protein] | 15734884 |
C113580 | U 0126 | U 0126 affects the reaction [1-Methyl-4-phenylpyridinium affects the expression of TP53 mRNA] | 12710931 |
C113580 | U 0126 | [U 0126 co-treated with 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine] results in increased expression of TP53 protein | 22101421 |
C113580 | U 0126 | U 0126 inhibits the reaction [[Cisplatin co-treated with chrysin] affects the localization of TP53 protein] | 25770930 |
C113580 | U 0126 | U 0126 inhibits the reaction [[Cisplatin co-treated with chrysin] results in increased phosphorylation of TP53 protein] | 25770930 |
C113580 | U 0126 | U 0126 inhibits the reaction [sodium arsenite results in decreased phosphorylation of TP53 protein] | 22706169 |
C113580 | U 0126 | U 0126 results in increased expression of TP53 protein | 22101421 |
C113580 | U 0126 | U 0126 inhibits the reaction [Calcimycin results in increased expression of TP53 protein] | 16000378 |
C113580 | U 0126 | U 0126 inhibits the reaction [dibenzo(a,l)pyrene results in increased phosphorylation of TP53 protein] | 16005925 |
C113580 | U 0126 | U 0126 inhibits the reaction [Doxorubicin results in increased expression of and results in increased localization of TP53 protein modified form] | 18775851 |
C113580 | U 0126 | U 0126 inhibits the reaction [Doxorubicin results in increased phosphorylation of and results in increased localization of TP53 protein] | 18775851 |
C000602704 | UF010 compound | Etoposide promotes the reaction [UF010 compound results in increased expression of TP53 protein] | 25699604 |
C000602704 | UF010 compound | UF010 compound promotes the reaction [Etoposide results in increased expression of and results in increased acetylation of TP53 protein] | 25699604 |
C000602704 | UF010 compound | UF010 compound results in increased expression of TP53 protein | 25699604 |
C561310 | UNC 0638 | UNC 0638 inhibits the reaction [EHMT1 protein results in increased methylation of TP53 protein] | 21780790 |
C561310 | UNC 0638 | UNC 0638 inhibits the reaction [EHMT2 protein results in increased methylation of TP53 protein] | 21780790 |
D014498 | Uracil | TP53 protein affects the susceptibility to [Uracil co-treated with Tegafur] | 15182437 |
D014529 | Uridine | Uridine inhibits the reaction [tripterine results in increased expression of TP53 protein] | 27374097 |
D014580 | Ursodeoxycholic Acid | MDM2 mutant form inhibits the reaction [Ursodeoxycholic Acid results in increased ubiquitination of TP53 protein] | 20807506 |
D014580 | Ursodeoxycholic Acid | TP53 mutant form inhibits the reaction [[Oxaliplatin co-treated with Ursodeoxycholic Acid] results in increased activity of CASP3 protein] | 19728331 |
D014580 | Ursodeoxycholic Acid | TP53 mutant form inhibits the reaction [[Oxaliplatin co-treated with Ursodeoxycholic Acid] results in increased activity of CASP8 protein] | 19728331 |
D014580 | Ursodeoxycholic Acid | Ursodeoxycholic Acid results in increased ubiquitination of TP53 protein | 20807506 |
D014580 | Ursodeoxycholic Acid | MDM2 mutant form inhibits the reaction [Ursodeoxycholic Acid affects the localization of TP53 protein] | 17881359 |
D014580 | Ursodeoxycholic Acid | NR3C1 mutant form inhibits the reaction [Ursodeoxycholic Acid inhibits the reaction [TGFB1 protein results in increased expression of TP53 protein]] | 15222754 |
D014580 | Ursodeoxycholic Acid | NR3C2 mutant form inhibits the reaction [Ursodeoxycholic Acid inhibits the reaction [TGFB1 protein results in increased expression of TP53 protein]] | 15222754 |
D014580 | Ursodeoxycholic Acid | TP53 protein affects the susceptibility to Ursodeoxycholic Acid | 17431217 |
D014580 | Ursodeoxycholic Acid | Ursodeoxycholic Acid affects the localization of and results in decreased phosphorylation of TP53 protein | 17881359 |
D014580 | Ursodeoxycholic Acid | Ursodeoxycholic Acid affects the localization of TP53 protein | 17881359 |
D014580 | Ursodeoxycholic Acid | Ursodeoxycholic Acid inhibits the reaction [Deoxycholic Acid results in increased expression of TP53 mRNA] | 20137712 |
D014580 | Ursodeoxycholic Acid | Ursodeoxycholic Acid inhibits the reaction [E2F1 protein results in increased expression of TP53 protein] | 14514686 |
D014580 | Ursodeoxycholic Acid | Ursodeoxycholic Acid inhibits the reaction [TGFB1 protein results in increased expression of TP53 protein] | 14514686; 15222754; |
D014580 | Ursodeoxycholic Acid | Ursodeoxycholic Acid inhibits the reaction [TP53 protein results in increased expression of and results in increased localization of BAX protein] | 17881359 |
D014580 | Ursodeoxycholic Acid | Ursodeoxycholic Acid inhibits the reaction [TP53 protein results in increased expression of BAX mRNA] | 17881359 |
D014580 | Ursodeoxycholic Acid | Ursodeoxycholic Acid inhibits the reaction [TP53 protein results in increased expression of BAX protein] | 14514686; 17881359; |
D014580 | Ursodeoxycholic Acid | Ursodeoxycholic Acid promotes the reaction [TP53 protein binds to MDM2 protein] | 17881359 |
D014580 | Ursodeoxycholic Acid | [Ursodeoxycholic Acid promotes the reaction [TP53 protein binds to MDM2 protein]] which results in increased degradation of TP53 protein | 17881359 |
D014580 | Ursodeoxycholic Acid | Ursodeoxycholic Acid results in increased ubiquitination of and results in increased degradation of TP53 protein | 20807506 |
C073339 | usnic acid | usnic acid results in decreased expression of TP53 protein | 22285236 |
C073339 | usnic acid | usnic acid results in increased expression of TP53 protein | 22285236 |
C108850 | V 10367 | V 10367 inhibits the reaction [Hydrogen Peroxide results in increased expression of TP53 protein] | 12642403 |
D014635 | Valproic Acid | [Hydralazine co-treated with Valproic Acid] results in increased expression of TP53 mRNA | 17183730 |
D014635 | Valproic Acid | Valproic Acid affects the expression of TP53 mRNA | 25979313 |
D014635 | Valproic Acid | Valproic Acid results in decreased expression of TP53 mRNA | 28001369 |
D014635 | Valproic Acid | Valproic Acid results in increased expression of TP53 mRNA | 22580532; 22814014; |
D014635 | Valproic Acid | Valproic Acid results in increased methylation of TP53 gene | 29154799 |
D014635 | Valproic Acid | Valproic Acid results in increased expression of TP53 protein | 23562654 |
D014639 | Vanadium | Vanadium results in increased activity of TP53 protein | 19000753 |
D014639 | Vanadium | Vanadium inhibits the reaction [1,2-Dimethylhydrazine results in increased expression of TP53 protein] | 18155637 |
D014639 | Vanadium | Vanadium promotes the reaction [2-Acetylaminofluorene results in increased expression of TP53 protein] | 15565650 |
D017968 | Vanadium Compounds | Vanadium Compounds results in increased expression of and results in increased phosphorylation of TP53 protein | 26391003 |
C100058 | vanillin | vanillin results in decreased expression of TP53 mRNA | 17178418 |
D001335 | Vehicle Emissions | Vehicle Emissions analog results in increased mutagenesis of TP53 gene | 10682588 |
D001335 | Vehicle Emissions | [[Vehicle Emissions results in increased abundance of Particulate Matter] which results in decreased expression of MDM2 protein] which results in increased expression of TP53 protein | 28013216 |
D001335 | Vehicle Emissions | [Vehicle Emissions results in increased abundance of Particulate Matter] which results in increased expression of TP53 protein | 28013216 |
D001335 | Vehicle Emissions | Vehicle Emissions results in increased expression of TP53 mRNA | 23454527 |
D001335 | Vehicle Emissions | Vehicle Emissions analog results in increased phosphorylation of TP53 protein | 25500124 |
D001335 | Vehicle Emissions | Vehicle Emissions results in increased expression of TP53 mRNA | 24216475 |
D000069470 | Venlafaxine Hydrochloride | Venlafaxine Hydrochloride inhibits the reaction [Cisplatin results in increased expression of TP53 protein] | 29852128 |
D014747 | Vinblastine | TP53 protein affects the reaction [Vinblastine results in increased phosphorylation of JUN protein] | 12221076 |
D014747 | Vinblastine | TP53 protein affects the reaction [Vinblastine results in increased phosphorylation of MAPK8 protein] | 12221076 |
D014747 | Vinblastine | TP53 protein affects the reaction [Vinblastine results in increased phosphorylation of MAPK9 protein] | 12221076 |
D014750 | Vincristine | [Doxorubicin co-treated with Vincristine co-treated with Etoposide co-treated with Mitotane] results in decreased expression of TP53 protein | 9815696 |
D014750 | Vincristine | TP53 protein results in increased susceptibility to Vincristine | 14704126 |
D014750 | Vincristine | Vincristine results in increased activity of TP53 protein | 22010212 |
D014750 | Vincristine | Vincristine results in increased expression of TP53 protein | 12082016; 15131059; |
D014750 | Vincristine | Vincristine results in increased glutathionylation of TP53 protein | 17555331 |
D014752 | Vinyl Chloride | CYP2E1 gene polymorphism promotes the reaction [Vinyl Chloride affects the mutagenesis of TP53 gene] | 12705718 |
D014752 | Vinyl Chloride | CYP2E1 gene polymorphism promotes the reaction [Vinyl Chloride results in increased mutagenesis of TP53 gene] | 12010862; 17384900; |
D014752 | Vinyl Chloride | GSTM1 gene polymorphism affects the reaction [XRCC1 gene polymorphism affects the reaction [Vinyl Chloride affects the mutagenesis of TP53 gene]] | 16097394 |
D014752 | Vinyl Chloride | GSTT1 gene polymorphism affects the reaction [XRCC1 gene polymorphism affects the reaction [Vinyl Chloride affects the mutagenesis of TP53 gene]] | 16097394 |
D014752 | Vinyl Chloride | TP53 gene SNP results in increased susceptibility to Vinyl Chloride | 18226366 |
D014752 | Vinyl Chloride | TP53 polymorphism affects the susceptibility to Vinyl Chloride | 24464562 |
D014752 | Vinyl Chloride | Vinyl Chloride results in decreased expression of TP53 mRNA | 22076037 |
D014752 | Vinyl Chloride | Vinyl Chloride results in increased expression of TP53 protein | 12670519; 14979067; 16474264; |
D014752 | Vinyl Chloride | Vinyl Chloride results in increased expression of TP53 protein mutant form | 16474264 |
D014752 | Vinyl Chloride | Vinyl Chloride results in increased mutagenesis of TP53 gene | 12010862; 12670519; 16881598; 17384900; |
D014752 | Vinyl Chloride | XRCC1 gene polymorphism affects the reaction [Vinyl Chloride affects the mutagenesis of TP53 gene] | 16097394 |
D014752 | Vinyl Chloride | XRCC1 gene polymorphism promotes the reaction [Vinyl Chloride affects the mutagenesis of TP53 gene] | 14602524 |
D014752 | Vinyl Chloride | XRCC1 gene polymorphism promotes the reaction [Vinyl Chloride results in increased mutagenesis of TP53 gene] | 12010862; 16881598; |
D014757 | Viper Venoms | Viper Venoms results in increased expression of and affects the localization of TP53 protein | 27613483 |
D014810 | Vitamin E | [Selenium co-treated with Vitamin E] results in increased expression of TP53 mRNA | 19244175 |
D014810 | Vitamin E | [Vitamin E co-treated with Curcumin] results in decreased expression of TP53 protein | 30935902 |
D014810 | Vitamin E | Vitamin E inhibits the reaction [Benzo(a)pyrene results in increased phosphorylation of and results in increased activity of TP53 protein] | 24664296 |
D014810 | Vitamin E | Vitamin E inhibits the reaction [Benzo(a)pyrene results in increased phosphorylation of TP53 protein] | 15837074 |
D014810 | Vitamin E | Vitamin E results in increased expression of TP53 mRNA | 19244175 |
D014810 | Vitamin E | [Vitamin E co-treated with Selenium] inhibits the reaction [Malathion results in increased expression of TP53 mRNA] | 21628957 |
D014810 | Vitamin E | Vitamin E inhibits the reaction [cypermethrin results in increased expression of TP53 mRNA] | 24759048 |
D014810 | Vitamin E | Vitamin E inhibits the reaction [decamethrin results in increased expression of TP53 mRNA] | 25439240 |
D024483 | Vitamin K 3 | EUK-134 inhibits the reaction [Vitamin K 3 results in increased expression of TP53 protein] | 25005833 |
D024483 | Vitamin K 3 | SB 203580 inhibits the reaction [[sodium arsenite co-treated with Vitamin K 3] results in increased phosphorylation of TP53 protein] | 19082730 |
D024483 | Vitamin K 3 | [sodium arsenite co-treated with Vitamin K 3] results in increased phosphorylation of TP53 protein | 19082730 |
D024483 | Vitamin K 3 | Vitamin K 3 results in increased expression of TP53 protein | 21533478; 25005833; |
D000077337 | Vorinostat | [Vorinostat co-treated with Bortezomib] results in increased expression of TP53 protein | 17351739 |
D000077337 | Vorinostat | Vorinostat inhibits the reaction [Tretinoin inhibits the reaction [Cisplatin results in increased acetylation of TP53 protein]] | 21532991 |
D000077337 | Vorinostat | Vorinostat promotes the reaction [PML protein binds to TP53 protein] | 19631782 |
D000077337 | Vorinostat | Vorinostat promotes the reaction [Resveratrol results in increased acetylation of TP53 protein] | 19810103 |
D000077337 | Vorinostat | Vorinostat promotes the reaction [TP53 protein binds to PML protein binds to CREBBP protein] | 19631782 |
D000077337 | Vorinostat | Vorinostat results in increased acetylation of TP53 protein | 19084294 |
D000077337 | Vorinostat | Vorinostat results in increased activity of TP53 protein | 30818834 |
D000077337 | Vorinostat | Vorinostat results in increased expression of TP53 protein | 17351739 |
D014859 | Warfarin | Warfarin results in increased degradation of TP53 protein | 14634213 |
D014859 | Warfarin | Warfarin affects the expression of TP53 protein | 12872399 |
D014859 | Warfarin | SNAI2 protein promotes the reaction [TP53 protein results in increased susceptibility to Warfarin] | 29358327 |
D014859 | Warfarin | SNAI2 protein promotes the reaction [[TP53 protein results in increased susceptibility to Warfarin] which results in increased expression of BMP2 mRNA] | 29358327 |
D014859 | Warfarin | SNAI2 protein promotes the reaction [[TP53 protein results in increased susceptibility to Warfarin] which results in increased expression of RUNX2 mRNA] | 29358327 |
D014859 | Warfarin | SNAI2 protein promotes the reaction [[TP53 protein results in increased susceptibility to Warfarin] which results in increased expression of RUNX2 protein] | 29358327 |
D014859 | Warfarin | TP53 protein results in increased susceptibility to Warfarin | 29358327 |
D014859 | Warfarin | [TP53 protein results in increased susceptibility to Warfarin] which results in increased expression of BMP2 mRNA | 29358327 |
D014859 | Warfarin | [TP53 protein results in increased susceptibility to Warfarin] which results in increased expression of BMP2 protein | 29358327 |
D014859 | Warfarin | [TP53 protein results in increased susceptibility to Warfarin] which results in increased expression of CDKN1A protein | 29358327 |
D014859 | Warfarin | [TP53 protein results in increased susceptibility to Warfarin] which results in increased expression of EP300 protein | 29358327 |
D014859 | Warfarin | [TP53 protein results in increased susceptibility to Warfarin] which results in increased expression of RUNX2 mRNA | 29358327 |
D014859 | Warfarin | [TP53 protein results in increased susceptibility to Warfarin] which results in increased expression of RUNX2 protein | 29358327 |
D014859 | Warfarin | [TP53 protein results in increased susceptibility to Warfarin] which results in increased expression of SNAI2 protein | 29358327 |
D014859 | Warfarin | Warfarin promotes the reaction [TP53 protein binds to SNAI2 promoter] | 29358327 |
D014859 | Warfarin | Warfarin results in increased expression of and results in decreased acetylation of TP53 protein | 29358327 |
D014859 | Warfarin | Warfarin results in increased expression of TP53 mRNA | 29358327 |
D014874 | Water Pollutants, Chemical | Water Pollutants, Chemical results in increased expression of TP53 mRNA | 22326570; 23063069; |
C070417 | Win 55212-2 | Win 55212-2 results in increased expression of TP53 protein | 30776504 |
C009684 | withaferin A | withaferin A binds to TP53 protein | 22973447 |
C009684 | withaferin A | withaferin A inhibits the reaction [HSPA9 protein binds to TP53 protein] | 22973447 |
C009684 | withaferin A | [withaferin A inhibits the reaction [HSPA9 protein binds to TP53 protein]] which affects the localization of and results in increased activity of TP53 protein | 22973447 |
C009684 | withaferin A | withaferin A results in increased expression of TP53 mRNA | 22973447 |
C085514 | wogonin | wogonin results in increased expression of TP53 protein | 21457722 |
D000077191 | Wortmannin | Wortmannin inhibits the reaction [2-chloroethyl ethyl sulfide results in increased phosphorylation of TP53 protein] | 19111594 |
D000077191 | Wortmannin | Wortmannin inhibits the reaction [3,3'-diindolylmethane results in increased phosphorylation of TP53 protein] | 22290291 |
D000077191 | Wortmannin | Wortmannin inhibits the reaction [Asbestos, Serpentine results in increased expression of TP53 protein] | 12676607 |
D000077191 | Wortmannin | Wortmannin inhibits the reaction [Asbestos, Serpentine results in increased phosphorylation of TP53 protein] | 12676607 |
D000077191 | Wortmannin | Wortmannin inhibits the reaction [Benzo(a)pyrene results in increased phosphorylation of TP53 protein] | 15837074 |
D000077191 | Wortmannin | Wortmannin inhibits the reaction [Doxorubicin promotes the reaction [ATM protein results in increased phosphorylation of TP53 protein]] | 15489221 |
D000077191 | Wortmannin | Wortmannin inhibits the reaction [Mustard Gas results in increased expression of TP53 protein] | 22119920 |
D000077191 | Wortmannin | Wortmannin inhibits the reaction [Mustard Gas results in increased phosphorylation of TP53 protein] | 22119920 |
D000077191 | Wortmannin | Wortmannin inhibits the reaction [Nitric Oxide results in increased phosphorylation of TP53 protein] | 16024610 |
D000077191 | Wortmannin | Wortmannin inhibits the reaction [Resveratrol results in increased phosphorylation of TP53 protein] | 17534123 |
D000077191 | Wortmannin | Wortmannin inhibits the reaction [spermine nitric oxide complex results in increased phosphorylation of TP53 protein] | 16024610 |
D000077191 | Wortmannin | Wortmannin promotes the reaction [arsenic disulfide results in increased expression of and results in increased phosphorylation of TP53 protein] | 18298901 |
D000077191 | Wortmannin | Wortmannin results in decreased phosphorylation of and results in decreased expression of TP53 protein | 22290291 |
D000077191 | Wortmannin | Wortmannin results in decreased phosphorylation of TP53 protein | 22119920 |
D000077191 | Wortmannin | Wortmannin inhibits the reaction [Diethylnitrosamine results in increased expression of TP53 protein] | 11751435 |
D000077191 | Wortmannin | Wortmannin inhibits the reaction [Diethylnitrosamine results in increased phosphorylation of TP53 protein] | 11751435 |
C451735 | WP 744 | WP 744 results in increased expression of TP53 protein | 15555623 |
C022186 | xanthatin | TP53 protein promotes the reaction [xanthatin results in decreased expression of CDC25C protein modified form] | 29074359 |
C022186 | xanthatin | TP53 protein promotes the reaction [xanthatin results in decreased phosphorylation of CHEK1 protein] | 29074359 |
C022186 | xanthatin | TP53 protein promotes the reaction [xanthatin results in decreased stability of CDC25C protein] | 29074359 |
C022186 | xanthatin | TP53 protein results in increased susceptibility to xanthatin | 29074359 |
C104536 | xanthohumol | xanthohumol results in increased expression of TP53 | 26297991; 27317025; |
C104536 | xanthohumol | xanthohumol results in increased expression of TP53 mRNA | 23085367 |
C104536 | xanthohumol | xanthohumol results in increased expression of TP53 protein | 23085367 |
C000607970 | XI-006 | XI-006 inhibits the reaction [formononetin results in decreased expression of TP53 protein] | 28414026 |
C530084 | xinmaitong | xinmaitong affects the expression of TP53 protein | 12872399 |
C118180 | XK 469 | XK 469 results in increased expression of TP53 protein | 11774253 |
C108830 | Y 27632 | TP53 protein affects the susceptibility to Y 27632 | 20878077 |
C108830 | Y 27632 | TP53 protein promotes the reaction [Y 27632 results in decreased susceptibility to Cisplatin] | 20878077 |
C108830 | Y 27632 | Y 27632 inhibits the reaction [Cisplatin results in increased expression of TP53 mRNA] | 20878077 |
C108830 | Y 27632 | Y 27632 results in decreased expression of TP53 mRNA | 20878077 |
C108830 | Y 27632 | Y 27632 results in increased expression of TP53 protein | 11839765 |
D015025 | Zearalenone | [Zearalenone co-treated with Aflatoxin B1] promotes the reaction [deoxynivalenol results in increased expression of TP53 mRNA] | 30668976 |
D015025 | Zearalenone | Zearalenone results in increased expression of TP53 mRNA | 30668976 |
D015025 | Zearalenone | Acetylcysteine inhibits the reaction [fumonisin B1 promotes the reaction [Zearalenone results in increased expression of TP53 mRNA]] | 29109043 |
D015025 | Zearalenone | Acetylcysteine inhibits the reaction [Zearalenone promotes the reaction [fumonisin B1 results in increased expression of TP53 mRNA]] | 29109043 |
D015025 | Zearalenone | Acetylcysteine promotes the reaction [deoxynivalenol inhibits the reaction [Zearalenone results in increased expression of TP53 mRNA]] | 29109043 |
D015025 | Zearalenone | deoxynivalenol inhibits the reaction [Zearalenone results in increased expression of TP53 mRNA] | 29109043 |
D015025 | Zearalenone | fumonisin B1 inhibits the reaction [deoxynivalenol inhibits the reaction [Zearalenone results in increased expression of TP53 mRNA]] | 29109043 |
D015025 | Zearalenone | fumonisin B1 promotes the reaction [Zearalenone results in increased expression of TP53 mRNA] | 29109043 |
D015025 | Zearalenone | Zearalenone promotes the reaction [[deoxynivalenol co-treated with fumonisin B1] results in increased expression of TP53 mRNA] | 29109043 |
D015025 | Zearalenone | Zearalenone promotes the reaction [fumonisin B1 results in increased expression of TP53 mRNA] | 29109043 |
D015025 | Zearalenone | Zearalenone results in increased expression of TP53 mRNA | 29109043 |
C105427 | Zeocin | Zeocin results in increased stability of and results in increased expression of TP53 protein | 11741290 |
D015215 | Zidovudine | Zidovudine results in increased expression of TP53 protein | 16797627 |
D015032 | Zinc | TP53 protein inhibits the reaction [Zinc results in increased phosphorylation of MAPK1 protein] | 15880691 |
D015032 | Zinc | TP53 protein inhibits the reaction [Zinc results in increased phosphorylation of MAPK3 protein] | 15880691 |
D015032 | Zinc | TP53 protein promotes the reaction [Zinc results in increased abundance of Reactive Oxygen Species] | 15880691 |
D015032 | Zinc | TP53 protein results in increased susceptibility to Zinc | 15880691 |
D015032 | Zinc | Zinc affects the expression of TP53 protein | 16636310 |
D015032 | Zinc | Zinc affects the folding of TP53 protein | 16768444 |
D015032 | Zinc | Zinc affects the localization of TP53 protein | 12107073 |
D015032 | Zinc | Zinc binds to TP53 protein | 17327663 |
D015032 | Zinc | Zinc deficiency results in increased expression of TP53 mRNA | 18356318 |
D015032 | Zinc | Zinc results in increased expression of TP53 protein | 12888634; 15880691; |
D015032 | Zinc | [SLC30A10 protein affects the abundance of Zinc] which affects the expression of TP53 protein | 22427991 |
D015032 | Zinc | [SLC30A3 protein affects the abundance of Zinc] which affects the expression of TP53 protein | 22427991 |
D015032 | Zinc | Zinc binds to TP53 protein | 16909841 |
D019345 | Zinc Acetate | Acetylcysteine inhibits the reaction [[Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of TP53 protein] | 20530418 |
D019345 | Zinc Acetate | [Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of TP53 protein | 20530418 |
D019345 | Zinc Acetate | benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of TP53 protein] | 20530418 |
D019345 | Zinc Acetate | nutlin 3 inhibits the reaction [[Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of TP53 protein] | 20530418 |
C016837 | zinc chloride | zinc chloride inhibits the reaction [cobaltous chloride inhibits the reaction [Doxorubicin results in increased phosphorylation of and results in increased activity of TP53 protein]] | 19714248 |
D017967 | Zinc Compounds | Zinc Compounds results in increased expression of TP53 mRNA | 24035972 |
D017967 | Zinc Compounds | Zinc Compounds results in increased expression of TP53 protein | 24035972 |
D015034 | Zinc Oxide | Zinc Oxide affects the expression of TP53 protein | 28648595 |
D015034 | Zinc Oxide | Zinc Oxide results in increased phosphorylation of and results in increased expression of TP53 protein | 21903158 |
C017803 | zinc protoporphyrin | [zinc protoporphyrin results in decreased activity of HMOX1 protein] inhibits the reaction [cobaltiprotoporphyrin results in increased expression of TP53 protein] | 18042465 |
C017803 | zinc protoporphyrin | zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin results in decreased expression of TP53 protein] | 20357190 |
D019287 | Zinc Sulfate | [Acetylcysteine co-treated with N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine] inhibits the reaction [[Zinc Sulfate co-treated with prolinedithiocarbamate] results in decreased expression of TP53 protein] | 18951928 |
D019287 | Zinc Sulfate | Acetylcysteine inhibits the reaction [[Zinc Sulfate co-treated with prolinedithiocarbamate] results in decreased expression of TP53 protein] | 18951928 |
D019287 | Zinc Sulfate | benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Zinc Sulfate co-treated with prolinedithiocarbamate] results in decreased expression of TP53 protein] | 18951928 |
D019287 | Zinc Sulfate | N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine inhibits the reaction [[Zinc Sulfate co-treated with prolinedithiocarbamate] results in decreased expression of TP53 protein] | 18951928 |
D019287 | Zinc Sulfate | [Zinc Sulfate co-treated with prolinedithiocarbamate] results in decreased expression of TP53 protein | 18951928 |
D019287 | Zinc Sulfate | Zinc Sulfate inhibits the reaction [prolinedithiocarbamate results in increased phosphorylation of TP53 protein] | 18951928 |
D019287 | Zinc Sulfate | Zinc Sulfate results in increased phosphorylation of and results in increased expression of TP53 protein | 15001399 |
C484848 | ziyuglycoside I | TP53 protein affects the reaction [ziyuglycoside I results in decreased expression of BCL2 protein] | 28960612 |
C484848 | ziyuglycoside I | TP53 protein affects the reaction [ziyuglycoside I results in increased activity of CASP3 protein] | 28960612 |
C484848 | ziyuglycoside I | TP53 protein affects the reaction [ziyuglycoside I results in increased activity of CASP9 protein] | 28960612 |
C484848 | ziyuglycoside I | TP53 protein affects the reaction [ziyuglycoside I results in increased expression of BAX protein] | 28960612 |
C484848 | ziyuglycoside I | TP53 protein affects the reaction [ziyuglycoside I results in increased expression of BBC3 protein] | 28960612 |
C484848 | ziyuglycoside I | ziyuglycoside I results in increased expression of TP53 protein | 28960612 |
C484848 | ziyuglycoside I | ziyuglycoside I results in increased phosphorylation of and results in increased acetylation of TP53 protein | 28960612 |
C097270 | ZM 241385 | ZM 241385 inhibits the reaction [cordycepin results in increased phosphorylation of and results in increased expression of TP53 protein] | 24704558 |
D000077211 | Zoledronic Acid | [Tretinoin co-treated with Zoledronic Acid] results in decreased expression of TP53 protein | 20349282 |
D000077211 | Zoledronic Acid | Zoledronic Acid affects the activity of TP53 protein | 25596134 |
Keyword ID | Keyword Term |
---|---|
KW-0002 | 3D-structure |
KW-0007 | Acetylation |
KW-0010 | Activator |
KW-0877 | Alternative promoter usage |
KW-0025 | Alternative splicing |
KW-0053 | Apoptosis |
KW-0090 | Biological rhythms |
KW-0131 | Cell cycle |
KW-0963 | Cytoplasm |
KW-0206 | Cytoskeleton |
KW-0903 | Direct protein sequencing |
KW-0225 | Disease mutation |
KW-0238 | DNA-binding |
KW-0256 | Endoplasmic reticulum |
KW-0325 | Glycoprotein |
KW-0945 | Host-virus interaction |
KW-1017 | Isopeptide bond |
KW-0435 | Li-Fraumeni syndrome |
KW-0479 | Metal-binding |
KW-0488 | Methylation |
KW-0496 | Mitochondrion |
KW-1210 | Necrosis |
KW-0539 | Nucleus |
KW-0597 | Phosphoprotein |
KW-0621 | Polymorphism |
KW-1185 | Reference proteome |
KW-0678 | Repressor |
KW-0804 | Transcription |
KW-0805 | Transcription regulation |
KW-0043 | Tumor suppressor |
KW-0832 | Ubl conjugation |
KW-0862 | Zinc |
PROSITE ID | PROSITE Term |
---|---|
PS00348 | P53 |